"abacavir","44fb1e25-ad03-4a7f-9f35-2e29f5025661","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.2,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7. 1 Methadone</h2>
<p class=,'First,'>In a trial of 11 HIV-1-infected subjects receiving methadone-maintenance therapy with  600 mg of abacavir twice daily (twice the currently recommended dose), oral methadone clearance increased<span class=,'Italics,'> [see Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)].</span> This alteration will not result in a methadone dose modification in the majority of patients; however, an increased methadone dose may be required in a small number of patients.</p>
</div>
</div>"
"abiraterone","2ac063f0-4177-c90f-27c3-e70e29689255","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'DRUG_INTERACTIONS,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_834690db-8ffd-6abd-d006-c76dc5c0dba0,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Drugs that Inhibit or Induce CYP3A4 Enzymes</h2>
<p class=,'First,'>Based on <span class=,'Italics,'>in vitro</span> data, abiraterone acetate is a substrate of CYP3A4.</p>
<p>In a dedicated drug interaction trial, co-administration of rifampin, a strong CYP3A4 inducer, decreased exposure of abiraterone by 55%. Avoid concomitant strong CYP3A4 inducers during abiraterone acetate treatment. If a strong CYP3A4 inducer must be co-administered, increase the abiraterone acetate dosing frequency <span class=,'Italics,'>[see  Dosage and Administration (<a href=,'#_63bb0dd0-f77d-3c36-76a9-89bdf87d4b27,'>2.5</a>) </span> and <span class=,'Italics,'> Clinical Pharmacology (<a href=,'#PHARMACOKINETICS,'>12.3</a>)]</span>.</p>
<p>In a dedicated drug interaction trial, co-administration of ketoconazole, a strong inhibitor of CYP3A4, had no clinically meaningful effect on the pharmacokinetics of abiraterone <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#PHARMACOKINETICS,'>12.3</a>)]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_0c745339-c640-2e82-7bc8-66e270983ec8,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Effects of Abiraterone on Drug Metabolizing Enzymes </h2>
<p class=,'First,'>Abiraterone acetate is an inhibitor of the hepatic drug-metabolizing enzymes CYP2D6 and CYP2C8. In a CYP2D6 drug-drug interaction trial, the C<span class=,'Sub,'>max</span> and AUC of dextromethorphan (CYP2D6 substrate) were increased 2.8- and 2.9-fold, respectively, when dextromethorphan was given with abiraterone acetate 1,000 mg daily and prednisone 5 mg twice daily. Avoid co­-administration of abiraterone acetate with substrates of CYP2D6 with a narrow therapeutic index (e.g., thioridazine). If alternative treatments cannot be used, consider a dose reduction of the concomitant CYP2D6 substrate drug <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#PHARMACOKINETICS,'>12.3</a>)]</span>.</p>
<p>In a CYP2C8 drug-drug interaction trial in healthy subjects, the AUC of pioglitazone (CYP2C8 substrate) was increased by 46% when pioglitazone was given together with a single dose of 1,000 mg abiraterone acetate. Therefore, patients should be monitored closely for signs of toxicityrelated to a CYP2C8 substrate with a narrow therapeutic index if used concomitantly with abiraterone acetate <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#PHARMACOKINETICS,'>12.3</a>)]</span><span class=,'Italics,'>and Warnings and Precautions (5.6)]</span>.</p>
</div>
</div>"
"acarbose","1ba7a072-03b0-41f2-be7a-101145bdef3a","none found"
"acetazolamide","0700a910-79aa-4431-aecf-637fe14fcae8","none found"
"acetic acid","0c5ebd59-0e98-4ea1-b279-9202a19f6dbf","none found"
"acetylcysteine","4072b547-c242-4a40-8c91-5481b86cbf1e","none found"
"acyclovir","04e24e1f-ac6b-46b9-9ee2-61fb74a4e5ba","none found"
"aclidinium","4cefdf4c-9e01-4b98-804b-c520f1b9716e","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'s15,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>In vitro</span> studies suggest limited potential for CYP450-related metabolic drug interactions, thus no formal drug interaction studies have been performed with TUDORZA PRESSAIR <span class=,'Italics,'>[see <a href=,'#s35,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s16,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Sympathomimetics, Methylxanthines, Steroids</h2>
<p class=,'First,'>In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta<span class=,'Sub,'>2</span> agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s17,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Anticholinergics</h2>
<p class=,'First,'>There is a potential for an additive interaction with concomitantly used anticholinergic medications. Therefore, avoid coadministration of TUDORZA PRESSAIR with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic effects.</p>
</div>
</div>"
"activated charcoal","7da3506f-2799-434c-e053-2a91aa0adabb","none found"
"adalimumab","acdfaa71-27ed-4717-8e7d-f1a5fe0d1fa6","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'s56,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s57,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Methotrexate
</h2>
<p class=,'First,'>Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either adalimumab or MTX <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#s79,'>12.3</a>)]</span>.
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s58,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Biological Products
</h2>
<p class=,'First,'>In clinical studies in patients with RA, an increased risk of serious infections has been seen with the combination of TNF blockers with anakinra or abatacept, with no added benefit; therefore, use of IMRALDI with abatacept or anakinra is not recommended in patients with RA <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#s35,'>5.7</a> and <a href=,'#s39,'>5.11</a>)]</span>. A higher rate of serious infections has also been observed in patients with RA treated with rituximab who received subsequent treatment with a TNF blocker. There is insufficient information regarding the concomitant use of adalimumab and other biologic products for the treatment of RA, PsA, AS, CD, UC and Ps. Concomitant administration of IMRALDI with other biologic DMARDS (e.g., anakinra and abatacept) or other TNF blockers is not recommended based upon the possible increased risk for infections and other potential pharmacological interactions.
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s59,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Live Vaccines
</h2>
<p class=,'First,'>Avoid the use of live vaccines with IMRALDI <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#s38,'>5.10</a>)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s60,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Cytochrome P450 Substrates
</h2>
<p class=,'First,'>The formation of CYP450 enzymes may be suppressed by increased levels of cytokines (e.g., TNFα, IL-6) during chronic inflammation. It is possible for a molecule that antagonizes cytokine activity, such as adalimumab, to influence the formation of CYP450 enzymes. Upon initiation or discontinuation of IMRALDI in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed.
</p>
</div>
</div>"
"afatinib","fd638e5e-8032-e7ca-0179-95e96ab5d387","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Underline,'>Effect of P-glycoprotein (P-gp) Inhibitors and Inducers</span>
</p>
<p>Concomitant taking of P-gp inhibitors (including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) with GILOTRIF can increase exposure to afatinib <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]. </span>Reduce GILOTRIF daily dose as recommended <span class=,'Italics,'>[see <a href=,'#S2.5,'>Dosage and Administration (2.5)</a>].</span>
</p>
<p>Concomitant taking of P-gp inducers (including but not limited to rifampicin, carbamazepine, phenytoin, phenobarbital, and St. John's wort) with GILOTRIF can decrease exposure to afatinib <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]. </span>Increase GILOTRIF daily dose as recommended <span class=,'Italics,'>[see <a href=,'#S2.5,'>Dosage and Administration (2.5)</a>].</span>
</p>
</div>
</div>"
"albendazole","0a4ce2e1-db3d-4b24-98aa-0519fbaff547","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID54,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,'>
<a name=,'ID57,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Dexamethasone</h2>
<p class=,'First,'>
<a name=,'ID58,'></a>Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was co-administered with each dose of albendazole (15 mg/kg/day) in 8 neurocysticercosis patients.</p>
</div>
<div class=,'Section,'>
<a name=,'ID59,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Praziquantel</h2>
<p class=,'First,'>
<a name=,'ID60,'></a>In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n = 10) compared with a separate group of subjects (n = 6) given albendazole alone. Mean T<span class=,'Sub,'>max</span> and mean plasma elimination half-life of albendazole sulfoxide were unchanged. The pharmacokinetics of praziquantel were unchanged following co-administration with albendazole (400 mg).</p>
</div>
<div class=,'Section,'>
<a name=,'ID61,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Cimetidine</h2>
<p class=,'First,'>
<a name=,'ID62,'></a>Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) (n = 7) compared with albendazole (20 mg/kg/day) alone (n = 12). Albendazole sulfoxide plasma concentrations were unchanged 4 hours after dosing.</p>
</div>
<div class=,'Section,'>
<a name=,'ID63,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Theophylline</h2>
<p class=,'First,'>
<a name=,'ID64,'></a>Following a single dose of albendazole (400 mg), the pharmacokinetics of theophylline (aminophylline 5.8 mg/kg infused over 20 minutes) were unchanged. Albendazole induces cytochrome P450 1A in human hepatoma cells; therefore, it is recommended that plasma concentrations of theophylline be monitored during and after treatment.</p>
</div>
</div>"
"alclometasone","3e688309-880a-4890-bf00-90afd19084f6","none found"
"alendronic acid","00b5de12-6ee7-400f-92da-dcdc17249328","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_af644f85-6c82-47d6-98b9-4c8544c258c4,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_93848c47-a60d-4727-ae0a-9387194df94c,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Calcium Supplements/Antacids</h2>
<p class=,'First,'>Coadministration of alendronate sodium and calcium, antacids, or oral medications containing multivalent cations will interfere with absorption of alendronate sodium. Therefore, patients must wait at least one-half hour after taking alendronate sodium before taking any other oral medications. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_9428e500-308c-4550-a805-39e7535cacab,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Aspirin</h2>
<p class=,'First,'>In clinical studies, the incidence of upper gastrointestinal adverse events was increased in patients receiving concomitant therapy with daily doses of alendronate sodium greater than 10 mg and aspirin-containing products. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_99316cfc-1f93-46a1-a53b-9d9fb1218241,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Non-Steroidal Anti-Inflammatory Drugs</h2>
<p class=,'First,'>Alendronate sodium may be administered to patients taking non-steroidal anti-inflammatory drugs (NSAIDs). In a 3 year, controlled, clinical study (n = 2027) during which a majority of patients received concomitant NSAIDs, the incidence of upper gastrointestinal adverse events was similar in patients taking alendronate sodium 5 or 10 mg/day compared to those taking placebo. However, since NSAID use is associated with gastrointestinal irritation, caution should be used during concomitant use with alendronate sodium.</p>
</div>
</div>"
"alfuzosin","30f97b8e-4486-4b5f-896a-d7dfa1e2e33a","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID716,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,'>
<a name=,'ID717,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 CYP3A4 Inhibitors</h2>
<p class=,'First,'>Alfuzosin HCl extended-release tablets are contraindicated for use with potent CYP3A4 inhibitors such as ketoconazole, itraconazole, or ritonavir, since alfuzosin blood levels are increased <span class=,'Italics,'>[see <a href=,'#ID678,'>Contraindications (4)</a>, <a href=,'#ID691,'>Warnings and Precautions (5.4)</a> and <a href=,'#ID753,'>Clinical Pharmacology (12.3)</a>].</span>
</p>
</div>
<div class=,'Section,'>
<a name=,'ID719,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Alpha Adrenergic Antagonists</h2>
<p class=,'First,'>The pharmacokinetic and pharmacodynamic interactions between alfuzosin HCl extended-release tablets and other alpha adrenergic antagonists have not been determined. However, interactions may be expected, and alfuzosin HCl extended-release tablets should not be used in combination with other alpha adrenergic antagonists <span class=,'Italics,'>[see <a href=,'#ID691,'>Warnings and Precautions (5.4)</a>].</span>
</p>
</div>
<div class=,'Section,'>
<a name=,'ID721,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Antihypertensive Medication and Nitrates</h2>
<p class=,'First,'>There may be an increased risk of hypotension/postural hypotension and syncope when taking alfuzosin HCl extended-release tablets concomitantly with anti-hypertensive medication and nitrates <span class=,'Italics,'>[see <a href=,'#ID685,'>Warnings and Precautions (5.1)</a>].</span>
</p>
</div>
<div class=,'Section,'>
<a name=,'ID723,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 PDE5 Inhibitors</h2>
<p class=,'First,'>Caution is advised when alpha adrenergic antagonists, including alfuzosin HCl extended-release tablets, are coadministered with PDE5 inhibitors. Alpha adrenergic antagonists and PDE5 inhibitors are both vasodilators that can lower blood pressure. Concomitant use of these two drug classes can potentially cause symptomatic hypotension <span class=,'Italics,'>[see <a href=,'#ID691,'>Warnings and Precautions (5.4)</a>].</span>
</p>
</div>
</div>"
"trimeprazine","9de07d0d-44df-47da-b4b7-24f5fc803b46","none found"
"aliskiren","f3fd2503-25ef-4660-a29a-f62c491e28fb","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_223f5dda-8854-4b08-8818-b2186a22090c,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Cyclosporine: </span>Avoid coadministration of cyclosporine with aliskiren <span class=,'Italics,'>[see <a href=,'#LINK_23a43900-27ee-47a4-8d0e-1297038f15f0,'>Warnings and Precautions (5.7)</a> and <a href=,'#LINK_969fd8b8-d313-46fb-9ba5-364abcc95b56,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>
<span class=,'Italics,'>Itraconazole: </span>Avoid coadministration of itraconazole with aliskiren <span class=,'Italics,'>[see <a href=,'#LINK_23a43900-27ee-47a4-8d0e-1297038f15f0,'>Warnings and Precautions (5.7)</a> and <a href=,'#LINK_969fd8b8-d313-46fb-9ba5-364abcc95b56,'>Clinical Pharmacology (12.3)</a>].</span>
</p>
<p>
<span class=,'Italics,'>Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) including selective Cyclooxygenase-2 inhibitors (COX-2 inhibitors): </span>In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors with agents that affect the RAAS, including aliskiren, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving aliskiren and NSAID therapy.</p>
<p>The antihypertensive effect of aliskiren may be attenuated by NSAIDs.</p>
<p>
<span class=,'Italics,'>Dual Blockade of the Renin-Angiotensin-Aldosterone System (RAAS): </span>The concomitant use of aliskiren with other agents acting on the RAAS such as ACEIs or ARBs is associated with an increased risk of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Most patients receiving the combination of two drugs that inhibit the renin-angiotensin system do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of aliskiren with ACE inhibitors or ARBs, particularly in patients with CrCl less than 60 mL/min. Monitor blood pressure, renal function, and electrolytes in patients taking aliskiren and other agents that affect the RAAS <span class=,'Italics,'>[see <a href=,'#LINK_be9edff1-144d-4a50-a929-79e6a40ae7db,'>Warnings and Precautions (5.4,</a> <a href=,'#LINK_a3c16110-b18a-4264-a861-8023131c6ac6,'>5.5,</a> <a href=,'#LINK_c60d167c-0aa1-4869-810d-3bc4dc57ff78,'>5.6)</a>].</span>
</p>
<p>The concomitant use of aliskiren with an ARB or an ACEI in diabetic patients is contraindicated <span class=,'Italics,'>[<a href=,'#LINK_69a67555-6e7a-4562-b4f1-537f19bf6e8f,'>see Contraindications (4)</a>].</span>
</p>
<p>
<span class=,'Italics,'>Furosemide: </span>Oral coadministration of aliskiren and furosemide reduced exposure to furosemide. Monitor diuretic effects when furosemide is coadministered with aliskiren.</p>
</div>"
"allopurinol","005048dd-844f-468c-bf56-1a09727e3477","none found"
"alprazolam","01289569-acdc-4213-950d-9c313df4a90a","none found"
"alteplase","c669f77c-fa48-478b-a14b-80b20a0139c2","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>The interaction of Activase with other cardioactive or cerebroactive drugs has not been studied.  Anticoagulants and antiplatelet drugs increase the risk of bleeding if administered prior to, during, or after Activase therapy.</p>
<p>In the post-marketing setting, there have been reports of angioedema in patients (primarily patients with AIS) receiving concomitant angiotensin-converting enzyme inhibitors. <span class=,'Italics,'>[see <a href=,'#S5.2,'>Warnings and Precautions (5.2)</a>].</span>
</p>
</div>"
"amikacin","0b56f6df-a05d-4520-8bf0-d7cefe20f6ad","none found"
"amiloride","2b70cf0c-45be-428f-b396-5001ed4e30fc","none found"
"amlodipine","241e7477-ecae-4f84-8410-bbfaa9f57ed0","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'i4i_interactions_id_16de21c9-fd60-43a2-9322-d90f8b2c954b,'></a><a name=,'section-8,'></a>
<p></p>
<p class=,'First,'>{template}</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_08bb81dc-aff8-4121-abc4-d2e2b6012b4a,'></a><a name=,'section-8.1,'></a>
<p></p>
<h2>
<span class=,'Bold,'>7.1 Drug/Drug interactions</span>
</h2>
<p class=,'First,'>
<span class=,'Bold,'><span class=,'Italics,'>Diuretics: </span></span>Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with amlodipine besylate and benazepril hydrochloride. The possibility of hypotensive effects with amlodipine besylate and benazepril hydrochloride can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with amlodipine besylate and benazepril hydrochloride. </p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Potassium Supplements and Potassium-Sparing Diuretics: </span></span>Benazepril can attenuate potassium loss caused by thiazide diuretics. Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia. If concomitant use of such agents is indicated, monitor the patient’s serum potassium frequently. </p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Lithium: </span></span>Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. When coadministering amlodipine besylate and benazepril hydrochloride and lithium, frequent monitoring of serum lithium levels is recommended. </p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Gold: </span></span>Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patient on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy. </p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Other: </span></span>Benazepril has been used concomitantly with oral anticoagulants, beta-adrenergic-blocking agents, calciumblocking agents, cimetidine, diuretics, digoxin, hydralazine, and naproxen without evidence of clinically important adverse interactions. </p>
<p>In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, ACE inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, nonsteroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. </p>
<p>
<span class=,'Italics,'>In vitro</span> data in human plasma indicate that amlodipine has no effect on the protein binding of drugs tested (digoxin, phenytoin, warfarin, and indomethacin). Special studies have indicated that the coadministration of amlodipine with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers; that coadministration with cimetidine did not alter the pharmacokinetics of amlodipine; and that coadministration with warfarin did not change thewarfarin-induced prothrombin response time. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_d3b59bae-1212-41a0-bec0-8d6178b4e5e6,'></a><a name=,'section-8.2,'></a>
<p></p>
<h2>
<span class=,'Bold,'>7.2 Clinical Laboratory Test Findings</span>
</h2>
<p class=,'First,'>
<span class=,'Bold,'><span class=,'Italics,'>Serum Electrolytes: </span></span>[See <a href=,'#i4i_warnings_precautions_id_eb2eea2f-4ec2-4399-b21b-c753a63ca05e,'>Warnings and Precautions (5</a>)].  </p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Creatinine: </span></span>Minor reversible increases in serum creatinine were observed in patients with essential hypertension treated with amlodipine besylate and benazepril hydrochloride. Increases in creatinine are more likely to occur in patients with renal insufficiency or those pretreated with a diuretic and, based on experience with other ACE inhibitors, would be expected to be especially likely in patients with renal artery stenosis [see <a href=,'#i4i_warnings_precautions_id_eb2eea2f-4ec2-4399-b21b-c753a63ca05e,'>Warnings and Precautions (5)</a>]. </p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Other </span></span>(causal relationships unknown): Clinically important changes in standard laboratory tests were rarely associated with amlodipine besylate and benazepril hydrochloride administration. Elevations of serum bilirubin and uric acid have been reported as have scattered incidents of elevations of liver enzymes.</p>
</div>
</div>"
"amoxicillin","05e88717-2ce3-4b1a-88af-c3f61a2d8cd5","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Probenecid</h2>
<br/>
<p class=,'First,'>Probenecid decreases the renal tubular secretion of amoxicillin. Concurrent use of amoxicillin and probenecid may result in increased and prolonged blood levels of amoxicillin.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Oral Anticoagulants</h2>
<br/>
<p class=,'First,'>Abnormal prolongation of prothrombin time (increased international normalized ratio [INR]) has been reported in patients receiving amoxicillin and oral anticoagulants. Appropriate monitoring should be undertaken when anticoagulants are prescribed concurrently. Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Allopurinol</h2>
<br/>
<p class=,'First,'>The concurrent administration of allopurinol and amoxicillin increases the incidence of rashes in patients receiving both drugs as compared to patients receiving amoxicillin alone. It is not known whether this potentiation of amoxicillin rashes is due to allopurinol or the hyperuricemia present in these patients.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Oral Contraceptives</h2>
<br/>
<p class=,'First,'>Amoxicillin may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.5,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Other Antibacterials</h2>
<br/>
<p class=,'First,'>Chloramphenicol, macrolides, sulfonamides, and tetracyclines may interfere with the bactericidal effects of penicillin. This has been demonstrated <span class=,'Italics,'>in vitro</span>; however, the clinical significance of this interaction is not well documented.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.6,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6 Effects on Laboratory Tests</h2>
<br/>
<p class=,'First,'>High urine concentrations of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using CLINITEST<span class=,'Sup,'>®</span>, Benedict’s Solution, or Fehling’s Solution. Since this effect may also occur with amoxicillin, it is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as CLINISTIX<span class=,'Sup,'>®</span>) be used. <br/>
<br/>Following administration of ampicillin or amoxicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been noted. </p>
</div>
</div>"
"amphetamine","00242264-40d8-4267-a91a-727a1f088616","none found"
"amphotericin B","a0a54943-9ce4-4f3e-b681-a1a9144c16ce","none found"
"ampicillin","0a66c5c3-63bf-46e3-835e-26b555ab6954","none found"
"anagrelide","875cc32a-219c-4b6b-802a-98a47cbc9a78","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID40,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,'>
<a name=,'ID43,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Drug that Prolong QT</h2>
<p class=,'First,'>
<a name=,'ID44,'></a>Avoid use anagrelide in patients taking medications that may prolong QT interval (including, but not limited to, chloroquine, clarithromycin, haloperidol, methadone, moxifloxacin, amiodarone, disopyramide, procainamide, and pimozide) <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#ID24,'>5.1</a>) and Clinical Pharmacology (<a href=,'#ID74,'>12.2</a>)].</span>
</p>
</div>
<div class=,'Section,'>
<a name=,'ID45,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 PDE3 Inhibitors</h2>
<p class=,'First,'>
<a name=,'ID46,'></a>Anagrelide is a phosphodiesterase 3 (PDE3) inhibitor. Avoid use of drug products with similar properties such as inotropes and other PDE3 inhibitors (e.g., cilostazol, milrinone) <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#ID24,'>5.1</a>) and Clinical Pharmacology (<a href=,'#ID74,'>12.2</a>)].</span>
</p>
</div>
<div class=,'Section,'>
<a name=,'ID47,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Aspirin and Drugs that Increase Bleeding Risk</h2>
<p class=,'First,'>
<a name=,'ID48,'></a>Co-administration of single-dose or repeat-dose anagrelide and aspirin showed greater ex vivo anti-platelet aggregation effects than administration of aspirin alone <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#Laabe3d17-cc70-4835-a586-2ea333c3aaf0,'>12.3</a>)]</span>. Results from an observational study in patients with essential thrombocythemia suggest the rate of major hemorrhagic events (MHEs) in patients treated with anagrelide is higher than in those subjects treated with another cytoreductive treatment. The majority of the major hemorrhagic events occurred in patients who were also receiving concomitant anti-aggregatory treatment (primarily, aspirin). Therefore, the potential risks of the concomitant use of anagrelide with aspirin should be assessed, particularly in patients with a high-risk profile for hemorrhage, before treatment is initiated [see Warnings and Precautions (<a href=,'#ID26,'>5.3</a>)].</p>
<p>Monitor patients for bleeding, particularly those receiving concomitant therapy with other drugs known to cause bleeding (e.g., anticoagulants, PDE3 inhibitors, NSAIDs, antiplatelet agents, selective serotonin reuptake inhibitors).</p>
</div>
<div class=,'Section,'>
<a name=,'ID49,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 CYP450 Interactions</h2>
<p class=,'First,'>
<a name=,'ID50,'></a><span class=,'Italics,'>CYP1A2 inhibitors:</span> Anagrelide and its active metabolite are primarily metabolized by CYP1A2. Drugs that inhibit CYP1A2 (e.g., fluvoxamine, ciprofloxacin) could increase the exposure of anagrelide. Monitor patients for cardiovascular events and titrate doses accordingly when CYP1A2 inhibitors are co-administered. </p>
<p>
<span class=,'Italics,'>CYP1A2 inducers:</span> CYP1A2 inducers could decrease the exposure of anagrelide. Patients taking concomitant CYP1A2 inducers (e.g., omeprazole) may need to have their dose titrated to compensate for the decrease in anagrelide exposure. </p>
<p>
<span class=,'Italics,'>CYP1A2 substrates:</span> Anagrelide demonstrates limited inhibitory activity towards CYP1A2 <span class=,'Italics,'>in vitro</span> and may alter the exposure of concomitant CYP1A2 substrates (e.g. theophylline, fluvoxamine, ondansetron).</p>
</div>
</div>"
"anastrozole","03586c40-eb32-45c5-beb7-6762a6b78790","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section71,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Tamoxifen</h2>
<p class=,'First,'>Co-administration of anastrozole and tamoxifen in breast cancer patients reduced anastrozole plasma concentration by 27%. However, the co-administration of anastrozole and tamoxifen did not affect the pharmacokinetics of tamoxifen or N-desmethyltamoxifen. At a median follow-up of 33 months, the combination of anastrozole and tamoxifen did not demonstrate any efficacy benefit when compared with tamoxifen in all patients as well as in the hormone receptor-positive subpopulation. This treatment arm was discontinued from the trial. 
         
 
  
         
 
  
         
 
  <span class=,'Italics,'> [see Clinical Studies (
          
  
   
          
  
   
          
  
   <a href=,'#section141,'>14.1</a>)]
         
 
  
         
 
  
         
 
  </span>. Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole.  
        

 
        

 
        

 </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section72,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Estrogen</h2>
<p class=,'First,'>Estrogen-containing therapies should not be used with anastrozole as they may diminish its pharmacological action.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Warfarin</h2>
<p class=,'First,'>In a study conducted in 16 male volunteers, anastrozole did not alter the exposure (as measured by C
         
 
  
         
 
  
         
 
  <span class=,'Sub,'>max</span> and AUC), and anticoagulant activity (as measured by prothrombin time, activated partial thromboplastin time, and thrombin time) of both R- and S-warfarin. 
        

 
        

 
        

 </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Cytochrome P450</h2>
<p class=,'First,'>Based on 
         
 
  
         
 
  
         
 
  <span class=,'Italics,'>in vitro</span> and 
         
 
  
         
 
  
         
 
  <span class=,'Italics,'>in vivo</span> results, it is unlikely that co-administration of anastrozole 1 mg will affect other drugs as a result of inhibition of cytochrome P450 
         
 
  
         
 
  
         
 
  <span class=,'Italics,'> [see Clinical Pharmacology (
          
  
   
          
  
   
          
  
   <a href=,'#section123,'>12.3</a>)].
         
 
  
         
 
  
         
 
  </span>
</p>
</div>
</div>"
"apixaban","095a08ac-cf0e-497e-a682-ddef38d6b29c","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Apixaban is a substrate of both CYP3A4 and P-gp. Inhibitors of CYP3A4 and P-gp increase exposure to apixaban and increase the risk of bleeding. Inducers of CYP3A4 and P-gp decrease exposure to apixaban and increase the risk of stroke and other thromboembolic events.</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.3,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Combined P-gp Strong CYP3A4  Inhibitors</h2>
<p class=,'First,'>For patients receiving  apixaban 5 mg or 10 mg twice daily, the dose of apixaban should be decreased by 50% when coadministered with drugs that are combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) <span class=,'Italics,'>[see Dosage and Administration (2.5) and Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3)</a>].</span>
</p>
<p>For patients receiving apixaban at a dose of 2.5 mg twice daily, avoid coadministration with combined P-gp and strong CYP3A4 inhibitors <span class=,'Italics,'>[see Dosage and Administration (<a href=,'#Section_2.2,'>2.5</a>) and Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)].</span>
<br/>
<span class=,'Italics,'>Clarithromycin</span>
<br/> Although clarithromycin is a combined P-gp and strong CYP3A4 inhibitor, pharmacokinetic data suggest that no dose adjustment is necessary with concomitant administration with apixaban <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3)</a>].</span>
<br/>
<br/>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Combined P-gp Strong CYP3A4  Inducers</h2>
<p class=,'First,'>Avoid concomitant use of apixaban tablets with combined P-gp and strong CYP3A4 Inducers (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) because such drugs will decrease exposure to apixaban <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.1,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Anticoagulants and Antiplatelet Agents</h2>
<p class=,'First,'>Coadministration of antiplatelet agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding.</p>
<br/>
<p>APPRAISE-2, a placebo-controlled clinical trial of apixaban in high-risk, post-acute coronary syndrome patients treated with aspirin or the combination of aspirin and clopidogrel, was terminated early due to a higher rate of bleeding with apixaban compared to placebo. The rate of ISTH major bleeding was 2.8% per year with apixaban versus 0.6% per year with placebo in patients receiving single antiplatelet therapy and was 5.9% per year with apixaban versus 2.5% per year with placebo in those receiving dual antiplatelet therapy.</p>
<p>In ARISTOTLE, concomitant use of aspirin increased the bleeding risk on apixaban from 1.8% per year to 3.4% per year and concomitant use of aspirin and warfarin increased the bleeding risk from 2.7% per year to 4.6% per year. In this clinical trial, there was limited (2.3%) use of dual antiplatelet therapy with apixaban.</p>
</div>
</div>"
"apraclonidine","04ad82af-e7ba-4f40-a120-be9d33cf0c7b","none found"
"aprepitant","ec44482e-6194-4829-a3f7-ebe8d48a41a5","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'i4i_interactions_id_1c8b96ab-24e3-431d-8ec4-5d31e78fed9c,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Aprepitant is a substrate, a weak-to-moderate (dose-dependent) inhibitor, and an inducer of CYP3A4. Aprepitant is also an inducer of CYP2C9.</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_807cf647-b0d3-4534-8919-4519f8a90768,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Effect of Aprepitant on the Pharmacokinetics of Other Agents</h2>
<p class=,'First,'>
<span class=,'Italics,'><span class=,'Bold,'>CYP3A4 Substrates:</span></span>
</p>
<p>Weak inhibition of CYP3A4 by a single 40 mg dose of aprepitant is not expected to alter the plasma concentrations of concomitant medications that are primarily metabolized through CYP3A4 to a clinically significant degree. However, higher aprepitant doses or repeated dosing at any aprepitant dose may have a clinically significant effect.</p>
<p>As a moderate inhibitor of CYP3A4 at a dose of 125 mg/80 mg, aprepitant can increase plasma concentrations of concomitantly administered oral medications that are metabolized through CYP3A4 <span class=,'Italics,'>[see <a href=,'#i4i_contraindications_id_496b9c54-2ac9-4b1e-85a9-e907309d4432,'>Contraindications (4)</a>]</span>. The use of fosaprepitant may increase CYP3A4 substrate plasma concentrations to a lesser degree than the use of oral aprepitant (125 mg).</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>5-HT<span class=,'Sub,'>3</span> antagonists:</span></span> In clinical drug interaction studies, aprepitant did not have clinically important effects on the pharmacokinetics of ondansetron, granisetron, or hydrodolasetron (the active metabolite of dolasetron).</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Corticosteroids:</span></span>
</p>
<p>
<span class=,'Italics,'>Dexamethasone:</span> EMEND, when given as a regimen of 125 mg with dexamethasone coadministered orally as 20 mg on Day 1, and EMEND when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate, by 2.2-fold on Days 1 and 5. The oral dexamethasone doses should be reduced by approximately 50% when coadministered with EMEND (125 mg/80 mg regimen), to achieve exposures of dexamethasone similar to those obtained when it is given without EMEND. The daily dose of dexamethasone administered in clinical chemotherapy induced nausea and vomiting studies with EMEND reflects an approximate 50% reduction of the dose of dexamethasone <span class=,'Italics,'>[see <a href=,'#i4i_section_id_4d51ebb6-20d4-49a7-ab39-ea6c92216e71,'>Dosage and Administration (2.1)</a>]</span>. A single dose of EMEND (40 mg) when coadministered with a single oral dose of dexamethasone 20 mg, increased the AUC of dexamethasone by 1.45-fold. Therefore, no dose adjustment is recommended.</p>
<p>
<span class=,'Italics,'>Methylprednisolone: </span>EMEND, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3. The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with EMEND (125 mg/80 mg regimen) to achieve exposures of methylprednisolone similar to those obtained when it is given without EMEND. Although the concomitant administration of methylprednisolone with the single 40 mg dose of aprepitant has not been studied, a single 40 mg dose of EMEND produces a weak inhibition of CYP3A4 (based on midazolam interaction study) and it is not expected to alter the plasma concentrations of methylprednisolone to a clinically significant degree. Therefore, no dose adjustment is recommended.</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Chemotherapeutic agents:</span></span><span class=,'Italics,'> [see <a href=,'#i4i_warnings_precautions_id_999aab6d-7353-40ae-9e9e-932f286f1d5b,'>Warnings and Precautions (5.1)</a>]</span>
</p>
<p>
<span class=,'Italics,'>Docetaxel:</span> In a pharmacokinetic study, EMEND (125 mg/80 mg regimen) did not influence the pharmacokinetics of docetaxel.</p>
<p>
<span class=,'Italics,'>Vinorelbine</span>: In a pharmacokinetic study, EMEND (125 mg/80 mg regimen) did not influence the pharmacokinetics of vinorelbine to a clinically significant degree. </p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>CYP2C9 Substrates (Warfarin, Tolbutamide):</span></span>
</p>
<p>Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9. Coadministration of EMEND with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin, may result in lower plasma concentrations of these drugs.</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Warfarin:</span></span> A single 125-mg dose of EMEND was administered on Day 1 and 80 mg/day on Days 2 and 3 to healthy subjects who were stabilized on chronic warfarin therapy. Although there was no effect of EMEND on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-) warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with EMEND. In patients on chronic warfarin therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of EMEND with each chemotherapy cycle, or following administration of a single 40 mg dose of EMEND for the prevention of postoperative nausea and vomiting.</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Tolbutamide: </span></span>EMEND, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was administered orally prior to the administration of the 3-day regimen of EMEND and on Days 4, 8, and 15.</p>
<p>EMEND, when given as a 40-mg single oral dose on Day 1, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 8% on Day 2, 16% on Day 4, 15% on Day 8, and 10% on Day 15, when a single dose of tolbutamide 500 mg was administered orally prior to the administration of EMEND 40 mg and on Days 2, 4, 8, and 15. This effect was not considered clinically important.</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Oral contraceptives:</span></span> Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%. </p>
<p>In another study, a daily dose of an oral contraceptive containing ethinyl estradiol and norethindrone was administered on Days 1 through 21, and EMEND was given as a 3-day regimen of 125 mg on Day 8 and 80 mg/day on Days 9 and 10 with ondansetron 32 mg IV on Day 8 and oral dexamethasone given as 12 mg on Day 8 and 8 mg/day on Days 9, 10, and 11. In the study, the AUC of ethinyl estradiol decreased by 19% on Day 10 and there was as much as a 64% decrease in ethinyl estradiol trough concentrations during Days 9 through 21. While there was no effect of EMEND on the AUC of norethindrone on Day 10, there was as much as a 60% decrease in norethindrone trough concentrations during Days 9 through 21.</p>
<p>In another study, a daily dose of an oral contraceptive containing ethinyl estradiol and norgestimate (which is converted to norelgestromin) was administered on Days 1 through 21, and EMEND 40 mg was given on Day 8. In the study, the AUC of ethinyl estradiol decreased by 4% and 29% on Day 8 and Day 12, respectively, while the AUC of norelgestromin increased by 18% on Day 8 and decreased by 10% on Day 12. In addition, the trough concentrations of ethinyl estradiol and norelgestromin on Days 8 through 21 were generally lower following coadministration of the oral contraceptive with EMEND 40 mg on Day 8 compared to the trough levels following administration of the oral contraceptive alone.</p>
<p>The coadministration of EMEND may reduce the efficacy of hormonal contraceptives (these can include birth control pills, skin patches, implants, and certain IUDs) during and for 28 days after administration of the last dose of EMEND. Alternative or back-up methods of contraception should be used during treatment with EMEND and for 1 month following the last dose of EMEND.</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Midazolam:</span></span> EMEND increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of EMEND 125 mg on Day 1 and 80 mg/day on Days 2 through 5. The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with EMEND (125 mg/80 mg). A single dose of EMEND (40 mg) increased the AUC of midazolam by 1.2-fold on Day 1, when a single oral dose of midazolam 2 mg was coadministered on Day 1 with EMEND 40 mg; this effect was not considered clinically important.</p>
<p>In another study with intravenous administration of midazolam, EMEND was given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, and midazolam 2 mg IV was given prior to the administration of the 3-day regimen of EMEND and on Days 4, 8, and 15. EMEND increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of EMEND on Days 1 through 3. These effects were not considered clinically important. The AUC of midazolam on Day 15 was similar to that observed at baseline.</p>
<p>An additional study was completed with intravenous administration of midazolam and EMEND. Intravenous midazolam 2 mg was given 1 hour after oral administration of a single dose of EMEND 125 mg. The plasma AUC of midazolam was increased by 1.5-fold. Depending on clinical situations (e.g., elderly patients) and degree of monitoring available, dosage adjustment for intravenous midazolam may be necessary when it is coadministered with EMEND for the chemotherapy induced nausea and vomiting indication (125 mg on Day 1 followed by 80 mg on Days 2 and 3).</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_37c4ac6d-aabe-486e-902f-9a2c189c57c1,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Effect of Other Agents on the Pharmacokinetics of Aprepitant</h2>
<p class=,'First,'>Aprepitant is a substrate for CYP3A4; therefore, coadministration of EMEND with drugs that inhibit CYP3A4 activity may result in increased plasma concentrations of aprepitant. Consequently, concomitant administration of EMEND with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution. Because moderate CYP3A4 inhibitors (e.g., diltiazem) result in a 2-fold increase in plasma concentrations of aprepitant, concomitant administration should also be approached with caution.</p>
<p>Aprepitant is a substrate for CYP3A4; therefore, coadministration of EMEND with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of EMEND.</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Ketoconazole:</span></span> When a single 125-mg dose of EMEND was administered on Day 5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold. Concomitant administration of EMEND with strong CYP3A4 inhibitors should be approached cautiously. </p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Rifampin:</span></span> When a single 375-mg dose of EMEND was administered on Day 9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold. </p>
<p>Coadministration of EMEND with drugs that induce CYP3A4 activity may result in reduced plasma concentrations and decreased efficacy of EMEND.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_3b522f87-10bd-4ed1-9977-80e046330aae,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Additional Interactions</h2>
<p class=,'First,'>EMEND is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of EMEND with digoxin in a clinical drug interaction study.</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Diltiazem:</span></span> In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC. These pharmacokinetic effects did not result in clinically meaningful changes in ECG, heart rate or blood pressure beyond those changes induced by diltiazem alone.</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Paroxetine:</span></span> Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and C<span class=,'Sub,'>max</span> by approximately 20% of both aprepitant and paroxetine.</p>
</div>
</div>"
"aripiprazole","06529caf-698f-41da-81ec-d0ba5ab200d7","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_ac978bed-03c5-41e5-a9b3-9518b73c8d1c,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_775e18bc-c313-4963-a4e4-f328ef5dffef,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Drugs Having Clinically Important Interactions with Aripiprazole</h2>
<p class=,'First,'>
<span class=,'Bold,'>Table 25:     Clinically Important Drug Interactions with Aripiprazole:</span>
</p>
<div class=,'scrollingtable,'><table border=,'1,' cellpadding=,'0,' cellspacing=,'0,' width=,'800pt,'>
<col width=,'134.75pt,'/>
<col width=,'134.75pt,'/>
<col width=,'134.75pt,'/>
<tbody class=,'Headless,'>
<tr class=,'First,'>
<td align=,'center,' class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>
<span class=,'Bold,'>Concomitant Drug Name or Drug Class</span>
</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>
<span class=,'Bold,'>Clinical Rationale</span>
</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>
<span class=,'Bold,'>Clinical Recommendation</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Strong CYP3A4 Inhibitors (e.g., itraconazole, clarithromycin) or strong CYP2D6 inhibitors (e.g., quinidine, fluoxetine, paroxetine)</p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>The concomitant use of aripiprazole with strong CYP3A4 or CYP2D6 inhibitors increased the exposure of aripiprazole compared to the use of aripiprazole alone <span class=,'Italics,'>[see </span><span class=,'Italics,'><span class=,'Italics,'><span class=,'Italics,'><a href=,'#LINK_695fc817-660b-489c-a414-c05d073bd7f3,'>CLINICAL PHARMACOLOGY </a></span><span class=,'Italics,'><a href=,'#LINK_695fc817-660b-489c-a414-c05d073bd7f3,'>(12.3)</a></span></span></span><span class=,'Italics,'>].</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>With concomitant use of aripiprazole  with a strong CYP3A4 inhibitor or CYP2D6 inhibitor, reduce the aripiprazole dosage <span class=,'Italics,'>[see </span><span class=,'Italics,'><span class=,'Italics,'><a href=,'#LINK_9783979a-c601-466e-acf7-7a1c53807862,'>DOSAGE  AND </a></span><span class=,'Italics,'><a href=,'#LINK_9783979a-c601-466e-acf7-7a1c53807862,'>ADMINISTRATION (2.7)</a></span></span><span class=,'Italics,'>]</span>.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Strong CYP3A4 Inducers (e.g., carbamazepine, rifampin)</p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>The concomitant use of aripiprazole and carbamazepine decreased the exposure of aripiprazole compared to the use of aripiprazole alone <span class=,'Italics,'>[see <span class=,'Italics,'><span class=,'Italics,'><a href=,'#LINK_695fc817-660b-489c-a414-c05d073bd7f3,'>CLINICAL PHARMACOLOGY </a></span><span class=,'Italics,'><a href=,'#LINK_695fc817-660b-489c-a414-c05d073bd7f3,'>(12.3)</a></span></span>]</span>.</p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>With concomitant use of aripiprazole with a strong CYP3A4 inducer, consider increasing the aripiprazole dosage <span class=,'Italics,'>[see </span><span class=,'Italics,'><span class=,'Italics,'><a href=,'#LINK_9783979a-c601-466e-acf7-7a1c53807862,'>DOSAGE  AND </a></span><span class=,'Italics,'><a href=,'#LINK_9783979a-c601-466e-acf7-7a1c53807862,'>ADMINISTRATION (2.7)</a></span></span><span class=,'Italics,'>]</span>.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Antihypertensive Drugs</p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Due to its alpha adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents.</p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Monitor blood pressure and adjust dose accordingly <span class=,'Italics,'>[see <a href=,'#LINK_0e2f51c3-16ae-4ec5-a738-5e126e3608aa,'>WARNINGS AND PRECAUTIONS (5.8)</a>]</span>.</p>
</td>
</tr>
<tr class=,'Last,'>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Benzodiazepines (e.g., lorazepam)</p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>The intensity of sedation was greater with the   combination of oral aripiprazole and lorazepam as compared to that observed with aripiprazole alone. The orthostatic hypotension observed was greater with the combination as compared to that observed with lorazepam alone <span class=,'Italics,'>[see </span><span class=,'Italics,'><span class=,'Italics,'><a href=,'#LINK_0c14fa58-5cb0-4d16-ac5c-07dd6a3d32db,'>WARNINGS AND </a></span><span class=,'Italics,'><a href=,'#LINK_0c14fa58-5cb0-4d16-ac5c-07dd6a3d32db,'>PRECAUTIONS (5.7)</a></span></span><span class=,'Italics,'>]</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Monitor sedation and blood pressure. Adjust dose accordingly.</p>
</td>
</tr>
</tbody>
</table></div>
<br/>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_c92e500e-a550-4601-b516-666177f3841e,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Drugs Having No Clinically Important Interactions with Aripiprazole</h2>
<p class=,'First,'>Based on pharmacokinetic studies, no dosage adjustment of aripiprazole is required when administered concomitantly with famotidine, valproate, lithium, lorazepam.</p>
<p>In addition, no dosage adjustment is necessary for substrates of CYP2D6 (e.g., dextromethorphan, fluoxetine, paroxetine, or venlafaxine), CYP2C9 (e.g., warfarin), CYP2C19 (e.g., omeprazole, warfarin, escitalopram), or CYP3A4 (e.g., dextromethorphan) when co-administered with aripiprazole. Additionally, no dosage adjustment is necessary for valproate, lithium, lamotrigine, lorazepam, or sertraline when co-administered with aripiprazole. <span class=,'Italics,'>[see </span><span class=,'Italics,'><span class=,'Italics,'><a href=,'#LINK_695fc817-660b-489c-a414-c05d073bd7f3,'>CLINICAL </a></span><span class=,'Italics,'><a href=,'#LINK_695fc817-660b-489c-a414-c05d073bd7f3,'>PHARMACOLOGY (12.3)</a></span></span><span class=,'Italics,'>]</span>.</p>
</div>
</div>"
"arsenic trioxide","2b2a7ed9-5ed3-42fc-b19b-d50700396233","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'s31,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s32,'></a><a name=,'section-7.1,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Drugs That Can Prolong the QT/QTc Interval</span>
</p>
<p>Concomitant use of these drugs and Arsenic Trioxide Injection may increase the risk of serious QT/QTc interval prolongation. Discontinue or replace with an alternative drug that does not prolong the QT/QTc interval while patient is using Arsenic Trioxide Injection. Monitor ECGs more frequently in patients when it is not feasible to avoid concomitant use.
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s33,'></a><a name=,'section-7.2,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Drugs That Can Lead to Electrolyte Abnormalities</span>
</p>
<p>Electrolyte abnormalities increase the risk of serious QT/QTc interval prolongation. Avoid concomitant administration of drugs that can lead to electrolyte abnormalities. Monitor electrolytes more frequently in patients who must receive concomitant use of these drugs and Arsenic Trioxide Injection.
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s34,'></a><a name=,'section-7.3,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Drugs That Can Lead to Hepatotoxicity</span>
</p>
<p>Concomitant use of these drugs and Arsenic Trioxide Injection, particularly when given in combination with tretinoin, may increase the risk of serious hepatotoxicity. Discontinue or replace with an alternative drug that does not cause hepatotoxicity while the patient is using Arsenic Trioxide Injection. Monitor liver function tests more frequently in patients when it is not feasible to avoid concomitant use.
</p>
</div>
</div>"
"artemether","66e02264-6917-4185-9c36-9dc64eaaeb23","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'s7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7p1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1     Rifampin</h2>
<p class=,'First,'>Oral administration of rifampin, a strong CYP3A4 inducer, with Coartem Tablets resulted in significant decreases in exposure to artemether, dihydroartemisinin (DHA, metabolite of artemether) and lumefantrine by 89%, 85% and 68%, respectively, when compared to exposure values after Coartem Tablets alone. Concomitant use of strong inducers of CYP3A4 such as rifampin, carbamazepine, phenytoin, and St. John's wort is contraindicated with Coartem Tablets <span class=,'Italics,'>[see Contraindications (4)</span> and <span class=,'Italics,'>Clinical Pharmacology (12.3)]</span>. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7p2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2     Ketoconazole</h2>
<p class=,'First,'>Concurrent oral administration of ketoconazole, a potent CYP3A4 inhibitor, with a single dose of Coartem Tablets resulted in a moderate increase in exposure to artemether, DHA, and lumefantrine in a study of 15 healthy subjects. No dose adjustment of Coartem Tablets is necessary when administered with ketoconazole or other potent CYP3A4 inhibitors. However, due to the potential for increased concentrations of lumefantrine which could lead to QT prolongation, Coartem Tablets should be used cautiously with drugs that inhibit CYP3A4 <span class=,'Italics,'>[see Warnings and Precautions (5.1, 5.3)</span> and <span class=,'Italics,'>Clinical Pharmacology (12.3)]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7p3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3     Antiretroviral Drugs</h2>
<p class=,'First,'>Both artemether and lumefantrine are metabolized by CYP3A4. Antiretroviral drugs, such as protease inhibitors and non-nucleoside reverse transcriptase inhibitors, are known to have variable patterns of inhibition, induction or competition for CYP3A4. Therefore, the effects of antiretroviral drugs on the exposure to artemether, DHA, and lumefantrine are also variable <span class=,'Italics,'>[see Clinical Pharmacology (12.3)]</span>. Coartem Tablets should be used cautiously in patients on antiretroviral drugs because decreased artemether, DHA, and/or lumefantrine concentrations may result in a decrease of antimalarial efficacy of Coartem Tablets, and increased lumefantrine concentrations may cause QT prolongation <span class=,'Italics,'>[see Warnings and Precautions (5.3)]</span>. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7p4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4     Prior Use of Mefloquine</h2>
<p class=,'First,'>Administration of 3 doses of mefloquine followed 12 hours later by a 6-dose regimen of Coartem Tablets in 14 healthy volunteers demonstrated no effect of mefloquine on plasma concentrations of artemether or the artemether/DHA ratio. However, exposure to lumefantrine was reduced, possibly due to lower absorption secondary to a mefloquine-induced decrease in bile production. Patients should be monitored for decreased efficacy and food consumption should be encouraged with administration of Coartem Tablets <span class=,'Italics,'>[see Warnings and Precautions (5.2) </span>and<span class=,'Italics,'> Clinical Pharmacology (12.3)]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7p5,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5     Hormonal Contraceptives </h2>
<p class=,'First,'>In vitro, the metabolism of ethinyl estradiol and levonorgestrel was not induced by artemether, DHA, or lumefantrine. However, artemether has been reported to weakly induce, in humans, the activity of CYP2C19, CYP2B6, and CYP3A. Therefore, Coartem Tablets may potentially reduce the effectiveness of hormonal contraceptives. Patients using oral, transdermal patch, or other systemic hormonal contraceptives should be advised to use an additional non-hormonal method of birth control <span class=,'Italics,'>[see Warnings and Precautions (5.3)</span> and <span class=,'Italics,'>Clinical Pharmacology (12.3)]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7p6,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6     CYP2D6 Substrates</h2>
<p class=,'First,'>Lumefantrine inhibits CYP2D6 in vitro. Administration of Coartem Tablets with drugs that are metabolized by CYP2D6 may significantly increase plasma concentrations of the coadministered drug and increase the risk of adverse effects. Many of the drugs metabolized by CYP2D6 can prolong the QT interval and should not be administered with Coartem Tablets due to the potential additive effect on the QT interval (e.g., flecainide, imipramine, amitriptyline, clomipramine) <span class=,'Italics,'>[see Warnings and Precautions (5.1, 5.4)</span> and <span class=,'Italics,'>Clinical Pharmacology (12.3)]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7p7,'></a><a name=,'section-7.7,'></a>
<p></p>
<h2>7.7     Sequential Use of Quinine</h2>
<p class=,'First,'>A single dose of intravenous quinine (10 mg/kg bodyweight) concurrent with the final dose of a 6-dose regimen of Coartem Tablets demonstrated no effect of intravenous quinine on the systemic exposure of DHA or lumefantrine. Quinine exposure was also not altered. Exposure to artemether was decreased. This decrease in artemether exposure is not thought to be clinically significant.  However, quinine and other drugs that prolong the QT interval should be used cautiously following treatment with Coartem Tablets due to the long elimination half-life of lumefantrine and the potential for additive QT effects; ECG monitoring is advised if use of drugs that prolong the QT interval is medically required <span class=,'Italics,'>[see Warnings and Precautions (5.2) </span>and<span class=,'Italics,'> Clinical Pharmacology (12.3)]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7p8,'></a><a name=,'section-7.8,'></a>
<p></p>
<h2>7.8     Interaction with Drugs that are Known to Prolong the QT Interval</h2>
<p class=,'First,'>Coartem Tablets are to be used with caution when coadministered with drugs that may cause prolonged QT interval such as antiarrhythmics of classes IA and III, neuroleptics and antidepressant agents, certain antibiotics including some agents of the following classes: macrolides, fluoroquinolones, imidazole, and triazole antifungal agents <span class=,'Italics,'>[see Warnings and Precautions (5.1, 5.2)]</span>.</p>
</div>
</div>"
"artesunate","fe6d4a9e-4478-4603-8bcb-461191ca175b","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID_7d7e96d2-81f1-44c8-98a9-4bdf49ed994d,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_772f3228-cd3d-4efd-9791-bbf5c882ab74,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Effect of Other Drugs on Artesunate and Dihydroartemisinin (DHA) </h2>
<p class=,'First,'>
<span class=,'Underline,'>Ritonavir, Nevirapine or Strong UDP-Glucuronosyltransferase (UGT) Inducers</span>:</p>
<p>Published clinical reports or <span class=,'Italics,'>in vitro</span> reports indicate that concomitant use of Artesunate for Injection with oral ritonavir, nevirapine, or UGT inducers may decrease dihydroartemisinin (DHA) AUC and C<span class=,'Sub,'>max</span><span class=,'Italics,'> [see Clinical Pharmacology (<a href=,'#ID_daede854-31bd-4e44-bb45-c007bcede113,'>12.3</a>)]</span>, which may reduce the efficacy of Artesunate for Injection. If Artesunate for Injection is co-administered with ritonavir, nevirapine or strong UGT inducers (e.g., rifampin, carbamazepine, phenytoin), monitor for possible reduced antimalarial efficacy of Artesunate for Injection. </p>
<p>
<span class=,'Underline,'>Strong UGT Inhibitors</span>
</p>
<p>Published reports of in vitro data indicate that concomitant use of Artesunate for Injection with UGT inhibitors may increase DHA AUC and C<span class=,'Sub,'>max</span><span class=,'Italics,'> [see Clinical Pharmacology (<a href=,'#ID_daede854-31bd-4e44-bb45-c007bcede113,'>12.3</a>)]</span>, which may increase DHA associated adverse reactions. Monitor for adverse reactions when co-administering Artesunate for Injection with strong UGT inhibitors (e.g., axitinib, vandetanib, imatinib, diclofenac).</p>
</div>
</div>"
"ascorbic acid","1ac7a17e-75d0-4444-e054-00144ff88e88","none found"
"atenolol","00478eeb-f1c8-4355-a7c3-81c340b557d8","none found"
"atezolizumab","6fa682c9-a312-4932-9831-f286908660ee","none found"
"atomoxetine","0ab8d905-e890-4e91-a730-3e5d12f5c23f","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'s53,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s54,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Monoamine Oxidase Inhibitors </h2>
<dl>
<dt> </dt>
<dd>With other drugs that affect brain monoamine concentrations, there have been reports of serious, sometimes fatal reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) when taken in combination with an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Such reactions may occur when these drugs are given concurrently or in close proximity <span class=,'Italics,'>[see Contraindications (<a href=,'#s19,'>4.2</a>)]</span>.</dd>
</dl>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s55,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Effect of CYP2D6 Inhibitors on Atomoxetine </h2>
<dl>
<dt> </dt>
<dd>In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs). In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and C<span class=,'Sub,'>ss</span>, <span class=,'Sub,'>max</span> is about 3- to 4-fold greater than atomoxetine alone. </dd>
<dt> </dt>
<dd>In vitro studies suggest that coadministration of cytochrome P450 inhibitors to PMs will not increase the plasma concentrations of atomoxetine. </dd>
</dl>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s56,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Antihypertensive Drugs and Pressor Agents </h2>
<dl>
<dt> </dt>
<dd>Because of possible effects on blood pressure, Atomoxetine should be used cautiously with antihypertensive drugs and pressor agents (e.g., dopamine, dobutamine) or other drugs that increase blood pressure. </dd>
</dl>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s57,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Albuterol </h2>
<dl>
<dt> </dt>
<dd>Atomoxetine should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta<span class=,'Sub,'>2</span> agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure. Albuterol (600 mcg iv over 2 hours) induced increases in heart rate and blood pressure. These effects were potentiated by atomoxetine (60 mg BID for 5 days) and were most marked after the initial coadministration of albuterol and atomoxetine. However, these effects on heart rate and blood pressure were not seen in another study after the coadministration with inhaled dose of albuterol (200 to 800 mcg) and atomoxetine (80 mg QD for 5 days) in 21 healthy Asian subjects who were excluded for poor metabolizer status. </dd>
</dl>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s58,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Effect of Atomoxetine on P450 Enzymes </h2>
<dl>
<dt> </dt>
<dd>Atomoxetine did not cause clinically important inhibition or induction of cytochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9. </dd>
</dl>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s59,'></a><a name=,'section-7.5.1,'></a>
<p></p>
<dl>
<dt> </dt>
<dd>
<span class=,'Underline,'>CYP3A Substrate (e.g., Midazolam)</span> — Coadministration of atomoxetine (60 mg BID for 12 days) with midazolam, a model compound for CYP3A4 metabolized drugs (single dose of 5 mg), resulted in 15% increase in AUC of midazolam. No dose adjustment is recommended for drugs metabolized by CYP3A. </dd>
</dl>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s60,'></a><a name=,'section-7.5.2,'></a>
<p></p>
<dl>
<dt> </dt>
<dd>
<span class=,'Underline,'>CYP2D6 Substrate (e.g., Desipramine)</span> — Coadministration of atomoxetine (40 or 60 mg BID for 13 days) with desipramine, a model compound for CYP2D6 metabolized drugs (single dose of 50 mg), did not alter the pharmacokinetics of desipramine. No dose adjustment is recommended for drugs metabolized by CYP2D6. </dd>
</dl>
</div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s61,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6 Alcohol </h2>
<dl>
<dt> </dt>
<dd>Consumption of ethanol with atomoxetine did not change the intoxicating effects of ethanol. </dd>
</dl>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s62,'></a><a name=,'section-7.7,'></a>
<p></p>
<h2>7.7 Methylphenidate </h2>
<dl>
<dt> </dt>
<dd>Coadministration of methylphenidate with atomoxetine did not increase cardiovascular effects beyond those seen with methylphenidate alone. </dd>
</dl>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s63,'></a><a name=,'section-7.8,'></a>
<p></p>
<h2>7.8 Drugs Highly Bound to Plasma Protein </h2>
<dl>
<dt> </dt>
<dd>In vitro drug-displacement studies were conducted with atomoxetine and other highly-bound drugs at therapeutic concentrations. Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin. Similarly, these compounds did not affect the binding of atomoxetine to human albumin. </dd>
</dl>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s64,'></a><a name=,'section-7.9,'></a>
<p></p>
<h2>7.9 Drugs that Affect Gastric pH </h2>
<dl>
<dt> </dt>
<dd>Drugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) had no effect on atomoxetine bioavailability. </dd>
</dl>
</div>
</div>"
"atorvastatin","17335bb3-6a0b-492e-9960-d01996b705c9","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID62,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,'>
<a name=,'ID65,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Drug Interactions that may Increase the
Risk of Myopathy and Rhabdomyolysis
with Atorvastatin Calcium</h2>
<p class=,'First,'>
<a name=,'ID66,'></a>Atorvastatin calcium is a substrate of CYP3A4 and transporters (e.g., OATP1B1/1B3, P-gp, or BCRP). Atorvastatin calcium plasma levels can be significantly increased with concomitant administration of inhibitors of CYP3A4 and transporters. Table 3 includes a list of drugs that may increase exposure to atorvastatin calcium and may increase the risk of myopathy and rhabdomyolysis when used concomitantly and instructions for preventing or managing them <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#ID39,'>5.1</a>) and Clinical Pharmacology (<a href=,'#ID111,'>12.3</a>)].</span>
</p>
<a name=,'ID265,'></a>
<div class=,'scrollingtable,'><table class=,'Noautorules,' width=,'100%,'>
<caption>
<span>  Table 3 Drug Interactions that may Increase the Risk of Myopathy and Rhabdomyolysis with Atorvastatin Calcium </span>
</caption>
<col width=,'16%,'/>
<col width=,'83%,'/>
<tbody class=,'Headless,'>
<tr>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,'><span class=,'Bold,'> Cyclosporine or Gemfibrozil </span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule,'><span class=,'Italics,'>Clinical Impact: </span>
<br/>
</td><td align=,'left,' class=,'Botrule Rrule,' valign=,'top,'> Atorvastatin plasma levels were significantly increased with concomitant administration of atorvastatin calcium and cyclosporine, an inhibitor of CYP3A4 and OATP1B1 <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#ID111,'>12.3</a>)]. </span> Gemfibrozil may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of cyclosporine or gemfibrozil with atorvastatin calcium. <br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule,'><span class=,'Italics,'>Intervention: </span>
<br/>
</td><td align=,'left,' class=,'Botrule Rrule,'> Concomitant use of cyclosporine or gemfibrozil with atorvastatin calcium is not recommended. <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'> Anti-Viral Medications </span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Clinical Impact: </span>
<br/>
</td><td align=,'left,' class=,'Botrule Rrule,' valign=,'top,'> Atorvastatin plasma levels were significantly increased with concomitant administration of atorvastatin calcium with many anti-viral medications, which are inhibitors of CYP3A4 and/or transporters (e.g., BCRP, OATP1B1/1B3, P-gp, MRP2, and/or OAT2) <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#ID111,'>12.3</a>)]. </span> Cases of myopathy and rhabdomyolysis have been reported with concomitant use of ledipasvir plus sofosbuvir with atorvastatin calcium. <br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Intervention: </span>
<br/>
</td><td align=,'left,' class=,'Botrule Rrule,' valign=,'top,'>          Concomitant use of tipranavir plus ritonavir or glecaprevir plus pibrentasvir with atorvastatin calcium is not recommended. <br/>          In patients taking lopinavir plus ritonavir, or simeprevir, consider the risk/benefit of concomitant use with atorvastatin. <br/>          In patients taking saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir, elbasvir plus grazoprevir or letermovir, do not exceed atorvastatin calcium 20 mg. <br/>          In patients taking nelfinavir, do not exceed atorvastatin calcium 40 mg <span class=,'Italics,'>[see Dosage and Administration (<a href=,'#ID26,'>2.6</a>)].</span>
<br/>          Consider the risk/benefit of concomitant use of ledipasvir plus sofosbuvir with atorvastatin calcium. <br/>          Monitor all patients for signs and symptoms of myopathy particularly during initiation of therapy and during upward dose titration of either drug.<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Examples: </span>
<br/>
</td><td align=,'left,' class=,'Botrule Rrule,' valign=,'top,'> Tipranavir plus ritonavir, glecaprevir plus pibrentasvir, lopinavir plus ritonavir, simeprevir, saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir, elbasvir plus grazoprevir, letermovir, nelfinavir, and ledipasvir plus sofosbuvir. <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'> Select Azole Antifungals or Macrolide Antibiotics </span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule,'><span class=,'Italics,'>Clinical Impact: </span>
<br/>
</td><td align=,'left,' class=,'Botrule Rrule,' valign=,'top,'> Atorvastatin plasma levels were significantly increased with concomitant administration of atorvastatin calcium with select azole antifungals or macrolide antibiotics, due to inhibition of CYP3A4 and/or transporters <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#ID111,'>12.3</a>)]. </span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule,'><span class=,'Italics,'>Intervention: </span>
<br/>
</td><td align=,'left,' class=,'Botrule Rrule,' valign=,'top,'> In patients taking clarithromycin or itraconazole, do not exceed atorvastatin calcium 20 mg <span class=,'Italics,'>[see Dosage and Administration (2.6)]. </span> Consider the risk/benefit of concomitant use of other azole antifungals or macrolide antibiotics with atorvastatin calcium. Monitor all patients for signs and symptoms of myopathy particularly during initiation of therapy and during upward dose titration of either drug. <br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule,'><span class=,'Italics,'>Examples: </span>
<br/>
</td><td align=,'left,' class=,'Botrule Rrule,'> Erythromycin, clarithromycin, itraconazole, ketoconazole, posaconazole, and voriconazole. <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'> Niacin </span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule,'><span class=,'Italics,'>Clinical Impact: </span>
<br/>
</td><td align=,'left,' class=,'Botrule Rrule,' valign=,'top,'> Cases of myopathy and rhabdomyolysis have been observed with concomitant use of lipid modifying dosages of niacin (&gt;1 gram/day niacin) with atorvastatin calcium. <br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule,'><span class=,'Italics,'>Intervention: </span>
<br/>
</td><td align=,'left,' class=,'Botrule Rrule,' valign=,'top,'> Consider if the benefit of using lipid modifying dosages of niacin concomitantly with atorvastatin calcium outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy particularly during initiation of therapy and during upward dose titration of either drug. <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'> Fibrates (other than Gemfibrozil) </span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule,'><span class=,'Italics,'>Clinical Impact: </span>
<br/>
</td><td align=,'left,' class=,'Botrule Rrule,' valign=,'top,'> Fibrates may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of fibrates with atorvastatin calcium. <br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule,'><span class=,'Italics,'>Intervention: </span>
<br/>
</td><td align=,'left,' class=,'Botrule Rrule,' valign=,'top,'> Consider if the benefit of using fibrates concomitantly with atorvastatin calcium outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy particularly during initiation of therapy and during upward dose titration of either drug. <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'> Colchicine </span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule,'><span class=,'Italics,'>Clinical Impact: </span>
<br/>
</td><td align=,'left,' class=,'Botrule Rrule,' valign=,'top,'> Cases of myopathy and rhabdomyolysis have been reported with concomitant use of colchicine with atorvastatin calcium. <br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule,'><span class=,'Italics,'>Intervention: </span>
<br/>
</td><td align=,'left,' class=,'Botrule Rrule,' valign=,'top,'> Consider the risk/benefit of concomitant use of colchicine with atorvastatin calcium. If concomitant use is decided, monitor patients for signs and symptoms of myopathy particularly during initiation of therapy and during upward dose titration of either drug. <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'> Grapefruit Juice</span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule,'><span class=,'Italics,'>Clinical Impact: </span>
<br/>
</td><td align=,'left,' class=,'Botrule Rrule,' valign=,'top,'> Grapefruit juice consumption, especially excessive consumption, more than 1.2 liters/daily, can raise the plasma levels of atorvastatin and may increase the risk of myopathy and rhabdomyolysis. <br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule,'><span class=,'Italics,'>Intervention: </span>
<br/>
</td><td align=,'left,' class=,'Botrule Rrule,' valign=,'top,'> Avoid intake of large quantities of grapefruit juice, more than 1.2 liters daily, when taking atorvastatin calcium. <br/>
</td>
</tr>
</tbody>
</table></div>
</div>
<div class=,'Section,'>
<a name=,'ID67,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Drug Interactions that may Decrease
Exposure to Atorvastatin Calcium</h2>
<p class=,'First,'>
<a name=,'ID68,'></a>Table 4 presents drug interactions that may decrease exposure to atorvastatin calcium and instructions for preventing or managing them.</p>
<a name=,'ID266,'></a>
<div class=,'scrollingtable,'><table class=,'Noautorules,' width=,'100%,'>
<caption>
<span>  Table 4 Drug Interactions that may Decrease Exposure to Atorvastatin Calcium </span>
</caption>
<col width=,'21%,'/>
<col width=,'78%,'/>
<tbody class=,'Headless,'>
<tr>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,'><span class=,'Bold,'> Rifampin</span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule,'><span class=,'Italics,'>Clinical Impact: </span>
<br/>
</td><td align=,'left,' class=,'Botrule Rrule,' valign=,'top,'> Concomitant administration of atorvastatin calcium with rifampin, an inducer of cytochrome P450 3A4 and inhibitor of OATP1B1, can lead to variable reductions in plasma concentrations of atorvastatin. Due to the dual interaction mechanism of rifampin, delayed administration of atorvastatin calcium after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations. <br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule,'><span class=,'Italics,'>Intervention: </span>
<br/>
</td><td align=,'left,' class=,'Botrule Rrule,'> Administer atorvastatin calcium and rifampin simultaneously. <br/>
</td>
</tr>
</tbody>
</table></div>
</div>
<div class=,'Section,'>
<a name=,'ID69,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Atorvastatin Calcium Effects on Other
Drugs</h2>
<p class=,'First,'>
<a name=,'ID70,'></a>Table 5 presents atorvastatin calcium's effect on other drugs and instructions for preventing or managing them.</p>
<a name=,'ID267,'></a>
<div class=,'scrollingtable,'><table class=,'Noautorules,' width=,'100%,'>
<caption>
<span>  Table 5 Atorvastatin Calcium Effects on Other Drugs </span>
</caption>
<col width=,'21%,'/>
<col width=,'78%,'/>
<tbody class=,'Headless,'>
<tr>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,'><span class=,'Bold,'> Oral Contraceptives</span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule,'><span class=,'Italics,'>Clinical Impact: </span>
<br/>
</td><td align=,'left,' class=,'Botrule Rrule,' valign=,'top,'> Co-administration of atorvastatin calcium and an oral contraceptive increased plasma concentrations of norethindrone and ethinyl estradiol <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#ID111,'>12.3</a>)]. </span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule,'><span class=,'Italics,'>Intervention: </span>
<br/>
</td><td align=,'left,' class=,'Botrule Rrule,'> Consider this when selecting an oral contraceptive for patients taking atorvastatin calcium. <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'> Digoxin</span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule,'><span class=,'Italics,'>Clinical Impact: </span>
<br/>
</td><td align=,'left,' class=,'Botrule Rrule,' valign=,'top,'> When multiple doses of atorvastatin calcium and digoxin were co-administered, steady state plasma digoxin concentrations increased <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#ID111,'>12.3</a>)]. </span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule,'><span class=,'Italics,'>Intervention: </span>
<br/>
</td><td align=,'left,' class=,'Botrule Rrule,'> Monitor patients taking digoxin appropriately. <br/>
</td>
</tr>
</tbody>
</table></div>
</div>
</div>"
"atracurium","5562756e-7475-2d4c-696e-757834416c6c","none found"
"atropine","4f1bbc1d-9585-20b2-e054-00144ff88e88","none found"
"azathioprine","00e3b33f-2ee1-4cb4-8082-3d119754dbe3","none found"
"azilsartan","52b27c75-9f5a-4816-bafd-dace9d7d2063","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1	Non-steroidal Anti-Inflammatory Agents, including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)</h2>
<p class=,'First,'>In patients who are elderly, volume-depleted (including those on diuretic therapy), or who have compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including azilsartan, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving azilsartan and NSAID therapy.</p>
<p>The antihypertensive effect of angiotensin II receptor antagonists, including azilsartan, may be attenuated by NSAIDs, including selective COX-2 inhibitors.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2	Dual Blockade of the Renin-Angiotensin System (RAS)</h2>
<p class=,'First,'>Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on Edarbi and other agents that affect the RAS.</p>
<p>Do not coadminister aliskiren with Edarbi in patients with diabetes. Avoid use of aliskiren with Edarbi in patients with renal impairment (GFR &lt;60 mL/min).</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3	Lithium</h2>
<p class=,'First,'>Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor agonists. Monitor serum lithium levels during concomitant use.</p>
</div>
</div>"
"azithromycin","53e2801a-323d-448e-8278-92d672904b0f","none found"
"aztreonam","67300ca3-8c53-4ce4-8e86-2c03be1f9b8a","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-8,'></a>
<p></p>
<p class=,'First,'>No formal clinical studies of drug interactions with CAYSTON have been conducted.</p>
</div>"
"baclofen","0308ca55-2461-4500-8e35-1d26282d3679","none found"
"barium sulfate","c759668b-5cf1-b237-00c8-a5e4733b6f4c","none found"
"beclomethasone","f85ef4d3-d8a6-43c8-90fa-85f5ba5429e3","none found"
"bedaquiline","1534c9ae-4948-4cf4-9f66-222a99db6d0e","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1	CYP3A4 Inducers/Inhibitors</h2>
<p class=,'First,'>Bedaquiline exposure may be reduced during co-administration with inducers of CYP3A4 and increased during co-administration with inhibitors of CYP3A4.</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1.1,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Underline,'>CYP3A4 Inducers</span>
</p>
<p>Due to the possibility of a reduction of the therapeutic effect of bedaquiline because of the decrease in systemic exposure, co-administration of strong CYP3A4 inducers, such as rifamycins (i.e., rifampin, rifapentine and rifabutin), or moderate CYP3A4 inducers should be avoided during treatment with SIRTURO <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1.2,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Underline,'>CYP3A4 inhibitors</span>
</p>
<p>Due to the potential risk of adverse reactions to bedaquiline because of the increase in systemic exposure, prolonged co-administration of bedaquiline and strong CYP3A4 inhibitors, such as ketoconazole or itraconazole, for more than 14 consecutive days should be avoided unless the benefit outweighs the risk <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>. Appropriate clinical monitoring for SIRTURO-related adverse reactions is recommended.</p>
</div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2	Other Antimicrobial Medications</h2>
<p class=,'First,'>No dose-adjustment of isoniazid or pyrazinamide is required during co-administration with SIRTURO.</p>
<p>In a placebo-controlled clinical trial in adult patients with MDR-TB, no major impact of co-administration of SIRTURO on the pharmacokinetics of ethambutol, kanamycin, pyrazinamide, ofloxacin or cycloserine was observed.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3	Antiretroviral Medications</h2>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.3.1,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Underline,'>Lopinavir/ritonavir</span>
</p>
<p>Although clinical data in HIV/MDR-TB co-infected patients on the combined use of lopinavir (400 mg)/ritonavir (100 mg) with SIRTURO are not available, use SIRTURO with caution when co-administered with lopinavir/ritonavir and only if the benefit outweighs the risk <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.3.2,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Underline,'>Nevirapine</span>
</p>
<p>No dosage adjustment of bedaquiline is required when co-administered with nevirapine <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.3.3,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Underline,'>Efavirenz</span>
</p>
<p>Concomitant administration of bedaquiline and efavirenz, or other moderate CYP3A inducers, should be avoided <span class=,'Italics,'>[see <a href=,'#S5.5,'>Warnings and Precautions (5.5)</a>]</span>.</p>
</div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4	QT Interval Prolonging Drugs</h2>
<p class=,'First,'>In a drug interaction study of bedaquiline and ketoconazole in adults, a greater effect on QTc was observed after repeated dosing with bedaquiline and ketoconazole in combination than after repeated dosing with the individual drugs. Additive or synergistic QT prolongation was observed when bedaquiline was co-administered with other drugs that prolong the QT interval.</p>
<p>In Study 3, mean increases in QTc were larger in the 17 adult patients who were taking clofazimine with bedaquiline at Week 24 (mean change from reference of 31.9 ms) than in patients who were not taking clofazimine with bedaquiline at Week 24 (mean change from baseline of 12.3 ms). Monitor ECGs if SIRTURO is co-administered to patients receiving other drugs that prolong the QTc interval, and discontinue SIRTURO if evidence of serious ventricular arrhythmia or QTcF interval greater than 500 ms. <span class=,'Italics,'>[see <a href=,'#S5.2,'>Warnings and Precautions (5.2)</a> and <a href=,'#S12.2,'>Clinical Pharmacology (12.2)</a>]</span>.</p>
</div>
</div>"
"bendamustine","9759a4ae-82ca-40cf-9c02-e1cadb21cbdc","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'s_0700,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s_0701,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Effect of Other Drugs on BELRAPZO </h2>
<p class=,'First,'>
<span class=,'Underline,'>CYP1A2 Inhibitors</span>
<br/>The coadministration of BELRAPZO with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with BELRAPZO <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#s_1203,'>12.3</a>)]</span>. Consider alternative therapies that are not CYP1A2 inhibitors during treatment with BELRAPZO.</p>
<p>
<span class=,'Underline,'>CYP1A2 Inducers</span>
<br/>The coadministration of BELRAPZO with CYP1A2 inducers may decrease bendamustine
									plasma concentrations and may result in decreased efficacy of BELRAPZO <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#s_1203,'>12.3</a>)]</span>. Consider alternative therapies that are not CYP1A2 inducers during treatment with BELRAPZO.
								</p>
</div>
</div>"
"bendroflumethiazide","d2d226ea-1624-47ee-82bf-e9660b75029f","none found"
"penicillin G benzathine","012d46f1-d0a0-4676-a879-cd320297ab16","none found"
"benznidazole","8983d6a0-f63f-4f8e-bba4-38223f39e29b","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID_596e9297-dc2f-4e5c-9e5b-684c601bdf89,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_73bdb390-3c5e-4972-bf62-b1f203157e7f,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Disulfiram </h2>
<p class=,'First,'>Psychotic reactions have been reported in patients who are concurrently taking disulfiram and nitroimidazole agents (structurally related to benznidazole, but not with benznidazole). Benznidazole Tablets should not be given to patients who have taken disulfiram within the last two weeks 
         
 
  <span class=,'Italics,'>[see Contraindications (
          
  
   <a href=,'#ID_d17b43de-9522-4207-8b30-ddeb5a791dec,'>4.2</a>)]
         
 
  </span>.
        

 </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_90144484-f177-4449-bbb9-f947caf062e7,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Alcohol and Products Containing Propylene Glycol </h2>
<p class=,'First,'>
<span class=,'Italics,'>In</span><span class=,'Italics,'> vitro</span> studies showed that benznidazole, at concentrations from 0.03 μM to 100 μM, does not inhibit the enzymatic activity of human alcohol dehydrogenase (ALDH). Benznidazole Tablets are not expected to cause alcohol aversion or a disulfiram-like reaction as a result of ethanol ingestion.
        

 </p>
</div>
</div>"
"benzyl benzoate","015fafb6-23f7-4566-9c23-386eee7b035d","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'s32,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>There are no known drug-drug interactions. Although, fulvestrant is metabolized by CYP 3A4 <span class=,'Italics,'>in vitro</span>, drug interactions studies with ketoconazole or rifampin did not alter fulvestrant pharmacokinetics. Dose adjustment is not needed in patients co-prescribed CYP 3A4 inhibitors or inducers <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#s56,'>12.3</a>)]</span>.
</p>
</div>"
"penicillin G","07fe2b47-34ac-4a20-be67-3c788c77b207","none found"
"betamethasone","02db1402-701c-483c-bfd6-8b7a543ae8ef","none found"
"betaxolol","4aa6e51b-80a3-4022-87e2-0692f24ae9ca","none found"
"bevacizumab","939b5d1f-9fb2-4499-80ef-0607aa6b114e","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Underline,'>Effects of Avastin on Other Drugs</span>
</p>
<p>No clinically meaningful effect on the pharmacokinetics of irinotecan or its active metabolite SN38, interferon alfa, carboplatin or paclitaxel was observed when Avastin was administered in combination with these drugs; however, 3 of the 8 patients receiving Avastin with paclitaxel and carboplatin had lower paclitaxel exposure after four cycles of treatment (at Day 63) than those at Day 0, while patients receiving paclitaxel and carboplatin alone had a greater paclitaxel exposure at Day 63 than at Day 0.</p>
</div>
</div>"
"bicalutamide","6d27f9b0-6b93-42fa-807e-fc819c0da14f","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'williamsonbk1285098148271,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Clinical studies have not shown any drug interactions between bicalutamide and LHRH analogs (goserelin or leuprolide).  There is no evidence that bicalutamide induces hepatic enzymes. </p>
<p>
<span class=,'Italics,'>In vitro</span> studies have shown that R-bicalutamide is an inhibitor of CYP 3A4 with lesser inhibitory effects on CYP 2C9, 2C19 and 2D6 activity. Clinical studies have shown that with co-administration of bicalutamide, mean midazolam (a CYP 3A4 substrate) levels may be increased 1.5-fold (for C
       
 
  
       
 
  <span class=,'Sub,'>max</span>) and 1.9-fold (for AUC).  Hence, caution should be exercised when bicalutamide is co-administered with CYP 3A4 substrates.
      

 
      

 
      

 
      

 </p>
<p>
<span class=,'Italics,'>In vitro</span> protein-binding studies have shown that bicalutamide can displace coumarin anticoagulants from binding sites. PT/INR should be closely monitored in patients concomitantly receiving coumarin anticoagulants and bicalutamide. Adjustment of the anticoagulant dose may be necessary.
					 
       
 
  <span class=,'Italics,'>[see 
        
  
   <a href=,'#Section_5.2,'>Warnings and Precautions (5.2)</a> and 
        
  
   <a href=,'#williamsonbk1285098002847,'>Adverse reaction (6.2)</a> ]
       
 
  </span>
</p>
</div>"
"bisoprolol","428ef54d-8828-4756-a087-a1b7b2d6b8d6","none found"
"bleomycin","497e462a-a295-4db1-9002-d2633efbd676","none found"
"bortezomib","042329d6-8077-4af2-816f-cd0a2bbcbbd3","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'s47,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s48,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Effect of Strong CYP3A4 Inhibitors on Bortezomib
</h2>
<p class=,'First,'>Monitor patients for signs of bortezomib toxicity and consider a Bortezomib for Injection dose reduction if Bortezomib for Injection must be given with strong CYP3A4 inhibitors.
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s49,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.3 Effect of Strong CYP3A4 Inducers on Bortezomib
</h2>
<p class=,'First,'>Avoid strong CYP3A4 inducers. The coadministration of a strong CYP3A4 inducer is expected to decrease the exposure of Bortezomib for Injection. Efficacy may be reduced when Bortezomib for Injection is coadministered with strong CYP3A4 inducers. 
</p>
<p>Avoid St. John's Wort (
         
 
  <span class=,'Italics,'>Hypericum perforatum</span>), as it may decrease Bortezomib exposure unpredictably.

        

 </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s50,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.4  Effect of Dexamethasone on Bortezomib
</h2>
<p class=,'First,'>The coadministration of dexamethasone had no effect on bortezomib  exposure.
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s51,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.5 Effect of Melphalan-Prednisone on Bortezomib
</h2>
<p class=,'First,'>The coadministration of melphalan-prednisone had no clinically important effect on bortezomib exposure.
</p>
</div>
</div>"
"bosutinib","adc84ad5-a04d-4fee-9ba8-91f7abd928e3","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Effect of Other Drugs on BOSULIF</h2>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1.1,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Strong or Moderate CYP3A Inhibitors</span>
</p>
<p>Concomitant use with a strong or moderate CYP3A inhibitor increased bosutinib C<span class=,'Sub,'>max</span> and AUC compared to BOSULIF alone <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span> which may increase the risk of toxicities. Avoid the concomitant use of strong or moderate CYP3A inhibitors with BOSULIF.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1.2,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Strong CYP3A Inducers</span>
</p>
<p>Concomitant use with a strong CYP3A inducer decreased bosutinib C<span class=,'Sub,'>max</span> and AUC compared to BOSULIF alone <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span> which may reduce BOSULIF efficacy. Avoid the concomitant use of strong CYP3A inducers with BOSULIF<span class=,'Italics,'>.</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1.3,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Proton Pump Inhibitors (PPI)</span>
</p>
<p>Concomitant use with a PPI decreased bosutinib C<span class=,'Sub,'>max</span> and AUC compared to BOSULIF alone <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span> which may reduce BOSULIF efficacy. As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing.</p>
</div>
</div>
</div>"
"brexpiprazole","2d301358-6291-4ec1-bd87-37b4ad9bd850","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Drugs Having Clinically Important Interactions with REXULTI</h2>
<div class=,'scrollingtable,'><table width=,'75%,'>
<caption>
<span>Table 10: Clinically Important Drug Interactions with REXULTI</span>
</caption>
<col align=,'left,' valign=,'middle,' width=,'20%,'/>
<col align=,'left,' valign=,'top,' width=,'80%,'/>
<tfoot>
<tr>
<td align=,'left,' colspan=,'2,'>
<dl class=,'Footnote,'>
<dt>
<a href=,'#footnote-reference-9,' name=,'footnote-9,'>*</a>
</dt>
<dd>In the clinical trials examining the adjunctive use of REXULTI in the treatment of MDD, dosage was not adjusted for strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). Thus, CYP considerations are already factored into general dosing recommendations, and REXULTI may be administered without dosage adjustment in patients with MDD.</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody class=,'Headless,'>
<tr class=,'Botrule First,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Strong CYP3A4 Inhibitors</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Clinical Impact:</span></td><td align=,'left,' class=,'Rrule,'>Concomitant use of REXULTI with strong CYP3A4 inhibitors increased the exposure of brexpiprazole compared to the use of REXULTI alone <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>].</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention:</span></td><td align=,'left,' class=,'Rrule,'>With concomitant use of REXULTI with a strong CYP3A4 inhibitor, reduce the REXULTI dosage<span class=,'Italics,'> [see <a href=,'#S2.5,'>Dosage and Administration (2.5)</a>].</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Examples:</span></td><td align=,'left,' class=,'Rrule,'>itraconazole, clarithromycin, ketoconazole</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Strong CYP2D6 Inhibitors<a class=,'Sup,' href=,'#footnote-9,' name=,'footnote-reference-9,'>*</a></span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Clinical Impact:</span></td><td align=,'left,' class=,'Rrule,'>Concomitant use of REXULTI with strong CYP2D6 inhibitors increased the exposure of brexpiprazole compared to the use of REXULTI alone <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>].</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention:</span></td><td align=,'left,' class=,'Rrule,'>With concomitant use of REXULTI with a strong CYP2D6 inhibitor, reduce the REXULTI dosage <span class=,'Italics,'>[see <a href=,'#S2.5,'>Dosage and Administration (2.5)</a>].</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Examples:</span></td><td align=,'left,' class=,'Rrule,'>paroxetine, fluoxetine, quinidine</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Both CYP3A4 Inhibitors and CYP2D6 Inhibitors</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Clinical Impact:</span></td><td align=,'left,' class=,'Rrule,'>Concomitant use of REXULTI with 1) a strong CYP3A4 inhibitor and a strong CYP2D6 inhibitor;  or 2) a moderate CYP3A4 inhibitor and a strong CYP2D6 inhibitor; or 3) a strong CYP3A4 inhibitor and a moderate CYP2D6 inhibitor; or 4) a moderate CYP3A4 inhibitor and a moderate CYP2D6 inhibitor increased the exposure of brexpiprazole compared to the use of REXULTI alone <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>].</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention:</span></td><td align=,'left,' class=,'Rrule,'>With concomitant use of REXULTI with 1) a strong CYP3A4 inhibitor and a strong CYP2D6 inhibitor;  or 2) a moderate CYP3A4 inhibitor and a strong CYP2D6 inhibitor; or 3) a strong CYP3A4 inhibitor and a moderate CYP2D6 inhibitor; or 4) a moderate CYP3A4 inhibitor and a moderate CYP2D6 inhibitor,  decrease the REXULTI dosage <span class=,'Italics,'>[see <a href=,'#S2.5,'>Dosage and Administration (2.5)</a>].</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Examples:</span></td><td align=,'left,' class=,'Rrule,'>1) itraconazole + quinidine<br/>2) fluconazole + paroxetine<br/>3) itraconazole + duloxetine<br/>4) fluconazole + duloxetine</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Strong CYP3A4 Inducers</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Clinical Impact:</span></td><td align=,'left,' class=,'Rrule,'>Concomitant use of REXULTI and a strong CYP3A4 inducer decreased the exposure of brexpiprazole compared to the use of REXULTI alone <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>].</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention:</span></td><td align=,'left,' class=,'Rrule,'>With concomitant use of REXULTI with a strong CYP3A4 inducer, increase the REXULTI dosage <span class=,'Italics,'>[see <a href=,'#S2.5,'>Dosage and Administration (2.5)</a>].</span></td>
</tr>
<tr class=,'Last,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Examples:</span></td><td align=,'left,' class=,'Rrule,'>rifampin, St. John's wort</td>
</tr>
</tbody>
</table></div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Drugs Having No Clinically Important Interactions with REXULTI</h2>
<p class=,'First,'>Based on pharmacokinetic studies, no dosage adjustment of REXULTI is required when administered concomitantly with CYP2B6 inhibitors (e.g., ticlopidine) or gastric pH modifiers (e.g., omeprazole). Additionally, no dosage adjustment for substrates of CYP2D6 (e.g., dextromethorphan), CYP3A4 (e.g., lovastatin), CYP2B6 (e.g., bupropion), BCRP (e.g., rosuvastatin), or P-gp (e.g., fexofenadine) is required when administered concomitantly with REXULTI.</p>
</div>
</div>"
"brinzolamide","ec29d07f-99ac-45ed-af0a-d9b7d1a8c032","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_07572b22-fb6f-4ed5-a2ba-398b086640f4,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_3e303994-09d1-4ce5-b1dc-535783386b9b,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Oral Carbonic Anhydrase Inhibitors</h2>
<p class=,'First,'>There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and brinzolamide ophthalmic suspension 1%. The concomitant administration of brinzolamide ophthalmic suspension 1% and oral carbonic anhydrase inhibitors is not recommended.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_2663002a-0111-4c2d-81c9-82d705b4ed9a,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 High-Dose Salicylate Therapy</h2>
<p class=,'First,'>Carbonic anhydrase inhibitors may produce acid-base and electrolyte alterations. These alterations were not reported in the clinical trials with brinzolamide. However, in patients treated with oral carbonic anhydrase inhibitors, rare instances of acid-base alterations have occurred with high-dose salicylate therapy. Therefore, the potential for such drug interactions should be considered in patients receiving brinzolamide ophthalmic suspension 1%.</p>
</div>
</div>"
"brivaracetam","3cf2f439-0e97-443e-8e33-25ecef616f6c","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1  Rifampin</h2>
<p class=,'First,'>Co-administration with rifampin decreases BRIVIACT plasma concentrations likely because of CYP2C19 induction <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>. Prescribers should increase the BRIVIACT dose by up to 100% (i.e., double the dosage) in patients while receiving concomitant treatment with rifampin <span class=,'Italics,'>[see <a href=,'#S2.6,'>Dosage and Administration (2.6)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2  Carbamazepine</h2>
<p class=,'First,'>Co-administration with carbamazepine may increase exposure to carbamazepine-epoxide, the active metabolite of carbamazepine. Though available data did not reveal any safety concerns, if tolerability issues arise when co-administered, carbamazepine dose reduction should be considered <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3  Phenytoin</h2>
<p class=,'First,'>Because BRIVIACT can increase plasma concentrations of phenytoin, phenytoin levels should be monitored in patients when concomitant BRIVIACT is added to or discontinued from ongoing phenytoin therapy <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4  Levetiracetam</h2>
<p class=,'First,'>BRIVIACT provided no added therapeutic benefit to levetiracetam when the two drugs were co-administered <span class=,'Italics,'>[see <a href=,'#S14,'>Clinical Studies (14)</a>].</span>
</p>
</div>
</div>"
"bromocriptine","0ee2da00-faf8-4c51-a696-9462fa4f6050","none found"
"budesonide","2414058b-5d39-42f2-915f-03a5e1101ab5","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_5b24b7f9-d697-4ffc-bb01-2211b499a997,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_92fb5f2b-893f-4a61-be31-d231344112cb,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Inhibitors of Cytochrome P450 3A4</h2>
<p class=,'First,'>The main route of metabolism of corticosteroids, including budesonide, is via cytochrome P450 (CYP) isoenzyme 3A4 (CYP3A4). After oral administration of ketoconazole, a strong inhibitor of CYP3A4, the mean plasma concentration of orally administered budesonide increased. Concomitant administration of a CYP3A4 inhibitor may inhibit the metabolism of, and increase the systemic exposure to, budesonide. Caution should be exercised when considering the coadministration of budesonide inhalation suspension with long-term ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) [<span class=,'Italics,'>see Warnings and Precautions (<a href=,'#LINK_043a6ce8-526f-46fe-81e2-dc222bb1d972,'>5.12</a>), Clinical Pharmacology (<a href=,'#LINK_968959ff-2ce2-4bd7-a233-8fed18f641d7,'>12.3</a>)</span>]. </p>
</div>
</div>"
"bumetanide","0103d18a-89d8-4495-8185-68e20872f224","none found"
"buprenorphine","03819118-86f6-4329-adaf-4599e7b71f46","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_50e026b9-1684-437b-be8c-b89599ae056c,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Table 3 includes clinically significant drug interactions with Buprenorphine Sublingual Tablets.</p>
<div class=,'scrollingtable,'><table border=,'1,' cellpadding=,'0,' cellspacing=,'0,' width=,'100%,'>
<caption>
<span>Table 3: Clinically Significant Drug Interactions </span>
</caption>
<col width=,'medium,'/>
<col width=,'medium,'/>
<tbody class=,'Headless,'>
<tr class=,'First,'>
<td class=,'Toprule,' colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>Benzodiazepines or other Central Nervous System (CNS) Depressants</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Due to additive pharmacologic effects, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Cessation of benzodiazepines or other CNS depressants is preferred in most cases of concomitant use. In some cases, monitoring in a higher level of care for taper may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or CNS depressant or decreasing to the lowest effective dose may be appropriate.</p>
<p> Before co-prescribing benzodiazepines for anxiety or insomnia, ensure that patients are appropriately diagnosed and consider alternative medications and non-pharmacologic treatments <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#LINK_a6a9d499-4dcd-4116-9129-9c63a23b9889,'>5.2</a>, <a href=,'#LINK_2d53727e-4644-4eda-93f3-867615545a27,'>5.3</a>)]</span>.</p>
<p>If concomitant use is warranted, strongly consider prescribing naloxone for the emergency treatment of opioid overdose, as is recommended for all patients in treatment for opioid use disorder <span class=,'Italics,'>[see Warnings and Precautions (<span class=,'Italics,'><a href=,'#LINK_2d53727e-4644-4eda-93f3-867615545a27,'>5</a></span><span class=,'Italics,'><a href=,'#LINK_2d53727e-4644-4eda-93f3-867615545a27,'>.3</a></span></span><span class=,'Italics,'>)].</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Examples:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Alcohol, non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, and other opioids.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,' colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>Inhibitors of CYP3A4</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>The concomitant use of buprenorphine and CYP3A4 inhibitors can increase the plasma concentration of buprenorphine, resulting in increased or prolonged opioid effects, particularly when an inhibitor is added after a stable dose of Buprenorphine Sublingual Tablets is achieved.</p>
<p>After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the buprenorphine plasma concentration will decrease <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#LINK_218d5389-33df-441b-825b-4f6a18634b78,'>12.3</a>)]</span>, potentially resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to buprenorphine.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>If concomitant use is necessary, consider dosage reduction of Buprenorphine Sublingual Tablets until stable drug effects are achieved. Monitor patients for respiratory depression and sedation at frequent intervals.</p>
<p>If a CYP3A4 inhibitor is discontinued, consider increasing the Buprenorphine Sublingual Tablets dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Examples:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g. ketoconazole), protease inhibitors (e.g., ritonavir)</p>
</td>
</tr>
<tr>
<td class=,'Toprule,' colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>CYP3A4 Inducers</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>The concomitant use of buprenorphine and CYP3A4 inducers can decrease the plasma concentration of buprenorphine <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#LINK_218d5389-33df-441b-825b-4f6a18634b78,'>12.3</a>)]</span>, potentially resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to buprenorphine.</p>
<p>After stopping a CYP3A4 inducer, as the effects of the inducer decline, the buprenorphine plasma concentration will increase <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#LINK_218d5389-33df-441b-825b-4f6a18634b78,'>12.3</a>)]</span>, which could increase or prolong both therapeutic effects and adverse reactions and may cause serious respiratory depression.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>If concomitant use is necessary, consider increasing the Buprenorphine Sublingual Tablets dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal.</p>
<p>If a CYP3A4 inducer is discontinued, consider Buprenorphine Sublingual Tablets dosage reduction and monitor for signs of respiratory depression.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Examples:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Rifampin, carbamazepine, phenytoin</p>
</td>
</tr>
<tr>
<td class=,'Toprule,' colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>Antiretrovirals: Non-nucleoside reverse transcriptase inhibitors (NNRTIs)</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are metabolized principally by CYP3A4. Efavirenz, nevirapine, and etravirine are known CYP3A inducers, whereas delavirdine is a CYP3A inhibitor. Significant pharmacokinetic interactions between NNRTIs (e.g., efavirenz and delavirdine) and buprenorphine have been shown in clinical studies, but these pharmacokinetic interactions did not result in any significant pharmacodynamic effects.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Patients who are on chronic Buprenorphine Sublingual Tablets treatment should have their dose monitored if NNRTIs are added to their treatment regimen.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Examples:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>efavirenz, nevirapine, etravirine, delavirdine</p>
</td>
</tr>
<tr>
<td class=,'Toprule,' colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>Antiretrovirals: Protease inhibitors (PIs)</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Studies have shown some antiretroviral protease inhibitors (PIs) with CYP3A4 inhibitory activity (nelfinavir, lopinavir/ritonavir, ritonavir) have little effect on buprenorphine pharmacokinetic and no significant pharmacodynamic effects. Other PIs with CYP3A4 inhibitory activity (atazanavir and atazanavir/ritonavir) resulted in elevated levels of buprenorphine and norbuprenorphine, and patients in one study reported increased sedation. Symptoms of opioid excess have been found in postmarketing reports of patients receiving buprenorphine and atazanavir with and without ritonavir concomitantly.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Monitor patients taking Buprenorphine Sublingual Tablets and atazanavir with and without ritonavir, and reduce dose of Buprenorphine Sublingual Tablets if warranted.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Examples:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>atazanavir, ritonavir</p>
</td>
</tr>
<tr>
<td class=,'Toprule,' colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>Antiretrovirals: Nucleoside reverse transcriptase inhibitors (NRTIs)</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Nucleoside reverse transcriptase inhibitors (NRTIs) do not appear to induce or inhibit the P450 enzyme pathway, thus no interactions with buprenorphine are expected.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>None</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Bold,'>Serotonergic Drugs</span>
</p>
</td><td class=,'Lrule Toprule,'></td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue Buprenorphine Sublingual Tablets if serotonin syndrome is suspected.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Examples:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).</p>
</td>
</tr>
<tr>
<td class=,'Toprule,' colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>Monoamine Oxidase Inhibitors (MAOIs)</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma).</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>The use of Buprenorphine Sublingual Tablets is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Examples:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>phenelzine, tranylcypromine, linezolid</p>
</td>
</tr>
<tr>
<td class=,'Toprule,' colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>Muscle Relaxants</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Buprenorphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Monitor patients receiving muscle relaxants and Buprenorphine Sublingual Tablets for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of Buprenorphine Sublingual Tablets and/or the muscle relaxant as necessary. Due to the risk of respiratory depression with concomitant use of skeletal muscle relaxants and opioids, strongly consider prescribing naloxone for the emergency treatment of opioid overdose <span class=,'Italics,'>[see Dosage and </span><span class=,'Italics,'>Administration (<a href=,'#LINK_9d039b5c-8909-455f-8f84-e77f5f2e2aba,'>2.3</a>), Warnings and Precautions (<a href=,'#LINK_a6a9d499-4dcd-4116-9129-9c63a23b9889,'>5.2</a>, <a href=,'#LINK_2d53727e-4644-4eda-93f3-867615545a27,'>5.3</a>)]</span>.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,' colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>Diuretics</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,' colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>Anticholinergic Drugs</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.</p>
</td>
</tr>
<tr class=,'Last,'>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Monitor patients for signs of urinary retention or reduced gastric motility when Buprenorphine Sublingual Tablets are used concomitantly with anticholinergic drugs.</p>
</td>
</tr>
</tbody>
</table></div>
</div>"
"cabergoline","57cbd81e-fdb9-4060-80ee-6e8581c463a4","none found"
"caffeine citrate","5d05ebf4-fd27-3bd1-5634-b41e33abc41f","none found"
"leucovorin calcium","084227c1-90eb-4653-807a-eb98cb3cefb8","none found"
"candesartan","8ceb5658-b03c-475d-9ef0-2cd0645191d3","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Agents Increasing Serum Potassium</h2>
<p class=,'First,'>Coadministration of candesartan cilexetil with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Lithium</h2>
<p class=,'First,'>Increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists, including candesartan cilexetil. Monitor serum lithium levels.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)</h2>
<p class=,'First,'>In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including candesartan, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving candesartan and NSAID therapy.</p>
<p>The antihypertensive effect of angiotensin II receptor antagonists, including candesartan may be attenuated by NSAIDs including selective COX-2 inhibitors.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Combination Blockade of the Renin-Angiotensin System (RAS)</h2>
<p class=,'First,'>Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. Closely monitor blood pressure, renal function and electrolytes in patients on candesartan cilexetil and other agents that affect the RAS. Do not co-administer aliskiren with candesartan cilexetil in patients with diabetes. Avoid use of aliskiren with candesartan cilexetil in patients with renal impairment (GFR &lt;60 ml/min) <span class=,'Italics,'>[see Contraindications (<a href=,'#Section_4,'>4</a>)]</span>.</p>
</div>
</div>"
"capecitabine","007e3432-c8aa-2a76-52ba-c346924c08a7","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'DRUG_INTERACTIONS,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_5b8eec5f-d0cc-dfd1-b66a-087aa82412ba,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2> 7.1 Drug-Drug Interactions </h2>
<p class=,'First,'>
<span class=,'Underline,'>Anticoagulants </span>
</p>
<p>Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon [see <span class=,'Bold,'><a href=,'#BOXED_WARNING,'> Boxed Warning</a></span>]. These events occurred within several days and up to several months after initiating capecitabine therapy and, in a few cases, within 1 month after stopping capecitabine. These events occurred in patients with and without liver metastases. In a drug interaction study with single-dose warfarin administration, there was a significant increase in the mean AUC of S-warfarin [see<span class=,'Bold,'> Clinical Pharmacology </span><span class=,'Bold,'><a href=,'#PHARMACOKINETICS,'>(12.3)</a></span>]. The maximum observed INR value increased by 91%. This interaction is probably due to an inhibition of cytochrome P450 2C9 by capecitabine and/or its metabolites.</p>
<p>
<span class=,'Underline,'></span><span class=,'Underline,'>Phenytoin</span>
</p>
<p>The level of phenytoin should be carefully monitored in patients taking capecitabine and phenytoin dose may need to be reduced [see<span class=,'Bold,'> Dosage and Administration (</span><a href=,'#_e9682189-3d93-58ed-8d77-7650a905e4a2,'>2.3</a><span class=,'Bold,'>)</span>]. Postmarketing reports indicate that some patients receiving capecitabine and phenytoin had toxicity associated with elevated phenytoin levels. Formal drug-drug interaction studies with phenytoin have not been conducted, but the mechanism of interaction is presumed to be inhibition of the CYP2C9 isoenzyme by capecitabine and/or its metabolites.</p>
<p>
<span class=,'Underline,'>Leucovorin </span>
</p>
<p>The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin. Deaths from severe  enterocolitis,  diarrhea,  and  dehydration  have  been reported in elderly patients receiving weekly leucovorin and fluorouracil.</p>
<p>
<span class=,'Underline,'>CYP2C9 substrates </span>
</p>
<p>Other than warfarin, no formal drug-drug interaction studies between capecitabine and other CYP2C9 substrates have been conducted. Care should be exercised when capecitabine is coadministered with CYP2C9 substrates.</p>
<p>
<span class=,'Underline,'>Allopurinol </span>
</p>
<p>  Concomitant use with allopurinol may decrease concentration of capecitabine’s active metabolites [see <span class=,'Bold,'>Clinical Pharmacology (<a href=,'#PHARMACOKINETICS,'>12.3</a>)</span>], which may decrease capecitabine efficacy. Avoid the use of allopurinol during treatment with capecitabine.</p>
<p></p>
<p></p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_12541747-0e3d-7826-a50f-71523d5272c4,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2> 7.2 Drug-Food Interaction </h2>
<p class=,'First,'>Food was shown to reduce both the rate and extent of absorption of capecitabine [see<span class=,'Bold,'> Clinical Pharmacology <a href=,'#PHARMACOKINETICS,'> (12.3)</a></span>]. In all clinical trials, patients were instructed to administer capecitabine within 30 minutes after a meal. It is recommended that capecitabine be administered with food [see<span class=,'Bold,'> Dosage and Administration <a href=,'#DOSAGE_AND_ADMINISTRATION,'> (2)</a></span>].</p>
</div>
</div>"
"capreomycin","808e4421-2b9c-41e1-a82c-39256b112ae8","none found"
"capsaicin","433da27d-04fb-481a-bbb0-874bb72c806a","none found"
"captopril","137ac94a-2461-4b33-9221-5ca80ed7a417","none found"
"carbamazepine","19fa8a00-51a0-4f8f-8060-45f7053ceb29","none found"
"carbocysteine","5cb4c09c-3be7-4744-b9e8-26b7dd29cd45","none found"
"carbomer","79b15110-e484-4b84-8947-15653746773c","none found"
"carboplatin","2ccca2f5-518d-438c-8e62-5b1bcf2005b7","none found"
"carboxymethylcellulose sodium","2861a407-7898-489d-a43c-1e316341863e","none found"
"carvedilol","354d1689-53f9-42d3-8308-08b6d9a04404","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'i4i_interactions_id_1410eac2-2d1e-47e1-8362-2cdf8dc06d5d,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_b721ed17-13d0-4515-85c2-6b230fcead05,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 CYP2D6 Inhibitors and Poor Metabolizers</h2>
<p class=,'First,'>Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol <span class=,'Italics,'>[see <a href=,'#i4i_pharmacokinetics_id_9731176e-71e1-4390-97f4-619e87cb81ed,'>Clinical Pharmacology (12.3)</a>]</span>.  Retrospective analysis of side effects in clinical trials showed that poor 2D6 metabolizers had a higher rate of dizziness during up-titration, presumably resulting from vasodilating effects of the higher concentrations of the α-blocking R(+) enantiomer.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_b556d46e-081f-4be2-963f-53cd4de643a5,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Hypotensive Agents</h2>
<p class=,'First,'>Patients taking both agents with β-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.</p>
<p>Concomitant administration of clonidine with agents with β-blocking properties may potentiate blood-pressure and hear-trate-lowering effects. When concomitant treatment with agents with β-blocking properties and clonidine is to be terminated, the β-blocking agent should be discontinued first. Clonidine therapy can then be discontinued several days later by gradually decreasing the dosage. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_19d0e99f-fa82-4d33-a38c-1c5087500d9f,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Cyclosporine</h2>
<p class=,'First,'> Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection. In about 30% of patients, the dose of cyclosporine had to be reduced in order to maintain cyclosporine concentrations within the therapeutic range, while in the remainder no adjustment was needed. On the average for the group, the dose of cyclosporine was reduced about 20% in these patients. Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_d76b4b3a-08cd-4bd4-a1a2-3911c76d4d33,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Digitalis Glycosides</h2>
<p class=,'First,'>Both digitalis glycosides and β-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia<span class=,'Italics,'>.</span> Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly. Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing carvedilol <span class=,'Italics,'>[see <a href=,'#i4i_section_id_9a429875-9199-404e-96aa-9130c85afbe7,'>Clinical Pharmacology (12.5)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_6e1df511-34dd-40ab-af09-a254bec48e6b,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Inducers/Inhibitors of Hepatic Metabolism</h2>
<p class=,'First,'>Rifampin reduced plasma concentrations of carvedilol by about 70% <span class=,'Italics,'>[see <a href=,'#i4i_section_id_9a429875-9199-404e-96aa-9130c85afbe7,'>Clinical Pharmacology (12.5)</a>]</span>. Cimetidine increased AUC by about 30% but caused no change in C<span class=,'Sub,'>max</span><span class=,'Italics,'>[see <a href=,'#i4i_section_id_9a429875-9199-404e-96aa-9130c85afbe7,'>Clinical Pharmacology (12.5)</a>]</span>. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_32f1e490-bff0-400e-8f1f-1b3026150e92,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6 Amiodarone</h2>
<p class=,'First,'>Amiodarone, and its metabolite desethyl amiodarone, inhibitors of CYP2C9 and P glycoprotein, increased concentrations of the S(-) enantiomer of carvedilol by at least 2-fold <span class=,'Italics,'>[see <a href=,'#i4i_section_id_9a429875-9199-404e-96aa-9130c85afbe7,'>Clinical Pharmacology (12.5)</a>]</span>.</p>
<p>The concomitant administration of amiodarone or other CYP2C9 inhibitors such as fluconazole with carvedilol may enhance the β-blocking properties of carvedilol resulting in further slowing of the heart rate or cardiac conduction. Patients should be observed for signs of bradycardia or heart block, particularly when one agent is added to pre-existing treatment with the other.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_1e8427f5-7d98-45b5-9454-50e1cd61caf1,'></a><a name=,'section-7.7,'></a>
<p></p>
<h2>7.7 Calcium Channel Blockers</h2>
<p class=,'First,'>Conduction disturbance (rarely with hemodynamic compromise) has been observed when carvedilol is co-administered with diltiazem. As with other agents with β-blocking properties, if carvedilol is to be administered with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_6fdb2972-ca4f-4e48-86dc-e84720a819ce,'></a><a name=,'section-7.8,'></a>
<p></p>
<h2>7.8 Insulin or Oral Hypoglycemics</h2>
<p class=,'First,'>Agents with β-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics. Therefore, in patients taking insulin or oral hypoglycemics, regular monitoring of blood glucose is recommended <span class=,'Italics,'>[see <a href=,'#i4i_section_id_ba1748db-235a-4d89-97a8-4a2b6304bc5f,'>Warnings and Precautions (5.6)</a>]</span>.</p>
</div>
</div>"
"cefaclor","2f61354e-bcb0-41aa-955f-51eabc11387b","none found"
"cephalexin","02806e6f-8746-4740-9327-ba58d320bff1","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1	Metformin</h2>
<p class=,'First,'>Administration of cephalexin with metformin results in increased plasma metformin concentrations and decreased renal clearance of metformin.</p>
<br/>
<p>Careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin   [<span class=,'Italics,'>see Clinical Pharmacology (12.2) </span> ].</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2	Probenecid</h2>
<p class=,'First,'>The renal excretion of cephalexin is inhibited by probenecid. Co-administration of probenecid with cephalexin is not recommended.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3	Interaction With Laboratory or Diagnostic Testing</h2>
<p class=,'First,'>A false-positive reaction may occur when testing for the presence of glucose in the urine using Benedict’s solution or Fehling’s solution.</p>
</div>
</div>"
"cefazolin","00dd6da7-50a8-44c9-b2dc-7948973df392","none found"
"cefepime","be5f8ca6-7232-423a-a2d5-cccb7abe7921","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'i4i_interactions_id_s7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'34074-5,'>
<a name=,'ID_e03bc417-b150-41a7-b143-0ca0c35ee277,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Drug/Laboratory Test Interactions </h2>
<p class=,'First,'>The administration of cefepime may result in a false-positive reaction for glucose in the urine with certain methods. It is recommended that glucose tests based on enzymatic glucose oxidase reactions be used <a href=,'#i4i_drug_lab_interaction_id_115b31fa-c49f-49ce-afdf-d459a0c87c90,'>[see Warning and Precautions (5.5)]</a><span class=,'Italics,'>.</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_s7.1,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Aminoglycosides</h2>
<p class=,'First,'>Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with Cefepime Injection because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibacterial drugs.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_s7.2,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Diuretics</h2>
<p class=,'First,'>Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.</p>
</div>
</div>"
"cefixime","6f1df975-f825-4301-87da-d7eba56a6890","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Carbamazepine</h2>
<p class=,'First,'>Elevated carbamazepine levels have been reported in postmarketing experience when cefixime is administered concomitantly. Drug monitoring may be of assistance in detecting alterations in carbamazepine plasma concentrations.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Warfarin and Anticoagulants</h2>
<p class=,'First,'>Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Drug/Laboratory Test Interactions</h2>
<p class=,'First,'>A false-positive reaction for ketones in the urine may occur with tests using nitroprusside but not with those using nitroferricyanide. </p>
<p>The administration of cefixime may result in a false-positive reaction for glucose in the urine using Clinitest<span class=,'Sup,'>®**</span>, Benedict’s solution, or Fehling’s solution. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix<span class=,'Sup,'>®** </span>or TesTape<span class=,'Sup,'>®**</span>) be used. A false-positive direct Coombs test has been reported during treatment with other cephalosporins; therefore, it should be recognized that a positive Coombs test may be due to the drug. </p>
<p>**Clinitest<span class=,'Sup,'>® </span>and Clinistix<span class=,'Sup,'>® </span>are registered trademarks of Ames Division, Miles Laboratories, Inc. Tes-Tape<span class=,'Sup,'>® </span>is a registered trademark of Eli Lilly and Company.</p>
</div>
</div>"
"cefotaxime","ef1a6dc6-bc3d-4f09-8f92-7ff328f56561","none found"
"ceftaroline","3ecde48b-75a2-4beb-9999-369f3f61bb8a","none found"
"ceftazidime","112c5457-8d71-49f5-b531-9761d7d38c93","none found"
"ceftriaxone","1781fc07-5a2a-4b31-aad9-d0457eb704f4","none found"
"cefuroxime","19902965-d2d6-433f-982d-0095014df4e8","none found"
"celecoxib","03c40e1c-c274-48d9-9c70-5f2a670e49cc","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_93869e4e-072e-4529-aef5-761fb3a6d1b1,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>See Table 3 for  clinically significant drug interactions  with celecoxib.</p>
<div class=,'scrollingtable,'><table>
<caption>
<span>Table 3: Clinically Significant Drug Interactions with Celecoxib</span>
</caption>
<col/>
<col/>
<tbody class=,'Headless,'>
<tr class=,'First,'>
<td class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'> <span class=,'Bold,'>  Drugs</span><span class=,'Bold,'> That</span><span class=,'Bold,'> Interfere w</span><span class=,'Bold,'>ith  Hemostasis</span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Lrule Rrule,' valign=,'top,'> <span class=,'Italics,'>Clinical  Impact:</span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'> <ul class=,'Disk,'>
<li>Celecoxib and anticoagulants such as  warfarin have a synergistic effect on bleeding. The concomitant use of Celecoxib and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone.</li>
<li>Serotonin release by platelets  plays an important  role in hemostasis. Case-control and cohort epidemiological studies  showed that concomitant use of drugs that interfere  with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone.</li>
</ul>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Lrule Rrule,' valign=,'top,'> <span class=,'Italics,'>Intervention:</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'> Monitor patients  with concomitant use of celecoxib  with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [<span class=,'Italics,'>see </span><span class=,'Italics,'><a href=,'#LINK_c567e811-3129-4615-9802-6c822560bbcc,'>Warnings and Precautions  (5.11)</a></span>].<br/>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'> <span class=,'Bold,'>  Aspirin</span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Lrule Rrule,' valign=,'top,'> <span class=,'Italics,'>Clinical  Impact:</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'> Controlled  clinical studies  showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical  study, the concomitant use of an NSAID and aspirin  was associated  with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [<span class=,'Italics,'>see <span class=,'Italics,'><a href=,'#LINK_5069f2c7-1a91-4542-a9be-3aa4f8dbb0bc,'>Warnings and Precautions (5.2)</a></span></span>].<br/>In  two studies in healthy volunteers, and in patients  with osteoarthritis and established heart disease  respectively, celecoxib (200 to 400 mg daily) has demonstrated a lack of interference  with the cardioprotective antiplatelet effect of aspirin (100 to 325 mg).<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Lrule Rrule,' valign=,'top,'> <span class=,'Italics,'>Intervention:</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'> Concomitant use of celecoxib and analgesic doses of aspirin is  not generally recommended because of the increased risk of bleeding [<span class=,'Italics,'>see <span class=,'Italics,'><a href=,'#LINK_c567e811-3129-4615-9802-6c822560bbcc,'>Warnings and Precautions (5.11)</a></span></span>].<br/>Celecoxib is not a substitute for low dose aspirin for cardiovascular protection.<br/>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'> <span class=,'Bold,'>  ACE</span><span class=,'Bold,'> Inhibitors,</span><span class=,'Bold,'> Angiotensin</span><span class=,'Bold,'> Receptor</span><span class=,'Bold,'> Blockers,</span><span class=,'Bold,'> and</span><span class=,'Bold,'> Beta-Blockers</span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Lrule Rrule,' valign=,'top,'> <span class=,'Italics,'>Clinical  Impact:</span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'> <ul class=,'Disk,'>
<li>NSAIDs may diminish the antihypertensive effect of angiotensin converting  enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol).</li>
<li>In patients  who are  elderly, volume-depleted (including those on diuretic therapy), or  have renal impairment, co-administration of an NSAID  with ACE inhibitors or ARBs may result in deterioration of renal function,  including possible acute renal failure. These effects are usually reversible.</li>
</ul>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Lrule Rrule,' valign=,'top,'> <span class=,'Italics,'>Intervention:</span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'> <ul class=,'Disk,'>
<li>During concomitant use of celecoxib and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained.</li>
<li>During concomitant use of celecoxib and ACE-inhibitors or ARBs in patients  who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [<span class=,'Italics,'>see <span class=,'Italics,'><a href=,'#LINK_2ce69f4f-9899-4506-91c2-9d2771f1355f,'>Warnings and Precautions (5.6)</a></span></span>]<span class=,'Italics,'>.</span>
</li>
<li>When these drugs are administered  concomitantly, patients should be adequately hydrated. Assess renal function at the beginning of the concomitant treatment and periodically thereafter.</li>
</ul>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'> <span class=,'Bold,'>  Diuretics</span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Lrule Rrule,' valign=,'top,'> <span class=,'Italics,'>Clinical  Impact:</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'> Clinical studies, as  well as post-marketing observations,  showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin  synthesis.<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Lrule Rrule,' valign=,'top,'> <span class=,'Italics,'>Intervention:</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'> During concomitant use of celecoxib  with diuretics, observe patients for signs of  worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [<span class=,'Italics,'>see </span><span class=,'Italics,'><a href=,'#LINK_2ce69f4f-9899-4506-91c2-9d2771f1355f,'>Warnings and Precautions  (5.6)</a></span>].<br/>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'> <span class=,'Bold,'>  Digoxin</span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Lrule Rrule,' valign=,'top,'> <span class=,'Italics,'>Clinical  Impact:</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'> The concomitant use of Celecoxib  with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Lrule Rrule,' valign=,'top,'> <span class=,'Italics,'>Intervention:</span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'> During concomitant use of celecoxib and digoxin, monitor serum digoxin levels.<br/>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'> <span class=,'Bold,'>  Lithium</span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Lrule Rrule,' valign=,'top,'> <span class=,'Italics,'>Clinical  Impact:</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'> NSAIDs have produced elevations in plasma  lithium levels and reductions in renal lithium clearance<span class=,'Italics,'>. </span>The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%.  This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis.<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Lrule Rrule,' valign=,'top,'> <span class=,'Italics,'>Intervention:</span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'> During concomitant use of celecoxib and lithium, monitor patients for signs of  lithium toxicity.<br/>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'> <span class=,'Bold,'>  Methotrexate</span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Lrule Rrule,' valign=,'top,'> <span class=,'Italics,'>Clinical  Impact:</span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'> Concomitant use of NSAIDs and methotrexate may  increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal  dysfunction).<br/>Celecoxib has no effect on  methotrexate pharmacokinetics.<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Lrule Rrule,' valign=,'top,'> <span class=,'Italics,'>Intervention:</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'> During concomitant use of celecoxib and methotrexate, monitor patients for methotrexate toxicity.<br/>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'> <span class=,'Bold,'>  Cyclosporine</span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Lrule Rrule,' valign=,'top,'> <span class=,'Italics,'>Clinical  Impact:</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'> Concomitant use of celecoxib and  cyclosporine may increase cyclosporine’s  nephrotoxicity.<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Lrule Rrule,' valign=,'top,'> <span class=,'Italics,'>Intervention:</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'> During concomitant use of celecoxib and  cyclosporine, monitor patients for signs of  worsening renal function.<br/>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'> <span class=,'Bold,'>  NSAIDs a</span><span class=,'Bold,'>nd  Salicylates</span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Lrule Rrule,' valign=,'top,'> <span class=,'Italics,'>Clinical  Impact:</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'> Concomitant use of Celecoxib  with other NSAIDs or  salicylates (e.g., diflunisal, salsalate) increases the risk of GI  toxicity, with little or no increase in efficacy [<span class=,'Italics,'>see <span class=,'Italics,'><a href=,'#LINK_5069f2c7-1a91-4542-a9be-3aa4f8dbb0bc,'>Warnings and Precautions (5.2)</a></span></span>]<span class=,'Italics,'>.</span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Lrule Rrule,' valign=,'top,'> <span class=,'Italics,'>Intervention:</span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'> The concomitant use of Celecoxib  with other NSAIDs or  salicylates is not recommended.<br/>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'> <span class=,'Bold,'> Pemetrexed</span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Lrule Rrule,' valign=,'top,'> <span class=,'Italics,'>Clinical  Impact:</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'> Concomitant use of celecoxib and pemetrexed may increase the risk of pemetrexed-associated  myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information).<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Lrule Rrule,' valign=,'top,'> <span class=,'Italics,'>Intervention:</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'> During concomitant use of celecoxib and pemetrexed, in patients  with renal impairment  whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity.<br/>NSAIDs  with short elimination half-lives (e.g.,  diclofenac, indomethacin) should be avoided for a period of  two days before, the day of, and  two days  following administration of pemetrexed.<br/>In the absence of data regarding potential interaction  between pemetrexed and NSAIDs  with longer half-lives (e.g., meloxicam, nabumetone), patients taking these  NSAIDs should interrupt dosing for at least five  days before, the day of, and  two days  following pemetrexed administration.<br/>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'> <span class=,'Bold,'> CYP2C9 Inhibitors or inducers</span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Lrule Rrule,' valign=,'top,'> <span class=,'Italics,'>Clinical  Impact:</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'> Celecoxib metabolism is predominantly mediated via  cytochrome P450 (CYP) 2C9 in the liver. Co­-administration of celecoxib  with drugs that are known to inhibit  CYP2C9 (e.g. fluconazole) may enhance the exposure and toxicity of celecoxib  whereas co-administration  with CYP2C9 inducers (e.g. rifampin) may lead to compromised efficacy of celecoxib.<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Lrule Rrule,' valign=,'top,'> <span class=,'Italics,'>Intervention</span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'> Evaluate each patient's medical history  when consideration is  given to prescribing celecoxib. A dosage adjustment may be  warranted when celecoxib is administered  with CYP2C9 inhibitors or inducers. [<span class=,'Italics,'>see <span class=,'Italics,'><a href=,'#LINK_1282d1e7-d3fe-4731-98c7-457eed99b078,'>Clinical  Pharmacology (12.3)</a></span></span>].<br/>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'> <span class=,'Bold,'>  CYP2D6</span><span class=,'Bold,'> substrates</span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Lrule Rrule,' valign=,'top,'> <span class=,'Italics,'>Clinical  Impact:</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'> <span class=,'Italics,'>In vitro </span>studies  indicate that celecoxib, although not a substrate, is an inhibitor of CYP2D6. Therefore, there is a potential for an <span class=,'Italics,'>in vivo </span>drug interaction  with drugs that are metabolized by  CYP2D6 (e.g. atomoxetine), and celecoxib may enhance the exposure and toxicity of these drugs.<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Lrule Rrule,' valign=,'top,'> <span class=,'Italics,'>Intervention</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'> Evaluate each patient's medical history  when consideration is  given to prescribing celecoxib. A dosage adjustment may be  warranted when celecoxib is administered  with CYP2D6 substrates. [<span class=,'Italics,'>see <span class=,'Italics,'><a href=,'#LINK_1282d1e7-d3fe-4731-98c7-457eed99b078,'>Clinical  Pharmacology (12.3)</a></span></span>].<br/>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'> <span class=,'Bold,'>  Corticosteroids</span>
<br/>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Lrule Rrule,' valign=,'top,'> <span class=,'Italics,'>Clinical  Impact:</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'> Concomitant use of corticosteroids  with celecoxib may increase the risk of GI ulceration or bleeding.<br/>
</td>
</tr>
<tr class=,'Last,'>
<td align=,'right,' class=,'Lrule Rrule,' valign=,'top,'> <span class=,'Italics,'>Intervention</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'> Monitor patients  with concomitant use of celecoxib  with corticosteroids for signs of bleeding [see <span class=,'Italics,'><a href=,'#LINK_5069f2c7-1a91-4542-a9be-3aa4f8dbb0bc,'>Warnings and Precautions (5.2)</a></span>].<br/>
</td>
</tr>
</tbody>
</table></div>
</div>"
"certolizumab pegol","b4c2c9dc-a0bb-4d64-a667-a67ebe88392d","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Use with Anakinra, Abatacept, Rituximab, and Natalizumab</h2>
<p class=,'First,'>An increased risk of serious infections has been seen in clinical studies of other TNF-blocking agents used in combination with anakinra or abatacept, with no added benefit. Formal drug interaction studies have not been performed with rituximab or natalizumab. Because of the nature of the adverse events seen with these combinations with TNF blocker therapy, similar toxicities may also result from the use of CIMZIA in these combinations. There is not enough information to assess the safety and efficacy of such combination therapy. Therefore, the use of CIMZIA in combination with anakinra, abatacept, rituximab, or natalizumab is not recommended 
         
 
  <span class=,'Italics,'>[see 
          
  
   <a href=,'#S5.8,'>Warnings and Precautions (5.8)</a>]
         
 
  </span>.
        

 </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Live Vaccines</h2>
<p class=,'First,'>Avoid use of live (including attenuated) vaccines concurrently with CIMZIA 
         
 
  <span class=,'Italics,'>[see 
          
  
   <a href=,'#S5.10,'>Warnings and Precautions (5.10)</a>]
         
 
  </span>.
        

 </p>
</div>
<div class=,'Section,' data-sectioncode=,'34075-2,'>
<a name=,'S7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Laboratory Tests</h2>
<p class=,'First,'>Interference with certain coagulation assays has been detected in patients treated with CIMZIA. Certolizumab pegol may cause erroneously elevated activated partial thromboplastin time (aPTT) assay results in patients without coagulation abnormalities. This effect has been observed with the PTT-Lupus Anticoagulant (LA) test and Standard Target Activated Partial Thromboplastin time (STA-PTT) Automate tests from Diagnostica Stago, and the HemosIL APTT-SP liquid and HemosIL lyophilized silica tests from Instrumentation Laboratories. Other aPTT assays may be affected as well. Interference with thrombin time (TT) and prothrombin time (PT) assays has not been observed. There is no evidence that CIMZIA therapy has an effect on 
         
 
  <span class=,'Italics,'>in vivo</span> coagulation.
        

 </p>
</div>
</div>"
"chlordiazepoxide","2f1d49ad-13cb-2a23-e054-00144ff88e88","none found"
"chlorhexidine","26d68a24-6809-4653-9096-11292f2900ce","none found"
"chloroquine","06c69e2b-211b-4746-9f3a-f86d36520570","none found"
"chlorpheniramine","168b94d6-95ef-4c2d-97bc-c3f0042fd82e","none found"
"chlorpromazine","9575c766-3758-6f33-e053-2995a90ae6b1","none found"
"cyclosporine","f3dc2a50-1084-4190-a6f3-37034a04db86","none found"
"cilostazol","151d1497-7655-44ce-8e97-dd1cd91f686a","none found"
"cimetidine","3a2f773d-b67f-4e83-b8d7-fce6b2887efe","none found"
"ciprofloxacin","0230000a-7549-4547-bd73-4dd57fae9c6b","none found"
"cisplatin","76aea034-6d58-4390-a164-36aa09c1f101","none found"
"citalopram","04ac5286-fc2e-4990-a574-ea21131ef731","none found"
"clarithromycin","0be243c6-de02-45dd-8210-cab1bbc8dfa7","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID_9c2aa377-e8e2-4acd-bc5f-21e82e2a8a8b,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Co-administration of clarithromycin tablets is known to inhibit CYP3A, and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug.</p>
<p>Clarithromycin tablets should be used with caution in patients receiving treatment with other drugs known to be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow safety margin (e.g., carbamazepine) and/or the substrate is extensively metabolized by this enzyme. Adjust dosage when appropriate and monitor serum concentrations of drugs primarily metabolized by CYP3A closely in patients concurrently receiving clarithromycin.</p>
<div class=,'scrollingtable,'><table width=,'100%,'>
<caption>
<span>Table 8. Clinically Significant Drug Interactions with Clarithromycin Tablets</span>
</caption>
<col width=,'22%,'/>
<col width=,'18%,'/>
<col width=,'60%,'/>
<tbody class=,'Headless,'>
<tr class=,'First,'>
<td align=,'center,' class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Drugs That Are Affected By Clarithromycin Tablets</span>
</p>
</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Drug(s) with</span>
</p>
<p>
<span class=,'Bold,'>Pharmacokinetics</span>
</p>
<p>
<span class=,'Bold,'>Affected by</span>
</p>
<p>
<span class=,'Bold,'>Clarithromycin Tablets</span>
</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Recommendation</span>
</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Comments</span>
</p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Antiarrhythmics:</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule Toprule,' valign=,'top,'></td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Disopyramide</p>
<p>Quinidine</p>
<p>Dofetilide</p>
<p>Amiodarone</p>
<p>Sotalol</p>
<p>Procainamide</p>
</td><td valign=,'top,'>
<p class=,'First,'>Not Recommended</p>
</td><td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Disopyramide, Quinidine:</span> There have been postmarketing reports of 
           
     
      <span class=,'Italics,'>torsades de pointes </span>occurring with concurrent use of clarithromycin and quinidine or disopyramide. Electrocardiograms should be monitored for QTc prolongation during coadministration of clarithromycin with these drugs 
           
     
      <span class=,'Italics,'>[see Warnings and Precautions (</span><span class=,'Italics,'><a href=,'#ID_a7596f57-7103-4a57-9449-f1f781c3f9b8,'>5.2</a></span><span class=,'Italics,'>)]</span>.
          
    
     </p>
<p>Serum concentrations of these medications should also be monitored. There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with disopyramide and quinidine.</p>
<p>There have been postmarketing reports of hypoglycemia with the concomitant administration of clarithromycin and disopyramide. Therefore, blood glucose levels should be monitored during concomitant administration of clarithromycin and disopyramide.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Digoxin</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Use With Caution</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Digoxin:</span> Digoxin is a substrate for P-glycoprotein (Pgp) and clarithromycin is known to inhibit Pgp. When clarithromycin and digoxin are co‑administered, inhibition of Pgp by clarithromycin may lead to increased exposure of digoxin. Elevated digoxin serum concentrations in patients receiving clarithromycin and digoxin concomitantly have been reported in postmarketing surveillance. Some patients have shown clinical signs consistent with digoxin toxicity, including potentially fatal arrhythmias. Monitoring of serum digoxin concentrations should be considered, especially for patients with digoxin concentrations in the upper therapeutic range.
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Oral Anticoagulants:</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule Toprule,' valign=,'top,'></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Warfarin</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Use With Caution</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Oral anticoagulants:</span> Spontaneous reports in the postmarketing period suggest that concomitant administration of clarithromycin and oral anticoagulants may potentiate the effects of the oral anticoagulants. Prothrombin times should be carefully monitored while patients are receiving clarithromycin and oral anticoagulants simultaneously 
           
     
      <span class=,'Italics,'>[see Warnings and Precautions (
            
      
       <a href=,'#ID_fe6a3ef4-f95e-4325-a01c-96e584b03c25,'>5.4</a>)]
           
     
      </span>.
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Antiepileptics:</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule Toprule,' valign=,'top,'></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Carbamazepine</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Use With Caution</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Carbamazepine:</span> Concomitant administration of single doses of clarithromycin and carbamazepine has been shown to result in increased plasma concentrations of carbamazepine. Blood level monitoring of carbamazepine may be considered. Increased serum concentrations of carbamazepine were observed in clinical trials with clarithromycin. There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with carbamazepine.
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Antifungals:</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule Toprule,' valign=,'top,'></td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Itraconazole</p>
</td><td valign=,'top,'>
<p class=,'First,'>Use With Caution</p>
</td><td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Itraconazole:</span> Both clarithromycin and itraconazole are substrates and inhibitors of CYP3A, potentially leading to a bi-directional drug interaction when administered concomitantly (see also Itraconazole under “Drugs That Affect Clarithromycin Tablets” in the table below). Clarithromycin may increase the plasma concentrations of itraconazole. Patients taking itraconazole and clarithromycin concomitantly should be monitored closely for signs or symptoms of increased or prolonged adverse reactions.
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Fluconazole</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>No Dose Adjustment</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Fluconazole:</span><span class=,'Italics,'>[see Pharmacokinetics (
            
      
       <a href=,'#ID_57948296-7474-4799-90ec-95c0197eea54,'>12.3</a>)]
           
     
      </span>
</p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Anti-Gout Agents:</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule Toprule,' valign=,'top,'></td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Colchicine (in patients with renal or hepatic impairment)</p>
</td><td valign=,'top,'>
<p class=,'First,'>Contraindicated</p>
</td><td class=,'Botrule Lrule Rrule,' rowspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Underline,'>Colchicine:</span> Colchicine is a substrate for both CYP3A and the efflux transporter, P-glycoprotein (Pgp). Clarithromycin and other macrolides are known to inhibit CYP3A and Pgp. The dose of colchicine should be reduced when co-administered with clarithromycin in patients with normal renal and hepatic function 
           
     
      <span class=,'Italics,'>[see Contraindications (
            
      
       <a href=,'#ID_46073efd-5f30-43ee-9437-d3d24b4c068c,'>4.4</a>) and Warnings and Precautions (
            
      
       <a href=,'#ID_fe6a3ef4-f95e-4325-a01c-96e584b03c25,'>5.4</a>)]
           
     
      </span>.
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Colchicine (in patients with normal renal and hepatic function)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Use With Caution</p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Antipsychotics:</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule Toprule,' valign=,'top,'></td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Pimozide</p>
</td><td valign=,'top,'>
<p class=,'First,'>Contraindicated</p>
</td><td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Pimozide:</span><span class=,'Italics,'> [See Contraindications (
            
      
       <a href=,'#ID_1d90dfec-c4e6-4c29-8f78-a104067932c3,'>4.2</a>)]
           
     
      </span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Quetiapine</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'></td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Quetiapine:</span> Quetiapine is a substrate for CYP3A4, which is inhibited by clarithromycin. Co‑administration with clarithromycin could result in increased quetiapine exposure and possible quetiapine related toxicities. There have been postmarketing reports of somnolence, orthostatic hypotension, altered state of consciousness, neuroleptic malignant syndrome, and QT prolongation during concomitant administration. Refer to quetiapine prescribing information for recommendations on dose reduction if co‑administered with CYP3A4 inhibitors such as clarithromycin.
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Antispasmodics:</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule Toprule,' valign=,'top,'></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Tolterodine (patients deficient in CYP2D6 activity)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Use With Caution</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Tolterodine:</span> The primary route of metabolism for tolterodine is via CYP2D6. However, in a subset of the population devoid of CYP2D6, the identified pathway of metabolism is via CYP3A. In this population subset, inhibition of CYP3A results in significantly higher serum concentrations of tolterodine. Tolterodine 1 mg twice daily is recommended in patients deficient in CYP2D6 activity (poor metabolizers) when co-administered with clarithromycin.
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Antivirals:</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule Toprule,' valign=,'top,'></td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Atazanavir</p>
</td><td valign=,'top,'>
<p class=,'First,'>Use With Caution</p>
</td><td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Atazanavir:</span> Both clarithromycin and atazanavir are substrates and inhibitors of CYP3A, and there is evidence of a bi-directional drug interaction (see Atazanavir under “Drugs That Affect Clarithromycin Tablets” in the table below) 
           
     
      <span class=,'Italics,'>[see Pharmacokinetics (
            
      
       <a href=,'#ID_57948296-7474-4799-90ec-95c0197eea54,'>12.3</a>)]
           
     
      </span>.
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Saquinavir (in patients with decreased renal function)</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Saquinavir:</span> Both clarithromycin and saquinavir are substrates and inhibitors of CYP3A and there is evidence of a bi-directional drug interaction (see Saquinavir under “Drugs That Affect Clarithromycin Tablets” in the table below) 
           
     
      <span class=,'Italics,'>[see Pharmacokinetics (
            
      
       <a href=,'#ID_57948296-7474-4799-90ec-95c0197eea54,'>12.3</a>)]
           
     
      </span>.
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Ritonavir</p>
<p>Etravirine</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Ritonavir, Etravirine:</span> (see Ritonavir and Etravirine under “Drugs That Affect Clarithromycin Tablets” in the table below) 
           
     
      <span class=,'Italics,'>[see Pharmacokinetics (
            
      
       <a href=,'#ID_57948296-7474-4799-90ec-95c0197eea54,'>12.3</a>)]
           
     
      </span>.
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Maraviroc</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Maraviroc:</span> Clarithromycin may result in increases in maraviroc exposures by inhibition of CYP3A metabolism. See maraviroc prescribing information for dose recommendation when given with strong CYP3A inhibitors such as clarithromycin.
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Boceprevir (in patients with normal renal function)</p>
<p>Didanosine</p>
</td><td valign=,'top,'>
<p class=,'First,'>No Dose Adjustment</p>
</td><td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Boceprevir:</span> Both clarithromycin and boceprevir are substrates and inhibitors of CYP3A, potentially leading to a bi-directional drug interaction when co‑administered. No dose adjustments are necessary for patients with normal renal function (see boceprevir prescribing information).
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Zidovudine</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'></td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Zidovudine:</span> Simultaneous oral administration of clarithromycin immediate-release tablets and zidovudine to HIV-infected adult patients may result in decreased steady-state zidovudine concentrations. Administration of clarithromycin and zidovudine should be separated by at least two hours 
           
     
      <span class=,'Italics,'>[see Pharmacokinetics (
            
      
       <a href=,'#ID_57948296-7474-4799-90ec-95c0197eea54,'>12.3</a>)]
           
     
      </span>.
          
    
     </p>
<p>The impact of co-administration of clarithromycin extended-release tablets or granules and zidovudine has not been evaluated.</p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Calcium Channel Blockers:</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule Toprule,' valign=,'top,'></td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Verapamil</p>
</td><td valign=,'top,'>
<p class=,'First,'>Use With Caution</p>
</td><td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Verapamil:</span> Hypotension, bradyarrhythmias, and lactic acidosis have been observed in patients receiving concurrent verapamil, 
           
     
      <span class=,'Italics,'>[see Warnings and Precautions (
            
      
       <a href=,'#ID_fe6a3ef4-f95e-4325-a01c-96e584b03c25,'>5.4</a>)]
           
     
      </span>.
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Amlodipine</p>
<p>Diltiazem</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Amlodipine, Diltiazem:</span><span class=,'Italics,'> [See Warnings and Precautions (
            
      
       <a href=,'#ID_fe6a3ef4-f95e-4325-a01c-96e584b03c25,'>5.4</a>)]
           
     
      </span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Nifedipine</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'></td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Nifedipine:</span> Nifedipine is a substrate for CYP3A. Clarithromycin and other macrolides are known to inhibit CYP3A. There is potential of CYP3A‑mediated interaction between nifedipine and clarithromycin. Hypotension and peripheral edema were observed when clarithromycin was taken concomitantly with nifedipine 
           
     
      <span class=,'Italics,'>[see Warnings and Precautions (
            
      
       <a href=,'#ID_fe6a3ef4-f95e-4325-a01c-96e584b03c25,'>5.4</a>)]
           
     
      </span>.
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Ergot Alkaloids:</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule Toprule,' valign=,'top,'></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Ergotamine</p>
<p>Dihydroergotamine</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Contraindicated</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Ergotamine, Dihydroergotamine:</span> Postmarketing reports indicate that coadministration of clarithromycin with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterized by vasospasm and ischemia of the extremities and other tissues including the central nervous system 
           
     
      <span class=,'Italics,'>[see Contraindications (
            
      
       <a href=,'#ID_265603af-4dba-443d-8341-604be0ca835e,'>4.6</a>)]
           
     
      </span>.
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Gastroprokinetic Agents:</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule Toprule,' valign=,'top,'></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Cisapride</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Contraindicated</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Cisapride:</span><span class=,'Italics,'> [See Contraindications (
            
      
       <a href=,'#ID_1d90dfec-c4e6-4c29-8f78-a104067932c3,'>4.2</a>)]
           
     
      </span>
</p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Lipid-lowering agents: Lomitapide</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule Toprule,' valign=,'top,'></td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Lovastatin</p>
<p>Simvastatin</p>
</td><td valign=,'top,'>
<p class=,'First,'>Contraindicated</p>
</td><td class=,'Botrule Lrule Rrule,' rowspan=,'3,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Lomitapide, Lovastatin, Simvastatin:</span> Clarithromycin may increase the exposure of these drugs by inhibition of CYP3A metabolism, thereby increasing the risk of toxicities from these drugs 
           
     
      <span class=,'Italics,'>[see Contraindications (
            
      
       <a href=,'#_4.5_HMG-CoA_Reductase,'>4.5</a>) and Warnings and Precautions (
            
      
       <a href=,'#ID_fe6a3ef4-f95e-4325-a01c-96e584b03c25,'>5.4</a>)]
           
     
      </span>
</p>
<p>
<span class=,'Underline,'>Atorvastatin, Pravastatin, Fluvastatin:</span><span class=,'Italics,'>[See Warnings and Precautions (
            
      
       <a href=,'#ID_fe6a3ef4-f95e-4325-a01c-96e584b03c25,'>5.4</a>)]
           
     
      </span>
</p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Atorvastatin</p>
<p>Pravastatin</p>
</td><td valign=,'top,'>
<p class=,'First,'>Use With Caution</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Fluvastatin</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>No Dose Adjustment</p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Hypoglycemic Agents:</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule Toprule,' valign=,'top,'></td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Nateglinide</p>
<p>Pioglitazone</p>
<p>Repaglinide</p>
<p>Rosiglitazone</p>
</td><td valign=,'top,'>
<p class=,'First,'>Use With Caution</p>
</td><td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Nateglinide, Pioglitazone, Repaglinide, Rosiglitazone:</span><span class=,'Italics,'> [See Warnings and Precautions (
            
      
       <a href=,'#ID_fe6a3ef4-f95e-4325-a01c-96e584b03c25,'>5.4</a>) and Adverse Reactions (
            
      
       <a href=,'#ID_cf1527c0-dacb-4cb5-8205-c3db61242e53,'>6.2</a>)]
           
     
      </span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Insulin</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'></td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Insulin:</span><span class=,'Italics,'> [See Warnings and Precautions (
            
      
       <a href=,'#ID_fe6a3ef4-f95e-4325-a01c-96e584b03c25,'>5.4</a>) and Adverse Reactions (
            
      
       <a href=,'#ID_cf1527c0-dacb-4cb5-8205-c3db61242e53,'>6.2</a>)]
           
     
      </span>
</p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Immunosuppressants:</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule Toprule,' valign=,'top,'></td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Cyclosporine</p>
</td><td valign=,'top,'>
<p class=,'First,'>Use With Caution</p>
</td><td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Cyclosporine:</span> There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with cyclosporine.
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Tacrolimus</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'></td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Tacrolimus:</span> There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with tacrolimus.
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Phosphodiesterase inhibitors:</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule Toprule,' valign=,'top,'></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Sildenafil</p>
<p>Tadalafil</p>
<p>Vardenafil</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Use With Caution</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Sildenafil, Tadalafil, Vardenafil:</span> Each of these phosphodiesterase inhibitors is primarily metabolized by CYP3A, and CYP3A will be inhibited by concomitant administration of clarithromycin. Co-administration of clarithromycin with sildenafil, tadalafil, or vardenafil will result in increased exposure of these phosphodiesterase inhibitors. Co-administration of these phosphodiesterase inhibitors with clarithromycin is not recommended. Increased systemic exposure of these drugs may occur with clarithromycin; reduction of dosage for phosphodiesterase inhibitors should be considered (see their respective prescribing information).
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Proton Pump Inhibitors:</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule Toprule,' valign=,'top,'></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Omeprazole</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>No Dose Adjustment</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Omeprazole:</span> The mean 24-hour gastric pH value was 5.2 when omeprazole was administered alone and 5.7 when coadministered with clarithromycin as a result of increased omeprazole exposures 
           
     
      <span class=,'Italics,'>[see Pharmacokinetics (
            
      
       <a href=,'#ID_57948296-7474-4799-90ec-95c0197eea54,'>12.3</a>)]
           
     
      </span> (see also Omeprazole under “Drugs That Affect Clarithromycin Tablets” in the table below).
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Xanthine Derivatives:</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule Toprule,' valign=,'top,'></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Theophylline</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Use With Caution</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Theophylline:</span> Clarithromycin use in patients who are receiving theophylline may be associated with an increase of serum theophylline concentrations 
           
     
      <span class=,'Italics,'>[see Pharmacokinetics (
            
      
       <a href=,'#ID_57948296-7474-4799-90ec-95c0197eea54,'>12.3</a>)]
           
     
      </span>. Monitoring of serum theophylline concentrations should be considered for patients receiving high doses of theophylline or with baseline concentrations in the upper therapeutic range.
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Triazolobenzodiazepines and Other Related Benzodiazepines:</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule Toprule,' valign=,'top,'></td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Midazolam</p>
</td><td valign=,'top,'>
<p class=,'First,'>Use With Caution</p>
</td><td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Midazolam:</span> When oral midazolam is co‑administered with clarithromycin, dose adjustments may be necessary and possible prolongation and intensity of effect should be anticipated 
           
     
      <span class=,'Italics,'>[see Warnings and Precautions (
            
      
       <a href=,'#ID_fe6a3ef4-f95e-4325-a01c-96e584b03c25,'>5.4</a>) and Pharmacokinetics (
            
      
       <a href=,'#ID_57948296-7474-4799-90ec-95c0197eea54,'>12.3</a>)]
           
     
      </span>.
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Alprazolam</p>
<p>Triazolam</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Triazolam, Alprazolam:</span> Caution and appropriate dose adjustments should be considered when triazolam or alprazolam is co-administered with clarithromycin. There have been postmarketing reports of drug interactions and central nervous system (CNS) effects (e.g., somnolence and confusion) with the concomitant use of clarithromycin and triazolam. Monitoring the patient for increased CNS pharmacological effects is suggested.
          
    
     </p>
<p>In postmarketing experience, erythromycin has been reported to decrease the clearance of triazolam and midazolam, and thus, may increase the pharmacologic effect of these benzodiazepines.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Temazepam</p>
<p>Nitrazepam</p>
<p>Lorazepam</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>No Dose Adjustment</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Temazepam, Nitrazepam, Lorazepam:</span> For benzodiazepines which are not metabolized by CYP3A (e.g., temazepam, nitrazepam, lorazepam), a clinically important interaction with clarithromycin is unlikely.
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Cytochrome P450 Inducers:</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule Toprule,' valign=,'top,'></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Rifabutin</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Use With Caution</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Rifabutin:</span> Concomitant administration of rifabutin and clarithromycin resulted in an increase in rifabutin, and decrease in clarithromycin serum levels together with an increased risk of uveitis (see Rifabutin under “Drugs That Affect Clarithromycin Tablets” in the table below).
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Other Drugs Metabolized by CYP3A:</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule Toprule,' valign=,'top,'></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Alfentanil</p>
<p>Bromocriptine</p>
<p>Cilostazol</p>
<p>Methylprednisolone</p>
<p>Vinblastine</p>
<p>Phenobarbital</p>
<p>St. John’s Wort</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Use With Caution</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with alfentanil, methylprednisolone, cilostazol, bromocriptine, vinblastine, phenobarbital, and St. John’s Wort.</p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Other Drugs Metabolized by CYP450 Isoforms Other than CYP3A:</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule Toprule,' valign=,'top,'></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Hexobarbital</p>
<p>Phenytoin</p>
<p>Valproate</p>
</td><td valign=,'top,'>
<p class=,'First,'>Use With Caution</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>There have been postmarketing reports of interactions of clarithromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, and valproate.</p>
</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule,' colspan=,'3,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Drugs that Affect Clarithromycin Tablets</span>
</p>
</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Drug(s) that Affect the</span>
</p>
<p>
<span class=,'Bold,'>Pharmacokinetics of</span>
</p>
<p>
<span class=,'Bold,'>Clarithromycin Tablets</span>
</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Recommendation</span>
</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Comments</span>
</p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Antifungals:</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule Toprule,' valign=,'top,'></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Itraconazole</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Use With Caution</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Itraconazole:</span> Itraconazole may increase the plasma concentrations of clarithromycin. Patients taking itraconazole and clarithromycin concomitantly should be monitored closely for signs or symptoms of increased or prolonged adverse reactions (see also Itraconazole under “Drugs That Are Affected By Clarithromycin Tablets” in the table above).
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Antivirals:</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule Toprule,' valign=,'top,'></td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Atazanavir</p>
</td><td valign=,'top,'>
<p class=,'First,'>Use With Caution</p>
</td><td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Atazanavir:</span> When clarithromycin is co-administered with atazanavir, the dose of clarithromycin should be decreased by 50% 
           
     
      <span class=,'Italics,'>[see Clinical Pharmacology (
            
      
       <a href=,'#ID_57948296-7474-4799-90ec-95c0197eea54,'>12.3</a>)]
           
     
      </span>.
          
    
     </p>
<p>Since concentrations of 14-OH clarithromycin are significantly reduced when clarithromycin is co‑administered with atazanavir, alternative antibacterial therapy should be considered for indications other than infections due to 
           
     
      <span class=,'Italics,'>Mycobacterium avium </span>complex. Doses of clarithromycin greater than 1000 mg per day should not be co-administered with protease inhibitors.
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Ritonavir (in patients with decreased renal function)</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Ritonavir:</span> Since concentrations of 14-OH clarithromycin are significantly reduced when clarithromycin is co-administered with ritonavir, alternative antibacterial therapy should be considered for indications other than infections due to 
           
     
      <span class=,'Italics,'>Mycobacterium avium [see Pharmacokinetics (
            
      
       <a href=,'#ID_57948296-7474-4799-90ec-95c0197eea54,'>12.3</a>)]
           
     
      </span>.
          
    
     </p>
<p>Doses of clarithromycin greater than 1000 mg per day should not be co-administered with protease inhibitors.</p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Saquinavir (in patients with decreased renal function)</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Saquinavir:</span> When saquinavir is co-administered with ritonavir, consideration should be given to the potential effects of ritonavir on clarithromycin (refer to ritonavir above) 
           
     
      <span class=,'Italics,'>[see Pharmacokinetics (
            
      
       <a href=,'#ID_57948296-7474-4799-90ec-95c0197eea54,'>12.3</a>)]
           
     
      </span>.
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Etravirine</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Etravirine:</span> Clarithromycin exposure was decreased by etravirine; however, concentrations of the active metabolite, 14-OH-clarithromycin, were increased. Because 14-OH-clarithromycin has reduced activity against 
           
     
      <span class=,'Italics,'>Mycobacterium avium </span>complex (MAC), overall activity against this pathogen may be altered; therefore alternatives to clarithromycin should be considered for the treatment of MAC.
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Saquinavir (in patients with normal renal function)</p>
<p>Ritonavir (in patients with normal renal function)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>No Dose Adjustment</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'></td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Proton Pump Inhibitors:</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule Toprule,' valign=,'top,'></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Omeprazole</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Use With Caution</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Omeprazole:</span> Clarithromycin concentrations in the gastric tissue and mucus were also increased by concomitant administration of omeprazole 
           
     
      <span class=,'Italics,'>[see Pharmacokinetics (
            
      
       <a href=,'#ID_57948296-7474-4799-90ec-95c0197eea54,'>12.3</a>)]
           
     
      </span>.
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Miscellaneous Cytochrome P450 Inducers:</p>
</td><td valign=,'top,'></td><td class=,'Lrule Rrule Toprule,' valign=,'top,'></td>
</tr>
<tr class=,'Last,'>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Efavirenz</p>
<p>Nevirapine</p>
<p>Rifampicin</p>
<p>Rifabutin</p>
<p>Rifapentine</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Use With Caution</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Inducers of CYP3A enzymes, such as efavirenz, nevirapine, rifampicin, rifabutin, and rifapentine will increase the metabolism of clarithromycin, thus decreasing plasma concentrations of clarithromycin, while increasing those of 14-OH-clarithromycin. Since the microbiological activities of clarithromycin and 14-OH-clarithromycin are different for different bacteria, the intended therapeutic effect could be impaired during concomitant administration of clarithromycin and enzyme inducers. Alternative antibacterial treatment should be considered when treating patients receiving inducers of CYP3A. There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with rifabutin (see Rifabutin under “Drugs That Are Affected By Clarithromycin Tablets” in the table above).</p>
</td>
</tr>
</tbody>
</table></div>
</div>"
"clindamycin","5f35ccc3-15b3-4672-9c1f-986e8af6a0d3","none found"
"clobazam","07e0ae51-cc71-427f-83cb-311b7fcc5993","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Opioids</h2>
<p class=,'First,'>The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites, and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and follow patients closely for respiratory depression and sedation <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#Section_5.1,'>5.1</a>)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 CNS Depressants and Alcohol</h2>
<p class=,'First,'>Concomitant use of clobazam oral suspension with other CNS depressants may increase the risk of sedation and somnolence <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#Section_5.2,'>5.</a>4)].</span>
</p>
<p>Alcohol, as a CNS depressant, will interact with clobazam oral suspension in a similar way and also increases clobazam’s maximum plasma exposure by approximately 50%. Therefore, caution patients or their caregivers against simultaneous use with other CNS depressant drugs or alcohol, and caution that the effects of other CNS depressant drugs or alcohol may be potentiated <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#Section_5.2,'>5.</a>4)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Effect of Clobazam oral suspension on Other Drugs</h2>
<p class=,'First,'>
<span class=,'Underline,'>Hormonal Contraceptives</span>
<br/> Clobazam oral suspension is a weak CYP3A4 inducer. As some hormonal contraceptives are metabolized by CYP3A4, their effectiveness may be diminished when given with clobazam oral suspension. Additional non- hormonal forms of contraception are recommended when using clobazam oral suspension<span class=,'Italics,'> [see Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>), Patient Counseling Information (<a href=,'#Section_14,'>17</a>)].</span>
</p>
<p>
<span class=,'Underline,'>
<br/> Drugs Metabolized by CYP2D6</span>
<br/> Clobazam oral suspension inhibits CYP2D6. Dose adjustment of drugs metabolized by CYP2D6 may be necessary<span class=,'Italics,'> [see Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)].<br/>
</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Effect of Other Drugs on Clobazam oral suspension</h2>
<p class=,'First,'>
<span class=,'Underline,'>Strong and moderate inhibitors of CYP2C19</span>
<br/> Strong and moderate inhibitors of CYP2C19 may result in increased exposure to N-desmethylclobazam, the active metabolite of clobazam. This may increase the risk of dose-related adverse reactions. Dosage adjustment of clobazam oral suspension may be necessary when co-administered with strong CYP2C19 inhibitors (e.g., fluconazole, fluvoxamine, ticlopidine) or moderate CYP2C19 inhibitors (e.g., omeprazole)<span class=,'Italics,'> [see Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)].</span>
</p>
<br/>
</div>
</div>"
"clomiphene","49860a2f-92f2-4da8-b78f-0efc005d725a","none found"
"clomipramine","b1739aa5-69d8-4a69-be58-6d789ea2a516","none found"
"clonazepam","00f01bd8-af64-4dcc-9975-8e433e32187f","none found"
"clonidine","ada02f1f-ae78-4435-879e-492ae862d504","none found"
"clopidogrel","063cd1eb-98fd-422e-8145-bba04c497efe","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.7,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 CYP2C19 Inducers</h2>
<p class=,'First,'>Since clopidogrel is metabolized to its active metabolite partly by CYP2C19, use of drugs that induce the activity of this enzyme would be expected to result in increased drug levels of the active metabolite of clopidogrel.<br/> Rifampin strongly induces CYP2C19 resulting to both an increase level of clopidogrel active metabolite and platelet inhibition, which in particular might potentiate the risk of bleeding. As a precaution, avoid concomitant use of strong CYP2C19 inducers [<span class=,'Italics,'>see Warnings and Precautions (<a href=,'#Section_5.1,'>5.1</a>) and Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)].</span>
</p>
<br/>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.1,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 CYP2C19 Inhibitors</h2>
<p class=,'First,'>
<span><a name=,'OLE_LINK2,'></a></span>Clopidogrel is metabolized to its active metabolite in part by CYP2C19. Concomitant use of drugs that inhibit the activity of this enzyme results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition [<span class=,'Italics,'>see Warnings and Precautions (<a href=,'#Section_5.1,'>5.1</a>)</span>].<br/>  <br/>
<span class=,'Underline,'>Omeprazole or Esomeprazole<br/>
</span>Avoid concomitant use of clopidogrel with omeprazole or esomeprazole. In clinical studies, omeprazole was shown to reduce significantly the antiplatelet activity of clopidogrel when given concomitantly or 12 hours apart. A similar reduction in antiplatelet activity was observed with esomeprazole when given concomitantly with clopidogrel. Dexlansoprazole, lansoprazole, and pantoprazole had less effect on the antiplatelet activity of clopidogrel than did omeprazole or esomeprazole [<span class=,'Italics,'>see Warnings and Precautions (<a href=,'#Section_5.1,'>5.1</a>) and Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)</span>].<br/>
<span><a name=,'OLE_LINK1,'></a></span>
</p>
<br/>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.6,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Opioids</h2>
<p class=,'First,'>As with other oral P2Y<span class=,'Sub,'>12</span> inhibitors, coadministration of opioid agonists delay and reduce the absorption of clopidogrel, presumably because of slowed gastric emptying, resulting in reduced exposure to its metabolites [<span class=,'Italics,'>see Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)</span>]. Consider the use of a parenteral antiplatelet agent in acute coronary syndrome patients requiring coadministration of morphine or other opioid agonists.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.2,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)</h2>
<p class=,'First,'>Coadministration of clopidogrel and NSAIDs increases the risk of gastrointestinal bleeding.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.3,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Warfarin (CYP2C9 Substrates)</h2>
<p class=,'First,'>Although the administration of clopidogrel 75 mg per day did not modify the pharmacokinetics of S-warfarin (a CYP2C9 substrate) or INR in patients receiving long-term warfarin therapy, coadministration of clopidogrel with warfarin increases the risk of bleeding because of independent effects on hemostasis. </p>
<br/>
<p>However, at high concentrations <span class=,'Italics,'>in vitr</span>o, clopidogrel inhibits CYP2C9. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.4,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6 SSRIs and SNRIs</h2>
<p class=,'First,'>Since selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) affect platelet activation, the concomitant administration of SSRIs and SNRIs with clopidogrel may increase the risk of bleeding.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.5,'></a><a name=,'section-7.7,'></a>
<p></p>
<h2>7.7 Repaglinide (CYP2C8 Substrates)</h2>
<p class=,'First,'>The acyl-β-glucuronide metabolite of clopidogrel is a strong inhibitor of CYP2C8. Clopidogrel can increase the systemic exposure to drugs that are primarily cleared by CYP2C8, thereby needing dose adjustment and appropriate monitoring. <br/>
<br/>Clopidogrel increased repaglinide exposures by 3.9-fold to 5.1-fold <span class=,'Italics,'>[see Clinical Pharmacology (12.3)]</span>. Avoid concomitant use of repaglinide with clopidogrel. If concomitant use cannot be avoided, initiate repaglinide at 0.5 mg before each meal and do not exceed a total daily dose of 4 mg. Increased frequency of glucose monitoring may be required during concomitant use.</p>
</div>
</div>"
"clotrimazole","00b35b4e-848b-4477-a735-2f88a16af9ef","none found"
"cloxacillin","7aefe003-c331-4577-991a-4ad768d6726d","none found"
"clozapine","17cfeede-2f72-ebe4-4b63-fdd7ed149231","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'s7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'34073-7,'>
<a name=,'ID_1a450530-0a29-4e48-a74f-7ea7968cdc2e,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Potential for Other Drugs to Affect Clozapine</h2>
<p class=,'First,'>Clozapine is a substrate for many cytochrome P450 isozymes, in particular CYP1A2, CYP3A4, and CYP2D6. Use caution when administering clozapine concomitantly with drugs that are inducers or inhibitors of these enzymes.</p>
<p>
<span class=,'Italics,'><span class=,'Underline,'>CYP1A2 Inhibitors</span></span>
</p>
<p>Concomitant use of clozapine and CYP1A2 inhibitors can increase plasma levels of clozapine, potentially resulting in adverse reactions. Reduce the clozapine dose to one-third of the original dose when clozapine is coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or enoxacin). The clozapine dose should be increased to the original dose when coadministration of strong CYP1A2 inhibitors is discontinued <span class=,'Italics,'>[see Dosage and Administration (<a href=,'#ID_add77aee-2de1-43d6-8e44-ddee4357d305,'>2.6</a>), Clinical Pharmacology (<a href=,'#ID_4db2fd61-c3de-43e1-b441-93ba76fa2158,'>12.3</a>)]</span>.</p>
<p>Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine. Monitor patients closely when clozapine is coadministered with these inhibitors. Consider reducing the clozapine dosage if necessary <span class=,'Italics,'>[see Dosage and Administration (<a href=,'#ID_add77aee-2de1-43d6-8e44-ddee4357d305,'>2.6</a>)]</span>. </p>
<p>
<span class=,'Italics,'><span class=,'Underline,'>CYP2D6 and CYP3A4 Inhibitors</span></span>
</p>
<p>Concomitant treatment with clozapine and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#ID_4db2fd61-c3de-43e1-b441-93ba76fa2158,'>12.3</a>)]</span>. Use caution and monitor patients closely when using such inhibitors. Consider reducing the clozapine dose <span class=,'Italics,'>[see Dosage and Administration (<a href=,'#ID_add77aee-2de1-43d6-8e44-ddee4357d305,'>2.6</a>)]</span>. </p>
<p>
<span class=,'Italics,'><span class=,'Underline,'>CYP1A2 and CYP3A4 Inducers</span></span>
</p>
<p>Concomitant treatment with drugs that induce CYP1A2 or CYP3A4 can decrease the plasma concentration of clozapine, resulting in decreased effectiveness of clozapine. Tobacco smoke is a moderate inducer of CYP1A2. Strong CYP3A4 inducers include carbamazepine, phenytoin, St. John’s wort, and rifampin. It may be necessary to increase the clozapine dose if used concomitantly with inducers of these enzymes. However, concomitant use of clozapine and strong CYP3A4 inducers is not recommended <span class=,'Italics,'>[see Dosage and Administration (<a href=,'#ID_add77aee-2de1-43d6-8e44-ddee4357d305,'>2.6</a>)]</span>. </p>
<p>Consider reducing the clozapine dosage when discontinuing coadministered enzyme inducers; because discontinuation of inducers can result in increased clozapine plasma levels and an increased risk of adverse reactions <span class=,'Italics,'>[see Dosage and Administration (<a href=,'#ID_add77aee-2de1-43d6-8e44-ddee4357d305,'>2.6</a>)]</span>. </p>
<p>
<span class=,'Italics,'><span class=,'Underline,'>Anticholinergic Drugs</span></span>
</p>
<p>Concomitant treatment with clozapine and other drugs with anticholinergic activity (e.g., benztropine, cyclobenzaprine, diphenhydramine) can increase the risk for anticholinergic toxicity and severe gastrointestinal adverse reactions related to hypomotility. Avoid concomitant use of clozapine with anticholinergic drugs when possible <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#ID_be74a3b4-65ce-4057-9e7c-f5de1da93970,'>5.8</a>, <a href=,'#ID_c0c2ed92-50f0-425f-a332-06500c85ddf3,'>5.16</a>)]</span>.</p>
<p>
<span class=,'Italics,'><span class=,'Underline,'>Drugs that Cause QT Interval Prolongation</span></span>
</p>
<p>Use caution when administering concomitant medications that prolong the QT interval or inhibit the metabolism of clozapine. Drugs that cause QT prolongation include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, thioridazine, mesoridazine, droperidol, and pimozide), specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin), Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class III antiarrhythmics (e.g., amiodarone, sotalol), and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus) <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#ID_b83ed02b-e536-4afe-ae19-fa196c6b4a9a,'>5.10</a>)]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'34073-7,'>
<a name=,'ID_161b952e-5c4c-439c-9827-250075902cff,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Potential for Clozapine to Affect Other Drugs</h2>
<p class=,'First,'>Concomitant use of clozapine with other drugs metabolized by CYP2D6 can increase levels of these CYP2D6 substrates. Use caution when coadministering clozapine with other drugs that are metabolized by CYP2D6. It may be necessary to use lower doses of such drugs than usually prescribed. Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).</p>
</div>
</div>"
"nonacog alfa","85faa5bc-cee5-4ef1-8d80-bdbcb7eba1e4","none found"
"colchicine","14d4be16-d355-4baf-b4cd-4d97d4b2dca0","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'DRUG_INTERACTIONS,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Colchicine is a substrate of the efflux transporter P-glycoprotein (P-gp). Of the cytochrome P450 enzymes tested, CYP3A4 was mainly involved in the metabolism of colchicine. If colchicine is administered with drugs that inhibit P-gp, most of which also inhibit CYP3A4, increased concentrations of colchicine are likely. Fatal drug interactions have been reported.   </p>
<p>Physicians should ensure that patients are suitable candidates for treatment with colchicine and remain alert for signs and symptoms of toxicities related to increased colchicine exposure as a result of a drug interaction. Signs and symptoms of colchicine toxicity should be evaluated promptly and, if toxicity is suspected, colchicine should be discontinued immediately.   </p>
<p>
<span class=,'Italics,'> Table 4</span> provides recommendations as a result of other potentially significant drug interactions. <span class=,'Italics,'>Table 1</span> provides recommendations for strong and moderate CYP3A4 inhibitors and P-gp inhibitors.</p>
<p>
<span class=,'Bold,'>Table 4. Other Potentially Significant Drug Interactions</span>
</p>
<p></p>
<div class=,'scrollingtable,'><table frame=,'box,' rules=,'all,'>
<tbody align=,'center,' class=,'Headless,'>
<tr class=,'First,'>
<td align=,'left,'><span class=,'Bold,'>Concomitant Drug Class or</span><span class=,'Bold,'> Food</span></td><td><span class=,'Bold,'>Noted or Anticipated</span><span class=,'Bold,'>Outcome</span></td><td><span class=,'Bold,'>Clinical Comment</span></td>
</tr>
<tr>
<td align=,'left,'><span class=,'Bold,'>HMG-Co A Reductase Inhibitors:<br/>
</span>atorvastatin, fluvastatin,lovastatin, pravastatin,simvastatin</td><td align=,'left,' rowspan=,'2,'>Pharmacokinetic and/or pharmacodynamicinteraction: the addition ofone drug to a stable long-termregimen of the other hasresulted in myopathy andrhabdomyolysis (including afatality)</td><td align=,'left,' rowspan=,'3,'>Weigh the potential benefits and risks and carefully monitor patientsfor any signs or symptoms of muscle pain, tenderness, or weakness, particularly during initialtherapy; monitoring CPK (creatine phosphokinase) will not necessarily prevent the occurrence of severemyopathy.</td>
</tr>
<tr>
<td align=,'left,'>
<br/>
<span class=,'Bold,'>Other Lipid-Lowering Drugs:<br/>
</span>fibrates, gemfibrozil</td>
</tr>
<tr class=,'Last,'>
<td align=,'left,'><span class=,'Bold,'>
<br/>Digitalis Glycosides:</span>digoxin</td><td align=,'left,'>P-gp substrate;rhabdomyolysis has beenreported</td>
</tr>
</tbody>
</table></div>
<p></p>
<p></p>
</div>"
"cholestyramine resin","06261db5-1435-4b91-8b54-71bfcfb1368c","none found"
"colistimethate","6d6e13e2-dc33-4b7b-84d0-66146a57c552","none found"
"colistin","94bd9798-5d36-48d0-924b-319662c97e8c","none found"
"vitamin B12","41ac0dc1-0a71-4c69-8e25-ba838f5f16a3","none found"
"cyclophosphamide","15d30249-4714-4b13-b8ca-5dff38424282","none found"
"cytarabine","34803a0e-f54d-4147-8f9f-7d0e3a007756","none found"
"dabigatran","1a214cf1-b41e-46f6-8f24-e3637e6d2612","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Reduction of Risk
of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation</h2>
<p class=,'First,'>The concomitant use of PRADAXA
with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran
and should generally be avoided <span class=,'Italics,'>[see Clinical Pharmacology
(<a href=,'#Section_12.3,'>12.3</a>)]</span>.</p>
<p>P-gp inhibition and impaired renal function
are the major independent factors that result in increased exposure
to dabigatran <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)]</span>.  Concomitant use of P-gp
inhibitors in patients with renal impairment is expected to produce
increased exposure of dabigatran compared to that seen with either
factor alone.</p>
<p>In patients
with moderate renal impairment (CrCl 30-50 mL/min), reduce the dose
of PRADAXA to 75 mg twice daily when administered concomitantly with
the P-gp inhibitors dronedarone or systemic ketoconazole. The use
of the P-gp inhibitors verapamil, amiodarone, quinidine, clarithromycin,
and ticagrelor does not require a dose adjustment of PRADAXA.  These
results should not be extrapolated to other P-gp inhibitors <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#Section_5.5,'>5.5</a>), Use in Specific Populations (<a href=,'#Section_8.6,'>8.6</a>), and Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)]</span>.</p>
<p>The concomitant
use of PRADAXA and P-gp inhibitors in patients with severe renal impairment
(CrCl 15-30 mL/min) should be avoided <span class=,'Italics,'>[see Warnings and Precautions
(<a href=,'#Section_5.5,'>5.5</a>), Use in Specific Populations
(<a href=,'#Section_8.6,'>8.6</a>), and Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Treatment and Reduction
in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary
Embolism</h2>
<p class=,'First,'>Avoid
use of PRADAXA and P-gp inhibitors in patients with CrCl &lt;50 mL/min <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#Section_5.5,'>5.5</a>), Use in Specific Populations (<a href=,'#Section_8.6,'>8.6</a>), and Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism Following
Hip Replacement Surgery</h2>
<p class=,'First,'>In patients with CrCl ≥50 mL/min who have
concomitant administration of P-gp inhibitors such as dronedarone
or systemic ketoconazole, it may be helpful to separate the timing
of administration of dabigatran and the P-gp inhibitor by several
hours. The concomitant use of PRADAXA and P-gp inhibitors in patients
with CrCl &lt;50 mL/min should be avoided <span class=,'Italics,'>[see Warnings and
Precautions (<a href=,'#Section_5.5,'>5.5</a>), Use in Specific
Populations (<a href=,'#Section_8.6,'>8.6</a>) and Clinical Pharmacology
(<a href=,'#Section_12.2,'>12.2</a>, <a href=,'#Section_12.3,'>12.3</a>)]</span>.</p>
</div>
</div>"
"dacarbazine","26e91082-7698-4680-beab-07c47802f0f9","none found"
"dalteparin","23527b8b-9b28-4e6d-9751-33b143975ac7","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>The use of FRAGMIN in patients receiving oral anticoagulants, platelet inhibitors, and thrombolytic agents may increase the risk of bleeding <span class=,'Italics,'>[see <a href=,'#S5,'>Warnings and Precautions (5)</a>]</span>.</p>
</div>"
"dapagliflozin","01f90c94-71cb-4a1f-81ff-8004b850529b","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID_39306089-4d82-4f96-a8a6-b1a6091b9a35,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_6766ab8f-879f-4da2-813b-a6beb9631fc4,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Positive Urine Glucose Test </h2>
<p class=,'First,'>Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors as SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. Use alternative methods to monitor glycemic control.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_c3810af9-8afe-4b22-88da-d0644a9ab6e8,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Interference with 1,5-anhydroglucitol (1,5-AG) Assay </h2>
<p class=,'First,'>Monitoring glycemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control.</p>
</div>
</div>"
"dapsone","0792169d-c6f9-4af0-93ae-b75d710c47a9","none found"
"daptomycin","770d55a5-54d2-4cbd-968b-e08cd6777df8","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1	HMG-CoA Reductase Inhibitors</h2>
<p class=,'First,'>In healthy adult subjects, concomitant administration of Daptomycin for injection and simvastatin had no effect on plasma trough concentrations of simvastatin, and there were no reports of skeletal myopathy <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>However, inhibitors of HMG-CoA reductase may cause myopathy, which is manifested as muscle pain or weakness associated with elevated levels of creatine phosphokinase (CPK). In the adult Phase 3 <span class=,'Italics,'>S. aureus </span>bacteremia/endocarditis trial, some patients who received prior or concomitant treatment with an HMG-CoA reductase inhibitor developed elevated CPK <span class=,'Italics,'>[see <a href=,'#S6.1,'>Adverse Reactions (6.1)</a>]</span>. Experience with the coadministration of HMG-CoA reductase inhibitors and Daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin for injection.</p>
</div>
<div class=,'Section,' data-sectioncode=,'34074-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2	Drug-Laboratory Test Interactions</h2>
<p class=,'First,'>Clinically relevant plasma concentrations of daptomycin have been observed to cause a significant concentration-dependent false prolongation of prothrombin time (PT) and elevation of International Normalized Ratio (INR) when certain recombinant thromboplastin reagents are utilized for the assay. The possibility of an erroneously elevated PT/INR result due to interaction with a recombinant thromboplastin reagent may be minimized by drawing specimens for PT or INR testing near the time of trough plasma concentrations of daptomycin. However, sufficient daptomycin concentrations may be present at trough to cause interaction.</p>
<p>If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin for injection, it is recommended that clinicians:</p>
<ol class=,'Arabic,'>
<li>Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin for injection dose (i.e., at trough concentration). If the PT/INR value obtained at trough remains substantially elevated above what would otherwise be expected, consider evaluating PT/INR utilizing an alternative method.</li>
<li>Evaluate for other causes of abnormally elevated PT/INR results.</li>
</ol>
</div>
</div>"
"darbepoetin alfa","0fd36cb9-c4f6-4167-93c9-8530865db3f9","none found"
"darifenacin","7ae60119-e22c-4806-a5d8-db7c9e8984a2","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 CYP3A4 Inhibitors</h2>
<p class=,'First,'>The systemic exposure of darifenacin from darifenacin extended-release tablets is increased in the presence of CYP3A4 inhibitors. The daily dose of darifenacin should not exceed 7.5 mg when co-administered with potent CYP3A4 inhibitors (for example, ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone). No dosing adjustments are recommended in the presence of moderate CYP3A4 inhibitors (for example, erythromycin, fluconazole, diltiazem and verapamil)<span class=,'Italics,'> [see Dosage and Administration (<a href=,'#Section_2,'>2</a>) and Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)]. </span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 CYP2D6 Inhibitors</h2>
<p class=,'First,'>No dosing adjustments are recommended in the presence of CYP2D6 inhibitors (for example, paroxetine, fluoxetine, quinidine and duloxetine) <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 CYP2D6 Substrates</h2>
<p class=,'First,'>Caution should be taken when darifenacin is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window (for example, flecainide, thioridazine and tricyclic antidepressants) <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)]. </span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 CYP3A4 Substrates</h2>
<p class=,'First,'>Darifenacin (30 mg daily) did not have a significant impact on midazolam (7.5 mg) pharmacokinetics <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)]. </span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.5,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Combination oral contraceptives</h2>
<p class=,'First,'>Darifenacin (10 mg three times daily) had no effect on the pharmacokinetics of the combination oral contraceptives containing levonorgestrel and ethinyl estradiol <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)]. </span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.6,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6 Warfarin</h2>
<p class=,'First,'>Darifenacin had no significant effect on prothrombin time when a single dose of warfarin 30 mg was coadministered with darifenacin (30 mg daily) at steady-state. Standard therapeutic prothrombin time monitoring for warfarin should be continued.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.7,'></a><a name=,'section-7.7,'></a>
<p></p>
<h2>7.7 Digoxin</h2>
<p class=,'First,'>Darifenacin (30 mg daily) did not have a clinically relevant effect on the pharmacokinetics of digoxin (0.25 mg) at steady-state. Routine therapeutic drug monitoring for digoxin should be continued <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)]. </span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.8,'></a><a name=,'section-7.8,'></a>
<p></p>
<h2>7.8 Other Anticholinergic Agents</h2>
<p class=,'First,'>The concomitant use of darifenacin with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision and other anticholinergic pharmacological effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to effects on gastrointestinal motility.</p>
</div>
</div>"
"darunavir","13671be1-b4b4-44c9-a27d-0727f937bb3c","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>See also <span class=,'Italics,'><a href=,'#S4,'>Contraindications (4)</a></span> and <span class=,'Italics,'><a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a></span>.</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1	Potential for PREZISTA/ritonavir to Affect Other Drugs</h2>
<p class=,'First,'>PREZISTA co-administered with ritonavir is an inhibitor of CYP3A and CYP2D6. Co-administration of PREZISTA and ritonavir with drugs that are primarily metabolized by CYP3A and CYP2D6 may result in increased plasma concentrations of such drugs, which could increase or prolong their therapeutic effect and adverse events (see<a href=,'#table9,'> Table 9</a>).</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2	Potential for Other Drugs to Affect Darunavir</h2>
<p class=,'First,'>Darunavir and ritonavir are metabolized by CYP3A. Drugs that induce CYP3A activity would be expected to increase the clearance of darunavir and ritonavir, resulting in lowered plasma concentrations of darunavir and ritonavir. Co-administration of darunavir and ritonavir and other drugs that inhibit CYP3A may decrease the clearance of darunavir and ritonavir and may result in increased plasma concentrations of darunavir and ritonavir (see<a href=,'#table9,'> Table 9</a>).</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3	Established and Other Potentially Significant Drug Interactions</h2>
<p class=,'First,'>Table 9 provides dosing recommendations as a result of drug interactions with PREZISTA/ritonavir. These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious adverse events or loss of efficacy.</p>
<a name=,'table9,'></a>
<div class=,'scrollingtable,'><table width=,'100%,'>
<caption>
<span>Table 9: Established and Other Potentially Significant Drug Interactions: Alterations in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction [See<a href=,'#S12.3,'> Clinical Pharmacology (12.3) </a>for Magnitude of Interaction, Tables 12 and 13]</span>
</caption>
<col align=,'left,' valign=,'top,' width=,'33%,'/>
<col align=,'left,' valign=,'top,' width=,'34%,'/>
<col align=,'left,' valign=,'top,' width=,'33%,'/>
<thead>
<tr class=,'First Last,'>
<th align=,'left,' class=,'Lrule Rrule,'>Concomitant Drug Class:<br/>Drug Name</th><th align=,'left,' class=,'Rrule,'>Effect on Concentration of Darunavir or Concomitant Drug</th><th align=,'left,' class=,'Rrule,'>Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr class=,'Botrule First,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'3,'><span class=,'Bold,'>HIV-1-Antiviral Agents: Nucleoside Reverse Transcriptase Inhibitors (NRTIs)</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>didanosine</td><td align=,'left,' class=,'Rrule,'>↔ darunavir<br/>↔ didanosine</td><td align=,'left,' class=,'Rrule,'>Didanosine should be administered one hour before or two hours after PREZISTA/ritonavir (which are administered with food).</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'3,'><span class=,'Bold,'>HIV-1-Antiviral Agents: HIV-Protease Inhibitors (PIs)</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>indinavir<br/> <br/>(The reference regimen for indinavir was indinavir/ritonavir 800/100 mg twice daily.)</td><td align=,'left,' class=,'Rrule,'>↑ darunavir<br/>↑ indinavir</td><td align=,'left,' class=,'Rrule,'>The appropriate dose of indinavir in combination with PREZISTA/ritonavir has not been established.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>lopinavir/ritonavir</td><td align=,'left,' class=,'Rrule,'>↓ darunavir<br/>↔ lopinavir</td><td align=,'left,' class=,'Rrule,'>Appropriate doses of the combination have not been established. Hence, it is not recommended to co-administer lopinavir/ritonavir and PREZISTA, with or without ritonavir.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>saquinavir</td><td align=,'left,' class=,'Rrule,'>↓ darunavir<br/>↔ saquinavir</td><td align=,'left,' class=,'Rrule,'>Appropriate doses of the combination have not been established. Hence, it is not recommended to co-administer saquinavir and PREZISTA, with or without ritonavir.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'3,'><span class=,'Bold,'>HIV-1-Antiviral Agents: CCR5 co-receptor antagonists</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>maraviroc</td><td align=,'left,' class=,'Rrule,'>↑ maraviroc</td><td align=,'left,' class=,'Rrule,'>Maraviroc concentrations are increased when co-administered with PREZISTA/ritonavir. When used in combination with PREZISTA/ritonavir, the dose of maraviroc should be 150 mg twice daily.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'3,'><span class=,'Bold,'>Other Agents</span></td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Antiarrhythmics</span>:<br/>bepridil,<br/>lidocaine (systemic),<br/>quinidine,<br/>amiodarone,<br/>flecainide,<br/>propafenone</td><td align=,'left,' class=,'Rrule,'>↑ antiarrhythmics</td><td align=,'left,' class=,'Rrule,'>Concentrations of these drugs may be increased when co-administered with PREZISTA/ritonavir. Caution is warranted and therapeutic concentration monitoring, if available, is recommended for antiarrhythmics when co-administered with PREZISTA/ritonavir.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>digoxin</td><td align=,'left,' class=,'Rrule,'>↑ digoxin</td><td align=,'left,' class=,'Rrule,'>The lowest dose of digoxin should initially be prescribed. The serum digoxin concentrations should be monitored and used for titration of digoxin dose to obtain the desired clinical effect.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Anticoagulant</span>:<br/>warfarin</td><td align=,'left,' class=,'Rrule,'>↓ warfarin<br/>↔ darunavir</td><td align=,'left,' class=,'Rrule,'>Warfarin concentrations are decreased when co-administered with PREZISTA/ritonavir. It is recommended that the international normalized ratio (INR) be monitored when warfarin is combined with PREZISTA/ritonavir.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Anticonvulsant</span>:<br/>carbamazepine</td><td align=,'left,' class=,'Rrule,'>↔ darunavir<br/>↑ carbamazepine</td><td align=,'left,' class=,'Rrule,'>The dose of either darunavir/ritonavir or carbamazepine does not need to be adjusted when initiating co-administration with darunavir/ritonavir and carbamazepine. Clinical monitoring of carbamazepine concentrations and its dose titration is recommended to achieve the desired clinical response.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Anticonvulsant</span>:<br/>phenobarbital,<br/>phenytoin</td><td align=,'left,' class=,'Rrule,'>↔ darunavir<br/>↓ phenytoin<br/>↓ phenobarbital</td><td align=,'left,' class=,'Rrule,'>Co-administration of PREZISTA/ritonavir may cause a decrease in the steady-state concentrations of phenytoin and phenobarbital. Phenytoin and phenobarbital levels should be monitored when co-administering with PREZISTA/ritonavir.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Antidepressant</span>:<br/>trazodone,<br/>desipramine</td><td align=,'left,' class=,'Rrule,'>↑ trazodone<br/>↑ desipramine</td><td align=,'left,' class=,'Rrule,'>Concomitant use of trazodone or desipramine and PREZISTA/ritonavir may increase plasma concentrations of trazodone or desipramine which may lead to adverse events such as nausea, dizziness, hypotension and syncope. If trazodone or desipramine is used with PREZISTA/ritonavir, the combination should be used with caution, and a lower dose of trazodone or desipramine should be considered.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Anti-infective</span>:<br/>clarithromycin</td><td align=,'left,' class=,'Rrule,'>↔ darunavir<br/>↑ clarithromycin</td><td align=,'left,' class=,'Rrule,'>No dose adjustment of the combination is required for patients with normal renal function. For patients with renal impairment, the following dose adjustments should be considered: 							<ul>
<li>For subjects with CLcr of 30–60 mL/min, the dose of clarithromycin should be reduced by 50%.</li>
<li>For subjects with CLcr of &lt; 30 mL/min, the dose of clarithromycin should be reduced by 75%.</li>
</ul>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Antifungals</span>:<br/>ketoconazole,<br/>itraconazole,<br/>voriconazole</td><td align=,'left,' class=,'Rrule,'>↑ ketoconazole<br/>↑ darunavir<br/>↑ itraconazole<br/>(not studied)<br/>↓ voriconazole<br/>(not studied)</td><td align=,'left,' class=,'Rrule,'>Ketoconazole and itraconazole are potent inhibitors as well as substrates of CYP3A. Concomitant systemic use of ketoconazole, itraconazole, and darunavir/ritonavir may increase plasma concentration of darunavir.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'></td><td align=,'left,' class=,'Rrule,'></td><td align=,'left,' class=,'Rrule,'>Plasma concentrations of ketoconazole or itraconazole may be increased in the presence of darunavir/ritonavir. When co-administration is required, the daily dose of ketoconazole or itraconazole should not exceed 200 mg.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'></td><td align=,'left,' class=,'Rrule,'></td><td align=,'left,' class=,'Rrule,'>Plasma concentrations of voriconazole may be decreased in the presence of darunavir/ritonavir. Voriconazole should not be administered to patients receiving darunavir/ritonavir unless an assessment of the benefit/risk ratio justifies the use of voriconazole.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Anti-gout</span>:<br/>colchicine</td><td align=,'left,' class=,'Rrule,'>↑ colchicine</td><td align=,'left,' class=,'Rrule,'><span class=,'Underline,'>Treatment of gout-flares – co-administration of colchicine in patients on PREZISTA/ritonavir:</span>
<br/>0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (half tablet) 1 hour later. Treatment course to be repeated no earlier than 3 days.<br/> <br/>
<p class=,'First,'>
<span class=,'Underline,'>Prophylaxis of gout-flares – co-administration of colchicine in patients on PREZISTA/ritonavir:</span>
<br/>If the original regimen was 0.6 mg twice a day, the regimen should be adjusted to 0.3 mg once a day.<br/>If the original regimen was 0.6 mg once a day, the regimen should be adjusted to 0.3 mg once every other day. </p>
<br/>
<p>
<span class=,'Underline,'>Treatment of familial Mediterranean fever – co-administration of colchicine in patients on PREZISTA/ritonavir:</span>
<br/>maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day).<br/>Patients with renal or hepatic impairment should not be given colchicine with PREZISTA/ritonavir.</p>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Antimycobacterial</span>:<br/>rifabutin</td><td align=,'left,' class=,'Botrule Rrule,' rowspan=,'2,'>↑ darunavir<br/>↑ rifabutin<br/>↑ 25-<span class=,'Italics,'>O</span>-desacetylrifabutin</td><td align=,'left,' class=,'Botrule Rrule,' rowspan=,'2,'>Dose reduction of rifabutin by at least 75% of the usual dose (300 mg once daily) is recommended (i.e., a maximum dose of 150 mg every other day). Increased monitoring for adverse events is warranted in patients receiving this combination and further dose reduction of rifabutin may be necessary.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>The reference regimen for rifabutin was 300 mg once daily</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>β-Blockers</span>:<br/> <br/>metoprolol,<br/>timolol</td><td align=,'left,' class=,'Rrule,'>↑ beta-blockers</td><td align=,'left,' class=,'Rrule,'>Caution is warranted and clinical monitoring of patients is recommended. A dose decrease may be needed for these drugs when co-administered with PREZISTA/ritonavir.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Benzodiazepines</span>:<br/>parenterally administered midazolam</td><td align=,'left,' class=,'Rrule,'>↑ midazolam</td><td align=,'left,' class=,'Rrule,'>Concomitant use of parenteral midazolam with PREZISTA/ritonavir may increase plasma concentrations of midazolam. Co-administration should be done in a setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered. Co-administration of oral midazolam with PREZISTA/ritonavir is CONTRAINDICATED.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Calcium Channel</span>
<br/>
<span class=,'Bold,'>Blockers</span>:<br/>felodipine,<br/>nifedipine,<br/>nicardipine</td><td align=,'left,' class=,'Rrule,'>↑ calcium channel blockers </td><td align=,'left,' class=,'Rrule,'>Plasma concentrations of calcium channel blockers (e.g., felodipine, nifedipine, nicardipine) may increase when PREZISTA/ritonavir are co-administered. Caution is warranted and clinical monitoring of patients is recommended.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Corticosteroid</span>:<br/>
<span class=,'Bold,'>Systemic</span>:<br/>dexamethasone</td><td align=,'left,' class=,'Rrule,'>↓ darunavir</td><td align=,'left,' class=,'Rrule,'>Systemic dexamethasone induces CYP3A and can thereby decrease darunavir plasma concentrations. This may result in loss of therapeutic effect to PREZISTA.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Corticosteroid</span>:<br/>
<span class=,'Bold,'>Inhaled/Nasal</span>:<br/>fluticasone</td><td align=,'left,' class=,'Rrule,'>↑ fluticasone</td><td align=,'left,' class=,'Rrule,'>Concomitant use of inhaled fluticasone and PREZISTA/ritonavir may increase plasma concentrations of fluticasone. Alternatives should be considered, particularly for long-term use.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Endothelin receptor antagonists</span>:<br/>bosentan</td><td align=,'left,' class=,'Rrule,'>↑ bosentan</td><td align=,'left,' class=,'Rrule,'>
<p class=,'First,'>
<span class=,'Underline,'>Co-administration of bosentan in patients on PREZISTA/ritonavir:</span>
<br/>In patients who have been receiving PREZISTA/ritonavir for at least 10 days, start bosentan at 62.5 mg once daily or every other day based upon individual tolerability. </p>
<br/>
<p>
<span class=,'Underline,'>Co-administration of PREZISTA/ritonavir in patients on bosentan:</span>
<br/>Discontinue use of bosentan at least 36 hours prior to initiation of PREZISTA/ritonavir. After at least 10 days following the initiation of PREZISTA/ritonavir, resume bosentan at 62.5 mg once daily or every other day based upon individual tolerability.</p>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Hepatitis C Virus (HCV) Direct-Acting Agents: <br/>NS3-4A protease inhibitors:</span>
<br/>boceprevir<br/>telaprevir</td><td align=,'left,' class=,'Rrule,'>↓ darunavir <br/>↓ boceprevir<br/>↓ telaprevir</td><td align=,'left,' class=,'Rrule,'>
<p class=,'First,'>Concomitant administration of PREZISTA/ritonavir and boceprevir or telaprevir  resulted in reduced steady-state exposures to darunavir and boceprevir or telaprevir.  It is not recommended to co-administer boceprevir or telaprevir and PREZISTA/ritonavir.</p>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>HMG-CoA</span>
<br/>
<span class=,'Bold,'>Reductase Inhibitors</span>:<br/>pravastatin,<br/>atorvastatin,<br/>rosuvastatin</td><td align=,'left,' class=,'Rrule,'>↑ pravastatin<br/>↑ atorvastatin<br/> ↑ rosuvastatin</td><td align=,'left,' class=,'Rrule,'>Titrate atorvastatin, pravastatin or rosuvastatin dose carefully and use the lowest necessary dose while monitoring for safety.  Do not exceed atorvastatin  20 mg/day.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Immunosuppressants</span>:<br/>cyclosporine,<br/>tacrolimus,<br/>sirolimus</td><td align=,'left,' class=,'Rrule,'>↑ immunosuppressants</td><td align=,'left,' class=,'Rrule,'>Plasma concentrations of cyclosporine, tacrolimus or sirolimus may be increased when co-administered with PREZISTA/ritonavir. Therapeutic concentration monitoring of the immunosuppressive agent is recommended when co-administered with PREZISTA/ritonavir.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Inhaled beta agonist</span>:<br/>salmeterol</td><td align=,'left,' class=,'Rrule,'>↑ salmeterol</td><td align=,'left,' class=,'Rrule,'>Concurrent administration of salmeterol and PREZISTA/ritonavir is not recommended. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Narcotic Analgesic/Treatment of Opioid Dependence</span>:<br/>methadone,<br/>buprenorphine,<br/>buprenorphine/naloxone</td><td align=,'left,' class=,'Rrule,'>↓ methadone<br/>↔  buprenorphine, naloxone<br/>↑ norbuprenorphine (metabolite)</td><td align=,'left,' class=,'Rrule,'>No adjustment of methadone dosage is required when initiating co-administration of PREZISTA/ritonavir. However, clinical monitoring is recommended as the dose of methadone during maintenance therapy may need to be adjusted in some patients.<br/>No dose adjustment for buprenorphine or buprenorphine/naloxone is required with concurrent administration of PREZISTA/ritonavir. Clinical monitoring is recommended if PREZISTA/ritonavir and buprenorphine or buprenorphine/naloxone are coadministered.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Neuroleptics</span>:<br/>risperidone,<br/>thioridazine</td><td align=,'left,' class=,'Rrule,'>↑ neuroleptics</td><td align=,'left,' class=,'Rrule,'>A dose decrease may be needed for these drugs when co-administered with PREZISTA/ritonavir.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Oral Contraceptives/estrogen</span>:<br/>ethinyl estradiol,<br/>norethindrone</td><td align=,'left,' class=,'Rrule,'>↓ ethinyl estradiol<br/>↓ norethindrone</td><td align=,'left,' class=,'Rrule,'>Plasma concentrations of ethinyl estradiol are decreased due to induction of its metabolism by ritonavir. Alternative methods of nonhormonal contraception are recommended.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>PDE-5 inhibitors</span>:<br/>sildenafil,<br/>vardenafil,<br/>tadalafil</td><td align=,'left,' class=,'Rrule,'>↑ PDE-5 inhibitors (only the use of sildenafil at doses used for treatment of erectile dysfunction has been studied with PREZISTA/ritonavir)</td><td align=,'left,' class=,'Rrule,'>
<p class=,'First,'>Co-administration with PREZISTA/ritonavir may result in an increase in PDE-5 inhibitor-associated adverse events, including hypotension, syncope, visual disturbances and priapism.</p>
<br/>
<p>
<span class=,'Underline,'>Use of PDE-5 inhibitors for pulmonary arterial hypertension (PAH):</span>
</p>
<ul>
<li>Use of sildenafil is contraindicated when used for the treatment of pulmonary arterial hypertension (PAH) [<span class=,'Italics,'>see <a href=,'#S4,'>Contraindications (4)</a></span>].</li>
<li>The following dose adjustments are recommended for use of tadalafil with PREZISTA/ritonavir:<br/>
<span class=,'Underline,'>Co-administration of tadalafil in patients on PREZISTA/ritonavir:</span>
<br/>In patients receiving PREZISTA/ritonavir for at least one week, start tadalafil at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability.<br/>
<span class=,'Underline,'>Co-administration of PREZISTA/ritonavir in patients on tadalafil:</span>
<br/>Avoid use of tadalafil during the initiation of PREZISTA/ritonavir. Stop tadalafil at least 24 hours prior to starting PREZISTA/ritonavir. After at least one week following the initiation of PREZISTA/ritonavir, resume tadalafil at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability. </li>
</ul>
<p>
<span class=,'Underline,'>Use of PDE-5 inhibitors for erectile dysfunction:</span>
<br/>Sildenafil at a single dose not exceeding 25 mg in 48 hours, vardenafil at a single dose not exceeding 2.5 mg dose in 72 hours, or tadalafil at a single dose not exceeding 10 mg dose in 72 hours can be used with increased monitoring for PDE-5 inhibitor-associated adverse events. </p>
</td>
</tr>
<tr class=,'Last,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Selective Serotonin Reuptake Inhibitors (SSRIs)</span>:<br/>sertraline,<br/>paroxetine</td><td align=,'left,' class=,'Rrule,'>↔ darunavir<br/>↓ sertraline <br/>↓ paroxetine</td><td align=,'left,' class=,'Rrule,'>If sertraline or paroxetine is co-administered with PREZISTA/ritonavir, the recommended approach is a careful dose titration of the SSRI based on a clinical assessment of antidepressant response. In addition, patients on a stable dose of sertraline or paroxetine who start treatment with PREZISTA/ritonavir should be monitored for antidepressant response.</td>
</tr>
</tbody>
</table></div>
<p>In addition to the drugs included in Table 9, the interaction between PREZISTA/ritonavir and the following drugs were evaluated in clinical studies and no dose adjustments are needed for either drug [see <span class=,'Italics,'><a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a></span>]: atazanavir, efavirenz, etravirine, nevirapine, omeprazole, ranitidine, rilpivirine, and tenofovir disoproxil fumarate.</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.3.1,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Other nucleoside reverse transcriptase inhibitors (NRTIs</span><span class=,'Italics,'>)</span>:</p>
<p>Based on the different elimination pathways of the other NRTIs (zidovudine, zalcitabine, emtricitabine, stavudine, lamivudine and abacavir) that are primarily renally excreted, no drug interactions are expected for these drugs and PREZISTA/ritonavir.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.3.2,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Other </span><span class=,'Italics,'>PIs</span>:</p>
<p>The co-administration of PREZISTA/ritonavir and PIs other than lopinavir/ritonavir, saquinavir, atazanavir, and indinavir has not been studied. Therefore, such co-administration is not recommended.</p>
</div>
</div>
</div>"
"dasabuvir","ab74e474-9fd6-902c-9bd9-16dc9541edd0","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'section_7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section_7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Potential for VIEKIRA PAK to Affect Other Drugs </h2>
<p class=,'First,'>
<a name=,'p97608291393359740,'></a>Ombitasvir, paritaprevir, and dasabuvir are inhibitors of UGT1A1, and ritonavir is an inhibitor of CYP3A4. Paritaprevir is an inhibitor of OATP1B1 and OATP1B3 and paritaprevir, ritonavir and dasabuvir are inhibitors of BCRP. Co-administration of VIEKIRA PAK with drugs that are substrates of CYP3A, UGT1A1, BCRP, OATP1B1 or OATP1B3 may result in increased plasma concentrations of such drugs <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>), Warnings and Precautions (<a href=,'#section_5.5,'>5.5</a>), and Clinical Pharmacology (<a href=,'#section_12.3,'>12.3</a>)]</span>. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section_7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Potential for Other Drugs to Affect One or More Components of VIEKIRA PAK</h2>
<p class=,'First,'>
<a name=,'p947414291393359886,'></a>Paritaprevir and ritonavir are primarily metabolized by CYP3A enzymes. Co-administration of VIEKIRA PAK with strong inhibitors of CYP3A may increase paritaprevir and ritonavir concentrations. Dasabuvir is primarily metabolized by CYP2C8 enzymes. Co-administration of VIEKIRA PAK with drugs that inhibit CYP2C8 may increase dasabuvir plasma concentrations. Ombitasvir is primarily metabolized via amide hydrolysis while CYP enzymes play a minor role in its metabolism. Ombitasvir, paritaprevir, dasabuvir and ritonavir are substrates of P-gp. Ombitasvir, paritaprevir and dasabuvir are substrates of BCRP. Paritaprevir is a substrate of OATP1B1 and OATP1B3. Inhibition of P-gp, BCRP, OATP1B1 or OATP1B3 may increase the plasma concentrations of the various components of VIEKIRA PAK.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section_7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>
<span class=,'Bold,'>7.3 Established and Other Potential Drug Interactions </span>
</h2>
<p class=,'First,'>
<a name=,'p537789291575489420,'></a>Clearance of HCV infection with direct-acting antivirals may lead to changes in hepatic function, which may impact the safe and effective use of concomitant medications. For example, altered blood glucose control resulting in serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies. Management of hypoglycemia in these cases required either discontinuation or dose modification of concomitant medications used for diabetes treatment.</p>
<p>
<a name=,'p499539291575489434,'></a>Frequent monitoring of relevant laboratory parameters (e.g. International Normalized Ratio [INR] in patients taking warfarin, blood glucose levels in diabetic patients) or drug concentrations of concomitant medications such as CYP P450 substrates with a narrow therapeutic index (e.g. certain immunosuppressants) is recommended to ensure safe and effective use. Dose adjustments of concomitant medications may be necessary.</p>
<p>
<a name=,'p138401291393360042,'></a>If dose adjustments of concomitant medications are made due to treatment with VIEKIRA PAK, doses should be re-adjusted after administration of VIEKIRA PAK is completed. Dose adjustment is not required for VIEKIRA PAK.</p>
<p>
<a name=,'p66753291395762943,'></a><a href=,'#table_4,'>Table 4</a> provides the effect of co-administration of VIEKIRA PAK on concentrations of concomitant drugs  and the effect of concomitant drugs on the various components of VIEKIRA PAK. See <span class=,'Italics,'>Contraindications (<a href=,'#section_4,'>4</a>)</span> for drugs that are contraindicated with VIEKIRA PAK. Refer to the ritonavir prescribing information for other potentially significant drug interactions with ritonavir.</p>
<a name=,'table_4,'></a>
<div class=,'scrollingtable,'><table border=,'1,' cellpadding=,'1,' frame=,'box,' width=,'100%,'>
<caption>
<span>Table 4. Drug Interactions </span>
</caption>
<colgroup>
<col width=,'24%,'/>
<col width=,'25%,'/>
<col width=,'49%,'/>
</colgroup>
<tbody class=,'Headless,'>
<tr class=,'First,'>
<td align=,'center,' class=,'Botrule Lrule Rrule Toprule,'><span class=,'Bold,'>Concomitant Drug Class: Drug Name</span></td><td align=,'center,' class=,'Botrule Lrule Rrule Toprule,'><span class=,'Bold,'>Effect on Concentration</span></td><td align=,'center,' class=,'Botrule Lrule Rrule Toprule,'><span class=,'Bold,'>Clinical Comments</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,'><span class=,'Bold,'>ALPHA1-ADRENORECEPTOR ANTAGONIST</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>alfuzosin HCl*</td><td class=,'Botrule Lrule Rrule Toprule,'>↑ alfuzosin HCl</td><td class=,'Botrule Lrule Rrule Toprule,'>Contraindicated due to potential for hypotension <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>)]</span>.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,'><span class=,'Bold,'>ANDROGEN RECEPTOR INHIBITOR</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>apalutamide*</td><td class=,'Botrule Lrule Rrule Toprule,'>↓ ombitasvir<br/>↓ paritaprevir<br/>↓ ritonavir</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Contraindicated due to potential loss of therapeutic activity of VIEKIRA PAK <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>)]</span>.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,'><span class=,'Bold,'>ANGIOTENSIN RECEPTOR BLOCKERS e.g.</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>valsartan<span class=,'Sup,'>*</span>
<br/> losartan<span class=,'Sup,'>*</span>
<br/>candesartan<span class=,'Sup,'>*</span></td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ angiotensin receptor blockers</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Decrease the dose of the angiotensin receptor blockers and monitor patients for signs and symptoms of hypotension and/or worsening renal function. If such events occur, consider further dose reduction of the angiotensin receptor blocker or switching to an alternative to the angiotensin receptor blocker.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,' valign=,'top,'><span class=,'Bold,'>ANTI-ANGINAL</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>ranolazine*</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ ranolazine</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Contraindicated due to potential for serious and/or life-threatening reactions <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>)]</span>.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,'><span class=,'Bold,'>ANTIARRHYTHMICS</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>dronedarone*</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ dronedarone</td><td class=,'Botrule Lrule Rrule Toprule,'>Contraindicated due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>)]</span>.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>amiodarone<span class=,'Sup,'>*</span>,<br/>bepridil<span class=,'Sup,'>*</span>,<br/>disopyramide<span class=,'Sup,'>*</span>,flecainide<span class=,'Sup,'>*</span>,<br/>lidocaine (systemic)<span class=,'Sup,'>*</span>,<br/>mexiletine<span class=,'Sup,'>*</span>,<br/>propafenone<span class=,'Sup,'>*</span>,<br/>quinidine<span class=,'Sup,'>*</span></td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ antiarrhythmics</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>For contraindicated antiarrhythmics <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>)]</span>.<br/>
<br/>Therapeutic concentration monitoring (if available) is recommended for antiarrhythmics when co-administered with VIEKIRA PAK. </td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,'><span class=,'Bold,'>ANTICANCER AGENTS/KINASE INHIBITORS</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>encorafenib*<br/>fostamatinib*<br/>ibrutinib*<br/>ivosidenib*</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ anticancer agents/<br/>kinase inhibitors</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Co-administration of VIEKIRA PAK with these anticancer agents/kinase inhibitors may result in increased risk for adverse events. Refer to the prescribing information of these agents for details on co-administration with strong CYP3A inhibitors.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,'><span class=,'Bold,'>ANTICONVULSANTS</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>carbamazepine*,<br/>phenytoin*, <br/>phenobarbital*</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↓ ombitasvir<br/>↓ paritaprevir<br/>↓ ritonavir</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Contraindicated due to potential loss of therapeutic activity of VIEKIRA PAK <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>)]</span>.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,'><span class=,'Bold,'>ANTIDIABETIC DRUGS</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>metformin</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↔ metformin</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Monitor for signs of onset of lactic acidosis such as respiratory distress, somnolence, and non-specific abdominal distress or worsening renal function. Concomitant metformin use in patients with renal insufficiency or hepatic impairment is not recommended. Refer to the prescribing information of metformin for further guidance.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,' valign=,'top,'><span class=,'Bold,'>ANTI-GOUT</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>colchicine*</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ colchicine</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Contraindicated due to potential for serious and/or life-threatening reactions in patients with renal and/or hepatic impairment <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>)]</span>.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,'><span class=,'Bold,'>ANTIFUNGALS</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>ketoconazole</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ ketoconazole</td><td class=,'Botrule Lrule Rrule Toprule,'>When VIEKIRA PAK is co-administered with ketoconazole, the maximum daily dose of ketoconazole should be limited to 200 mg per day.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>voriconazole<span class=,'Sup,'>*</span></td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↓ voriconazole </td><td class=,'Botrule Lrule Rrule Toprule,'>Co-administration of VIEKIRA PAK with voriconazole is not recommended unless an assessment of the benefit-to-risk ratio justifies the use of voriconazole.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,' valign=,'top,'><span class=,'Bold,'>ANTIHYPERLIPIDEMIC AGENT</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>gemfibrozil</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ dasabuvir<br/>↑ paritaprevir</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Contraindicated due to increase in dasabuvir exposures by 10-fold which may increase the risk of QT prolongation  <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>)]</span>.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,' valign=,'top,'><span class=,'Bold,'>ANTIMYCOBACTERIAL</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>rifampin*</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↓ ombitasvir</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Contraindicated due to potential loss of therapeutic activity of VIEKIRA PAK <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>)]</span>.</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,' valign=,'top,'><span class=,'Bold,'>ANTIPSYCHOTICS</span></td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>lurasidone*</td><td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ lurasidone </td><td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Contraindicated due to potential for serious and/or life-threatening reactions <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>)]</span>.</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>pimozide*</td><td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ pimozide</td><td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Contraindicated due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>)]</span>.</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>quetiapine<span class=,'Sup,'>*</span></td><td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ quetiapine</td><td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>For contraindicated antipsychotics <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>)]</span>.<br/>
<br/>
<ul class=,'Disc,'>
<li>Initiation of VIEKIRA PAK in patients taking quetiapine: Consider alternative anti-HCV therapy to avoid increases in quetiapine exposures. If coadministration is necessary, reduce the quetiapine dose to 1/6<span class=,'Sup,'>th</span> of the current dose and monitor for quetiapine-associated adverse reactions. Refer to the quetiapine prescribing information for the recommendations on adverse reaction monitoring.</li>
<li>Initiation of quetiapine in patients taking VIEKIRA PAK: Refer to the quetiapine prescribing information for initial dosing and titration of quetiapine.</li>
</ul>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,' valign=,'top,'><span class=,'Bold,'>CALCIUM CHANNEL BLOCKERS</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>amlodipine<br/>nifedipine<span class=,'Sup,'>*</span>
<br/>diltiazem<span class=,'Sup,'>*</span>
<br/> verapamil<span class=,'Sup,'>*</span></td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ calcium channel blockers	</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Decrease the dose of the calcium channel blocker. The dose of amlodipine should be decreased by at least 50%. Clinical monitoring of patients is recommended for edema and/or signs and symptoms of hypotension. If such events occur, consider further dose reduction of the calcium channel blocker or switching to an alternative to the calcium channel blocker.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,'><span class=,'Bold,'>CORTICOSTEROIDS (INHALED/NASAL)</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>fluticasone<span class=,'Sup,'>*</span></td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ fluticasone</td><td class=,'Botrule Lrule Rrule Toprule,'>Concomitant use of VIEKIRA PAK with inhaled or nasal fluticasone may reduce serum cortisol concentrations.  Alternative corticosteroids should be considered, particularly for long term use.  </td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,'><span class=,'Bold,'>DIURETICS</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>furosemide</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ furosemide (C<span class=,'Sub,'>max</span>)</td><td class=,'Botrule Lrule Rrule Toprule,'>Clinical monitoring of patients is recommended and therapy should be individualized based on patient’s response.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,' valign=,'top,'><span class=,'Bold,'>ERGOT DERIVATIVES</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>ergotamine*,<br/>dihydroergotamine*,<br/>methylergonovine*</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ ergot derivatives</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Contraindicated due to potential for acute ergot toxicity characterized by vasospasm. Tissue ischemia has been associated with co-administration of ritonavir and ergonovine, ergotamine, dihydroergotamine, or methylergonovine <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>)]</span>.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,' valign=,'top,'><span class=,'Bold,'>ETHINYL ESTRADIOL-CONTAINING PRODUCTS</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>ethinyl estradiol-containing <br/>medications such as <br/>combined oral <br/>contraceptives</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↔ ethinyl estradiol</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Contraindicated due to potential for ALT elevations <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>) and Warnings and Precautions (<a href=,'#section_5.3,'>5.3</a>)]</span>.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,' valign=,'top,'><span class=,'Bold,'>GI MOTILITY AGENT</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>cisapride*</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ cisapride</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Contraindicated due to potential for serious and/or life threatening reactions such as cardiac arrhythmias <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>)]</span>.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,' valign=,'top,'><span class=,'Bold,'>GnRH RECEPTOR ANTAGONISTS</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>elagolix*</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ elagolix</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Co-administration of VIEKIRA PAK with elagolix 200 mg twice daily for more than 1 month is not recommended.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,' valign=,'top,'><span class=,'Bold,'>HERBAL PRODUCT</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>St. John’s Wort* <br/>
<span class=,'Italics,'>(Hypericum perforatum)</span></td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↓ ombitasvir<br/>↓ paritaprevir<br/>↓ ritonavir</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Contraindicated due to potential loss of therapeutic activity of VIEKIRA PAK <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>)]</span>.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,'><span class=,'Bold,'>HIV-ANTIVIRAL AGENTS</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>efavirenz*</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ efavirenz<br/>↓ paritaprevir<br/>↓ ritonavir</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Contraindicated as co-administration of efavirenz based regimens with paritaprevir and ritonavir was poorly tolerated and resulted in liver enzyme elevations <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>)]</span>.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>atazanavir/ritonavir<br/>once daily </td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ paritaprevir</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>When coadministered with VIEKIRA PAK, atazanavir 300 mg (without ritonavir) should only be given in the morning.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>darunavir/ritonavir</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↓ darunavir (C<span class=,'Sub,'>trough</span>)</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Treatment naïve patients or treatment experienced  patients with no darunavir associated substitutions: <br/>
<br/>Darunavir 800 mg once daily (without ritonavir) can be co-administered with VIEKIRA PAK.<br/>
<br/>Treatment experienced patients with at least one darunavir resistance associated substitution or with no baseline resistance information:<br/>
<br/> Co-administration of darunavir/ritonavir 600/100 mg twice daily with VIEKIRA PAK is not recommended.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>lopinavir/ritonavir</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ paritaprevir</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Co-administration of VIEKIRA PAK with lopinavir/ritonavir is not recommended.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>rilpivirine </td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ rilpivirine</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>For contraindicated non-nucleoside reverse transcriptase inhibitors <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>)]</span>.<br/>
<br/>Co-administration of VIEKIRA PAK with rilpivirine once daily is not recommended due to potential for QT interval prolongation with higher concentrations of rilpivirine.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,'><span class=,'Bold,'>HMG CoA REDUCTASE INHIBITORS</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>atorvastatin<br/>lovastatin, <br/>simvastatin</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ atorvastatin<br/>↑ lovastatin, <br/>↑ simvastatin</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Contraindicated due to potential for myopathy including rhabdomyolysis <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>)]</span>.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>rosuvastatin</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ rosuvastatin</td><td class=,'Botrule Lrule Rrule Toprule,'>For contraindicated HMG-CoA Reductase Inhibitors <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>)]</span>.<br/>
<br/>When VIEKIRA PAK is co-administered with rosuvastatin, the dose of rosuvastatin should not exceed 10 mg per day.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>pravastatin</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ pravastatin</td><td class=,'Botrule Lrule Rrule Toprule,'>When VIEKIRA PAK is co-administered with pravastatin, the dose of pravastatin should not exceed 40 mg per day.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,'><span class=,'Bold,'>IMMUNOSUPPRESSANTS</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>everolimus<br/>sirolimus<br/>tacrolimus</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ everolimus<br/>↑ sirolimus<br/>↑ tacrolimus</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Contraindicated due to potential for serious and/or life threatening immunosuppressant-associated adverse events <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>)]</span>.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>cyclosporine</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ cyclosporine</td><td class=,'Botrule Lrule Rrule Toprule,'>For contraindicated immunosuppressants <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>)]</span>.<br/>
<br/>When initiating therapy with VIEKIRA PAK, reduce cyclosporine dose to 1/5<span class=,'Sup,'>th</span> of the patient’s current cyclosporine dose. Measure cyclosporine blood concentrations to determine subsequent dose modifications.  Upon completion of VIEKIRA PAK therapy, the appropriate time to resume pre-VIEKIRA PAK dose of cyclosporine should be guided by assessment of cyclosporine blood concentrations. Frequent assessment of renal function and cyclosporine-related side effects is recommended. </td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,'><span class=,'Bold,'>LONG ACTING BETA-ADRENOCEPTOR AGONIST</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>salmeterol<span class=,'Sup,'>*</span></td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ salmeterol</td><td class=,'Botrule Lrule Rrule Toprule,'>Concurrent administration of VIEKIRA PAK and salmeterol is not recommended. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,' valign=,'top,'><span class=,'Bold,'>MUSCLE RELAXANTS</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>carisoprodol</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↓ carisoprodol<br/>↔ mepobramate<br/>(metabolite of carisoprodol)</td><td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Increase dose if clinically indicated.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>cyclobenzaprine</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↓cyclobenzaprine<br/>↓norcyclobenzaprine<br/>(metabolite of cyclobenzaprine)</td><td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Increase dose if clinically indicated.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,' valign=,'top,'><span class=,'Bold,'>MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>lomitapide*</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ lomitapide</td><td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Contraindicated due to potential for serious adverse events including hepatotoxicity <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>)]</span>.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,'><span class=,'Bold,'>NARCOTIC ANALGESICS</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>buprenorphine/<br/>naloxone</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ buprenorphine<br/>↑ norbuprenorphine<br/>(metabolite of buprenorphine)</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Patients should be closely monitored for sedation and cognitive effects.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>hydrocodone/acetaminophen<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>fentanyl</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ hydrocodone<br/>↔ acetaminophen<br/>
<br/>
<br/>
<br/>
<br/>
<br/>↑ fentanyl</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Reduce the dose of hydrocodone by  50%  and monitor patients for respiratory depression and sedation at frequent intervals. Upon completion of VIEKIRA PAK therapy, adjust the hydrocodone dose and monitor for signs of opioid withdrawal.<br/>
<br/>Careful monitoring of therapeutic effects and adverse effects of fentanyl (including potentially fatal respiratory depression) is recommended when fentanyl is co-administered with VIEKIRA PAK.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,'><span class=,'Bold,'>PROTON PUMP INHIBITORS</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>omeprazole</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↓ omeprazole</td><td class=,'Botrule Lrule Rrule Toprule,'>Monitor patients for decreased efficacy of omeprazole. Consider increasing the omeprazole dose in patients whose symptoms are not well controlled; avoid use of more than 40 mg per day of omeprazole.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,' valign=,'top,'><span class=,'Bold,'>PHOSPHODIESTERASE-5 (PDE5) INHIBITOR</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>sildenafil* when dosed as <br/>Revatio for the treatment of<br/>pulmonary arterial <br/>hypertension (PAH)</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ sildenafil</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Contraindicated due to potential for sildenafil-associated adverse events such as visual disturbances, hypotension, priapism, and syncope <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>)]</span>.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,' valign=,'top,'><span class=,'Bold,'>SEDATIVES/HYPNOTICS</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>triazolam* <br/>orally administered <br/>midazolam*</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ triazolam <br/>↑ midazolam</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Contraindicated due to potential for serious and/or life threatening events such as prolonged or increased sedation or respiratory depression <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>)]</span>.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,'><span class=,'Bold,'>SEDATIVES/HYPNOTICS</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>alprazolam</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↑ alprazolam</td><td class=,'Botrule Lrule Rrule Toprule,'>For contraindicated Sedatives/Hypnotics <span class=,'Italics,'>[see Contraindications (<a href=,'#section_4,'>4</a>)]</span>.<br/>
<br/>Clinical monitoring of patients is recommended. A decrease in alprazolam dose can be considered based on clinical response.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>diazepam</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↓ diazepam<br/>↓ nordiazepam<br/>(metabolite of diazepam)</td><td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Increase dose if clinically indicated.</td>
</tr>
<tr class=,'Last,'>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,' valign=,'top,'><span class=,'Italics,'>See Clinical Pharmacology, Tables <a href=,'#table_7,'>7</a> and <a href=,'#table_9,'>8</a></span>.<br/>The direction of the arrow indicates the direction of the change in exposures (C<span class=,'Sub,'>max</span> and AUC) (↑ =<span class=,'Italics,'> increase of more than 20%,</span> ↓ = <span class=,'Italics,'>decrease of more than 20%,</span> ↔ = <span class=,'Italics,'>no change or change less than 20%).</span>
<br/>
<span class=,'Sup,'>*</span>not studied.</td>
</tr>
</tbody>
</table></div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section_7.4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Drugs without Clinically Significant Interactions with VIEKIRA PAK</h2>
<p class=,'First,'>
<a name=,'p130988291393947814,'></a>No dose adjustments are recommended when VIEKIRA PAK is co-administered with the following medications: abacavir, dolutegravir, digoxin, duloxetine, emtricitabine/tenofovir disoproxil fumarate, escitalopram, lamivudine, methadone, progestin only contraceptives, raltegravir, sofosbuvir, sulfamethoxazole, trimethoprim, and zolpidem.</p>
</div>
</div>"
"dasatinib","0e7f054c-7a27-4192-bd1c-6115d8be858f","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.1a,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1   Drugs That May Increase Dasatinib Plasma Concentrations</h2>
<p class=,'First,'>
<span class=,'Bold,'>CYP3A4 Inhibitors:</span>  Dasatinib is a CYP3A4 substrate. In a study of 18 patients with solid tumors, 20-mg SPRYCEL once daily coadministered with 200 mg of ketoconazole twice daily increased the dasatinib C<span class=,'Sub,'>max</span> and AUC by four- and five-fold, respectively. Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 may increase exposure to dasatinib and should be avoided. In patients receiving treatment with SPRYCEL, close monitoring for toxicity and a SPRYCEL dose reduction should be considered if systemic administration of a potent CYP3A4 inhibitor cannot be avoided <span class=,'Italics,'>[see Dosage and Administration <a href=,'#Section_2.1,'>(2.1)</a>]</span>. 
								</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2   Drugs That May Decrease Dasatinib Plasma Concentrations</h2>
<p class=,'First,'>
<span class=,'Bold,'>CYP3A4 Inducers:</span> When a single morning dose of SPRYCEL was administered following 8 days of continuous evening administration of 600 mg of rifampin, a potent CYP3A4 inducer, the mean C<span class=,'Sub,'>max</span> and AUC of dasatinib were decreased by 81% and 82%, respectively. Alternative agents with less enzyme induction potential should be considered. If SPRYCEL must be administered with a CYP3A4 inducer, a dose increase in SPRYCEL should be considered <span class=,'Italics,'>[see Dosage and Administration <a href=,'#Section_2.1,'>(2.1)</a>]</span>.
								</p>
<p>
<span class=,'Bold,'>Antacids:</span> Nonclinical data demonstrate that the solubility of dasatinib is pH dependent. In a study of 24 healthy subjects, administration of 30 mL of aluminum hydroxide/magnesium hydroxide 2 hours prior to a single 50-mg dose of SPRYCEL was associated with no relevant change in dasatinib AUC; however, the dasatinib C<span class=,'Sub,'>max</span> increased 26%. When 30 mL of aluminum hydroxide/magnesium hydroxide was administered to the same subjects concomitantly with a 50-mg dose of SPRYCEL, a 55% reduction in dasatinib AUC and a 58% reduction in C<span class=,'Sub,'>max</span> were observed. Simultaneous administration of SPRYCEL with antacids should be avoided. If antacid therapy is needed, the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of SPRYCEL. 
								</p>
<p>
<span class=,'Bold,'>H<span class=,'Sub,'>2</span> Antagonists/Proton Pump Inhibitors:</span>  Long-term suppression of gastric acid secretion by H<span class=,'Sub,'>2</span> antagonists or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure. In a study of 24 healthy subjects, administration of a single 50-mg dose of SPRYCEL 10 hours following famotidine reduced the AUC and C<span class=,'Sub,'>max</span> of dasatinib by 61% and 63%, respectively. In a study of 14 healthy subjects, administration of a single 100-mg dose of SPRYCEL 22 hours following a 40-mg omeprazole dose at steady state reduced the AUC and C<span class=,'Sub,'>max</span> of dasatinib by 43% and 42%, respectively. The concomitant use of H<span class=,'Sub,'>2</span> antagonists or proton pump inhibitors with SPRYCEL is not recommended. The use of antacids (at least 2 hours prior to or 2 hours after the dose of SPRYCEL) should be considered in place of H<span class=,'Sub,'>2</span> antagonists or proton pump inhibitors in patients receiving SPRYCEL therapy. 
								</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3   Drugs That May Have Their Plasma Concentration Altered By Dasatinib</h2>
<p class=,'First,'>
<span class=,'Bold,'>CYP3A4 Substrates:</span>  Single-dose data from a study of 54 healthy subjects indicate that the mean C<span class=,'Sub,'>max</span> and AUC of simvastatin, a CYP3A4 substrate, were increased by 37% and 20%, respectively, when simvastatin was administered in combination with a single 100-mg dose of SPRYCEL. Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL. 
								</p>
</div>
</div>"
"daunorubicin","227784a8-ce68-4dd4-8ac5-a65265969677","none found"
"deferoxamine","598fba68-f46e-4b6e-894c-63c2940b2063","none found"
"delafloxacin","fb77637a-88d9-4aea-958f-e270030ce30d","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1     Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins</h2>
<p class=,'First,'>Fluoroquinolones form chelates with alkaline earth and transition metal cations. Oral administration of BAXDELA with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of BAXDELA, resulting in systemic concentrations considerably lower than desired. Therefore, BAXDELA should be taken at least 2 hours before or 6 hours after these agents <span class=,'Italics,'>[see <a href=,'#S2.1,'>Dosage and Administration (2.1)</a>]</span>.</p>
<p>There are no data concerning an interaction of intravenous BAXDELA with oral antacids, sucralfate, multivitamins, didanosine, or metal cations. However, BAXDELA should not be co-administered with any solution containing multivalent cations, e.g., magnesium, through the same intravenous line <span class=,'Italics,'>[see <a href=,'#S2.1,'>Dosage and Administration (2.1)</a>]</span>.</p>
</div>
</div>"
"denosumab","628f0998-1206-4001-aeee-18133aa9f3bf","none found"
"desipramine","3433c754-cc2e-4e72-bd82-16ed4af3144d","none found"
"desloratadine","0fe374d0-c14b-4102-b568-eb79165fc7ef","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1  Inhibitors of Cytochrome P450 3A4</h2>
<p class=,'First,'>In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [<span class=,'Italics,'>See<a href=,'#S12.3,'> Clinical Pharmacology (12.3)</a></span>.]</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2  Fluoxetine</h2>
<p class=,'First,'>In controlled clinical studies co-administration of desloratadine with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [<span class=,'Italics,'>See<a href=,'#S12.3,'> Clinical Pharmacology (12.3)</a></span>.]</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3  Cimetidine</h2>
<p class=,'First,'>In controlled clinical studies co-administration of desloratadine with cimetidine, a histamine H<span class=,'Sub,'>2</span>-receptor antagonist, resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [<span class=,'Italics,'>See<a href=,'#S12.3,'> Clinical Pharmacology (12.3)</a>.</span>]</p>
</div>
</div>"
"desmopressin","043be50e-73b5-45bf-9316-776d4f675170","none found"
"dexamethasone","0372f916-0a26-4115-8075-2d575bfbc15e","none found"
"dexlansoprazole","c83616c9-c222-4e3e-91bd-c7839406bb2a","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'section-7,'></a>
<p></p>
<a href=,'http://,'></a>7.1 Drugs with pH-Dependent Absorption 
Pharmacokinetics<p class=,'First,'>KAPIDEX causes inhibition of gastric acid secretion. KAPIDEX is 
likely to substantially decrease the systemic concentrations of the HIV protease 
inhibitor atazanavir, which is dependent upon the presence of gastric acid for 
absorption, and may result in a loss of therapeutic effect of atazanavir and the 
development of HIV resistance. Therefore, KAPIDEX should not be co-administered 
with atazanavir. </p>
<p>It is theoretically possible that KAPIDEX may interfere with the absorption 
of other drugs where gastric pH is an important determinant of oral 
bioavailability (e.g., ampicillin esters, digoxin, iron salts, 
ketoconazole).</p>
<a href=,'http://,'></a><a href=,'http://,'></a><a href=,'http://,'></a>7.2 Warfarin<p>Co-administration of KAPIDEX 90 mg and warfarin 25 mg did not 
affect the pharmacokinetics of warfarin or INR <span class=,'Italics,'>[see <a href=,'#S12.6,'>Clinical Pharmacology (12.6)</a>]</span>. However, there have been 
reports of increased INR and prothrombin time in patients receiving PPIs and 
warfarin concomitantly. Increases in INR and prothrombin time may lead to 
abnormal bleeding and even death. Patients treated with KAPIDEX and warfarin 
concomitantly may need to be monitored for increases in INR and prothrombin 
time.</p>
</div>"
"dextran 40","df5c4e20-fc58-4b22-95f5-7d981708f587","none found"
"diazepam","01f04ee4-fff9-499a-8213-984e16368084","none found"
"diazoxide","abe317a5-6c63-469c-89c8-9fedfe859c3d","none found"
"diclofenac","82427c70-58a3-4b8e-a0d5-128c9c1569f8","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>See <a href=,'#table4,'>Table 4</a> for clinically significant drug interactions with diclofenac.</p>
<a name=,'table4,'></a>
<div class=,'scrollingtable,'><table width=,'85%,'>
<caption>
<span>Table 4 Clinically Significant Drug Interactions with Diclofenac</span>
</caption>
<col align=,'left,' valign=,'top,' width=,'30%,'/>
<col align=,'left,' valign=,'top,' width=,'70%,'/>
<tbody class=,'Headless,'>
<tr class=,'Botrule First,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Drugs That Interfere with Hemostasis</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Clinical Impact:</span></td><td align=,'left,' class=,'Rrule,'>
<ul class=,'Disc,'>
<li>Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone.</li>
<li>Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone.</li>
</ul>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention:</span></td><td align=,'left,' class=,'Rrule,'>Monitor patients with concomitant use of Diclofenac Capsules with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [<span class=,'Italics,'>see <a href=,'#S5.11,'>Warnings and Precautions (5.11)</a></span>].</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Aspirin</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Clinical Impact:</span></td><td align=,'left,' class=,'Rrule,'>Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [s<span class=,'Italics,'>ee <a href=,'#S5.2,'>Warnings and Precautions (5.2)</a></span>].</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention:</span></td><td align=,'left,' class=,'Rrule,'>Concomitant use of Diclofenac Capsules and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [<span class=,'Italics,'>see <a href=,'#S5.11,'>Warnings and Precautions (5.11)</a></span>]. <br/>Diclofenac Capsules is not a substitute for low dose aspirin for cardiovascular protection.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Clinical Impact:</span></td><td align=,'left,' class=,'Rrule,'>
<ul class=,'Disc,'>
<li>NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol).</li>
<li>In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible.</li>
</ul>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention:</span></td><td align=,'left,' class=,'Rrule,'>
<ul class=,'Disc,'>
<li>During concomitant use of Diclofenac Capsules and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained.</li>
<li>During concomitant use of Diclofenac Capsules and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [<span class=,'Italics,'>see <a href=,'#S5.6,'>Warnings and Precautions (5.6)</a></span>].</li>
<li>When these drugs are administered concomitantly, patients should be adequately hydrated. Assess renal function at the beginning of the concomitant treatment and periodically thereafter.</li>
</ul>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Diuretics</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Clinical Impact</span>:</td><td align=,'left,' class=,'Rrule,'>Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention:</span></td><td align=,'left,' class=,'Rrule,'>During concomitant use of Diclofenac Capsules with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [<span class=,'Italics,'>see <a href=,'#S5.6,'>Warnings and Precautions (5.6)</a></span>].</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Digoxin</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Clinical Impact:</span></td><td align=,'left,' class=,'Rrule,'>The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention:</span></td><td align=,'left,' class=,'Rrule,'>During concomitant use of Diclofenac Capsules and digoxin, monitor serum digoxin levels.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Lithium</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Clinical Impact:</span></td><td align=,'left,' class=,'Rrule,'>NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance. The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention:</span></td><td align=,'left,' class=,'Rrule,'>During concomitant use of Diclofenac Capsules and lithium, monitor patients for signs of lithium toxicity.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Methotrexate</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Clinical Impact:</span></td><td align=,'left,' class=,'Rrule,'>Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction).</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention:</span></td><td align=,'left,' class=,'Rrule,'>During concomitant use of Diclofenac Capsules and methotrexate, monitor patients for methotrexate toxicity.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Cyclosporine</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Clinical Impact:</span></td><td align=,'left,' class=,'Rrule,'>Concomitant use of Diclofenac Capsules and cyclosporine may increase cyclosporine's nephrotoxicity.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention:</span></td><td align=,'left,' class=,'Rrule,'>During concomitant use of Diclofenac Capsules and cyclosporine, monitor patients for signs of worsening renal function.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>NSAIDs and Salicylates</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Clinical Impact:</span></td><td align=,'left,' class=,'Rrule,'>Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy [<span class=,'Italics,'>see <a href=,'#S5.2,'>Warnings and Precautions (5.2)</a></span>].</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention:</span></td><td align=,'left,' class=,'Rrule,'>The concomitant use of diclofenac with other NSAIDs or salicylates is not recommended.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Pemetrexed</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Clinical Impact:</span></td><td align=,'left,' class=,'Rrule,'>Concomitant use of Diclofenac Capsules and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information).</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention:</span></td><td align=,'left,' class=,'Rrule,'>During concomitant use of Diclofenac Capsules and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity. <br/>NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. <br/>In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Inhibitors or Inducers of Cytochrome P450 2C9</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Clinical Impact:</span></td><td align=,'left,' class=,'Rrule,'>Diclofenac is metabolized by cytochrome P450 enzymes, predominantly by CYP2C9. <br/>Co-administration of diclofenac with CYP2C9 inhibitors (e.g. voriconazole) may enhance the exposure and toxicity of diclofenac whereas co-administration with CYP2C9 inducers (e.g. rifampin) may lead to compromised efficacy of diclofenac.</td>
</tr>
<tr class=,'Botrule Last,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention:</span></td><td align=,'left,' class=,'Rrule,'>A dosage adjustment may be warranted when diclofenac is administered with CYP2C9 inhibitors or inducers [<span class=,'Italics,'>see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a></span>].</td>
</tr>
</tbody>
</table></div>
</div>"
"didanosine","829e744d-7bd4-43dc-9b58-ffb016cb8e67","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'i4i_interactions_id_8a5a4ab5-a763-45e0-af9c-8ba908f0be2b,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_3227315d-4343-459c-a331-0441a2aebf5e,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Established Drug Interactions </h2>
<p class=,'First,'>Clinical recommendations based on the results of drug interaction studies are listed in <a href=,'#id_eb58c4c7-c626-44fb-b8cb-e5410ee902d4,'>Table 5</a>. Pharmacokinetic results of drug interaction studies are shown in Tables 9 to 12 [<span class=,'Italics,'>see Contraindications (<a href=,'#i4i_section_id_21f39101-3b88-4b77-9b98-d727cc28bfeb,'>4.1</a> and <a href=,'#i4i_section_id_2c69de80-4e75-4492-86bd-a3a2d0bb394b,'>4.2</a>), Clinical Pharmacology (<a href=,'#i4i_pharmacokinetics_id_c1b134fa-d9d3-456e-8e91-4a513f6d4811,'>12.3</a>)</span>]. </p>
<a name=,'id_eb58c4c7-c626-44fb-b8cb-e5410ee902d4,'></a>
<div class=,'scrollingtable,'><table border=,'single,' width=,'454.000,'>
<caption>
<span>Table 5: Established Drug Interactions Based on Studies with Didanosine Delayed-Release Capsules or Studies with Buffered Formulations of Didanosine and Expected to Occur with Didanosine Delayed-Release Capsules </span>
</caption>
<col width=,'23.8%,'/>
<col width=,'28.9%,'/>
<col width=,'47.4%,'/>
<tfoot>
<tr class=,'Last,'>
<td align=,'left,' class=,'Botrule Lrule Rrule,' colspan=,'3,' valign=,'top,'>↑ Indicates increase. <br/>↓ Indicates decrease. </td>
</tr>
</tfoot>
<tbody class=,'Headless,'>
<tr class=,'First,'>
<td align=,'center,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Drug</td><td align=,'center,' class=,'Botrule Rrule,' valign=,'top,'>Effect</td><td align=,'center,' class=,'Botrule Rrule,' valign=,'top,'>Clinical Comment</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule Lrule Rrule,' valign=,'top,'>ganciclovir</td><td align=,'center,' class=,'Botrule Rrule,' valign=,'top,'>↑didanosine concentration</td><td align=,'left,' class=,'Botrule Rrule,' valign=,'top,'>If there is no suitable alternative to ganciclovir, then use in combination with didanosine delayed-release capsules with caution. Monitor for didanosine-associated toxicity.</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule Lrule Rrule,' valign=,'top,'>methadone</td><td align=,'center,' class=,'Botrule Rrule,' valign=,'top,'>↓didanosine concentration</td><td align=,'left,' class=,'Botrule Rrule,' valign=,'top,'>If coadministration of methadone and didanosine is necessary, the recommended formulation of didanosine is didanosine delayed-release capsules. Patients should be closely monitored for adequate clinical response when didanosine delayed-release capsules are coadministered with methadone, including monitoring for changes in HIV RNA viral load. Do not coadminister methadone with didanosine pediatric powder due to significant decreases in didanosine concentrations. </td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule Lrule Rrule,' valign=,'top,'>nelfinavir</td><td align=,'center,' class=,'Botrule Rrule,' valign=,'top,'>No interaction 1 hour after didanosine</td><td align=,'left,' class=,'Botrule Rrule,' valign=,'top,'>Administer nelfinavir 1 hour after didanosine delayed-release capsules. </td>
</tr>
<tr class=,'Last,'>
<td align=,'left,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>tenofovir disoproxil</p>fumarate</td><td align=,'center,' class=,'Rrule,' valign=,'top,'>↑didanosine concentration</td><td align=,'left,' class=,'Botrule Rrule,' valign=,'top,'>
<p class=,'First,'>A dose reduction of didanosine delayed-release capsules to the following dosage once daily taken together with tenofovir disoproxil fumarate and a light meal (400 kcalories or less and 20% fat or less ) or in the fasted state is recommended.
                                    </p>
<ul>
<li>250 mg (adults weighing at least 60 kg with creatinine clearance of at least 60 mL/min)</li>
<li>200 mg (adults weighing less than 60 kg with creatinine clearance of at least 60 mL/min)</li>
</ul>Patients should be monitored for didanosine-associated toxicities and clinical response.</td>
</tr>
</tbody>
</table></div>
<p>Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate <br/>[<a href=,'#id_eb58c4c7-c626-44fb-b8cb-e5410ee902d4,'>Table 5</a> and <span class=,'Italics,'>see Clinical Pharmacokinetics (<a href=,'#i4i_pharmacokinetics_id_c1b134fa-d9d3-456e-8e91-4a513f6d4811,'>12.3</a>, Tables 9 and 10)</span>]. Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy. Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release capsules should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response. Didanosine delayed-release capsules should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [<span class=,'Italics,'>see Dosage and Administration (<a href=,'#i4i_section_id_1e196b40-d87d-4a70-a9ad-1a0678789aa3,'>2.3</a>), Warnings and Precautions (<a href=,'#i4i_warnings_precautions_id_7f858167-9cfe-44d4-a88d-4a5ace780a7e,'>5</a>)</span>]. Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_de319cfc-1524-41da-ac94-595725386169,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Predicted Drug Interactions </h2>
<p class=,'First,'>Predicted drug interactions with didanosine delayed-release capsules are listed in <a href=,'#id_629bba0c-54f5-4264-bb4b-6ca486becd9e,'>Table 6</a>.</p>
<a name=,'id_629bba0c-54f5-4264-bb4b-6ca486becd9e,'></a>
<div class=,'scrollingtable,'><table width=,'444.000,'>
<caption>
<span>Table 6: Predicted Drug Interactions with Didanosine Delayed-Release Capsules</span>
</caption>
<col width=,'33.3%,'/>
<col width=,'33.3%,'/>
<col width=,'33.3%,'/>
<tfoot>
<tr class=,'Last,'>
<td align=,'left,' class=,'Botrule Lrule,' colspan=,'3,' valign=,'top,'>↑ Indicates increase.</td>
</tr>
</tfoot>
<tbody class=,'Headless,'>
<tr class=,'First Toprule,'>
<td align=,'center,' valign=,'top,'><span class=,'Bold,'>Drug or Drug Class</span></td><td align=,'center,' class=,'Toprule,' valign=,'top,'><span class=,'Bold,'>Effect</span></td><td align=,'center,' valign=,'top,'><span class=,'Bold,'>Clinical Comment</span></td>
</tr>
<tr>
<td align=,'center,' valign=,'top,'>Drugs that may cause pancreatic toxicity</td><td align=,'center,' valign=,'top,'>↑risk of pancreatitis</td><td align=,'center,' valign=,'top,'>Use only with extreme caution.
                                 </td>
</tr>
<tr class=,'Last,'>
<td align=,'center,' valign=,'top,'>Neurotoxic drugs</td><td align=,'center,' valign=,'top,'>↑risk of neuropathy</td><td align=,'center,' valign=,'top,'>Use with caution.
                                 </td>
</tr>
</tbody>
</table></div>
<p> </p>
</div>
</div>"
"digoxin","00d8b2a1-064b-4b33-a1ca-cbf1b0aa294f","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_3bf44236-adc5-402b-bf89-f299d291e11e,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Digoxin has a narrow therapeutic index, increased monitoring of serum digoxin concentrations and for potential signs and symptoms of clinical toxicity is necessary when initiating, adjusting, or discontinuing drugs that may interact with digoxin. Prescribers should consult the prescribing information of any drug which is co-prescribed with digoxin for potential drug interaction information.</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_ea3de17c-22d2-46e1-9cc0-583771795abf,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 P-Glycoprotein (PGP) Inducers/Inhibitors</h2>
<p class=,'First,'>Digoxin is a substrate of P-glycoprotein, at the level of intestinal absorption, renal tubular section and biliary-intestinal secretion. Therefore, drugs that induce/inhibit P-glycoprotein have the potential to alter digoxin pharmacokinetics.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_dc8260cd-b7fe-49f0-a594-120e47d29312,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Pharmacokinetic Drug Interactions</h2>
<div class=,'scrollingtable,'><table width=,'100%,'>
<col width=,'20%,'/>
<col width=,'21%,'/>
<col width=,'20%,'/>
<col width=,'38%,'/>
<tfoot>
<tr class=,'First Last,'>
<td align=,'left,' class=,'Botrule,' colspan=,'4,' valign=,'top,'> NA = Not available/reported</td>
</tr>
</tfoot>
<tbody class=,'Headless,'>
<tr class=,'First,'>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'4,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Digoxin concentrations increased greater than 50%</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'> </p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Digoxin Serum   </span>
<br/>
<span class=,'Bold,'>Concentration Increase</span>
</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Digoxin AUC   </span>
<br/>
<span class=,'Bold,'>Increase</span>
</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Recommendations</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Amiodarone</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>70%</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>NA</p>
</td><td class=,'Botrule Lrule Rrule,' rowspan=,'15,' valign=,'top,'>
<p class=,'First,'>Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing dose by approximately 30-50% or by modifying the dosing frequency and continue monitoring. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Captopril </p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>58%</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>39%</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Clarithromycin</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>NA</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>70%</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Dronedarone</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>NA</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>150%</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Gentamicin</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>129 to 212%</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>NA</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Erythromycin</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>100%</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>NA</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Itraconazole</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>80%</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>NA</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Lapatinib</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>NA</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>180%</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Propafenone</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>NA</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>60 to 270%</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Quinidine</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>100%</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>NA</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Ranolazine</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>50%</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>NA</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Ritonavir</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>NA</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>86%</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Telaprevir</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>50%</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>85%</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Tetracycline</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>100%</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>NA</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Verapamil</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>50 to 75%</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>NA</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'4,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Digoxin concentrations increased less than 50%</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Atorvastatin</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>22%</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>15%</p>
</td><td class=,'Botrule Lrule Rrule,' rowspan=,'16,' valign=,'top,'>
<p class=,'First,'>Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing the dose by approximately 15-30% or by modifying the dosing frequency and continue monitoring.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Carvedilol</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>16%</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>14%</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Conivaptan</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'> 33% </p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'> 43% </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Diltiazem</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>20%</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>NA</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Indomethacin</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>40%</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>NA</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Nefazodone</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>27%</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>15%</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Nifedipine</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>45%</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>NA</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Propantheline</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>24%</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>24%</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Quinine</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>NA</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>33%</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Rabeprazole</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'> 29%</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'> 19%</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Saquinavir</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>27%</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>49%</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Spironolactone     </p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>25%</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>NA</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Telmisartan</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>20 to 49%</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>NA</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Ticagrelor</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>31%</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'> 28% </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Tolvaptan</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>30%</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>20%</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Trimethoprim</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>22 to 28%</p>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>NA</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'4,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Digoxin concentrations increased, but magnitude is unclear</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'3,' valign=,'top,'>
<p class=,'First,'>Alprazolam, azithromycin, cyclosporine, diclofenac,                                                       
             
     
      <br/>diphenoxylate, epoprostenol, esomeprazole, ibuprofen,                                                       
             
     
      <br/>ketoconazole, lansoprazole, metformin, omeprazole,                                                       
             
     
      <br/>
</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Measure serum digoxin concentrations before initiating concomitant drugs. Continue monitoring and reduce digoxin dose as necessary.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'4,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Digoxin concentrations decreased</span>
</p>
</td>
</tr>
<tr class=,'Last,'>
<td class=,'Botrule Lrule Rrule,' colspan=,'3,' valign=,'top,'>
<p class=,'First,'>Acarbose, activated charcoal, albuterol, antacids, certain                                                       
             
     
      <br/>cancer chemotherapy or radiation therapy, cholestyramine,                                                       
             
     
      <br/>colestipol, extenatide, kaolin-pectin, meals high in bran,                                                       
             
     
      <br/>metoclopramide, miglitol, neomycin, penicillamine,                                                       
             
     
      <br/>phenytoin, rifampin, St. John’s Wort, sucralfate and                                                      
             
     
      <br/>sulfasalazine                                                
            
    
     </p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Measure serum digoxin concentrations before initiating concomitant drugs. Continue monitoring and increase digoxin dose by approximately 20-40% as necessary.</p>
</td>
</tr>
</tbody>
</table></div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_75fbde56-58ad-44f8-97c4-1ad8c724d094,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Potentially Significant Pharmacodynamic Drug Interactions</h2>
<p class=,'First,'>Because of considerable variability of pharmacodynamic interactions, the dosage of digoxin should be individualized when patients receive these medications concurrently.</p>
<div class=,'scrollingtable,'><table width=,'100%,'>
<col width=,'37%,'/>
<col width=,'21%,'/>
<col width=,'42%,'/>
<tbody class=,'Headless,'>
<tr class=,'First,'>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Drugs that Affect Renal Function</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>A decline in GFR or tubular secretion, as from ACE inhibitors, angiotensin receptor blockers, nonsteroidal anti-inflammatory drugs [NSAIDS], COX-2 inhibitors may impair the excretion of digoxin.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Antiarrthymics</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Dofetilide</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Concomitant administration with digoxin was associated with a higher rate of torsades de pointes</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'> </p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Sotalol</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Proarrhythmic events were more common in patients receiving sotalol and digoxin than on either alone; it is not clear whether this represents an interaction or is related to the presence of CHF, a known risk factor for proarrhythmia, in patients receiving digoxin.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'> </p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Dronedarone</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Sudden death was more common in patients receiving digoxin with dronedarone than on either alone; it is not clear whether this represents an interaction or is related to the presence of advanced heart disease, a known risk factor for sudden death in patients receiving digoxin. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Parathyroid Hormone Analog</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Teriparatide</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Sporadic case reports have suggested that hypercalcemia may predispose patients to digitalis toxicity. Teriparatide transiently increases serum calcium.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Thyroid supplement</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Thyroid</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Treatment of hypothyroidism in patients taking digoxin may increase the dose requirements of digoxin.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Sympathomimetics</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Epinephrine                                                      
             
     
      <br/>Norepinephrine                                                           
             
     
      <br/>Dopamine                                                
            
    
     </p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Can increase the risk of cardiac arrhythmias</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Neuromuscular Blocking Agents     </p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Succinylcholine</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>May cause sudden extrusion of potassium from muscle cells causing arrhythmias in patients taking digoxin.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Supplements</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Calcium</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>If administered rapidly by intravenous route, can produce serious arrhythmias in digitalized patients.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Beta-adrenergic blockers and calcium channel blockers</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'> </p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Additive effects on AV node conduction can result in bradycardia and advanced or complete heart block.</p>
</td>
</tr>
<tr class=,'Last,'>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Hyperpolarization-activated cyclic nucleotide-gated channel blocker</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Ivabradine</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Can increase the risk of bradycardia.</p>
</td>
</tr>
</tbody>
</table></div>
</div>
<div class=,'Section,' data-sectioncode=,'34074-5,'>
<a name=,'LINK_57711ff6-21ee-491c-a788-35ce752c5cf5,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Drug/Laboratory Test Interactions</h2>
<p class=,'First,'>Endogenous substances of unknown composition (digoxin-like immunoreactive substances [DLIS]) can interfere with standard radioimmunoassays for digoxin. The interference most often causes results to be falsely positive or falsely elevated, but sometimes it causes results to be falsely reduced. Some assays are more subject to these failings than others. Several LC/MS/MS methods are available that may provide less susceptibility to DLIS interference. DLIS are present in up to half of all neonates and in varying percentages of pregnant women, patients with hypertrophic cardiomyopathy, patients with renal or hepatic dysfunction, and other patients who are volume-expanded for any reason. The measured levels of DLIS (as digoxin equivalents) are usually low (0.2 to 0.4 ng/mL), but sometimes they reach levels that would be considered therapeutic or even toxic. </p>
<p>In some assays, spironolactone, canrenone, and potassium canrenoate may be falsely detected as digoxin, at levels up to 0.5 ng/mL. Some traditional Chinese and Ayurvedic medicine substances like Chan Su, Siberian Ginseng, Asian Ginseng, Ashwagandha or Dashen can cause similar interference. </p>
<p>Spironolactone and DLIS are much more extensively protein-bound than digoxin. As a result, assays of free digoxin levels in protein-free ultrafiltrate (which tend to be about 25% less than total levels, consistent with the usual extent of protein binding) are less affected by spironolactone or DLIS. It should be noted that ultrafiltration does not solve all interference problems with alternative medicines. The use of an LC/MS/MS method may be the better option according to the good results it provides, especially in terms of specificity and limit of quantization.</p>
</div>
</div>"
"dihydrocodeine","76e033b0-01c1-42df-bb64-f8ca401cfb6b","none found"
"dimercaprol","bee9a137-160f-47e8-a551-ca461ae4f51e","none found"
"diphtheria toxoid vaccine, inactivated","70bfb8c1-6d1a-4b0a-8a21-7a7ed8e748c9","none found"
"dipyridamole","02e40b4e-80bb-4456-9d16-6f8a2f7ec5f0","none found"
"docetaxel","0dd863ec-f9dc-456c-9df5-4e9210d6cbb0","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID119,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID122,'></a><a name=,'section-7.1,'></a>
<p></p>
<p class=,'First,'>Docetaxel is a CYP3A4 substrate. In vitro studies have shown that the metabolism of docetaxel may be modiﬁed by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4.</p>
<p>
<span class=,'Italics,'> In vivo</span> studies showed that the exposure of docetaxel increased 2.2-fold when it was coadministered with ketoconazole, a potent inhibitor of CYP3A4. Protease inhibitors, particularly ritonavir, may increase the exposure of docetaxel. Concomitant use of docetaxel and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. In patients receiving treatment with docetaxel, close monitoring for toxicity and a docetaxel dose reduction could be considered if systemic administration of a potent CYP3A4 inhibitor cannot be avoided [<span class=,'Italics,'><a href=,'#ID21,'>see Dosage and Administration (2.7)</a>, <a href=,'#ID144,'>Clinical Pharmacology (12.3)</a></span>].</p>
</div>
</div>"
"docusate sodium","014d2ea7-e704-477a-8616-6bce2d9ea162","none found"
"domperidone","e55d075e-2fe2-4405-b57a-59b85067e0c0","none found"
"dopamine","867a48f5-d5f1-4cd7-8c6d-c281e5893553","none found"
"doxazosin","024b6cd8-1d27-491a-88e1-90bf6e147e01","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'_18bd497e-cbf3-1657-61ac-353bbfd252eb,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_18971fe7-6b3c-ef26-981e-7351d27c3383,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 CYP 3A Inhibitors</h2>
<p class=,'First,'>
<span class=,'Italics,'>In vitro</span> studies suggest that doxazosin is a substrate of CYP 3A4. Strong CYP3A inhibitors may increase exposure to doxazosin. Monitor blood pressure and for symptoms of hypotension when doxazosin tablets are used concomitantly with strong CYP3A inhibitors [<span class=,'Italics,'>see Clinical Pharmacology (<a href=,'#_2c9dde0a-b674-09f9-5797-8e011569b45b,'>12.3</a>)</span>]. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_1bfeb979-1eeb-fa5b-61b3-ede45133a65d,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Phosphodiesterase-5 (PDE-5) Inhibitors</h2>
<p class=,'First,'>Concomitant administration of doxazosin tablets with a phosphodiesterase-5 (PDE-5) inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension. Monitor blood pressure and for symptoms of hypotension [<span class=,'Italics,'>see Warnings and Precautions (<a href=,'#_c6d2ffbb-758c-b20e-8e5d-a78cd057de60,'>5.1</a>)</span>].</p>
</div>
</div>"
"doxepin","8a81bc13-b35d-7b8d-e053-2995a90a1b09","none found"
"doxorubicin","00634b2b-4e48-4178-8877-28582af894ad","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1	Effect of Other Drugs on Doxorubicin Hydrochloride Injection</h2>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1.1,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Underline,'>Inhibitors of CYP3A4, CYP2D6, and P-gp</span>
</p>
<p>Concomitant use of doxorubicin hydrochloride with inhibitors of CYP3A4, CYP2D6, or P-glycoprotein (P-gp), increased concentrations of doxorubicin, which may increase the incidence and severity of adverse reactions of doxorubicin hydrochloride. Avoid concomitant use of Doxorubicin Hydrochloride Injection with inhibitors of CYP3A4, CYP2D6, or P-gp.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1.2,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Underline,'>Inducers of CYP3A4, CYP2D6, or P-gp</span>
</p>
<p>Concomitant use of doxorubicin hydrochloride with inducers of CYP3A4, CYP2D6, or P-gp may decrease the concentration of doxorubicin. Avoid concomitant use of Doxorubicin Hydrochloride Injection with inducers of CYP3A4, CYP2D6, or P-gp.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1.3,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Underline,'>Paclitaxel</span>
</p>
<p>Paclitaxel, when given prior to doxorubicin hydrochloride, increases the plasma-concentrations of doxorubicin and its metabolites. Administer Doxorubicin Hydrochloride Injection prior to paclitaxel if used concomitantly. </p>
</div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2	Concomitant Use of Trastuzumab</h2>
<p class=,'First,'>Concomitant use of trastuzumab and doxorubicin hydrochloride results in an increased risk of cardiac dysfunction. Avoid concomitant administration of Doxorubicin Hydrochloride Injection and trastuzumab <span class=,'Italics,'>[see <a href=,'#S5.1,'>Warnings and Precautions (5.1)</a>].</span>
</p>
<p>Patients receiving doxorubicin after stopping treatment with trastuzumab may also be at an increased risk of developing cardiotoxicity. Trastuzumab may persist in the circulation for up to 7 months. Therefore, avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab when possible. If anthracyclines are used before this time, carefully monitor cardiac function.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3	Concomitant Use of Dexrazoxane</h2>
<p class=,'First,'>Do not administer dexrazoxane as a cardioprotectant at the initiation of doxorubicin hydrochloride-containing chemotherapy regimens. In a randomized trial in women with metastatic breast cancer, initiation of dexrazoxane with doxorubicin hydrochloride-based chemotherapy resulted in a significantly lower tumor response rate (48% vs. 63%; p=0.007) and shorter time to progression compared to doxorubicin hydrochloride-based chemotherapy alone.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4	Concomitant Use of 6-Mercaptopurine</h2>
<p class=,'First,'>Doxorubicin hydrochloride may potentiate 6-mercaptopurine-induced hepatotoxicity. In 11 patients with refractory leukemia treated with 6-mercaptopurine (500 mg/m<span class=,'Sup,'>2</span> intravenously daily for 5 days per cycle every 2–3 weeks) and doxorubicin hydrochloride (50 mg/m<span class=,'Sup,'>2</span> intravenous once per cycle every 2–3 weeks) alone or with vincristine and prednisone, all developed hepatic dysfunction manifested by increased total serum bilirubin, alkaline phosphatase and aspartate aminotransferase.</p>
</div>
</div>"
"doxycycline","00ea3641-18da-4a6f-a779-e16075464d2b","none found"
"dronabinol","0bb05433-4ffb-4b0e-42f4-7549b3646bc1","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'section_7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'34073-7,'>
<a name=,'section_7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Additive CNS Effects</h2>
<p class=,'First,'>
<a name=,'p143486291490729608,'></a>Additive CNS effects (e.g., dizziness, confusion, sedation, somnolence) may occur when dronabinol capsules are taken concomitantly with drugs that have similar effects on the central nervous system such as CNS depressants <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#section_5.1,'>5.1</a>)]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'34073-7,'>
<a name=,'section_7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Additive Cardiac Effects</h2>
<p class=,'First,'>
<a name=,'p143392291490729716,'></a>Additive cardiac effects (e.g., hypotension, hypertension, syncope, tachycardia) may occur when dronabinol capsules are taken concomitantly with drugs that have similar effects on the cardiovascular system <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#section_5.2,'>5.2</a>)]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'34073-7,'>
<a name=,'section_7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Effect of Other Drugs on Dronabinol</h2>
<p class=,'First,'>
<a name=,'p1514414291476470270,'></a>Dronabinol is primarily metabolized by CYP2C9 and CYP3A4 enzymes based on published <span class=,'Italics,'>in vitro</span> studies. Inhibitors of these enzymes may increase, while inducers may decrease, the systemic exposure of dronabinol and/or its active metabolite resulting in an increase in dronabinol-related adverse reactions or loss of efficacy of dronabinol capsules.</p>
<p>
<a name=,'p156379291476470288,'></a>Monitor for potentially increased dronabinol-related adverse reactions when dronabinol capsules are co-administered with inhibitors of CYP2C9 (e.g., amiodarone, fluconazole) and inhibitors of CYP3A4 enzymes (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, erythromycin, grapefruit juice).</p>
</div>
<div class=,'Section,' data-sectioncode=,'34073-7,'>
<a name=,'section_7.4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Highly Protein-Bound Drugs</h2>
<p class=,'First,'>
<a name=,'p1561915291476470418,'></a>Dronabinol is highly bound to plasma proteins, and therefore, might displace and increase the free fraction of other concomitantly administered protein-bound drugs.</p>
<p>
<a name=,'p156638291476470435,'></a>Although this displacement has not been confirmed <span class=,'Italics,'>in vivo</span>, monitor patients for increased adverse reactions to narrow therapeutic index drugs that are highly protein‑bound (e.g., warfarin, cyclosporine, amphotericin B) when initiating treatment or increasing the dosage of dronabinol capsules.</p>
</div>
</div>"
"dronedarone","236d4549-f44b-4677-b857-acedd10b9920","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Dronedarone is metabolized primarily by CYP 3A and is a moderate inhibitor of CYP 3A and CYP 2D6 <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>. Dronedarone's blood levels can therefore be affected by inhibitors and inducers of CYP 3A, and dronedarone can interact with drugs that are substrates of CYP 3A and CYP 2D6.</p>
<p>Dronedarone has no significant potential to inhibit CYP 1A2, CYP 2C9, CYP 2C19, CYP 2C8 and CYP 2B6. It has the potential to inhibit P-glycoprotein (P-gP) transport.</p>
<p>Pharmacodynamic interactions can be expected with beta-blockers; calcium antagonists and digoxin <span class=,'Italics,'>[see <a href=,'#S7.1,'>Drug Interactions (7.1)</a>]</span>. </p>
<p>In clinical trials, patients treated with dronedarone received concomitant medications including beta-blockers, digoxin, calcium antagonists (including those with heart rate-lowering effects), statins and oral anticoagulants. </p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Pharmacodynamic Interactions</h2>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1.1,'></a>
<p></p>
<p class=,'First,'>Drugs prolonging the QT interval (inducing Torsade de Pointes) </p>
<p>Co-administration of drugs prolonging the QT interval (such as certain phenothiazines, tricyclic antidepressants, certain macrolide antibiotics, and Class I and III antiarrhythmics) is contraindicated because of the potential risk of Torsade de Pointes-type ventricular tachycardia <span class=,'Italics,'>[see <a href=,'#S4,'>Contraindications (4)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1.2,'></a>
<p></p>
<p class=,'First,'>Digoxin</p>
<p>Digoxin can potentiate the electrophysiologic effects of dronedarone (such as decreased AV-node conduction). In clinical trials, increased levels of digoxin were observed when dronedarone was co-administered with digoxin. Gastrointestinal disorders were also increased.</p>
<p>Because of the pharmacokinetic interaction <span class=,'Italics,'>[see <a href=,'#S7.3,'>Drug Interaction (7.3)</a>]</span> and possible pharmacodynamic interaction, consider the need for continued digoxin therapy. If digoxin treatment is continued, halve the dose of digoxin, monitor serum levels closely, and observe for toxicity.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1.3,'></a>
<p></p>
<p class=,'First,'>Calcium channel blockers</p>
<p>Calcium channel blockers with depressant effects on the sinus and AV nodes could potentiate dronedarone's effects on conduction.</p>
<p>Give low doses of calcium channel blockers initially and increase only after ECG verification of good tolerability <span class=,'Italics,'>[see <a href=,'#S7.3,'>Drug Interactions (7.3)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1.4,'></a>
<p></p>
<p class=,'First,'>Beta-blockers </p>
<p>In clinical trials, bradycardia was more frequently observed when dronedarone was given in combination with beta-blockers.</p>
<p>Give low dose of beta-blockers initially, and increase only after ECG verification of good tolerability <span class=,'Italics,'>[see <a href=,'#S7.3,'>Drug Interactions (7.3)</a>]</span>.</p>
</div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Effects of Other Drugs on Dronedarone</h2>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.1,'></a>
<p></p>
<p class=,'First,'>Ketoconazole and other potent CYP 3A inhibitors</p>
<p>Repeated doses of ketoconazole, a strong CYP 3A inhibitor, resulted in a 17-fold increase in dronedarone exposure and a 9-fold increase in C<span class=,'Sub,'>max</span>. Concomitant use of ketoconazole as well as other potent CYP 3A inhibitors such as itraconazole, voriconazole, ritonavir, clarithromycin, and nefazodone is contraindicated <span class=,'Italics,'>[see <a href=,'#S4,'>Contraindications (4)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.2,'></a>
<p></p>
<p class=,'First,'>Grapefruit juice</p>
<p>Grapefruit juice, a moderate inhibitor of CYP 3A, resulted in a 3-fold increase in dronedarone exposure and a 2.5-fold increase in C<span class=,'Sub,'>max</span>. Therefore, patients should avoid grapefruit juice beverages while taking MULTAQ.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.3,'></a>
<p></p>
<p class=,'First,'>Rifampin and other CYP 3A inducers</p>
<p>Rifampin decreased dronedarone exposure by 80%. Avoid rifampin or other CYP 3A inducers such as phenobarbital, carbamazepine, phenytoin, and St John's wort with dronedarone because they decrease its exposure significantly.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.4,'></a>
<p></p>
<p class=,'First,'>Calcium channel blockers</p>
<p>Verapamil and diltiazem are moderate CYP 3A inhibitors and increase dronedarone exposure by approximately 1.4-to 1.7-fold <span class=,'Italics,'>[see<a href=,'#S7.1,'> Drug Interactions (7.1</a>, <a href=,'#S7.3,'>7.3)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.5,'></a>
<p></p>
<p class=,'First,'>Pantoprazole</p>
<p>Pantoprazole, a drug that increases gastric pH, did not have a significant effect on dronedarone pharmacokinetics. </p>
</div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Effects of Dronedarone on Other Drugs</h2>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.3.1,'></a>
<p></p>
<p class=,'First,'>Statins </p>
<p>Dronedarone increased simvastatin/simvastatin acid exposure by 4- and 2-fold, respectively. Because of multiple mechanisms of interaction with statins (CYPs and transporters), follow statin label recommendations for use with CYP 3A and P-gP inhibitors such as dronedarone. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.3.2,'></a>
<p></p>
<p class=,'First,'>Calcium channel blockers</p>
<p>Dronedarone increases calcium channel blocker (verapamil, diltiazem or nifedipine) exposure by 1.4- to 1.5-fold <span class=,'Italics,'>[see <a href=,'#S7.1,'>Drug Interactions (7.1)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.3.3,'></a>
<p></p>
<p class=,'First,'>Sirolimus, tacrolimus, and other CYP3A substrates with narrow therapeutic range </p>
<p>Dronedarone can increase plasma concentrations of tacrolimus, sirolimus, and other CYP 3A substrates with a narrow therapeutic range when given orally. Monitor plasma concentrations and adjust dosage appropriately.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.3.4,'></a>
<p></p>
<p class=,'First,'>Beta-blockers and other CYP 2D6 substrates</p>
<p>Dronedarone increased propranolol exposure by approximately 1.3-fold following single dose administration. Dronedarone increased metoprolol exposure by 1.6-fold following multiple dose administration <span class=,'Italics,'>[see <a href=,'#S7.1,'>Drug Interaction (7.1)</a>]. </span>Other CYP 2D6 substrates, including other beta-blockers, tricyclic antidepressants, and selective serotonin reuptake inhibitors (SSRIs) may have increased exposure upon co-administration with dronedarone.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.3.5,'></a>
<p></p>
<p class=,'First,'>P-glycoprotein substrates</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.3.5.1,'></a>
<p></p>
<h4></h4>
<p class=,'First,'>
<span class=,'Italics,'>Digoxin</span>
</p>
<p>Dronedarone increased digoxin exposure by 2.5-fold by inhibiting the P-gP transporter [<span class=,'Italics,'>see <a href=,'#S7.1,'>Drug Interactions (7.1)</a></span>].</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.3.5.2,'></a>
<p></p>
<h4></h4>
<p class=,'First,'>
<span class=,'Italics,'>Dabigatran</span>
</p>
<p>Exposure to dabigatran is higher when it is administered with dronedarone than when it is administered alone (1.7- to 2-fold).</p>
<p>Other P-gP substrates are expected to have increased exposure when co-administered with dronedarone.</p>
</div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.3.6,'></a>
<p></p>
<p class=,'First,'>Warfarin and losartan (CYP 2C9 substrates)</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.3.6.1,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Losartan</span>
</p>
<p>No interaction was observed between dronedarone and losartan.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.3.6.2,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Warfarin</span>
</p>
<p>When healthy subjects were administered dronedarone 600 mg twice daily, exposure to S-warfarin was higher than when warfarin was administered alone (1.2-fold). Exposure to R-warfarin was unchanged and there were no clinically significant increases in INR.</p>
<p>More patients experienced clinically significant INR elevations (≥ 5) usually within 1 week after starting dronedarone vs. placebo in patients taking oral anticoagulants in ATHENA. However, no excess risk of bleeding was observed in the dronedarone group.</p>
<p>Postmarketing cases of increased INR with or without bleeding events have been reported in warfarin-treated patients initiated on dronedarone. Monitor INR after initiating dronedarone in patients taking warfarin.</p>
</div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.3.7,'></a>
<p></p>
<p class=,'First,'>Theophylline (CYP 1A2 substrate)</p>
<p>Dronedarone does not increase steady state theophylline exposure.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.3.8,'></a>
<p></p>
<p class=,'First,'>Oral contraceptives</p>
<p>No decreases in ethinylestradiol and levonorgestrel concentrations were observed in healthy subjects receiving dronedarone concomitantly with oral contraceptives.</p>
</div>
</div>
</div>"
"dulaglutide","463050bd-2b1c-40f5-b3c3-0a04bb433309","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'s32,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s33,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Oral Medications
</h2>
<p class=,'First,'>TRULICITY delays gastric emptying and thus has the potential to reduce the rate of absorption of concomitantly administered oral medications. The delay in gastric emptying is dose-dependent but is attenuated with the recommended dose escalation to higher doses of TRULICITY <span class=,'Italics,'>[see Dosage and Administration (<a href=,'#s5,'>2.1</a>)]</span>. The delay is largest after the first dose and diminishes with subsequent doses. In clinical pharmacology studies, TRULICITY 1.5 mg did not affect the absorption of the tested orally administered medications to a clinically relevant degree <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#s59,'>12.3</a>)]</span>. There is limited experience with the use of concomitant medications in clinical trials with TRULICITY doses of 3 mg and 4.5 mg.
</p>
<p>Monitor drug levels of oral medications with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with TRULICITY.
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s34,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin
</h2>
<p class=,'First,'>When initiating TRULICITY, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#s12,'>5.3</a>) and Adverse Reactions (<a href=,'#s17,'>6</a>)].</span>
</p>
</div>
</div>"
"duloxetine","0500c320-2954-46a0-9437-091753f56bab","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Both CYP1A2 and CYP2D6 are responsible for duloxetine metabolism.</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Inhibitors of CYP1A2</h2>
<br/>
<p class=,'First,'>When duloxetine 60 mg was co-administered with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to male subjects (n=14) duloxetine AUC was increased approximately 6-fold, the C<span class=,'Sub,'>max</span> was increased about 2.5-fold, and duloxetine t<span class=,'Sub,'>1/2 </span>was increased approximately 3-fold. Other drugs that inhibit CYP1A2 metabolism include cimetidine and quinolone antimicrobials such as ciprofloxacin and enoxacin <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#Section_5.12,'>5.12</a>)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Inhibitors of CYP2D6</h2>
<br/>
<p class=,'First,'>Concomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine. Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine) <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#Section_5.12,'>5.12</a>)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Dual Inhibition of CYP1A2 and CYP2D6</h2>
<br/>
<p class=,'First,'>Concomitant administration of duloxetine 40 mg twice daily with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to CYP2D6 poor metabolizer subjects (n=14) resulted in a 6-fold increase in duloxetine AUC and C<span class=,'Sub,'>max</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin</h2>
<br/>
<p class=,'First,'>Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding. Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs or SNRIs are coadministerd with warfarin. Concomitant administration of warfarin (2 to 9 mg once daily) under steady state conditions with duloxetine 60 or 120 mg once daily for up to    14 days in healthy subjects (n=15) did not significantly change INR from baseline (mean INR changes ranged from 0.05 to + 0.07). The total warfarin (protein bound plus free drug) pharmacokinetics (AUC<span class=,'Sub,'>τ,ss</span>, C<span class=,'Sub,'>max,ss</span> or t<span class=,'Sub,'>max,ss)</span> for both R- and S-warfarin were not altered by duloxetine. Because of the potential effect of duloxetine on platelets, patients receiving warfarin therapy should be carefully monitored when duloxetine is initiated or discontinued <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#Section_5.5,'>5.5</a>)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.5,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Lorazepam</h2>
<br/>
<p class=,'First,'>Under steady-state conditions for duloxetine (60 mg Q 12 hours) and lorazepam (2 mg Q 12 hours), the pharmacokinetics of duloxetine were not affected by co-administration.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.6,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6 Temazepam</h2>
<p class=,'First,'>Under steady-state conditions for duloxetine (20 mg qhs) and temazepam (30 mg qhs), the pharmacokinetics of duloxetine were not affected by co-administration.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.7,'></a><a name=,'section-7.7,'></a>
<p></p>
<h2>7.7 Drugs that Affect Gastric Acidity</h2>
<br/>
<p class=,'First,'>Duloxetine delayed-release capsules have an enteric coating that resists dissolution until reaching a segment of the gastrointestinal tract where the pH exceeds 5.5. In extremely acidic conditions, duloxetine delayed-release capsules, unprotected by the enteric coating, may undergo hydrolysis to form naphthol. Caution is advised in using duloxetine delayed-release capsules in patients with conditions that may slow gastric emptying (e.g., some diabetics). Drugs that raise the gastrointestinal pH may lead to an earlier release of duloxetine. However, co-administration of duloxetine delayed-release capsules with aluminum- and magnesium-containing antacids (51 mEq) or duloxetine delayed-release capsules with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40 mg oral dose. It is unknown whether the concomitant administration of proton pump inhibitors affects duloxetine absorption <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#Section_5.14,'>5.14</a>)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.8,'></a><a name=,'section-7.8,'></a>
<p></p>
<h2>7.8 Drugs Metabolized by CYP1A2</h2>
<br/>
<p class=,'First,'>
<span class=,'Italics,'>In vitro</span> drug interaction studies demonstrate that duloxetine does not induce CYP1A2 activity. Therefore, an increase in the metabolism of CYP1A2 substrates (e.g., theophylline, caffeine) resulting from induction is not anticipated, although clinical studies of induction have not been performed. Duloxetine is an inhibitor of the CYP1A2 isoform in <span class=,'Italics,'>in vitro </span>studies, and in two clinical studies the average (90% confidence interval) increase in theophylline AUC was 7% (1% to 15%) and 20% (13% to 27%) when co-administered with duloxetine (60 mg twice daily).</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.9,'></a><a name=,'section-7.9,'></a>
<p></p>
<h2>7.9 Drugs Metabolized by CYP2D6</h2>
<br/>
<p class=,'First,'>Duloxetine is a moderate inhibitor of CYP2D6. When duloxetine was administered (at a dose of 60 mg twice daily) in conjunction with a single 50 mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold<span class=,'Italics,'> [see Warnings and Precautions (<a href=,'#Section_5.12,'>5.12</a>)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.10,'></a><a name=,'section-7.10,'></a>
<p></p>
<h2>7.10 Drugs Metabolized by CYP2C9</h2>
<br/>
<p class=,'First,'>Results of<span class=,'Italics,'> in vitro</span> studies demonstrate that duloxetine does not inhibit activity. In a clinical study, the pharmacokinetics of S-warfarin, a CYP2C9 substrate, were not significantly affected by duloxetine<span class=,'Italics,'> [see Drug Interactions (<a href=,'#Section_7.4,'>7.4</a>)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.11,'></a><a name=,'section-7.11,'></a>
<p></p>
<h2>7.11 Drugs Metabolized by CYP3A</h2>
<br/>
<p class=,'First,'>Results of <span class=,'Italics,'>in vitro</span> studies demonstrate that duloxetine does not inhibit or induce CYP3A activity. Therefore, an increase or decrease in the metabolism of CYP3A substrates (e.g., oral contraceptives and other steroidal agents) resulting from induction or inhibition is not anticipated, although clinical studies have not been performed.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.12,'></a><a name=,'section-7.12,'></a>
<p></p>
<h2>7.12 Drugs Metabolized by CYP2C19</h2>
<br/>
<p class=,'First,'>Results of <span class=,'Italics,'>in vitro</span> studies demonstrate that duloxetine does not inhibit CYP2C19 activity at therapeutic concentrations. Inhibition of the metabolism of CYP2C19 substrates is therefore not anticipated, although clinical studies have not been performed.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.13,'></a><a name=,'section-7.13,'></a>
<p></p>
<h2>7.13 Monoamine Oxidase Inhibitors (MAOIs)</h2>
<p class=,'First,'>
<span class=,'Italics,'>[See Dosage and Administration (<a href=,'#Section_2.7,'>2.8</a>, <a href=,'#Section_2.8,'>2.9</a>), Contraindications (<a href=,'#Section_4,'>4</a>), and Warnings and Precautions (<a href=,'#Section_5.4,'>5.4</a>)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.14,'></a><a name=,'section-7.14,'></a>
<p></p>
<h2>7.14 Serotonergic Drugs</h2>
<p class=,'First,'>
<span class=,'Italics,'>[See Dosage and Administration (2.8, 2.9), Contraindications (4), and Warnings and Precautions (5.4)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.15,'></a><a name=,'section-7.15,'></a>
<p></p>
<h2>7.15 Alcohol</h2>
<br/>
<p class=,'First,'>When duloxetine delayed-release capsules and ethanol were administered several hours apart so that peak concentrations of each would coincide, duloxetine delayed-release capsules did not increase the impairment of mental and motor skills caused by alcohol. <br/> In the duloxetine delayed-release capsules clinical trials database, three duloxetine delayed-release capsules-treated patients had liver injury as manifested by ALT and total bilirubin elevations, with evidence of obstruction. Substantial intercurrent ethanol use was present in each of these cases, and this may have contributed to the abnormalities seen<span class=,'Italics,'> [see Warnings and Precautions (<a href=,'#Section_5.2,'>5.2</a>, <a href=,'#Section_5.12,'>5.12</a>)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.16,'></a><a name=,'section-7.16,'></a>
<p></p>
<h2>7.16 CNS Drugs</h2>
<p class=,'First,'>
<span class=,'Italics,'>[See Warnings and Precautions (<a href=,'#Section_5.12,'>5.12</a>)]. </span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.17,'></a><a name=,'section-7.17,'></a>
<p></p>
<h2>7.17 Drugs Highly Bound to Plasma Protein</h2>
<br/>
<p class=,'First,'>Because duloxetine is highly bound to plasma protein, administration of duloxetine delayed-release capsules to a patient taking another drug that is highly protein bound may cause increased free concentrations of the other drug, potentially resulting in adverse reactions. However, co-administration of duloxetine (60 or 120 mg) with warfarin  (2 to 9 mg), a highly protein-bound drug, did not result in significant changes in INR and in the pharmacokinetics of either total S- or total R-warfarin (protein bound plus free drug) <span class=,'Italics,'>[see Drug Interactions (7.4)].</span>
</p>
</div>
</div>"
"dutasteride","e537c60d-9ba2-4e7f-a405-2b915dcd7ead","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_e1e12795-daf4-4b22-a912-c257bb7a371d,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_60fb5d1e-f8d8-4cc9-bac3-491920de8218,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Cytochrome P450 3A Inhibitors</h2>
<p class=,'First,'>Dutasteride is extensively metabolized in humans by the cytochrome P450 (CYP)3A4 and CYP3A5 isoenzymes. The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. Because of the potential for drug-drug interactions, use caution when prescribing dutasteride to patients taking potent, chronic CYP3A4 enzyme inhibitors (e.g., ritonavir) <span class=,'Italics,'>[see <a href=,'#LINK_33186b33-7c07-4fea-9c01-8d76312a8d4e,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_f5045fe6-5159-4f19-b0e5-04b841265ab5,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Alpha-adrenergic Antagonists</h2>
<p class=,'First,'>The administration of dutasteride in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. The effect of administration of tamsulosin or terazosin on dutasteride pharmacokinetic parameters has not been evaluated.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_010b3112-6cb0-4276-b6c2-d66296c796d3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Calcium Channel Antagonists</h2>
<p class=,'First,'>Co-administration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. The change in dutasteride exposure is not considered to be clinically significant. No dose adjustment is recommended <span class=,'Italics,'>[see <a href=,'#LINK_33186b33-7c07-4fea-9c01-8d76312a8d4e,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_5cf3610c-3cac-49fc-a14c-d925a083a69c,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Cholestyramine</h2>
<p class=,'First,'>Administration of a single 5 mg dose of dutasteride followed 1 hour later by 12 g of cholestyramine does not affect the relative bioavailability of dutasteride <span class=,'Italics,'>[see <a href=,'#LINK_33186b33-7c07-4fea-9c01-8d76312a8d4e,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_c459468c-6d76-46c3-b3da-99dabd144e17,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Digoxin</h2>
<p class=,'First,'>Dutasteride does not alter the steady-state pharmacokinetics of digoxin when administered concomitantly at a dose of 0.5 mg/day for 3 weeks <span class=,'Italics,'>[see <a href=,'#LINK_33186b33-7c07-4fea-9c01-8d76312a8d4e,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_9579f556-a8fa-48c7-8882-184b90aabe9c,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6 Warfarin</h2>
<p class=,'First,'>Concomitant administration of dutasteride 0.5 mg/day for 3 weeks with warfarin does not alter the steady-state pharmacokinetics of the S- or R-warfarin isomers or alter the effect of warfarin on prothrombin time <span class=,'Italics,'>[see <a href=,'#LINK_33186b33-7c07-4fea-9c01-8d76312a8d4e,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>"
"edoxaban","e77d3400-56ad-11e3-949a-0800200c9a66","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_7_1_Anticoagulants__Antiplatelets_,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>
<span class=,'Bold,'>7.1</span><span class=,'Bold,'>		      	Anticoagulants, Antiplatelets, Thrombolytics, and SSRIs/SNRIs</span>
</h2>
<p class=,'First,'>Co-administration of anticoagulants, antiplatelet drugs, thrombolytics and SSRIs or SNRIs may increase the risk of bleeding. Promptly evaluate any signs or symptoms of blood loss if patients are treated concomitantly with anticoagulants, aspirin, other platelet aggregation inhibitors, and/or NSAIDs <span class=,'Italics,'>[</span><span class=,'Italics,'>see</span> <span class=,'Italics,'>Warnings and Precaution</span><span class=,'Italics,'>s (</span><span class=,'Italics,'><a href=,'#_5_3_Risk_of,'>5.3</a></span><span class=,'Italics,'>)</span><span class=,'Italics,'>]</span>.</p>
<p>Long-term concomitant treatment with SAVAYSA and other anticoagulants is not recommended because of increased risk of bleeding <span class=,'Italics,'>[see Warnings and Precautions (</span><span class=,'Italics,'><a href=,'#_5_3_Risk_of,'>5.3</a></span><span class=,'Italics,'>)].</span> Short term co-administration may be needed for patients transitioning to or from SAVAYSA <span class=,'Italics,'>[</span><span class=,'Italics,'>see</span> <span class=,'Italics,'>Dosage and Administration</span><span class=,'Italics,'> (</span><span class=,'Italics,'><a href=,'#_2_4_Transition_to,'>2.4</a></span><span class=,'Italics,'>)</span><span class=,'Italics,'>]</span>. </p>
<p>In clinical studies with SAVAYSA concomitant use of aspirin (low dose ≤ 100 mg/day) or thienopyridines, and NSAIDs was permitted and resulted in increased rates of Clinically Relevant Bleeding. Carefully monitor for bleeding in patients who require chronic treatment with low dose aspirin and/or NSAIDs <span class=,'Italics,'>[</span><span class=,'Italics,'>see</span> <span class=,'Italics,'>Warnings and Precautio</span><span class=,'Italics,'>ns (</span><span class=,'Italics,'><a href=,'#_5_3_Risk_of,'>5.3</a></span><span class=,'Italics,'>) and Clinical Pharmacology (</span><span class=,'Italics,'><a href=,'#_12_3_Pharmacokinetics,'>12.3</a></span><span class=,'Italics,'>)</span><span class=,'Italics,'>]</span>.</p>
<p>As with other anticoagulants the possibility may exist that patients are at an increased risk of bleeding in case of concomitant use with SSRIs or SNRIs due to their reported effect on platelets <span class=,'Italics,'>[see <a href=,'#_5_3_Risk_of,'>Warnings and Precautions (5.3)</a>].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_7_2_P_gp_Inducers,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>
<span class=,'Bold,'>7.2</span><span class=,'Bold,'>		      	P-gp Inducers</span>
</h2>
<p class=,'First,'>Avoid the concomitant use of SAVAYSA with rifampin <span class=,'Italics,'>[</span><span class=,'Italics,'>see</span> <span class=,'Italics,'>Clinical Pharmacolo</span><span class=,'Italics,'>gy (</span><span class=,'Italics,'><a href=,'#_12_3_Pharmacokinetics,'>12.3</a></span><span class=,'Italics,'>)</span><span class=,'Italics,'>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.3,'></a>
<p></p>
<h2>
<span class=,'Bold,'>7.3</span><span class=,'Bold,'>		      	P-gp Inhibitors</span>
</h2>
<p class=,'First,'>
<span class=,'Underline,'>Treatment of NVAF</span>
</p>
<p>Based on clinical experience from the ENGAGE AF-TIMI 48 study, dose reduction in patients concomitantly receiving P-gp inhibitors resulted in edoxaban blood levels that were lower than in patients who were given the full dose. Consequently, no dose reduction is recommended for concomitant P-gp inhibitor use <span class=,'Italics,'>[</span><span class=,'Italics,'>see</span> <span class=,'Italics,'>Dosage and Administratio</span><span class=,'Italics,'>n (</span><span class=,'Italics,'><a href=,'#_2_1_Nonvalvular_Atrial,'>2.1</a></span><span class=,'Italics,'>), Clinical Pharmacology (</span><span class=,'Italics,'><a href=,'#_12_3_Pharmacokinetics,'>12.3</a></span><span class=,'Italics,'>), and Clinical Studies (</span><span class=,'Italics,'><a href=,'#_14_1_Nonvalvular_Atrial,'>14.1</a></span><span class=,'Italics,'>)</span><span class=,'Italics,'>]</span>.</p>
<p>
<span class=,'Underline,'>Treatment of Deep Vein Thrombosis and Pulmonary Embolism</span>
</p>
<p>
<span class=,'Italics,'>[</span><span class=,'Italics,'>see</span> <span class=,'Italics,'>Clinical Studies </span><span class=,'Italics,'>(</span><span class=,'Italics,'><a href=,'#_14_2_Treatment_of,'>14.2</a></span><span class=,'Italics,'>)</span><span class=,'Italics,'>]</span>
</p>
</div>
</div>"
"efavirenz","4c57ad7f-321a-46c8-851a-c895466eb8e1","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Potential for Efavirenz to Affect other Drugs</h2>
<p class=,'First,'>Efavirenz has been shown <span class=,'Italics,'>in vivo</span> to induce CYP3A and CYP2B6. Other compounds that are substrates of CYP3A or CYP2B6 may have decreased plasma concentrations when coadministered with efavirenz. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Potential for Other Drugs to Affect Efavirenz</h2>
<p class=,'First,'>Drugs that induce CYP3A activity (e.g., phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations <span class=,'Italics,'>[see <a href=,'#Section_2.1,'>Dosage and Administration (2.2)</a>].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.4,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3  QT Prolonging Drugs</h2>
<p class=,'First,'>There is limited information available on the potential for a pharmacodynamic interaction between efavirenz and drugs that prolong the QTc interval. QTc prolongation has been observed with the use of efavirenz <span class=,'Italics,'>[see <a href=,'#Section_12.2,'>Clinical Pharmacology (12.2)</a>]</span>. Consider alternatives to efavirenz when coadministered with a drug with a known risk of Torsade de Pointes.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.5,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4  Established and Other Potentially Significant Drug Interactions</h2>
<p class=,'First,'>Drug interactions with efavirenz are summarized in Table 5. For pharmacokinetics data, [<span class=,'Italics,'>see Clinical Pharmacology (12.3)] </span>Tables 7 and 8. This table includes potentially significant interactions, but is not all inclusive.</p>
<br/>
<div class=,'scrollingtable,'><table border=,'0,' cellpadding=,'0,' cellspacing=,'0,' width=,'639,'>
<caption>
<span> Table 5: Established and Other Potentially Significant Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction 
			</span>
</caption>
<colgroup>
<col width=,'24.6558197747184%,'/>
<col width=,'24.5306633291614%,'/>
<col width=,'50.8135168961201%,'/>
</colgroup>
<tbody class=,'Headless,'>
<tr class=,'Botrule First,'>
<td class=,'Lrule Rrule,' valign=,'bottom,'><span class=,'Bold,'>Concomitant Drug</span>
<br/>
<span class=,'Bold,'>Class: Drug Name</span>
<br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'bottom,'><span class=,'Bold,'>Effect</span>
<br/>
</td><td class=,'Rrule,' valign=,'bottom,'><span class=,'Bold,'>Clinical Comment</span>
<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'><span class=,'Italics,'>HIV antiviral agents</span>
<br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'middle,'><span class=,'Bold,'> </span>
<br/>
</td><td class=,'Rrule,' valign=,'middle,'><span class=,'Bold,'> </span>
<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'>Protease inhibitor:<br/>    Fosamprenavir     Calcium</td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <br/>↓ amprenavir<span class=,'Bold,'></span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'middle,'>Fosamprenavir (unboosted): Appropriate doses of the combinations with respect to safety and efficacy have not been established.<br/>Fosamprenavir/ritonavir: An additional 100 mg/day (300 mg total) of ritonavir is recommended when efavirenz is administered with fosamprenavir/ritonavir once daily.  No change in the ritonavir dose is required when efavirenz is administered with fosamprenavir plus ritonavir twice daily.<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'>Protease inhibitor:<br/>    Atazanavir<br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <br/>↓ atazanavir*<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'><span class=,'Italics,'>Treatment-naive patients: </span>When coadministered with efavirenz, the recommended dose of atazanavir is 400 mg with ritonavir 100 mg (together once daily with food) and efavirenz 600 mg (once daily on an empty stomach, preferably at bedtime).<br/>
<span class=,'Italics,'>Treatment-experienced patients: </span>Coadministration of efavirenz and atazanavir is not recommended.<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'>Protease inhibitor:<br/>    Indinavir<span class=,'Bold,'></span>
<br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <br/>↓ indinavir*<span class=,'Bold,'></span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>The optimal dose of indinavir, when given in combination with efavirenz, is not known. Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz. <span class=,'Bold,'></span>
<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'>Protease inhibitor: <br/>    Lopinavir/ritonavir <br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <br/>↓ lopinavir*<span class=,'Sup,'></span>
<br/>
<span class=,'Sup,'> </span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Lopinavir/ritonavir once daily dosing is not recommended when coadministered with efavirenz. <br/>The dose of lopinavir/ritonavir must be increased when coadministered with efavirenz. See the lopinavir/ritonavir prescribing information for dose adjustments of lopinavir/ritonavir when coadministered with efavirenz in adult and pediatric patients.             <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'>Protease inhibitor: <br/>     Ritonavir<br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <br/>↑ ritonavir*<br/>↑ efavirenz*<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Monitor for elevation of liver enzymes and for adverse clinical experiences (e.g., dizziness, nausea, paresthesia) when efavirenz is coadministered with ritonavir.     <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'>Protease inhibitor:  <br/>     Saquinavir<br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'middle,'>↓ saquinavir*<span class=,'Sup,'></span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Appropriate doses of the combination of efavirenz and saquinavir/ritonavir with respect to safety and efficacy have not been established.<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'>NNRTI:<br/>  Other NNRTIs<br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'middle,'>↑ or ↓ efavirenz <br/>and/or NNRTI<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Combining two NNRTIs has not been shown to be beneficial. Efavirenz should not be coadministered with other NNRTIs.<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'>CCR5 co-receptor<br/>antagonist:<br/>Maraviroc <br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'middle,'>↓ maraviroc*<br/>
</td><td class=,'Rrule,' valign=,'middle,'>Refer to the full prescribing information for maraviroc for guidance on coadministration with efavirenz. <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Hepatitis C antiviral agents</span>
<br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> <br/>
</td><td class=,'Rrule,' valign=,'middle,'> <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'>Boceprevir<br/>
</td><td class=,'Rrule,' valign=,'middle,'>          ↓ boceprevir*<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'middle,'>Concomitant administration of boceprevir with efavirenz is not recommended because it may result in loss of therapeutic effect of boceprevir.<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'>Elbasvir/Grazoprevir <br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'middle,'>↓ elbasvir<br/>↓ grazoprevir<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'middle,'>Coadministration of efavirenz with elbasvir/grazoprevir is contraindicated <span class=,'Italics,'>[see Contraindications (4)] </span>because it may lead to loss of virologic response to elbasvir/grazoprevir.<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'>Pibrentasvir/Glecaprevir<span class=,'Italics,'></span>
<br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'middle,'>↓ pibrentasvir<br/>↓ glecaprevir <br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'middle,'>Coadministration of efavirenz is not recommended because it may lead to reduced therapeutic effect of pibrentasvir/glecaprevir.<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'>Simeprevir<br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'middle,'>↓ simeprevir*<br/> <br/>↔ efavirenz*<br/> <br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'middle,'>Concomitant administration of simeprevir with efavirenz is not recommended because it may result in loss of therapeutic effect of simeprevir. <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'>Velpatasvir/ Sofosbuvir<br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'middle,'>↓ velpatasvir<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'middle,'>Coadministration of efavirenz and sofosbuvir/velpatasvir is not recommended because it may result in loss of therapeutic effect of sofosbuvir/velpatasvir.<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'>Velpatasvir/Sofosbuvir/ Voxilaprevir<br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'middle,'>↓ velpatasvir<br/>↓ voxilaprevir<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'middle,'>Coadministration of efavirenz and sofosbuvir/velpatasvir/ voxilaprevir is not recommended because it may result in loss of therapeutic effect of sofosbuvir/velpatasvir/ voxilaprevir.<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'><span class=,'Italics,'>Other agents</span>
<br/>
</td><td class=,'Rrule,' valign=,'middle,'> <br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'middle,'> <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Anticoagulant:  <br/>      Warfarin<br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'middle,'>↑ or ↓ warfarin<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Monitor INR and adjust warfarin dosage if necessary.   <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'> Anticonvulsants: <br/>      Carbamazepine<br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <br/>↓ carbamazepine*<span class=,'Sup,'></span>
<br/>↓ efavirenz*<span class=,'Sup,'></span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'> <br/>There are insufficient data to make a dose recommendation for efavirenz. Alternative anticonvulsant treatment should be used. <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'>      Phenytoin<br/>      Phenobarbital<br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'top,'>↓ anticonvulsant<br/>              ↓ efavirenz<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Potential for reduction in anticonvulsant and/or efavirenz plasma levels; periodic monitoring of anticonvulsant plasma levels should be conducted.<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Antidepressants: <br/>      Bupropion<br/> <br/> <br/>      Sertraline<br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'middle,'>↓ bupropion*<span class=,'Sup,'></span>
<br/> <br/> <br/> <br/>↓ sertraline*<span class=,'Sup,'></span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Increases in bupropion dosage should be guided by clinical response. Bupropion dose should not exceed the maximum recommended dose.  <br/> <br/>Increases in sertraline dosage should be guided by clinical<br/>response.  <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'>Antifungals:<br/>                   Voriconazole<br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <br/>↓ voriconazole*<br/>↑ efavirenz*<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'> <br/>Efavirenz and voriconazole should not be coadministered at standard doses. When voriconazole is coadministered with efavirenz, voriconazole maintenance dose should be increased to 400 mg every 12 hours and efavirenz dose should be decreased to 300 mg once daily using the capsule formulation. <br/>    <span class=,'Italics,'></span>
<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'>      Itraconazole <br/> <br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'middle,'>↓ itraconazole*<span class=,'Sup,'></span>
<br/>↓ hydroxyitraconazole*<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Consider alternative antifungal treatment because no dose recommendation for itraconazole can be made.<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'>      Ketoconazole<br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'top,'>↓ ketoconazole<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Consider alternative antifungal treatment because no dose recommendation for ketoconazole can be made. <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'>      Posaconazole<br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'top,'>↓ posaconazole*<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Avoid concomitant use unless the benefit outweighs the risks.<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'>  Anti-infective:<br/>      Clarithromycin<br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'top,'>↓ clarithromycin*<br/>↑ 14-OH metabolite*<span class=,'Sup,'></span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Consider alternatives to macrolide antibiotics because of the risk of QT interval prolongation.  <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'>  Antimycobacterials:<br/>     Rifabutin<br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <br/>↓ rifabutin*<span class=,'Sup,'></span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Increase daily dose of rifabutin by 50%. Consider doubling the rifabutin dose in regimens where rifabutin is given 2 or 3 times a week.<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'>     Rifampin<br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'top,'>↓ efavirenz*<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Increase efavirenz to 800 mg once daily when coadministered with rifampin to patients weighing 50 kg or more. <br/> <br/> <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'>Antimalarials: Artemether/lumefantrine <br/> <br/> <br/>Atovaquone/ <br/>proguanil<br/> <br/> <br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'top,'>↓ artemether* <br/>↓ dihydroartemisinin* <br/>↓ lumefantrine* <br/> <br/>↓ atovaquone<br/>↓ proguanil<br/> <br/> <br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Consider alternatives to artemether/lumefantrine because of the risk of QT interval prolongation. <br/> <br/> <br/> <br/>Concomitant administration is not recommended.<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'>Calcium channel <br/>blockers:<br/>Diltiazem<br/> <br/> <br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'middle,'>↓ diltiazem*<br/>↓ desacetyl diltiazem*<br/>↓ N-monodesmethyl diltiazem*<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'> <br/>Diltiazem dose adjustments should be guided by clinical response (refer to the full prescribing information for diltiazem). No dose adjustment of efavirenz is necessary when administered with diltiazem.<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'>Others (e.g., <br/>felodipine,<br/>nicardipine,<br/>nifedipine,<br/>verapamil)<br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'top,'>↓ calcium channel blocker<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>When coadministered with efavirenz, dosage adjustment of calcium channels blocker may be needed and should be guided by clinical response (refer to the full prescribing information for the calcium channel blocker).   <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'>  HMG-CoA reductase<br/>  inhibitors:<br/>      Atorvastatin  <br/>      Pravastatin<br/>      Simvastatin<br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <br/> <br/> ↓ atorvastatin*<br/>↓ pravastatin*<br/>↓ simvastatin* <br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Plasma concentrations of atorvastatin, pravastatin, and simvastatin decreased. Consult the full prescribing information for the HMG-CoA reductase inhibitor for guidance on individualizing the dose.<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Hormonal contraceptives:<br/>   Oral<br/>     Ethinyl estradiol/<br/>     Norgestimate<br/> <br/> <br/>   Implant<br/>     Etonogestrel<br/> <br/> <br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <br/> <br/>↓ active metabolites of    norgestimate*<br/> <br/> <br/>↓ etonogestrel<br/> <br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'> <br/>A reliable method of barrier contraception should be used in addition to hormonal contraceptives.<br/> <br/> <br/> <br/>A reliable method of barrier contraception should be used in addition to hormonal contraceptives. Decreased exposure of etonogestrel may be expected. There have been postmarketing reports of contraceptive failure with etonogestrel in efavirenz-exposed patients.<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'>Immunosuppressants:<br/>  Cyclosporine, tacrolimus, sirolimus, and others metabolized by CYP3A<br/> <br/>
</td><td class=,'Rrule,' valign=,'top,'> <br/>↓ immunosuppressant<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Dose adjustments of the immunosuppressant may be required. Close monitoring of immunosuppressant concentrations for at least 2 weeks (until stable concentrations are reached) is recommended when starting or stopping treatment with efavirenz.    <br/>
</td>
</tr>
<tr class=,'Last,'>
<td class=,'Lrule Rrule,' valign=,'top,'>Narcotic analgesic:<br/>      Methadone<br/>
</td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <br/>↓ methadone*<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'> <br/>Monitor for signs of methadone withdrawal and increase methadone dose if required to alleviate withdrawal symptoms.   <br/>
</td>
</tr>
</tbody>
</table></div>
<p>* The interaction between efavirenz and the drug was evaluated in a clinical study. All other drug interactions shown are predicted. </p>
<p>This table is not all-inclusive.</p>
<br/>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.6,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5  Drugs Without Clinically Significant Interactions with Efavirenz</h2>
<p class=,'First,'>No dosage adjustment is recommended when efavirenz is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lorazepam, nelfinavir, nucleoside reverse transcriptase inhibitors (abacavir, emtricitabine, lamivudine, stavudine, tenofovir disoproxil fumarate, zidovudine), paroxetine, and raltegravir.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.7,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6 Cannabinoid Test Interaction</h2>
<p class=,'First,'>Efavirenz does not bind to cannabinoid receptors. False-positive urine cannabinoid test results have been reported with some screening assays in uninfected and HIV-infected subjects receiving efavirenz. Confirmation of positive screening tests for cannabinoids by a more specific method is recommended.</p>
</div>
</div>"
"eflornithine","a2c3d206-b893-4f65-a2f6-c11fa9a0e486","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID_1C735180-4A38-7EEF-E184-9BBCE80DF36C,'></a><a name=,'section-11,'></a>
<p></p>
<p class=,'First,'>It is not known if VANIQA has any interaction with other topically applied drug products.</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_497cbd19-8145-38b4-1b16-90119b924e2e,'></a><a name=,'section-11.1,'></a>
<p></p>
<h2>Carcinogenesis, Mutagenesis and Impairment of Fertility</h2>
<p class=,'First,'>In a 12-month photocarcinogenicity study in hairless albino mice, animals treated with the vehicle alone showed an increased incidence of skin tumors induced by exposure to ultraviolet (UVA/UVB) light, whereas mice treated topically with VANIQA at doses up to 600 mg/kg [19X the Maximum Recommended Human Dose (MRHD) based on body surface area (BSA)] showed an incidence of skin tumors equivalent to untreated-control animals.</p>
<p>A 2-year dermal carcinogenicity study in CD1 mice treated with VANIQA revealed no evidence of carcinogenicity at daily doses up to 600 mg/kg (950X the MRHD based on AUC comparisons).</p>
<p>Eflornithine did not elicit mutagenic effects in an Ames reverse-mutation assay or clastogenicity in primary human lymphocytes, with and without metabolic activation, In a dermal micronucleus assay, eflornithine hydrochloride cream, 13.9%, at doses up to 900 mg/kg (58X the MRHD based on BSA) in rats yielded no evidence of genotoxicity.</p>
<p>In a dermal fertility and early embryonic development study in rats treated with VANIQA, there were no adverse reproductive effects at doses up to 450 mg/kg (29X the MRHD based on BSA). In a peri- and postnatal study in rats, eflornithine administered in the drinking water was associated with maternal toxicity and reduced pup weights at doses of at least 625 mg/kg (40X the MRHD based on BSA) and a slightly reduced fertility index, which was considered to be of questionable biological significance, at 1698 mg/kg (110X the MRHD based on BSA). No effects were seen with an oral dose of 223 mg/kg (14X the MRHD based on BSA). In the latter study, the multiples of the human exposure are likely much higher, since eflornithine is well absorbed orally in rats, whereas minimal absorption occurs in humans treated topically.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_e9b2dabe-3894-7557-0837-53455b95efaa,'></a><a name=,'section-11.2,'></a>
<p></p>
<h2>Pregnancy</h2>
<p class=,'First,'>Teratogenic Effects: Pregnancy Category C<br/>In the first dermal embryo-fetal development study in rats treated with eflornithine hydrochloride cream, 13.9% (in which no precautions were taken to prevent ingestion of drug from application sites), maternal toxicity and fetal effects including reduced numbers of live fetuses, decreased fetal weights, and delayed ossification and development of the viscera were observed at doses of 225 and 450 mg/kg (15X and 29X the MRHD based on BSA, respectively). When the study was repeated under conditions that avoided ingestion from application sites, no maternal, fetal or teratogenic effects were observed at doses up to 450 mg/kg (29X the MRHD based on BSA). In the first study in which no precautions were taken to prevent ingestion, circulating plasma levels were 11- to 14-fold higher than in the second study in which ingestion was prevented. In a dermal embryo-fetal development study in rabbits treated with VANIQA (eflornithine hydrochloride) Cream, 13.9% no adverse maternal or fetal effects occurred at doses up to 90 mg/kg (11X the MRHD based on BSA). Significant dermal irritation, as well as possible ingestion of VANIQA occurred at 300 mg/kg/day (36X the MRHD based on BSA) and was associated with maternal deaths, abortions, increased fetal resorptions, and reduced fetal weights, Fetotoxicity in the absence of maternal toxicity has been reported in oral studies with eflornithine with fetal no-effect doses of 80 mg/kg in rats and 45 mg/kg in rabbits. In these studies, no evidence of teratogenicity was observed in rats given up to 200 mg/kg or in rabbits given up to 135 mg/kg.</p>
<p>Although VANIQA was not formally studied in pregnant patients, 22 pregnancies occurred during the trials. Nineteen of these pregnancies occurred while patients were using VANIQA. Of the 19 pregnancies, there were 9 healthy infants, 4 spontaneous abortions, 5 induced/elective abortions, and 1 birth defect (Down's Syndrome to a 35-year-old). Because there are no adequate and well-controlled studies in pregnant women, the risk/benefit ratio of using VANIQA in women with unwanted facial hair who are pregnant should be weighed carefully with serious consideration for either not implementing or discontinuing use of VANIQA.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_1c80dda4-14ea-c364-91d3-c79bb1f9516c,'></a><a name=,'section-11.3,'></a>
<p></p>
<h2>Nursing Mothers</h2>
<p class=,'First,'>It is not known whether or not eflornithine hydrochloride is excreted in human milk. Caution should be exercised when VANIQA is administered to a nursing woman.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_f5982985-555d-894c-cfca-fca4a8f30cd9,'></a><a name=,'section-11.4,'></a>
<p></p>
<h2>Pediatric Use</h2>
<p class=,'First,'>The safety and effectiveness of this product have not been established in pediatric patients less than 12 years of age.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_d44ec6f4-f9c4-8bf8-92b4-a78d5a4a6fb8,'></a><a name=,'section-11.5,'></a>
<p></p>
<h2>Geriatric Use</h2>
<p class=,'First,'>Of the 1373 patients on active treatment in clinical studies of VANIQA, approximately 7% were 65 years or older and approximately 1% were 75 or older. No apparent differences in safety were observed between older patients and younger patients.</p>
</div>
</div>"
"empagliflozin","5777b8a8-ada6-4950-8548-43a1de11f075","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1  Diuretics</h2>
<p class=,'First,'>Coadministration of empagliflozin with diuretics resulted in increased urine volume and frequency of voids, which might enhance the potential for volume depletion <span class=,'Italics,'>[see <a href=,'#S5.1,'>Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2  Insulin or Insulin Secretagogues</h2>
<p class=,'First,'>Coadministration of empagliflozin with insulin or insulin secretagogues increases the risk for hypoglycemia <span class=,'Italics,'>[see <a href=,'#S5.5,'>Warnings and Precautions (5.5)</a>].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3  Positive Urine Glucose Test</h2>
<p class=,'First,'>Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors as SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests.  Use alternative methods to monitor glycemic control.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4  Interference with 1,5-anhydroglucitol (1,5-AG) Assay</h2>
<p class=,'First,'>Monitoring glycemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors.  Use alternative methods to monitor glycemic control.</p>
</div>
</div>"
"emtricitabine","2b8d1718-01c4-49a8-b345-9583b51a5b7b","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID66,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>
<a name=,'ID67,'></a>The potential for drug interactions with emtricitabine has been studied in combination with AZT, indinavir, d4T, famciclovir, and tenofovir DF (TDF). There were no clinically significant drug interactions for any of these drugs. Drug interactions trials are described elsewhere in the labeling 
       
 
  <span class=,'Italics,'>[see Clinical Pharmacology (
        
  
   <a href=,'#ID90,'>12.3</a>)].
       
 
  </span>
</p>
</div>"
"enoxaparin","066f27ec-352c-4051-ba29-248e292690db","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Whenever possible, agents which may enhance the risk of hemorrhage should be discontinued prior to initiation of enoxaparin sodium therapy.  These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, salicylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.  If coadministration is essential, conduct close clinical and laboratory monitoring<span class=,'Italics,'> [see <a href=,'#S5.1,'>Warnings and Precautions (5.1)</a>]</span>.</p>
</div>"
"entecavir","955c0fd5-909c-4033-9191-7dce1ea4fcaf","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Since entecavir is primarily eliminated by the kidneys <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>],</span> coadministration of entecavir tablets with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug. Coadministration of entecavir with lamivudine, adefovir dipivoxil, or tenofovir disoproxil fumarate did not result in significant drug interactions. The effects of coadministration of entecavir tablets with other drugs that are renally eliminated or are known to affect renal function have not been evaluated, and patients should be monitored closely for adverse events when entecavir tablets are coadministered with such drugs.</p>
</div>"
"enzalutamide","381cd215-78c9-4208-8595-7ae7a279b236","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'i4i_interactions_id_95e7e5ea-8a64-4b94-be6e-b07a80ef3c01,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_d0a04c0b-f728-4f4a-982b-74621844660a,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Drugs that Inhibit CYP2C8</h2>
<p class=,'First,'>Co-administration of a strong CYP2C8 inhibitor (gemfibrozil) increased the composite area under the plasma concentration-time curve (AUC) of enzalutamide plus N-desmethyl enzalutamide by 2.2-fold. Co‑administration of XTANDI with strong CYP2C8 inhibitors should be avoided if possible. If co-administration of XTANDI with a strong CYP2C8 inhibitor cannot be avoided, reduce the dose of XTANDI <span class=,'Italics,'>[see <a href=,'#i4i_dosage_admin_id_6b2ad128-3683-4af7-aa7f-f56e6d0c6e30,'>Dosage and Administration</a> (<a href=,'#ID_49bd185f-3dc1-467e-8c79-58191b1c49ae,'>2.2</a>) and <a href=,'#i4i_clinical_pharmacology_id_df96fa8e-40da-499c-9b30-bf4ba2607d60,'>Clinical Pharmacology</a> (<a href=,'#i4i_pharmacokinetics_id_ce3237da-0bda-41a4-aeaa-09489ee3d6c0,'>12.3</a>)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_06eda248-5f46-43b7-8ed5-426f909644dc,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Drugs that Induce CYP3A4</h2>
<p class=,'First,'>Co-administration of rifampin (strong CYP3A4 inducer and moderate CYP2C8 inducer) decreased the composite AUC of enzalutamide plus N-desmethyl enzalutamide by 37%. Co-administration of strong CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine) with XTANDI should be avoided if possible. St John’s wort may decrease enzalutamide exposure and should be avoided. If co-administration of a strong CYP3A4 inducer with XTANDI cannot be avoided, increase the dose of XTANDI <span class=,'Italics,'>[see <a href=,'#i4i_dosage_admin_id_6b2ad128-3683-4af7-aa7f-f56e6d0c6e30,'>Dosage and Administration</a> (<a href=,'#ID_49bd185f-3dc1-467e-8c79-58191b1c49ae,'>2.2</a>) and <a href=,'#i4i_clinical_pharmacology_id_df96fa8e-40da-499c-9b30-bf4ba2607d60,'>Clinical Pharmacology</a> (<a href=,'#i4i_pharmacokinetics_id_ce3237da-0bda-41a4-aeaa-09489ee3d6c0,'>12.3</a>)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_4166cda9-55e6-4c73-a1de-da77f29e3fc0,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Effect of XTANDI on Drug Metabolizing Enzymes</h2>
<p class=,'First,'>Enzalutamide is a strong CYP3A4 inducer and a moderate CYP2C9 and CYP2C19 inducer in humans. At steady-state, XTANDI reduced the plasma exposure to midazolam (CYP3A4 substrate), warfarin (CYP2C9 substrate), and omeprazole (CYP2C19 substrate). Concomitant use of XTANDI with narrow therapeutic index drugs that are metabolized by CYP3A4 (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus and tacrolimus), CYP2C9 (e.g., phenytoin, warfarin) and CYP2C19 (e.g., S-mephenytoin, clopidogrel) should be avoided, as enzalutamide may decrease their exposure. If co-administration with warfarin cannot be avoided, conduct additional INR monitoring <span class=,'Italics,'>[see <a href=,'#i4i_clinical_pharmacology_id_df96fa8e-40da-499c-9b30-bf4ba2607d60,'>Clinical Pharmacology</a> (<a href=,'#i4i_pharmacokinetics_id_ce3237da-0bda-41a4-aeaa-09489ee3d6c0,'>12.3</a>)]</span>.</p>
</div>
</div>"
"ephedrine","2c203482-8a04-40fc-93d2-74b30dec7742","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_7205441f-0ad2-40fd-a6cb-fb1d206011e6,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'scrollingtable,'><table>
<col width=,'25%,'/>
<col width=,'75%,'/>
<tbody class=,'Headless,'>
<tr class=,'First,'>
<td align=,'center,' class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'>Interactions that Augment the Pressor Effect</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'>Oxytocin and oxytocic drugs</span></td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'><span class=,'Italics,'>Clinical Impact: </span></td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Serious postpartum hypertension has been described in patients who received both a vasopressor (i.e., methoxamine, phenylephrine, ephedrine) and an oxytocic (i.e., methylergonovine, ergonovine). Some of these patients experienced a stroke. </td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'><span class=,'Italics,'>Intervention: </span></td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Carefully monitor the blood pressure of individuals who have received both ephedrine and an oxytocic.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'>Clonidine, propofol, monoamine oxidase inhibitors (MAOIs), atropine</span></td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'><span class=,'Italics,'>Clinical Impact: </span></td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>These drugs augment the pressor effect of ephedrine.</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'><span class=,'Italics,'>Intervention: </span></td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Carefully monitor the blood pressure of individuals who have received both ephedrine and any of these drugs.</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'>Interactions that Antagonize the Pressor Effect</span></td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'><span class=,'Italics,'>Clinical Impact: </span></td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>These drugs antagonize the pressor effect of ephedrine.</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'><span class=,'Italics,'>Intervention: </span></td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Carefully monitor the blood pressure of individuals who have received both ephedrine and any of these drugs.</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'><span class=,'Italics,'>Examples: </span></td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'>Other Drug Interactions</span></td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'>Guanethidine</span></td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'><span class=,'Italics,'>Clinical Impact: </span></td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness.  </td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'><span class=,'Italics,'>Intervention: </span></td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Clinician should monitor patient for blood pressor response and adjust the dosage or choice of pressor accordingly.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'>Rocuronium</span></td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'><span class=,'Italics,'>Clinical Impact: </span></td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Ephedrine may reduce the onset time of neuromuscular blockade when used for intubation with rocuronium if administered simultaneously with anesthetic induction.</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'><span class=,'Italics,'>Intervention: </span></td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Be aware of this potential interaction. No treatment or other interventions are needed.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'>Epidural anesthesia</span></td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'><span class=,'Italics,'>Clinical Impact: </span></td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Ephedrine may decrease the efficacy of epidural blockade by hastening the regression of sensory analgesia. </td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'><span class=,'Italics,'>Intervention: </span></td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Monitor and treat the patient according to clinical practice.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'>Theophylline</span></td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'><span class=,'Italics,'>Clinical Impact: </span></td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Concomitant use of ephedrine may increase the frequency of nausea, nervousness, and insomnia.</td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'><span class=,'Italics,'>Intervention: </span></td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Monitor patient for worsening symptoms and manage symptoms according to clinical practice.</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'>Cardiac glycosides</span></td>
</tr>
<tr>
<td align=,'right,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'><span class=,'Italics,'>Clinical Impact: </span></td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Giving ephedrine with a cardiac glycoside, such as digitalis, may increase the possibility of arrhythmias.</td>
</tr>
<tr class=,'Last,'>
<td align=,'right,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'><span class=,'Italics,'>Intervention: </span></td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Carefully monitor patients on cardiac glycosides who are also administered ephedrine.</td>
</tr>
</tbody>
</table></div>
</div>"
"epinephrine","04f07f15-55e2-411b-abb8-07eab37f5664","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_e9446de4-65cf-42d3-95b2-65baa9e895e2,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Underline,'>Cardiac Glycosides, Diuretics, and Anti-arrhythmics</span>
</p>
<p>Patients who receive epinephrine while concomitantly taking cardiac glycosides, diuretics, or anti-arrhythmics should be observed carefully for the development of cardiac arrhythmias [<span class=,'Italics,'>see Warnings and Precautions (<a href=,'#LINK_c08ae0f2-7b03-436a-8ae5-261dee74937b,'>5.5</a>)</span>]. </p>
<p>
<span class=,'Underline,'>Antidepressants, Monoamine Oxidase Inhibitors, Levothyroxine, and Antihistamines</span>
<br/>
</p>
<p>The effects of epinephrine may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine. </p>
<p>
<span class=,'Underline,'>Beta-Adrenergic Blockers</span>
<br/>
</p>
<p>The cardiostimulating and bronchodilating effects of epinephrine are antagonized by beta-adrenergic blocking drugs, such as propranolol. </p>
<p>
<span class=,'Underline,'>Alpha-Adrenergic Blockers</span>
<br/>
</p>
<p>The vasoconstricting and hypertensive effects of epinephrine are antagonized by alpha-adrenergic blocking drugs, such as phentolamine. </p>
<p>
<span class=,'Underline,'>Ergot Alkaloids</span>
<br/>
</p>
<p>Ergot alkaloids may also reverse the pressor effects of epinephrine.</p>
</div>"
"eplerenone","4743a48b-d4b5-4054-85e1-9d64cc40de25","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'i4i_interactions_id_bb29e1f9-8fc1-4de5-a9ef-c611087fb900,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_bc490280-3710-430d-9f0d-2b8dc05f9fda,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 CYP3A4 Inhibitors</h2>
<p class=,'First,'>Because eplerenone metabolism is predominantly mediated via CYP3A4, do not use eplerenone with drugs that are strong inhibitors of CYP3A4. [See <a href=,'#i4i_contraindications_id_f72ef5c2-3a76-46d7-a27d-6b739594346c,'>4 CONTRAINDICATIONS</a> and <span class=,'Bold,'>CLINICAL PHARMACOLOGY</span>, <a href=,'#i4i_pharmacokinetics_id_fc76b8b6-9e06-4054-9b25-54852a5386f4,'>12.3 Pharmacokinetics</a>.]</p>
<p>In patients with hypertension taking moderate CYP3A4 inhibitors, reduce the starting dose of eplerenone to 25 mg once daily. [See <span class=,'Bold,'>DOSAGE AND ADMINISTRATION</span>, <a href=,'#i4i_section_id_022f4029-76e3-4937-b925-361f16f6fd15,'>2.4 Dose Modifications for Specific Populations </a>) and <span class=,'Bold,'>CLINICAL PHARMACOLOGY</span>, <a href=,'#i4i_pharmacokinetics_id_fc76b8b6-9e06-4054-9b25-54852a5386f4,'>12.3 Pharmacokinetics</a>.]</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_0d7e8598-855a-4648-9d7a-84bfd7560f7d,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 ACE Inhibitors and Angiotensin II Receptor Antagonists </h2>
<p class=,'First,'>
<span class=,'Underline,'>Congestive Heart Failure Post-Myocardial Infarction</span>
</p>
<p>In EPHESUS [see <span class=,'Bold,'>CLINICAL STUDIES</span>, <a href=,'#i4i_section_id_696b0a03-2b09-4b49-9a5a-412e1ce4b17d,'>14.1 Congestive Heart Failure Post-Myocardial Infarction </a>], 3,020 (91%) patients receiving eplerenone 25 mg to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB). Rates of patients with maximum potassium levels &gt;5.5 mEq/L were similar regardless of the use of ACEI/ARB.</p>
<p>
<span class=,'Underline,'>Hypertension</span>
</p>
<p>In clinical studies of patients with hypertension, the addition of eplerenone 50 mg to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09 mEq/L to 0.13 mEq/L). In a study in diabetics with microalbuminuria, eplerenone 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium &gt;5.5 mEq/L) from 17% on enalapril alone to 38%.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_819ee5b8-51fc-4696-b376-4d96db088179,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Lithium</h2>
<p class=,'First,'>A drug interaction study of eplerenone with lithium has not been conducted. Lithium toxicity has been reported in patients receiving lithium concomitantly with diuretics and ACE inhibitors. Serum lithium levels should be monitored frequently if eplerenone is administered concomitantly with lithium.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_6b461c29-2ff2-48e2-b1b6-f487cebc8f58,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)</h2>
<p class=,'First,'>A drug interaction study of eplerenone with an NSAID has not been conducted. The administration of other potassium-sparing antihypertensives with NSAIDs has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function. Therefore, when eplerenone and NSAIDs are used concomitantly, patients should be observed to determine whether the desired effect on blood pressure is obtained and monitored for changes in serum potassium levels.</p>
</div>
</div>"
"epoetin alfa","1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5","none found"
"eprosartan","b1dfcac3-ef66-4d3e-9d58-37d3f516eb31","none found"
"eravacycline","a4b188d4-f467-470c-ad7b-25ffbdd8862a","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID_eeaf0d4e-356f-4e49-a33a-bcf9d6a36d8c,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_1f272349-df5d-4cbb-90bc-4ac8fbaa272f,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Effect of Strong CYP3A Inducers on XERAVA </h2>
<p class=,'First,'>Concomitant use of strong CYP3A inducers decreases the exposure of eravacycline, which may reduce the efficacy of XERAVA <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#ID_6c3e81ef-d60e-4fd9-876a-0e0feb26376d,'>12.3</a>)]</span>.  Increase XERAVA dose in patients with concomitant use of a strong CYP3A inducer <span class=,'Italics,'>[see Dosage and Administration (<a href=,'#ID_1a770201-a6a0-4734-a79a-d62d44e98eec,'>2.3</a>)]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_61a89304-f776-47e5-b5ff-43356c61b326,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Anticoagulant Drugs </h2>
<p class=,'First,'>Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.</p>
</div>
</div>"
"ergocalciferol","0525e04f-91b7-4d75-8ff9-a6fb5705d993","none found"
"erlotinib","c35e019d-ec34-4e61-9400-a7ae7913e025","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID78,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>
<a name=,'ID79,'></a><span class=,'Bold,'>CYP3A4 Inhibitors</span>
</p>
<p>Coadministration of erlotinib with a strong CYP3A4 inhibitor or a combined CYP3A4 and CYP1A2 inhibitor increased erlotinib exposure. Erlotinib is metabolized primarily by CYP3A4 and to a lesser extent by CYP1A2. Increased erlotinib exposure may increase the risk of exposure-related toxicity <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#ID106,'>12.3</a>)]</span>.</p>
<p>Avoid coadministering erlotinib with strong CYP3A4 inhibitors (e.g., boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit or grapefruit juice) or a combined CYP3A4 and CYP1A2 inhibitor (e.g., ciprofloxacin). Reduce the erlotinib dosage when coadministering with a strong CYP3A4 inhibitor or a combined CYP3A4 and CYP1A2 inhibitor if coadministration is unavoidable <span class=,'Italics,'>[see Dosage and Administration (<a href=,'#ID24,'>2.4</a>)]</span>.</p>
<p>
<span class=,'Bold,'>CYP3A4 Inducers</span>
</p>
<p>Pre-treatment with a CYP3A4 inducer prior to erlotinib decreased erlotinib exposure <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#ID106,'>12.3</a>)]. </span>Increase the erlotinib dosage if coadministration with CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin, rifabutin, rifapentine, phenobarbital and St. John's wort) is unavoidable <span class=,'Italics,'>[see Dosage and Administration (<a href=,'#ID24,'>2.4</a>)]</span>.</p>
<p>
<span class=,'Bold,'>CYP1A2 Inducers and Cigarette Smoking</span>
</p>
<p>Cigarette smoking decreased erlotinib exposure. Avoid smoking tobacco (CYP1A2 inducer) and avoid concomitant use of erlotinib with moderate CYP1A2 inducers (e.g., teriflunomide, rifampin, or phenytoin). Increase the erlotinib dosage in patients that smoke tobacco or when coadministration with moderate CYP1A2 inducers is unavoidable <span class=,'Italics,'>[see Dosage and Administration (<a href=,'#ID24,'>2.4</a>) and Clinical Pharmacology (<a href=,'#ID106,'>12.3</a>)]</span>.</p>
<p>
<span class=,'Bold,'>Drugs That Increase Gastric pH</span>
</p>
<p>Coadministration of erlotinib with proton pump inhibitors (e.g., omeprazole) and H<span class=,'Sub,'>2</span> receptor antagonists (e.g., ranitidine) decreased erlotinib exposure <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#ID106,'>12.3</a>)]</span>. For proton pump inhibitors, avoid concomitant use if possible. For H<span class=,'Sub,'>2</span> receptor antagonists and antacids, modify the dosing schedule <span class=,'Italics,'>[see Dosage and Administration (<a href=,'#ID24,'>2.4</a>)]</span>. Increasing the dose of erlotinib when coadministered with gastric PH elevating agents is not likely to compensate for the loss of exposure.</p>
<p>
<span class=,'Bold,'>A</span><span class=,'Bold,'>n</span><span class=,'Bold,'>ticoagulants</span>
</p>
<p>Interaction with coumarin-derived anticoagulants, including warfarin, leading to increased International Normalized Ratio (INR) and bleeding adverse reactions, which in some cases were fatal, have been reported in patients receiving erlotinib. Regularly monitor prothrombin time or INR in patients taking coumarin-derived anticoagulants. Dose modifications of erlotinib are not recommended <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#ID53,'>5.9</a>) and Adverse Reactions (<a href=,'#ID62,'>6.1</a>)]</span>.</p>
</div>"
"erythromycin","018c94b5-8379-4b08-a18c-fad9c0219c0b","none found"
"escitalopram","4d5c3142-b850-49b9-9f5c-81fe15ea7bfb","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Monoamine Oxidase Inhibitors (MAOIs)</h2>
<p class=,'First,'>
<span class=,'Italics,'>[See Dosage and Administration (<a href=,'#Section_2.5,'>2.5</a> and <a href=,'#Section_2.6,'>2.6</a>), Contraindications (<a href=,'#Section_4.1,'>4.1</a>) and Warnings and Precautions (<a href=,'#Section_5.2,'>5.2</a>)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Serotonergic Drugs</h2>
<p class=,'First,'>
<span class=,'Italics,'>[See Dosage and Administration (<a href=,'#Section_2.5,'>2.5</a> and <a href=,'#Section_2.6,'>2.6</a>), Contraindications (<a href=,'#Section_4.1,'>4.1</a>) and Warnings and Precautions (<a href=,'#Section_5.2,'>5.2</a>)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Triptans</h2>
<br/>
<p class=,'First,'>There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan. If concomitant treatment of escitalopram oxalate with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#Section_5.2,'>5.2</a>)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 CNS Drugs</h2>
<p class=,'First,'>Given the primary CNS effects of escitalopram, caution should be used when it is taken in combination with other centrally acting drugs</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.5,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Alcohol</h2>
<p class=,'First,'>Although escitalopram oxalate did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking escitalopram oxalate is not recommended.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.6,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6 Drugs That Interfere with Hemostasis (NSAIDs, Aspirin, Warfarin, etc.)</h2>
<br/>
<p class=,'First,'>Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin may potentiate the risk of bleeding. Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs and SNRIs are coadministered with warfarin. Patients receiving warfarin therapy should be carefully monitored when escitalopram oxalate is initiated or discontinued.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.7,'></a><a name=,'section-7.7,'></a>
<p></p>
<h2>7.7 Cimetidine</h2>
<br/>
<p class=,'First,'>In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg twice a day cimetidine for 8 days resulted in an increase in citalopram AUC and C<span class=,'Sub,'>max</span> of 43% and 39%, respectively. The clinical significance of these findings is unknown.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.8,'></a><a name=,'section-7.8,'></a>
<p></p>
<h2>7.8 Digoxin</h2>
<p class=,'First,'>In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.9,'></a><a name=,'section-7.9,'></a>
<p></p>
<h2>7.9 Lithium</h2>
<br/>
<p class=,'First,'>Coadministration of racemic citalopram (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium. Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice. Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when escitalopram oral solution and lithium are coadministered.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.10,'></a><a name=,'section-7.10,'></a>
<p></p>
<h2>7.10 Pimozide and Celexa</h2>
<p class=,'First,'>In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Racemic citalopram did not alter the mean AUC or C<span class=,'Sub,'>max</span> of pimozide. The mechanism of this pharmacodynamic interaction is not known.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.11,'></a><a name=,'section-7.11,'></a>
<p></p>
<h2>7.11 Sumatriptan</h2>
<p class=,'First,'>There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of an SSRI and sumatriptan. If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.12,'></a><a name=,'section-7.12,'></a>
<p></p>
<h2>7.12 Theophylline</h2>
<p class=,'First,'>Combined administration of racemic citalopram (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline. The effect of theophylline on the pharmacokinetics of citalopram was not evaluated.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.13,'></a><a name=,'section-7.13,'></a>
<p></p>
<h2>7.13 Warfarin</h2>
<p class=,'First,'>Administration of 40 mg/day racemic citalopram for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate. Prothrombin time was increased by 5%, the clinical significance of which is unknown.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.14,'></a><a name=,'section-7.14,'></a>
<p></p>
<h2>7.14 Carbamazepine</h2>
<p class=,'First,'>Combined administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate. Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.15,'></a><a name=,'section-7.15,'></a>
<p></p>
<h2>7.15 Triazolam</h2>
<p class=,'First,'>Combined administration of racemic citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.16,'></a><a name=,'section-7.16,'></a>
<p></p>
<h2>7.16 Ketoconazole</h2>
<p class=,'First,'>Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg), a potent CYP3A4 inhibitor, decreased the C<span class=,'Sub,'>max</span> and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.17,'></a><a name=,'section-7.17,'></a>
<p></p>
<h2>7.17 Ritonavir</h2>
<p class=,'First,'>Combined administration of a single dose of ritonavir (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and escitalopram (20 mg) did not affect the pharmacokinetics of either ritonavir or escitalopram.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.18,'></a><a name=,'section-7.18,'></a>
<p></p>
<h2>7.18 CYP3A4 and -2C19 Inhibitors</h2>
<p class=,'First,'>
<span class=,'Italics,'>In vitro</span> studies indicated that CYP3A4 and -2C19 are the primary enzymes involved in the metabolism of escitalopram. <br/> However, coadministration of escitalopram (20 mg) and ritonavir (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of escitalopram. Because escitalopram is metabolized by multiple enzyme systems, inhibition of a single enzyme may not appreciably decrease escitalopram clearance.</p>
<br/>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.19,'></a><a name=,'section-7.19,'></a>
<p></p>
<h2>7.19 Drugs Metabolized by Cytochrome P4502D6</h2>
<p class=,'First,'>
<span class=,'Italics,'>In vitro</span> studies did not reveal an inhibitory effect of escitalopram on CYP2D6. In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism. However, there are limited <span class=,'Italics,'>in vivo</span> data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in C<span class=,'Sub,'>max</span> and a 100% increase in AUC of desipramine. The clinical significance of this finding is unknown. Nevertheless, caution is indicated in the coadministration of escitalopram and drugs metabolized by CYP2D6.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.20,'></a><a name=,'section-7.20,'></a>
<p></p>
<h2>7.20 Metoprolol</h2>
<p class=,'First,'>Administration of 20 mg/day escitalopram oxalate for 21 days in healthy volunteers resulted in a 50% increase in C<span class=,'Sub,'>max</span> and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg). Increased metoprolol plasma levels have been associated with decreased cardioselectivity. Co-administration of escitalopram oxalate and metoprolol had no clinically significant effects on blood pressure or heart rate.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.21,'></a><a name=,'section-7.21,'></a>
<p></p>
<h2>7.21 Electroconvulsive Therapy (ECT)</h2>
<p class=,'First,'>There are no clinical studies of the combined use of ECT and escitalopram.</p>
</div>
</div>"
"esomeprazole","7a7b80f1-fd8a-a78f-e053-2991aa0a7098","none found"
"estradiol","0178a92c-62b1-d5cf-cf54-2c85af88a74a","none found"
"estriol","9b6e29b3-7286-4408-9a44-7d8589d1d958","none found"
"etanercept","2dc2ed4b-f234-4ccc-bd95-0b63ac3ef421","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Specific drug interaction studies have not been conducted with Enbrel.</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_7_1_Vaccines,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1
		     
	Vaccines</h2>
<p class=,'First,'>Most PsA patients receiving Enbrel were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had 2-fold rises in titers compared to patients not receiving Enbrel.  The clinical significance of this is unknown.  Patients receiving Enbrel may receive concurrent vaccinations, except for live vaccines.  No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel.</p>
<p>Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with varicella zoster immune globulin <span class=,'Italics,'>[</span><span class=,'Italics,'>see Warnings and Precautions </span><span class=,'Italics,'>(</span><span class=,'Italics,'><a href=,'#_5_8_Immunizations,'>5.8</a></span><span class=,'Italics,'>, </span><span class=,'Italics,'><a href=,'#_5_10_Immunosuppression,'>5.10</a></span><span class=,'Italics,'>)</span><span class=,'Italics,'>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_7_2_Immune_Modulating_Biologic,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2
		     
	Immune-Modulating Biologic Products </h2>
<p class=,'First,'>In a study in which patients with active RA were treated for up to 24 weeks with concurrent Enbrel and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with Enbrel alone (0%) <span class=,'Italics,'>[see Warnings and Precautions </span><span class=,'Italics,'>(</span><span class=,'Italics,'><a href=,'#_5_12_Use_with,'>5.12</a></span><span class=,'Italics,'>)</span><span class=,'Italics,'>]</span> and did not result in higher ACR response rates compared to Enbrel alone.  The most common infections consisted of bacterial pneumonia (4 cases) and cellulitis (4 cases).  One patient with pulmonary fibrosis and pneumonia died due to respiratory failure.  Two percent of patients treated concurrently with Enbrel and anakinra developed neutropenia (ANC &lt; 1 x 10<span class=,'Sup,'>9</span>/L).</p>
<p>In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences of serious adverse events, including infections, and did not demonstrate increased clinical benefit <span class=,'Italics,'>[see Warnings and Precautions (</span><span class=,'Italics,'><a href=,'#_5_12_Use_with,'>5.12</a></span><span class=,'Italics,'>)]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_7_3_Cyclophosphamide,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3
		     
	Cyclophosphamide</h2>
<p class=,'First,'>The use of Enbrel in patients receiving concurrent cyclophosphamide therapy is not recommended <span class=,'Italics,'>[</span><span class=,'Italics,'>see </span><span class=,'Italics,'>Warnings and Precautions</span><span class=,'Bold Italics,'> </span><span class=,'Italics,'>(</span><span class=,'Italics,'><a href=,'#_5_11_Use_in,'>5.11</a></span><span class=,'Italics,'>)</span><span class=,'Italics,'>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.4,'></a>
<p></p>
<h2>7.4
		     
	Sulfasalazine</h2>
<p class=,'First,'>Patients in a clinical study who were on established therapy with sulfasalazine, to which Enbrel was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either Enbrel or sulfasalazine alone.  The clinical significance of this observation is unknown.</p>
</div>
</div>"
"ethambutol","2f857930-d002-4abe-9907-bfd8fd7fe5ed","none found"
"ethanol","35a21f89-cf5f-4e8b-8400-3ef7023bc49c","none found"
"ethionamide","04a413fe-95f4-47a7-42ac-283a9e78297d","none found"
"ethosuximide","01e8e8ee-b19f-4b3f-a140-9c7391393e1c","none found"
"etoposide","003ce7e0-f787-469d-8b44-3c2acdcae6d7","none found"
"ezetimibe","03609879-bad2-4e75-83fe-1e1a2fd300c3","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'i4i_interactions_id_e8f5a94c-0c98-4a72-aa96-6c88035b1d26,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>[See Clinical Pharmacology<a href=,'#i4i_pharmacokinetics_id_0842fe52-3f50-42e0-8627-5ad985caf74c,'> (12.3)</a>.]</span>
</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_727ec799-5171-4575-aa33-44bbd792c18c,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Cyclosporine</h2>
<p class=,'First,'>Caution should be exercised when using ezetimibe and cyclosporine concomitantly due to increased exposure to both ezetimibe and cyclosporine. Cyclosporine concentrations should be monitored in patients receiving ezetimibe and cyclosporine.</p>
<p>The degree of increase in ezetimibe exposure may be greater in patients with severe renal insufficiency. In patients treated with cyclosporine, the potential effects of the increased exposure to ezetimibe from concomitant use should be carefully weighed against the benefits of alterations in lipid levels provided by ezetimibe.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_c4e3e941-c372-4839-8237-6ac807ee0123,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Fibrates</h2>
<p class=,'First,'>The efficacy and safety of co-administration of ezetimibe with fibrates other than fenofibrate have not been studied.</p>
<p>Fibrates may increase cholesterol excretion into the bile, leading to cholelithiasis. In a preclinical study in dogs, ezetimibe increased cholesterol in the gallbladder bile <span class=,'Italics,'>[see </span><span class=,'Bold,'>NONCLINICAL TOXICOLOGY<a href=,'#i4i_animal_pharmacology_id_8bd7dc85-188e-4b6f-855d-0e1954578305,'>(13.2)</a>]</span>. Co-administration of ezetimibe with fibrates other than fenofibrate is not recommended until use in patients is adequately studied.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_d6725ace-50bf-426b-9196-4da0d4b3bdeb,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Fenofibrate</h2>
<p class=,'First,'>If cholelithiasis is suspected in a patient receiving ezetimibe and fenofibrate, gallbladder studies are indicated and alternative lipid-lowering therapy should be considered <span class=,'Italics,'>[see </span><span class=,'Bold,'>ADVERSE REACTIONS <a href=,'#i4i_section_id_3a125e6f-379e-498d-a88e-be64b01c174d,'> (6.1)</a></span><span class=,'Italics,'> and the product labeling for fenofibrate]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_9b75ae9e-d687-41bd-b3c0-354b5860bba7,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Cholestyramine</h2>
<p class=,'First,'>Concomitant cholestyramine administration decreased the mean area under the curve (AUC) of total ezetimibe approximately 55%. The incremental LDL-C reduction due to adding ezetimibe to cholestyramine may be reduced by this interaction.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_3258eda9-1c29-4725-8fb3-35b3d6e11cb7,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Coumarin Anticoagulants</h2>
<p class=,'First,'>If ezetimibe is added to warfarin, a coumarin anticoagulant, the International Normalized Ratio (INR) should be appropriately monitored.</p>
</div>
</div>"
"febuxostat","14f1555c-2565-42c7-b3f5-dd5f03fed67a","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'i4i_interactions_ID_s7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_ID_s7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Xanthine Oxidase Substrate Drugs</h2>
<p class=,'First,'>Febuxostat is an XO inhibitor. Based on a drug interaction study in healthy patients, febuxostat altered the metabolism of theophylline (a substrate of XO) in humans <span class=,'Italics,'>[see <a href=,'#i4i_pharmacokinetics_ID_s12.3,'>Clinical Pharmacology (12.3)</a>]</span>. Therefore, use with caution when coadministering febuxostat with theophylline.</p>
<p>Drug interaction studies of febuxostat with other drugs that are metabolized by XO (e.g., mercaptopurine and azathioprine) have not been conducted. Inhibition of XO by febuxostat may cause increased plasma concentrations of these drugs leading to toxicity <span class=,'Italics,'>[see <a href=,'#i4i_pharmacokinetics_ID_s12.3,'>Clinical Pharmacology (12.3)</a>]</span>. Febuxostat is contraindicated in patients being treated with azathioprine or mercaptopurine <span class=,'Italics,'>[see <a href=,'#i4i_contraindications_ID_s4,'>Contraindications (4)</a>].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_ID_s7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Cytotoxic Chemotherapy Drugs</h2>
<p class=,'First,'>Drug interaction studies of febuxostat with cytotoxic chemotherapy have not been conducted. No data are available regarding the safety of febuxostat during cytotoxic chemotherapy. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_ID_s7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 <span class=,'Italics,'>In Vivo</span> Drug Interaction Studies</h2>
<p class=,'First,'>Based on drug interaction studies in healthy patients, febuxostat does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine <span class=,'Italics,'>[see <a href=,'#i4i_pharmacokinetics_ID_s12.3,'>Clinical Pharmacology (12.3)</a>]</span>. Therefore, febuxostat may be used concomitantly with these medications.</p>
</div>
</div>"
"felodipine","2c4dd9a4-61ca-4c88-90f6-12d9e0fdb7cd","none found"
"fenofibrate","07913d99-c2d8-4078-9f1f-acad2a83b3d8","none found"
"fentanyl","2a0092d8-f782-45ec-b8a8-c72156bbd5d5","none found"
"fexofenadine","07460764-43fa-49fd-ae77-d4571cb9f944","none found"
"filgrastim","3bc802bd-76b4-4f45-8571-a436ec26228e","none found"
"finasteride","0c3b40ab-0dd9-4e1c-a8bc-bf2b36066314","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Cytochrome P450-Linked Drug Metabolizing Enzyme System </h2>
<br/>No drug interactions of clinical importance have been identified. Finasteride does not appear to affect the cytochrome P450-linked drug metabolizing enzyme system. Compounds that have been tested in man have included antipyrine, digoxin, propranolol, theophylline, and warfarin and no clinically meaningful interactions were found. </div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Other Concomitant Therapy</h2>
<br/>Although specific interaction studies were not performed, finasteride tablets USP was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H<span class=,'Sub,'>2</span> antagonists and quinolone anti-infectives without evidence of clinically significant adverse interactions.</div>
</div>"
"fingolimod","cc9e1c8c-0e2b-44e2-878b-27057f786be9","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'s7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7p1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>
								7.1     QT Prolonging Drugs
							</h2>
<p class=,'First,'>GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT prolonging drugs with a known risk of torsades de pointes (e.g., citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility <span class=,'Italics,'>[see Dosage and Administration (2.4), Warnings and Precautions (5.1)]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7p2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>
								7.2     Ketoconazole
							</h2>
<p class=,'First,'>The blood levels of fingolimod and fingolimod-phosphate are increased by 1.7-fold when used concomitantly with ketoconazole. Patients who use GILENYA and systemic ketoconazole concomitantly should be closely monitored, as the risk of adverse reactions is greater.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7p3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>
								7.3     Vaccines
							</h2>
<p class=,'First,'>GILENYA reduces the immune response to vaccination. Vaccination may be less effective during and for up to 2 months after discontinuation of treatment with GILENYA <span class=,'Italics,'>[see Clinical Pharmacology (12.2)]</span>. Avoid the use of live attenuated vaccines during and for 2 months after treatment with GILENYA because of the risk of infection. It is recommended that pediatric patients, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines prior to initiating GILENYA therapy.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7p4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>
								7.4     Antineoplastic, Immunosuppressive, or Immune-Modulating Therapies
							</h2>
<p class=,'First,'>Antineoplastic, immune-modulating, or immunosuppressive therapies, (including corticosteroids) are expected to increase the risk of immunosuppression, and the risk of additive immune system effects must be considered if these therapies are coadministered with GILENYA. When switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating GILENYA <span class=,'Italics,'>[see Warnings and Precautions (5.2)]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7p5,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>
								7.5     Drugs That Slow Heart Rate or Atrioventricular Conduction (e.g., beta blockers or diltiazem)
							</h2>
<p class=,'First,'>Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or AV conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers, such as diltiazem or verapamil) is limited. Because initiation of GILENYA treatment may result in an additional decrease in heart rate, concomitant use of these drugs during GILENYA initiation may be associated with severe bradycardia or heart block. Seek advice from the physician prescribing these drugs regarding the possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction before initiating GILENYA. Patients who cannot switch should have overnight continuous ECG monitoring after the first dose <span class=,'Italics,'>[see Dosage and Administration (2.4), Warnings and Precautions (5.1)]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7p6,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>
								7.6     Laboratory Test Interaction
							</h2>
<p class=,'First,'>Because GILENYA reduces blood lymphocyte counts via redistribution in secondary lymphoid organs, peripheral blood lymphocyte counts cannot be utilized to evaluate the lymphocyte subset status of a patient treated with GILENYA. A recent CBC should be available before initiating treatment with GILENYA.</p>
</div>
</div>"
"flecainide","14e89448-3a18-42e3-8537-2589be1ef94e","none found"
"fluconazole","029d82ed-a6ce-4a2e-9f15-fbb78afdbf58","none found"
"flucytosine","01d874f9-e073-4092-94ad-da361551d4bf","none found"
"fludarabine","8039c2e3-ffe5-3997-e053-2991aa0ad9d0","none found"
"fludrocortisone","001e72ea-2c9e-468c-90cc-6c347234e2a9","none found"
"fluorescein","c1ffe119-7fba-940f-e053-2a95a90a7a17","none found"
"fluorouracil","06475bd8-66d9-4f88-90e4-b367480dab39","none found"
"fluoxetine","06d71a33-5578-4012-b11d-764f45bc1e6a","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_a699d031-d079-465a-9e8d-8ea63ae2c7b0,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>As with all drugs, the potential for interaction by a variety of mechanisms (e.g., pharmacodynamic, pharmacokinetic drug inhibition or enhancement, etc.) is a possibility.</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_49c00c2c-0e44-4961-8e29-bffa5f566dae,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Monoamine Oxidase Inhibitors (MAOI)</h2>
<p class=,'First,'>
<span class=,'Italics,'>[See Dosage and Administration (2.9, 2.10), Contraindications (<a href=,'#LINK_5b0d5a29-1ba7-42f1-9ad1-da8d3e8a2b92,'>4.1</a>), and Warnings and Precautions (<a href=,'#LINK_b22fca4f-4644-4a88-adcd-6e3024545dec,'>5.2</a>)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_8eb31492-dab0-46ab-be13-49e0ae22c6a2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 CNS Acting Drugs</h2>
<p class=,'First,'>Caution is advised if the concomitant administration of fluoxetine and such drugs is required. In evaluating individual cases, consideration should be given to using lower initial doses of the concomitantly administered drugs, using conservative titration schedules, and monitoring of clinical status [<span class=,'Italics,'>see Clinical Pharmacology (<a href=,'#LINK_704282a6-f1aa-4096-afda-a156e06602cb,'>12.3</a>)</span>]<span class=,'Italics,'>.</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_c3824818-42d0-48ed-b1b4-01f2f9f4891d,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Serotonergic Drugs</h2>
<p class=,'First,'>
<span class=,'Italics,'>[See Dosage and Administration (2.9, 2.10), Contraindications (<a href=,'#LINK_5b0d5a29-1ba7-42f1-9ad1-da8d3e8a2b92,'>4.1</a>), and Warnings and Precautions (<a href=,'#LINK_b22fca4f-4644-4a88-adcd-6e3024545dec,'>5.2</a>)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_589f67f2-63d9-4a6a-808c-2017eb0e6290,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Drugs that Interfere with Hemostasis (e.g., NSAIDS, Aspirin, Warfarin)</h2>
<p class=,'First,'>Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding. Altered anticoagulant effects, including increased bleeding, have been reported when SNRIs or SSRIs are coadministered with warfarin. Patients receiving warfarin therapy should be carefully monitored when fluoxetine is initiated or discontinued [<span class=,'Italics,'>see Warnings and Precautions (<a href=,'#LINK_6a8c234c-c525-4d29-8850-a0d7a8bbacd2,'>5.7</a>)</span>]<span class=,'Italics,'>.</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_5d24cfe1-d99a-4497-a948-6fa233fda9d7,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Electroconvulsive Therapy (ECT)</h2>
<p class=,'First,'>There are no clinical studies establishing the benefit of the combined use of ECT and fluoxetine. There have been rare reports of prolonged seizures in patients on fluoxetine receiving ECT treatment. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_c61fb7d5-6d8c-44bf-8739-6d780aa0a928,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6 Potential for Other Drugs to affect Fluoxetine</h2>
<p class=,'First,'>
<span class=,'Italics,'>Drugs Tightly Bound to Plasma Proteins</span> — Because fluoxetine is tightly bound to plasma proteins, adverse effects may result from displacement of protein-bound fluoxetine by other tightly-bound drugs [<span class=,'Italics,'>see Clinical Pharmacology (<a href=,'#LINK_704282a6-f1aa-4096-afda-a156e06602cb,'>12.3</a>)</span>]<span class=,'Italics,'>.</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_ce85cc32-424a-477c-a2b3-568f3b93b10f,'></a><a name=,'section-7.7,'></a>
<p></p>
<h2>7.7 Potential for Fluoxetine to affect Other Drugs</h2>
<p class=,'First,'>
<span class=,'Italics,'>Pimozide</span> — Concomitant use in patients taking pimozide is contraindicated. Pimozide can prolong the QT interval. Fluoxetine can increase the level of pimozide through inhibition of CYP2D6. Fluoxetine can also prolong the QT interval. Clinical studies of pimozide with other antidepressants demonstrate an increase in drug interaction or QT prolongation. While a specific study with pimozide and fluoxetine has not been conducted, the potential for drug interactions or QT prolongation warrants restricting the concurrent use of pimozide and fluoxetine <span class=,'Italics,'>[see Contraindications (</span><a href=,'#LINK_a2e6dfe6-5cf1-4795-b3bb-b22e24d7efae,'>4.2</a><span class=,'Italics,'>), Warnings and Precautions (<a href=,'#LINK_e409fce2-414d-47f0-b4e2-0b78a68b1c22,'>5.11</a>), and Drug Interactions (<a href=,'#LINK_912b356f-139e-4268-90fa-15ee1bee4861,'>7.8</a>)].</span>
</p>
<p>
<span class=,'Italics,'>Thioridazine</span> — Thioridazine should not be administered with fluoxetine or within a minimum of 5 weeks after fluoxetine has been discontinued, because of the risk of QT Prolongation [<span class=,'Italics,'>see Contraindications (<a href=,'#LINK_a2e6dfe6-5cf1-4795-b3bb-b22e24d7efae,'>4.2</a>), Warnings and Precautions (<a href=,'#LINK_e409fce2-414d-47f0-b4e2-0b78a68b1c22,'>5.11</a>), and Drug Interactions (<a href=,'#LINK_912b356f-139e-4268-90fa-15ee1bee4861,'>7.8</a>)</span>]<span class=,'Italics,'>. </span>
</p>
<p>In a study of 19 healthy male subjects, which included 6 slow and 13 rapid hydroxylators of debrisoquin, a single 25 mg oral dose of thioridazine produced a 2.4-fold higher C<span class=,'Sub,'>max</span> and a 4.5-fold higher AUC for thioridazine in the slow hydroxylators compared with the rapid hydroxylators. The rate of debrisoquin hydroxylation is felt to depend on the level of CYP2D6 isozyme activity. Thus, this study suggests that drugs which inhibit CYP2D6, such as certain SSRIs, including fluoxetine, will produce elevated plasma levels of thioridazine.</p>
<p>Thioridazine administration produces a dose-related prolongation of the QT interval, which is associated with serious ventricular arrhythmias, such as Torsades de Pointes-type arrhythmias, and sudden death. This risk is expected to increase with fluoxetine-induced inhibition of thioridazine metabolism.</p>
<p>
<span class=,'Italics,'>Drugs Metabolized by CYP2D6</span> — Fluoxetine inhibits the activity of CYP2D6, and may make individuals with normal CYP2D6 metabolic activity resemble a poor metabolizer. Coadministration of fluoxetine with other drugs that are metabolized by CYP2D6, including certain antidepressants (e.g., TCAs), antipsychotics (e.g., phenothiazines and most atypicals), and antiarrhythmics (e.g., propafenone, flecainide, and others) should be approached with caution. Therapy with medications that are predominantly metabolized by the CYP2D6 system and that have a relatively narrow therapeutic index (see list below) should be initiated at the low end of the dose range if a patient is receiving fluoxetine concurrently or has taken it in the previous 5 weeks. Thus, his/her dosing requirements resemble those of poor metabolizers. If fluoxetine is added to the treatment regimen of a patient already receiving a drug metabolized by CYP2D6, the need for decreased dose of the original medication should be considered. Drugs with a narrow therapeutic index represent the greatest concern (e.g., flecainide, propafenone, vinblastine, and TCAs). Due to the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, thioridazine should not be administered with fluoxetine or within a minimum of 5 weeks after fluoxetine has been discontinued [<span class=,'Italics,'>see Contraindications (<a href=,'#LINK_302b01de-aa42-41af-8f48-475db4638112,'>4.2</a>)</span>]<span class=,'Italics,'>. </span>
</p>
<p>
<span class=,'Italics,'>Tricyclic Antidepressants (TCAs)</span> — In 2 studies, previously stable plasma levels of imipramine and desipramine have increased greater than 2- to 10-fold when fluoxetine has been administered in combination. This influence may persist for 3 weeks or longer after fluoxetine is discontinued. Thus, the dose of TCAs may need to be reduced and plasma TCA concentrations may need to be monitored temporarily when fluoxetine is coadministered or has been recently discontinued [see <span class=,'Italics,'>Warnings and Precautions</span> (<span class=,'Italics,'><a href=,'#LINK_b22fca4f-4644-4a88-adcd-6e3024545dec,'>5.2</a></span>) and <span class=,'Italics,'>Clinical Pharmacology (<a href=,'#LINK_704282a6-f1aa-4096-afda-a156e06602cb,'>12.3</a>)</span>]<span class=,'Italics,'>.</span>
</p>
<p>
<span class=,'Italics,'>Benzodiazepines</span> — The half-life of concurrently administered diazepam may be prolonged in some patients [<span class=,'Italics,'>see Clinical Pharmacology (</span><a href=,'#LINK_704282a6-f1aa-4096-afda-a156e06602cb,'>12.3</a><span class=,'Italics,'>)</span>]<span class=,'Italics,'>. </span>Coadministration of alprazolam and fluoxetine has resulted in increased alprazolam plasma concentrations and in further psychomotor performance decrement due to increased alprazolam levels.</p>
<p>
<span class=,'Italics,'>Antipsychotics</span> — Some clinical data suggests a possible pharmacodynamic and/or pharmacokinetic interaction between SSRIs and antipsychotics. Elevation of blood levels of haloperidol and clozapine has been observed in patients receiving concomitant fluoxetine<span class=,'Italics,'>.</span>
</p>
<p>
<span class=,'Italics,'>Anticonvulsants</span> — Patients on stable doses of phenytoin and carbamazepine have developed elevated plasma anticonvulsant concentrations and clinical anticonvulsant toxicity following initiation of concomitant fluoxetine treatment.</p>
<p>
<span class=,'Italics,'>Lithium</span> — There have been reports of both increased and decreased lithium levels when lithium was used concomitantly with fluoxetine. Cases of lithium toxicity and increased serotonergic effects have been reported. Lithium levels should be monitored when these drugs are administered concomitantly [<span class=,'Italics,'>see Warnings and Precautions (<a href=,'#LINK_b22fca4f-4644-4a88-adcd-6e3024545dec,'>5.2</a></span>)].</p>
<p>
<span class=,'Italics,'>Drugs Tightly Bound to Plasma Proteins</span> — Because fluoxetine is tightly bound to plasma proteins, the administration of fluoxetine to a patient taking another drug that is tightly bound to protein (e.g., Coumadin<span class=,'Sup,'>®</span>, digitoxin) may cause a shift in plasma concentrations potentially resulting in an adverse effect [<span class=,'Italics,'>see Clinical Pharmacology (<a href=,'#LINK_704282a6-f1aa-4096-afda-a156e06602cb,'>12.3</a>)</span>].</p>
<p>
<span class=,'Italics,'>Drugs Metabolized by CYP3A4</span> — In an <span class=,'Italics,'>in vivo</span> interaction study involving coadministration of fluoxetine with single doses of terfenadine (a CYP3A4 substrate), no increase in plasma terfenadine concentrations occurred with concomitant fluoxetine. </p>
<p>Additionally, <span class=,'Italics,'>in vitro</span> studies have shown ketoconazole, a potent inhibitor of CYP3A4 activity, to be at least 100 times more potent than fluoxetine or norfluoxetine as an inhibitor of the metabolism of several substrates for this enzyme, including astemizole, cisapride, and midazolam. These data indicate that fluoxetine’s extent of inhibition of CYP3A4 activity is not likely to be of clinical significance.</p>
<p>
<span class=,'Italics,'>Olanzapine</span> — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. The magnitude of the impact of this factor is small in comparison to the overall variability between individuals, and therefore dose modification is not routinely recommended.</p>
<p>
<span class=,'Italics,'>When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for Symbyax.</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_912b356f-139e-4268-90fa-15ee1bee4861,'></a><a name=,'section-7.8,'></a>
<p></p>
<h2>7.8 Drugs that Prolong the QT Interval</h2>
<p class=,'First,'>Do not use fluoxetine in combination with thioridazine or pimozide. Use fluoxetine with caution in combination with other drugs that cause QT prolongation. These include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, mesoridazine, droperidol); specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin); Class 1A antiarrhythmic medications (e.g., quinidine, procainamide); Class III antiarrhythmics (e.g., amiodarone, sotalol); and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus). Fluoxetine is primarily metabolized by CYP2D6. Concomitant treatment with CYP2D6 inhibitors can increase the concentration of fluoxetine. Concomitant use of other highly protein-bound drugs can increase the concentration of fluoxetine<span class=,'Italics,'> [see Contraindications (<a href=,'#LINK_a2e6dfe6-5cf1-4795-b3bb-b22e24d7efae,'>4.2</a>), Warnings and Precautions (<a href=,'#LINK_e409fce2-414d-47f0-b4e2-0b78a68b1c22,'>5.11</a>), Drug Interactions (<a href=,'#LINK_ce85cc32-424a-477c-a2b3-568f3b93b10f,'>7.7</a>), and Clinical Pharmacology (<a href=,'#LINK_704282a6-f1aa-4096-afda-a156e06602cb,'>12.3</a>)].</span>
</p>
</div>
</div>"
"fluphenazine","1967dc24-f2a5-4095-baa9-a9d1c5410311","none found"
"flurazepam","048f5b08-71ff-4b14-bafa-922ce27a6213","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID_9e989a41-e1b0-473e-a5a5-3f8a30a2db51,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Benzodiazepines, including flurazepam, produce additive CNS depressant effects when co-administered with ethanol or other CNS depressants (e.g., psychotropic medications, anticonvulsants, antihistamines). Downward dose adjustment of flurazepam and/or concomitant CNS depressants may be necessary because of additive effects.</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_55470e06-b551-426f-b982-13caffb4e758,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1	Drug Interactions </h2>
<p class=,'First,'>The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites, and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and follow patients closely for respiratory depression and sedation.</p>
</div>
</div>"
"flurbiprofen","043665e5-c6e0-4353-9933-6ba9e4860842","none found"
"fluticasone","0120296b-bebc-4a2d-8058-6caf41f96e52","none found"
"fluvastatin","aad8b373-0aec-4efb-8e61-3d8114b31127","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_a2485075-26df-4640-bc14-60a0ab9ac2d3,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_99ec6b30-0086-4035-a11f-3b8749d6cf5e,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Cyclosporine</h2>
<p class=,'First,'>Cyclosporine coadministration increases fluvastatin exposure. Therefore, in patients taking cyclosporine, therapy should be limited to fluvastatin 20 mg twice daily [<span class=,'Italics,'>see Warnings and Precautions (<a href=,'#LINK_b40e052a-10e3-40aa-8b86-46c855f03c5e,'>5.1</a>) and Clinical Pharmacology (<a href=,'#LINK_c10990b6-453a-440b-ab04-6fee0949c8a2,'>12.3</a>)</span>].</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_42ce4287-8a14-4d2a-ad2b-3a78e6ad6eac,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Fluconazole</h2>
<p class=,'First,'>Administration of fluvastatin 40 mg single dose to healthy volunteers pre-treated with fluconazole for 4 days results in an increase of fluvastatin exposure. Therefore, in patients taking fluconazole, therapy should be limited to fluvastatin 20 mg twice daily [<span class=,'Italics,'>see Clinical Pharmacology (<a href=,'#LINK_c10990b6-453a-440b-ab04-6fee0949c8a2,'>12.3</a>)</span>]<span class=,'Italics,'>. </span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_51c34387-b663-4a88-beec-f6ab44f905d3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Gemfibrozil</h2>
<p class=,'First,'>Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are coadministered with gemfibrozil, concomitant administration of fluvastatin sodium with gemfibrozil should be avoided.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_f4bfd279-d9bf-4b3a-bbe3-ae74a19ee579,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Other Fibrates</h2>
<p class=,'First,'>Because it is known that the risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates, fluvastatin sodium should be administered with caution when used concomitantly with other fibrates [<span class=,'Italics,'>see Warnings and Precautions (<a href=,'#LINK_b40e052a-10e3-40aa-8b86-46c855f03c5e,'>5.1</a>) and Clinical Pharmacology (<a href=,'#LINK_c10990b6-453a-440b-ab04-6fee0949c8a2,'>12.3</a>)</span>]. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_5ff9613a-2c39-4109-9ca1-3ad3ee18ddf2,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Niacin</h2>
<p class=,'First,'>The risk of skeletal muscle effects may be enhanced when fluvastatin sodium is used in combination with lipid-modifying doses (≥ 1 g/day) of niacin; a reduction in fluvastatin sodium dosage should be considered in this setting [<span class=,'Italics,'>see Warnings and Precautions (<a href=,'#LINK_b40e052a-10e3-40aa-8b86-46c855f03c5e,'>5.1</a>)</span>].</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_6ab05132-3c50-412b-ba63-c75d697438e9,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6 Glyburide</h2>
<p class=,'First,'>Concomitant administration of fluvastatin and glyburide increased glyburide exposures. Patients on concomitant therapy of glyburide and fluvastatin should continue to be monitored appropriately [<span class=,'Italics,'>see Clinical Pharmacology (<a href=,'#LINK_c10990b6-453a-440b-ab04-6fee0949c8a2,'>12.3</a>)</span>]. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_e5009326-c955-4f0d-8c36-918b121d42a5,'></a><a name=,'section-7.7,'></a>
<p></p>
<h2>7.7 Phenytoin</h2>
<p class=,'First,'>Concomitant administration of fluvastatin and phenytoin increased phenytoin exposures. Patients should continue to be monitored appropriately when fluvastatin therapy is initiated or when fluvastatin dose is changed [<span class=,'Italics,'>see Clinical Pharmacology (<a href=,'#LINK_c10990b6-453a-440b-ab04-6fee0949c8a2,'>12.3</a>)</span>]. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_f62deab9-8e61-4a74-9de6-1017f74acff8,'></a><a name=,'section-7.8,'></a>
<p></p>
<h2>7.8 Warfarin</h2>
<p class=,'First,'>Bleeding and/or increased prothrombin times have been reported in patients taking coumarin anticoagulants concomitantly with other HMG-CoA reductase inhibitors. Therefore, patients receiving warfarin-type anticoagulants should have their prothrombin times closely monitored when fluvastatin sodium is initiated or the dosage of fluvastatin sodium is changed. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_66740683-a1b0-4075-8856-1e9d1b725145,'></a><a name=,'section-7.9,'></a>
<p></p>
<h2>7.9 Colchicine</h2>
<p class=,'First,'>Cases of myopathy, including rhabdomyolysis, have been reported with fluvastatin coadministered with colchicine, and caution should be exercised when prescribing fluvastatin with colchicine.</p>
</div>
</div>"
"fluvoxamine","6eeb14df-6fcf-a737-5359-5744eb4accea","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'i4i_interactions_ID_B9D62920-2EC5-4DD3-9D34-BCD65074C1BC,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_ID_FC48C1B0-7B96-4C8F-AD2C-C5364B2D213A,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Potential Interactions with Drugs that Inhibit or are Metabolized by Cytochrome P450 Isoenzymes</h2>
<p class=,'First,'>Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds. The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary <span class=,'Italics,'>in vitro</span> data are also available. Based on a finding of substantial interactions of fluvoxamine with certain of these drugs [see later parts of this section and also Warnings and Precautions (<a href=,'#i4i_warnings_precautions_ID_44DEE04E-C1E2-497E-BD0F-C2270EA6CF7F,'>5</a>)] and limited <span class=,'Italics,'>in vitro</span> data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).</p>
<p>
<span class=,'Italics,'>In vitro</span> data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.</p>
<p>Approximately 7% of the normal population has a genetic code that leads to reduced levels of activity of CYP2D6. Such individuals have been referred to as ,'poor metabolizers,' (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants. While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an <span class=,'Italics,'>in vivo</span> study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 ,'extensive metabolizers,' (EM): mean C<span class=,'Sub,'>max</span>, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group. This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6. Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).</p>
<p>The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.</p>
<p>A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin. If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached <span class=,'Italics,'>[see Contraindications(<a href=,'#i4i_warnings_precautions_ID_44DEE04E-C1E2-497E-BD0F-C2270EA6CF7F,'>4</a>), Warnings and Precautions (<a href=,'#i4i_contraindications_ID_79E042C9-E77E-49D2-99F8-96F668C28034,'>5</a>)]. </span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_ID_DE1446CD-D021-405D-8DDC-F5B469626E8D,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 CNS Active Drugs</h2>
<p class=,'First,'>
<span class=,'Bold,'><span class=,'Italics,'>Antipsychotics</span></span>
</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'></span></span><span class=,'Italics,'> See Warnings and Precautions</span> (<a href=,'#i4i_section_ID_1D8ACBEB-53AB-46F4-A211-C1A5D9B30C51,'>5.2</a>).</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Benzodiazepines</span></span>
</p>
<p>
<span class=,'Italics,'>See Warnings and Precautions</span> (<a href=,'#i4i_section_ID_6FC3A16F-E47C-4073-9F45-64393FB2EA39,'>5.8</a>).</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Alprazolam</span></span>
</p>
<p>
<span class=,'Italics,'>See Warnings and Precautions</span> (<a href=,'#i4i_section_ID_6FC3A16F-E47C-4073-9F45-64393FB2EA39,'>5.8</a>).</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Diazepam</span></span>
</p>
<p>
<span class=,'Italics,'> See Warnings and Precautions</span> (<a href=,'#i4i_section_ID_6FC3A16F-E47C-4073-9F45-64393FB2EA39,'>5.8</a>).</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Lorazepam</span></span>
</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'></span></span>A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N=12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction. On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Alcohol</span></span>
</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'></span></span>Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other. As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Carbamazepine</span></span>
</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'></span></span>Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Clozapine</span></span>
</p>
<p>
<span class=,'Italics,'> See Warnings and Precautions</span> (<a href=,'#i4i_section_ID_6FC3A16F-E47C-4073-9F45-64393FB2EA39,'>5.8</a>).</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Lithium</span></span>
</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'></span></span>As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution. Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Methadone</span></span>
</p>
<p> See Warnings and Precautions (<a href=,'#i4i_section_ID_6FC3A16F-E47C-4073-9F45-64393FB2EA39,'>5.8</a>).</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Monoamine Oxidase Inhibitors</span></span>
</p>
<p>See Dosage and Administration (<a href=,'#_ef8d28a0-eeb7-98b6-dc28-2ef233d5f755,'>2.</a>4 and <a href=,'#_20552493-9499-108b-3c5f-5aad0689301d,'>2.</a>5), Contraindications (<a href=,'#i4i_contraindications_ID_79E042C9-E77E-49D2-99F8-96F668C28034,'>4</a>), and Warnings and Precautions (<a href=,'#i4i_section_ID_1D8ACBEB-53AB-46F4-A211-C1A5D9B30C51,'>5.2</a>). </p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Pimozide</span></span>
</p>
<p> See Contraindications (<a href=,'#i4i_contraindications_ID_79E042C9-E77E-49D2-99F8-96F668C28034,'>4</a>) and Warnings and Precautions (<a href=,'#i4i_section_ID_29114D1C-EC8C-490A-9E9A-F34DA63B6319,'>5.6</a>).</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Ramelteon</span></span>
</p>
<p> See Warnings and Precautions (<a href=,'#i4i_section_ID_BA0F8C5F-0B5D-4D89-B4BB-E7667F717DDE,'>5.8</a>).</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Serotonergic Drugs</span></span>
</p>
<p>
<span class=,'Italics,'> See Dosage and Administration</span> (<a href=,'#_20552493-9499-108b-3c5f-5aad0689301d,'>2.</a>4, <a href=,'#_ef8d28a0-eeb7-98b6-dc28-2ef233d5f755,'>2.</a>5), <span class=,'Italics,'>Contraindications</span> (<a href=,'#i4i_contraindications_ID_79E042C9-E77E-49D2-99F8-96F668C28034,'>4</a>), and <span class=,'Italics,'>Warnings and Precautions</span> (<a href=,'#i4i_section_ID_1D8ACBEB-53AB-46F4-A211-C1A5D9B30C51,'>5.2</a>). </p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Tacrine</span></span>
</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'></span></span>In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five-and eight-fold increases in tacrine C<span class=,'Sub,'>max</span> and AUC, respectively, compared to the administration of tacrine alone. Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Thioridazine</span></span>
</p>
<p>
<span class=,'Italics,'> See Contraindications</span> (<a href=,'#i4i_contraindications_ID_79E042C9-E77E-49D2-99F8-96F668C28034,'>4</a>), <span class=,'Italics,'>Warnings and Precautions</span> (<a href=,'#_A9AD7587-E0DA-BE86-94D7-CAE20180A82E,'>5.4</a>).</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Tizanidine</span></span>
</p>
<p>
<span class=,'Italics,'> See Contraindications</span> (<a href=,'#i4i_contraindications_ID_79E042C9-E77E-49D2-99F8-96F668C28034,'>4</a>) and<span class=,'Italics,'> Warnings And Precautions</span> (<a href=,'#i4i_section_ID_D2CC7E3F-D6A2-4F49-9555-C18BDB30073B,'>5.5</a>).</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Tricyclic Antidepressants (TCAs)</span></span>
</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'></span></span>Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine. Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Triptans</span></span>
</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'></span></span>There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan. If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#i4i_section_ID_1D8ACBEB-53AB-46F4-A211-C1A5D9B30C51,'>5.2</a>)].</span>
</p>
<p>
<span class=,'Bold Italics,'>Sumatriptan</span>
</p>
<p>
<span class=,'Bold,'></span>There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan. If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Tryptophan</span></span>
</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'></span></span>Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution. Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan [<span class=,'Italics,'>see Warnings and Precautions</span> (<a href=,'#i4i_section_ID_1D8ACBEB-53AB-46F4-A211-C1A5D9B30C51,'>5.2</a>)].</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_ID_852F90BA-4959-4150-A78B-CB87CA985610,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Other Drugs</h2>
<p class=,'First,'>
<span class=,'Bold,'><span class=,'Italics,'>Alosetron</span></span>
</p>
<p>See Contraindications (<a href=,'#i4i_section_ID_12D6D681-8DB1-473D-AD8A-6F1FCA46422B,'>4</a>),  Warnings and Precautions (<a href=,'#i4i_contraindications_ID_79E042C9-E77E-49D2-99F8-96F668C28034,'>5.7</a>), and Lotronex<span class=,'Sup,'>TM </span>(alosetron) package insert.</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Digoxin</span></span>
</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'></span></span>Administration of fluvoxamine maleate 100 mg daily for 18 days (N=8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Diltiazem</span></span>
</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'></span></span>Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Mexiletine</span></span>
</p>
<p> See Warnings and Precautions (<a href=,'#i4i_section_ID_6FC3A16F-E47C-4073-9F45-64393FB2EA39,'>5.8</a>).</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Propranolol and Other Beta-Blockers</span></span>
</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'></span></span>Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.</p>
<p>One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.</p>
<p>If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended. No dosage adjustment is required for fluvoxamine maleate tablets.</p>
<p>Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N=6) did not affect the plasma concentrations of atenolol. Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Theophylline</span></span>
</p>
<p> See Warnings and Precautions (<a href=,'#i4i_section_ID_6FC3A16F-E47C-4073-9F45-64393FB2EA39,'>5.8</a>).</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.)</span></span>
</p>
<p> See Warnings and Precautions (<a href=,'#i4i_section_ID_6FC3A16F-E47C-4073-9F45-64393FB2EA39,'>5.8</a>, <a href=,'#i4i_section_ID_213B1CA0-F1E8-4C65-95AD-C91F55D74B41,'>5.10</a>).</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_ID_F86BF17A-167E-4064-9F30-AC17D445E3E1,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Effects of Smoking on Fluvoxamine Metabolism</h2>
<p class=,'First,'>Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_ID_0137C47E-A497-4776-B18F-2F7EB5491FAF,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Electroconvulsive Therapy (ECT)</h2>
<p class=,'First,'>There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.</p>
</div>
</div>"
"folic acid","05d54ff8-b455-4887-bf9c-bc273315b346","none found"
"fomepizole","256910fe-91f2-48f6-b0b4-55edc52dacd4","none found"
"fosfomycin","ad155d62-9b49-4a50-a2ae-d3aad8155936","none found"
"furosemide","01a5f094-b473-4e46-9e61-69d5ec6dd766","none found"
"gabapentin","01b810b7-f4c8-4412-bbc5-b9220d8770d8","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Drug-interactions,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'34073-7,'>
<a name=,'D7-1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1	Other Antiepileptic Drugs</h2>
<p class=,'First,'>Gabapentin is not appreciably metabolized nor does it interfere with the metabolism of commonly coadministered antiepileptic drugs <span class=,'Italics,'><a href=,'#C12-3,'>[see Clinical Pharmacology (12.3)]</a></span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'34073-7,'>
<a name=,'D7-2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2	Opioids	</h2>
<p class=,'First,'>
<span class=,'Underline,'>Hydrocodone</span>
</p>
<p>Coadministration of Gabapentin with hydrocodone decreases hydrocodone exposure<span class=,'Italics,'><a href=,'#C12-3,'> [see Clinical Pharmacology (12.3)]</a>.</span> The potential for alteration in hydrocodone exposure and effect should be considered when Gabapentin is started or discontinued in a patient taking hydrocodone</p>
<p>
<span class=,'Underline,'>Morphine</span>
</p>
<p>When gabapentin is administered with morphine, patients should be observed for signs of central nervous system (CNS) depression, such as somnolence, sedation and respiratory depression <span class=,'Italics,'><a href=,'#C12-3,'>[see Clinical Pharmacology (12.3)]</a></span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'34073-7,'>
<a name=,'D7-3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3	Maalox<span class=,'Sup,'>®</span> (aluminum hydroxide, magnesium hydroxide)</h2>
<p class=,'First,'>The mean bioavailability of gabapentin was reduced by about 20% with concomitant use of an antacid (Maalox<span class=,'Sup,'>®</span>) containing magnesium and aluminum hydroxides. It is recommended that gabapentin be taken at least 2 hours following Maalox administration <span class=,'Italics,'><a href=,'#C12-3,'>[see Clinical Pharmacology (12.3)]</a></span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'34073-7,'>
<a name=,'D7-4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4	Drug/Laboratory Test Interactions</h2>
<p class=,'First,'>Because false positive readings were reported with the Ames N-Multistix SG<span class=,'Sup,'>®</span> dipstick test for urinary protein when gabapentin was added to other antiepileptic drugs, the more specific sulfosalicylic acid precipitation procedure is recommended to determine the presence of urine protein.</p>
</div>
</div>"
"galantamine","4e05d1da-0eb8-4fe0-8259-f1ebb170e0dc","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Use with Anticholinergics</h2>
<p class=,'First,'>Galantamine has the potential to interfere with the activity of anticholinergic medications <span class=,'Italics,'>[see <a href=,'#Section_12.3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Use With Cholinomimetics and Other Cholinesterase Inhibitors</h2>
<p class=,'First,'>A synergistic effect is expected when cholinesterase inhibitors are given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol <span class=,'Italics,'>[see <a href=,'#Section_12.3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>"
"gatifloxacin","3dd6ac6b-877a-46c7-bbc8-c7119f341abe","none found"
"gemcitabine","4031017d-d768-46de-8081-476bcb883f5e","none found"
"gemfibrozil","05bfbcdc-03ab-4fba-9582-980602410ef9","none found"
"gentamicin","63413469-c676-48a3-a945-7d2489b535ef","none found"
"glatiramer acetate","f38b5606-d2d7-44ec-912f-46882aa2fa7b","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID_d6da45c4-8c6f-46ec-952c-a6617ce72b8e,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Interactions between glatiramer acetate and other drugs have not been fully evaluated. Results from existing clinical trials do not suggest any significant interactions of glatiramer acetate with therapies commonly used in MS patients, including the concurrent use of corticosteroids for up to 28 days. Glatiramer acetate has not been formally evaluated in combination with interferon beta. </p>
</div>"
"glyburide","04201349-2a01-4fc1-9920-1ef7376d352f","none found"
"glucose","085614c7-ada4-4e2c-87c0-c9bc2f18365a","none found"
"glutaral","a38d64df-ffd5-f721-e053-2995a90a2ed8","none found"
"nitroglycerin","7da79fdf-0969-1ddd-e053-2991aa0a3ec4","none found"
"glycopyrronium","02541cfd-b209-49b9-a73f-13ef18dce06d","none found"
"golimumab","f86cb4a7-c358-4136-ae57-b32bda9bba00","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1      Methotrexate</h2>
<p class=,'First,'>For the treatment of RA, SIMPONI should be used with methotrexate (MTX) <span class=,'Italics,'>[see <a href=,'#S14.1,'>Clinical Studies (14.1)</a>]</span>. Since the presence or absence of concomitant MTX did not appear to influence the efficacy or safety of SIMPONI in the treatment of PsA or AS, SIMPONI can be used with or without MTX in the treatment of PsA and AS <span class=,'Italics,'>[see <a href=,'#S14.2,'>Clinical Studies (14.2</a>, <a href=,'#S14.3,'>14.3)</a> and <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2       Biological Products for RA, PsA, and/or AS</h2>
<p class=,'First,'>An increased risk of serious infections has been seen in clinical RA trials of other TNF blockers used in combination with anakinra or abatacept, with no added benefit; therefore, use of SIMPONI with abatacept or anakinra is not recommended <span class=,'Italics,'>[see <a href=,'#S5.6,'>Warnings and Precautions (5.6</a>, <a href=,'#S5.7,'>5.7)</a>]</span>. A higher rate of serious infections has also been observed in RA patients treated with rituximab who received subsequent treatment with a TNF blocker. The concomitant use of SIMPONI with biologics approved to treat RA, PsA, or AS is not recommended because of the possibility of an increased risk of infection.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3       Live Vaccines/Therapeutic Infectious Agents</h2>
<p class=,'First,'>Live vaccines should not be given concurrently with SIMPONI <span class=,'Italics,'>[see <a href=,'#S5.10,'>Warnings and Precautions (5.10)</a>]</span>.</p>
<p>Therapeutic infectious agents should not be given concurrently with SIMPONI <span class=,'Italics,'>[see <a href=,'#S5.10,'>Warnings and Precautions (5.10)</a>]</span>.</p>
<p>Infants born to women treated with SIMPONI during their pregnancy may be at increased risk of infection for up to 6 months. Administration of live vaccines to infants exposed to SIMPONI <span class=,'Italics,'>in utero</span> is not recommended for 6 months following the mother's last SIMPONI injection during pregnancy <span class=,'Italics,'>[see <a href=,'#S8.1,'>Use in Specific Populations (8.1)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4       Cytochrome P450 Substrates</h2>
<p class=,'First,'>The formation of CYP450 enzymes may be suppressed by increased levels of cytokines (e.g., TNFα) during chronic inflammation. Therefore, it is expected that for a molecule that antagonizes cytokine activity, such as golimumab, the formation of CYP450 enzymes could be normalized. Upon initiation or discontinuation of SIMPONI in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed.</p>
</div>
</div>"
"griseofulvin","37b4d132-84f1-4394-b468-7e74eeec61eb","none found"
"haloperidol","0027b8a3-73bf-4005-a7e3-b035f451a861","none found"
"heparin sodium, porcine","02fb700d-a28c-4d45-b78d-382dc0d5986c","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'s26,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s27,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Oral Anticoagulants
</h2>
<p class=,'First,'>Heparin sodium may prolong the one-stage prothrombin time. Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn, if a valid prothrombin time is to be obtained.
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s28,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Platelet Inhibitors
</h2>
<p class=,'First,'>Drugs such as NSAIDS (including salicylic acid, ibuprofen, indomethacin, and celecoxib), dextran, phenylbutazone, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIb/IIIa antagonists (including abciximab, eptifibatide, and tirofiban), and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium. To reduce the risk of bleeding, a reduction in the dose of antiplatelet agent or heparin is recommended.
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s29,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Other Interactions
</h2>
<p class=,'First,'>Digitalis, tetracyclines, nicotine or antihistamines may partially counteract the anticoagulant action of heparin sodium. Intravenous nitroglycerin administered to heparinized patients may result in a decrease of the partial thromboplastin time with subsequent rebound effect upon discontinuation of nitroglycerin.
</p>
<p>Careful monitoring of partial thromboplastin time and adjustment of heparin dosage are recommended during coadministration of heparin and intravenous nitroglycerin.
</p>
<p>Antithrombin III (human) – The anticoagulant effect of heparin is enhanced by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency. To reduce the risk of bleeding, a reduced dosage of heparin is recommended during treatment with antithrombin III (human).
</p>
</div>
</div>"
"hepatitis B surface antigen vaccine","47ef5267-5624-48d4-91e2-483e93755f6f","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1	Concomitant Administration with Other Vaccines</h2>
<p class=,'First,'>Do not mix RECOMBIVAX HB with any other vaccine in the same syringe or vial. Use separate injection sites and syringes for each vaccine. </p>
<p>In clinical trials in children, RECOMBIVAX HB was concomitantly administered with one or more of the following US licensed vaccines: Diphtheria, Tetanus and whole cell Pertussis; oral Poliomyelitis vaccine; Measles, Mumps, and Rubella Virus Vaccine, Live; Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)] or a booster dose of Diphtheria, Tetanus, acellular Pertussis. Safety and immunogenicity were similar for concomitantly administered vaccines compared to separately administered vaccines. </p>
<p>In another clinical trial, a related HBsAg-containing product, Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant) combination product (no longer licensed), was given concomitantly with eIPV (enhanced inactivated Poliovirus vaccine) or VARIVAX<span class=,'Sup,'>® </span>[Varicella Virus Vaccine Live (Oka/Merck)], using separate sites and syringes for injectable vaccines. No serious vaccine-related adverse events were reported, and no impairment of immune response to these individually tested vaccine antigens was demonstrated. </p>
<p>The Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant) combination product (no longer licensed) has also been administered concomitantly with the primary series of DTaP to a limited number of infants. No serious vaccine-related adverse events were reported.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2	Concomitant Administration with Immune Globulin</h2>
<p class=,'First,'>RECOMBIVAX HB may be administered concomitantly with HBIG. The first dose of RECOMBIVAX HB may be given at the same time as HBIG, but the injections should be administered at different sites.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3	Interference with Laboratory Tests</h2>
<p class=,'First,'>Hepatitis B surface antigen (HBsAg) derived from hepatitis B vaccines has been transiently detected in blood samples following vaccination. Serum HBsAg detection may not have diagnostic value within 28 days after receipt of a hepatitis B vaccine, including RECOMBIVAX HB.</p>
</div>
</div>"
"homatropine","0184de92-e728-4390-95f6-a463f583416a","none found"
"hydralazine","061c4a3a-53ac-471b-ac6c-aab10a50b03a","none found"
"hydrochlorothiazide","01f1f478-5493-439f-9b99-f4f82023781c","none found"
"hydrocodone","36710b35-419c-4e64-8bd1-29b81a4c8e03","none found"
"hydrocortisone","058bb2ff-ff51-4a3b-ba47-cb02272d0631","none found"
"hydroxocobalamin","17e7d7d8-d27c-4888-84b9-45305df62066","none found"
"hydroxychloroquine","006801ed-d93f-4346-863a-cc03e6712520","none found"
"hydroxyurea","0a5c7030-5fac-4708-b309-f9d07103285a","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_c56c5920-d2a6-47d7-99c6-65b372c5ed45,'></a><a name=,'section-8,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_fb9d4c33-98ab-42c0-88a2-5c06792d1762,'></a><a name=,'section-8.1,'></a>
<p></p>
<h2>
<span class=,'Bold,'>7.1 Increased Toxicity with Concomitant Use of Antiretroviral Drugs</span>
</h2>
<p class=,'First,'>Pancreatitis</p>
<p>In patients with HIV infection during therapy with hydroxyurea and didanosine, with or without stavudine, fatal and nonfatal pancreatitis have occurred. Hydroxyurea is not indicated for the treatment of HIV infection; however, if patients with HIV infection are treated with hydroxyurea, and in particular, in combination with didanosine and/or stavudine, close monitoring for signs and symptoms of pancreatitis is recommended. Permanently discontinue therapy with hydroxyurea in patients who develop signs and symptoms of pancreatitis.</p>
<p>Hepatotoxicity</p>
<p>Hepatotoxicity and hepatic failure resulting in death have been reported during postmarketing surveillance in patients with HIV infection treated with hydroxyurea and other antiretroviral drugs. Fatal hepatic events were reported most often in patients treated with the combination of hydroxyurea, didanosine, and stavudine. Avoid this combination.</p>
<p>Peripheral Neuropathy</p>
<p>Peripheral neuropathy, which was severe in some cases, has been reported in patients with HIV infection receiving hydroxyurea in combination with antiretroviral drugs, including didanosine, with or without stavudine.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_9148298e-81c0-4a4e-be5c-e9a8587bbe76,'></a><a name=,'section-8.2,'></a>
<p></p>
<h2>
<span class=,'Bold,'>7.2 Laboratory Test Interference</span>
</h2>
<p class=,'First,'>Interference with Uric Acid, Urea, or Lactic Acid Assays</p>
<p>Studies have shown that there is an analytical interference of hydroxyurea with the enzymes (urease, uricase, and lactate dehydrogenase) used in the determination of urea, uric acid, and lactic acid, rendering falsely elevated results of these in patients treated with hydroxyurea.</p>
</div>
</div>"
"ibandronic acid","9fad4982-95af-d711-f50a-867311835143","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1	Melphalan/Prednisolone</h2>
<p class=,'First,'>Intravenous ibandronate (6 mg) did not interact with intravenous melphalan (10 mg/m<span class=,'Sup,'>2</span>) or oral prednisolone (60 mg/m<span class=,'Sup,'>2</span>) <span class=,'Italics,'> [see<a href=,'#S12.3,'> Clinical Pharmacology (12.3)</a>]</span>. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2	Tamoxifen</h2>
<p class=,'First,'>There was no interaction between oral 30 mg tamoxifen and intravenous 2 mg ibandronate <span class=,'Italics,'>[see<a href=,'#S12.3,'> Clinical Pharmacology (12.3)</a>]</span>. </p>
<p></p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3	Bone Imaging Agents</h2>
<p class=,'First,'>Bisphosphonates are known to interfere with the use of bone-imaging agents. Specific studies with ibandronate sodium have not been performed.</p>
</div>
</div>"
"ibuprofen","00872852-680a-41b3-901b-b991b12a176d","none found"
"ifosfamide","c90ab05f-8fe5-437e-a1c0-8b11ef63291e","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_408c3e2f-5822-4492-be91-32a6d260da8f,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Ifosfamide is a substrate for both CYP3A4 and CYP2B6.</p>
<div class=,'Section,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_d0916520-38b5-4040-9560-fbaaa2d5eb3e,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Inducers of CYP3A4</h2>
<p class=,'First,'>CYP3A4 inducers (e.g., carbamazepine, phenytoin, fosphenytoin, phenobarbital, rifampin, St. John Wort) may increase the metabolism of ifosfamide to its active alkylating metabolites. CYP3A4 inducers may increase the formation of the neurotoxic/nephrotoxic ifosfamide metabolite, chloroacetaldehyde. Closely monitor patients taking ifosfamide with CYP3A4 inducers for toxicities and consider dose adjustment.</p>
</div>
<div class=,'Section,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_c15a5e12-303c-4f3f-b484-558fc85c2782,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Inhibitors of CYP3A4</h2>
<p class=,'First,'>CYP3A4 inhibitors (e.g., ketoconazole, fluconazole, itraconazole, sorafenib, aprepitant, fosaprepitant, grapefruit, grapefruit juice) may decrease the metabolism of ifosfamide to its active alkylating metabolites, perhaps decreasing the effectiveness of ifosfamide treatment. </p>
</div>
</div>"
"imatinib","559dd8e5-11f9-70cd-3fb0-9f9eb8484a37","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'DRUG_INTERACTIONS,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_310c8945-4e62-eaa1-3eec-fc4c153fab7a,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2> 7.1 Agents Inducing CYP3A Metabolism  </h2>
<p class=,'First,'> Concomitant administration of imatinib mesylate and strong CYP3A4 inducers may reduce total exposure of imatinib; consider alternative agents [see <span class=,'Bold,'>Clinical Pharmacology</span> (<a href=,'#PHARMACOKINETICS,'>12.3</a>)].</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_6f634c5c-900c-f85c-cd26-cb875890d0b6,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2> 7.2 Agents Inhibiting CYP3A Metabolism  </h2>
<p class=,'First,'>Concomitant administration of imatinib mesylate and strong CYP3A4 inhibitors may result in a significant imatinib exposure increase. Grapefruit juice may also increase plasma concentrations of imatinib; avoid grapefruit juice [see <span class=,'Bold,'>Clinical Pharmacology</span> (<a href=,'#PHARMACOKINETICS,'>12.3</a>)].</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_6ca253b2-6e3e-d507-1589-1433e66ab4c4,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>
<span> 7.3 Interactions with Drugs Metabolized by CYP3A4</span><span class=,'Bold,'></span>
</h2>
<p class=,'First,'> Imatinib mesylate will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering imatinib mesylate with CYP3A4 substrates that have a narrow therapeutic window.</p>
<p>Because warfarin is metabolized by CYP2C9 and CYP3A4, use low-molecular weight or standard heparin instead of warfarin in patients who require anticoagulation [see <span class=,'Bold,'>Clinical Pharmacology</span> (<a href=,'#PHARMACOKINETICS,'>12.3</a>)].</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_a3531cee-72e1-78d2-cb37-071b890d3c69,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>
<span> 7.4 Interactions with Drugs Metabolized by CYP2D6 </span>
</h2>
<p class=,'First,'>Use caution when administering imatinib mesylate with CYP2D6 substrates that have a narrow therapeutic window.</p>
</div>
</div>"
"imipramine","53faac6a-fdb9-4d60-814d-b4aab9c9da58","none found"
"indinavir","01c5574c-1056-49c6-af20-e950db3f4139","none found"
"indomethacin","009097a5-2c1e-4f5d-8054-896cf896cb3d","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>See 
       
 
  <a href=,'#_RefT2,'>Table 2</a> for clinically significant drug interactions with indomethacin.
      

 </p>
<a name=,'_RefT2,'></a>
<div class=,'scrollingtable,'><table width=,'90%,'>
<caption>
<span>Table 2 Clinically Significant Drug Interactions with Indomethacin</span>
</caption>
<col width=,'20%,'/>
<col width=,'80%,'/>
<thead>
<tr class=,'First Last,'>
<th align=,'left,' class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'>Drugs That Interfere with Hemostasis</span></th>
</tr>
</thead>
<tbody>
<tr class=,'First,'>
<td align=,'center,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
</p>
</td><td class=,'Botrule Rrule Toprule,' valign=,'top,'>
<ul>
<li>Indomethacin and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of indomethacin and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone.
           </li>
<li>Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone.
           </li>
</ul>
</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Botrule Rrule,' valign=,'top,'>
<p class=,'First,'>Monitor patients with concomitant use of indomethacin capsules with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [
           
     
      <span class=,'Italics,'>see 
            
      
       <a href=,'#S5.11,'>Warnings and Precautions (5.11)</a></span>].
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Aspirin</span>
</p>
</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
</p>
</td><td class=,'Botrule Rrule,' valign=,'top,'>
<p class=,'First,'>Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [
           
     
      <span class=,'Italics,'>see 
            
      
       <a href=,'#S5.2,'>Warnings and Precautions (5.2)</a></span>].
          
    
     </p>
</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Botrule Rrule,' valign=,'top,'>
<p class=,'First,'>Concomitant use of indomethacin capsules and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [
           
     
      <span class=,'Italics,'>see 
            
      
       <a href=,'#S5.11,'>Warnings and Precautions (5.11)</a>]
           
     
      </span>.
           
     
      <br/>Indomethacin capsules are not substitute for low dose aspirin for cardiovascular protection.
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers</span>
</p>
</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
</p>
</td><td class=,'Botrule Rrule,' valign=,'top,'>
<ul>
<li>NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol).
           </li>
<li>In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible.
           </li>
</ul>
</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Botrule Rrule,' valign=,'top,'>
<ul>
<li>During concomitant use of indomethacin capsules and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained.
           </li>
<li>During concomitant use of indomethacin capsules and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [
            
      
       <span class=,'Italics,'>see 
             
       
        <a href=,'#S5.6,'>Warnings and Precautions (5.6)</a></span>]
            
      
       <span class=,'Italics,'>.</span>
</li>
<li>When these drugs are administered concomitantly, patients should be adequately hydrated. Assess renal function at the beginning of the concomitant treatment and periodically thereafter.
           </li>
</ul>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Diuretics</span>
</p>
</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
</p>
</td><td class=,'Botrule Rrule,' valign=,'top,'>
<p class=,'First,'>Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis.
           
     
      <br/>
<br/>It has been reported that the addition of triamterene to a maintenance schedule of
           
     
      <br/>indomethacin capsules resulted in reversible acute renal failure in two of four healthy volunteers. Indomethacin capsules and triamterene should not be administered together.
           
     
      <br/>
<br/>Both indomethacin capsules and potassium-sparing diuretics may be associated with increased serum potassium levels. The potential effects of indomethacin capsules and potassium-sparing diuretics on potassium levels and renal function should be considered when these agents are administered concurrently.
          
    
     </p>
</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Botrule Rrule,' valign=,'top,'>
<p class=,'First,'>Indomethacin and triamterene should not be administered together.
           
     
      <br/>During concomitant use of indomethacin capsules with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects.
           
     
      <br/>Be aware that indomethacin and potassium-sparing diuretics may both be associated with increased serum potassium levels [
           
     
      <span class=,'Italics,'>see 
            
      
       <a href=,'#S5.6,'>Warnings and Precautions (5.6)</a></span>].
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Digoxin</span>
</p>
</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
</p>
</td><td class=,'Botrule Rrule,' valign=,'top,'>
<p class=,'First,'>The concomitant use of indomethacin with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.</p>
</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Botrule Rrule,' valign=,'top,'>
<p class=,'First,'>During concomitant use of indomethacin capsules and digoxin, monitor serum digoxin levels.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Lithium</span>
</p>
</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
</p>
</td><td class=,'Botrule Rrule,' valign=,'top,'>
<p class=,'First,'>NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance
           
     
      <span class=,'Italics,'>.</span> The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis.
          
    
     </p>
</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Botrule Rrule,' valign=,'top,'>
<p class=,'First,'>During concomitant use of indomethacin capsules and lithium, monitor patients for signs of lithium toxicity.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Methotrexate</span>
</p>
</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
</p>
</td><td class=,'Botrule Rrule,' valign=,'top,'>
<p class=,'First,'>Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction).</p>
</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Botrule Rrule,' valign=,'top,'>
<p class=,'First,'>During concomitant use of indomethacin capsules and methotrexate, monitor patients for methotrexate toxicity.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Cyclosporine</span>
</p>
</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
</p>
</td><td class=,'Botrule Rrule,' valign=,'top,'>
<p class=,'First,'>Concomitant use of indomethacin capsules and cyclosporine may increase cyclosporine’s nephrotoxicity.</p>
</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Botrule Rrule,' valign=,'top,'>
<p class=,'First,'>During concomitant use of indomethacin capsules and cyclosporine, monitor patients for signs of worsening renal function.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>NSAIDs and Salicylates</span>
</p>
</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
</p>
</td><td class=,'Botrule Rrule,' valign=,'top,'>
<p class=,'First,'>Concomitant use of indomethacin with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy [
           
     
      <span class=,'Italics,'>see 
            
      
       <a href=,'#S5.2,'>Warnings and Precautions (5.2)</a></span>]
           
     
      <span class=,'Italics,'>.</span>
<br/>Combined use with diflunisal may be particularly hazardous because diflunisal causes significantly higher plasma levels of indomethacin [
           
     
      <span class=,'Italics,'>see 
            
      
       <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a></span>]. In some patients, combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.
          
    
     </p>
</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Botrule Rrule,' valign=,'top,'>
<p class=,'First,'>The concomitant use of indomethacin with other NSAIDs or salicylates, especially diflunisal, is not recommended.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Pemetrexed</span>
</p>
</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
</p>
</td><td class=,'Botrule Rrule,' valign=,'top,'>
<p class=,'First,'>Concomitant use of indomethacin capsules and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information).</p>
</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Botrule Rrule,' valign=,'top,'>
<p class=,'First,'>During concomitant use of indomethacin capsules and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity.
           
     
      <br/>
<br/>NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed.
           
     
      <br/>
<br/>In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration.
          
    
     </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Probenecid</span>
</p>
</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
</p>
</td><td class=,'Botrule Rrule,' valign=,'top,'>
<p class=,'First,'>When indomethacin is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased.</p>
</td>
</tr>
<tr class=,'Last,'>
<td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Botrule Rrule,' valign=,'top,'>
<p class=,'First,'>During the concomitant use of indomethacin capsules and probenecid, a lower total daily dosage of indomethacin may produce a satisfactory therapeutic effect. When increases in the dose of indomethacin are made, they should be made carefully and in small increments.</p>
</td>
</tr>
</tbody>
</table></div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_071dc762-31d6-4ad5-be5c-94a27ee367e9,'></a><a name=,'section-7.1,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Underline,'>Effects on Laboratory Tests</span>
</p>
<p>Indomethacin capsules reduces basal plasma renin activity (PRA), as well as those elevations of PRA induced by furosemide administration, or salt or volume depletion. These facts should be considered when evaluating plasma renin activity in hypertensive patients.</p>
<p>False-negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported. Thus, results of the DST should be interpreted with caution in these patients.</p>
</div>
</div>"
"infliximab","a0a046c1-056d-45a9-bfd9-13b47c24f257","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Other Biological Products</h2>
<p class=,'First,'>The combination of REMICADE with other biological products used to treat the same conditions as REMICADE is not recommended <span class=,'Italics,'>[see <a href=,'#S5.10,'>Warnings and Precautions (5.10)</a>]</span>.</p>
<p>An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of REMICADE and anakinra or abatacept is not recommended <span class=,'Italics,'>[see <a href=,'#S5.10,'>Warnings and Precautions (5.10)</a>]</span>.</p>
<p>The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including REMICADE, should be avoided because of the possibility of increased immunosuppression and increased risk of infection.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2	Methotrexate and Other Concomitant Medications</h2>
<p class=,'First,'>Specific drug interaction studies, including interactions with methotrexate (MTX), have not been conducted. The majority of patients in RA or CD clinical studies received one or more concomitant medications. In RA, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents (NSAIDs), folic acid, corticosteroids and/or narcotics. Concomitant CD medications were antibiotics, antivirals, corticosteroids, 6-MP/AZA and aminosalicylates. In PsA clinical trials, concomitant medications included MTX in approximately half of the patients as well as NSAIDs, folic acid and corticosteroids. Concomitant MTX use may decrease the incidence of anti-infliximab antibody production and increase infliximab concentrations.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3	Immunosuppressants</h2>
<p class=,'First,'>Patients with CD who received immunosuppressants tended to experience fewer infusion reactions compared to patients on no immunosuppressants <span class=,'Italics,'>[see <a href=,'#S6.1,'>Adverse Reactions (6.1)</a>]</span>. Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of CD including corticosteroids, antibiotics (metronidazole or ciprofloxacin) and aminosalicylates.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4	Cytochrome P450 Substrates</h2>
<p class=,'First,'>The formation of CYP450 enzymes may be suppressed by increased levels of cytokines (e.g., TNFα, IL-1, IL-6, IL-10, IFN) during chronic inflammation. Therefore, it is expected that for a molecule that antagonizes cytokine activity, such as infliximab, the formation of CYP450 enzymes could be normalized. Upon initiation or discontinuation of REMICADE in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.5,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5	Live Vaccines/Therapeutic Infectious Agents</h2>
<p class=,'First,'>It is recommended that live vaccines not be given concurrently with REMICADE. It is also recommended that live vaccines not be given to infants after <span class=,'Italics,'>in utero</span> exposure to infliximab for at least 6 months following birth<span class=,'Italics,'> [see<a href=,'#S5.13,'> Warnings and Precautions (5.13)</a>]</span>.</p>
<p>It is recommended that therapeutic infectious agents not be given concurrently with REMICADE<span class=,'Italics,'> [see<a href=,'#S5.13,'> Warnings and Precautions (5.13)</a>]</span>.</p>
</div>
</div>"
"insulin aspart, human","8dddb455-b5f3-4317-a7ec-de90a0311ae3","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'i4i_interactions_id_ddfdb67c-93b9-4d18-8d10-f67a37844f7c,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'scrollingtable,'><table width=,'100%,'>
<col width=,'32%,'/>
<col width=,'67%,'/>
<tbody class=,'Headless,'>
<tr class=,'First,'>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Drugs That May Increase the Risk of Hypoglycemia</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Drugs:</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), and  sulfonamide antibiotics. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Dose adjustment and increased frequency of glucose monitoring may be required when insulin aspart is co-administered with these drugs. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Drugs That May Decrease the Blood Glucose Lowering Effect of insulin aspart </span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Drugs:</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Dose adjustment and increased frequency of glucose monitoring may be required when insulin aspart is co-administered with these drugs. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of insulin aspart </span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Drugs:</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Alcohol, beta-blockers, clonidine, and lithium salts. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.  Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Dose adjustment and increased frequency of glucose monitoring may be required when insulin aspart is co-administered with these drugs.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Drugs That May Blunt Signs and Symptoms of Hypoglycemia</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Drugs:</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Beta-blockers, clonidine, guanethidine and reserpine</p>
</td>
</tr>
<tr class=,'Last,'>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Increased frequency of glucose monitoring may be required when insulin aspart is co-administered with these drugs.</p>
</td>
</tr>
</tbody>
</table></div>
</div>"
"insulin degludec","456c5e87-3dfd-46fa-8ac0-c6128d4c97c6","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID_f6e74fa4-8152-42b3-9259-53938653df70,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Table 5 includes clinically significant drug interactions with TRESIBA.</p>
<p>
<span class=,'Bold,'>Table 5: Clinically Significant Drug Interactions with TRESIBA</span>
</p>
<div class=,'scrollingtable,'><table width=,'100%,'>
<col width=,'25%,'/>
<col width=,'75%,'/>
<tbody class=,'Headless,'>
<tr class=,'First,'>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,' valign=,'middle,'>
<dl>
<dt> </dt>
<dd>
<span class=,'Bold,'>Drugs That May Increase the Risk of Hypoglycemia</span>
</dd>
</dl>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<dl>
<dt> </dt>
<dd>
<span class=,'Italics,'>Drugs:</span>
</dd>
</dl>
</td><td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<dl>
<dt> </dt>
<dd>Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors. </dd>
</dl>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<dl>
<dt> </dt>
<dd>
<span class=,'Italics,'>Intervention:</span>
</dd>
</dl>
</td><td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<dl>
<dt> </dt>
<dd>Dose reductions and increased frequency of glucose monitoring may be required when TRESIBA is co-administered with these drugs.</dd>
</dl>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<dl>
<dt> </dt>
<dd>
<span class=,'Bold,'>Drugs That May Decrease the Blood Glucose Lowering Effect of TRESIBA</span>
</dd>
</dl>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<dl>
<dt> </dt>
<dd>
<span class=,'Italics,'>Drugs:</span>
</dd>
</dl>
</td><td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<dl>
<dt> </dt>
<dd>Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.</dd>
</dl>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<dl>
<dt> </dt>
<dd>
<span class=,'Italics,'>Intervention:</span>
</dd>
</dl>
</td><td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<dl>
<dt> </dt>
<dd>Dose increases and increased frequency of glucose monitoring may be required when TRESIBA is co-administered with these drugs.</dd>
</dl>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<dl>
<dt> </dt>
<dd>
<span class=,'Bold,'>Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of TRESIBA</span>
</dd>
</dl>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<dl>
<dt> </dt>
<dd>
<span class=,'Italics,'>Drugs:</span>
</dd>
</dl>
</td><td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<dl>
<dt> </dt>
<dd>Alcohol, beta-blockers, clonidine, and lithium salts.  Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia. </dd>
</dl>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<dl>
<dt> </dt>
<dd>
<span class=,'Italics,'>Intervention:</span>
</dd>
</dl>
</td><td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<dl>
<dt> </dt>
<dd>Dose adjustment and increased frequency of glucose monitoring may be required when TRESIBA is co-administered with these drugs. </dd>
</dl>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<dl>
<dt> </dt>
<dd>
<span class=,'Bold,'>Drugs That May Blunt Signs and Symptoms of Hypoglycemia </span>
</dd>
</dl>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<dl>
<dt> </dt>
<dd>
<span class=,'Italics,'>Drugs:</span>
</dd>
</dl>
</td><td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<dl>
<dt> </dt>
<dd>Beta-blockers, clonidine, guanethidine, and reserpine</dd>
</dl>
</td>
</tr>
<tr class=,'Last,'>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<dl>
<dt> </dt>
<dd>
<span class=,'Italics,'>Intervention:</span>
</dd>
</dl>
</td><td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<dl>
<dt> </dt>
<dd>Increased frequency of glucose monitoring may be required when TRESIBA is co-administered with these drugs. </dd>
</dl>
</td>
</tr>
</tbody>
</table></div>
</div>"
"insulin detemir","80967086-8161-4ff7-ab17-f03d8319f651","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'i4i_interactions_id_df22af12-683f-4c71-87ae-e32669a0b348,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Table 7 includes clinically significant drug interactions with LEVEMIR.</p>
<p>
<span class=,'Bold,'>Table 7: Clinically Significant Drug Interactions with LEVEMIR</span>
</p>
<div class=,'scrollingtable,'><table cellpadding=,'0.75pt,' cellspacing=,'0.75pt,' width=,'100%,'>
<col width=,'14%,'/>
<col width=,'0%,'/>
<col width=,'86%,'/>
<tbody class=,'Headless,'>
<tr class=,'First,'>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,' valign=,'middle,'>
<p class=,'First,'>  <span class=,'Bold,'>Drugs That May Increase the Risk of Hypoglycemia </span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>  Drugs: </p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'middle,'>
<p class=,'First,'>Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>  Intervention: </p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'middle,'>
<p class=,'First,'>Dose reductions and increased frequency of glucose monitoring may be required when LEVEMIR is co-administered with these drugs. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'3,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>  Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>  Drugs: </p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'middle,'>
<p class=,'First,'>Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>  Intervention: </p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'middle,'>
<p class=,'First,'>Dose increases and increased frequency of glucose monitoring may be required when LEVEMIR is co-administered with these drugs. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'3,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>  Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of LEVEMIR </span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>  Drugs: </p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'middle,'>
<p class=,'First,'>Alcohol, beta-blockers, clonidine, and lithium salts. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>  Intervention: </p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'middle,'>
<p class=,'First,'>Dose adjustment and increased frequency of glucose monitoring may be required when LEVEMIR is co-administered with these drugs. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'3,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>  Drugs That May Blunt Signs and Symptoms of Hypoglycemia </span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>  Drugs: </p>
</td><td class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>Beta-blockers, clonidine, guanethidine, and reserpine </p>
</td>
</tr>
<tr class=,'Last,'>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'middle,'>
<p class=,'First,'> Intervention: </p>
</td><td class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>Increased frequency of glucose monitoring may be required when LEVEMIR is co-administered with these drugs. </p>
</td>
</tr>
</tbody>
</table></div>
</div>"
"insulin glargine","257ca17b-6ff7-4f2e-9037-4c185bac5768","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Table 3 includes clinically significant drug interactions with TOUJEO.</p>
<div class=,'scrollingtable,'><table width=,'75%,'>
<caption>
<span>Table 3: Clinically Significant Drug Interactions with TOUJEO</span>
</caption>
<col align=,'left,' valign=,'middle,' width=,'20%,'/>
<col align=,'left,' valign=,'middle,' width=,'80%,'/>
<tbody class=,'Headless,'>
<tr class=,'Botrule First,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Drugs That May Increase the Risk of Hypoglycemia</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Drugs:</span></td><td align=,'left,' class=,'Rrule,'>Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention:</span></td><td align=,'left,' class=,'Rrule,'>Dose reductions and increased frequency of glucose monitoring may be required when TOUJEO is coadministered with these drugs.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Drugs That May Decrease the Blood Glucose Lowering Effect of TOUJEO</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Drugs:</span></td><td align=,'left,' class=,'Rrule,'>Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention:</span></td><td align=,'left,' class=,'Rrule,'>Dose increases and increased frequency of glucose monitoring may be required when TOUJEO is coadministered with these drugs.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of TOUJEO</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Drugs:</span></td><td align=,'left,' class=,'Rrule,'>Alcohol, beta-blockers, clonidine, and lithium salts. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention:</span></td><td align=,'left,' class=,'Rrule,'>Dose adjustment and increased frequency of glucose monitoring may be required when TOUJEO is coadministered with these drugs.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Drugs That May Blunt Signs and Symptoms of Hypoglycemia </span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Drugs:</span></td><td align=,'left,' class=,'Rrule,'>Beta-blockers, clonidine, guanethidine, and reserpine.</td>
</tr>
<tr class=,'Last,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention:</span></td><td align=,'left,' class=,'Rrule,'>Increased frequency of glucose monitoring may be required when TOUJEO is coadministered with these drugs.</td>
</tr>
</tbody>
</table></div>
</div>"
"insulin glulisine, human","e7af6a7a-8046-4fb4-9979-4ec4230b23aa","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'scrollingtable,'><table width=,'100%,'>
<caption>
<span>Table 6: Clinically Significant Drug Interactions with APIDRA</span>
</caption>
<col align=,'right,' valign=,'top,' width=,'25%,'/>
<col align=,'left,' valign=,'top,' width=,'75%,'/>
<thead>
<tr class=,'First Last,'>
<th align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'>Drugs that May Increase the Risk of Hypoglycemia</th>
</tr>
</thead>
<tbody>
<tr class=,'Botrule First,'>
<td align=,'right,' class=,'Lrule Rrule,'><span class=,'Italics,'>Drugs:</span></td><td align=,'left,' class=,'Rrule,'>Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'right,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention:</span></td><td align=,'left,' class=,'Rrule,'>Dose adjustment and increased frequency of glucose monitoring may be required when APIDRA is coadministered with these drugs.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Drugs that May Decrease the Blood Glucose Lowering Effect of APIDRA</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'right,' class=,'Lrule Rrule,'><span class=,'Italics,'>Drugs:</span></td><td align=,'left,' class=,'Rrule,'>Atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, phenothiazine derivatives, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'right,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention:</span></td><td align=,'left,' class=,'Rrule,'>Dose adjustment and increased frequency of glucose monitoring may be required when APIDRA is coadministered with these drugs.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Drugs that May Increase or Decrease the Blood Glucose Lowering Effect of APIDRA</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'right,' class=,'Lrule Rrule,'><span class=,'Italics,'>Drugs:</span></td><td align=,'left,' class=,'Rrule,'>Alcohol, beta-blockers, clonidine, and lithium salts. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'right,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention:</span></td><td align=,'left,' class=,'Rrule,'>Dose adjustment and increased frequency of glucose monitoring may be required when APIDRA is coadministered with these drugs.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Drugs that May Blunt Signs and Symptoms of Hypoglycemia</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'right,' class=,'Lrule Rrule,'><span class=,'Italics,'>Drugs:</span></td><td align=,'left,' class=,'Rrule,'>Beta-blockers, clonidine, guanethidine, and reserpine.</td>
</tr>
<tr class=,'Last,'>
<td align=,'right,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention:</span></td><td align=,'left,' class=,'Rrule,'>Increased frequency of glucose monitoring may be required when APIDRA is coadministered with these drugs.</td>
</tr>
</tbody>
</table></div>
</div>"
"iohexol","164b27b9-97ae-4279-896f-1c4afa583dd1","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1	Drug-Drug Interactions</h2>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1.1,'></a>
<p></p>
<ul class=,'Disc,'>
<li>
<span class=,'Bold,'>Metformin</span>
</li>
</ul>
<p class=,'First,'>In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an estimated Glomerular Filtration Rate (eGFR) between 30 and 60 mL/min/1.73 m<span class=,'Sup,'>2</span>; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure, and reinstitute metformin only after renal function is stable.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1.2,'></a>
<p></p>
<ul class=,'Disc,'>
<li>
<span class=,'Bold,'>Radioactive Iodine</span>
</li>
</ul>
<p class=,'First,'>Administration of iodinated contrast agents may interfere with thyroid uptake of radioactive iodine (I-131 and I-123) and decrease therapeutic and diagnostic efficacy in patients with carcinoma of the thyroid. The decrease in efficacy lasts for 6-8 weeks.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1.3,'></a>
<p></p>
<ul class=,'Disc,'>
<li>
<span class=,'Bold,'>Beta-adrenergic Blocking Agents</span>
</li>
</ul>
<p class=,'First,'>The use of beta-adrenergic blocking agents lowers the threshold for and increases the severity of contrast reactions, and reduces the responsiveness of treatment of hypersensitivity reactions with epinephrine. Because of the risk of hypersensitivity reactions, use caution when administering OMNIPAQUE to patients taking beta-blockers.</p>
</div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Drug Laboratory Test Interactions</h2>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.1,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Underline,'>Effect on Thyroid Tests</span>
</p>
<p>If iodine-containing isotopes are to be administered for the diagnosis of thyroid disease, the iodine-binding capacity of thyroid tissue may be reduced for up to 2 weeks after contrast agent administration. Thyroid function tests which do not depend on iodine estimation, e.g., T<span class=,'Sub,'>3</span> resin uptake or direct thyroxine assays, are not affected.</p>
</div>
</div>
</div>"
"ipratropium bromide","050dbc2c-1d92-4f47-9155-895a43fa56d3","none found"
"isoflurane","13c9c37a-0c3d-450a-a61e-d2796818b18f","none found"
"isoniazid","0013c0c8-513a-48f3-a918-5bc1750c96a7","none found"
"isosorbide dinitrate","16818b32-ee5e-4e07-b848-31e892c4b98a","none found"
"isosorbide mononitrate","499e4a0c-ca87-42bf-b227-f13a59692db4","none found"
"itraconazole","23126370-8d6a-4027-bd8f-860e2776ba3a","none found"
"ivermectin","23bb1ccf-1a35-438d-a0df-3ecc4fa30033","none found"
"ketamine","0068df96-5465-4972-97d8-c9d198b2d7c1","none found"
"lactulose","0f19e4ed-c90a-4330-a7fa-bf911aa98f09","none found"
"lamivudine","253ca106-d120-4483-9e5c-41b164044c9d","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'_7_DRUG_INTERACTIONS,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Lamivudine is predominantly eliminated in the urine by active organic cationic secretion. The possibility of interactions with other drugs administered concurrently should be considered, particularly when their main route of elimination is active renal secretion via the organic cationic transport system (e.g., trimethoprim). No data are available regarding interactions with other drugs that have renal clearance mechanisms similar to that of lamivudine.</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1,'></a>
<p></p>
<h2>
<span class=,'Bold,'>7.1 Interferon- and Ribavirin-Based Regimens</span>
</h2>
<p class=,'First,'>Although no evidence of a pharmacokinetic or pharmacodynamic interaction (e.g., loss of HIV-1/HCV virologic suppression) was seen when ribavirin was coadministered with lamivudine in HIV-1/HCV co-infected patients, hepatic decompensation (some fatal) has occurred in HIV-1/HCV co-infected patients receiving combination antiretroviral therapy for HIV-1 and interferon alfa with or without ribavirin [see <a href=,'#_5_4_Use_With,'>Warnings and Precautions (5.4)</a>, <a href=,'#_12_3_Pharmacokinetics,'>Clinical Pharmacology (12.3)</a>].</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_7_2_Zalcitabine,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>
<span class=,'Bold,'>7.2 Zalcitabine</span>
</h2>
<p class=,'First,'>Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another. Therefore, use of lamivudine in combination with zalcitabine is not recommended. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_7_3_Trimethoprim_Sulfamethoxazole__,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>
<span class=,'Bold,'>7.3 Trimethoprim/Sulfamethoxazole (TMP/SMX)</span>
</h2>
<p class=,'First,'>No change in dose of either drug is recommended. There is no information regarding the effect on lamivudine pharmacokinetics of higher doses of TMP/SMX such as those used to treat PCP.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_7_4_Drugs_with,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>
<span class=,'Bold,'>7.4 Drugs with No Observed Interactions With Lamivudine</span>
</h2>
<p class=,'First,'>A drug interaction study showed no clinically significant interaction between lamivudine and zidovudine.</p>
</div>
</div>"
"lamotrigine","05405214-6215-432a-aa53-f7e03f35c7b1","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID110,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID253,'></a><a name=,'section-7.1,'></a>
<p></p>
<p class=,'First,'>
<a name=,'ID111,'></a>Significant drug interactions with lamotrigine are summarized in Table 13. Additional details of these drug interaction studies are provided in the Clinical Pharmacology section
                                    <span class=,'Italics,'>[see ].
                                        <a href=,'#ID146,'>Clinical Pharmacology (12.3)</a></span>
</p>
<a name=,'ID112,'></a>
<div class=,'scrollingtable,'><table width=,'100%,'>
<caption>
<span>Table 13. Established and Other Potentially Significant Drug Interactions</span>
</caption>
<col width=,'34%,'/>
<col width=,'33%,'/>
<col width=,'33%,'/>
<thead>
<tr class=,'First Last,'>
<td align=,'center,' class=,'Botrule Lrule Rrule Toprule,' colspan=,'1,' valign=,'top,'><span class=,'Bold,'>Concomitant </span><span class=,'Bold,'>Drug</span><span class=,'Bold,'>
<br/>
</span></td><td align=,'center,' class=,'Botrule Lrule Rrule Toprule,' colspan=,'1,' valign=,'top,'><span class=,'Bold,'>Effect </span><span class=,'Bold,'>on </span><span class=,'Bold,'>Concentration </span><span class=,'Bold,'>of </span><span class=,'Bold,'>Lamotrigine </span><span class=,'Bold,'>or </span><span class=,'Bold,'>
<br/>
</span><span class=,'Bold,'>Concomitant </span><span class=,'Bold,'>Drug</span><span class=,'Bold,'>
<br/>
</span></td><td align=,'center,' class=,'Botrule Lrule Rrule Toprule,' colspan=,'1,' valign=,'top,'><span class=,'Bold,'>Clinical </span><span class=,'Bold,'>Comment </span><span class=,'Bold,'>
<br/>
</span></td>
</tr>
</thead>
<tfoot>
<tr class=,'First Last,'>
<td align=,'left,' colspan=,'3,'>
<p class=,'First,'></p>
<p class=,'Footnote,'>↓= Decreased (induces lamotrigine gluronidation).
                                                    <br/>
</p>
<p class=,'Footnote,'>↑= Increased (inhibits lamotrigine glucuronidation).
                                                    <br/>
</p>
<p class=,'Footnote,'>?= Conflicting data.
                                                    <br/>
</p>
</td>
</tr>
</tfoot>
<tbody>
<tr class=,'First,'>
<td align=,'left,' class=,'Lrule Rrule Toprule,' valign=,'top,'>Estrogen-containing oral  contraceptive preparations  containing 30 mcg ethinylestradiol  and 150 mcg levonorgestrel
                                                <br/>
<br/>
<br/>
<br/>
</td><td align=,'center,' class=,'Lrule Rrule Toprule,' valign=,'top,'>↓ lamotrigine
                                                <br/>
<br/>
<br/>
<br/>
<br/>
</td><td align=,'center,' class=,'Lrule Rrule Toprule,' valign=,'top,'>Decreased lamotrigine levels  approximately 50%.
                                                <br/>
<br/>
<br/>
<br/>
<br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<br/>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>↓ levonorgestrel
                                                <br/>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>Decrease in levonorgestrel component by 19%.
                                                <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule Toprule,' valign=,'top,'>Carbamazepine (CBZ) and  CBZ epoxide
                                                <br/>
<br/>
</td><td align=,'center,' class=,'Lrule Rrule Toprule,' valign=,'top,'>↓ lamotrigine
                                                <br/>
<br/>
</td><td align=,'center,' class=,'Lrule Rrule Toprule,' valign=,'top,'>Addition of carbamazepine decreases lamotrigine  concentration approximately 40%.
                                                <br/>
<br/>
<br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<br/>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>? CBZ epoxide
                                                <br/>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>May increase CBZ epoxide levels
                                                <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Phenobarbital/Primidone
                                                <br/>
</td><td align=,'center,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↓ lamotrigine
                                                <br/>
</td><td align=,'center,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Decreased lamotrigine  concentration approximately 40%.
                                                <br/>
<br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Phenytoin (PHT)
                                                <br/>
</td><td align=,'center,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↓ lamotrigine
                                                <br/>
</td><td align=,'center,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Decreased lamotrigine  concentration approximately 40%
                                                <br/>
<br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Rifampin
                                                <br/>
</td><td align=,'center,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>↓ lamotrigine
                                                <br/>
</td><td align=,'center,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Decreased lamotrigine AUC  approximately 40%
                                                <br/>
<br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule Toprule,' valign=,'top,'>Valproate
                                                <br/>
</td><td align=,'center,' class=,'Lrule Rrule Toprule,' valign=,'top,'>↑ lamotrigine
                                                <br/>
<br/>
</td><td align=,'center,' class=,'Lrule Rrule Toprule,' valign=,'top,'>Increased lamotrigine concentrations slightly  more than 2-fold.
                                                <br/>
<br/>
<br/>
</td>
</tr>
<tr class=,'Last,'>
<td align=,'left,' class=,'Botrule Lrule Rrule,' valign=,'top,'>
<br/>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>? valproate
                                                <br/>
</td><td align=,'center,' class=,'Botrule Lrule Rrule,' valign=,'top,'>Decreased valproate concentrations an average of  25% over a 3-week period then stabilized in healthy volunteers;  no change in controlled clinical trials in epilepsy patients.
                                                <br/>
<br/>
<br/>
<br/>
</td>
</tr>
</tbody>
</table></div>
</div>
</div>"
"latanoprost","1fba56a6-c8dc-4f34-b05d-efdea75d2fea","none found"
"lenalidomide","5fa97bf5-28a2-48f1-8955-f56012d296be","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1	 Digoxin</h2>
<p class=,'First,'>When digoxin was co-administered with multiple doses of REVLIMID (10 mg/day) the digoxin C<span class=,'Sub,'>max</span> and AUC<span class=,'Sub,'>inf</span> were increased by 14%. Periodically monitor digoxin plasma levels, in accordance with clinical judgment and based on standard clinical practice in patients receiving this medication, during administration of REVLIMID.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2	Concomitant Therapies That May Increase the Risk of Thrombosis</h2>
<p class=,'First,'>Erythropoietic agents, or other agents that may increase the risk of thrombosis, such as estrogen containing therapies, should be used with caution after making a benefit-risk assessment in patients receiving REVLIMID <span class=,'Italics,'>[see <a href=,'#S5.4,'>Warnings and Precautions (5.4)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3	Warfarin</h2>
<p class=,'First,'>Co-administration of multiple doses of REVLIMID (10 mg/day) with a single dose of warfarin (25 mg) had no effect on the pharmacokinetics of lenalidomide or R- and S-warfarin. Expected changes in laboratory assessments of PT and INR were observed after warfarin administration, but these changes were not affected by concomitant REVLIMID administration. It is not known whether there is an interaction between dexamethasone and warfarin. Close monitoring of PT and INR is recommended in patients with MM taking concomitant warfarin.</p>
</div>
</div>"
"letrozole","35c73219-c39e-4e10-b944-76009b061e79","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'><span class=,'Bold,'>Tamoxifen </span></span>
<br/>
<br/> Coadministration of letrozole tablets and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels of 38% on average (study P015). Clinical experience in the second-line breast cancer trials (AR/BC2 and AR/BC3) indicates that the therapeutic effect of letrozole tablets therapy is not impaired if letrozole tablets is administered immediately after tamoxifen.<br/>
<br/>
<span class=,'Italics,'><span class=,'Bold,'>Cimetidine </span></span>
<br/>
<br/> A pharmacokinetic interaction study with cimetidine (study P0004) showed no clinically significant effect on letrozole pharmacokinetics. <br/>
<br/>
<span class=,'Italics,'><span class=,'Bold,'>Warfarin </span></span>
<br/>
<br/> An interaction study (P017) with warfarin showed no clinically significant effect of letrozole on warfarin pharmacokinetics. <br/>
<br/>
<span class=,'Italics,'><span class=,'Bold,'>Other anticancer agents <br/>
</span></span>
<br/> There is no clinical experience to date on the use of letrozole tablets in combination with other anticancer agents.</p>
</div>"
"levetiracetam","097e5606-dd5e-4518-ab97-f71f68786444","none found"
"levobunolol","5ab1efbe-530b-4787-b40a-c7dbf18161e1","none found"
"levocetirizine","1ceff0e6-1e66-4494-b986-1bd23eb6813e","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>In vitro</span> data indicate that levocetirizine is unlikely to produce pharmacokinetic interactions through inhibition or induction of liver drug-metabolizing enzymes. No <span class=,'Italics,'>in vivo</span> drug-drug interaction studies have been performed with levocetirizine. Drug interaction studies have been performed with racemic cetirizine.</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Antipyrine, Azithromycin, Cimetidine, Erythromycin, Ketoconazole, Theophylline, and Pseudoephedrine</h2>
<p class=,'First,'>Pharmacokinetic interaction studies performed with racemic cetirizine demonstrated that cetirizine did not interact with antipyrine, pseudoephedrine, erythromycin, azithromycin, ketoconazole, and cimetidine. There was a small decrease (~16%) in the clearance of cetirizine caused by a 400 mg dose of theophylline. It is possible that higher theophylline doses could have a greater effect.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Ritonavir</h2>
<p class=,'First,'>Ritonavir increased the plasma AUC of cetirizine by about 42% accompanied by an increase in half-life (53%) and a decrease in clearance (29%) of cetirizine. The disposition of ritonavir was not altered by concomitant cetirizine administration.</p>
</div>
</div>"
"levofloxacin","08bc9790-34b2-42d5-934d-3731b8005019","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID1037,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID1041,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins</h2>
<p class=,'First,'>While the chelation by divalent cations is less marked than with other fluoroquinolones, concurrent administration of levofloxacin Tablets with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc may interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. Tablets with antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamins preparations with zinc or didanosine may substantially interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. These agents should be taken at least two hours before or two hours after oral levofloxacin administration.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID1043,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Warfarin</h2>
<p class=,'First,'>No significant effect of levofloxacin on the peak plasma concentrations, AUC, and other disposition parameters for R- and S- warfarin was detected in a clinical study involving healthy volunteers. Similarly, no apparent effect of warfarin on levofloxacin absorption and disposition was observed. However, there have been reports during the postmarketing experience in patients that levofloxacin enhances the effects of warfarin. Elevations of the prothrombin time in the setting of concurrent warfarin and levofloxacin use have been associated with episodes of bleeding. Prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests should be closely monitored if levofloxacin is administered concomitantly with warfarin. Patients should also be monitored for evidence of bleeding <span class=,'Italics,'>[see</span> <span class=,'Italics,'>Adverse</span> <span class=,'Italics,'>Reactions</span> <span class=,'Italics,'>(<a href=,'#ID895,'>6.3</a>);</span> <span class=,'Italics,'>Patient</span> <span class=,'Italics,'>Counseling</span> <span class=,'Italics,'>Information</span> <span class=,'Italics,'>(<a href=,'#_Ref,'>17.4</a>)].</span> </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID1045,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Antidiabetic Agents</h2>
<p class=,'First,'>Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with fluoroquinolones and an antidiabetic agent. Therefore, careful monitoring of blood glucose is recommended when these agents are co-administered <span class=,'Italics,'>[see</span> <span class=,'Italics,'>Warnings</span> <span class=,'Italics,'>and</span> <span class=,'Italics,'>Precautions</span> <span class=,'Italics,'>(<a href=,'#ID877,'>5.12</a>);</span> <span class=,'Italics,'>Adverse</span> <span class=,'Italics,'>Reactions</span> <span class=,'Italics,'>(<a href=,'#ID890,'>6.2</a>)</span>, <span class=,'Italics,'>Patient</span> <span class=,'Italics,'>Counseling</span> <span class=,'Italics,'>Information</span> <span class=,'Italics,'>(<a href=,'#_Ref,'>17.4</a>)].</span> </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID1047,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Non-Steriodal Anti-Inflammatory Drugs</h2>
<p class=,'First,'>The concomitant administration of a non-steroidal anti-inflammatory drug with a fluoroquinolone, including levofloxacin, may increase the risk of CNS stimulation and convulsive seizures <span class=,'Italics,'>[see</span> <span class=,'Italics,'>Warnings</span> <span class=,'Italics,'>and</span> <span class=,'Italics,'>Precautions</span> <span class=,'Italics,'>(<a href=,'#ID867,'>5.4</a>)].</span> </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID1049,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Theophylline</h2>
<p class=,'First,'>No significant effect of levofloxacin on the plasma concentrations, AUC, and other disposition parameters for theophylline was detected in a clinical study involving healthy volunteers. Similarly, no apparent effect of theophylline on levofloxacin absorption and disposition was observed. However, concomitant administration of other fluoroquinolones with theophylline has resulted in prolonged elimination half-life, elevated serum theophylline levels, and a subsequent increase in the risk of theophylline-related adverse reactions in the patient population. Therefore, theophylline levels should be closely monitored and appropriate dosage adjustments made when levofloxacin is co-administered. Adverse reactions, including seizures, may occur with or without an elevation in serum theophylline levels <span class=,'Italics,'>[see</span> <span class=,'Italics,'>Warnings</span> <span class=,'Italics,'>and</span> <span class=,'Italics,'>Precautions</span> <span class=,'Italics,'>(<a href=,'#ID867,'>5.4</a>)].</span> </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID1051,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6 Cyclosporine</h2>
<p class=,'First,'>No significant effect of levofloxacin on the peak plasma concentrations, AUC, and other disposition parameters for cyclosporine was detected in a clinical study involving healthy volunteers. However, elevated serum levels of cyclosporine have been reported in the patient population when co-administered with some other fluoroquinolones. Levofloxacin C<span class=,'Sub,'>max</span> and k<span class=,'Sub,'>e</span> were slightly lower while T<span class=,'Sub,'>max</span> and t½ were slightly longer in the presence of cyclosporine than those observed in other studies without concomitant medication. The differences, however, are not considered to be clinically significant. Therefore, no dosage adjustment is required for levofloxacin or cyclosporine when administered concomitantly.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID1053,'></a><a name=,'section-7.7,'></a>
<p></p>
<h2>7.7 Digoxin</h2>
<p class=,'First,'>No significant effect of levofloxacin on the peak plasma concentrations, AUC, and other disposition parameters for digoxin was detected in a clinical study involving healthy volunteers. Levofloxacin absorption and disposition kinetics were similar in the presence or absence of digoxin. Therefore, no dosage adjustment for levofloxacin or digoxin is required when administered concomitantly.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID1055,'></a><a name=,'section-7.8,'></a>
<p></p>
<h2>7.8 Probenecid and Cimetidine</h2>
<p class=,'First,'>No significant effect of probenecid or cimetidine on the C<span class=,'Sub,'>max</span> of levofloxacin was observed in a clinical study involving healthy volunteers. The AUC and t½ of levofloxacin were higher while CL/F and CL<span class=,'Sub,'>R</span> were lower during concomitant treatment of levofloxacin with probenecid or cimetidine compared to levofloxacin alone. However, these changes do not warrant dosage adjustment for levofloxacin when probenecid or cimetidine is co-administered.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID1057,'></a><a name=,'section-7.9,'></a>
<p></p>
<h2>7.9 Interactions with Laboratory or Diagnostic Testing</h2>
<p class=,'First,'>Some fluoroquinolones, including levofloxacin, may produce false-positive urine screening results for opiates using commercially available immunoassay kits. Confirmation of positive opiate screens by more specific methods may be necessary.</p>
</div>
</div>"
"levonorgestrel","0518a86b-af59-455e-b834-04fa8b20a637","none found"
"levothyroxine","3177aea1-c0c6-4ae1-b20e-3ca66a949e2c","none found"
"lidocaine","21ef5e41-7b70-c913-803b-98b37271180d","none found"
"linagliptin","b1da67d4-51e0-41b7-9fe1-7f38c0d1baa1","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1  Inducers of P-glycoprotein or CYP3A4 Enzymes</h2>
<p class=,'First,'>Rifampin decreased linagliptin exposure, suggesting that the efficacy of TRADJENTA may be reduced when administered in combination with a strong P-gp or CYP3A4 inducer. Therefore, use of alternative treatments is strongly recommended when linagliptin is to be administered with a strong P-gp or CYP3A4 inducer <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2  Insulin Secretagogues or Insulin</h2>
<p class=,'First,'>Coadministration of TRADJENTA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia <span class=,'Italics,'>[see <a href=,'#S5.3,'>Warnings and Precautions (5.3)</a>]</span>.</p>
</div>
</div>"
"linezolid","02192109-08e9-428a-bc5e-c606c2870b0d","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1	Monoamine Oxidase Inhibitors</h2>
<p class=,'First,'>Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. [<span class=,'Italics,'>see <a href=,'#S4.2,'>Contraindications (4.2)</a> and <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2	Adrenergic and Serotonergic Agents</h2>
<p class=,'First,'>Linezolid has the potential for interaction with adrenergic and serotonergic agents. [<span class=,'Italics,'>see <a href=,'#S5.3,'>Warnings and Precautions (5.3</a>, <a href=,'#S5.6,'>5.6)</a> and <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a></span>].</p>
</div>
</div>"
"liraglutide","1d18f106-0584-4fee-97ab-32771a64b809","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'i4i_interactions_id_5f716f18-4733-40e5-bcc6-608d33df7372,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_053b0e6a-1127-4aec-ae1e-72138872aeef,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Oral Medications</h2>
<p class=,'First,'>VICTOZA causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. In clinical pharmacology trials, VICTOZA did not affect the absorption of the tested orally administered medications to any clinically relevant degree. Nonetheless, caution should be exercised when oral medications are concomitantly administered with VICTOZA.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_5795780e-fa0e-44bd-a740-7e1b87f35ca1,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin </h2>
<p class=,'First,'>When initiating VICTOZA, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia <span class=,'Italics,'>[see <a href=,'#i4i_warnings_precautions_id_243b9c34-5373-46ae-babd-5a0c97d984dd,'>Warnings and Precautions</a> (<a href=,'#i4i_section_id_a7fd0763-ead5-4e34-aadf-fe9cd4e9068f,'>5.4</a>) and <a href=,'#i4i_adverse_effects_id_69c44aa3-32cf-4760-a646-ef06abdcf555,'>Adverse Reactions</a> (<a href=,'#i4i_adverse_effects_id_69c44aa3-32cf-4760-a646-ef06abdcf555,'>6</a>)].</span>
</p>
</div>
</div>"
"lisinopril","02c23f9c-f3cf-4366-ae1e-56296f1fedf9","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'s7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Diuretics</h2>
<p class=,'First,'>Initiation of lisinopril in patients on diuretics may result in excessive reduction of blood pressure. The possibility of hypotensive effects with lisinopril can be minimized by either decreasing or discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If this is not possible, reduce the starting dose of lisinopril<span class=,'Italics,'> [see <a href=,'#s2.2,'>Dosage and Administration (2.2)</a> and <a href=,'#s5.4,'>Warnings and Precautions (5.4)</a>]</span>.</p>
<p>Lisinopril attenuates potassium loss caused by thiazide-type diuretics. Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, monitor the patient’s serum potassium frequently.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Antidiabetics</h2>
<p class=,'First,'>Concomitant administration of lisinopril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)</h2>
<p class=,'First,'>In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including lisinopril, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.</p>
<p>The antihypertensive effect of ACE inhibitors, including lisinopril, may be attenuated by NSAIDs.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7.4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Dual Blockade of the Renin-Angiotensin System (RAS)</h2>
<p class=,'First,'>Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.<br/>
<br/>The VA NEPHRON trial enrolled 1448 patients with type 2 diabetes, elevated urinary-albumin-to-creatinine ratio, and decreased estimated glomerular filtration rate (GFR 30 to 89.9 ml/min), randomized them to lisinopril or placebo on a background of losartan therapy and followed them for a median of 2.2 years. Patients receiving the combination of losartan and lisinopril did not obtain any additional benefit compared to monotherapy for the combined endpoint of decline in GFR, end state renal disease, or death, but experienced an increased incidence of hyperkalemia and acute kidney injury compared with the monotherapy group. <br/>
<br/>In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on lisinopril and other agents that affect the RAS.</p>
<p>Do not co-administer aliskiren with lisinopril in patients with diabetes. Avoid use of aliskiren with lisinopril in patients with renal impairment (GFR &lt;60 ml/min).</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7.5,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Lithium</h2>
<p class=,'First,'>Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs, which cause elimination of sodium, including ACE inhibitors. Lithium toxicity was usually reversible upon discontinuation of lithium and the ACE inhibitor. Monitor serum lithium levels during concurrent use. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7.6,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6 Gold</h2>
<p class=,'First,'>Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including lisinopril.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'L79523a31-61ec-49e3-a34b-b0e1d7ff96a4,'></a><a name=,'section-7.7,'></a>
<p></p>
<h2>7.7 mTOR Inhibitors</h2>
<p class=,'First,'>Patients taking concomitant mTOR inhibitor (e.g. temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema.<span class=,'Italics,'> [see <a href=,'#s5.2,'>Warnings and Precautions (5.2)</a>]</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_3d9358ad-fd64-4e1f-bc66-69ce1b1bbbfa,'></a><a name=,'section-7.8,'></a>
<p></p>
<h2>7.8 Neprilysin Inhibitor   </h2>
<p class=,'First,'>Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema. <span class=,'Italics,'>[<a href=,'#s5.2,'>see Warnings and Precautions (5.2)</a>]</span>
</p>
</div>
</div>"
"lithium carbonate","083ca85f-a450-4fe9-973e-47a13cd18dd1","none found"
"loratadine","00608f79-20db-4a7d-a204-89779f01ad48","none found"
"lorazepam","0007892c-8c17-400d-b820-020aa32f433b","none found"
"lovastatin","027bd594-6a0a-4e6d-bd3c-4f33fdb4166a","none found"
"medroxyprogesterone","1403a9a9-c04a-432f-8819-4850f779312e","none found"
"medroxyprogesterone","1403a9a9-c04a-432f-8819-4850f779312e","none found"
"medroxyprogesterone acetate","0930a471-6ff1-43a1-b3ea-948ca3f99d06","none found"
"mefenamic acid","4c275df4-f044-4867-8498-f46d34103bbb","none found"
"mefloquine","09716a24-d7da-42b2-af29-c03a1b6670bd","none found"
"meloxicam","0060d1b1-4cfc-4b69-86a8-9bd44a071e94","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'i4i_interactions_id_32410517-f8d4-4354-bc88-6ecfb99302dc,'></a><a name=,'section-8,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_60f864a6-43a7-4379-a58d-756cd576e4b0,'></a><a name=,'section-8.1,'></a>
<p></p>
<p class=,'First,'>See also <span class=,'Bold,'>Clinical Pharmacology (<a href=,'#i4i_pharmacokinetics_id_019296f0-66ef-4820-8829-df91956cb2d0,'>12.3</a>). </span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_b6e54e60-2275-4283-8b4e-5f04a00d3dc3,'></a><a name=,'section-8.2,'></a>
<p></p>
<h2>7.1 ACE-inhibitors</h2>
<p class=,'First,'>NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking meloxicam concomitantly with ACE-inhibitors. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_6802bad1-54d3-46d2-bd19-0cacf4670d31,'></a><a name=,'section-8.3,'></a>
<p></p>
<h2>7.2 Aspirin</h2>
<p class=,'First,'>When meloxicam is administered with aspirin (1000 mg three times daily) to healthy volunteers, an increase the AUC (10%) and C<span class=,'Sub,'>max</span> (24%) of meloxicam was noted. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. </p>
<p>Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a substitute for aspirin for cardiovascular prophylaxis. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_720ceea9-3045-4ce3-ac48-2ee53485c4a0,'></a><a name=,'section-8.4,'></a>
<p></p>
<h2>7.3 Diuretics</h2>
<p class=,'First,'>Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. However, studies with furosemide agents and meloxicam have not demonstrated a reduction in natriuretic effect. Furosemide single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of meloxicam. Nevertheless, during concomitant therapy with meloxicam, patients should be observed closely for signs of renal failure [see <span class=,'Bold,'>WARNINGS AND PRECAUTIONS (<a href=,'#i4i_section_id_00424c6f-9c8d-46ae-b2e0-40ba7336cfc4,'>5.6</a>)], </span>as well as to ensure diuretic efficacy. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_12da9b88-50f9-480e-99f2-0c3e4854b5d1,'></a><a name=,'section-8.5,'></a>
<p></p>
<h2>7.4 Lithium</h2>
<p class=,'First,'>In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg twice daily with meloxicam 15 mg every day as compared to subjects receiving lithium alone. These effects have been attributed to inhibition of renal prostaglandin synthesis by meloxicam. Closely monitor patients on lithium treatment for signs of lithium toxicity when meloxicam is introduced, adjusted, or withdrawn. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_6bfcdd71-8927-49dc-90ad-d0b225533b2a,'></a><a name=,'section-8.6,'></a>
<p></p>
<h2>7.5 Methotrexate</h2>
<p class=,'First,'>NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. Therefore, NSAIDs may reduce the elimination of methotrexate, thereby enhancing the toxicity of methotrexate. Use caution when meloxicam is administered concomitantly with methotrexate [see <span class=,'Bold,'>CLINICAL PHARMACOLOGY (<a href=,'#i4i_pharmacokinetics_id_019296f0-66ef-4820-8829-df91956cb2d0,'>12.3</a>)]. </span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_ab460026-6988-40a2-8946-bc181113bdb1,'></a><a name=,'section-8.7,'></a>
<p></p>
<h2>7.6 Cyclosporine</h2>
<p class=,'First,'>Meloxicam, like other NSAIDs, may affect renal prostaglandins, thereby altering the renal toxicity of certain drugs. Therefore, concomitant therapy with meloxicam may increase cyclosporine's nephrotoxicity. Use caution when meloxicam is administered concomitantly with cyclosporine. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_06e381b9-2bc2-43e5-b423-74188463494e,'></a><a name=,'section-8.8,'></a>
<p></p>
<h2>7.7 Warfarin</h2>
<p class=,'First,'>The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone. </p>
<p>Monitor anticoagulant activity, particularly in the first few days after initiating or changing meloxicam therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding than with the use of either drug alone. Use caution when administering meloxicam with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced [see <span class=,'Bold,'>CLINICAL PHARMACOLOGY (<a href=,'#i4i_pharmacokinetics_id_019296f0-66ef-4820-8829-df91956cb2d0,'>12.3</a>)].</span>
</p>
</div>
</div>"
"melphalan","02b34eda-6390-43e2-b299-c7d99850610a","none found"
"memantine","304a3059-4f7f-4ec4-839d-86492bb5e07b","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'DRUG_INTERACTIONS,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_5df13f1a-6c0c-aaa3-4cf0-4dbe1451ad73,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Drugs that Make the Urine Alkaline</h2>
<p class=,'First,'>The clearance of memantine was reduced by about 80% under alkaline urine conditions at pH 8. Therefore, alterations of urine pH towards the alkaline condition may lead to an accumulation of the drug with a possible increase in adverse effects. Urine pH is altered by diet, drugs (e.g., carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g., renal tubular acidosis or severe infections of the urinary tract). Hence, memantine should be used with caution under these conditions.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_4d97a629-0845-541d-620c-a5867d33f6a5,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Use with Other N-methyl-D-aspartate (NMDA) Antagonists</h2>
<p class=,'First,'>The combined use of memantine hydrochloride with other NMDA antagonists (amantadine, ketamine, and dextromethorphan) has not been systematically evaluated and such use should be approached with caution.</p>
</div>
</div>"
"mercaptopurine","15904472-4c32-4224-95d3-eb131a7ff9c8","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID_239d3e7f-1b20-4ed4-bee2-bea747c1ebc5,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_0ee61f0e-9ed1-4817-9ae2-2a16f9fa4c0b,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1	Allopurinol  </h2>
<p class=,'First,'>Allopurinol can inhibit the first-pass oxidative metabolism of mercaptopurine by xanthine oxidase, which can lead to an increased risk of mercaptopurine adverse reactions (i.e., myelosuppression, nausea, and vomiting) <span class=,'Italics,'>[see <a href=,'#ID_5b7ca743-e272-49eb-b06f-d8aa29349acc,'>Warnings and Precautions (5.1)</a>, <a href=,'#ID_00f84b8b-1f8f-4650-9099-8e1c121f67d3,'>Adverse Reactions (6.1)</a>]</span>. Reduce the dose of mercaptopurine tablets when coadministered with allopurinol <span class=,'Italics,'>[see <a href=,'#ID_7729bf9d-d50f-4c5f-a3f7-8f1f99e8bc63,'>Dosage and Administration (2.4)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_7641fac2-289b-4ae5-bafc-ff277064370e,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2	Warfarin  </h2>
<p class=,'First,'>The concomitant administration of mercaptopurine tablets and warfarin may decrease the anticoagulant effectiveness of warfarin. Monitor the international normalized ratio (INR) in patients receiving warfarin and adjust the warfarin dosage as appropriate. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_5ed1c58a-4de7-49a9-9f9a-6a456652a87b,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3	Myelosuppressive Products  </h2>
<p class=,'First,'>Mercaptopurine tablets can cause myelosuppression. Myelosuppression may be increased when mercaptopurine tablets are coadministered with other products that cause myelosuppression. Enhanced myelosuppression has been noted in some patients also receiving trimethoprim-sulfamethoxazole. Monitor the CBC and adjust the dose of mercaptopurine tablets for excessive myelosuppression <span class=,'Italics,'>[see <a href=,'#ID_6cd83867-14b0-448f-a1ab-ab96b6b8df41,'>Dosage and Administration (2.1)</a>, <a href=,'#ID_5b7ca743-e272-49eb-b06f-d8aa29349acc,'>Warnings and Precautions (5.1)</a>]</span>. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_7bec32a5-b81b-414c-b540-4c3cb03bfdbe,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4	Aminosalicylates  </h2>
<p class=,'First,'>Aminosalicylates (e.g., mesalamine, olsalazine or sulfasalazine) may inhibit the TPMT enzyme, which may increase the risk of myelosuppression when coadministered with mercaptopurine tablets. When aminosalicylates and mercaptopurine tablets are coadministered, use the lowest possible doses for each drug and monitor more frequently for myelosuppression <span class=,'Italics,'>[see <a href=,'#ID_5b7ca743-e272-49eb-b06f-d8aa29349acc,'>Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_2d701531-f66e-4dff-b6ae-75550c1479d7,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5	Hepatotoxic Products  </h2>
<p class=,'First,'>Mercaptopurine tablets can cause hepatotoxicity. Hepatotoxicity may be increased when mercaptopurine tablets are coadministered with other products that cause hepatotoxicity. Monitor liver tests more frequently in patients who are receiving mercaptopurine tablets with other hepatotoxic products <span class=,'Italics,'>[see <a href=,'#ID_bfef2dcf-ce51-481d-9c8e-ed6f0da20250,'>Warnings and Precautions (5.2)</a>]</span>. </p>
</div>
</div>"
"meropenem","06d84c55-94ff-46e5-8477-b8881c12eb0a","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 	Probenecid</h2>
<p class=,'First,'>Probenecid competes with meropenem for active tubular secretion, resulting in increased plasma concentrations of meropenem. Co-administration of probenecid with meropenem is not recommended.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 	Valproic Acid</h2>
<p class=,'First,'>Case reports in the literature have shown that co-administration of carbapenems, including meropenem, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures. Although the mechanism of this interaction is unknown, data from in vitro and animal studies suggest that carbapenems may inhibit the hydrolysis of valproic acid's glucuronide metabolite (VPA-g) back to valproic acid, thus decreasing the serum concentrations of valproic acid. If administration of Meropenem for Injection, USP is necessary, then supplemental anti-convulsant therapy should be considered <span class=,'Italics,'>[see <a href=,'#S5.4,'>Warnings and Precautions (5.4)</a>].</span>
</p>
</div>
</div>"
"mesalamine","b2a5b110-7537-4ffc-bf0a-f0fe13379c9d","none found"
"mesna","2a2a526f-636b-7920-4261-6c626f612a2a","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'s24,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>No clinical drug interaction studies have been conducted with mesna.
</p>
</div>"
"metformin","06ade2e1-5981-4e3d-b7e9-7ff083eb4551","none found"
"methimazole","06833532-64c2-439a-a4ee-ed30989b61e4","none found"
"methotrexate","02862eb3-5508-4ea9-99fb-262551b6beeb","none found"
"methoxy polyethylene glycol-epoetin beta","22c56f2a-f73c-60e7-e054-00144ff88e88","none found"
"methyldopa","00206aae-7db1-4ae9-8500-b03fd6788d74","none found"
"methylphenidate","7d66dbf9-3966-4949-b7c9-d2ca8c7f3278","none found"
"methylprednisolone","01f0126c-da22-4ac0-8755-3bc589602e6a","none found"
"methylene blue","fde64824-2be5-4d85-8d57-5098ca6890bb","none found"
"metoclopramide","014551c8-5610-4445-9e65-b25cb3ef0657","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_d54086d8-283d-4481-8e98-7ec01c7cca80,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_d11afc82-dd79-4ced-932f-b2fe6f63e34e,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Effects of Other Drugs on Metoclopramide</h2>
<p class=,'First,'>Table 3 displays the effects of other drugs on metoclopramide.</p>
<div class=,'scrollingtable,'><table>
<caption>
<span>Table 3. Effects of Other Drugs on Metoclopramide</span>
</caption>
<col width=,'21%,'/>
<col width=,'79%,'/>
<tbody class=,'Headless,'>
<tr class=,'First,'>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Antipsychotics</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Potential for additive effects, including increased frequency and severity of tardive dyskinesia (TD), other extrapyramidal symptoms (EPS), and neuroleptic malignant syndrome (NMS).</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Avoid concomitant use [<span class=,'Italics,'>see Warnings and Precautions (<a href=,'#LINK_980cb187-87a2-4e2a-b367-a358259738f0,'>5.1</a>, <a href=,'#LINK_7dd04353-125b-42cf-b77d-fa62ad4dfdd7,'>5.2</a>, <a href=,'#LINK_31388884-1b23-4bc4-a985-9e06cf3ca731,'>5.3</a>)</span>].</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Strong CYP2D6 Inhibitors, not Included in Antipsychotic Category Above</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Increased plasma concentrations of metoclopramide; risk of exacerbation of extrapyramidal symptoms [<span class=,'Italics,'>see Clinical Pharmacology (<a href=,'#LINK_ac86103b-35d6-4eca-801b-c29662347ce8,'>12.3</a>)</span>].</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Reduce the metoclopramide dosage [<span class=,'Italics,'>see Dosage and Administration (<a href=,'#LINK_0e8c2d7d-593d-4d30-bf25-0d4483df1bae,'>2.2</a>, <a href=,'#LINK_1593d6b9-9dc2-45dc-8b13-24b36853fae7,'>2.3</a>)</span>].</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Examples</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>quinidine, bupropion, fluoxetine, and paroxetine</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Monoamine Oxidase Inhibitors</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Increased risk of hypertension [<span class=,'Italics,'>see Warnings and Precautions (<a href=,'#LINK_70927ef6-07ea-48bc-ac1b-f7f705db0b9f,'>5.5</a>)</span>].</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Avoid concomitant use.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Central Nervous System (CNS) Depressants</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Increased risk of CNS depression [<span class=,'Italics,'>see Warnings and Precautions (<a href=,'#LINK_2c226615-81ce-41a1-b4e0-1581ffec1b42,'>5.8</a>)</span>].</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Avoid metoclopramide or the interacting drug, depending on the importance of the drug to the patient.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Examples</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>alcohol, sedatives, hypnotics, opiates and anxiolytics</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Drugs that Impair Gastrointestinal Motility</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Decreased systemic absorption of metoclopramide.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Monitor for reduced therapeutic effect.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Examples</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>antiperistaltic antidiarrheal drugs, anticholinergic drugs, and opiates</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Dopaminergic Agonists and Other Drugs that Increase Dopamine Concentrations</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Decreased therapeutic effect of metoclopramide due to opposing effects on dopamine.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Monitor for reduced therapeutic effect.</p>
</td>
</tr>
<tr class=,'Last,'>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Examples</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>apomorphine, bromocriptine, cabergoline, levodopa, pramipexole, ropinirole, and rotigotine</p>
</td>
</tr>
</tbody>
</table></div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_3907b727-e574-472a-9e5a-7344669f71e5,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Effects of Metoclopramide on Other Drugs</h2>
<p class=,'First,'>Table 4 displays the effects of metoclopramide on other drugs.</p>
<div class=,'scrollingtable,'><table>
<caption>
<span>Table 4. Effects of Metoclopramide on Other Drugs</span>
</caption>
<col width=,'21%,'/>
<col width=,'79%,'/>
<tfoot>
<tr>
<td align=,'left,' colspan=,'2,'>
<dl class=,'Footnote,'>
<dt>
<a href=,'#footnote-reference-3,' name=,'footnote-3,'>*</a>
</dt>
<dd>Interaction does not apply to posaconazole delayed-release tablets</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody class=,'Headless,'>
<tr class=,'First,'>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Dopaminergic Agonists and Drugs Increasing Dopamine Concentrations</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Opposing effects of metoclopramide and the interacting drug on dopamine. Potential exacerbation of symptoms (e.g., parkinsonian symptoms).</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Avoid concomitant use [<span class=,'Italics,'>see Warnings and Precautions (<a href=,'#LINK_7dd04353-125b-42cf-b77d-fa62ad4dfdd7,'>5.2</a>)</span>].</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Examples</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Apomorphine, bromocriptine, cabergoline, levodopa, pramipexole, ropinirole, rotigotine</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Succinylcholine, Mivacurium</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Metoclopramide inhibits plasma cholinesterase leading to enhanced neuromuscular blockade.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Monitor for signs and symptoms of prolonged neuromuscular blockade</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Drugs with Absorption Altered due to Increased Gastrointestinal Motility</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>The effect of metoclopramide on other drugs is variable. Increased gastrointestinal (GI) motility by metoclopramide may impact absorption of other drugs leading to decreased or increased drug exposure.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Drugs with Decreased Absorption (e.g., digoxin, atovaquone, posaconazole oral suspension</span><a class=,'Sup,' href=,'#footnote-3,' name=,'footnote-reference-3,'>*</a><span class=,'Underline,'>, fosfomycin)</span>: Monitor for reduced therapeutic effect of the interacting drug. For digoxin monitor therapeutic drug concentrations and increase the digoxin dose as needed (see prescribing information for digoxin).</p>
<p>
<span class=,'Underline,'>Drugs with Increased Absorption (e.g., sirolimus, tacrolimus, cyclosporine)</span>: Monitor therapeutic drug concentrations and adjust the dose as needed. See prescribing information for the interacting drug.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Insulin</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Increased GI motility by metoclopramide may increase delivery of food to the intestines and increase blood glucose.</p>
</td>
</tr>
<tr class=,'Last,'>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Monitor blood glucose and adjust insulin dosage regimen as needed.</p>
</td>
</tr>
</tbody>
</table></div>
</div>
</div>"
"metronidazole","0030514f-879d-416d-b422-24b67e334b36","none found"
"miconazole","a44c3b24-dae2-4993-a49f-71e4eb63b231","none found"
"midazolam","365bd582-21ca-451e-bc8a-f59f29f63ed6","none found"
"miltefosine","bcb387ac-2e90-4f5e-94b2-d3635190678e","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>In vitro</span> and animal metabolism studies showed that miltefosine did not markedly induce or inhibit the activity of the major human cytochrome P450 enzymes <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#S12.3,'>12.3</a>)]</span>.  The potential of miltefosine to interact with drug transporters has not been evaluated.  </p>
</div>"
"minocycline","37baf13f-cc65-44a1-93d9-e5213875af1a","none found"
"mirabegron","aaaf3bea-1b21-4edf-9300-b7159ea9ede8","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID_f90dfb9d-13b7-40bc-8627-76ee13463948,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Drug interaction studies were conducted to investigate the effect of co-administered drugs on the pharmacokinetics of mirabegron and the effect of mirabegron on the pharmacokinetics of co-administered drugs (e.g., ketoconazole, rifampin, solifenacin succinate, tamsulosin, and oral contraceptives) <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#ID_e4c6545e-a259-489f-8908-c6023494e0b5,'>12.3</a>)]</span>. No dose adjustment is recommended when these drugs are co-administered with mirabegron.</p>
<p>The following are drug interactions for which monitoring is recommended:</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_51b99841-cb66-4948-8876-9ff28651dba8,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Drugs Metabolized by CYP2D6 </h2>
<p class=,'First,'>Since mirabegron is a moderate CYP2D6 inhibitor, the systemic exposure of drugs metabolized by CYP2D6 enzyme, such as metoprolol and desipramine, is increased when co-administered with mirabegron. Therefore, appropriate monitoring and dose adjustment may be necessary when MYRBETRIQ is co-administered with these drugs, especially with narrow therapeutic index CYP2D6 substrates, such as thioridazine, flecainide, and propafenone <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#ID_43ceef13-9860-4153-b0f1-811e2cbf289b,'>5.4</a>) and Clinical Pharmacology (<a href=,'#ID_e4c6545e-a259-489f-8908-c6023494e0b5,'>12.3</a>)]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_76821fc5-6cb2-4498-990b-6e97ac85439c,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Digoxin </h2>
<p class=,'First,'>When given in combination, 100 mg mirabegron increased mean digoxin C<span class=,'Sub,'>max</span> from 1.01 to 1.3 ng/mL (29%) and AUC from 16.7 to 19.3 ng.h/mL (27%). Concomitant administration of 0.25 mg digoxin with a combination of 5 mg solifenacin and 50 mg mirabegron increased digoxin AUC<span class=,'Sub,'>tau</span> and C<span class=,'Sub,'>max</span> by approximately 10% and 14%, respectively. For patients who are initiating a combination of mirabegron and digoxin, the lowest dose for digoxin should initially be considered. Serum digoxin concentrations should be monitored and used for titration of the digoxin dose to obtain the desired clinical effect <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#ID_e4c6545e-a259-489f-8908-c6023494e0b5,'>12.3</a>)]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_9ed3b02f-366c-4e70-93cb-924454482c1a,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Warfarin </h2>
<p class=,'First,'>The mean C<span class=,'Sub,'>max</span> of S- and R-warfarin was increased by approximately 4% and AUC by approximately 9% when administered as a single dose of 25 mg after multiple doses of 100 mg mirabegron. Following a single dose administration of 25 mg warfarin, mirabegron had no effect on the warfarin pharmacodynamic endpoints such as International Normalized Ratio (INR) and prothrombin time. However, the effect of mirabegron on multiple doses of warfarin and on warfarin pharmacodynamic end points such as INR and prothrombin time has not been fully investigated <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#ID_e4c6545e-a259-489f-8908-c6023494e0b5,'>12.3</a>)]</span>.</p>
</div>
</div>"
"mirtazapine","310d8699-2c46-44e8-8c5f-79f01517a4a6","none found"
"misoprostol","14f73ae3-7d8d-4d10-b668-8bd5adf8032c","none found"
"modafinil","01f6690c-1410-42ad-8eb3-e7df32eab3ba","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID_f6b0ef82-0409-4c77-be07-975f215a8c5b,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Underline,'>Effects of Modafinil on CYP3A4/5 Substrates</span>
</p>
<p>The clearance of drugs that are substrates for CYP3A4/5 (e.g., steroidal contraceptives, cyclosporine, midazolam, and triazolam) may be increased by modafinil via induction of metabolic enzymes, which results in lower systemic exposure. Dosage adjustment of these drugs should be considered when these drugs are used concomitantly with modafinil <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#ID_c746ca5e-5348-45ec-800f-59442a9385db,'>12.3</a>)]</span>.</p>
<p>The effectiveness of steroidal contraceptives may be reduced when used with modafinil and for one month after discontinuation of therapy. Alternative or concomitant methods of contraception are recommended for patients taking steroidal contraceptives (e.g., ethinyl estradiol) when treated concomitantly with modafinil and for one month after discontinuation of modafinil treatment.</p>
<p>Blood levels of cyclosporine may be reduced when used with modafinil. Monitoring of circulating cyclosporine concentrations and appropriate dosage adjustment for cyclosporine should be considered when used concomitantly with modafinil.</p>
<p>
<span class=,'Underline,'>Effects of Modafinil on CYP2C19 Substrates</span>
</p>
<p>Elimination of drugs that are substrates for CYP2C19 (e.g., phenytoin, diazepam, propranolol, omeprazole, and clomipramine) may be prolonged by modafinil via inhibition of metabolic enzymes, with resultant higher systemic exposure. In individuals deficient in the CYP2D6 enzyme, the levels of CYP2D6 substrates which have ancillary routes of elimination through CYP2C19, such as tricyclic antidepressants and selective serotonin reuptake inhibitors, may be increased by co-administration of modafinil. Dose adjustments of these drugs and other drugs that are substrates for CYP2C19 may be necessary when used concomitantly with modafinil <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#ID_c746ca5e-5348-45ec-800f-59442a9385db,'>12.3</a>)]</span>.</p>
<p>
<span class=,'Underline,'>Warfarin</span>
</p>
<p>More frequent monitoring of prothrombin times/INR should be considered whenever modafinil is coadministered with warfarin <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#ID_c746ca5e-5348-45ec-800f-59442a9385db,'>12.3</a>)]</span>.</p>
<p>
<span class=,'Underline,'>Monoamine Oxidase (MAO) Inhibitors </span>
</p>
<p>Caution should be used when concomitantly administering MAO inhibitors and modafinil.</p>
</div>"
"mometasone","015a259c-a0cb-4440-b8f2-0a31aa76fb88","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>No drug-drug interaction studies have been conducted with mometasone furoate cream.</p>
</div>"
"montelukast","4c411d3e-47b6-481b-b846-419ed4cbb947","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>No dose adjustment is needed when montelukast sodium  is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers 
       
 
  <span class=,'Italics,'>[see Clinical Pharmacology (
        
  
   <a href=,'#Section_12.3,'>12.3</a>)].
       
 
  </span>
</p>
</div>"
"moxifloxacin","d66f080b-da56-4473-8785-920d9700f72d","none found"
"mycophenolate mofetil","1b44c6c4-dfb5-47ed-8201-d7173b3b9887","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Effect of Other Drugs on Mycophenolate Mofetil</h2>
<p class=,'First,'>
<span class=,'Bold,'> Table 5.Drug Interactions with Mycophenolate Mofetil that Affect Mycophenolic Acid (MPA) Exposure</span><span class=,'Bold,'></span>
</p>
<br/>
<div class=,'scrollingtable,'><table border=,'0,' cellpadding=,'0,' cellspacing=,'0,' width=,'619.9795,'>
<col width=,'24.0802316850799%,'/>
<col width=,'75.9197683149201%,'/>
<tbody class=,'Headless,'>
<tr class=,'Botrule First,'>
<td align=,'justify,' class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'> Antacids with Magnesium or Aluminum Hydroxide </span>
<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Clinical Impact</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Concomitant use with an antacid containing magnesium or aluminum hydroxide decreases MPA systemic exposure 
            
    
     <span class=,'Italics,'>[see Clinical Pharmacology (
             
     
      <a href=,'#Section_12.3,'>12.3</a>)]
            
    
     </span>, which may reduce mycophenolate mofetil efficacy. 
            
    
     <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Prevention or Management</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Administer magnesium or aluminum hydroxide containing antacids at least 2h after mycophenolate mofetil administration. 
            
    
     <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'>Proton Pump Inhibitors (PPIs) </span>
<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Clinical Impact</span>
<br/> 
            
    
     <br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Concomitant use with PPIs decreases MPA systemic exposure 
            
    
     <span class=,'Italics,'>[see Clinical Pharmacology (
             
     
      <a href=,'#Section_12.3,'>12.3</a>)]
            
    
     </span>, which may reduce mycophenolate mofetil efficacy 
            
    
     <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Prevention or Management</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Monitor patients for alterations in efficacy when PPIs are co-administered with mycophenolate mofetil 
            
    
     <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Examples</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Lansoprazole, pantoprazole 
            
    
     <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'>Drugs that Interfere with Enterohepatic Recirculation</span>
<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Clinical Impact</span>
<br/> 
            
    
     <br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Concomitant use with drugs that directly interfere with enterohepatic recirculation, or indirectly interfere with enterohepatic recirculation by altering the gastrointestinal flora, can decrease MPA systemic exposure 
            
    
     <span class=,'Italics,'>[see Clinical Pharmacology (
             
     
      <a href=,'#Section_12.3,'>12.3</a>)]
            
    
     </span>, which may reduce mycophenolate mofetil efficacy. 
            
    
     <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Prevention or Management</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Monitor patients for alterations in efficacy or mycophenolate mofetil related adverse reactions when these drugs are co-administered with mycophenolate mofetil 
            
    
     <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Examples</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of antimicrobials 
            
    
     <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'>Drugs Modulating Glucuronidation </span>
<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Clinical Impact</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Concomitant use with drugs inducing glucuronidation decreases MPA systemic exposure, potentially reducing mycophenolate mofetil efficacy, while use with drugs inhibiting glucuronidation increases MPA systemic exposure 
            
    
     <span class=,'Italics,'>[see Clinical Pharmacology (
             
     
      <a href=,'#Section_12.3,'>12.3</a>)]
            
    
     </span>, which may increase the risk of mycophenolate mofetil related adverse reactions. 
            
    
     <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Prevention or Management</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Monitor patients for alterations in efficacy or mycophenolate mofetil related adverse reactions when these drugs are co-administered with  mycophenolate mofetil
            
    
     <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Examples</span>
<br/> 
            
    
     <br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Telmisartan (induces glucuronidation); isavuconazole (inhibits glucuronidation). 
            
    
     <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'>Calcium Free Phosphate Binders </span>
<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Clinical Impact</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Concomitant use with calcium free phosphate binders decrease MPA systemic exposure 
            
    
     <span class=,'Italics,'>[see Clinical Pharmacology (
             
     
      <a href=,'#Section_12.3,'>12.3</a>)]
            
    
     </span>, which may reduce mycophenolate mofetil efficacy. 
            
    
     <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Prevention or Management</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Administer calcium free phosphate binders at least 2 hours after mycophenolate mofetil
            
    
     <br/>
</td>
</tr>
<tr class=,'Last,'>
<td align=,'center,' class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Examples</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Sevelamer
            
    
     <br/>
</td>
</tr>
</tbody>
</table></div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Effect of Mycophenolate Mofetil on Other Drugs</h2>
<p class=,'First,'>
<span class=,'Bold,'>Table 6.  Drug Interactions with Mycophenolate Mofetil that Affect Other Drugs</span>
</p>
<div class=,'scrollingtable,'><table border=,'0,' cellpadding=,'0,' cellspacing=,'0,' width=,'619.9795,'>
<col width=,'23.1148771854553%,'/>
<col width=,'76.8851228145447%,'/>
<tbody class=,'Headless,'>
<tr class=,'Botrule First,'>
<td align=,'justify,' class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'> Drugs that Undergo Renal Tubular Secretion </span>
<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Clinical Impact</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>When concomitantly used with mycophenolate mofetil, its metabolite MPAG, may compete with drugs eliminated by renal tubular secretion which may increase plasma concentrations and/or adverse reactions associated with these drugs 
            
    
     <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Prevention or Management</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Monitor for drug-related adverse reactions in patients with renal impairment
            
    
     <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Examples</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Acyclovir, ganciclovir, probenecid, valacyclovir, valganciclovir 
            
    
     <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'>Combination Oral Contraceptives </span>
<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Clinical Impact</span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'>Concomitant use with mycophenolate mofetil decreased the systemic exposure to levonorgestrel, but did not affect the systemic exposure to ethinylestradiol 
            
    
     <span class=,'Italics,'>[see Clinical Pharmacology (
             
     
      <a href=,'#Section_12.3,'>12.3</a>)]
            
    
     </span>, which may result in reduced combination oral contraceptive effectiveness. 
            
    
     <span class=,'Bold,'></span>
<br/>
</td>
</tr>
<tr class=,'Last,'>
<td align=,'center,' class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Prevention or Management</span>
<br/>
</td><td align=,'justify,' class=,'Rrule,' valign=,'top,'>Use additional barrier contraceptive methods.
            
    
     <br/>
</td>
</tr>
</tbody>
</table></div>
</div>
</div>"
"naloxone","73c1bad3-6ac3-8682-e053-2a91aa0a176a","none found"
"naproxen","000155a8-709c-44e5-a75f-cd890f3a7caf","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID_185e9de4-ea5d-4287-8b72-ae8e12eace8c,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>See Table 1 for clinically significant drug interactions with naproxen.</p>
<p>
<span class=,'Bold,'>Table 1: Clinically Significant Drug Interactions with naproxen</span>
</p>
<div class=,'scrollingtable,'><table width=,'100%,'>
<col width=,'19%,'/>
<col width=,'81%,'/>
<tbody class=,'Headless,'>
<tr class=,'First,'>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>Drugs That Interfere with Hemostasis </span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>• Naproxen and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of naproxen and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. <br/>• Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone.  </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Monitor patients with concomitant use of naproxen tablets or naproxen sodium tablets with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [<span class=,'Italics,'>see Warnings and Precautions (<a href=,'#ID_bf3a434f-356d-4d45-b03b-1908966ef02c,'>5.12</a>)</span>]. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>Aspirin </span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>A pharmacodynamic (PD) study has demonstrated an interaction in which lower dose naproxen (220mg/day or 220mg twice daily) interfered with the antiplatelet effect of low-dose immediate-release aspirin, with the interaction most marked during the washout period of naproxen (<span class=,'Italics,'>see </span><span class=,'Italics,'><a href=,'#ID_86e2b110-5291-48d2-bf67-ee0333970f91,'>12.2</a></span><span class=,'Italics,'>Pharmacodynamics)</span>. There is reason to expect that the interaction would be present with prescription doses of naproxen or with enteric-coated low-dose aspirin; however, the peak interference with aspirin function may be later than observed in the PD study due to the longer washout period.</p>
<p>Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [<span class=,'Italics,'>see Warnings and Precautions (<a href=,'#ID_cbc401cb-e068-46ec-b635-3dd17ba9204e,'>5.2</a>)</span>].</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'bottom,'>
<p class=,'First,'>Because there may be an increased risk of cardiovascular events following discontinuation of naproxen due to the interference with the antiplatelet effect of aspirin during the washout period, for patients taking low-dose aspirin for cardioprotection who require intermittent analgesics, consider use of an NSAID that does not interfere with the antiplatelet effect of aspirin, or non-NSAID analgesics where appropriate.</p>
<p>Concomitant use of naproxen tablets or naproxen sodium tablets and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [<span class=,'Italics,'>see Warnings and Precautions (</span><span class=,'Italics,'><a href=,'#ID_bf3a434f-356d-4d45-b03b-1908966ef02c,'>5.12</a></span><span class=,'Italics,'>)</span>].</p>
<p>Naproxen tablets or naproxen sodium tablets are not substitutes for low dose aspirin for cardiovascular protection. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers </span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>• NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol). <br/>• In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>• During concomitant use of naproxen tablets or naproxen sodium tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. <br/>• During concomitant use of naproxen tablets or naproxen sodium tablets and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [<span class=,'Italics,'>see Warnings and Precautions (<a href=,'#ID_38fe759f-c6a2-488d-b229-b503dd89a14f,'>5.6</a>)</span>].<br/>• When these drugs are administered concomitantly, patients should be adequately hydrated. Assess renal function at the beginning of the concomitant treatment and periodically thereafter. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>Diuretics </span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'bottom,'>
<p class=,'First,'>Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>During concomitant use of naproxen tablets or naproxen sodium tablets with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [<span class=,'Italics,'>see Warnings and Precautions (<a href=,'#ID_38fe759f-c6a2-488d-b229-b503dd89a14f,'>5.6</a>)</span>].</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>Digoxin </span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>The concomitant use of naproxen with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>During concomitant use of naproxen tablets or naproxen sodium tablets and digoxin, monitor serum digoxin levels. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>Lithium </span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'bottom,'>
<p class=,'First,'>NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance<span class=,'Italics,'>. </span>The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>During concomitant use of naproxen tablets or naproxen sodium tablets and lithium, monitor patients for signs of lithium toxicity. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>Methotrexate </span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction). </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>During concomitant use of naproxen tablets or naproxen sodium tablets and methotrexate, monitor patients for methotrexate toxicity. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>Cyclosporine </span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Concomitant use of naproxen tablets or naproxen sodium tablets and cyclosporine may increase cyclosporine’s nephrotoxicity. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>During concomitant use of naproxen tablets or naproxen sodium tablets and cyclosporine, monitor patients for signs of worsening renal function. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>NSAIDs and Salicylates </span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Concomitant use of naproxen with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy [<span class=,'Italics,'>see Warnings and Precautions (<a href=,'#ID_cbc401cb-e068-46ec-b635-3dd17ba9204e,'>5.2</a>)</span>].</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>The concomitant use of naproxen with other NSAIDs or salicylates is not recommended. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>Pemetrexed </span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Concomitant use of naproxen tablets and naproxen sodium tablets and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information). </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>During concomitant use of naproxen tablets and naproxen sodium tablets and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity. <br/>
<br/>NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. <br/>
<br/>In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration.  </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>Antacids and Sucralfate </span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Concomitant administration of some antacids (magnesium oxide or aluminum hydroxide) and sucralfate can delay the absorption of naproxen. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Concomitant administration of antacids such as magnesium oxide or aluminum hydroxide, and sucralfate with naproxen tablets and naproxen sodium tablets is not recommended.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>Cholestyramine </span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'middle,'>
<p class=,'First,'>Concomitant administration of cholestyramine can delay the absorption of naproxen. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Concomitant administration of cholestyramine with naproxen tablets or naproxen sodium tablets is not recommended. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>Probenecid </span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Patients simultaneously receiving naproxen tablets or naproxen sodium tablets and probenecid should be observed for adjustment of dose if required. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>Other albumin-bound drugs </span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Naproxen is highly bound to plasma albumin; it thus has a theoretical potential for interaction with other albumin-bound drugs such as coumarin-type anticoagulants, sulphonylureas, hydantoins, other NSAIDs, and aspirin<span class=,'Italics,'>. </span>
</p>
</td>
</tr>
<tr class=,'Last,'>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention: </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Patients simultaneously receiving naproxen tablets or naproxen sodium tablets and a hydantoin, sulphonamide or sulphonylurea should be observed for adjustment of dose if required. </p>
</td>
</tr>
</tbody>
</table></div>
<p>
<span class=,'Bold,'>Drug/Laboratory Test Interactions</span>
</p>
<div class=,'scrollingtable,'><table width=,'100%,'>
<col width=,'19%,'/>
<col width=,'81%,'/>
<tbody class=,'Headless,'>
<tr class=,'First,'>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>Bleeding times </span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact: </span>
</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>Naproxen may decrease platelet aggregation and prolong bleeding time. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention: </span>
</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>This effect should be kept in mind when bleeding times are determined. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>Porter-Silber test </span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact: </span>
</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>The administration of naproxen may result in increased urinary values for 17-ketogenic steroids because of an interaction between the drug and/or its metabolites with m-di-nitrobenzene used in this assay. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention: </span>
</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'bottom,'>
<p class=,'First,'>Although 17-hydroxy-corticosteroid measurements (Porter-Silber test) do not appear to be artifactually altered, it is suggested that therapy with naproxen be temporarily discontinued 72 hours before adrenal function tests are performed if the Porter-Silber test is to be used. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>Urinary assays of 5-hydroxy indoleacetic acid (5HIAA) </span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact: </span>
</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>Naproxen may interfere with some urinary assays of 5-hydroxy indoleacetic acid </p>
<p>(5HIAA).  </p>
</td>
</tr>
<tr class=,'Last,'>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention: </span>
</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>This effect should be kept in mind when urinary 5-hydroxy indoleacetic acid is determined. </p>
</td>
</tr>
</tbody>
</table></div>
</div>"
"naratriptan","41c29652-32f8-48dc-9038-0e2195aa2084","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID55,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,'>
<a name=,'ID56,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Ergot-Containing Drugs</h2>
<p class=,'First,'>
<a name=,'ID57,'></a>Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours of each other is contraindicated.</p>
</div>
<div class=,'Section,'>
<a name=,'ID58,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Other 5-HT 1 Agonists</h2>
<p class=,'First,'>
<a name=,'ID59,'></a>Concomitant use of other 5-HT 1B/1D agonists (including triptans) within 24 hours of treatment with naratriptan is contraindicated because the risk of vasospastic reactions may be additive.</p>
</div>
<div class=,'Section,'>
<a name=,'ID60,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome</h2>
<p class=,'First,'>
<a name=,'ID61,'></a>Cases of serotonin syndrome have been reported during co-administration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors <span class=,'Italics,'>[see </span><span class=,'Italics,'><a href=,'#ID40,'>Warnings and Precautions (5.7) </a></span><span class=,'Italics,'>]. </span>
</p>
</div>
</div>"
"natamycin","2818fcb8-5bac-41fb-864e-3b598308a428","none found"
"nelfinavir","303c9bc8-eaff-4a65-9c60-7de6bddec348","none found"
"neostigmine","81243f47-bd25-bd02-518a-087badcca755","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'DRUG_INTERACTIONS,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>The pharmacokinetic interaction between neostigmine methylsulfate and other drugs has not been studied. Neostigmine methylsulfate is metabolized by microsomal enzymes in the liver. Use with caution when using neostigmine methylsulfate injection with other drugs which may alter the activity of metabolizing enzymes or transporters. </p>
</div>"
"nevirapine","397abf17-eb19-44b0-8b69-cddc72a0d752","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID85,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID88,'></a><a name=,'section-7.1,'></a>
<p></p>
<p class=,'First,'>
<a name=,'ID89,'></a>Nevirapine is principally metabolized by the liver via the cytochrome P450 isoenzymes, 3A and 2B6. Nevirapine is known to be an inducer of these enzymes. As a result, drugs that are metabolized by these enzyme systems may have lower than expected plasma levels when co-administered with nevirapine. </p>
<p>The specific pharmacokinetic changes that occur with co-administration of nevirapine and other drugs are listed in <span class=,'Italics,'>Clinical Pharmacology</span>, Table 5. Clinical comments about possible dosage modifications based on established drug interactions are listed in Table 4. The data in Tables 4 and 5 are based on the results of drug interaction trials conducted in HIV-1 seropositive subjects unless otherwise indicated. In addition to established drug interactions, there may be potential pharmacokinetic interactions between nevirapine and other drug classes that are metabolized by the cytochrome P450 system. These potential drug interactions are also listed in Table 4. Although specific drug interaction trials in HIV-1 seropositive subjects have not been conducted for some classes of drugs listed in Table 4, additional clinical monitoring may be warranted when co-administering these drugs.</p>
<p>The <span class=,'Italics,'>in vitro </span>interaction between nevirapine and the antithrombotic agent warfarin is complex. As a result, when giving these drugs concomitantly, plasma warfarin levels may change with the potential for increases in coagulation time. When warfarin is co-administered with nevirapine, anticoagulation levels should be monitored frequently.</p>
<a name=,'ID90,'></a>
<div class=,'scrollingtable,'><table class=,'Noautorules,' width=,'98%,'>
<caption>
<span>  Table 4 Established and Potential Drug Interactions: Use With Caution, Alteration in Dose or Regimen May Be Needed Due to Drug Interaction Established Drug Interactions: See Clinical Pharmacology (12.3),  Table 5 for Magnitude of Interaction. </span>
</caption>
<col width=,'34%,'/>
<col width=,'27%,'/>
<col width=,'38%,'/>
<tbody class=,'Headless,'>
<tr>
<td align=,'left,' class=,'Botrule Toprule,' valign=,'top,'><span class=,'Bold,'> Drug Name</span>
<br/>
</td><td align=,'left,' class=,'Botrule Toprule,' valign=,'top,'><span class=,'Bold,'> Effect on concentration of Nevirapine or Concomitant drug</span>
<br/>
</td><td align=,'left,' class=,'Botrule Toprule,' valign=,'top,'><span class=,'Bold,'> Clinical Comment</span>
<br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'> HIV Antiviral Agents: Protease Inhibitors (PIs) </span>
<br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'>
<br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule,' valign=,'top,'> Atazanavir/Ritonavir*<br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> ↓ Atazanavir<br/> ↑ Nevirapine <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> Do not co-administer nevirapine with atazanavir because nevirapine substantially decreases atazanavir exposure and there is a potential risk for nevirapine-associated toxicity due to increased nevirapine exposures. <br/>
</td>
</tr>
<tr>
<td align=,'left,' valign=,'top,'> Fosamprenavir* <br/>
</td><td align=,'left,' valign=,'top,'> ↓ Amprenavir<br/> ↑ Nevirapine <br/>
</td><td align=,'left,' valign=,'top,'> Co-administration of nevirapine and fosamprenavir without ritonavir is not recommended. <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule,' valign=,'top,'> Fosamprenavir/Ritonavir* <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> ↓ Amprenavir<br/> ↑ Nevirapine <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> No dosing adjustments are required when nevirapine is co-administered with 700/100 mg of fosamprenavir/ritonavir twice daily. The combination of nevirapine administered with fosamprenavir/ritonavir once daily has not been studied. <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule,' valign=,'top,'> Indinavir* <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> ↓ Indinavir<br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> The appropriate doses of this combination of indinavir and nevirapine with respect to efficacy and safety have not been established. <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule,' valign=,'top,'> Lopinavir/Ritonavir* <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> ↓ Lopinavir<br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> Dosing in adult patients: <br/> A dose adjustment of lopinavir/ritonavir to 500/125 mg tablets twice daily or 533/133 mg (6.5 mL) oral solution twice daily is recommended when used in combination with nevirapine. Neither lopinavir/ritonavir tablets nor oral solution should be administered once daily in combination with nevirapine.<br/> Dosing in pediatric patients:<br/> Please refer to the Kaletra<span class=,'Sup,'>®</span> prescribing information for dosing recommendations based on body surface area and body weight. Neither lopinavir/ritonavir tablets nor oral solution should be administered once daily in combination with nevirapine.<br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule,' valign=,'top,'> Nelfinavir* <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> ↓Nelfinavir M8 Metabolite<br/> ↓ Nelfinavir C<span class=,'Sub,'>min</span>
<br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> The appropriate doses of the combination of nevirapine and nelfinavir with respect to safety and efficacy have not been established. <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule,' valign=,'top,'> Saquinavir/ritonavir <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> The interaction between nevirapine and saquinavir/ritonavir has not been evaluated <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> The appropriate doses of the combination of nevirapine and saquinavir/ritonavir with respect to safety and efficacy have not been established. <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule,' colspan=,'3,' valign=,'top,'><span class=,'Bold,'> HIV Antiviral Agents: Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) </span>
<br/>
</td>
</tr>
<tr>
<td align=,'left,' valign=,'top,'> Efavirenz* <br/>
</td><td align=,'left,' valign=,'top,'> ↓Efavirenz<br/>
</td><td align=,'left,' valign=,'top,'> The appropriate doses of these combinations with respect to safety and efficacy have not been established. <br/>
</td>
</tr>
<tr>
<td align=,'left,' valign=,'top,'> Delavirdine <br/> Etravirine <br/> Rilpivirine <br/>
</td><td valign=,'top,'></td><td align=,'left,' valign=,'top,'> Plasma concentrations may be altered. Nevirapine should not be coadministered with another NNRTI as this combination has not been shown to be beneficial. <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Toprule,' colspan=,'3,' valign=,'top,'><span class=,'Bold,'> Hepatitis C Antiviral Agents</span>
<br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Toprule,' valign=,'top,'> Boceprevir <br/>
</td><td align=,'left,' class=,'Toprule,' valign=,'top,'> Plasma concentrations of boceprevir may be decreased due to induction of CYP3A4/5 by nevirapine. <br/>
</td><td align=,'left,' class=,'Toprule,' valign=,'top,'> Nevirapine and boceprevir should not be coadministered because decreases in boceprevir plasma concentrations may result in a reduction in efficacy. <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Toprule,' valign=,'top,'> Telaprevir <br/>
</td><td align=,'left,' class=,'Toprule,' valign=,'top,'> Plasma concentrations of telaprevir may be decreased due to induction of CYP3A4 by nevirapine and plasma concentrations of nevirapine may be increased due to inhibition of CYP3A4 by telaprevir<br/>
</td><td align=,'left,' class=,'Toprule,' valign=,'top,'> Nevirapine and telaprevir should not be coadministered because changes in plasma concentrations of nevirapine, telaprevir, or both may result in a reduction in telaprevir efficacy or an increase in nevirapine-associated adverse events.<br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Toprule,' colspan=,'3,' valign=,'top,'><span class=,'Bold,'> Other Agents</span>
<br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Toprule,' valign=,'top,'><span class=,'Bold,'> Analgesics:</span>
<br/> Methadone*<br/>
</td><td align=,'left,' class=,'Toprule,' valign=,'top,'> ↓ Methadone<br/>
</td><td align=,'left,' class=,'Toprule,' valign=,'top,'> Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone-maintained patients beginning nevirapine therapy should be monitored for evidence of withdrawal and methadone dose should be adjusted accordingly.<br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Toprule,' valign=,'top,'><span class=,'Bold,'> Antiarrhythmics:</span>
<br/> Amiodarone, disopyramide, lidocaine<br/>
</td><td align=,'left,' class=,'Toprule,' valign=,'top,'> Plasma concentrations may be decreased.<br/>
</td><td align=,'left,' class=,'Toprule,' valign=,'top,'> Appropriate doses for this combination have not been established.<br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Toprule,' valign=,'top,'><span class=,'Bold,'> Antibiotics:</span>
<br/> Clarithromycin*<br/>
</td><td align=,'left,' class=,'Toprule,' valign=,'top,'> ↓ Clarithromycin<br/> ↑ 14-OH clarithromycin<br/>
</td><td align=,'left,' class=,'Toprule,' valign=,'top,'> Clarithromycin exposure was significantly decreased by nevirapine; however, 14-OH metabolite concentrations were increased. Because clarithromycin active metabolite has reduced activity against <span class=,'Italics,'>Mycobacterium avium- intracellulare complex</span> , overall activity against this pathogen may be altered. Alternatives to clarithromycin, such as azithromycin, should be considered.<br/>
</td>
</tr>
<tr>
<td align=,'left,' valign=,'top,'> Rifabutin*<br/>
<br/>
</td><td align=,'left,' valign=,'top,'> ↑ Rifabutin<br/>
</td><td align=,'left,' valign=,'top,'> Rifabutin and its metabolite concentrations were moderately increased. Due to high intersubject variability, however, some patients may experience large increases in rifabutin exposure and may be at higher risk for rifabutin toxicity. Therefore, caution should be used in concomitant administration.<br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule,' valign=,'top,'> Rifampin*<br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> ↓ Nevirapine<br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> Nevirapine and rifampin should not be administered concomitantly because decreases in nevirapine plasma concentrations may reduce the efficacy of the drug. Physicians needing to treat patients co-infected with tuberculosis and using a nevirapine-containing regimen may use rifabutin instead.<br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule,' valign=,'top,'><span class=,'Bold,'> Anticonvulsants:</span>
<br/> Carbamazepine, clonazepam, ethosuximide <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> Plasma concentrations of nevirapine <br/> and the anticonvulsant may be decreased. <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> Use with caution and monitor virologic response and levels of anticonvulsants. <br/>
</td>
</tr>
<tr>
<td align=,'left,' valign=,'top,'><span class=,'Bold,'> Antifungals: </span>
<br/> Fluconazole* <br/>
<br/>
</td><td align=,'left,' valign=,'top,'> ↑ Nevirapine <br/>
</td><td align=,'left,' valign=,'top,'> Because of the risk of increased exposure to nevirapine, caution should be used in concomitant administration, and patients should be monitored closely for nevirapine-associated adverse events. <br/>
</td>
</tr>
<tr>
<td align=,'left,' valign=,'top,'> Ketoconazole* <br/>
</td><td align=,'left,' valign=,'top,'> ↓ Ketoconazole<br/>
</td><td align=,'left,' valign=,'top,'> Nevirapine and ketoconazole should not be administered concomitantly because decreases in ketoconazole plasma concentrations may reduce the efficacy of the drug. <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule,' valign=,'top,'> Itraconazole <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> ↓ Itraconazole <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> Nevirapine and itraconazole should not be administered concomitantly due to potential decreases in itraconazole plasma concentrations that may reduce efficacy of the drug. <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule,' valign=,'top,'><span class=,'Bold,'> Antithrombotics: </span>
<br/> Warfarin <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> Plasma concentrations may be increased. <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> Potential effect on anticoagulation. Monitoring of anticoagulation levels is recommended. <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule,' valign=,'top,'><span class=,'Bold,'> Calcium channel blockers: </span> Diltiazem, nifedipine, verapamil <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> Plasma concentrations may be decreased. <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> Appropriate doses for these combinations have not been established. <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule,' valign=,'top,'><span class=,'Bold,'> Cancer chemotherapy: </span>
<br/> Cyclophosphamide <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> Plasma concentrations may be decreased. <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> Appropriate doses for this combination have not been established. <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule,' valign=,'top,'><span class=,'Bold,'> Ergot alkaloids: </span>
<br/> Ergotamine <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> Plasma concentrations may be decreased. <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> Appropriate doses for this combination have not been established. <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule,' valign=,'top,'><span class=,'Bold,'> Immunosuppressants: </span>
<br/> Cyclosporine, tacrolimus, sirolimus <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> Plasma concentrations may be decreased. <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> Appropriate doses for these combinations have not been established. <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule,' valign=,'top,'><span class=,'Bold,'> Motility agents: </span>
<br/> Cisapride <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> Plasma concentrations may be decreased. <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> Appropriate doses for this combination have not been established. <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule,' valign=,'top,'><span class=,'Bold,'> Opiate agonists: </span>
<br/> Fentanyl <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> Plasma concentrations may be decreased. <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> Appropriate doses for this combination have not been established. <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule,' valign=,'top,'><span class=,'Bold,'> Oral contraceptives: </span>
<br/> Ethinyl estradiol and Norethindrone* <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> ↓Ethinyl estradiol<br/> ↓Norethindrone <br/>
</td><td align=,'left,' class=,'Botrule,' valign=,'top,'> Despite lower ethinyl estradiol and norethindrone exposures when coadministered with nevirapine, literature reports suggest that nevirapine has no effect on pregnancy rates among HIV-infected women on combined oral contraceptives. When coadministered with Nevirapine, no dose adjustment of ethinyl estradiol or norethindrone is needed when used in combination for contraception.<br/> When these oral contraceptives are used for hormonal regulation during Nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored.<br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule,' colspan=,'3,' valign=,'top,'><span class=,'Bold,'> * </span> The interaction between Nevirapine and the drug was evaluated in a clinical study. All other drug interactions shown are predicted.<br/>
</td>
</tr>
</tbody>
</table></div>
</div>
</div>"
"nicotine","0d026350-1c4e-4377-b24e-b586cbc794e5","none found"
"niacin","3b3e7629-1a19-46c9-8795-8e280b318af3","none found"
"nifedipine","0cc236dc-95fa-49cc-aeb8-6590de157585","none found"
"nifurtimox","90d09714-a8b1-4696-8ada-f99dc54d0721","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID_39b7a7de-a98e-4d7b-b1e5-5951afd71be4,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Concomitant use of LAMPIT with alcohol may increase the incidence and severity of undesirable effects similar to other nitrofurans and nitroheterocyclic compounds. LAMPIT is contraindicated in patients who consume alcohol during treatment <span class=,'Italics,'>[see Dosage and Administration (<a href=,'#ID_a65f475c-cb08-498f-8642-43335868e445,'>2.2</a>) Contraindications (<a href=,'#ID_ec4d78da-4525-43dd-9ed7-61a6bfd54736,'>4</a>)].</span>
</p>
</div>"
"nilotinib","6093952a-5248-45cb-ad17-33716a411146","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7p1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1
		     
	Effect of Other Drugs on Tasigna</h2>
<p class=,'First,'>
<span class=,'Underline,'>Strong CYP3A Inhibitors</span>
</p>
<p>Concomitant use with a strong CYP3A inhibitor increased nilotinib concentrations compared to Tasigna alone<span class=,'Italics,'> [see Clinical Pharmacology (12.3)]</span>, which may increase the risk of Tasigna toxicities. Avoid concomitant use of strong CYP3A inhibitors with Tasigna. If patients must be coadministered a strong CYP3A4 inhibitor, reduce Tasigna dose <span class=,'Italics,'>[see Dosage and Administration (2.8)]</span>.</p>
<p>
<span class=,'Underline,'>Strong CYP3A Inducers</span>
</p>
<p>Concomitant use with a strong CYP3A inducer decreased nilotinib concentrations compared to Tasigna alone <span class=,'Italics,'>[see Clinical Pharmacology (12.3)]</span>, which may reduce Tasigna efficacy. Avoid concomitant use of strong CYP3A inducers with Tasigna.</p>
<p>
<span class=,'Underline,'>Proton Pump Inhibitors</span>
</p>
<p>Concomitant use with a proton pump inhibitor (PPI) decreased nilotinib concentrations compared to Tasigna alone <span class=,'Italics,'>[see Clinical Pharmacology (12.3)]</span>, which may reduce Tasigna efficacy. Avoid concomitant use of PPI with Tasigna. As an alternative to PPIs, use H2 blockers approximately 10 hours before or approximately 2 hours after the dose of Tasigna, or use antacids approximately 2 hours before or approximately 2 hours after the dose of Tasigna.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7p2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2
		     
	Drugs That Prolong the QT Interval</h2>
<p class=,'First,'>Avoid coadministration of Tasigna with agents that may prolong the QT interval, such as anti-arrhythmic drugs <span class=,'Italics,'>[see Boxed Warning, Dosage and Administration (2.4), Warnings and Precautions (5.2), Drug Interactions (7.1), Clinical Pharmacology (12.2)]</span>.</p>
</div>
</div>"
"nitrofurantoin","11dcea9c-0c62-4153-976b-bd1f8ef1f6d9","none found"
"nivolumab","f570b9c4-6846-4de2-abfa-4d0a4ae4e394","none found"
"norethindrone","0d2f8fea-3675-40d2-afd9-9fcb148dbd4b","none found"
"nortriptyline","8a7f45d4-4d45-91cc-e053-2a95a90a55d8","none found"
"nystatin","01c469b3-ec10-452c-8c02-3e7d22e40297","none found"
"ocrelizumab","9da42362-3bb5-4b83-b4bb-b59fd4e55f0d","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1	Immunosuppressive or Immune-Modulating Therapies </h2>
<p class=,'First,'>The concomitant use of OCREVUS and other immune-modulating or immunosuppressive therapies, including immunosuppressant doses of corticosteroids, is expected to increase the risk of immunosuppression. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with OCREVUS. When switching from drugs with prolonged immune effects, such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone, consider the duration and mode of action of these drugs because of additive immunosuppressive effects when initiating OCREVUS <span class=,'Italics,'>[see <a href=,'#S5.2,'>Warnings and Precautions (5.2)</a>].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Vaccinations</h2>
<p class=,'First,'>A Phase 3b randomized, open-label study examined the concomitant use of OCREVUS and several non-live vaccines in adults 18-55 years of age with relapsing forms of MS (68 subjects undergoing treatment with OCREVUS at the time of vaccination and 34 subjects not undergoing treatment with OCREVUS at the time of vaccination).  Concomitant exposure to OCREVUS attenuated antibody responses to tetanus toxoid-containing vaccine, pneumococcal polysaccharide, pneumococcal conjugate vaccines, and seasonal inactivated influenza vaccines.  The impact of the observed attenuation on vaccine effectiveness in this patient population is unknown.  The safety and effectiveness of live or live-attenuated vaccines administered concomitantly with OCREVUS have not been assessed <span class=,'Italics,'>[see <a href=,'#S5.2,'>Warnings and Precautions (5.2)</a>]</span>.</p>
</div>
</div>"
"olanzapine","143303d2-a70c-45a7-930e-04ade1c3cb18","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<br/>
<p class=,'First,'>The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies.</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Potential for Other Drugs to Affect Olanzapine</h2>
<p class=,'First,'>
<span class=,'Underline,'>Diazepam</span> — The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine 
  
         
 
  <span class=,'Italics,'>[see 
   
          
  
   <a href=,'#Section_7.2,'>Drug Interactions (7.2)</a>] 
  
         
 
  </span>.
 
        

 </p>
<p>
<br/>
<br/>
<span class=,'Underline,'>Cimetidine and Antacids</span> — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.
  
         
 
  <br/>
<br/>
<br/>
<br/>
<span class=,'Underline,'>Inducers of CYP1A2</span> — Carbamazepine therapy (200 mg bid) causes an approximately 50% increase in the clearance of olanzapine. This increase is likely due to the fact that carbamazepine is a potent inducer of CYP1A2 activity. Higher daily doses of carbamazepine may cause an even greater increase in olanzapine clearance.
  
         
 
  <br/>
<br/>
<br/>
<br/>
<span class=,'Underline,'>Alcohol</span> — Ethanol (45 mg/70 kg single dose) did not have an effect on olanzapine pharmacokinetics. The co-administration of alcohol (i.e., ethanol) with olanzapine potentiated the orthostatic hypotension observed with olanzapine 
  
         
 
  <span class=,'Italics,'>[see 
   
          
  
   <a href=,'#Section_7.2,'>Drug Interactions (7.2)</a>] 
  
         
 
  </span>.
  
         
 
  <br/>
<br/>
<br/>
<br/>
<span class=,'Underline,'>Inhibitors of CYP1A2</span>
<br/>
<br/>
<br/>
<br/>
<span class=,'Italics,'>Fluvoxamine: </span>Fluvoxamine, a CYP1A2 inhibitor, decreases the clearance of olanzapine. This results in a mean increase in olanzapine Cmax following fluvoxamine of 54% in female nonsmokers and 77% in male smokers. The mean increase in olanzapine AUC is 52% and 108%, respectively. Lower doses of olanzapine should be considered in patients receiving concomitant treatment with fluvoxamine.
  
         
 
  <br/>
<br/>
<br/>
<br/>
<span class=,'Underline,'>Inhibitors of CYP2D6</span>
<br/>
<br/>
<br/>
<br/>
<span class=,'Italics,'>Fluoxetine: </span>Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. The magnitude of the impact of this factor is small in comparison to the overall variability between individuals, and therefore dose modification is not routinely recommended. When using olanzapine and fluoxetine in combination, also refer to the Drug Interactions section of the package insert for Symbyax.
  
         
 
  <br/>
<br/>
<br/>
<br/>
<span class=,'Underline,'>Warfarin</span> — Warfarin (20 mg single dose) did not affect olanzapine pharmacokinetics 
  
         
 
  <span class=,'Italics,'>[see 
   
          
  
   <a href=,'#Section_7.2,'>Drug Interactions (7.2)</a>] 
  
         
 
  </span>.
  
         
 
  <br/>
<br/>
<br/>
<br/>
<span class=,'Underline,'>Inducers of CYP1A2 or Glucuronyl Transferase</span> — Omeprazole and rifampin may cause an increase in olanzapine clearance.
  
         
 
  <br/>
<br/>
<br/>
<br/>
<span class=,'Underline,'>Charcoal</span> — The administration of activated charcoal (1 g) reduced the Cmax and AUC of oral olanzapine by about 60%. As peak olanzapine levels are not typically obtained until about 6 hours after dosing, charcoal may be a useful treatment for olanzapine overdose.
 
        

 </p>
<p>
<span class=,'Underline,'>Anticholinergic Drugs</span> — Concomitant treatment with olanzapine and other drugs with anticholinergic activity can increase the risk for severe gastrointestinal adverse reactions related to hypomotility. Olanzapine should be used with caution in patients receiving medications having anticholinergic (antimuscarinic) effects 
  
         
 
  <span class=,'Italics,'>[see </span><span class=,'Italics,'><a href=,'#Section_5.14,'>Warnings and Precautions (5.14)</a>]. 
  
         
 
  </span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Potential for Olanzapine to Affect Other Drugs</h2>
<p class=,'First,'></p>
<p>
<span class=,'Underline,'>CNS Acting Drugs</span> — Given the primary CNS effects of olanzapine, caution should be used when olanzapine is taken in combination with other centrally acting drugs and alcohol.
         
 
  
         
 
  <br/>
<br/>
<span class=,'Underline,'>Antihypertensive Agents</span> — Olanzapine, because of its potential for inducing hypotension, may enhance the effects of certain antihypertensive agents.
         
 
  
         
 
  <br/>
<br/>
<span class=,'Underline,'>Levodopa and Dopamine Agonists</span> — Olanzapine may antagonize the effects of levodopa and dopamine agonists.
         
 
  
         
 
  <br/>
<br/>
<span class=,'Underline,'>Lithium</span> — Multiple doses of olanzapine (10 mg for 8 days) did not influence the kinetics of lithium. Therefore, concomitant olanzapine administration does not require dosage adjustment of lithium 
         
 
  
         
 
  <span class=,'Italics,'>[see 
          
  
   
          
  
   <a href=,'#Section_5.16,'>Warnings and Precautions (5.16)</a>]
         
 
  
         
 
  </span>.
         
 
  
         
 
  <br/>
<br/>
<span class=,'Underline,'>Valproate</span> — Olanzapine (10 mg daily for 2 weeks) did not affect the steady state plasma concentrations of valproate. Therefore, concomitant olanzapine administration does not require dosage adjustment of valproate 
         
 
  
         
 
  <span class=,'Italics,'>[see 
          
  
   
          
  
   <a href=,'#Section_5.16,'>Warnings and Precautions (5.16)</a>]
         
 
  
         
 
  </span>.
         
 
  
         
 
  <br/>
<br/>
<span class=,'Underline,'>Effect of Olanzapine on Drug Metabolizing Enzymes</span> — In vitro studies utilizing human liver microsomes suggest that olanzapine has little potential to inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A. Thus, olanzapine is unlikely to cause clinically important drug interactions mediated by these enzymes.
         
 
  
         
 
  <br/>
<br/>
<span class=,'Underline,'>Imipramine</span> — Single doses of olanzapine did not affect the pharmacokinetics of imipramine or its active metabolite desipramine.
         
 
  
         
 
  <br/>
<br/>
<span class=,'Underline,'>Warfarin</span> — Single doses of olanzapine did not affect the pharmacokinetics of warfarin 
         
 
  
         
 
  <span class=,'Italics,'>[see 
          
  
   
          
  
   <a href=,'#Section_7.1,'>Drug Interactions (7.1)</a>]
         
 
  
         
 
  </span>.
         
 
  
         
 
  <br/>
<br/>
<span class=,'Underline,'>Diazepam</span> — Olanzapine did not influence the pharmacokinetics of diazepam or its active metabolite N-desmethyldiazepam. However, diazepam co-administered with olanzapine increased the orthostatic hypotension observed with either drug given alone 
         
 
  
         
 
  <span class=,'Italics,'>[see 
          
  
   
          
  
   <a href=,'#Section_7.1,'>Drug Interactions (7.1)</a>]
         
 
  
         
 
  </span>.
         
 
  
         
 
  <br/>
<br/>
<span class=,'Underline,'>Alcohol</span> — Multiple doses of olanzapine did not influence the kinetics of ethanol 
         
 
  
         
 
  <span class=,'Italics,'>[see 
          
  
   
          
  
   <a href=,'#Section_7.1,'>Drug Interactions (7.1)</a>]
         
 
  
         
 
  </span>.
         
 
  
         
 
  <br/>
<br/>
<span class=,'Underline,'>Biperiden</span> — Multiple doses of olanzapine did not influence the kinetics of biperiden.
         
 
  
         
 
  <br/>
<br/>
<span class=,'Underline,'>Theophylline</span> — Multiple doses of olanzapine did not affect the pharmacokinetics of theophylline or its metabolites.
        

 
        

 </p>
</div>
</div>"
"olopatadine","06467360-22fe-4a48-b234-06dbff30e853","none found"
"olsalazine","373c321f-cd33-4c11-a2d6-73f38384c27f","none found"
"omadacycline","51591524-4703-44c6-8bde-dce3e6a463d1","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Anticoagulant Drugs</h2>
<p class=,'First,'>Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage while also taking NUZYRA.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Antacids and Iron Preparations</h2>
<p class=,'First,'>Absorption of oral tetracyclines, including NUZYRA, is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron containing preparations <span class=,'Italics,'>[see <a href=,'#S2.1,'>Dosage and Administration (2.1)</a>].</span>
</p>
</div>
</div>"
"ondansetron","22fbef24-a6f6-4256-984c-a7f62a79428a","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'i4i_interactions_id_5d102f68-a18f-46f4-8386-fa0a997b3a5a,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_04cf123c-27ee-45df-8627-392f7497fb39,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Drugs Affecting Cytochrome P-450 Enzymes</h2>
<p class=,'First,'>Ondansetron does not appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver. Because ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of ondansetron 
         
 
  <span class=,'Italics,'>[see Clinical Pharmacology (12.3)]</span>. On the basis of limited available data, no dosage adjustment is recommended for patients on these drugs.
        

 </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_4611357b-23c5-4c55-a8f9-5319a4ecee15,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Apomorphine</h2>
<p class=,'First,'>Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with ondansetron is contraindicated 
         
 
  <span class=,'Italics,'>[see Contraindications (4)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_0ce6a014-2c99-40a9-b46e-2c1f48ba7eb9,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Phenytoin, Carbamazepine, and Rifampin</h2>
<p class=,'First,'>In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs 
         
 
  <span class=,'Italics,'>[see Clinical Pharmacology (12.3)]</span>.
        

 </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_406687cb-aa48-4b19-894f-10c05dd9e761,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Tramadol</h2>
<p class=,'First,'>Although there are no data on pharmacokinetic drug interactions between ondansetron and tramadol, data from two small trials indicate that concomitant use of ondansetron may result in reduced analgesic activity of tramadol. Patients on concomitant ondansetron self administered tramadol more frequently in these trials, leading to an increased cumulative dose in patient-controlled administration (PCA) of tramadol.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_c0e6c2a3-bd6c-4c2b-8885-16e594fe8974,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Serotonergic Drugs</h2>
<p class=,'First,'>Serotonin syndrome (including altered mental status, autonomic instability, and neuromuscular symptoms) has been described following the concomitant use of 5-HT
         
 
  <span class=,'Sub,'>3</span> receptor antagonists and other serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) 
         
 
  <span class=,'Italics,'>[see Warnings and Precautions (5.3)]</span>.
        

 </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_aa5b1a8e-45d9-4a45-98b1-b048501ccadf,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6 Chemotherapy</h2>
<p class=,'First,'>In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.</p>
<p>In a crossover trial in 76 pediatric patients, intravenous ondansetron did not increase blood levels of high-dose methotrexate.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_67a105da-26c3-45eb-a626-dcea48aa05d6,'></a><a name=,'section-7.7,'></a>
<p></p>
<h2>7.7 Temazepam</h2>
<p class=,'First,'>The coadministration of ondansetron had no effect on the pharmacokinetics and pharmacodynamics of temazepam.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_18d6a72d-ffd9-4d11-a902-c863180f184f,'></a><a name=,'section-7.8,'></a>
<p></p>
<h2>7.8 Alfentanil and Atracurium</h2>
<p class=,'First,'>Ondansetron does not alter the respiratory depressant effects produced by alfentanil or the degree of neuromuscular blockade produced by atracurium. Interactions with general or local anesthetics have not been studied.</p>
</div>
</div>"
"oseltamivir","03a2a7f0-406c-4784-84c1-5fd5f5be4773","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'i4i_interactions_id_0839a745-bd97-40c0-8cef-3d8e46350a3c,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_ed699a43-0786-4018-b83c-a90e432a8bb7,'></a><a name=,'section-7.1,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Underline,'>Influenza Vaccines</span>
</p>
<p>The concurrent use of TAMIFLU with live attenuated influenza vaccine (LAIV) intranasal has not been evaluated. However, because of the potential for interference between these products, LAIV should not be administered within 2 weeks before or 48 hours after administration of TAMIFLU, unless medically indicated. The concern about possible interference arises from the potential for antiviral drugs to inhibit replication of live vaccine virus. Trivalent inactivated influenza vaccine can be administered at any time relative to use of TAMIFLU.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_5309f705-bde8-45eb-9cb0-a01a41fb809e,'></a><a name=,'section-7.2,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Underline,'>Overall Drug Interaction Profile for Oseltamivir</span>
</p>
<p>Information derived from pharmacology and pharmacokinetic studies of oseltamivir suggests that clinically significant drug interactions are unlikely.</p>
<p>Oseltamivir is extensively converted to oseltamivir carboxylate by esterases, located predominantly in the liver. Drug interactions involving competition for esterases have not been extensively reported in literature. Low protein binding of oseltamivir and oseltamivir carboxylate suggests that the probability of drug displacement interactions is low.</p>
<p>In vitro studies demonstrate that neither oseltamivir nor oseltamivir carboxylate is a good substrate for P450 mixed-function oxidases or for glucuronyl transferases.</p>
<p>Clinically important drug interactions involving competition for renal tubular secretion are unlikely due to the known safety margin for most of these drugs, the elimination characteristics of oseltamivir carboxylate (glomerular filtration and anionic tubular secretion) and the excretion capacity of these pathways. Coadministration of probenecid results in an approximate two-fold increase in exposure to oseltamivir carboxylate due to a decrease in active anionic tubular secretion in the kidney. However, due to the safety margin of oseltamivir carboxylate, no dose adjustments are required when coadministering with probenecid.</p>
<p>No pharmacokinetic interactions have been observed when coadministering oseltamivir with amoxicillin, acetaminophen, aspirin, cimetidine, antacids (magnesium and aluminum hydroxides and calcium carbonates), or warfarin.</p>
</div>
</div>"
"oxaliplatin","36e7a154-759a-487b-b67f-6c605d017c7d","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID91,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>
<a name=,'ID92,'></a>No specific cytochrome P-450-based drug interaction studies have been conducted. No pharmacokinetic interaction between 85 mg/m<span class=,'Sup,'>2</span><span class=,'Sup,'> </span>oxaliplatin and 5-fluorouracil/leucovorin has been observed in patients treated every 2 weeks. Increases of 5-fluorouracil plasma concentrations by approximately 20% have been observed with doses of 130 mg/m<span class=,'Sup,'>2</span><span class=,'Sup,'> </span>oxaliplatin injection dosed every 3 weeks. Because platinum-containing species are eliminated primarily through the kidney, clearance of these products may be decreased by coadministration of potentially nephrotoxic compounds; although, this has not been specifically studied <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#ID113,'>12.3</a>)]. </span>
</p>
</div>"
"oxcarbazepine","17325a80-fb9c-4a83-b4b4-98e0b999d852","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Oxcarbazepine can inhibit CYP2C19 and induce CYP3A4/5 with potentially important effects on plasma concentrations of other drugs. The inhibition of CYP2C19 by oxcarbazepine and MHD can cause increased plasma concentrations of drugs that are substrates of CYP2C19. Oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine calcium antagonists, oral contraceptives and cyclosporine resulting in a lower plasma concentration of these drugs. [<span class=,'Italics,'>see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>
</p>
<p>In addition, several AEDs that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD. No autoinduction has been observed with oxcarbazepine.</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Antiepileptic Drugs</h2>
<p class=,'First,'>Potential interactions between oxcarbazepine and other AEDs were assessed in clinical studies. The effect of these interactions on mean AUCs and C<span class=,'Sub,'>min</span> are summarized in Table 7.</p>
<a name=,'t7,'></a>
<div class=,'scrollingtable,'><table width=,'100%,'>
<caption>
<span>Table 7 Summary of AED Interactions with Oxcarbazepine</span>
</caption>
<col align=,'center,' valign=,'middle,' width=,'21%,'/>
<col align=,'center,' valign=,'middle,' width=,'16%,'/>
<col align=,'center,' valign=,'middle,' width=,'21%,'/>
<col align=,'center,' valign=,'middle,' width=,'21%,'/>
<col align=,'center,' valign=,'middle,' width=,'21%,'/>
<thead>
<tr class=,'First Last,' valign=,'bottom,'>
<th align=,'left,'>AED Coadministered</th><th align=,'center,'>Dose of AED<br/>(mg/day)</th><th align=,'center,'>Oxcarbazepine Dose<br/>(mg/day)</th><th align=,'center,'>Influence of Oxcarbazepine on AED Concentration<br/>(Mean Change, 90% Confidence Interval)</th><th align=,'center,'>Influence of AED on MHD Concentration<br/>(Mean Change, 90% Confidence Interval)</th>
</tr>
</thead>
<tfoot>
<tr>
<td align=,'left,' colspan=,'5,'>
<dl class=,'Footnote,'>
<dt>
<a href=,'#footnote-reference-1,' name=,'footnote-1,'>*</a>
</dt>
<dd>nc denotes a mean change of less than 10%</dd>
<dt>
<a href=,'#footnote-reference-2,' name=,'footnote-2,'>†</a>
</dt>
<dd>Pediatrics</dd>
<dt>
<a href=,'#footnote-reference-3,' name=,'footnote-3,'>‡</a>
</dt>
<dd>Mean increase in adults at high oxcarbazepine doses</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody>
<tr class=,'Botrule First,'>
<td align=,'center,'>Carbamazepine</td><td align=,'center,'>400-2000</td><td align=,'center,'>900</td><td align=,'center,'>nc<a class=,'Sup,' href=,'#footnote-1,' name=,'footnote-reference-1,'>*</a></td><td align=,'center,'>40% decrease<br/>[CI: 17% decrease, 57% decrease]</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,'>Phenobarbital</td><td align=,'center,'>100-150</td><td align=,'center,'>600-1800</td><td align=,'center,'>14% increase<br/>[CI: 2% increase, 24% increase]</td><td align=,'center,'>25% decrease<br/>[CI: 12% decrease, 51% decrease]</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,'>Phenytoin</td><td align=,'center,'>250-500</td><td align=,'center,'>600-1800<br/>&gt;1200-2400</td><td align=,'center,'>nc<a class=,'Sup,' href=,'#footnote-1,'>*</a><span class=,'Sup,'>,</span><a class=,'Sup,' href=,'#footnote-2,' name=,'footnote-reference-2,'>†</a>
<br/>up to 40% increase<a class=,'Sup,' href=,'#footnote-3,' name=,'footnote-reference-3,'>‡</a>
<br/>[CI: 12% increase, 60% increase]</td><td align=,'center,'>30% decrease<br/>[CI: 3% decrease, 48% decrease]</td>
</tr>
<tr class=,'Last,'>
<td align=,'center,'>Valproic acid</td><td align=,'center,'>400-2800</td><td align=,'center,'>600-1800</td><td align=,'center,'>nc<a class=,'Sup,' href=,'#footnote-1,'>*</a></td><td align=,'center,'>18% decrease<br/>[CI: 13% decrease, 40% decrease]</td>
</tr>
</tbody>
</table></div>
<p>In vivo, the plasma levels of phenytoin increased by up to 40% when oxcarbazepine was given at doses above 1200 mg/day. Therefore, when using doses of oxcarbazepine greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of phenytoin may be required. The increase of phenobarbital level, however, is small (15%) when given with oxcarbazepine.</p>
<p>Strong inducers of cytochrome P450 enzymes (i.e., carbamazepine, phenytoin and phenobarbital) have been shown to decrease the plasma levels of MHD (29%-40%).</p>
<p>No autoinduction has been observed with oxcarbazepine.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Hormonal Contraceptives</h2>
<p class=,'First,'>Coadministration of oxcarbazepine with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG). The mean AUC values of EE were decreased by 48% [90% CI: 22-65] in one study and 52% [90% CI: 38-52] in another study. The mean AUC values of LNG were decreased by 32% [90% CI: 20-45] in one study and 52% [90% CI: 42-52] in another study. Therefore, concurrent use of oxcarbazepine with hormonal contraceptives may render these contraceptives less effective. Studies with other oral or implant contraceptives have not been conducted.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Calcium Antagonists</h2>
<p class=,'First,'>After repeated coadministration of oxcarbazepine, the AUC of felodipine was lowered by 28% [90% CI: 20-33]. Verapamil produced a decrease of 20% [90% CI: 18-27] of the plasma levels of MHD.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Other Drug Interactions</h2>
<p class=,'First,'>Cimetidine, erythromycin and dextropropoxyphene had no effect on the pharmacokinetics of MHD. Results with warfarin show no evidence of interaction with either single or repeated doses of oxcarbazepine.</p>
</div>
<div class=,'Section,' data-sectioncode=,'34074-5,'>
<a name=,'S7.5,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Drug/Laboratory Test Interactions</h2>
<p class=,'First,'>There are no known interactions of oxcarbazepine with commonly used laboratory tests.</p>
</div>
</div>"
"oxybutynin","06301e49-2bcf-4ff1-8f33-39ccde1a2dd0","none found"
"oxycodone","08b29d8d-6145-494d-bfa0-c493179f5b5e","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Table 1 includes clinically significant drug interactions with oxycodone hydrochloride oral solution. <br/>  <br/> Table 1: Clinically Significant Drug Interactions with Oxycodone hydrochloride oral solution </p>
<br/>
<div class=,'scrollingtable,'><table border=,'0,' cellpadding=,'0,' cellspacing=,'0,' width=,'100%,'>
<colgroup>
<col width=,'23.5679396092362%,'/>
<col width=,'76.4320603907638%,'/>
</colgroup>
<tbody class=,'Headless,'>
<tr class=,'Botrule First,'>
<td class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'>Inhibitors of CYP3A4 and CYP2D6</span>  <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Clinical Impact: </span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'>The concomitant use of oxycodone hydrochloride oral solution and CYP3A4 inhibitors can increase the plasma concentration of oxycodone, resulting in increased or prolonged opioid effects. These effects could be more pronounced with concomitant use of Oxycodone hydrochloride oral solution and CYP2D6 and CYP3A4 inhibitors, particularly when an inhibitor is added after a stable dose of Oxycodone hydrochloride oral solution is achieved <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#Section_5.6,'>5.6</a>)].</span>
<br/>After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the oxycodone plasma concentration will decrease<span class=,'Italics,'> [see Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)]</span>, resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to oxycodone.<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Intervention: </span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'>If concomitant use is necessary, consider dosage reduction of Oxycodone hydrochloride oral solution until stable drug effects are achieved  <br/>Monitor patients for respiratory depression and sedation at frequent intervals. <br/>If a CYP3A4 inhibitor is discontinued, consider increasing the Oxycodone hydrochloride oral solution dosage until stable drug effects are achieved<span class=,'Italics,'> [see Dosage and Administration (<a href=,'#Section_2.2,'>2.2</a>)].</span> Monitor for signs of opioid withdrawal. <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Examples </span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'>Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g. ketoconazole), protease inhibitors (e.g., ritonavir) <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'>CYP3A4 Inducers</span>
<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Clinical Impact: </span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'>The concomitant use of oxycodone hydrochloride oral solution and CYP3A4 inducers can decrease the plasma concentration of oxycodone<span class=,'Italics,'> [see Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)],</span> resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to oxycodone <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#Section_5.6,'>5.6</a>)].</span>  <br/>After stopping a CYP3A4 inducer, as the effects of the inducer decline, the oxycodone plasma concentration will increase <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)]</span>, which could increase or prolong both the therapeutic effects and adverse reactions, and may cause serious respiratory depression. <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Intervention: </span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'>If concomitant use is necessary, consider increasing the oxycodone hydrochloride oral solution dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal. If a CYP3A4 inducer is discontinued, consider oxycodone hydrochloride oral solution dosage reduction and monitor for signs of respiratory depression. <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'>Examples <br/>
</td><td class=,'Rrule,' valign=,'top,'>Rifampin, carbamazepine, phenytoin <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'>Benzodiazepines and other Central Nervous System (CNS) Depressants </span>
<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Clinical Impact: </span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'>Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death. <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Intervention: </span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'>Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients closely for signs of respiratory depression and sedation <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#Section_5.7,'>5.7</a>)].</span>
<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Examples: </span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'>Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol. <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'>Serotonergic Drugs </span>
<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Clinical Impact: </span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'>The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#Section_5.9,'>5.9</a>)].</span>
<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Intervention: </span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'>If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue oxycodone hydrochloride oral solution if serotonin syndrome is suspected. <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Examples: </span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'>Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue). <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'>Monoamine Oxidase Inhibitors (MAOIs) </span>
<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Clinical Impact: </span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'>MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#Section_5.4,'>5.4</a>)].</span>
<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Intervention: </span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'>The use of oxycodone hydrochloride oral solution is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.  <br/>If urgent use of an opioid is necessary, use test doses and frequent titration of small doses to treat pain while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression. <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Examples </span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'>phenelzine, tranylcypromine, linezolid <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'>Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics </span>
<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Clinical Impact: </span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'>May reduce the analgesic effect of oxycodone hydrochloride oral solution and/or precipitate withdrawal symptoms.  <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Intervention: </span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'>Avoid concomitant use. <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Examples: </span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'>butorphanol, nalbuphine, pentazocine, buprenorphine <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'>Muscle Relaxants</span>
<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Clinical Impact: </span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'>Oxycodone may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Intervention: </span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'>Monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of oxycodone hydrochloride oral solution and/or the muscle relaxant as necessary. <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'>Diuretics</span>
<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Clinical Impact: </span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'>Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.  <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Intervention: </span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'>Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed. <br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' colspan=,'2,' valign=,'top,'><span class=,'Bold,'>Anticholinergic Drugs</span>
<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Clinical Impact: </span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'>The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. <br/>
</td>
</tr>
<tr class=,'Last,'>
<td class=,'Lrule Rrule,' valign=,'top,'><span class=,'Italics,'>Intervention: </span>
<br/>
</td><td class=,'Rrule,' valign=,'top,'>Monitor patients for signs of urinary retention or reduced gastric motility when oxycodone hydrochloride oral solution is used concomitantly with anticholinergic drugs. <br/>
</td>
</tr>
</tbody>
</table></div>
<br/>
</div>"
"aminosalicylic acid","6f2753dc-5f0c-4f49-9335-e519afb69ba6","none found"
"paclitaxel","4dbbb7c8-a4b5-484d-a2a4-4d925010fc44","none found"
"paroxetine","1383d713-79b9-45bd-bd06-65707f28bc99","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID_4a6bd315-c953-473a-85ea-8097c2f343e6,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>No drug-drug interaction studies have been conducted with paroxetine capsules.</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_2d83e202-14b0-4026-af74-7259dc025df1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Potential for Paroxetine Capsules to Affect Other Drugs </h2>
<p class=,'First,'>Paroxetine is a strong CYP2D6 inhibitor. Clinical drug interaction studies have been performed with substrates of CYP2D6 and show that paroxetine can inhibit the metabolism of drugs metabolized by CYP2D6 <span class=,'Italics,'>[see Clinical Pharmacology (12.3)]</span>. Table 2 contains examples of drugs with a metabolism that may be affected by co-administration with paroxetine capsules.</p>
<p>
<span class=,'Bold,'>Table 2 Effects of Paroxetine on Other Drugs</span>
</p>
<div class=,'scrollingtable,'><table width=,'100%,'>
<col width=,'33%,'/>
<col width=,'33%,'/>
<col width=,'33%,'/>
<tbody class=,'Headless,'>
<tr class=,'First,'>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Concomitant Drug Name</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Effect of Paroxetine on Other Drugs</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Clinical Recommendations</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Thioridazine</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Increased plasma concentrations of thioridazine</p>
<p>Potential QTc prolongation</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Concomitant use of thioridazine and paroxetine capsules is contraindicated.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Pimozide</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Increased plasma concentrations of pimozide.</p>
<p>Potential QTc prolongation</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Concomitant use of pimozide and paroxetine capsules in contraindicated.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Tamoxifen</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Reduced plasma concentrations of active tamoxifen metabolite</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Consider avoiding concomitant use of tamoxifen and paroxetine capsules.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Tricyclic Antidepressants (TCA) (e.g., Desipramine)</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Increased plasma concentrations and elimination half-life</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Plasma TCA concentrations may need to be monitored and the dose of TCA may need to be reduced if a TCA is co-administered with paroxetine capsules. Monitor tolerability.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Risperidone</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Increased plasma concentration of risperidone</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>A lower dosage of risperdone may be necessary (see the Full Prescribing Information for risperdone). Monitor tolerability.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Atomoxetine</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Increased exposure of atomoxetine</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>A lower dosage of risperdone may be necessary (see the Full Prescribing Information for risperdone). Monitor tolerability.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Drugs Highly Bound to Plasma Protein (e.g., Warfarin)</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Increased free plasma concentrations</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>The dosage of warfarin may need to be reduced. Monitor tolerability and the International Normalized Ratio.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Digoxin</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Decreased plasma concentrations of digoxin</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Dosage of digoxin may need to be increased. Monitor digoxin concentration and clinical effect.</p>
</td>
</tr>
<tr class=,'Last,'>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Theophylline</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Increased plasma concentrations of theophylline</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Dosage of theophylline may need to be decreased. Monitor theophylline concentrations and tolerability.</p>
</td>
</tr>
</tbody>
</table></div>
<p>Use caution if co-administering paroxetine capsules with other drugs that are metabolized by CYP2D6, including nortriptyline, amitriptyline, imipramine, desipramine, fluoxetine, phenothiazines, risperidone, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_ee431307-104e-4cac-95d3-7242822d2724,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Potential for Other Drugs to Affect Paroxetine Capsules </h2>
<p class=,'First,'>The metabolism and pharmacokinetics of paroxetine may be affected by the induction and inhibition of drug metabolizing enzymes such as CYP2D6. Table 3 contains a list of drugs that may affect the pharmacokinetics of paroxetine capsules when administered concomitantly <span class=,'Italics,'>[see Clinical Pharmacology (12.3)]</span>.</p>
<p>
<span class=,'Bold,'>Table 3 Effects of Other Drugs on Paroxetine</span>
</p>
<div class=,'scrollingtable,'><table width=,'100%,'>
<col width=,'33%,'/>
<col width=,'33%,'/>
<col width=,'33%,'/>
<tbody class=,'Headless,'>
<tr class=,'First,'>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Concomitant Drug Name</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Effect of Concomitant Drug on Paroxetine</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Clinical Recommendations</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Phenobarbital</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Decreased paroxetine exposure</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' rowspan=,'4,' valign=,'middle,'>
<p class=,'First,'>No dose adjustment for paroxetine capsules.</p>
<p>Monitor clinical effect of paroxetine capsules.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Phenytoin</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Decreased paroxetine exposure</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Fosamprenavir/Ritonavir</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Decreased plasma concentration of paroxetine</p>
</td>
</tr>
<tr class=,'Last,'>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Cimedtidine</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Increased plasma concentration of paroxetine</p>
</td>
</tr>
</tbody>
</table></div>
<p>Use caution if co-administering paroxetine capsules with other drugs that inhibit CYP2D6 (e.g., quinidine).</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_5947b966-499f-4ba6-a330-ebb91457c129,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Other Potentially Significant Drug Interactions </h2>
<p class=,'First,'>
<span class=,'Bold,'><span class=,'Underline,'>Monoamine Oxidase Inhibitors (MAOIs)</span></span>
</p>
<p>Serious adverse reactions such as serotonin syndrome have been reported in patients receiving a concomitant SSRI and MAOI, in patients started on an SSRI who recently received an MAOI and in patients started on an MAOI who recently received an SSRI. Therefore, concomitant use of MAOIs with paroxetine capsules or use of paroxetine capsules and an MAOI within 14 days of each other is contraindicated <span class=,'Italics,'>[see Dosage and Administration (2.2), Contraindications (4.1) and Warnings and Precautions (5.2)]</span>.</p>
<p>
<span class=,'Bold,'><span class=,'Underline,'>Serotonergic Drugs</span></span>
</p>
<p>If concomitant use of paroxetine capsules with other serotonergic drugs (e.g., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John’s Wort) is clinically warranted, consider the increased risk of serotonin syndrome and carefully observe the patient, particularly during treatment initiation <span class=,'Italics,'>[see Warnings and Precautions (5.2)]</span>.</p>
<p>An interaction between paroxetine and tryptophan may occur when they are co-administered. Adverse experiences, consisting primarily of headache, nausea, sweating, and dizziness, have been reported when tryptophan was administered to patients taking paroxetine. Consequently, concomitant use of paroxetine capsules with tryptophan is not recommended.</p>
<p>If concomitant use of paroxetine capsules with a serotonergic drug is warranted, carefully observe the patient, particularly during treatment initiation. There have been postmarketing reports of serotonin syndrome with the use of an SSRI and a triptan.</p>
<p>Paroxetine capsules contain paroxetine, which is also the active ingredient in other drugs. The concomitant use of paroxetine capsules with other paroxetine products is not recommended <span class=,'Italics,'>[see Indications and Usage (1)]</span>.</p>
<p>
<span class=,'Underline,'>Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin)</span>
</p>
<p>Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs are co-administered with NSAIDs, aspirin, and warfarin or other drugs that affect coagulation. There may be a pharmacodynamics interaction between paroxetine and warfarin that causes an increased bleeding diathesis despite unaltered prothrombin time. Carefully monitor patients receiving warfarin therapy when paroxetine capsules is initiated or discontinued <span class=,'Italics,'>[see Warnings and Precautions (5.4)]</span>.</p>
</div>
</div>"
"pegaspargase","ac7b6a6f-6ddb-48c6-8088-d8a8e3fea6ce","none found"
"pembrolizumab","9333c79b-d487-4538-a9f0-71b91a02b287","none found"
"penicillamine","01e79d8f-8c74-4f48-b761-9f225fabf93d","none found"
"pentamidine","c484f16e-9d97-4416-84a4-8ad8deaf5e19","none found"
"peppermint oil","0f1295c4-d37e-40d0-93f6-425e3b7881cc","none found"
"perindopril","fbb31482-9ac8-48c6-b814-5d467f22051b","none found"
"permethrin","041444b6-a71e-4d13-8d24-f2d104bf721d","none found"
"pertuzumab","17f85d17-ab71-4f5b-9fe3-0b8c822f69ff","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>No drug-drug interactions were observed between pertuzumab and trastuzumab, or between pertuzumab and docetaxel, paclitaxel, or carboplatin.</p>
</div>"
"phenobarbital","002ede85-8d0b-42c2-8567-cc174936aa0f","none found"
"penicillin V","066d5989-bec7-4917-86ac-3ec89882709e","none found"
"phenytoin","093fd736-5971-47af-b4ef-08c1696cebe8","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Phenytoin is extensively bound to plasma proteins and is prone to competitive displacement. Phenytoin is primarily metabolized by the hepatic cytochrome P450 enzyme CYP2C9 and to a lesser extent by CYP2C19 and is particularly susceptible to inhibitory drug interactions because it is subject to saturable metabolism. Inhibition of metabolism may produce significant increases in circulating phenytoin concentrations and enhance the risk of drug toxicity. Monitoring of phenytoin serum levels is recommended when a drug interaction is suspected.</p>
<p>Phenytoin is a potent inducer of hepatic drug-metabolizing enzymes.</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Drugs that Affect Phenytoin Concentrations</h2>
<p class=,'First,'>Table 2 includes commonly occurring drug interactions that affect phenytoin concentrations. However, this list is not intended to be inclusive or comprehensive. Individual prescribing information from relevant drugs should be consulted.</p>
<p>The addition or withdrawal of these agents in patients on phenytoin therapy may require an adjustment of the phenytoin dose to achieve optimal clinical outcome.</p>
<a name=,'table2,'></a>
<div class=,'scrollingtable,'><table width=,'95%,'>
<caption>
<span>Table 2: Drugs That Affect Phenytoin Concentrations</span>
</caption>
<col align=,'left,' valign=,'middle,' width=,'30%,'/>
<col align=,'left,' valign=,'middle,' width=,'70%,'/>
<thead>
<tr class=,'First Last,'>
<th align=,'left,' class=,'Lrule Rrule,'>Interacting Agent</th><th align=,'left,' class=,'Rrule,'>Examples</th>
</tr>
</thead>
<tfoot>
<tr>
<td align=,'left,' colspan=,'2,'>
<dl class=,'Footnote,'>
<dt>
<a href=,'#footnote-reference-1,' name=,'footnote-1,'>*</a>
</dt>
<dd>Antacids may affect absorption of phenytoin.</dd>
<dt>
<a href=,'#footnote-reference-2,' name=,'footnote-2,'>†</a>
</dt>
<dd>The induction potency of St. John's wort may vary widely based on preparation.</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody>
<tr class=,'Botrule First,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Drugs that may increase phenytoin serum levels</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Antiepileptic drugs</td><td align=,'left,' class=,'Rrule,'>Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Azoles</td><td align=,'left,' class=,'Rrule,'>Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Antineoplastic agents</td><td align=,'left,' class=,'Rrule,'>Capecitabine, fluorouracil</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Antidepressants</td><td align=,'left,' class=,'Rrule,'>Fluoxetine, fluvoxamine, sertraline</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Gastric acid reducing agents</td><td align=,'left,' class=,'Rrule,'>H<span class=,'Sub,'>2</span> antagonists (cimetidine), omeprazole</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Sulfonamides</td><td align=,'left,' class=,'Rrule,'>Sulfamethizole, sulfaphenazole, sulfadiazine, sulfamethoxazole-trimethoprim</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Other</td><td align=,'left,' class=,'Rrule,'>Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen, fluvastatin, isoniazid, methylphenidate, phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Drugs that may decrease phenytoin serum levels</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Antacids<a class=,'Sup,' href=,'#footnote-1,' name=,'footnote-reference-1,'>*</a></td><td align=,'left,' class=,'Rrule,'>Calcium carbonate, aluminum hydroxide, magnesium hydroxide<br/>  <span class=,'Italics Underline,'>Prevention or Management:</span> Phenytoin and antacids should not be taken at the same time of day</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Antineoplastic agents <br/>(usually in combination)</td><td align=,'left,' class=,'Rrule,'>Bleomycin, carboplatin, cisplatin, doxorubicin, methotrexate</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Antiviral agents</td><td align=,'left,' class=,'Rrule,'>Fosamprenavir, nelfinavir, ritonavir</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Antiepileptic drugs</td><td align=,'left,' class=,'Rrule,'>Carbamazepine, vigabatrin</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Other</td><td align=,'left,' class=,'Rrule,'>Chronic alcohol abuse, diazepam, diazoxide, folic acid, reserpine, rifampin, St. John's wort<a class=,'Sup,' href=,'#footnote-2,' name=,'footnote-reference-2,'>†</a>, sucralfate, theophylline</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Drugs that may either increase or decrease phenytoin serum levels</span></td>
</tr>
<tr class=,'Last,'>
<td align=,'left,' class=,'Lrule Rrule,'>Antiepileptic drugs</td><td align=,'left,' class=,'Rrule,'>Phenobarbital, valproate sodium, valproic acid</td>
</tr>
</tbody>
</table></div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Drugs Affected by Phenytoin</h2>
<p class=,'First,'>Table 3 includes commonly occurring drug interactions affected by phenytoin. However, this list is not intended to be inclusive or comprehensive. Individual drug package inserts should be consulted. The addition or withdrawal of phenytoin during concomitant therapy with these agents may require adjustment of the dose of these agents to achieve optimal clinical outcome.</p>
<a name=,'table3,'></a>
<div class=,'scrollingtable,'><table width=,'95%,'>
<caption>
<span>Table 3: Drugs Affected by Phenytoin</span>
</caption>
<col align=,'left,' valign=,'middle,' width=,'30%,'/>
<col align=,'left,' valign=,'middle,' width=,'70%,'/>
<thead>
<tr class=,'First Last,'>
<th align=,'left,' class=,'Lrule Rrule,'>Interacting Agent</th><th align=,'left,' class=,'Rrule,'>Examples</th>
</tr>
</thead>
<tfoot>
<tr>
<td align=,'left,' colspan=,'2,'>
<dl class=,'Footnote,'>
<dt>
<a href=,'#footnote-reference-3,' name=,'footnote-3,'>*</a>
</dt>
<dd>The effect of phenytoin on phenobarbital, valproic acid and sodium valproate serum levels is unpredictable</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody>
<tr class=,'Botrule First,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Drugs whose efficacy is impaired by phenytoin</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Azoles</td><td align=,'left,' class=,'Rrule,'>Fluconazole, ketoconazole, itraconazole, posaconazole, voriconazole</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Antineoplastic agents</td><td align=,'left,' class=,'Rrule,'>Irinotecan, paclitaxel, teniposide</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Delavirdine</td><td align=,'left,' class=,'Rrule,'>Phenytoin can substantially reduce the concentrations of delavirdine. This can lead to loss of virologic response and possible resistance <span class=,'Italics,'>[see <a href=,'#S4,'>Contraindications (4)</a>].</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Neuromuscular blocking agents</td><td align=,'left,' class=,'Rrule,'>Cisatracurium, pancuronium, rocuronium and vecuronium: resistance to the neuromuscular blocking action of the nondepolarizing neuromuscular blocking agents has occurred in patients chronically administered phenytoin. Whether or not phenytoin has the same effect on other non-depolarizing agents is unknown.<br/>  <span class=,'Italics Underline,'>Prevention or Management:</span> Patients should be monitored closely for more rapid recovery from neuromuscular blockade than expected, and infusion rate requirements may be higher.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Warfarin</td><td align=,'left,' class=,'Rrule,'>Increased and decreased PT/INR responses have been reported when phenytoin is coadministered with warfarin</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Other</td><td align=,'left,' class=,'Rrule,'>Corticosteroids, doxycycline, estrogens, furosemide, oral contraceptives, paroxetine, quinidine, rifampin, sertraline, theophylline, and vitamin D</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Drugs whose level is decreased by phenytoin</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Antiepileptic drugs<a class=,'Sup,' href=,'#footnote-3,' name=,'footnote-reference-3,'>*</a></td><td align=,'left,' class=,'Rrule,'>Carbamazepine, felbamate, lamotrigine, topiramate, oxcarbazepine</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Antilipidemic agents</td><td align=,'left,' class=,'Rrule,'>Atorvastatin, fluvastatin, simvastatin</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Antiviral agents</td><td align=,'left,' class=,'Rrule,'>Efavirenz, lopinavir/ritonavir, indinavir, nelfinavir, ritonavir, saquinavir Fosamprenavir: phenytoin when given with fosamprenavir alone may decrease the concentration of amprenavir, the active metabolite. Phenytoin when given with the combination of fosamprenavir and ritonavir may increase the concentration of amprenavir</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Calcium channel blockers</td><td align=,'left,' class=,'Rrule,'>Nifedipine, nimodipine, nisoldipine, verapamil</td>
</tr>
<tr class=,'Last,'>
<td align=,'left,' class=,'Lrule Rrule,'>Other</td><td align=,'left,' class=,'Rrule,'>Albendazole (decreases active metabolite), chlorpropamide, clozapine, cyclosporine, digoxin, disopyramide, folic acid, methadone, mexiletine, praziquantel, quetiapine</td>
</tr>
</tbody>
</table></div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Drug Enteral Feeding/Nutritional Preparations Interaction</h2>
<p class=,'First,'>Literature reports suggest that patients who have received enteral feeding preparations and/or related nutritional supplements have lower than expected phenytoin serum levels. It is therefore suggested that phenytoin not be administered concomitantly with an enteral feeding preparation. More frequent serum phenytoin level monitoring may be necessary in these patients.</p>
</div>
<div class=,'Section,' data-sectioncode=,'34074-5,'>
<a name=,'S7.4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Drug/Laboratory Test Interactions</h2>
<p class=,'First,'>Care should be taken when using immunoanalytical methods to measure serum phenytoin concentrations.</p>
</div>
</div>"
"vitamin K1","4b352b5f-32d6-4c28-b58c-b34ea2b78a87","none found"
"pilocarpine","f168b0a9-4e9a-47f7-b391-edcea871956e","none found"
"pimozide","70b079e2-a1f7-4a93-8685-d60a4d7c1280","none found"
"piroxicam","0c12b60f-ec25-4c59-8b2e-4445e600d051","none found"
"pitolisant","8daa5562-824e-476c-9652-26ceef3d4b0e","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'s_0700,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s_0701,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Drugs Having Clinically Important Interactions with WAKIX</h2>
<a name=,'table2,'></a>
<div class=,'scrollingtable,'><table class=,'Noautorules,' width=,'750,'>
<caption>
<span>Table 2: Clinically Significant Drug Interactions with WAKIX</span>
</caption>
<col align=,'left,' width=,'35%,'/>
<col align=,'left,' width=,'65%,'/>
<tbody class=,'Headless,'>
<tr valign=,'top,'>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,'><span class=,'Bold,'>Effect of Other Drugs on WAKIX</span></td>
</tr>
<tr valign=,'top,'>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,'><span class=,'Bold,'>Strong CYP2D6 Inhibitors</span></td>
</tr>
<tr valign=,'top,'>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'><span class=,'Italics,'>Clinical Implication:</span></td><td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'>Concomitant administration of WAKIX with strong CYP2D6 inhibitors increases pitolisant exposure by 2.2-fold. </td>
</tr>
<tr valign=,'top,'>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'><span class=,'Italics,'>Prevention or Management:</span></td><td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'>Reduce the dose of WAKIX by half <span class=,'Italics,'>[see see Dosage and Administration (<a href=,'#s_0204,'>2.4</a>), Clinical Pharmacology (<a href=,'#s_1203,'>12.3</a>)]</span>.</td>
</tr>
<tr valign=,'top,'>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'><span class=,'Italics,'>Examples:</span></td><td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'>paroxetine, fluoxetine, bupropion</td>
</tr>
<tr valign=,'top,'>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,'><span class=,'Bold,'>Strong CYP3A4 Inducers</span></td>
</tr>
<tr valign=,'top,'>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'><span class=,'Italics,'>Clinical Implication:</span></td><td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'>Concomitant use of WAKIX with strong CYP3A4 inducers decreases exposure of pitolisant by 50%.</td>
</tr>
<tr valign=,'top,'>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'><span class=,'Italics,'>Prevention or Management:</span></td><td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'>Assess for loss of efficacy after initiation of a strong CYP3A4 inducer. For patients stable on WAKIX 8.9 mg or 17.8 mg once daily, increase the dose of WAKIX to reach double the original daily dose (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days. If concomitant dosing of a strong CYP3A4 inducer is discontinued, decrease WAKIX dosage by half <span class=,'Italics,'>[see see Dosage and Administration (<a href=,'#s_0204,'>2.4</a>), Clinical Pharmacology (<a href=,'#s_1203,'>12.3</a>)]</span>.</td>
</tr>
<tr valign=,'top,'>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'><span class=,'Italics,'>Examples:</span></td><td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'>rifampin, carbamazepine, phenytoin</td>
</tr>
<tr valign=,'top,'>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,'><span class=,'Bold,'>Histamine-1 (H1) Receptor Antagonists</span></td>
</tr>
<tr valign=,'top,'>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'><span class=,'Italics,'>Clinical Implication:</span></td><td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'>WAKIX increases the levels of histamine in the brain; therefore, H1 receptor antagonists that cross the blood-brain barrier may reduce the effectiveness of WAKIX.</td>
</tr>
<tr valign=,'top,'>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'><span class=,'Italics,'>Prevention or Management:</span></td><td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'>Avoid centrally acting H1 receptor antagonists.</td>
</tr>
<tr valign=,'top,'>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'><span class=,'Italics,'>Examples:</span></td><td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'>pheniramine maleate, diphenhydramine, promethazine (anti-histamines) imipramine, clomipramine, mirtazapine (tri or tetracyclic antidepressants) </td>
</tr>
<tr valign=,'top,'>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,'><span class=,'Bold,'>QT Interval Prolongation</span></td>
</tr>
<tr valign=,'top,'>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'><span class=,'Italics,'>Clinical Implication:</span></td><td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'>Concomitant use of drugs that prolong the QT interval may add to the QT effects of WAKIX and increase the risk of cardiac arrhythmia. </td>
</tr>
<tr valign=,'top,'>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'><span class=,'Italics,'>Prevention or Management:</span></td><td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'>Avoid the use of WAKIX in combination with other drugs known to prolong the QT interval <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#s_0501,'>5.1</a>)]</span>.</td>
</tr>
<tr valign=,'top,'>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'><span class=,'Italics,'>Examples:</span></td><td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'>Class 1A antiarrhythmics: quinidine, procainamide, disopyramide;
												<br/>Class 3 antiarrhythmics: amiodarone, sotalol;
												<br/>Antipsychotics: ziprasidone, chlorpromazine, thioridazine;
												<br/>Antibiotics: moxifloxacin</td>
</tr>
<tr valign=,'top,'>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,'><span class=,'Bold,'>Effect of WAKIX on Other Drugs</span></td>
</tr>
<tr valign=,'top,'>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,'><span class=,'Bold,'>Sensitive CYP3A4 Substrates</span></td>
</tr>
<tr valign=,'top,'>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'><span class=,'Italics,'>Clinical Implication:</span></td><td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'>WAKIX is a borderline/weak inducer of CYP3A4. Therefore, reduced effectiveness of sensitive CYP3A4 substrates may occur when used concomitantly with WAKIX <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#s_1203,'>12.3</a>)]</span>. The effectiveness of hormonal contraceptives (e.g., ethinyl estradiol) may be reduced when used with WAKIX and effectiveness may be reduced for 21 days after discontinuation of therapy.</td>
</tr>
<tr valign=,'top,'>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'><span class=,'Italics,'>Prevention or Management:</span></td><td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'>Patients using hormonal contraception should be advised to use an alternative non-hormonal contraceptive method during treatment with WAKIX and for at least 21 days after discontinuation of treatment <span class=,'Italics,'>[see Use in Specific Populations (<a href=,'#s_0803,'>8.3</a>)].</span></td>
</tr>
<tr valign=,'top,'>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'><span class=,'Italics,'>Examples:</span></td><td align=,'left,' class=,'Botrule Lrule Rrule Toprule,'>midazolam, hormonal contraceptives, cyclosporine</td>
</tr>
</tbody>
</table></div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s_0702,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Drugs Having No Clinically Important Interactions with WAKIX</h2>
<p class=,'First,'>A clinical study was conducted to evaluate the concomitant use of WAKIX with modafinil or sodium oxybate. This study demonstrated no clinically relevant effect of modafinil or sodium oxybate on the pharmacokinetics of WAKIX and no effect of WAKIX on the pharmacokinetics of modafinil or sodium oxybate <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#s_1203,'>12.3</a>)]</span>.</p>
<p>A clinical study showed that strong CYP3A4 inhibitors (e.g., ketoconazole, grapefruit juice) have no effect on the pharmacokinetics of WAKIX <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#s_1203,'>12.3</a>)]</span>.</p>
</div>
</div>"
"plazomicin","0b82ffed-27f4-4f5c-8135-670c148f0e12","none found"
"podofilox","6af07697-5203-43e0-ba35-83683af851c3","none found"
"podophyllin","a83e0fd8-20cf-bc98-e053-2a95a90ae66d","none found"
"polygeline","a6190e09-e11b-6d25-e053-2995a90a1da2","none found"
"polyvinyl alcohol","01deb112-edf1-4ed6-bc04-672d02ce66ab","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_502b69ea-bc62-44f2-99bf-3b1e2befd8e4,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_aad62dd8-4638-413c-99a9-24543dc3b1dc,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1
Drugs and Supplements Increasing Serum Potassium</h2>
<p class=,'First,'>Concomitant administration of spironolactone with potassium supplementation or drugs that can increase potassium may lead to severe hyperkalemia. In general, discontinue potassium supplementation in heart failure patients who start spironolactone
         
 
  <span class=,'Italics,'> [see 
          
  
   <a href=,'#LINK_248d0a7c-d6e7-49d0-97d1-efcd3248692e,'>Warnings and Precautions (5.1)</a></span> and 
         
 
  <span class=,'Italics,'><a href=,'#LINK_40da22ab-9880-419c-aac4-3222230c217b,'>Clinical Pharmacology (12.3)</a>]
         
 
  </span>. Check serum potassium levels when ACE inhibitor or ARB therapy is altered in patients receiving spironolactone.
        

 </p>
<p>Examples of drugs that can increase potassium include: </p>
<ul class=,'Disc,'>
<li>ACE inhibitors </li>
<li>angiotensin receptor blockers </li>
<li>non-steroidal anti-inflammatory drugs (NSAIDs) </li>
<li>heparin and low molecular weight heparin </li>
<li>trimethoprim </li>
</ul>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_82fe4600-4a75-4177-b2a7-42d04e77c422,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Lithium</h2>
<p class=,'First,'>Like other diuretics, spironolactone reduces the renal clearance of lithium, thus increasing the risk of lithium toxicity. Monitor lithium levels periodically when spironolactone is co-administered 
         
 
  <span class=,'Italics,'>[see 
          
  
   <a href=,'#LINK_40da22ab-9880-419c-aac4-3222230c217b,'>Clinical Pharmacology (12.3)</a>]
         
 
  </span>.
        

 </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_febce621-b166-46c1-a83a-adfb45bc170e,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Nonsteroidal anti-inflammatory drugs (NSAIDs)</h2>
<p class=,'First,'>In some patients, the administration of an NSAID can reduce the diuretic, natriuretic, and antihypertensive effect of diuretics. Therefore, when spironolactone and NSAIDs are used concomitantly, monitor closely to determine if the desired effect of the diuretic is obtained 
         
 
  <span class=,'Italics,'>[see 
          
  
   <a href=,'#LINK_40da22ab-9880-419c-aac4-3222230c217b,'>Clinical Pharmacology (12.3)</a>]
         
 
  </span>.
        

 </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_3d983fdb-3c66-4e79-8088-139190fb93a4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Digoxin</h2>
<p class=,'First,'>Spironolactone and its metabolites interfere with radioimmunoassays for digoxin and increase the apparent exposure to digoxin. It is unknown to what extent, if any, spironolactone may increase actual digoxin exposure. In patients taking concomitant digoxin, use an assay that does not interact with spironolactone.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_4b87dd60-1de4-4ddb-95af-28596126d9ef,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Cholestyramine</h2>
<p class=,'First,'>Hyperkalemic metabolic acidosis has been reported in patients given spironolactone concurrently with cholestyramine. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_b2163e71-e135-446b-8697-960787f3b050,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6 Acetylsalicylic Acid</h2>
<p class=,'First,'>Acetylsalicylic acid may reduce the efficacy of spironolactone. Therefore, when spironolactone and acetylsalicylic acid are used concomitantly, spironolactone may need to be titrated to higher maintenance dose and the patient should be observed closely to determine if the desired effect is obtained 
         
 
  <span class=,'Italics,'>[see 
          
  
   <a href=,'#LINK_40da22ab-9880-419c-aac4-3222230c217b,'>Clinical Pharmacology (12.3)</a>]
         
 
  </span>. 
        

 </p>
</div>
</div>"
"potassium chloride","142c30ff-a839-4616-8167-ad4b07d8456f","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_3cbf8658-f087-4e22-b1c5-bd3768a93850,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_47d40867-0427-4206-b848-9679ca06c036,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Potassium-Sparing Diuretics</h2>
<p class=,'First,'>Use with potassium-sparing diuretic can produce severe hyperkalemia. Avoid concomitant use.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_c2aaf14d-4640-4a31-90e1-f88813e9a48f,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Renin-Angiotensin-Aldosterone System Inhibitors</h2>
<p class=,'First,'>Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy.<br/>
</p>
<br/>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_29d613ef-7ad1-4a38-b654-2dbac0f9b9d6,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)</h2>
<p class=,'First,'>NSAIDS may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients on concomitant NSAIDs.</p>
</div>
</div>"
"potassium iodide","d9e02a48-8129-9076-78b2-db01750bd220","none found"
"povidone-iodine","0bd3de76-b726-41f1-87bc-14ab8a1eca8e","none found"
"pralidoxime","241f42a0-1a33-40e8-8221-201767d999e5","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'s21,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s22,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Succinylcholine and Mivacurium
</h2>
<p class=,'First,'>Since pralidoxime in DuoDote reactivates cholinesterases and succinylcholine and mivacurium are metabolized by cholinesterases, patients with organophosphorus nerve agent or organophosphorus insecticide poisoning who have received DuoDote may exhibit accelerated reversal of the neuromuscular blocking effects of succinylcholine and mivacurium (relative to poisoned patients who have not received pralidoxime). Monitor for neuromuscular effects with concomitant administration.
</p>
</div>
</div>"
"pramipexole","a7405a56-de1c-4875-b57f-210c991474ba","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>See also <span class=,'Italics,'>Dosage and Administration <a href=,'#Section_2.4,'>(2.2)</a>and Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)</span>
</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Dopamine Antagonists</h2>
<p class=,'First,'>Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of pramipexole dihydrochloride tablets.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Drug/Laboratory Test Interactions</h2>
<p class=,'First,'>There are no known interactions between pramipexole and laboratory tests.</p>
</div>
</div>"
"prasugrel","04e7e0e8-2199-438f-83db-6b8f0f219b99","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'s28,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s29,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Warfarin</h2>
<p class=,'First,'>Coadministration of prasugrel and warfarin increases the risk of bleeding 
         
 
  <span class=,'Italics,'>[see Warnings and Precautions (
          
  
   <a href=,'#s13,'>5.1</a>) and Clinical Pharmacology (
          
  
   <a href=,'#s51,'>12.3</a>)]
         
 
  </span>.
        

 </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s30,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Non-Steroidal Anti-Inflammatory Drugs</h2>
<p class=,'First,'>Coadministration of prasugrel and NSAIDs (used chronically) may increase the risk of bleeding 
         
 
  <span class=,'Italics,'>[see Warnings and Precautions (
          
  
   <a href=,'#s13,'>5.1</a>)]
         
 
  </span>.
        

 </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s300,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Opioids</h2>
<p class=,'First,'>As with other oral P2Y
         
 
  <span class=,'Sub,'>12</span> inhibitors, co-administration of opioid agonists delay and reduce the absorption of prasugrel’s active metabolite presumably because of slowed gastric emptying 
         
 
  <span class=,'Italics,'>[see Clinical Pharmacology (
          
  
   <a href=,'#s51,'>12.3</a>)]
         
 
  </span>.
        

 </p>
<p>Consider the use of a parenteral anti-platelet agent in acute coronary syndrome patients requiring co-administration of morphine or other opioid agonists.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s31,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Other Concomitant Medications</h2>
<p class=,'First,'>Prasugrel tablets can be administered with drugs that are inducers or inhibitors of cytochrome P450 enzymes 
         
 
  <span class=,'Italics,'>[see Clinical Pharmacology (
          
  
   <a href=,'#s51,'>12.3</a>)]
         
 
  </span>.
        

 </p>
<p>Prasugrel tablets can be administered with aspirin (75-mg to 325-mg per day), heparin, GPIIb/IIIa inhibitors, statins, digoxin, and drugs that elevate gastric pH, including proton pump inhibitors and H
         
 
  <span class=,'Sub,'>2</span> blockers 
         
 
  <span class=,'Italics,'>[see Clinical Pharmacology (
          
  
   <a href=,'#s51,'>12.3</a>)]
         
 
  </span>.
        

 </p>
</div>
</div>"
"pravastatin","056475c8-59c2-469c-9175-7162065726f5","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'i4i_interactions_id_ae59c377-6ea4-4365-93b7-933e87ffe118,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Bold,'>For the concurrent therapy of either cyclosporine, fibrates, niacin (nicotinic acid), or erythromycin, the risk of myopathy increases 
   <span class=,'Italics,'>[see 
    <a href=,'#i4i_section_id_72e7bd66-c029-4e07-a36d-916ba68f7fab,'>Warnings and Precautions (5.1)</a> and 
    <a href=,'#i4i_pharmacokinetics_id_b914af30-9729-4d26-9261-c018fcfeb22e,'>Clinical Pharmacology (12.3)</a>]. 
   </span></span>
</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_b4e83b8f-2e44-4294-8b55-85e836bc3540,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Cyclosporine</h2>
<p class=,'First,'>The risk of myopathy/rhabdomyolysis is increased with concomitant administration of cyclosporine. Limit pravastatin to 20 mg once daily for concomitant use with cyclosporine 
         
 
  <span class=,'Italics,'>[see 
          
  
   <a href=,'#i4i_section_id_44c430bc-9ef0-477c-a084-47dbc69d0408,'>Dosage and Administration (2.6)</a>, 
          
  
   <a href=,'#i4i_section_id_72e7bd66-c029-4e07-a36d-916ba68f7fab,'>Warnings and Precautions (5.1)</a>, and 
          
  
   <a href=,'#i4i_pharmacokinetics_id_b914af30-9729-4d26-9261-c018fcfeb22e,'>Clinical Pharmacology (12.3)</a>].
         
 
  </span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_64ee3fbb-e6f1-442e-8cbe-93e518470867,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Clarithromycin and Other Macrolide Antibiotics</h2>
<p class=,'First,'>The risk of myopathy/rhabdomyolysis is increased with concomitant administration of clarithromycin. Limit pravastatin to 40 mg once daily for concomitant use with clarithromycin 
         
 
  <span class=,'Italics,'>[see 
          
  
   <a href=,'#i4i_section_id_e141e9cb-01e3-44ab-84e3-04670ac0b555,'>Dosage and Administration (2.7)</a>, 
          
  
   <a href=,'#i4i_section_id_72e7bd66-c029-4e07-a36d-916ba68f7fab,'>Warnings and Precautions (5.1)</a>, and 
          
  
   <a href=,'#i4i_pharmacokinetics_id_b914af30-9729-4d26-9261-c018fcfeb22e,'>Clinical Pharmacology (12.3)</a>].
         
 
  </span>
</p>
<p>Other macrolides (e.g., erythromycin and azithromycin) have the potential to increase statin exposures while used in combination. Pravastatin should be used cautiously with macrolide antibiotics due to a potential increased risk of myopathies.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_0dae0ee0-ac53-4ac4-9d0a-a51b2042154a,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Colchicine</h2>
<p class=,'First,'>The risk of myopathy/rhabdomyolysis is increased with concomitant administration of colchicine 
         
 
  <span class=,'Italics,'>[see 
          
  
   <a href=,'#i4i_section_id_72e7bd66-c029-4e07-a36d-916ba68f7fab,'>Warnings and Precautions (5.1)</a>].
         
 
  </span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_b4de3766-17a4-43ea-a45e-416c183fefb8,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Gemfibrozil</h2>
<p class=,'First,'>Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are coadministered with gemfibrozil, concomitant administration of pravastatin sodium with gemfibrozil should be avoided 
         
 
  <span class=,'Italics,'>[see 
          
  
   <a href=,'#i4i_section_id_72e7bd66-c029-4e07-a36d-916ba68f7fab,'>Warnings and Precautions (5.1)</a>].
         
 
  </span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_8c390154-bac8-41f7-b25c-559d41d70fdf,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Other Fibrates</h2>
<p class=,'First,'>Because it is known that the risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates, pravastatin sodium should be administered with caution when used concomitantly with other fibrates 
         
 
  <span class=,'Italics,'>[see 
          
  
   <a href=,'#i4i_section_id_72e7bd66-c029-4e07-a36d-916ba68f7fab,'>Warnings and Precautions (5.1)</a>].
         
 
  </span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'i4i_section_id_c3f4eb05-3ec4-4282-8736-5b85ba56e13a,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6 Niacin</h2>
<p class=,'First,'>The risk of skeletal muscle effects may be enhanced when pravastatin is used in combination with niacin; a reduction in pravastatin sodium dosage should be considered in this setting 
         
 
  <span class=,'Italics,'>[see 
          
  
   <a href=,'#i4i_section_id_72e7bd66-c029-4e07-a36d-916ba68f7fab,'>Warnings and Precautions (5.1)</a>].
         
 
  </span>
</p>
</div>
</div>"
"prednisolone","246703b1-a792-4653-a391-02d3c6212cb7","none found"
"pregabalin","031f843b-9251-49c7-b2e7-be4cbd2e2295","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Lc5df898a-8fd7-4969-b080-949c5aefb4c4,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (less than 2% of a dose recovered in urine as metabolites), and does not bind to plasma proteins, its pharmacokinetics are unlikely to be affected by other agents through metabolic interactions or protein binding displacement. <span class=,'Italics,'>In vitro</span> and <span class=,'Italics,'>in vivo</span> studies showed that pregabalin is unlikely to be involved in significant pharmacokinetic drug interactions. <span>Specifically, there are no pharmacokinetic interactions between pregabalin and the following antiepileptic drugs: carbamazepine, valproic acid, lamotrigine, phenytoin, phenobarbital, and topiramate. Important pharmacokinetic interactions would also not be expected to occur between pregabalin and commonly used antiepileptic drugs </span><span class=,'Italics,'>[see <a href=,'#L666335c0-b2b1-4dae-829a-23a60e05402e,'>Clinical Pharmacology (12)</a>]</span><span>.</span>
</p>
<p>
<span class=,'Italics,'>Pharmacodynamics</span>
</p>
<p>Multiple oral doses of pregabalin were co-administered with oxycodone, lorazepam, or ethanol. Although no pharmacokinetic interactions were seen, additive effects on cognitive and gross motor functioning were seen when pregabalin was co-administered with these drugs. No clinically important effects on respiration were seen.</p>
</div>"
"primaquine","0c8c2bc6-428b-40b6-8114-6df80290878d","none found"
"probenecid","38a2d4c1-e329-2dbb-e054-00144ff8d46c","none found"
"procainamide","8192d79d-da2b-2532-e053-2991aa0ae8ad","none found"
"penicillin G procaine","07fe2b47-34ac-4a20-be67-3c788c77b207","none found"
"prochlorperazine","383744db-ba57-478a-8041-2ecc26d3e1ec","none found"
"proguanil","0100f9fd-5d4a-4ee6-9c7f-0b60e69e78b8","none found"
"promethazine","4f681538-7ac4-484c-9e6d-b571d73b9e0b","none found"
"propafenone","2492317c-8b04-477e-a5d2-53e791fface9","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID_9ebc2f79-d53a-4d54-827a-bf8324ed4867,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_83309fa3-c340-4a59-9bef-c140dda1ea98,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1	CYP2D6 and CYP3A4 Inhibitors  </h2>
<p class=,'First,'>Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, grapefruit juice) can be expected to cause increased plasma levels of propafenone. The combination of CYP3A4 inhibition and either CYP2D6 deficiency or CYP2D6 inhibition with administration of propafenone may increase the risk of adverse reactions, including proarrhythmia. Therefore, simultaneous use of propafenone hydrochloride tablets with both a CYP2D6 inhibitor and a CYP3A4 inhibitor should be avoided <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#ID_f476e858-ad7f-42f0-9941-5c53167e2445,'>5.4</a>), Dosage and Administration (<a href=,'#ID_4cb6a7c9-4ff9-41a0-97af-f2650be406dd,'>2</a>)]</span>.</p>
<p>
<span class=,'Underline,'>Amiodarone</span>
<br/>Concomitant administration of propafenone and amiodarone can affect conduction and repolarization and is not recommended.</p>
<p>
<span class=,'Underline,'>Cimetidine</span>
<br/>Concomitant administration of propafenone immediate-release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone.</p>
<p>
<span class=,'Underline,'>Fluoxetine</span>
<br/>Concomitant administration of propafenone and fluoxetine in extensive metabolizers increased the S-propafenone C<span class=,'Sub,'>max</span> and AUC by 39% and 50%, respectively, and the R-propafenone C<span class=,'Sub,'>max</span> and AUC by 71% and 50%, respectively.</p>
<p>
<span class=,'Underline,'>Quinidine</span>
<br/>Small doses of quinidine completely inhibit the CYP2D6 hydroxylation metabolic pathway, making all patients, in effect, slow metabolizers <span class=,'Italics,'>[see Clinical Pharmacology (</span><span class=,'Italics,'><a href=,'#ID_76209303-d50f-4fd0-a919-1a933d2d58d4,'>12.3</a></span><span class=,'Italics,'>)]</span>. Concomitant administration of quinidine (50 mg 3 times daily) with 150 mg immediate-release propafenone 3 times daily decreased the clearance of propafenone by 60% in extensive metabolizers, making them slow metabolizers. Steady-state plasma concentrations more than doubled for propafenone and decreased 50% for 5-OH-propafenone. A 100-mg dose of quinidine tripled steady-state concentrations of propafenone. Avoid concomitant use of propafenone and quinidine.</p>
<p>
<span class=,'Underline,'>Rifampin</span>
<br/>Concomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5-OH-propafenone by 65%. The concentrations of norpropafenone increased by 30%. In slow metabolizers, there was a 50% decrease in propafenone plasma concentrations and an increase in the AUC and C<span class=,'Sub,'>max</span> of norpropafenone by 74% and 20%, respectively. Urinary excretion of propafenone and its metabolites decreased significantly. Similar results were noted in elderly patients: Both the AUC and C<span class=,'Sub,'>max</span> of propafenone decreased by 84%, with a corresponding decrease in AUC and C<span class=,'Sub,'>max</span> of 5-OH-propafenone by 69% and 57%, respectively.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_556a9584-8379-4e82-9c9d-c0c4df772d7e,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 	Digoxin  </h2>
<p class=,'First,'>Concomitant use of propafenone and digoxin increased steady-state serum digoxin exposure (AUC) in patients by 60% to 270% and decreased the clearance of digoxin by 31% to 67%. Monitor plasma digoxin levels of patients receiving propafenone and adjust digoxin dosage as needed.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_5d410f69-2379-4a28-a801-8f1b68e752e2,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 	Warfarin  </h2>
<p class=,'First,'>The concomitant administration of propafenone and warfarin increased warfarin plasma concentrations at steady state by 39% in healthy volunteers and prolonged the prothrombin time (PT) in patients taking warfarin. Adjust the warfarin dose as needed by monitoring INR (international normalized ratio).</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_08f6f08c-e9bb-4fe6-ab0b-76983eb28a56,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 	Orlistat  </h2>
<p class=,'First,'>Orlistat may limit the fraction of propafenone available for absorption. In postmarketing reports, abrupt cessation of orlistat in patients stabilized on propafenone has resulted in severe adverse events including convulsions, atrioventricular block, and acute circulatory failure.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_4d2ece98-1221-4da6-8775-c1e3a8f029e4,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 	Beta-Antagonists  </h2>
<p class=,'First,'>Concomitant use of propafenone and propranolol in healthy subjects increased propranolol plasma concentrations at steady state by 113%. In 4 patients, administration of metoprolol with propafenone increased the metoprolol plasma concentrations at steady state by 100% to 400%. The pharmacokinetics of propafenone was not affected by the coadministration of either propranolol or metoprolol. In clinical trials using propafenone immediate-release tablets, subjects who were receiving beta-blockers concurrently did not experience an increased incidence of side effects.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_c329a1fe-354e-46fe-b45f-975b8dfc291e,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6 	Lidocaine  </h2>
<p class=,'First,'>No significant effects on the pharmacokinetics of propafenone or lidocaine have been seen following their concomitant use in patients. However, concomitant use of propafenone and lidocaine has been reported to increase the risks of central nervous system side effects of lidocaine.</p>
</div>
</div>"
"propofol","008eb28a-6a54-479f-9530-273b8376f764","none found"
"propylthiouracil","84eae11a-b572-4570-b288-ac2cdd374186","none found"
"alprostadil","bb155759-3889-4cb3-9695-42a588f4f689","none found"
"dinoprostone","ab03de5b-782c-4f81-a8dc-7ef9969dd0cf","none found"
"protamine sulfate (USP)","7a31fc4c-579f-45cc-9559-39cfad9a57b3","none found"
"pyridostigmine","0b296555-c32f-42db-b5f3-ea981a3dd2f8","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Mefloquine</h2>
<p class=,'First,'>A potential interaction between the antimalarial drug mefloquine and pyridostigmine bromide exists through a possible additive effect on the gastrointestinal tract. The most common complaint about both drugs is loose bowels. It has been reported that simple additive effects on the atrial rate occur when mefloquine and pyridostigmine bromide are combined.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Other Anticholinesterase Drugs</h2>
<p class=,'First,'>Because anticholinesterase drugs are often used in the treatment of glaucoma, the use of pyridostigmine bromide in such situations may have an additive effect that may cause or exacerbate problems with night vision.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Narcotics</h2>
<p class=,'First,'>The bradycardia associated with the use of narcotics may exacerbate pyridostigmine-induced bradycardia.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Drugs that Interfere with Neuromuscular Transmission</h2>
<p class=,'First,'>Particular caution should be observed in the administration of depolarizing neuromuscular blocking agents (eg, succinylcholine) during surgery since the degree of neuromuscular blockade that ensues may be enhanced by previously administered pyridostigmine bromide. Doses of non-depolarizing neuromuscular blocking agents (eg, pancuronium bromide) may need to be increased in patients previously administered pyridostigmine bromide. Atropine antagonizes the muscarinic effects of pyridostigmine bromide, and this interaction is utilized to counteract the muscarinic symptoms of pyridostigmine bromide toxicity. Anticholinesterase agents are sometimes effective in reversing neuromuscular block induced by aminoglycoside antibiotics. However, aminoglycoside antibiotics, local and some general anesthetics, antiarrhythmic agents, and other drugs that interfere with neuromuscular transmission should be used cautiously, if at all, during treatment with pyridostigmine bromide.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.5,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol)</h2>
<p class=,'First,'>Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine bromide by increasing production of acetylcholine.</p>
</div>
</div>"
"pyridoxine","946c8e50-08d0-755d-e053-2a95a90a84de","none found"
"quetiapine","02b19885-2987-4c46-8d2a-5e59656f72e8","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID1508,'></a><a name=,'section-8,'></a>
<p></p>
<div class=,'Section,'>
<a name=,'ID1509,'></a><a name=,'section-8.1,'></a>
<p></p>
<h2>7.1 Effect of Other Drugs on Quetiapine</h2>
<p class=,'First,'>
<a name=,'ID1510,'></a>The risks of using quetiapine in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor effects of alcohol in a clinical trial in subjects with selected psychotic disorders, and alcoholic beverages should be limited while taking quetiapine.  </p>
<p>Quetiapine exposure is increased by the prototype CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, indinavir, ritonavir, nefazodone, etc.) and decreased by the prototype CYP3A4 inducers (e.g, phenytoin, carbamazepine, rifampin, avasimibe, St. John's wort etc.). Dose adjustment of quetiapine will be necessary if it is co-administered with potent CYP3A4 inducers or inhibitors.</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>CYP3A4</span></span> 
         
 
  <span class=,'Bold,'><span class=,'Italics,'>Inhibitors</span></span>
</p>
<p>Coadministration of ketoconazole, a potent inhibitor of cytochrome CYP3A4, resulted in significant increase in quetiapine exposure. The dose of quetiapine should be reduced to one sixth of the original dose if co-administered with a strong CYP3A4 inhibitor [see 
         
 
  <span class=,'Bold,'>DOSAGE</span> 
         
 
  <span class=,'Bold,'>AND</span> 
         
 
  <span class=,'Bold,'>ADMINISTRATION</span> (
         
 
  <span class=,'Bold,'><a href=,'#ID1399,'>2.5</a></span>) and 
         
 
  <span class=,'Bold,'>CLINICAL</span> 
         
 
  <span class=,'Bold,'>PHARMACOLOGY</span> (
         
 
  <span class=,'Bold,'><a href=,'#ID1552,'>12.3</a></span>)].
        

 </p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>CYP3A4</span></span> 
         
 
  <span class=,'Bold,'><span class=,'Italics,'>Inducers</span></span>
</p>
<p>Coadministration of quetiapine and phenytoin, a CYP3A4 inducer increased the mean oral clearance of quetiapine by 5-fold. Increased doses of quetiapine up to 5 fold may be required to maintain control of symptoms of schizophrenia in patients receiving quetiapine and phenytoin, or other known potent CYP3A4 inducers [see 
         
 
  <span class=,'Bold,'>DOSAGE</span> 
         
 
  <span class=,'Bold,'>AND</span> 
         
 
  <span class=,'Bold,'>ADMINISTRATION</span> (
         
 
  <span class=,'Bold,'><a href=,'#ID1401,'>2.6</a></span>) and 
         
 
  <span class=,'Bold,'>CLINICAL</span> 
         
 
  <span class=,'Bold,'>PHARMACOLOGY</span> (
         
 
  <span class=,'Bold,'><a href=,'#ID1552,'>12.3</a></span>)]. When the CYP3A4 inducer is discontinued, the dose of quetiapine should be reduced to the original level within 7 to 14 days [see 
         
 
  <span class=,'Bold,'>DOSAGE</span> 
         
 
  <span class=,'Bold,'>AND</span> 
         
 
  <span class=,'Bold,'>ADMINISTRATION</span> (
         
 
  <span class=,'Bold,'><a href=,'#ID1401,'>2.6</a></span>)].
        

 </p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Anticholinergic Drugs</span></span>
</p>
<p>Concomitant treatment with quetiapine and other drugs with anticholinergic activity can increase the risk for severe gastrointestinal adverse reactions related to hypomotility. Quetiapine should be used with caution in patients receiving medications having anticholinergic (antimuscarinic) effects [see 
         
 
  <span class=,'Bold,'>WARNINGS AND PRECAUTIONS (
          
  
   <a href=,'#ID1670,'>5.20</a>)
         
 
  </span>].
        

 </p>
<p>The potential effects of several concomitant medications on quetiapine pharmacokinetics were studied [see 
         
 
  <span class=,'Bold,'>CLINICAL</span> 
         
 
  <span class=,'Bold,'>PHARMACOLOGY</span> (
         
 
  <span class=,'Bold,'><a href=,'#ID1552,'>12.3</a></span>)].
        

 </p>
</div>
<div class=,'Section,'>
<a name=,'ID1511,'></a><a name=,'section-8.2,'></a>
<p></p>
<h2>7.2 Effect of Quetiapine on Other Drugs</h2>
<p class=,'First,'>
<a name=,'ID1512,'></a>Because of its potential for inducing hypotension, quetiapine may enhance the effects of certain antihypertensive agents.</p>
<p>Quetiapine may antagonize the effects of levodopa and dopamine agonists.</p>
<p>There are no clinically relevant pharmacokinetic interactions of quetiapine on other drugs based on the CYP pathway. Quetiapine and its metabolites are non-inhibitors of major metabolizing CYP's (1A2, 2C9, 2C19, 2D6 and 3A4).</p>
</div>
</div>"
"quinapril","0a0aff51-3b61-4cde-a415-0694afec99eb","none found"
"quinidine","02a34403-3cb9-4de7-8c40-9da281a8e5e1","none found"
"quinine","0b5bbefd-5b56-46f9-84f5-1456371577fd","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Table 1 below presents clinically significant drug interactions with quinine sulfate capsules.</p>
<p>
<span class=,'Bold,'>Table 1: Clinically Significant Drug Interactions with quinine sulfate capsules</span>
</p>
<div class=,'scrollingtable,'><table cellpadding=,'2.9pt,' width=,'100%,'>
<col width=,'30%,'/>
<col width=,'30%,'/>
<col width=,'40%,'/>
<thead>
<tr class=,'First Last,'>
<th align=,'center,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'><span class=,'Bold,'>Drug(s)</span></th><th align=,'center,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'><span class=,'Bold,'>Clinical Impact</span></th><th align=,'center,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'><span class=,'Bold,'>Recommendation</span></th>
</tr>
</thead>
<tbody>
<tr class=,'First,'>
<td align=,'center,' class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Effects of Drugs and Other Substances on Quinine Pharmacokinetics</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Antacids</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Antacids containing aluminum and/or magnesium may delay or decrease absorption of quinine. </p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Concomitant administration of these antacids withquinine sulfate capsules should be avoided.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Antiepileptics (AEDs) (carbamazepine, phenobarbital, and phenytoin)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Carbamazepine, phenobarbital, and phenytoin are CYP3A4 inducers and may decrease quinine plasma concentrations if used concurrently with quinine sulfate capsules.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>If concomitant administration with carbamazepine or phenobarbital cannot be avoided, frequent monitoring of anticonvulsant drug concentrations is recommended. Additionally, patients should be monitored closely for adverse reactions associated with these anticonvulsants.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Histamine H<span class=,'Sub,'>2</span>-receptor blockers [cimetidine, ranitidine (nonspecific CYP450 inhibitors)]</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>When quinine is to be given concomitantly with a histamine H<span class=,'Sub,'>2</span>-receptor blocker, the use of ranitidine is preferred over cimetidine. Although cimetidine and ranitidine may be used concomitantly with quinine sulfate capsules<span class=,'Italics,'> [see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Patients should be monitored closely for adverse events associated with quinine.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Ketoconazole (CYP3A4 inhibitor)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>No change in the quinine sulfate capsules dosage regimen is necessary with concomitant ketoconazole <span class=,'Italics,'>[see <a href=,'#ID_381d1070-9a30-4952-96c4-80a527ae84d3,'>Clinical Pharmacology (12.3)].</a></span>
</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Patients should be monitored closely for adverse reactions associated with quinine.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Macrolide antibiotics (erythromycin, troleandomycin) (CYP3A4 inhibitors)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Increased quinine plasma levels have been observed when used concomitantly <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Concomitant administration of macrolide antibiotics such as erythromycin or troleandomycin with quinine sulfate capsules should be avoided <span class=,'Italics,'>[see <a href=,'#S5.3,'>Warnings and Precautions (5.4)</a>]</span>.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Rifampin (CYP3A4 inducer)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Decreased quinine plasma levels have been observed when used concomitantly <span class=,'Italics,'>[see <a href=,'#ID_381d1070-9a30-4952-96c4-80a527ae84d3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Concomitant administration of rifampin with quinine sulfate capsules should be avoided <span class=,'Italics,'>[see <a href=,'#S5.4,'>Warnings and Precautions (5.5)</a>]</span>.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Ritonavir</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Increased quinine plasma levels have been observed when used concomitantly <span class=,'Italics,'>[see <a href=,'#ID_381d1070-9a30-4952-96c4-80a527ae84d3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Concomitant administration of ritonavir with quinine sulfate capsules should be avoided.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Tetracycline</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Tetracycline may be concomitantly administered with quinine sulfate capsules<span class=,'Italics,'> [see <a href=,'#ID_381d1070-9a30-4952-96c4-80a527ae84d3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Patients should be monitored closely for adverse reactions associated with quinine sulfate.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Theophylline or aminophylline</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>No change in the quinine sulfate capsules dosage regimen is necessary with concomitant theophylline or aminophylline <span class=,'Italics,'>[see <a href=,'#ID_381d1070-9a30-4952-96c4-80a527ae84d3,'>Clinical Pharmacology (12.3)].</a></span>
</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Patients should be monitored closely for adverse reactions associated with quinine.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Urinary alkalizers (acetazolamide, sodium bicarbonate)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Urinary alkalinizing agents may increase plasma quinine concentrations.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Use caution if using concomitantly.</p>
</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule,' colspan=,'3,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Effects of Quinine on the Pharmacokinetics of Other Drugs</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Anticonvulsants (carbamazepine, phenobarbital, and phenytoin)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Carbamazepine, phenobarbital, and phenytoin are CYP3A4 inducers and may decrease quinine plasma concentrations if used concurrently with quinine sulfate capsules<span class=,'Italics,'> [see <a href=,'#ID_381d1070-9a30-4952-96c4-80a527ae84d3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>If concomitant administration with carbamazepine or phenobarbital cannot be avoided, frequent monitoring of anticonvulsant drug concentrations is recommended. Patients should be monitored closely for adverse reactions associated with these anticonvulsants.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Astemizole (CYP3A4 substrate)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Elevated plasma astemizole concentrations were reported in a subject who experienced torsades de pointes after receiving three doses of quinine sulfate for nocturnal leg cramps concomitantly with chronic astemizole 10 mg/day.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>The concurrent use of quinine sulfate capsules with astemizole and other CYP3A4 substrates with QT prolongation potential (e.g., cisapride, terfenadine, halofantrine, pimozide and quinidine) should also be avoided <span class=,'Italics,'>[see <a href=,'#S5.3,'>Warnings and Precautions (5.4)</a>]</span>.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Atorvastatin (CYP3A4 substrate)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Rhabdomyolysis with acute renal failure secondary to myoglobinuria was reported in a patient taking atorvastatin administered with a single dose of quinine. Quinine may increase plasma concentrations of atorvastatin, thereby increasing the risk of myopathy or rhabdomyolysis. Thus, clinicians considering combined therapy of quinine sulfate capsules with atorvastatin or other HMG-CoA reductase inhibitors (“statins”) that are CYP3A4 substrates (e.g., simvastatin, lovastatin) should carefully weigh the potential benefits and risks of each medication. If quinine sulfate capsules is used concomitantly with any of these statins, lower starting and maintenance doses of the statin should be considered.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Patients should also be monitored closely for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during initial therapy. If marked creatine phosphokinase (CPK) elevation occurs or myopathy (defined as muscle aches or muscle weakness in conjunction with CPK values &gt;10 times the upper limit of normal) is diagnosed or suspected, atorvastatin or other statin should be discontinued.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Desipramine (CYP2D6 substrate)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Quinine may inhibit the metabolism of drugs that are CYP2D6 substrates if used at antimalarial doses (greater than or equal to 600 mg) <span class=,'Italics,'>[see <a href=,'#ID_381d1070-9a30-4952-96c4-80a527ae84d3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Patients taking medications that are CYP2D6 substrates with quinine sulfate capsules should be monitored closely for adverse reactions associated with these medications.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Digoxin (P-gp substrate)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Digoxin levels may be increased with use of quinine <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>If quinine sulfate capsules is administered to patients receiving digoxin, plasma digoxin concentrations should be closely monitored, and the digoxin dose adjusted, as necessary <span class=,'Italics,'>[see <a href=,'#S5.7,'>Warnings and Precautions (5.8)</a>]</span>.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Mefloquine</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>The concomitant administration of mefloquine and quinine sulfate capsules may produce electrocardiographic abnormalities (including QTc prolongation) and may increase the risk of seizures <span class=,'Italics,'>[see <a href=,'#ID_381d1070-9a30-4952-96c4-80a527ae84d3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Avoid concomitant use <span class=,'Italics,'>[see <a href=,'#S5.3,'>Warnings and Precautions (5.4)</a>]</span>.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Neuromuscular blocking agents (pancuronium, succinylcholine, tubocurarine)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Quinine may also enhance the neuromuscular blocking effects of succinylcholine and tubocurarine <span class=,'Italics,'>[see <a href=,'#ID_381d1070-9a30-4952-96c4-80a527ae84d3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Avoid concomitant use <span class=,'Italics,'>[see <a href=,'#S5.5,'>Warnings and Precautions (5.6)</a>]</span>.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Ritonavir</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Ritonavir has significant effect on quinine pharmacokinetics <span class=,'Italics,'>[see <a href=,'#ID_381d1070-9a30-4952-96c4-80a527ae84d3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>The concomitant administration of quinine sulfate capsules with ritonavir should be avoided.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Theophylline or aminophylline (CYP1A2 substrate)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Increased quinine plasma levels when used concomitantly <span class=,'Italics,'>[see <a href=,'#ID_381d1070-9a30-4952-96c4-80a527ae84d3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>If quinine sulfate capsules is co-administered to patients receiving theophylline or aminophylline, plasma theophylline concentrations should be monitored frequently to ensure therapeutic concentrations.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Warfarin and oral anticoagulants</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Cinchona alkaloids, including quinine, may have the potential to depress hepatic enzyme synthesis of vitamin K-dependent coagulation pathway proteins and may enhance the action of warfarin and other oral anticoagulants. Quinine may also interfere with the anticoagulant effect of heparin.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>In patients receiving these anticoagulants, the prothrombin time (PT), partial thromboplastin time (PTT), or international normalization ratio (INR) should be closely monitored as appropriate, during concurrent therapy with quinine sulfate capsules.</p>
</td>
</tr>
<tr class=,'Last,'>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Drug/Laboratory Interactions</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Quinine may produce an elevated value for urinary 17-ketogenic steroids when the Zimmerman method is used.</p>
<p>Quinine may interfere with urine qualitative dipstick protein assays as well as quantitative methods (e.g., pyrogallol red-molybdate).</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Special attention to patients using quinine is needed to minimize errors in the interpretation of laboratory results.</p>
</td>
</tr>
</tbody>
</table></div>
</div>"
"quinine sulfate","0b5bbefd-5b56-46f9-84f5-1456371577fd","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Table 1 below presents clinically significant drug interactions with quinine sulfate capsules.</p>
<p>
<span class=,'Bold,'>Table 1: Clinically Significant Drug Interactions with quinine sulfate capsules</span>
</p>
<div class=,'scrollingtable,'><table cellpadding=,'2.9pt,' width=,'100%,'>
<col width=,'30%,'/>
<col width=,'30%,'/>
<col width=,'40%,'/>
<thead>
<tr class=,'First Last,'>
<th align=,'center,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'><span class=,'Bold,'>Drug(s)</span></th><th align=,'center,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'><span class=,'Bold,'>Clinical Impact</span></th><th align=,'center,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'><span class=,'Bold,'>Recommendation</span></th>
</tr>
</thead>
<tbody>
<tr class=,'First,'>
<td align=,'center,' class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Effects of Drugs and Other Substances on Quinine Pharmacokinetics</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Antacids</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Antacids containing aluminum and/or magnesium may delay or decrease absorption of quinine. </p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Concomitant administration of these antacids withquinine sulfate capsules should be avoided.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Antiepileptics (AEDs) (carbamazepine, phenobarbital, and phenytoin)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Carbamazepine, phenobarbital, and phenytoin are CYP3A4 inducers and may decrease quinine plasma concentrations if used concurrently with quinine sulfate capsules.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>If concomitant administration with carbamazepine or phenobarbital cannot be avoided, frequent monitoring of anticonvulsant drug concentrations is recommended. Additionally, patients should be monitored closely for adverse reactions associated with these anticonvulsants.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Histamine H<span class=,'Sub,'>2</span>-receptor blockers [cimetidine, ranitidine (nonspecific CYP450 inhibitors)]</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>When quinine is to be given concomitantly with a histamine H<span class=,'Sub,'>2</span>-receptor blocker, the use of ranitidine is preferred over cimetidine. Although cimetidine and ranitidine may be used concomitantly with quinine sulfate capsules<span class=,'Italics,'> [see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Patients should be monitored closely for adverse events associated with quinine.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Ketoconazole (CYP3A4 inhibitor)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>No change in the quinine sulfate capsules dosage regimen is necessary with concomitant ketoconazole <span class=,'Italics,'>[see <a href=,'#ID_381d1070-9a30-4952-96c4-80a527ae84d3,'>Clinical Pharmacology (12.3)].</a></span>
</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Patients should be monitored closely for adverse reactions associated with quinine.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Macrolide antibiotics (erythromycin, troleandomycin) (CYP3A4 inhibitors)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Increased quinine plasma levels have been observed when used concomitantly <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Concomitant administration of macrolide antibiotics such as erythromycin or troleandomycin with quinine sulfate capsules should be avoided <span class=,'Italics,'>[see <a href=,'#S5.3,'>Warnings and Precautions (5.4)</a>]</span>.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Rifampin (CYP3A4 inducer)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Decreased quinine plasma levels have been observed when used concomitantly <span class=,'Italics,'>[see <a href=,'#ID_381d1070-9a30-4952-96c4-80a527ae84d3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Concomitant administration of rifampin with quinine sulfate capsules should be avoided <span class=,'Italics,'>[see <a href=,'#S5.4,'>Warnings and Precautions (5.5)</a>]</span>.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Ritonavir</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Increased quinine plasma levels have been observed when used concomitantly <span class=,'Italics,'>[see <a href=,'#ID_381d1070-9a30-4952-96c4-80a527ae84d3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Concomitant administration of ritonavir with quinine sulfate capsules should be avoided.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Tetracycline</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Tetracycline may be concomitantly administered with quinine sulfate capsules<span class=,'Italics,'> [see <a href=,'#ID_381d1070-9a30-4952-96c4-80a527ae84d3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Patients should be monitored closely for adverse reactions associated with quinine sulfate.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Theophylline or aminophylline</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>No change in the quinine sulfate capsules dosage regimen is necessary with concomitant theophylline or aminophylline <span class=,'Italics,'>[see <a href=,'#ID_381d1070-9a30-4952-96c4-80a527ae84d3,'>Clinical Pharmacology (12.3)].</a></span>
</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Patients should be monitored closely for adverse reactions associated with quinine.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Urinary alkalizers (acetazolamide, sodium bicarbonate)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Urinary alkalinizing agents may increase plasma quinine concentrations.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Use caution if using concomitantly.</p>
</td>
</tr>
<tr>
<td align=,'center,' class=,'Botrule Lrule Rrule,' colspan=,'3,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Effects of Quinine on the Pharmacokinetics of Other Drugs</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Anticonvulsants (carbamazepine, phenobarbital, and phenytoin)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Carbamazepine, phenobarbital, and phenytoin are CYP3A4 inducers and may decrease quinine plasma concentrations if used concurrently with quinine sulfate capsules<span class=,'Italics,'> [see <a href=,'#ID_381d1070-9a30-4952-96c4-80a527ae84d3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>If concomitant administration with carbamazepine or phenobarbital cannot be avoided, frequent monitoring of anticonvulsant drug concentrations is recommended. Patients should be monitored closely for adverse reactions associated with these anticonvulsants.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Astemizole (CYP3A4 substrate)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Elevated plasma astemizole concentrations were reported in a subject who experienced torsades de pointes after receiving three doses of quinine sulfate for nocturnal leg cramps concomitantly with chronic astemizole 10 mg/day.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>The concurrent use of quinine sulfate capsules with astemizole and other CYP3A4 substrates with QT prolongation potential (e.g., cisapride, terfenadine, halofantrine, pimozide and quinidine) should also be avoided <span class=,'Italics,'>[see <a href=,'#S5.3,'>Warnings and Precautions (5.4)</a>]</span>.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Atorvastatin (CYP3A4 substrate)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Rhabdomyolysis with acute renal failure secondary to myoglobinuria was reported in a patient taking atorvastatin administered with a single dose of quinine. Quinine may increase plasma concentrations of atorvastatin, thereby increasing the risk of myopathy or rhabdomyolysis. Thus, clinicians considering combined therapy of quinine sulfate capsules with atorvastatin or other HMG-CoA reductase inhibitors (“statins”) that are CYP3A4 substrates (e.g., simvastatin, lovastatin) should carefully weigh the potential benefits and risks of each medication. If quinine sulfate capsules is used concomitantly with any of these statins, lower starting and maintenance doses of the statin should be considered.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Patients should also be monitored closely for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during initial therapy. If marked creatine phosphokinase (CPK) elevation occurs or myopathy (defined as muscle aches or muscle weakness in conjunction with CPK values &gt;10 times the upper limit of normal) is diagnosed or suspected, atorvastatin or other statin should be discontinued.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Desipramine (CYP2D6 substrate)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Quinine may inhibit the metabolism of drugs that are CYP2D6 substrates if used at antimalarial doses (greater than or equal to 600 mg) <span class=,'Italics,'>[see <a href=,'#ID_381d1070-9a30-4952-96c4-80a527ae84d3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Patients taking medications that are CYP2D6 substrates with quinine sulfate capsules should be monitored closely for adverse reactions associated with these medications.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Digoxin (P-gp substrate)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Digoxin levels may be increased with use of quinine <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>If quinine sulfate capsules is administered to patients receiving digoxin, plasma digoxin concentrations should be closely monitored, and the digoxin dose adjusted, as necessary <span class=,'Italics,'>[see <a href=,'#S5.7,'>Warnings and Precautions (5.8)</a>]</span>.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Mefloquine</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>The concomitant administration of mefloquine and quinine sulfate capsules may produce electrocardiographic abnormalities (including QTc prolongation) and may increase the risk of seizures <span class=,'Italics,'>[see <a href=,'#ID_381d1070-9a30-4952-96c4-80a527ae84d3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Avoid concomitant use <span class=,'Italics,'>[see <a href=,'#S5.3,'>Warnings and Precautions (5.4)</a>]</span>.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Neuromuscular blocking agents (pancuronium, succinylcholine, tubocurarine)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Quinine may also enhance the neuromuscular blocking effects of succinylcholine and tubocurarine <span class=,'Italics,'>[see <a href=,'#ID_381d1070-9a30-4952-96c4-80a527ae84d3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Avoid concomitant use <span class=,'Italics,'>[see <a href=,'#S5.5,'>Warnings and Precautions (5.6)</a>]</span>.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Ritonavir</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Ritonavir has significant effect on quinine pharmacokinetics <span class=,'Italics,'>[see <a href=,'#ID_381d1070-9a30-4952-96c4-80a527ae84d3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>The concomitant administration of quinine sulfate capsules with ritonavir should be avoided.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Theophylline or aminophylline (CYP1A2 substrate)</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Increased quinine plasma levels when used concomitantly <span class=,'Italics,'>[see <a href=,'#ID_381d1070-9a30-4952-96c4-80a527ae84d3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>If quinine sulfate capsules is co-administered to patients receiving theophylline or aminophylline, plasma theophylline concentrations should be monitored frequently to ensure therapeutic concentrations.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Warfarin and oral anticoagulants</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Cinchona alkaloids, including quinine, may have the potential to depress hepatic enzyme synthesis of vitamin K-dependent coagulation pathway proteins and may enhance the action of warfarin and other oral anticoagulants. Quinine may also interfere with the anticoagulant effect of heparin.</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>In patients receiving these anticoagulants, the prothrombin time (PT), partial thromboplastin time (PTT), or international normalization ratio (INR) should be closely monitored as appropriate, during concurrent therapy with quinine sulfate capsules.</p>
</td>
</tr>
<tr class=,'Last,'>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Drug/Laboratory Interactions</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Quinine may produce an elevated value for urinary 17-ketogenic steroids when the Zimmerman method is used.</p>
<p>Quinine may interfere with urine qualitative dipstick protein assays as well as quantitative methods (e.g., pyrogallol red-molybdate).</p>
</td><td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>Special attention to patients using quinine is needed to minimize errors in the interpretation of laboratory results.</p>
</td>
</tr>
</tbody>
</table></div>
</div>"
"rabeprazole","01a343fb-784c-44a1-a058-22ad3c1dcd1c","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Table 2 includes drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them.</p>
<p>Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs.</p>
<p>
<span class=,'Bold,'>Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets and Interactions with Diagnostics</span>
</p>
<div class=,'scrollingtable,'><table cellpadding=,'0pt,' cellspacing=,'0pt,' width=,'100%,'>
<col width=,'27%,'/>
<col width=,'73%,'/>
<tbody class=,'Headless,'>
<tr class=,'First,'>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Antiretrovirals </span>
<br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span><span class=,'Bold,'> </span>
<br/>
</p>
</td><td class=,'Botrule Rrule,' valign=,'top,'>
<p class=,'First,'>The effect of PPI on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known.<br/>
<br/>•  Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the development of drug resistance.<br/>
<br/>•  Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with rabeprazole may increase toxicity.<br/>
<br/>•  There are other antiretroviral drugs which do not result in clinically relevant interactions with rabeprazole.<br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span> <br/>
</p>
</td><td class=,'Botrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Underline,'>Rilpivirine-containing products</span>: Concomitant use with rabeprazole sodium delayed-release tablets is contraindicated <span class=,'Italics,'>[see Contraindications (4)]</span>. See prescribing information. <br/>
<br/>
<span class=,'Underline,'>Atazanavir</span>: See prescribing information for atazanavir for dosing information. <br/>
<br/>
<span class=,'Underline,'>Nelfinavir</span>: Avoid concomitant use with rabeprazole sodium delayed-release tablets. See prescribing information for nelfinavir. <br/>
<br/>
<span class=,'Underline,'>Saquinavir:</span> See the prescribing information for saquinavir and monitor for potential saquinavir toxicities. <br/>
<br/>
<span class=,'Underline,'>Other antiretrovirals</span>: See prescribing information. <br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>Warfarin</span><span class=,'Underline,'> </span>
<br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span> <br/>
</p>
</td><td class=,'Botrule Rrule,' valign=,'middle,'>
<p class=,'First,'>Increased INR and prothrombin time in patients receiving PPIs, including rabeprazole, and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death <span class=,'Italics,'>[see Warnings and Precautions (5.2)]</span>. <br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span> <br/>
</p>
</td><td class=,'Botrule Rrule,' valign=,'middle,'>
<p class=,'First,'>Monitor INR and prothrombin time. Dose adjustment of warfarin may be needed to maintain target INR range. See prescribing information for warfarin. <br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>Methotrexate</span> <br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span> <br/>
</p>
</td><td class=,'Botrule Rrule,' valign=,'middle,'>
<p class=,'First,'>Concomitant use of rabeprazole with methotrexate (primarily at high dose) may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate, possibly leading to methotrexate toxicities. No formal drug interaction studies of methotrexate with PPIs have been conducted <span class=,'Italics,'>[see Warnings and Precautions (5.9)]</span>.<br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span> <br/>
</p>
</td><td class=,'Botrule Rrule,' valign=,'middle,'>
<p class=,'First,'>A temporary withdrawal of rabeprazole sodium delayed-release tablets may be considered in some patients receiving high dose methotrexate administration. <br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>Digoxin</span> <br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span> <br/>
</p>
</td><td class=,'Botrule Rrule,' valign=,'middle,'>
<p class=,'First,'>Potential for increased exposure of digoxin <span class=,'Italics,'>[see Clinical Pharmacology (12.3)]</span>.<br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span> <br/>
</p>
</td><td class=,'Botrule Rrule,' valign=,'middle,'>
<p class=,'First,'>Monitor digoxin concentrations. Dose adjustment of digoxin may be needed to maintain therapeutic drug concentrations. See prescribing information for digoxin. <br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole) </span> <br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
<br/>
</p>
</td><td class=,'Botrule Rrule,' valign=,'middle,'>
<p class=,'First,'>Rabeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. <br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention: </span>
<br/>
</p>
</td><td class=,'Botrule Rrule,' valign=,'middle,'>
<p class=,'First,'>Mycophenolate mofetil (MMF): Co-administration of PPIs in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH. The clinical relevance of reduced MPA exposure on organ rejection has not been established in transplant patients receiving rabeprazole sodium delayed-release tablets and MMF. Use rabeprazole sodium delayed-release tablets with caution in transplant patients receiving MMF. <br/> <br/>See the prescribing information for other drugs dependent on gastric pH for absorption. <br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>Combination Therapy with Clarithromycin and Amoxicillin</span>
<br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
<br/>
<span class=,'Bold,'> </span>
<br/>
</p>
</td><td class=,'Botrule Rrule,' valign=,'middle,'>
<p class=,'First,'>Concomitant administration of clarithromycin with other drugs can lead to serious adverse reactions, including potentially fatal arrhythmias, and are contraindicated.<br/> <br/>Amoxicillin also has drug interactions. <br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
<br/>
<span class=,'Bold,'><span class=,'Italics,'> </span></span>
<br/>
</p>
</td><td class=,'Botrule Rrule,' valign=,'middle,'>
<p class=,'First,'>See <span class=,'Italics,'>Contraindications </span>and <span class=,'Italics,'>Warnings and Precautions </span>in prescribing information for clarithromycin.<br/> <br/>See <span class=,'Italics,'>Drug Interactions </span>in prescribing information for amoxicillin.<br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>Tacrolimus</span> <br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
<br/>
</p>
</td><td class=,'Botrule Rrule,' valign=,'middle,'>
<p class=,'First,'>Potentially increased exposure of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19<span class=,'Italics,'>. </span>
<br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
<br/>
</p>
</td><td class=,'Botrule Rrule,' valign=,'middle,'>
<p class=,'First,'>Monitor tacrolimus whole blood trough concentrations. Dose adjustment of tacrolimus may be needed to maintain therapeutic drug concentrations. See prescribing information for tacrolimus. <br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>Interactions with Investigations of Neuroendocrine Tumors</span> <br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
<br/>
</p>
</td><td class=,'Botrule Rrule,' valign=,'middle,'>
<p class=,'First,'>Serum chromogranin A (CgA) levels increase secondary to PPI-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors<span class=,'Italics,'>. </span>
<br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
<br/>
</p>
</td><td class=,'Botrule Rrule,' valign=,'middle,'>
<p class=,'First,'>Temporarily stop rabeprazole sodium delayed-release tablets treatment at least 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high. If serial tests are performed (e.g. for monitoring), the same commercial laboratory should be used for testing, as reference ranges between tests may vary. <br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>Interaction with Secretin Stimulation Test</span> <br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
<br/>
</p>
</td><td class=,'Botrule Rrule,' valign=,'middle,'>
<p class=,'First,'>Hyper-response in gastrin secretion in response to secretin stimulation test, falsely suggesting gastrinoma. <br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
<br/>
</p>
</td><td class=,'Botrule Rrule,' valign=,'middle,'>
<p class=,'First,'>Temporarily stop treatment with rabeprazole sodium delayed-release tablets at least 14 days before assessing to allow gastrin levels to return to baseline.  <br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Bold,'>False Positive Urine Tests for THC</span> <br/>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact:</span>
<br/>
</p>
</td><td class=,'Botrule Rrule,' valign=,'middle,'>
<p class=,'First,'>There have been reports of false positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving PPIs. <br/>
</p>
</td>
</tr>
<tr class=,'Last,'>
<td class=,'Botrule Lrule Rrule,' valign=,'middle,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
<br/>
</p>
</td><td class=,'Botrule Rrule,' valign=,'middle,'>
<p class=,'First,'>An alternative confirmatory method should be considered to verify positive results. <br/>
</p>
</td>
</tr>
</tbody>
</table></div>
</div>"
"rabies immune globulin, human","f82880b8-998c-4659-8f20-6dcc81f258e9","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID_e00c7291-af44-4137-bddb-64a4c27ae1e7,'></a><a name=,'section-7,'></a>
<p></p>
<ul>
<li>Do not administer repeated doses of HYPERRAB once vaccine treatment has been initiated as this could prevent the full expression of active immunity expected from the rabies vaccine.(<a href=,'#ID_6deb42c4-ae89-428b-8290-8a78f5a89257,'>1</a>)</li>
<li>Other antibodies in the HYPERRAB preparation may interfere with the response to live vaccines such as measles, mumps, polio or rubella. Defer immunization with live vaccines for 4 months after HYPERRAB administration.(<a href=,'#ID_6deb42c4-ae89-428b-8290-8a78f5a89257,'>5</a>)</li>
</ul>
</div>"
"raloxifene","8f4fe353-c5de-44ba-9c68-b75a185f7dc5","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'L303f0633-f490-4c4f-9fe1-8c1506a1356d,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Cholestyramine: </span>User with raloxifene hydrochloride tablets is not recommended. Reduces the absorption and enterohepatic cycling of raloxifene. (<a href=,'#Ldcff45be-a8f9-429c-b486-56c2a538f6bf,'>7.1</a>, <a href=,'#L4a21b657-0f8d-40ba-9b30-703ec5502af1,'>12.3</a>)</p>
<ul>
<li>
<span class=,'Italics,'>Warfarin: </span>Monitor prothrombin time when starting or stopping Raloxifene hydrochloride tablets. (<a href=,'#L6e0ea2fa-f920-415d-b069-43b078055bc9,'>7.2</a>, <a href=,'#L4a21b657-0f8d-40ba-9b30-703ec5502af1,'>12.3</a>)</li>
<li>
<span class=,'Italics,'>Highly Protein-Bound Drugs: </span>Use with Raloxifene hydrochloride tablets with caution. Highly protein-bound drugs include diazepam, diazoxide, and lidocaine. Raloxifene hydrochloride is more than 95% bound to plasma proteins. (<a href=,'#L688300af-6381-4af9-8da9-f8d1710ce7ff,'>7.3</a>, <a href=,'#L4a21b657-0f8d-40ba-9b30-703ec5502af1,'>12.3</a>)</li>
</ul>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Ldcff45be-a8f9-429c-b486-56c2a538f6bf,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Cholestyramine</h2>
<p class=,'First,'>Concomitant administration of cholestyramine with raloxifene hydrochloride tablets is not recommended. Although not specifically studied, it is anticipated that other anion exchange resins would have a similar effect. Raloxifene hydrochloride tablets should not be co-administered with other anion exchange resins [see Clinical Pharmacology (<a href=,'#L4a21b657-0f8d-40ba-9b30-703ec5502af1,'>12.3</a>)].</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'L6e0ea2fa-f920-415d-b069-43b078055bc9,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Warfarin</h2>
<p class=,'First,'>If raloxifene hydrochloride tablets are given concomitantly with warfarin or other warfarin derivatives, prothrombin time should be monitored more closely when starting or stopping therapy with raloxifene hydrochloride tablets [see Clinical Pharmacology (<a href=,'#L4a21b657-0f8d-40ba-9b30-703ec5502af1,'>12.3</a>)].</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'L688300af-6381-4af9-8da9-f8d1710ce7ff,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Other Highly Protein-Bound Drugs</h2>
<p class=,'First,'>Raloxifene hydrochloride tablets should be used with caution with certain other highly protein-bound drugs such as diazepam, diazoxide, and lidocaine. Although not examined, raloxifene hydrochloride tablets might affect the protein binding of other drugs. Raloxifene is more than 95% bound to plasma proteins [see Clinical Pharmacology (<a href=,'#L4a21b657-0f8d-40ba-9b30-703ec5502af1,'>12.3</a>)].</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'La59129f4-b468-41f9-b8db-162e11b15686,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Systemic Estrogens</h2>
<p class=,'First First,'>The safety of concomitant use of raloxifene hydrochloride tablets with systemic estrogens has not been established and its use is not recommended.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'L900eda07-27dc-43e1-8373-ad12ff6210bb,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Other Concomitant Medications</h2>
<p class=,'First,'>Raloxifene hydrochloride tablets can be concomitantly administered with ampicillin, amoxicillin, antacids, corticosteroids, and digoxin [see Clinical Pharmacology (<a href=,'#L4a21b657-0f8d-40ba-9b30-703ec5502af1,'>12.3</a>)].</p>
<p>The concomitant use of raloxifene hydrochloride tablets and lipid-lowering agents has not been studied.</p>
</div>
</div>"
"raltegravir","442d9e67-1c2c-73f8-e054-00144ff8d46c","none found"
"ramipril","00bdb48f-8b8f-4cc5-bb63-77213f2279cb","none found"
"ranibizumab","de4e66cc-ca05-4dc9-8262-e00e9b41c36d","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Drug interaction studies have not been conducted with LUCENTIS.</p>
<p>LUCENTIS intravitreal injection has been used adjunctively with PDT. Twelve of 105 (11%) patients with neovascular AMD developed serious intraocular inflammation; in 10 of the 12 patients, this occurred when LUCENTIS was administered 7 days (± 2 days) after PDT.</p>
</div>"
"ranitidine","0e466ae5-a284-49be-b7a5-0f135e3ab9f4","none found"
"ranolazine","00979fb3-d70f-493d-94ca-2914cbadaa9d","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID24,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,'>
<a name=,'ID25,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Effects of Other Drugs on Ranolazine</h2>
<p class=,'First,'>
<a name=,'ID26,'></a><span class=,'Italics,'>Strong CYP3A Inhibitors</span>
</p>
<p>Do not use ranolazine with strong CYP3A inhibitors, including ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, and saquinavir <span class=,'Italics,'>[see <a href=,'#ID11,'>Contraindications (4)</a>, <a href=,'#ID57,'>Clinical Pharmacology (12.3)</a>].</span>
</p>
<p>
<span class=,'Italics,'>Moderate CYP3A Inhibitors</span>
</p>
<p>Limit the dose of ranolazine to 500 mg twice daily in patients on moderate CYP3A inhibitors, including diltiazem, verapamil, erythromycin, fluconazole, and grapefruit juice or grapefruit-containing products <span class=,'Italics,'>[see <a href=,'#ID6,'>Dosage and Administration (2.2)</a>, <a href=,'#ID57,'>Clinical Pharmacology (12.3)</a>].</span>
</p>
<p>
<span class=,'Italics,'>P-gp Inhibitors</span>
</p>
<p>Concomitant use of ranolazine and P-gp inhibitors, such as cyclosporine, may result in increases in ranolazine concentrations. Titrate ranolazine based on clinical response in patients concomitantly treated with predominant P-gp inhibitors such as cyclosporine <span class=,'Italics,'>[see <a href=,'#ID6,'>Dosage and Administration (2.2)</a>].</span>
</p>
<p>
<span class=,'Italics,'>CYP3A Inducers</span>
</p>
<p>Do not use ranolazine with CYP3A inducers such as rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, and St. John's wort <span class=,'Italics,'>[see <a href=,'#ID11,'>Contraindications (4)</a>, <a href=,'#ID57,'>Clinical Pharmacology (12.3)</a>].</span>
</p>
</div>
<div class=,'Section,'>
<a name=,'ID27,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Effects of Ranolazine on Other Drugs</h2>
<p class=,'First,'>
<a name=,'ID28,'></a><span class=,'Italics,'>Drugs Metabolized by CYP3A</span>
</p>
<p>Limit the dose of simvastatin in patients on any dose of ranolazine to 20 mg once daily, when ranolazine is co-administered. Dose adjustment of other sensitive CYP3A substrates (e.g., lovastatin) and CYP3A substrates with a narrow therapeutic range (e.g., cyclosporine, tacrolimus, sirolimus) may be required as ranolazine may increase plasma concentrations of these drugs <span class=,'Italics,'>[see <a href=,'#ID57,'>Clinical Pharmacology (12.3)</a>].</span>
</p>
<p>
<span class=,'Italics,'>Drugs Transported by P-gp</span>
</p>
<p>Concomitant use of ranolazine and digoxin results in increased exposure to digoxin. The dose of digoxin may have to be adjusted <span class=,'Italics,'>[see <a href=,'#ID57,'>Clinical Pharmacology (12.3)</a>].</span>
</p>
<p>
<span class=,'Italics,'>Drugs Metabolized by CYP2D6</span>
</p>
<p>The exposure to CYP2D6 substrates, such as tricyclic antidepressants and antipsychotics, may be increased during co-administration with ranolazine, and lower doses of these drugs may be required.</p>
<p>
<span class=,'Italics,'>Drugs Transported by OCT2</span>
</p>
<p>In subjects with type 2 diabetes mellitus, concomitant use of ranolazine 1000 mg twice daily and metformin results in increased plasma levels of metformin. When ranolazine 1000 mg twice daily is co-administered with metformin, metformin dose should not exceed 1700 mg/day. Monitor blood glucose levels and risks associated with high exposures of metformin.</p>
<p>Metformin exposure was not significantly increased when given with ranolazine 500 mg twice daily <span class=,'Italics,'>[see <a href=,'#ID57,'>Clinical Pharmacology (12.3)</a>].</span>
</p>
</div>
</div>"
"rasagiline","5dfeec8f-f4f3-4e06-915e-3244467516a6","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Meperidine</h2>
<p class=,'First,'>Serious, sometimes fatal reactions have been precipitated with concomitant use of meperidine (e.g., Demerol and other tradenames) and MAO inhibitors including selective MAO-B inhibitors <span class=,'Italics,'>[see Contraindications (<a href=,'#Section_4,'>4</a>)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Dextromethorphan</h2>
<p class=,'First,'>The concomitant use of rasagiline and dextromethorphan was not allowed in clinical studies. The combination of MAO inhibitors and dextromethorphan has been reported to cause brief episodes of psychosis or bizarre behavior. Therefore, in view of rasagiline’s MAO inhibitory activity, dextromethorphan is contraindicated for use with rasagiline <span class=,'Italics,'>[see Contraindications (<a href=,'#Section_4,'>4</a>)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 MAO Inhibitors</h2>
<p class=,'First,'>Rasagiline is contraindicated for use with other MAO inhibitors because of the increased risk of nonselective MAO inhibition that may lead to a hypertensive crisis <span class=,'Italics,'>[see Contraindications (<a href=,'#Section_4,'>4</a>)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Sympathomimetic Medications</h2>
<p class=,'First,'>The concomitant use of rasagiline and sympathomimetic medications was not allowed in clinical studies. Severe hypertensive reactions have followed the administration of sympathomimetics and nonselective MAO inhibitors. Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications. Severe hypertension has been reported in patients taking the recommended dose of rasagiline and ophthalmic drops containing sympathomimetic medications.<br/>Because rasagiline is a selective MAOI, hypertensive reactions are not ordinarily expected with the concomitant use of sympathomimetic medications. Nevertheless, caution should be exercised when concomitantly using recommended doses of rasagiline with any sympathomimetic medications including nasal, oral, and ophthalmic decongestants and cold remedies.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.5,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Antidepressants</h2>
<p class=,'First,'>Concomitant use of rasagiline with one of many classes of antidepressants (e.g., SSRIs, SNRIs, triazolopyridine, tricyclic or tetracyclic antidepressants) is not recommended<span class=,'Italics,'> [see Warnings and Precautions (<a href=,'#Section_5.2,'>5.2</a>) and Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)].</span> Concomitant use of rasagiline and MAO inhibitors is contraindicated <span class=,'Italics,'>[see Contraindications (<a href=,'#Section_4,'>4</a>)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.6,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6 Ciprofloxacin or Other CYP1A2 Inhibitors</h2>
<p class=,'First,'>Rasagiline plasma concentrations may increase up to 2 fold in patients using concomitant ciprofloxacin and other CYP1A2 inhibitors. This could result in increased adverse events. Patients taking concomitant ciprofloxacin or other CYP1A2 inhibitors should not exceed a dose of rasagiline 0.5 mg once daily <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#Section_5.4,'>5.4</a>) and Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.7,'></a><a name=,'section-7.7,'></a>
<p></p>
<h2>7.7 Tyramine/Rasagiline Interaction</h2>
<p class=,'First,'>MAO in the gastrointestinal tract and liver (primarily type A) provides protection from exogenous amines (e.g., tyramine) that have the capacity, if absorbed intact, to cause a tyramine reaction with hypertension including clinical syndromes referred to as hypertensive urgency, crisis, or emergency. Foods and medications containing large amounts of exogenous amines (e.g., from fermented cheese, herring, over-the-counter cough/cold medications) may cause release of norepinephrine resulting in a rise in systemic blood pressure.<br/>Results of a special tyramine challenge study indicate that rasagiline is selective for MAO-B at recommended doses and can be used without dietary tyramine restriction. However, certain foods may contain very high amounts (i.e., 150 mg or greater) of tyramine and could potentially cause a hypertensive reaction in individual patients taking rasagiline due to increased sensitivity to tyramine. Selectivity for inhibiting MAO-B diminishes in a dose-related manner as the dose is progressively increased above the recommended daily doses.<br/>There were no cases of hypertensive crisis in the clinical development program associated with 1 mg daily rasagiline treatment, in which most patients did not follow dietary tyramine restriction.<br/>There have been postmarketing reports of patients who experienced significantly elevated blood pressure (including rare cases of hypertensive crisis) after ingestion of unknown amounts of tyramine-rich foods while taking recommended doses of rasagiline. Patients should be advised to avoid foods containing a very large amount of tyramine while taking recommended doses of rasagiline <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#Section_5.1,'>5.1</a>)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.8,'></a><a name=,'section-7.8,'></a>
<p></p>
<h2>7.8 Dopaminergic Antagonists</h2>
<p class=,'First,'>It is possible that dopamine antagonists, such as antipsychotics or metoclopramide, could diminish the effectiveness of rasagiline.</p>
</div>
</div>"
"ribavirin","27c184e4-e8ac-4ec5-882f-cf4f27030e4c","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID289,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,'>
<a name=,'ID290,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Didanosine</h2>
<p class=,'First,'>
<a name=,'ID291,'></a>Exposure to didanosine or its active metabolite (dideoxyadenosine 5'-triphosphate) is increased when didanosine is coadministered with ribavirin, which could cause or worsen clinical toxicities; therefore, coadministration of ribavirin capsules and didanosine is contraindicated <span class=,'Italics,'>[see Contraindications (<a href=,'#ID256,'>4</a>)]</span>. Reports of fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in clinical trials. </p>
</div>
<div class=,'Section,'>
<a name=,'ID292,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Nucleoside Analogues</h2>
<p class=,'First,'>
<a name=,'ID293,'></a>Hepatic decompensation (some fatal) has occurred in cirrhotic HIV/HCV co-infected patients receiving combination antiretroviral therapy for HIV and interferon alpha and ribavirin. Patients receiving interferon with ribavirin and nucleoside reverse transcriptase inhibitors (NRTIs) should be closely monitored for treatment- associated toxicities, especially hepatic decompensation and anemia. Discontinuation of NRTIs should be considered as medically appropriate [see <span class=,'Italics,'>labeling for</span> <span class=,'Italics,'>individual NRTI product</span>]. Dose reduction or discontinuation of interferon, ribavirin, or both should also be considered if worsening clinical toxicities are observed, including hepatic decompensation (e.g., Child-Pugh greater than 6). </p>
<p>Ribavirin may antagonize the cell culture antiviral activity of stavudine and zidovudine against HIV. Ribavirin has been shown in cell culture to inhibit phosphorylation of lamivudine, stavudine and zidovudine, which could lead to decreased antiretroviral activity. However, in a study with another pegylated interferon in combination with ribavirin, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV/HCV virologic suppress) interaction was observed when ribavirin and lamivudine (n=18), stavudine (n=10), or zidovudine (n=6) were coadministered as part of a multidrug regimen in HIV/HCV co-infected subjects. Concomitant use of ribavirin with any of these drugs should be done with caution.</p>
</div>
<div class=,'Section,'>
<a name=,'ID294,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Drugs Metabolized by Cytochrome P-450</h2>
<p class=,'First,'>
<a name=,'ID295,'></a>Results of <span class=,'Italics,'>in vitro </span>studies using both human and rat liver microsome preparations indicated little or no cytochrome P-450 enzyme-mediated metabolism of ribavirin, with minimal potential for P-450 enzyme-based drug interactions. </p>
<p>No pharmacokinetic interactions were noted between INTRON A and ribavirin capsules in a multiple-dose pharmacokinetic study.</p>
</div>
<div class=,'Section,'>
<a name=,'ID395,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Azathioprine</h2>
<p class=,'First,'>
<a name=,'ID396,'></a>The use of ribavirin for the treatment of chronic hepatitis C in patients receiving azathioprine has been reported to induce severe pancytopenia and may increase the risk of azathioprine-related myelotoxicity. Inosine monophosphate dehydrogenase (IMDH) is required for one of the metabolic pathways of azathioprine. Ribavirin is known to inhibit IMDH, thereby leading to accumulation of an azathioprine metabolite, 6-methylthioinosine monophosphate (6-MTITP), which is associated with myelotoxicity (neutropenia, thrombocytopenia, and anemia). Patients receiving azathioprine with ribavirin should have complete blood counts, including platelet counts, monitored weekly for the first month, twice monthly for the second and third months of treatment, then monthly or more frequently if dosage or other therapy changes are necessary [see <span class=,'Italics,'>Warnings and Precautions (<a href=,'#ID425,'>5.8</a>)</span>].</p>
</div>
</div>"
"rifampin","0609253c-505b-c6d0-241e-90ffdba25ca2","none found"
"rifapentine","1502544d-1b3a-46bd-84f5-af92cab72ce8","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 	Protease Inhibitors and Reverse Transcriptase Inhibitors</h2>
<p class=,'First,'>Rifapentine is an inducer of CYP450 enzymes. Concomitant use of PRIFTIN with other drugs metabolized by these enzymes, such as protease inhibitors and certain reverse transcriptase inhibitors, may cause a significant decrease in plasma concentrations and loss of therapeutic effect of the protease inhibitor or reverse transcriptase inhibitor <span class=,'Italics,'>[see <a href=,'#S5.5,'>Warnings and Precautions (5.5)</a></span> and<span class=,'Italics,'><a href=,'#S12.3,'> Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 	Fixed-Dose Combination of Efavirenz, Emtricitabine, and Tenofovir</h2>
<p class=,'First,'>Once-weekly coadministration of 900 mg PRIFTIN with the antiretroviral fixed-dose combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in HIV-infected patients did not result in any substantial change in steady state exposures of efavirenz, emtricitabine, and tenofovir. No clinically significant change in CD4 cell counts or viral loads were noted <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 	Hormonal Contraceptives</h2>
<p class=,'First,'>PRIFTIN may reduce the effectiveness of hormonal contraceptives. Patients using hormonal contraception should be advised to use an alternative non-hormonal contraceptive method or add a barrier method of contraception during treatment with PRIFTIN <span class=,'Italics,'>[see <a href=,'#S8.3,'>Use in Specific Populations (8.3)</a></span> and <span class=,'Italics,'><a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 	Cytochrome P450 3A4 and 2C8/9</h2>
<p class=,'First,'>Rifapentine is an inducer of cytochromes P450 3A4 and P450 2C8/9. Therefore, PRIFTIN may increase the metabolism of other coadministered drugs that are metabolized by these enzymes. Induction of enzyme activities by PRIFTIN occurred within 4 days after the first dose. Enzyme activities returned to baseline levels 14 days after discontinuing PRIFTIN.</p>
<p>Rifampin has been reported to accelerate the metabolism and may reduce the activity of the following drugs; hence, PRIFTIN may also increase the metabolism and decrease the activity of these drugs. Dosage adjustments of the drugs in Table 4 or of other drugs metabolized by cytochrome P450 3A4 or P450 2C8/9 may be necessary if they are given concurrently with PRIFTIN.</p>
<div class=,'scrollingtable,'><table width=,'100%,'>
<caption>
<span>Table 4: Drug Interactions with PRIFTIN: Dosage Adjustment May be Necessary</span>
</caption>
<col align=,'center,' valign=,'top,' width=,'50%,'/>
<col align=,'center,' valign=,'top,' width=,'50%,'/>
<thead>
<tr class=,'First Last,'>
<th align=,'center,' class=,'Lrule Rrule,'>Drug Class</th><th align=,'center,' class=,'Rrule,'>Examples of Drugs Within Class 											</th>
</tr>
</thead>
<tbody>
<tr class=,'Botrule First,'>
<td align=,'center,' class=,'Lrule Rrule,'>Antiarrhythmics</td><td align=,'center,' class=,'Rrule,'>Disopyramide, mexiletine, quinidine, tocainide</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,'>Antibiotics</td><td align=,'center,' class=,'Rrule,'>Chloramphenicol, clarithromycin, dapsone, doxycycline;<br/> Fluoroquinolones (such as ciprofloxacin)</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,'>Oral Anticoagulants</td><td align=,'center,' class=,'Rrule,'>Warfarin</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,'>Anticonvulsants</td><td align=,'center,' class=,'Rrule,'>Phenytoin</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,'>Antimalarials</td><td align=,'center,' class=,'Rrule,'>Quinine</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,'>Azole Antifungals</td><td align=,'center,' class=,'Rrule,'>Fluconazole, itraconazole, ketoconazole</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,'>Antipsychotics</td><td align=,'center,' class=,'Rrule,'>Haloperidol</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,'>Barbiturates</td><td align=,'center,' class=,'Rrule,'>Phenobarbital</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,'>Benzodiazepines</td><td align=,'center,' class=,'Rrule,'>Diazepam</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,'>Beta-Blockers</td><td align=,'center,' class=,'Rrule,'>Propranolol</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,'>Calcium Channel Blockers</td><td align=,'center,' class=,'Rrule,'>Diltiazem, nifedipine, verapamil</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,'>Cardiac Glycoside Preparations</td><td align=,'center,' class=,'Rrule,'>Digoxin</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,'>Corticosteroids</td><td align=,'center,' class=,'Rrule,'>Prednisone</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,'>Fibrates</td><td align=,'center,' class=,'Rrule,'>Clofibrate</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,'>Oral Hypoglycemics</td><td align=,'center,' class=,'Rrule,'>Sulfonylureas (e.g., glyburide, glipizide)</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,'>Hormonal Contraceptives/Progestins</td><td align=,'center,' class=,'Rrule,'>Ethinyl estradiol, levonorgestrel</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,'>Immunosuppressants</td><td align=,'center,' class=,'Rrule,'>Cyclosporine, tacrolimus</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,'>Methylxanthines</td><td align=,'center,' class=,'Rrule,'>Theophylline</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,'>Narcotic analgesics</td><td align=,'center,' class=,'Rrule,'>Methadone</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,'>Phosphodiesterase-5 (PDE-5) Inhibitors</td><td align=,'center,' class=,'Rrule,'>Sildenafil</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'center,' class=,'Lrule Rrule,'>Thyroid preparations</td><td align=,'center,' class=,'Rrule,'>Levothyroxine</td>
</tr>
<tr class=,'Last,'>
<td align=,'center,' class=,'Lrule Rrule,'>Tricyclic antidepressants</td><td align=,'center,' class=,'Rrule,'>Amitriptyline, nortriptyline</td>
</tr>
</tbody>
</table></div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.5,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5	Other Interactions</h2>
<p class=,'First,'>The conversion of PRIFTIN to 25-desacetyl rifapentine is mediated by an esterase enzyme. There is minimal potential for PRIFTIN metabolism to be inhibited or induced by another drug, based upon the characteristics of the esterase enzymes.</p>
<p>Since PRIFTIN is highly bound to albumin, drug displacement interactions may also occur <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.6,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6	Interactions with Laboratory Tests</h2>
<p class=,'First,'>Therapeutic concentrations of rifampin have been shown to inhibit standard microbiological assays for serum folate and Vitamin B<span class=,'Sub,'>12</span>. Similar drug-laboratory interactions should be considered for PRIFTIN; thus, alternative assay methods should be considered.</p>
</div>
</div>"
"rifaximin","49df84cd-0ef6-446b-b2af-556abc665ad9","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID_61a2c4e9-135e-4447-827a-052b24c65f2c,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_4294fe22-004a-4d52-b266-49b43f6ee4b6,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Effects of XIFAXAN on Other Drugs</h2>
<p class=,'First,'>
<span class=,'Underline,'>Substrates of Cytochrome P450 enzymes</span>
</p>
<p>Rifaximin is not expected to inhibit cytochrome P450 isoenzymes 1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1 and CYP3A4 in clinical use based on <span class=,'Italics,'>in vitro</span> studies <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#ID_0eda2f03-e10e-49e5-9957-f8b2ae7b2a4d,'>12.3</a>)]</span>.</p>
<p>An <span class=,'Italics,'>in vitro</span> study has suggested that rifaximin induces CYP3A4 <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#ID_0eda2f03-e10e-49e5-9957-f8b2ae7b2a4d,'>12.3</a>)]</span>.  However, in patients with normal liver function, XIFAXAN at the recommended dosing regimen is not expected to induce CYP3A4.  It is unknown whether rifaximin can have a significant effect on the pharmacokinetics of concomitant CYP3A4 substrates in patients with reduced liver function who have elevated rifaximin concentrations.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_dcf14b59-3a55-4e6c-b826-20c86302fba9,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Effects of Other Drugs on XIFAXAN</h2>
<p class=,'First,'>
<span class=,'Italics,'>In vitro</span> studies suggested that rifaximin is a substrate of P-glycoprotein, OATP1A2, OATP1B1 and OATP1B3.  Concomitant cyclosporine, an inhibitor of P-glycoprotein and OATPs, significantly increased the systemic exposure to rifaximin. </p>
<p>
<span class=,'Underline,'>Cyclosporine </span>
</p>
<p>Co-administration of cyclosporine, with XIFAXAN resulted in 83-fold and 124-fold increases in rifaximin mean C<span class=,'Sub,'>max</span> and AUC<span class=,'Sub,'>∞</span> in healthy subjects.  The clinical significance of this increase in systemic exposure is unknown <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#ID_3978e881-44d0-4782-919e-9151f358dcdf,'>5.4</a>), Clinical Pharmacology (<a href=,'#ID_0eda2f03-e10e-49e5-9957-f8b2ae7b2a4d,'>12.3</a>)].</span>
</p>
</div>
</div>"
"risedronic acid","1d33f2ef-ec29-47b1-a1ce-8b1583c65ab4","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_76cb8588-b8d6-4c89-8669-abe4108e1e45,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>No specific drug-drug interaction studies were performed. Risedronate is not metabolized and does not induce or inhibit hepatic microsomal drug-metabolizing enzymes (for example, Cytochrome P450).</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_fdc75339-3ac2-4cb7-a7ef-8180946dc236,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Calcium Supplements/Antacids</h2>
<p class=,'First,'>Co-administration of risedronate sodium tablets and calcium, antacids, or oral medications containing divalent cations will interfere with the absorption of risedronate sodium tablets.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_184bd5cd-018f-4f37-89e5-c0588b9446e4,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Hormone Replacement Therapy</h2>
<p class=,'First,'>One study of about 500 early postmenopausal women has been conducted to date in which treatment with risedronate sodium tablets 5 mg daily plus estrogen replacement therapy was compared to estrogen replacement therapy alone. Exposure to study drugs was approximately 12 to 18 months and the primary endpoint was change in BMD. If considered appropriate, Risedronate sodium tablets may be used concomitantly with hormone replacement therapy.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_ace9d80c-878c-49e7-92f6-0f38e7ff83cc,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Aspirin/Nonsteroidal Anti-Inflammatory Drugs</h2>
<p class=,'First,'>Of over 5700 patients enrolled in the risedronate sodium tablets Phase 3 osteoporosis studies, aspirin use was reported by 31% of patients, 24% of whom were regular users (3 or more days per week). Forty-eight percent of patients reported NSAID use, 21% of whom were regular users. Among regular aspirin or NSAID users, the incidence of upper gastrointestinal adverse experiences in placebo-treated patients (24.8%) was similar to that in risedronate sodium-treated patients (24.5%).</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_f9d7f56d-6eb9-4b27-911c-8faccb1a6daa,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 H<span class=,'Sub,'>2</span> Blockers and Proton Pump Inhibitors (PPIs)</h2>
<p class=,'First,'>Of over 5700 patients enrolled in the risedronate sodium tablets Phase 3 osteoporosis studies, 21% used H<span class=,'Sub,'>2</span> blockers and/or PPIs. Among these patients, the incidence of upper gastrointestinal adverse experiences in the placebo-treated patients was similar to that in risedronate sodium-treated patients.</p>
</div>
</div>"
"risperidone","00c569bf-3bfa-4869-bc0d-e4b36887b7c1","none found"
"ritonavir","a32cb2e3-d4e5-4bbf-9d88-20b2b249e779","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_9888622d-b12e-4eb2-a123-bfcf93d314cc,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>When co-administering ritonavir with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. </p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_822e5115-59bb-4489-9ce9-03d2e8d8eb5d,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Potential for Ritonavir to Affect Other Drugs</h2>
<p class=,'First,'>Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of ritonavir with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated. Co-administration with other CYP3A substrates may require a dose adjustment or additional monitoring as shown in Table 4. </p>
<p>Ritonavir also inhibits CYP2D6 to a lesser extent. Co-administration of substrates of CYP2D6 with ritonavir could result in increases (up to 2-fold) in the AUC of the other agent, possibly requiring a proportional dosage reduction. Ritonavir also appears to induce CYP3A, CYP1A2, CYP2C9, CYP2C19, and CYP2B6 as well as other enzymes, including glucuronosyl transferase. </p>
<p>These examples are a guide and not considered a comprehensive list of all possible drugs that may interact with ritonavir. The healthcare provider should consult appropriate references for comprehensive information.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_28603080-dfb0-4f0d-a237-85d4e7c40cb6,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Established and Other Potentially Significant Drug Interactions</h2>
<p class=,'First,'>Table 4 provides a list of established or potentially clinically significant drug interactions. Alteration in dose or regimen may be recommended based on drug interaction studies or predicted interaction <span class=,'Italics,'>[see <span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>Contraindications (4)</a>, <a href=,'#LINK_bc9cea0d-8645-47bc-a7c7-6c42756dcde5,'>Warnings and Precautions (5.1)</a>, </span></span>and <span class=,'Italics,'><a href=,'#LINK_87471a6b-c62d-42d4-84bf-29d682ae10e4,'>Clinical Pharmacology (12.3)</a>]</span> for magnitude of interaction. </p>
<p>
<span class=,'Bold,'>Table 4. Established and Other Potentially Significant Drug Interactions</span>
</p>
<div class=,'scrollingtable,'><table border=,'1,' cellpadding=,'0,' cellspacing=,'0,' width=,'100%,'>
<col width=,'17pt,'/>
<col width=,'17pt,'/>
<col width=,'17pt,'/>
<tbody class=,'Headless,'>
<tr class=,'First,'>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>
<span class=,'Bold,'>Concomitant Drug Class: </span>
</p>
<p>
<span class=,'Bold,'>Drug Name </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>
<span class=,'Bold,'>Effect on Concentration of Ritonavir or Concomitant Drug </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>
<span class=,'Bold,'>Clinical Comment </span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,'>
<p class=,'First,'>
<span class=,'Bold,'><span class=,'Italics,'>HIV-Antiviral Agents </span></span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>HIV-1 Protease Inhibitor: atazanavir darunavir fosamprenavir </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ amprenavir </p>
<p>↑ atazanavir </p>
<p>↑ darunavir </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>See the complete prescribing information for fosamprenavir, atazanavir, darunavir for details on co-administration with ritonavir. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>HIV-1 Protease Inhibitor: indinavir </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ indinavir </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Appropriate doses for this combination, with respect to efficacy and safety, have not been established. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>HIV-1 Protease Inhibitor: saquinavir </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ saquinavir </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>See the complete prescribing information for saquinavir for details on co-administration of saquinavir and ritonavir. Saquinavir/ritonavir in combination with rifampin is not recommended due to the risk of severe hepatotoxicity (presenting as increased hepatic transaminases) if the three drugs are given together. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>HIV-1 Protease Inhibitor: tipranavir </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ tipranavir </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>See the complete prescribing information for tipranavir for details on co-administration of tipranavir and ritonavir. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Non-Nucleoside Reverse Transcriptase Inhibitor: delavirdine </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ ritonavir </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Appropriate doses of this combination with respect to safety and efficacy have not been established. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>HIV-1 CCR5 – antagonist: maraviroc </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ maraviroc </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>See the complete prescribing information for maraviroc for details on co-administration of maraviroc and ritonavir-containing protease inhibitors. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Integrase Inhibitor: raltegravir </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↓ raltegravir </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>The effects of ritonavir on raltegravir with ritonavir dosage regimens greater than 100 mg twice daily have not been evaluated, however raltegravir concentrations may be decreased with ritonavir co-administration. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,'>
<p class=,'First,'>
<span class=,'Bold,'><span class=,'Italics,'>Other Agents </span></span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Alpha 1-Adrenoreceptor Antagonist: alfuzosin </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ alfuzosin </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Contraindicated due to potential hypotension <span class=,'Italics,'>[see <span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>Contraindications </a></span><span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>(4)</a></span>]</span>. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Antianginal: ranolazine </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ ranolazine </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Contraindicated due to potential for serious and/or life-threatening reactions <span class=,'Italics,'>[see <span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>Contraindications </a></span><span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>(4)</a></span>]</span>. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Analgesics, Narcotic: </p>
<p>tramadol, </p>
<p>propoxyphene, </p>
<p>methadone, </p>
<p>fentanyl </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ analgesics </p>
<p>↓ methadone </p>
<p>↑ fentanyl </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>A dose decrease may be needed for these drugs when co-administered with ritonavir. Dosage increase of methadone may be considered. Careful monitoring of therapeutic and adverse effects (including potentially fatal respiratory depression) is recommended when fentanyl is concomitantly administered with ritonavir. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Anesthetic: </p>
<p>meperidine </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↓ meperidine/ </p>
<p>↑ normeperidine </p>
<p>(metabolite) </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Dosage increase and long-term use of meperidine with ritonavir are not recommended due to the increased concentrations of the metabolite normeperidine which has both analgesic activity and CNS stimulant activity (e.g., seizures). </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Antialcoholics: </p>
<p>disulfiram/ </p>
<p>metronidazole </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<br/>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Ritonavir formulations contain ethanol, which can produce disulfiram-like reactions when co-administered with disulfiram or other drugs that produce this reaction (e.g., metronidazole). </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Antiarrhythmics: amiodarone, dronedarone, flecainide, propafenone, quinidine </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ antiarrhythmics </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Contraindicated due to potential for cardiac arrhythmias <span class=,'Italics,'>[see <span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>Contraindications </a></span><span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>(4)</a></span>]</span>. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Antiarrhythmics: disopyramide, lidocaine, mexiletine </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ antiarrhythmics </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics when co-administered with ritonavir, if available. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Anticancer Agents: </p>
<p>abemaciclib, </p>
<p>apalutamide, </p>
<p>dasatinib, </p>
<p>encorafenib, </p>
<p>ibrutinib, </p>
<p>ivosidenib, </p>
<p>neratinib, </p>
<p>nilotinib, </p>
<p>venetoclax, </p>
<p>vinblastine, </p>
<p>vincristine </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ anticancer agents </p>
<p>↓ ritonavir<span class=,'Sup,'>#</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Apalutamide is contraindicated due to potential for loss of virologic response and possible resistance to ritonavir or to the class of protease inhibitors <span class=,'Italics,'>[see <span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>Contraindications </a></span><span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>(4)</a></span>]</span>. </p>
<p>Avoid co-administration of encorafenib or ivosidenib with ritonavir due to potential risk of serious adverse events such as QT interval prolongation. If co-administration of encorafenib with ritonavir cannot be avoided, modify dose as recommended in encorafenib USPI. If co-administration of ivosidenib with ritonavir cannot be avoided, reduce ivosidenib dose to 250 mg once daily. </p>
<p>Avoid use of neratinib, venetoclax or ibrutinib with ritonavir. </p>
<p>For vincristine and vinblastine, consideration should be given to temporarily withholding the ritonavir containing antiretroviral regimen in patients who develop significant hematologic or gastrointestinal side effects when ritonavir is administered concurrently with vincristine or vinblastine. </p>
<p>Clinicians should be aware that if the ritonavir containing regimen is withheld for a prolonged period, consideration should be given to altering the regimen to not include a CYP3A or P-gp inhibitor in order to control HIV-1 viral load. </p>
<p>A decrease in the dosage or an adjustment of the dosing interval of nilotinib and dasatinib may be necessary for patients requiring co-administration with strong CYP3A inhibitors such as ritonavir. Please refer to the nilotinib and dasatinib prescribing information for dosing instructions. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Anticoagulant: warfarin </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑↓ warfarin </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Initial frequent monitoring of the INR during ritonavir and warfarin co-administration is recommended. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Anticoagulant: rivaroxaban </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ rivaroxaban </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Avoid concomitant use of rivaroxaban and ritonavir. Co-administration of ritonavir and rivaroxaban may lead to risk of increased bleeding. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Anticonvulsants: </p>
<p>carbamazepine, </p>
<p>clonazepam, </p>
<p>ethosuximide </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ anticonvulsants </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>A dose decrease may be needed for these drugs when co-administered with ritonavir and therapeutic concentration monitoring is recommended for these anticonvulsants, if available. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Anticonvulsants: divalproex, lamotrigine, phenytoin </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↓ anticonvulsants </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>A dose increase may be needed for these drugs when co-administered with ritonavir and therapeutic concentration monitoring is recommended for these anticonvulsants, if available. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Antidepressants: nefazodone, </p>
<p>selective serotonin </p>
<p>reuptake inhibitors (SSRIs): e.g., </p>
<p>fluoxetine, </p>
<p>paroxetine, </p>
<p>tricyclics: e.g., </p>
<p>amitriptyline, nortriptyline </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ antidepressants </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>A dose decrease may be needed for these drugs when co-administered with ritonavir. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Antidepressant: </p>
<p>bupropion </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↓ bupropion </p>
<p>↓ active metabolite, hydroxybupropion </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Patients receiving ritonavir and bupropion concurrently should be monitored for an adequate clinical response to bupropion. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Antidepressant: </p>
<p>desipramine </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ desipramine </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Dosage reduction and concentration monitoring of desipramine is recommended. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Antidepressant: </p>
<p>trazodone </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ trazodone </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Adverse events of nausea, dizziness, hypotension and syncope have been observed following co-administration of trazodone and ritonavir. A lower dose of trazodone should be considered. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Antiemetic: dronabinol </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ dronabinol </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>A dose decrease of dronabinol may be needed when co-administered with ritonavir. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Antifungals: </p>
<p>ketoconazole </p>
<p>itraconazole </p>
<p>voriconazole </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ ketoconazole </p>
<p>↑ itraconazole </p>
<p>↓ voriconazole </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>High doses of ketoconazole or itraconazole (greater than 200 mg per day) are not recommended. </p>
<p>Co-administration of voriconazole and ritonavir doses of 400 mg every 12 hours or greater is contraindicated due to the potential for loss of antifungal response <span class=,'Italics,'>[see <span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>Contraindications </a></span><span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>(4)</a></span>]</span>. Co-administration of voriconazole and ritonavir 100 mg should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Anti-gout: </p>
<p>colchicine </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ colchicine </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Contraindicated due to potential for serious and/or life-threatening reactions in patients with renal and/or hepatic impairment <span class=,'Italics,'>[see <span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>Contraindications </a></span><span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>(4)</a></span>]</span>.<span class=,'Underline,'>
<br/>
<br/>For patients with normal renal or hepatic function: </span>
</p>
<p>
<span class=,'Italics,'>Treatment of gout flares-co-administration of colchicine in patients on ritonavir:</span>
<br/>0.6 mg (one tablet) for one dose, followed by 0.3 mg (half tablet) one hour later. Dose to be repeated no earlier than three days.<span class=,'Italics,'>
<br/>
<br/>Prophylaxis of gout flares-co-administration of colchicine in patients on ritonavir:</span>
<br/>If the original colchicine regimen was 0.6 mg twice a day, the regimen should be adjusted to 0.3 mg once a day.<br/>
<br/>If the original colchicine regimen was 0.6 mg once a day, the regimen should be adjusted to 0.3 mg once every other day.<span class=,'Italics,'>
<br/>
<br/>Treatment of familial Mediterranean fever (FMF)-co-administration of colchicine in patients on ritonavir:</span>
<br/>Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day). </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Anti-infective: clarithromycin </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ clarithromycin </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>For patients with renal impairment, adjust clarithromycin dose as follows: </p>
<ul class=,'Disc,'>
<li>For patients with CL<span class=,'Sub,'>CR</span> 30 to 60 mL per min the dose of clarithromycin should be reduced by 50%. </li>
<li>For patients with CL<span class=,'Sub,'>CR</span> less than 30 mL per min the dose of clarithromycin should be decreased by 75%. </li>
</ul>
<p>No dose adjustment for patients with normal renal function is necessary. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Antimycobacterial: bedaquiline </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ bedaquiline </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Bedaquiline should only be used with ritonavir if the benefit of co-administration outweighs the risk. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Antimycobacterial: rifabutin </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ rifabutin and rifabutin metabolite </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Dosage reduction of rifabutin by at least three-quarters of the usual dose of 300 mg per day is recommended (e.g., 150 mg every other day or three times a week). Further dosage reduction may be necessary. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Antimycobacterial: rifampin </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↓ ritonavir </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>May lead to loss of virologic response. Alternate antimycobacterial agents such as rifabutin should be considered. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Antiparasitic: atovaquone </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↓ atovaquone </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Clinical significance is unknown; however, increase in atovaquone dose may be needed. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Antiparasitic: quinine </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ quinine </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>A dose decrease of quinine may be needed when co-administered with ritonavir. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Antipsychotics: lurasidone </p>
<p>pimozide </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ lurasidone </p>
<p>↑ pimozide </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Contraindicated due to potential for serious and/or life-threatening reactions <span class=,'Italics,'>[see <span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>Contraindications </a></span><span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>(4)</a></span>]</span>. </p>
<p>Contraindicated due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias <span class=,'Italics,'>[see <span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>Contraindications </a></span><span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>(4)</a></span>]</span>. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Antipsychotics: perphenazine, risperidone, thioridazine </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ antipsychotics </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>A dose decrease may be needed for these drugs when co-administered with ritonavir. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Antipsychotics: </p>
<p>quetiapine </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ quetiapine</p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>
<span class=,'Underline,'>Initiation of ritonavir in patients taking quetiapine:</span>
<br/>
<br/>Consider alternative antiretroviral therapy to avoid increases in quetiapine exposures. If co-administration is necessary, reduce the quetiapine dose to 1/6 of the current dose and monitor for quetiapine-associated adverse reactions. Refer to the quetiapine prescribing information for recommendations on adverse reaction monitoring.<span class=,'Underline,'>
<br/>
<br/>Initiation of quetiapine in patients taking ritonavir:</span>
<br/>
<br/>Refer to the quetiapine prescribing information for initial dosing and titration of quetiapine. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>β-Blockers: </p>
<p>metoprolol, timolol </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ beta-blockers </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Caution is warranted and clinical monitoring of patients is recommended. A dose decrease may be needed for these drugs when co-administered with ritonavir.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Bronchodilator: theophylline </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↓ theophylline </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Increased dosage of theophylline may be required; therapeutic monitoring should be considered. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Calcium channel blockers: diltiazem, nifedipine, verapamil </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ calcium channel blockers </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Caution is warranted and clinical monitoring of patients is recommended. A dose decrease may be needed for these drugs when co-administered with ritonavir. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Digoxin </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ digoxin </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Concomitant administration of ritonavir with digoxin may increase digoxin levels. Caution should be exercised when co-administering ritonavir with digoxin, with appropriate monitoring of serum digoxin levels. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Endothelin receptor </p>
<p>antagonists: bosentan </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ bosentan</p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>
<span class=,'Underline,'>Co-administration of bosentan in patients on ritonavir:</span>
<br/>
<br/>In patients who have been receiving ritonavir for at least 10 days, start bosentan at 62.5 mg once daily or every other day based upon individual tolerability.<span class=,'Underline,'>
<br/>
<br/>Co-administration of ritonavir in patients on bosentan:</span>
<br/>
<br/>Discontinue use of bosentan at least 36 hours prior to initiation of ritonavir.<br/>
<br/>After at least 10 days following the initiation of ritonavir, resume bosentan at 62.5 mg once daily or every other day based upon individual tolerability. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>GnRH Receptor </p>
<p>Antagonists: </p>
<p>elagolix </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ elagolix </p>
<p>↓ ritonavir </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Concomitant use of elagolix 200 mg twice daily and ritonavir for more than 1 month is not recommended due to potential risk of adverse events such as bone loss and hepatic transaminase elevations. Limit concomitant use of elagolix 150 mg once daily and ritonavir to 6 months. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Ergot Derivatives: </p>
<p>dihydroergotamine, </p>
<p>ergotamine, </p>
<p>methylergonovine </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ ergot derivatives</p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Contraindicated due to potential for acute ergot toxicity characterized by vasospasm and ischemia of the extremities and other tissues including the central nervous system <span class=,'Italics,'>[see <span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>Contraindications </a></span><span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>(4)</a></span>]</span>.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>GI Motility Agent: cisapride </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ cisapride </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Contraindicated due to potential for cardiac arrhythmias <span class=,'Italics,'>[see <span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>Contraindications </a></span><span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>(4)</a></span>]</span>. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Hepatitis C direct acting antiviral: glecaprevir/pibrentasvir </p>
<p>simeprevir </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ glecaprevir </p>
<p>↑ pibrentasvir </p>
<p>↑simeprevir </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>It is not recommended to co-administer ritonavir with glecaprevir/pibrentasvir, or simeprevir. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Herbal Products: </p>
<p>St. John's Wort </p>
<p>(hypericum </p>
<p>perforatum) </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↓ ritonavir </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Contraindicated due to potential for loss of virologic response and possible resistance to ritonavir or to the class of protease inhibitors <span class=,'Italics,'>[see </span><span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>Contraindications (4)</a>]</span>.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Lipid-modifying agents </p>
<p>HMG-CoA Reductase Inhibitor: </p>
<p>lovastatin </p>
<p>simvastatin </p>
<p>atorvastatin rosuvastatin </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ lovastatin </p>
<p>↑ simvastatin </p>
<p>↑ atorvastatin </p>
<p>↑ rosuvastatin </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Contraindicated due to potential for myopathy including rhabdomyolysis <span class=,'Italics,'>[see <span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>Contraindications </a></span><span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>(4)</a></span>].</span>
</p>
<p>Titrate atorvastatin and rosuvastatin dose carefully and use the lowest necessary dose. If ritonavir is used with another protease inhibitor, see the complete prescribing information for the concomitant protease inhibitor for details on co-administration with atorvastatin and rosuvastatin. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Microsomal </p>
<p>triglyceride </p>
<p>transfer protein </p>
<p>(MTTP) </p>
<p>Inhibitor: </p>
<p>lomitapide </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ lomitapide</p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Lomitapide is a sensitive substrate for CYP3A4 metabolism. CYP3A4 inhibitors increase the exposure of lomitapide, with strong inhibitors increasing exposure approximately 27-fold. Concomitant use of moderate or strong CYP3A4 inhibitors with lomitapide is contraindicated due to potential for hepatotoxicity <span class=,'Italics,'>[see <span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>Contraindications </a></span><span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>(4)</a></span>]</span>. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Immunosuppressants: cyclosporine, tacrolimus, sirolimus (rapamycin) </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ immunosuppressants </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Therapeutic concentration monitoring is recommended for immunosuppressant agents when co-administered with ritonavir. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Kinase Inhibitors: fostamatinib <span class=,'Italics,'>(also see anticancer agents above) </span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ fostamatinib metabolite R406 </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Monitor for toxicities of R406 exposure resulting in dose-related adverse events such as hepatotoxicity and neutropenia. Fostamatinib dose reduction may be required. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Long-acting beta-</p>
<p>adrenoceptor agonist: </p>
<p>salmeterol </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ salmeterol</p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Concurrent administration of salmeterol and ritonavir is not recommended. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Oral Contraceptives or Patch Contraceptives: ethinyl estradiol </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↓ ethinyl estradiol </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Alternate methods of contraception should be considered. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>PDE5 Inhibitors: </p>
<p>avanafil </p>
<p>sildenafil, </p>
<p>tadalafil, </p>
<p>vardenafil </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ avanafil </p>
<p>↑ sildenafil </p>
<p>↑ tadalafil </p>
<p>↑ vardenafil </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Sildenafil when used for the treatment of pulmonary arterial hypertension (Revatio<span class=,'Sup,'>®</span>) is contraindicated due to the potential for sildenafil associated adverse events, including visual abnormalities, hypotension, prolonged erection, and syncope <span class=,'Italics,'>[see <span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>Contraindications </a></span><span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>(4)</a></span>]</span>.<br/>
<br/>Do not use ritonavir with avanafil because a safe and effective avanafil dosage regimen has not been established.<br/>
<br/>Particular caution should be used when prescribing sildenafil, tadalafil or vardenafil in patients receiving ritonavir. Co-administration of ritonavir with these drugs may result in an increase in PDE5 inhibitor associated adverse events, including hypotension, syncope, visual changes, and prolonged erection.<br/>
<br/>Use of PDE5 inhibitors for pulmonary arterial hypertension (PAH):<br/>
<br/>Sildenafil (Revatio<span class=,'Sup,'>®</span>) is contraindicated <span class=,'Italics,'>[see <span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>Contraindications </a></span><span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>(4)</a></span>]</span>.<br/>
<br/>The following dose adjustments are recommended for use of tadalafil (Adcirca<span class=,'Sup,'>®</span>) with ritonavir:<span class=,'Underline,'>
<br/>
<br/>Co-administration of ADCIRCA in patients on ritonavir:</span>
<br/>
<br/>In patients receiving ritonavir for at least one week, start ADCIRCA at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability.<span class=,'Underline,'>
<br/>
<br/>Co-administration of ritonavir in patients on ADCIRCA:</span>
<br/>
<br/>Avoid use of ADCIRCA during the initiation of ritonavir. Stop ADCIRCA at least 24 hours prior to starting ritonavir. After at least one week following the initiation of ritonavir, resume ADCIRCA at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability.<br/>
<br/>Use of PDE5 inhibitors for the treatment of erectile dysfunction:<br/>
<br/>It is recommended not to exceed the following doses: </p>
<ul class=,'Disc,'>
<li>Sildenafil: 25 mg every 48 hours </li>
<li>Tadalafil: 10 mg every 72 hours </li>
<li>Vardenafil: 2.5 mg every 72 hours </li>
</ul>
<p>Use with increased monitoring for adverse events. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Sedative/Hypnotics: buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ sedative/hypnotics </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>A dose decrease may be needed for these drugs when co-administered with ritonavir. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Sedative/Hypnotics: </p>
<p>triazolam, </p>
<p>orally administered </p>
<p>midazolam </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ triazolam </p>
<p>↑ midazolam </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Contraindicated due to potential for prolonged or </p>
<p>increased sedation or respiratory depression <span class=,'Italics,'>[see </span>
</p>
<p>
<span class=,'Italics,'><span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>Contraindications </a></span><span class=,'Italics,'><a href=,'#LINK_7419975c-49a3-412a-8bdd-c2d859a0c716,'>(4)</a></span>]</span>. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Sedative/Hypnotics: </p>
<p>Parenteral midazolam </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ midazolam </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Co-administration should be done in a setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Stimulant: methamphetamine </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ methamphetamine </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Use with caution. A dose decrease of methamphetamine may be needed when co-administered with ritonavir. </p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Systemic/Inhaled/Nasal/Ophthalmic<br/> Corticosteroids:<br/> e.g., betamethasone<br/> budesonide<br/> ciclesonide<br/> dexamethasone<br/> fluticasone<br/> methylprednisolone<br/> mometasone<br/> prednisone<br/> triamcinolone </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>↑ glucocorticoids </p>
</td><td class=,'Botrule Lrule Rrule Toprule,'>
<p class=,'First,'>Co-administration with corticosteroids whose exposures are significantly increased by strong CYP3A inhibitors can increase the risk for Cushing’s syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone (whose PK and/or PD are less affected by strong CYP3A inhibitors relative to other studied steroids) should be considered, particularly for long-term use. </p>
</td>
</tr>
<tr class=,'Last,'>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'3,'>
<p class=,'First,'>
<span class=,'Sup,'>#</span> refers to interaction with apalutamide. </p>
</td>
</tr>
</tbody>
</table></div>
</div>
</div>"
"rituximab","b172773b-3905-4a1c-ad95-bab4b6126563","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Formal drug interaction studies have not been performed with RITUXAN.  In patients with CLL, RITUXAN did not alter systemic exposure to fludarabine or cyclophosphamide.  In clinical trials of patients with RA, concomitant administration of methotrexate or cyclophosphamide did not alter the pharmacokinetics of rituximab.</p>
</div>"
"rivaroxaban","3e95389b-0a93-4560-98c5-02637fb2600f","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1	General Inhibition and Induction Properties</h2>
<p class=,'First,'>Rivaroxaban is a substrate of CYP3A4/5, CYP2J2, and the P-gp and ATP-binding cassette G2 (ABCG2) transporters. Combined P-gp and strong CYP3A inhibitors increase exposure to rivaroxaban and may increase the risk of bleeding. Combined P-gp and strong CYP3A inducers decrease exposure to rivaroxaban and may increase the risk of thromboembolic events.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2	Drugs that Inhibit Cytochrome P450 3A Enzymes and Drug Transport Systems</h2>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.1,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Underline,'>Interaction with Combined P-gp and Strong CYP3A Inhibitors</span>
</p>
<p>Avoid concomitant administration of XARELTO with known combined P-gp and strong CYP3A inhibitors (e.g., ketoconazole and ritonavir)<span class=,'Italics,'> [see<a href=,'#S5.6,'> Warnings and Precautions (5.6) </a>and<a href=,'#S12.3,'> Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>Although clarithromycin is a combined P-gp and strong CYP3A inhibitor, pharmacokinetic data suggests that no precautions are necessary with concomitant administration with XARELTO as the change in exposure is unlikely to affect the bleeding risk<span class=,'Italics,'> [see<a href=,'#S12.3,'> Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.2,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Underline,'>Interaction with Combined P-gp and Moderate CYP3A Inhibitors in Patients with Renal Impairment</span>
</p>
<p>XARELTO should not be used in patients with CrCl 15 to &lt;80 mL/min who are receiving concomitant combined P-gp and moderate CYP3A inhibitors (e.g., erythromycin) unless the potential benefit justifies the potential risk<span class=,'Italics,'> [see<a href=,'#S5.4,'> Warnings and Precautions (5.4) </a>and<a href=,'#S12.3,'> Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3	Drugs that Induce Cytochrome P450 3A Enzymes and Drug Transport Systems</h2>
<p class=,'First,'>Avoid concomitant use of XARELTO with drugs that are combined P-gp and strong CYP3A inducers (e.g., carbamazepine, phenytoin, rifampin, St. John's wort)<span class=,'Italics,'> [see<a href=,'#S5.6,'> Warnings and Precautions (5.6) </a>and<a href=,'#S12.3,'> Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4	Anticoagulants and NSAIDs/Aspirin</h2>
<p class=,'First,'>Coadministration of enoxaparin, warfarin, aspirin, clopidogrel and chronic NSAID use may increase the risk of bleeding<span class=,'Italics,'> [see<a href=,'#S12.3,'> Clinical Pharmacology (12.3)</a>].</span>
</p>
<p>Avoid concurrent use of XARELTO with other anticoagulants due to increased bleeding risk unless benefit outweighs risk. Promptly evaluate any signs or symptoms of blood loss if patients are treated concomitantly with aspirin, other platelet aggregation inhibitors, or NSAIDs<span class=,'Italics,'> [see<a href=,'#S5.2,'> Warnings and Precautions (5.2)</a>]</span>.</p>
</div>
</div>"
"ropinirole","1cdb9d61-5bbc-4026-a449-fec8c9ce5c65","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID_3f13c501-e8a0-421f-9086-14f99432c0f1,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_a64d0c3e-3987-4fed-909f-e5e7c898e047,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 CYP1A2 Inhibitors and Inducers</h2>
<p class=,'First,'>
<span class=,'Italics,'>In vitro</span> metabolism studies showed that CYP1A2 was the major enzyme responsible for the metabolism of ropinirole. There is thus the potential for inducers or inhibitors of this enzyme to alter the clearance of ropinirole. Therefore, if therapy with a drug known to be a potent inducer or inhibitor of CYP1A2 is stopped or started during treatment with ropinirole, adjustment of the dose of ropinirole may be required. Coadministration of ciprofloxacin, an inhibitor of CYP1A2, increases the AUC and C<span class=,'Sub,'>max</span> of ropinirole <span class=,'Italics,'>[see </span><span class=,'Italics,'><a href=,'#ID_bb199fd7-237d-48dd-b97d-92eda2bb0952,'>Clinical Pharmacology</a> (12.3)]. </span>Cigarette smoking is expected to increase the clearance of ropinirole since CYP1A2 is known to be induced by smoking <span class=,'Italics,'>[see </span><span class=,'Italics,'><a href=,'#ID_bb199fd7-237d-48dd-b97d-92eda2bb0952,'>Clinical Pharmacology</a> (12.3)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_d80a4eef-a745-42ac-b1f0-1dc268328e35,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Estrogens</h2>
<p class=,'First,'>Population pharmacokinetic analysis revealed that higher doses of estrogens (usually associated with hormone replacement therapy [HRT]) reduced the clearance of ropinirole. Starting or stopping HRT may require adjustment of dosage of ropinirole <span class=,'Italics,'>[see <a href=,'#ID_bb199fd7-237d-48dd-b97d-92eda2bb0952,'>Clinical Pharmacology</a> (12.3)].</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_1a29f204-a25e-4334-9650-9caf185eed8a,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 DopamineAntagonists</h2>
<p class=,'First,'>Because ropinirole is a dopamine agonist, it is possible that dopamine antagonists such as neuroleptics (e.g., phenothiazines, butyrophenones, thioxanthenes) or metoclopramide may reduce the efficacy of ropinirole. </p>
</div>
</div>"
"rosiglitazone","ef14122b-7fff-45fa-b13b-0ea9e48bd57d","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'section-9,'></a>
<p></p>
<a href=,'http://,'></a><span class=,'Bold,'>7.1</span> CYP2C8 Inhibitors and 
Inducers<p class=,'First,'>An inhibitor of CYP2C8 (e.g., gemfibrozil) may increase the AUC 
of rosiglitazone and an inducer of CYP2C8 (e.g., rifampin) may decrease the AUC 
of rosiglitazone. Therefore, if an inhibitor or an inducer of CYP2C8 is started 
or stopped during treatment with rosiglitazone, changes in diabetes treatment 
may be needed based upon clinical response. <span class=,'Italics,'>[See Clinical 
Pharmacology (12.4).]</span>
</p>
</div>"
"rosuvastatin","54931c99-b642-4476-a669-331136890485","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID453,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,'>
<a name=,'ID454,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Cyclosporine</h2>
<p class=,'First,'>
<a name=,'ID455,'></a>Cyclosporine increased rosuvastatin exposure and may result in increased risk of myopathy. Therefore, in patients taking cyclosporine, the dose of rosuvastatin tablets should not exceed 5 mg once daily <span class=,'Italics,'>[see Dosage and Administration (<a href=,'#ID412,'>2.4</a>)</span>, <span class=,'Italics,'>Warnings and Precautions (<a href=,'#ID430,'>5.1</a>) and</span><span class=,'Italics,'>Clinical Pharmacology (<a href=,'#ID502,'>12.3</a>)]</span>.</p>
</div>
<div class=,'Section,'>
<a name=,'ID456,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Gemfibrozil</h2>
<p class=,'First,'>
<a name=,'ID457,'></a>Gemfibrozil significantly increased rosuvastatin exposure. Due to an observed increased risk of myopathy/rhabdomyolysis, combination therapy with rosuvastatin tablets and gemfibrozil should be avoided. If used together, the dose of rosuvastatin should not exceed 10 mg once daily <span class=,'Italics,'>[see</span><span class=,'Italics,'> Clinical Pharmacology (<a href=,'#ID502,'>12.3</a>)]</span>.</p>
</div>
<div class=,'Section,'>
<a name=,'ID458,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Anti-viral Medications</h2>
<p class=,'First,'>
<a name=,'ID459,'></a>Coadministration of rosuvastatin with certain anti-viral drugs has differing effects on rosuvastatin exposure and may increase risk of myopathy.</p>
<p>The combination of sofosbuvir/velpatasvir/voxilaprevir which are anti-Hepatitis C virus (anti- HCV) drugs, increases rosuvastatin exposure. Similarly, the combination of ledipasvir/sofosbuvir may significantly increase rosuvastatin exposure. For these combinations of anti-HCV drugs, concomitant use with rosuvastatin tablets are not recommended.</p>
<p>Simeprevir and combinations of dasabuvir/ombitasvir/paritaprevir/ritonavir, elbasvir/grazoprevir, sofosbuvir/velpatasvir and glecaprevir/pibrentasvir which are anti-HCV drugs, increase rosuvastatin exposure. Combinations of atazanavir/ritonavir and lopinavir/ritonavir, which are anti-HIV-1 drugs, increase rosuvastatin exposure <span class=,'Italics,'>[see Table 4</span><span class=,'Italics,'></span><span class=,'Italics,'>Clinical</span><span class=,'Italics,'> Pharmacology (<a href=,'#ID502,'>12.3</a>)]</span>. For these anti-viral drugs, the dose of rosuvastatin tablets should not exceed 10 mg once daily.</p>
<p>The combinations of fosamprenavir/ritonavir or tipranavir/ritonavir, which are anti-HIV-1 drugs, produce little or no change in rosuvastatin exposure. No dose adjustment is needed for concomitant use with these combinations <span class=,'Italics,'>[see Dosage and Administration (<a href=,'#ID412,'>2.4</a></span><span class=,'Italics,'>),</span><span class=,'Italics,'>Warnings and  Precautions (<a href=,'#ID430,'>5.1</a>) and Clinical Pharmacology (<a href=,'#ID502,'>12.3</a>)]</span>.</p>
</div>
<div class=,'Section,'>
<a name=,'ID460,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Darolutamide</h2>
<p class=,'First,'>
<a name=,'ID461,'></a>Darolutamide increased rosuvastatin exposure more than 5 fold. Therefore, in patients taking darolutamide, the dose of rosuvastatin tablets should not exceed 5 mg once daily <span class=,'Italics,'>[see Dosage and  Administration (<a href=,'#ID412,'>2.4</a>)</span>, <span class=,'Italics,'>Warnings and Precautions (<a href=,'#ID430,'>5.1</a>) and Clinical Pharmacology (<a href=,'#ID502,'>12.3</a>)]</span>.</p>
</div>
<div class=,'Section,'>
<a name=,'ID462,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Regorafenib</h2>
<p class=,'First,'>
<a name=,'ID463,'></a>Regorafenib increased rosuvastatin exposure and may increase the risk of myopathy. If used together, the dose of rosuvastatin tablets should not exceed 10 mg once daily <span class=,'Italics,'>[see Dosage and  Administration (<a href=,'#ID412,'>2.4</a>)</span>, <span class=,'Italics,'>Warnings and Precautions (<a href=,'#ID430,'>5.1</a>) and Clinical Pharmacology (<a href=,'#ID502,'>12.3</a>)]</span>.</p>
</div>
<div class=,'Section,'>
<a name=,'ID464,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6 Coumarin Anticoagulants</h2>
<p class=,'First,'>
<a name=,'ID465,'></a>Rosuvastatin tablets significantly increased INR in patients receiving coumarin anticoagulants. Therefore, caution should be exercised when coumarin anticoagulants are given in conjunction with rosuvastatin tablets. In patients taking coumarin anticoagulants and rosuvastatin tablets concomitantly, INR should be determined before starting rosuvastatin tablets and frequently enough during early therapy to ensure that no significant alteration of INR occurs <span class=,'Italics,'>[see</span><span class=,'Italics,'> Warnings and Precautions (<a href=,'#ID434,'>5.4</a>) and  Clinical Pharmacology (<a href=,'#ID502,'>12.3</a>)]</span>.</p>
</div>
<div class=,'Section,'>
<a name=,'ID466,'></a><a name=,'section-7.7,'></a>
<p></p>
<h2>7.7 Niacin</h2>
<p class=,'First,'>
<a name=,'ID467,'></a>The risk of skeletal muscle effects may be enhanced when rosuvastatin tablets are used in combination with lipid-modifying doses (≥1 g/day) of niacin; caution should be used when prescribing with rosuvastatin tablets <span class=,'Italics,'>[see</span><span class=,'Italics,'> Warnings and Precautions (<a href=,'#ID430,'>5.1</a>)]</span>.</p>
</div>
<div class=,'Section,'>
<a name=,'ID468,'></a><a name=,'section-7.8,'></a>
<p></p>
<h2>7.8 Fenofibrate</h2>
<p class=,'First,'>
<a name=,'ID469,'></a>When rosuvastatin tablets were coadministered with fenofibrate, no clinically significant increase in the AUC of rosuvastatin or fenofibrate was observed. Because it is known that the risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concomitant use of fenofibrates, caution should be used when prescribing fenofibrates with rosuvastatin tablets <span class=,'Italics,'>[see</span><span class=,'Italics,'>  Warnings and Precautions (<a href=,'#ID430,'>5.1</a>) and Clinical Pharmacology (<a href=,'#ID502,'>12.3</a>)]</span>
</p>
</div>
<div class=,'Section,'>
<a name=,'ID470,'></a><a name=,'section-7.9,'></a>
<p></p>
<h2>7.9 Colchicine</h2>
<p class=,'First,'>
<a name=,'ID471,'></a>Cases of myopathy, including rhabdomyolysis, have been reported with HMG-CoA reductase inhibitors, including rosuvastatin, coadministered with colchicine, and caution should be exercised when prescribing rosuvastatin tablets with colchicine <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#ID430,'>5.1</a>)]</span>.</p>
</div>
</div>"
"albuterol","230d66fc-f62c-42a6-adb3-0a0f879c8ad4","none found"
"albuterol","230d66fc-f62c-42a6-adb3-0a0f879c8ad4","none found"
"salicylic acid","17b570e7-3cf8-2f20-e054-00144ff8d46c","none found"
"saquinavir","b8b53129-06ab-4143-b9b7-7675e49a52ef","none found"
"saxagliptin","d45fc842-2563-4421-86af-a55b3191e19b","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'s7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Strong Inhibitors of CYP3A4/5 Enzymes</h2>
<p class=,'First,'>Ketoconazole significantly increased saxagliptin
exposure. Similar significant increases in plasma concentrations of saxagliptin
are anticipated with other strong CYP3A4/5 inhibitors (e.g., atazanavir, clarithromycin,
indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and
telithromycin). The dose of ONGLYZA should be limited to 2.5 mg when coadministered
with a strong CYP3A4/5 inhibitor. [See <span class=,'Italics,'><a href=,'#s2.3,'>Dosage and
Administration (2.3)</a></span> and <span class=,'Italics,'><a href=,'#s12.3,'>Clinical
Pharmacology (12.3)</a></span>.]</p>
</div>
</div>"
"selenium sulfide","28b84e3c-ae44-40bb-93c4-2625e19f7e61","none found"
"sertraline","347db8a2-b214-4bb7-953a-2dad1076ab37","none found"
"sildenafil","15372a7c-2935-48dc-a55a-8966719b50be","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'DRUG-INTERACTIONS,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'34073-7,'>
<a name=,'Drug-Interactions-Nitrates,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Nitrates</h2>
<p class=,'First,'>Administration of sildenafil tablets with nitric oxide donors such as organic nitrates or organic nitrites in any form is contraindicated. Consistent with its known effects on the nitric oxide/cGMP pathway, sildenafil tablets were shown to potentiate the hypotensive effects of nitrates [see <span class=,'Italics,'>Dosage and Administration (2.3), Contraindications (4.1), Clinical Pharmacology (12.2)</span>].</p>
</div>
<div class=,'Section,' data-sectioncode=,'34073-7,'>
<a name=,'Alpha-blockers,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Alpha-blockers</h2>
<p class=,'First,'>Use caution when co-administering alpha-blockers with sildenafil tablets because of potential additive blood pressure-lowering effects. When sildenafil tablets are co-administered with an alpha-blocker, patients should be stable on alpha-blocker therapy prior to initiating sildenafil tablets treatment and sildenafil tablets should be initiated at the lowest dose [see <span class=,'Italics,'>Dosage and Administration (2.3), Warnings and Precautions (5.5), Clinical Pharmacology (12.2)</span>].</p>
</div>
<div class=,'Section,' data-sectioncode=,'34073-7,'>
<a name=,'Amlodipine,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Amlodipine</h2>
<p class=,'First,'>When sildenafil tablets 100 mg was co-administered with amlodipine (5 mg or 10 mg) to hypertensive patients, the mean additional reduction on supine blood pressure was 8 mmHg systolic and 7 mmHg diastolic [see <span class=,'Italics,'>Warnings and Precautions (5.5), Clinical Pharmacology (12.2)</span>].</p>
</div>
<div class=,'Section,' data-sectioncode=,'34073-7,'>
<a name=,'Ritonavir-and-other-CYP3A4-inhibitors,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Ritonavir and other CYP3A4 inhibitors</h2>
<p class=,'First,'>Co-administration of ritonavir, a strong CYP3A4 inhibitor, greatly increased the systemic exposure of sildenafil (11-fold increase in AUC). It is therefore recommended not to exceed a maximum single dose of 25 mg of sildenafil tablets in a 48-hour period [see <span class=,'Italics,'>Dosage and Administration (2.4), Warnings and Precautions (5.6), Clinical Pharmacology (12.3)</span>].</p>
<p>Co-administration of erythromycin, a moderate CYP3A4 inhibitor, resulted in a 160% and 182% increases in sildenafil C<span class=,'Sub,'>max</span> and AUC, respectively. Co-administration of saquinavir, a strong CYP3A4 inhibitor, resulted in 140% and 210% increases in sildenafil C<span class=,'Sub,'>max </span>and AUC, respectively. Stronger CYP3A4 inhibitors such as ketoconazole or itraconazole could be expected to have greater effects than seen with saquinavir. A starting dose of 25 mg of sildenafil tablets should be considered in patients taking erythromycin or strong CYP3A4 inhibitors (such as saquinavir, ketoconazole, itraconazole) [see <span class=,'Italics,'>Dosage and Administration (2.4), Clinical Pharmacology (12.3)</span>].</p>
</div>
<div class=,'Section,' data-sectioncode=,'34073-7,'>
<a name=,'Alcohol,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Alcohol</h2>
<p class=,'First,'>In a drug-drug interaction study sildenafil 50 mg given with alcohol 0.5 g/kg in which mean maximum blood alcohol levels of 0.08% was achieved, sildenafil did not potentiate the hypotensive effect of alcohol in healthy volunteers [see <span class=,'Italics,'>Clinical Pharmacology (12.2)</span>].</p>
</div>
</div>"
"silodosin","2300db48-477f-4357-8de9-f723737071b4","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID57,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,'>
<a name=,'ID58,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Moderate and Strong CYP3A4 Inhibitors</h2>
<p class=,'First,'>
<a name=,'ID59,'></a>In a clinical metabolic inhibition study, a 3.8-fold increase in silodosin maximum plasma concentrations and 3.2-fold increase in silodosin exposure were observed with concurrent administration of a strong CYP3A4 inhibitor, 400 mg ketoconazole. Use of strong CYP3A4 inhibitors such as itraconazole or ritonavir may cause plasma concentrations of silodosin to increase. Concomitant administration of strong CYP3A4 inhibitors and silodosin is contraindicated <span class=,'Italics,'>[see CONTRAINDICATIONS (<a href=,'#ID21,'>4</a>), WARNINGS AND PRECAUTIONS (<a href=,'#ID35,'>5.4</a>) and CLINICAL PHARMACOLOGY (<a href=,'#ID102,'>12.3</a>)].</span> </p>
<p>The effect of moderate CYP3A4 inhibitors on the pharmacokinetics of silodosin has not been evaluated. Concomitant administration with moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin, verapamil) may increase concentration of silodosin. Exercise caution and monitor patients for adverse events when co-administering silodosin with moderate CYP3A4 inhibitors.</p>
</div>
<div class=,'Section,'>
<a name=,'ID60,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Strong P-glycoprotein (P-gp) Inhibitors</h2>
<p class=,'First,'>
<a name=,'ID61,'></a>In vitro studies indicated that silodosin is a P-gp substrate. Ketoconazole, a CYP3A4 inhibitor that also inhibits P-gp, caused significant increase in exposure to silodosin. Inhibition of P-gp may lead to increased silodosin concentration. Silodosin is therefore not recommended in patients taking strong P-gp inhibitors such as cyclosporine <span class=,'Italics,'>[see CLINICAL PHARMACOLOGY (<a href=,'#ID102,'>12.3</a></span><span class=,'Italics,'>)</span><span class=,'Italics,'>].</span>
</p>
</div>
<div class=,'Section,'>
<a name=,'ID62,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Alpha-Blockers</h2>
<p class=,'First,'>
<a name=,'ID63,'></a>The pharmacodynamic interactions between silodosin and other alpha-blockers have not been determined. However, interactions may be expected, and silodosin should not be used in combination with other alpha-blockers <span class=,'Italics,'>[see WARNINGS AND PRECAUTIONS (<a href=,'#ID37,'>5.5</a>)]</span>. </p>
</div>
<div class=,'Section,'>
<a name=,'ID64,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Digoxin</h2>
<p class=,'First,'>
<a name=,'ID65,'></a>The effect of co-administration of silodosin and digoxin 0.25 mg/day for 7 days was evaluated in a clinical trial in 16 healthy males, aged 18 years to 45 years. Concomitant administration of silodosin and digoxin did not significantly alter the steady state pharmacokinetics of digoxin. No dose adjustment is required. </p>
</div>
<div class=,'Section,'>
<a name=,'ID66,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 PDE5 Inhibitors</h2>
<p class=,'First,'>
<a name=,'ID67,'></a>Co-administration of silodosin with a single dose of 100 mg sildenafil or 20 mg tadalafil was evaluated in a placebo-controlled clinical study that included 24 healthy male subjects, 45 years to 78 years of age. Orthostatic vital signs were monitored in the 12-hour period following concomitant dosing. During this period, the total number of positive orthostatic test results was greater in the group receiving silodosin plus a PDE5 inhibitor compared with silodosin alone. No events of symptomatic orthostasis or dizziness were reported in subjects receiving silodosin with a PDE5 inhibitor.</p>
</div>
<div class=,'Section,'>
<a name=,'ID68,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6 Other Concomitant Drug Therapy</h2>
<p class=,'First,'>
<a name=,'ID69,'></a><span class=,'Bold,'><span class=,'Italics,'>Antihypertensives </span></span>
</p>
<p>The pharmacodynamic interactions between silodosin and antihypertensives have not been rigorously investigated in a clinical study. However, approximately one-third of the patients in clinical studies used concomitant antihypertensive medications with silodosin. The incidence of dizziness and orthostatic hypotension in these patients was higher than in the general silodosin population (4.6% versus 3.8% and 3.4% versus 3.2%, respectively). Exercise caution during concomitant use with antihypertensives and monitor patients for possible adverse events <span class=,'Italics,'>[see WARNINGS AND PRECAUTIONS (<a href=,'#ID37,'>5.5</a>)].</span> </p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Metabolic Interactions </span></span>
</p>
<p>
<span class=,'Italics,'>In vitro </span>data indicate that silodosin does not have the potential to inhibit or induce cytochrome P450 enzyme systems. </p>
</div>
<div class=,'Section,'>
<a name=,'ID70,'></a><a name=,'section-7.7,'></a>
<p></p>
<h2>7.7 Food Interactions</h2>
<p class=,'First,'>
<a name=,'ID71,'></a>The effect of a moderate fat, moderate calorie meal on silodosin pharmacokinetics was variable and decreased silodosin maximum plasma concentration (C<span class=,'Sub,'>max</span>) by approximately 18% to 43% and exposure (AUC) by 4% to 49% across three different studies. Safety and efficacy clinical trials for silodosin were always conducted in the presence of food intake. Patients should be instructed to take silodosin with a meal to reduce risk of adverse events <span class=,'Italics,'>[see CLINICAL PHARMACOLOGY (<a href=,'#ID102,'>12.3</a>)].</span>
</p>
</div>
</div>"
"silver sulfadiazine","067895f9-a797-4cbd-a3d2-d611d512fe5b","none found"
"simvastatin","364238c7-11b0-442e-acd9-4a6f21b9d783","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'i4i_interactions_id_9f880b51-c206-4c2e-a637-a15949e4b65b,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>
<a href=,'http://,'></a>
</p>
<p>7.1 CYP3A4 Interactions</p>
<p>Simvastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of CYP3A4. Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.</p>
<p>The risk of myopathy is increased by reducing the elimination of simvastatin. Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin. <span class=,'Italics,'>[See </span>Warnings and Precautions (5.1)<span class=,'Italics,'> and </span>Clinical Pharmacology (12.3)<span class=,'Italics,'>.]</span>
</p>
<p>
<span class=,'Italics,'>Itraconazole, ketoconazole, and other antifungal azoles</span>
</p>
<p>
<span class=,'Italics,'>Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin</span>
</p>
<p>
<span class=,'Italics,'>HIV protease inhibitors</span>
</p>
<p>
<span class=,'Italics,'>Antidepressant nefazodone</span>
</p>
<p>
<span class=,'Italics,'>Grapefruit juice in large quantities (greater than 1 quart daily)</span>
</p>
<p>Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk. If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.</p>
<p>
<a href=,'http://,'></a>
</p>
<p>
<a href=,'http://,'></a>
</p>
<p>
<a href=,'http://,'></a>
</p>
<p>7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone</p>
<p>The risk of myopathy is increased by gemfibrozil<span class=,'Italics,'> [see </span>Dosage and Administration (2.5)<span class=,'Italics,'>]</span> and to a lesser extent by other fibrates and niacin (nicotinic acid) (greater than or equal to 1 g/day). <span class=,'Italics,'>[see</span> Warnings and Precautions (5.1)<span class=,'Italics,'>]</span>.</p>
<p>
<a href=,'http://,'></a>
</p>
<p>
<a href=,'http://,'></a>
</p>
<p>
<a href=,'http://,'></a>
</p>
<p>7.3 Cyclosporine or Danazol</p>
<p>The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin<span class=,'Italics,'> [see </span>Warnings and Precautions (5.1)<span class=,'Italics,'> and</span> Clinical Pharmacology (12.3)<span class=,'Italics,'>]</span>.</p>
<p>
<a href=,'http://,'></a>
</p>
<p>
<a href=,'http://,'></a>
</p>
<p>
<a href=,'http://,'></a>
</p>
<p>7.4 Amiodarone or Verapamil</p>
<p>The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin <span class=,'Italics,'>[see</span> Warnings and Precautions (5.1)<span class=,'Italics,'>]</span>.</p>
<p>
<a href=,'http://,'></a>
</p>
<p>
<a href=,'http://,'></a>
</p>
<p>
<a href=,'http://,'></a>
</p>
<p>7.5 Digoxin</p>
<p>In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma. Patients taking digoxin should be monitored appropriately when simvastatin is initiated<span class=,'Italics,'> [see </span>Clinical Pharmacology (12.3)<span class=,'Italics,'>]</span>.</p>
<p>
<a href=,'http://,'></a>
</p>
<p>
<a href=,'http://,'></a>
</p>
<p>
<a href=,'http://,'></a>
</p>
<p>7.6 Coumarin Anticoagulants</p>
<p>In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively. With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly. In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs. Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants. If the dose of simvastatin is changed or discontinued, the same procedure should be repeated. Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.</p>
</div>"
"siponimod","44492772-5aed-4627-bd85-e8e89f308bb3","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'s7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7p1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1     Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies</h2>
<p class=,'First,'>MAYZENT has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration <span class=,'Italics,'>[see Warnings and Precautions (5.1)]</span>.
								</p>
<p>When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive immunosuppressive effects <span class=,'Italics,'>[see Warnings and Precautions (5.10)]</span>.</p>
<p>Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with MAYZENT after alemtuzumab is not recommended.</p>
<p>MAYZENT can generally be started immediately after discontinuation of beta interferon or glatiramer acetate.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7p2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2     Anti-Arrhythmic Drugs, QT Prolonging Drugs, Drugs That May Decrease Heart Rate</h2>
<p class=,'First,'>MAYZENT has not been studied in patients taking QT prolonging drugs.</p>
<p>Class Ia (e.g., quinidine, procainamide) and Class III (e.g., amiodarone, sotalol) antiarrhythmic drugs have been associated with cases of Torsades de Pointes in patients with bradycardia. If treatment with MAYZENT is considered, advice from a cardiologist should be sought.</p>
<p>Because of the potential additive effects on heart rate, treatment with MAYZENT should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties, heart rate lowering calcium channel blockers (e.g., verapamil, diltiazem), or other drugs that may decrease heart rate (e.g., ivabradine, digoxin) <span class=,'Italics,'>[see Warnings and Precautions (5.3) and Drug Interactions (7.3)]</span>. If treatment with MAYZENT is considered, advice from a cardiologist should be sought regarding the switch to non-heart-rate lowering drugs or appropriate monitoring for treatment initiation.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7p3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3     Beta-Blockers</h2>
<p class=,'First,'>Caution should be applied when MAYZENT is initiated in patients receiving treatment with a beta-blocker because of the additive effects on lowering heart rate; temporary interruption of the beta-blocker treatment may be needed prior to initiation of MAYZENT [see Warnings and Precautions (5.3)]. Beta-blocker treatment can be initiated in patients receiving stable doses of MAYZENT <span class=,'Italics,'>[see Clinical Pharmacology (12.2)]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7p4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4     Vaccination</h2>
<p class=,'First,'>During and for up to one month after discontinuation of treatment with MAYZENT, vaccinations may be less effective; therefore MAYZENT treatment should be paused 1 week prior and for 4 weeks after vaccination <span class=,'Italics,'>[see Warnings and Precautions (5.1)]</span>.</p>
<p>The use of live attenuated vaccines may carry the risk of infection and should therefore be avoided during MAYZENT treatment and for up to 4 weeks after discontinuation of treatment with MAYZENT <span class=,'Italics,'>[see Warnings and Precautions (5.1)]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7p5,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5     CYP2C9 and CYP3A4 Inhibitors</h2>
<p class=,'First,'>Because of a significant increase in exposure to siponimod, concomitant use of MAYZENT and drugs that cause moderate CYP2C9 <span class=,'Underline,'>and</span> moderate or strong CYP3A4 inhibition is not recommended. This concomitant drug regimen can consist of a moderate CYP2C9/CYP3A4 dual inhibitor (e.g., fluconazole) or a moderate CYP2C9 inhibitor in combination with a separate - moderate or strong CYP3A4 inhibitor.</p>
<p>Caution should be exercised for concomitant use of MAYZENT with moderate CYP2C9 inhibitors.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7p6,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6     CYP2C9 and CYP3A4 Inducers</h2>
<p class=,'First,'>Because of a significant decrease in siponimod exposure, concomitant use of MAYZENT and drugs that cause moderate CYP2C9 <span class=,'Underline,'>and</span> strong CYP3A4 induction is not recommended for all patients. This concomitant drug regimen can consist of moderate CYP2C9/strong CYP3A4 dual inducer (e.g., rifampin or carbamazepine) or a moderate CYP2C9 inducer in combination with a separate strong CYP3A4 inducer. </p>
<p>Caution should be exercised for concomitant use of MAYZENT with moderate CYP2C9 inducers.</p>
<p>Concomitant use of MAYZENT and moderate (e.g., modafinil, efavirenz) or strong CYP3A4 inducers is not recommended for patients with CYP2C9*1/*3 and *2/*3 genotype <span class=,'Italics,'>[see Clinical Pharmacology (12.3)]</span>.</p>
</div>
</div>"
"sitagliptin","194c3718-5eb5-4cf5-85d0-2bb1ed8293b8","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1	Insulin Secretagogues or Insulin</h2>
<p class=,'First,'>Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. <span class=,'Italics,'>[See <a href=,'#S5.4,'>Warnings and Precautions (5.4)</a>.]</span>
</p>
</div>
</div>"
"sodium alginate","02eb5938-cd59-4a81-853d-a4148d813a94","none found"
"edetate calcium disodium","9bb1fef7-4159-4dca-8a8c-37e53ccc6bab","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_95d9db17-8ca7-4b9b-abf5-b843f7611246,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Table 1 includes clinically significant drug interactions with Morphine Sulfate Oral Solution.</p>
<p>
<span class=,'Bold,'>Table 1: Clinically Significant Drug Interactions with Morphine Sulfate Oral Solution</span>
</p>
<div class=,'scrollingtable,'><table border=,'1,' cellpadding=,'0,' cellspacing=,'0,'>
<col width=,'126.9pt,'/>
<col width=,'351.9pt,'/>
<tbody class=,'Headless,'>
<tr class=,'First,'>
<td colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>Benzodiazepines and Other Central Nervous System (CNS) Depressants<br/>
<br/>
</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact: </span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients closely for signs of respiratory depression and sedation. If concomitant use is warranted, consider prescribing naloxone for the emergency treatment of opioid overdose [<span class=,'Italics,'>see <a href=,'#LINK_668d502c-c386-44b1-8487-16eb59b65e37,'>Dosage and Administration (2.2),</a></span><span class=,'Italics,'><a href=,'#LINK_9ac33843-84d8-4c32-9941-e66e30a51085,'>Warnings and Precautions (5.2, 5.4, 5.6)</a></span>].</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Examples: </span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,' colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>Serotonergic Drugs</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact: </span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention: </span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue Morphine Sulfate Oral Solution if serotonin syndrome is suspected.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Examples: </span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).</p>
</td>
</tr>
<tr>
<td class=,'Toprule,' colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>Monoamine Oxidase Inhibitors (MAOIs)</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact: </span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [<span class=,'Italics,'>see <a href=,'#LINK_0306466a-f377-4ad9-b951-172fe965f7af,'>Warnings and Precautions (5.4</a>, <a href=,'#LINK_27b2f86f-2d59-4a57-9f10-5e9114c930df,'>5.8)</a></span>].</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention: </span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Do not use Morphine Sulfate Oral Solution in patients taking MAOIs or within 14 days of stopping such treatment.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Examples: </span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Phenelzine, tranylcypromine, linezolid.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,' colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact: </span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>May reduce the analgesic effect of Morphine Sulfate Oral Solution and/or precipitate withdrawal symptoms.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention: </span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Avoid concomitant use.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Examples: </span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Butorphanol, nalbuphine, pentazocine, buprenorphine.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,' colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>Muscle Relaxants</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact: </span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Morphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention: </span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of Morphine Sulfate Oral Solution and/or the muscle relaxant as necessary. Due to the risk of respiratory depression with concomitant use of skeletal muscle relaxants and opioids, consider prescribing naloxone for the emergency treatment of opioid overdose <span class=,'Italics,'>[see <a href=,'#LINK_668d502c-c386-44b1-8487-16eb59b65e37,'>Dosage and Administration (2.2)</a>, <a href=,'#LINK_0306466a-f377-4ad9-b951-172fe965f7af,'>Warnings and Precautions (5.4</a>, <span class=,'Underline,'><span class=,'Underline,'><a href=,'#LINK_9ac33843-84d8-4c32-9941-e66e30a51085,'>5.6</a></span><a href=,'#LINK_9ac33843-84d8-4c32-9941-e66e30a51085,'>)</a></span>]</span>.</p>
</td>
</tr>
<tr>
<td align=,'right,' class=,'Toprule,'><span class=,'Italics,'>Examples:</span></td><td class=,'Lrule Toprule,'>Cyclobenzaprine, metaxalone. </td>
</tr>
<tr>
<td class=,'Toprule,' colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>Cimetidine</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact: </span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>The concomitant use of morphine and cimetidine has been reported to precipitate apnea, confusion, and muscle twitching in an isolated report.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention: </span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Monitor patients for increased respiratory and CNS depression when Morphine Sulfate Oral Solution is used concomitantly with cimetidine.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,' colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>Diuretics</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact: </span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention: </span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,' colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>Anticholinergic Drugs</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact: </span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention: </span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Monitor patients for signs of urinary retention or reduced gastric motility when Morphine Sulfate Oral Solution is used concomitantly with anticholinergic drugs.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,' colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>P-Glycoprotein (P-gp) Inhibitors</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical Impact: </span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>The concomitant use of P-gp inhibitors can increase the exposure to morphine by two-fold and can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Intervention: </span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of Morphine Sulfate Oral Solution and/or the P-gp inhibitor as necessary.</p>
</td>
</tr>
<tr class=,'Last,'>
<td class=,'Toprule,'>
<p class=,'First,'>
<span class=,'Italics,'>Examples:</span>
</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Quinidine, verapamil.</p>
</td>
</tr>
</tbody>
</table></div>
<br/>
</div>"
"sodium chloride","24a08a93-df23-474b-873e-c59ec8855f9f","none found"
"sodium fluoride","260a44d8-72ab-4dae-982d-24918c97d5e5","none found"
"sodium lactate","a71a9ef2-ae6f-4280-a589-6f658a08b816","none found"
"sodium nitrite","52f01c6e-172a-47a9-98a6-9eab7651a032","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Formal drug interaction studies have not been conducted with Sodium Nitrite Injection.</p>
</div>"
"sodium nitroprusside","2fa687a2-10e7-45ae-953a-9d63564c2908","none found"
"sodium thiosulfate","82f55408-2de9-463d-85e8-b39c3b259f0b","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Formal drug interaction studies have not been conducted with Sodium Thiosulfate Injection.</p>
</div>"
"sodium valproate","7a687b2f-246d-4736-a20c-92421c263268","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_7a56c8b9-b5ef-41e3-b0c1-415224bd3ee9,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_d862b4a3-72cd-4479-9f8a-f6507756e35d,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Effects of Co-Administered Drugs on Valproate Clearance</h2>
<p class=,'First,'>Drugs that affect the level of expression of hepatic enzymes, particularly those that elevate levels of glucuronosyltransferases (such as ritonavir), may increase the clearance of valproate. For example, phenytoin, carbamazepine, and phenobarbital (or primidone) can double the clearance of valproate. Thus, patients on monotherapy will generally have longer half-lives and higher concentrations than patients receiving polytherapy with antiepilepsy drugs. </p>
<p>In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. </p>
<p>Because of these changes in valproate clearance, monitoring of valproate and concomitant drug concentrations should be increased whenever enzyme inducing drugs are introduced or withdrawn. </p>
<p>The following list provides information about the potential for an influence of several commonly prescribed medications on valproate pharmacokinetics. The list is not exhaustive nor could it be, since new interactions are continuously being reported. </p>
<p>
<span class=,'Underline,'>Drugs for which a potentially important interaction has been observed</span>
</p>
<p>
<span class=,'Italics,'>Aspirin <br/>
</span>A study involving the co-administration of aspirin at antipyretic doses (11 to 16 mg/kg) with valproate to pediatric patients (n = 6) revealed a decrease in protein binding and an inhibition of metabolism of valproate. <br/>Valproate free fraction was increased 4-fold in the presence of aspirin compared to valproate alone. The β-oxidation pathway consisting of 2-E-valproic acid, 3-OH-valproic acid, and 3-keto valproic acid was decreased from 25% of total metabolites excreted on valproate alone to 8.3% in the presence of aspirin. Caution should be observed if valproate and aspirin are to be co‑administered. </p>
<p>
<span class=,'Italics,'>Carbapenem Antibiotics <br/>
</span>A clinically significant reduction in serum valproic acid concentration has been reported in patients receiving carbapenem antibiotics (for example, ertapenem, imipenem, meropenem this is not a complete list) and may result in loss of seizure control. The mechanism of this interaction is not well understood. Serum valproic acid concentrations should be monitored frequently after initiating carbapenem therapy. Alternative antibacterial or anticonvulsant therapy should be considered if serum valproic acid concentrations drop significantly or seizure control deteriorates [see <span class=,'Bold,'>WARNINGS AND PRECAUTIONS (<a href=,'#LINK_71b79538-07bb-4c23-a32e-0f58eb3e72b2,'>5.12</a>)</span>]. </p>
<p>
<span class=,'Italics,'>Estrogen-Containing Hormonal Contraceptives<br/>
</span>Estrogen-containing hormonal contraceptives may increase the clearance of valproate, which may result in decreased concentration of valproate and potentially increased seizure frequency. Prescribers should monitor serum valproate concentrations and clinical response when adding or discontinuing estrogen containing products.</p>
<p>
<span class=,'Italics,'>Felbamate <br/>
</span>A study involving the co-administration of 1,200 mg/day of felbamate with valproate to patients with epilepsy (n = 10) revealed an increase in mean valproate peak concentration by 35% (from 86 to 115 mcg/mL) compared to valproate alone. Increasing the felbamate dose to 2,400 mg/day increased the mean valproate peak concentration to 133 mcg/mL (another 16% increase). A decrease in valproate dosage may be necessary when felbamate therapy is initiated. </p>
<p>
<span class=,'Italics,'>Rifampin <br/>
</span>A study involving the administration of a single dose of valproate (7 mg/kg) 36 hours after 5 nights of daily dosing with rifampin (600 mg) revealed a 40% increase in the oral clearance of valproate. Valproate dosage adjustment may be necessary when it is co-administered with rifampin. </p>
<p>
<span class=,'Underline,'>Drugs for which either no interaction or a likely clinically unimportant interaction has been observed </span>
</p>
<p>
<span class=,'Italics,'>Antacids <br/>
</span>A study involving the co-administration of valproate 500 mg with commonly administered antacids (Maalox, Trisogel, and Titralac - 160 mEq doses) did not reveal any effect on the extent of absorption of valproate. </p>
<p>
<span class=,'Italics,'>Chlorpromazine <br/>
</span>A study involving the administration of 100 to 300 mg/day of chlorpromazine to schizophrenic patients already receiving valproate (200 mg BID) revealed a 15% increase in trough plasma levels of valproate. </p>
<p>
<span class=,'Italics,'>Haloperidol <br/>
</span>A study involving the administration of 6 to 10 mg/day of haloperidol to schizophrenic patients already receiving valproate (200 mg BID) revealed no significant changes in valproate trough plasma levels. </p>
<p>
<span class=,'Italics,'>Cimetidine and Ranitidine <br/>
</span>Cimetidine and ranitidine do not affect the clearance of valproate. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_2cd85ef8-0efa-4162-b978-a71adcc8004b,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Effects of Valproate on Other Drugs</h2>
<p class=,'First,'>Valproate has been found to be a weak inhibitor of some P450 isozymes, epoxide hydrase, and glucuronosyltransferases. </p>
<p>The following list provides information about the potential for an influence of valproate co‑administration on the pharmacokinetics or pharmacodynamics of several commonly prescribed medications. The list is not exhaustive, since new interactions are continuously being reported. </p>
<p>
<span class=,'Underline,'>Drugs for which a potentially important valproate interaction has been observed </span>
</p>
<p>
<span class=,'Italics,'>Amitriptyline/Nortriptyline<br/>
</span>Administration of a single oral 50 mg dose of amitriptyline to 15 normal volunteers (10 males and 5 females) who received valproate (500 mg BID) resulted in a 21% decrease in plasma clearance of amitriptyline and a 34% decrease in the net clearance of nortriptyline. Rare postmarketing reports of concurrent use of valproate and amitriptyline resulting in an increased amitriptyline level have been received. Concurrent use of valproate and amitriptyline has rarely been associated with toxicity. Monitoring of amitriptyline levels should be considered for patients taking valproate concomitantly with amitriptyline. Consideration should be given to lowering the dose of amitriptyline/nortriptyline in the presence of valproate. </p>
<p>
<span class=,'Italics,'>Carbamazepine/carbamazepine-10,11-Epoxide<br/>
</span>Serum levels of carbamazepine (CBZ) decreased 17% while that of carbamazepine-10,11-epoxide (CBZ-E) increased by 45% upon co-administration of valproate and CBZ to epileptic patients. </p>
<p>
<span class=,'Italics,'>Clonazepam <br/>
</span>The concomitant use of valproate and clonazepam may induce absence status in patients with a history of absence type seizures. </p>
<p>
<span class=,'Italics,'>Diazepam <br/>
</span>Valproate displaces diazepam from its plasma albumin binding sites and inhibits its metabolism. Co-administration of valproate (1,500 mg daily) increased the free fraction of diazepam (10 mg) by 90% in healthy volunteers (n = 6). Plasma clearance and volume of distribution for free diazepam were reduced by 25% and 20%, respectively, in the presence of valproate. The elimination half‑life of diazepam remained unchanged upon addition of valproate. </p>
<p>
<span class=,'Italics,'>Ethosuximide <br/>
</span>Valproate inhibits the metabolism of ethosuximide. Administration of a single ethosuximide dose of 500 mg with valproate (800 to 1,600 mg/day) to healthy volunteers (n = 6) was accompanied by a 25% increase in elimination half-life of ethosuximide and a 15% decrease in its total clearance as compared to ethosuximide alone. Patients receiving valproate and ethosuximide, especially along with other anticonvulsants, should be monitored for alterations in serum concentrations of both drugs. </p>
<p>
<span class=,'Italics,'>Lamotrigine <br/>
</span>In a steady-state study involving 10 healthy volunteers, the elimination half-life of lamotrigine increased from 26 to 70 hours with valproate co-administration (a 165% increase). The dose of lamotrigine should be reduced when co-administered with valproate. Serious skin reactions (such as Stevens-Johnson syndrome and toxic epidermal necrolysis) have been reported with concomitant lamotrigine and valproate administration. See lamotrigine package insert for details on lamotrigine dosing with concomitant valproate administration. </p>
<p>
<span class=,'Italics,'>Phenobarbital <br/>
</span>Valproate was found to inhibit the metabolism of phenobarbital. Co-administration of valproate (250 mg BID for 14 days) with phenobarbital to normal subjects (n = 6) resulted in a 50% increase in half-life and a 30% decrease in plasma clearance of phenobarbital (60 mg single-dose). The fraction of phenobarbital dose excreted unchanged increased by 50% in presence of valproate. </p>
<p>There is evidence for severe CNS depression, with or without significant elevations of barbiturate or valproate serum concentrations. All patients receiving concomitant barbiturate therapy should be closely monitored for neurological toxicity. Serum barbiturate concentrations should be obtained, if possible, and the barbiturate dosage decreased, if appropriate. </p>
<p>Primidone, which is metabolized to a barbiturate, may be involved in a similar interaction with valproate. </p>
<p>
<span class=,'Italics,'>Phenytoin <br/>
</span>Valproate displaces phenytoin from its plasma albumin binding sites and inhibits its hepatic metabolism. Co-administration of valproate (400 mg TID) with phenytoin (250 mg) in normal volunteers (n = 7) was associated with a 60% increase in the free fraction of phenytoin. Total plasma clearance and apparent volume of distribution of phenytoin increased 30% in the presence of valproate. Both the clearance and apparent volume of distribution of free phenytoin were reduced by 25%. </p>
<p>In patients with epilepsy, there have been reports of breakthrough seizures occurring with the combination of valproate and phenytoin. The dosage of phenytoin should be adjusted as required by the clinical situation.</p>
<p>
<span class=,'Italics,'>Propofol<br/>
</span>The concomitant use of valproate and propofol may lead to increased blood levels of propofol. Reduce the dose of propofol when co-administering with valproate. Monitor patients closely for signs of increased sedation or cardiorespiratory depression.</p>
<p>
<span class=,'Italics,'>Rufinamide<br/>
</span>Based on a population pharmacokinetic analysis, rufinamide clearance was decreased by valproate. Rufinamide concentrations were increased by &lt;16% to 70%, dependent on concentration of valproate (with the larger increases being seen in pediatric patients at high doses or concentrations of valproate). Patients stabilized on rufinamide before being prescribed valproate should begin valproate therapy at a low dose, and titrate to a clinically effective dose [see <span class=,'Bold,'>Dosage and Administration (<a href=,'#LINK_c4c2d7c0-03c4-4d41-a61a-ab73b0c8bc5f,'>2.3</a>)</span>]. Similarly, patients on valproate should begin at a rufinamide dose lower than 10 mg/kg per day (pediatric patients) or 400 mg per day (adults).</p>
<p>
<span class=,'Italics,'>Tolbutamide <br/>
</span>From <span class=,'Italics,'>in vitro</span> experiments, the unbound fraction of tolbutamide was increased from 20% to 50% when added to plasma samples taken from patients treated with valproate. The clinical relevance of this displacement is unknown. </p>
<p>
<span class=,'Italics,'>Warfarin <br/>
</span>In an <span class=,'Italics,'>in vitro</span> study, valproate increased the unbound fraction of warfarin by up to 32.6%. The therapeutic relevance of this is unknown; however, coagulation tests should be monitored if valproate therapy is instituted in patients taking anticoagulants. </p>
<p>
<span class=,'Italics,'>Zidovudine <br/>
</span>In six patients who were seropositive for HIV, the clearance of zidovudine (100 mg q8h) was decreased by 38% after administration of valproate (250 or 500 mg q8h); the half-life of zidovudine was unaffected. </p>
<p>
<span class=,'Underline,'>Drugs for which either no interaction or a likely clinically unimportant interaction has been observed </span>
</p>
<p>
<span class=,'Italics,'>Acetaminophen <br/>
</span>Valproate had no effect on any of the pharmacokinetic parameters of acetaminophen when it was concurrently administered to three epileptic patients. </p>
<p>
<span class=,'Italics,'>Clozapine <br/>
</span>In psychotic patients (n = 11), no interaction was observed when valproate was co-administered with clozapine. </p>
<p>
<span class=,'Italics,'>Lithium <br/>
</span>Co-administration of valproate (500 mg BID) and lithium carbonate (300 mg TID) to normal male volunteers (n = 16) had no effect on the steady-state kinetics of lithium. </p>
<p>
<span class=,'Italics,'>Lorazepam <br/>
</span>Concomitant administration of valproate (500 mg BID) and lorazepam (1 mg BID) in normal male volunteers (n = 9) was accompanied by a 17% decrease in the plasma clearance of lorazepam. </p>
<p>
<span class=,'Italics,'>Olanzapine <br/>
</span>No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.</p>
<p>
<span class=,'Italics,'>Oral Contraceptive Steroids <br/>
</span>Administration of a single dose of ethinyloestradiol (50 mcg)/levonorgestrel (250 mcg) to 6 women on valproate (200 mg BID) therapy for 2 months did not reveal any pharmacokinetic interaction. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_5727e816-5040-467e-84a5-9781e8d86ef7,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Topiramate</h2>
<p class=,'First,'>Concomitant administration of valproate and topiramate has been associated with hyperammonemia with and without encephalopathy [see <span class=,'Bold,'>CONTRAINDICATIONS (<a href=,'#LINK_f87d2a83-e164-4212-9f5c-df772a06c750,'>4</a>)</span> and <span class=,'Bold,'>WARNINGS AND PRECAUTIONS (<a href=,'#LINK_a1a21241-62a9-4dd7-9e1b-d4109b7dafa1,'>5.8</a>, <a href=,'#LINK_d6af30f8-19a8-466b-a084-15bb0047a2c2,'>5.9</a>)</span>]. Concomitant administration of topiramate with valproate has also been associated with hypothermia in patients who have tolerated either drug alone. It may be prudent to examine blood ammonia levels in patients in whom the onset of hypothermia has been reported [see <span class=,'Bold,'>WARNINGS AND PRECAUTIONS (<a href=,'#LINK_a1a21241-62a9-4dd7-9e1b-d4109b7dafa1,'>5.8</a>, <a href=,'#LINK_095b63ed-cbe6-4f77-bcae-6951bf6e159a,'>5.10</a>)</span>]. </p>
</div>
</div>"
"sofosbuvir","46f4a73b-0cd6-4902-9092-3ac79e882c1a","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1	Potential for Drug Interaction</h2>
<p class=,'First,'>Any interactions that have been identified with ledipasvir or sofosbuvir individually may occur with ledipasvir and sofosbuvir.</p>
<p>After oral administration of ledipasvir and sofosbuvir, sofosbuvir is rapidly absorbed and subject to extensive first-pass hepatic extraction. In clinical pharmacology studies, both sofosbuvir and the inactive metabolite GS-331007 were monitored for purposes of pharmacokinetic analyses.</p>
<p>Ledipasvir is an inhibitor of the drug transporters P-gp and breast cancer resistance protein (BCRP) and may increase intestinal absorption of coadministered substrates for these transporters.</p>
<p>Ledipasvir and sofosbuvir are substrates of drug transporters P-gp and BCRP while GS-331007 is not. P-gp inducers (e.g., rifampin, St. John's wort) may decrease ledipasvir and sofosbuvir plasma concentrations, leading to reduced therapeutic effect of ledipasvir and sofosbuvir, and the use with P-gp inducers is not recommended with ledipasvir and sofosbuvir <span class=,'Italics,'>[see <a href=,'#S5.3,'>Warnings and Precautions (5.3)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2	Established and Potentially Significant Drug Interactions</h2>
<p class=,'First,'>Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact the safe and effective use of concomitant medications. For example, altered blood glucose control resulting in serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies. Management of hypoglycemia in these cases required either discontinuation or dose modification of concomitant medications used for diabetes treatment.</p>
<p>Frequent monitoring of relevant laboratory parameters (e.g., International Normalized Ratio [INR] in patients taking warfarin, blood glucose levels in diabetic patients) or drug concentrations of concomitant medications such as cytochrome P450 substrates with a narrow therapeutic index (e.g., certain immunosuppressants) is recommended to ensure safe and effective use. Dose adjustments of concomitant medications may be necessary.</p>
<p>Table 6 provides a listing of established or potentially clinically significant drug interactions. The drug interactions described are based on studies conducted with either ledipasvir and sofosbuvir tablets (90 mg/400 mg) or ledipasvir and sofosbuvir as individual agents, or are predicted drug interactions that may occur with ledipasvir and sofosbuvir <span class=,'Italics,'>[see <a href=,'#S5.2,'>Warnings and Precautions (5.2</a>, <a href=,'#S5.3,'>5.3)</a> and <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
<a name=,'Table6,'></a>
<div class=,'scrollingtable,'><table width=,'95%,'>
<caption>
<span>Table 6	Potentially Significant Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction<a class=,'Sup,' href=,'#footnote-6,' name=,'footnote-reference-6,'>*</a></span>
</caption>
<col align=,'left,' valign=,'top,' width=,'30%,'/>
<col align=,'left,' valign=,'top,' width=,'20%,'/>
<col align=,'left,' valign=,'top,' width=,'50%,'/>
<thead>
<tr class=,'First Last,'>
<th align=,'left,' class=,'Lrule Rrule,'>Concomitant  Drug Class: Drug Name</th><th align=,'center,' class=,'Rrule,'>Effect on Concentration<a class=,'Sup,' href=,'#footnote-7,' name=,'footnote-reference-7,'>†</a></th><th align=,'center,' class=,'Rrule,' valign=,'middle,'>Clinical Comment</th>
</tr>
</thead>
<tfoot>
<tr class=,'First Last,'>
<td align=,'left,' colspan=,'3,'>tenofovir DF = tenofovir disoproxil fumarate</td>
</tr>
<tr>
<td align=,'left,' colspan=,'3,'>
<dl class=,'Footnote,'>
<dt>
<a href=,'#footnote-reference-6,' name=,'footnote-6,'>*</a>
</dt>
<dd>This table is not all inclusive.</dd>
<dt>
<a href=,'#footnote-reference-7,' name=,'footnote-7,'>†</a>
</dt>
<dd>↓ = decrease, ↑ = increase</dd>
<dt>
<a href=,'#footnote-reference-8,' name=,'footnote-8,'>‡</a>
</dt>
<dd>These interactions have been studied in healthy adults.</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody>
<tr class=,'Botrule First,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Acid Reducing Agents:</span></td><td align=,'left,' class=,'Rrule,' rowspan=,'4,'>↓ ledipasvir</td><td align=,'left,' class=,'Rrule,'>Ledipasvir solubility decreases as pH increases. Drugs that increase gastric pH are expected to decrease concentration of ledipasvir.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Antacids (e.g., aluminum and magnesium hydroxide)</td><td align=,'left,' class=,'Rrule,'>It is recommended to separate antacid and ledipasvir and sofosbuvir administration by 4 hours.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>H<span class=,'Sub,'>2</span>-receptor antagonists<a class=,'Sup,' href=,'#footnote-8,' name=,'footnote-reference-8,'>‡</a> (e.g., famotidine)</td><td align=,'left,' class=,'Rrule,'>H<span class=,'Sub,'>2</span>-receptor antagonists may be administered simultaneously with or 12 hours apart from ledipasvir and sofosbuvir at a dose that does not exceed doses comparable to famotidine 40 mg twice daily.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Proton-pump inhibitors<a class=,'Sup,' href=,'#footnote-8,'>‡</a> (e.g., omeprazole)</td><td align=,'left,' class=,'Rrule,'>Proton-pump inhibitor doses comparable to omeprazole 20 mg or lower can be administered simultaneously with ledipasvir and sofosbuvir under fasted conditions.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Antiarrhythmics:</span>
<br/>amiodarone</td><td align=,'left,' class=,'Rrule,'>Effect on amiodarone, ledipasvir, and sofosbuvir concentrations unknown</td><td align=,'left,' class=,'Rrule,'>Coadministration of amiodarone with ledipasvir and sofosbuvir may result in serious symptomatic bradycardia. The mechanism of this effect is unknown. Coadministration of amiodarone with ledipasvir and sofosbuvir is not recommended; if coadministration is required, cardiac monitoring is recommended <span class=,'Italics,'>[see <a href=,'#S5.2,'>Warnings and Precautions (5.2)</a>, <a href=,'#S6.2,'>Adverse Reactions (6.2)</a>].</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>digoxin</td><td align=,'left,' class=,'Rrule,'>↑ digoxin</td><td align=,'left,' class=,'Rrule,'>Coadministration of ledipasvir and sofosbuvir with digoxin may increase the concentration of digoxin. Therapeutic concentration monitoring of digoxin is recommended when coadministered with ledipasvir and sofosbuvir.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Anticonvulsants:</span>
<br/>carbamazepine<a class=,'Sup,' href=,'#footnote-8,'>‡</a>
<br/>phenytoin<br/>phenobarbital</td><td align=,'left,' class=,'Rrule,'>↓ ledipasvir<br/>↓ sofosbuvir</td><td align=,'left,' class=,'Rrule,'>Coadministration of ledipasvir and sofosbuvir with carbamazepine, phenytoin, or phenobarbital is expected to decrease the concentration of ledipasvir and sofosbuvir, leading to reduced therapeutic effect of ledipasvir and sofosbuvir. Coadministration is not recommended.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Antimycobacterials:</span>
<br/>rifabutin<a class=,'Sup,' href=,'#footnote-8,'>‡</a>
<br/>rifampin<a class=,'Sup,' href=,'#footnote-8,'>‡</a>
<br/>rifapentine</td><td align=,'left,' class=,'Rrule,'>↓ ledipasvir<br/>↓ sofosbuvir</td><td align=,'left,' class=,'Rrule,'>Coadministration of ledipasvir and sofosbuvir with rifampin, rifabutin, or rifapentine is not recommended <span class=,'Italics,'>[see <a href=,'#S5.3,'>Warnings and Precautions (5.3)</a>].</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'3,'><span class=,'Bold,'>HIV Antiretrovirals:</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Regimens containing tenofovir DF without an HIV protease inhibitor/ritonavir or cobicistat</td><td align=,'left,' class=,'Rrule,'>↑ tenofovir</td><td align=,'left,' class=,'Rrule,'>Monitor for tenofovir-associated adverse reactions in patients receiving ledipasvir and sofosbuvir concomitantly with a regimen containing tenofovir DF without an HIV protease inhibitor/ritonavir or cobicistat. Refer to Viread<span class=,'Sup,'>®</span> or Truvada<span class=,'Sup,'>®</span> prescribing information for recommendations on renal monitoring.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Regimens containing tenofovir DF and an HIV protease inhibitor/ritonavir or cobicistat<ul>
<li>atazanavir/ritonavir or cobicistat + emtricitabine/tenofovir DF<a class=,'Sup,' href=,'#footnote-8,'>‡</a>
</li>
<li>darunavir/ritonavir or cobicistat + emtricitabine/tenofovir DF<a class=,'Sup,' href=,'#footnote-8,'>‡</a>
</li>
<li>lopinavir/ritonavir + emtricitabine/tenofovir DF</li>
</ul>
</td><td align=,'left,' class=,'Rrule,'>↑ tenofovir</td><td align=,'left,' class=,'Rrule,'>The safety of increased tenofovir concentrations in the setting of ledipasvir and sofosbuvir and an HIV protease inhibitor/ritonavir or cobicistat has not been established.<br/>Consider alternative HCV or antiretroviral therapy to avoid increases in tenofovir exposures. If coadministration is necessary, monitor for tenofovir-associated adverse reactions. Refer to Viread or Truvada prescribing information for recommendations on renal monitoring.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>elvitegravir, cobicistat, emtricitabine, tenofovir DF</td><td align=,'left,' class=,'Rrule,'>↑ tenofovir</td><td align=,'left,' class=,'Rrule,'>The safety of increased tenofovir concentrations in the setting of ledipasvir and sofosbuvir and the combination of elvitegravir, cobicistat, emtricitabine, and tenofovir DF has not been established. Coadministration is not recommended.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>tipranavir/ritonavir</td><td align=,'left,' class=,'Rrule,'>↓ ledipasvir<br/>↓ sofosbuvir</td><td align=,'left,' class=,'Rrule,'>Coadministration of ledipasvir and sofosbuvir with tipranavir/ritonavir is expected to decrease the concentration of ledipasvir and sofosbuvir, leading to reduced therapeutic effect of ledipasvir and sofosbuvir. Coadministration is not recommended.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>HCV Products:</span>
<br/>simeprevir<a class=,'Sup,' href=,'#footnote-8,'>‡</a></td><td align=,'left,' class=,'Rrule,'>↑ ledipasvir<br/>↑ simeprevir</td><td align=,'left,' class=,'Rrule,'>Concentrations of ledipasvir and simeprevir are increased when simeprevir is coadministered with ledipasvir.  Coadministration of ledipasvir and sofosbuvir with simeprevir is not recommended.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Herbal Supplements:</span>
<br/>St. John's wort <span class=,'Italics,'>(Hypericum perforatum)</span></td><td align=,'left,' class=,'Rrule,'>↓ ledipasvir<br/>↓ sofosbuvir</td><td align=,'left,' class=,'Rrule,'>Coadministration of ledipasvir and sofosbuvir with St. John's wort, a P-gp inducer, is not recommended <span class=,'Italics,'>[see <a href=,'#S5.3,'>Warnings and Precautions (5.3)</a>].</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>HMG-CoA Reductase Inhibitors:</span>
<br/>rosuvastatin</td><td align=,'left,' class=,'Rrule,'>↑ rosuvastatin</td><td align=,'left,' class=,'Rrule,'>Coadministration of ledipasvir and sofosbuvir with rosuvastatin may significantly increase the concentration of rosuvastatin, which is associated with increased risk of myopathy, including rhabdomyolysis. Coadministration of ledipasvir and sofosbuvir with rosuvastatin is not recommended.</td>
</tr>
<tr class=,'Last,'>
<td align=,'left,' class=,'Lrule Rrule,'>atorvastatin</td><td align=,'left,' class=,'Rrule,'>↑ atorvastatin</td><td align=,'left,' class=,'Rrule,'>Coadministration of ledipasvir and sofosbuvir with atorvastatin may be associated with increased risk of myopathy, including rhabdomyolysis. Monitor closely for HMG-CoA reductase inhibitor-associated adverse reactions, such as myopathy and rhabdomyolysis.</td>
</tr>
</tbody>
</table></div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3	Drugs without Clinically Significant Interactions with Ledipasvir and Sofosbuvir</h2>
<p class=,'First,'>Based on drug interaction studies conducted with ledipasvir, sofosbuvir, or ledipasvir and sofosbuvir tablets (90 mg/400 mg) no clinically significant drug interactions have been either observed or are expected when ledipasvir and sofosbuvir is used with the following drugs <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]:</span> abacavir, atazanavir/ritonavir, cyclosporine, darunavir/ritonavir, dolutegravir, efavirenz, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, emtricitabine, lamivudine, methadone, midazolam, oral contraceptives, pravastatin, raltegravir, rilpivirine, tacrolimus, or verapamil. See <a href=,'#Table6,'>Table 6</a> for use of ledipasvir and sofosbuvir with certain HIV antiretroviral regimens <span class=,'Italics,'>[see <a href=,'#S7.2,'>Drug Interactions (7.2)</a>]</span>.</p>
</div>
</div>"
"solifenacin","803c073a-eebc-4bee-b7e1-456bc7558afc","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Strong CYP3A4 Inhibitors</h2>
<p class=,'First,'>Solifenacin is a substrate of CYP3A4. Concomitant use of ketoconazole, a strong CYP3A4 inhibitor, significantly increased the exposure of solifenacin <span class=,'Italics,'>[see <a href=,'#Section_12.3,'>Clinical Pharmacology (12.3)</a>].</span> The dosage of solifenacin succinate greater than 5 mg once daily is not recommended when concomitantly used with strong CYP3A4 inhibitors <span class=,'Italics,'>[see <a href=,'#Section_2.4,'>Dosage and Administration (2.4)</a>]</span>.</p>
</div>
</div>"
"spironolactone","01deb112-edf1-4ed6-bc04-672d02ce66ab","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_502b69ea-bc62-44f2-99bf-3b1e2befd8e4,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_aad62dd8-4638-413c-99a9-24543dc3b1dc,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1
Drugs and Supplements Increasing Serum Potassium</h2>
<p class=,'First,'>Concomitant administration of spironolactone with potassium supplementation or drugs that can increase potassium may lead to severe hyperkalemia. In general, discontinue potassium supplementation in heart failure patients who start spironolactone
         
 
  <span class=,'Italics,'> [see 
          
  
   <a href=,'#LINK_248d0a7c-d6e7-49d0-97d1-efcd3248692e,'>Warnings and Precautions (5.1)</a></span> and 
         
 
  <span class=,'Italics,'><a href=,'#LINK_40da22ab-9880-419c-aac4-3222230c217b,'>Clinical Pharmacology (12.3)</a>]
         
 
  </span>. Check serum potassium levels when ACE inhibitor or ARB therapy is altered in patients receiving spironolactone.
        

 </p>
<p>Examples of drugs that can increase potassium include: </p>
<ul class=,'Disc,'>
<li>ACE inhibitors </li>
<li>angiotensin receptor blockers </li>
<li>non-steroidal anti-inflammatory drugs (NSAIDs) </li>
<li>heparin and low molecular weight heparin </li>
<li>trimethoprim </li>
</ul>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_82fe4600-4a75-4177-b2a7-42d04e77c422,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Lithium</h2>
<p class=,'First,'>Like other diuretics, spironolactone reduces the renal clearance of lithium, thus increasing the risk of lithium toxicity. Monitor lithium levels periodically when spironolactone is co-administered 
         
 
  <span class=,'Italics,'>[see 
          
  
   <a href=,'#LINK_40da22ab-9880-419c-aac4-3222230c217b,'>Clinical Pharmacology (12.3)</a>]
         
 
  </span>.
        

 </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_febce621-b166-46c1-a83a-adfb45bc170e,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Nonsteroidal anti-inflammatory drugs (NSAIDs)</h2>
<p class=,'First,'>In some patients, the administration of an NSAID can reduce the diuretic, natriuretic, and antihypertensive effect of diuretics. Therefore, when spironolactone and NSAIDs are used concomitantly, monitor closely to determine if the desired effect of the diuretic is obtained 
         
 
  <span class=,'Italics,'>[see 
          
  
   <a href=,'#LINK_40da22ab-9880-419c-aac4-3222230c217b,'>Clinical Pharmacology (12.3)</a>]
         
 
  </span>.
        

 </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_3d983fdb-3c66-4e79-8088-139190fb93a4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Digoxin</h2>
<p class=,'First,'>Spironolactone and its metabolites interfere with radioimmunoassays for digoxin and increase the apparent exposure to digoxin. It is unknown to what extent, if any, spironolactone may increase actual digoxin exposure. In patients taking concomitant digoxin, use an assay that does not interact with spironolactone.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_4b87dd60-1de4-4ddb-95af-28596126d9ef,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Cholestyramine</h2>
<p class=,'First,'>Hyperkalemic metabolic acidosis has been reported in patients given spironolactone concurrently with cholestyramine. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_b2163e71-e135-446b-8697-960787f3b050,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6 Acetylsalicylic Acid</h2>
<p class=,'First,'>Acetylsalicylic acid may reduce the efficacy of spironolactone. Therefore, when spironolactone and acetylsalicylic acid are used concomitantly, spironolactone may need to be titrated to higher maintenance dose and the patient should be observed closely to determine if the desired effect is obtained 
         
 
  <span class=,'Italics,'>[see 
          
  
   <a href=,'#LINK_40da22ab-9880-419c-aac4-3222230c217b,'>Clinical Pharmacology (12.3)</a>]
         
 
  </span>. 
        

 </p>
</div>
</div>"
"stavudine","081991e0-eee4-4fa3-ac3d-0c32cb03e7f3","none found"
"succimer","62035612-9505-3a3f-1ac8-e2dbd711d24e","none found"
"sulfacetamide","1c490337-c060-4f85-9998-f292edea92eb","none found"
"sulfadiazine","10549cba-9c15-4d2e-a68c-5afbc178591d","none found"
"sulfasalazine","029716bd-ee1a-484c-bf1f-ec8d02d5281b","none found"
"sumatriptan","0ec6d61f-2900-44f4-b444-8fd48603e1e8","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'inv-ec07c625-d972-48fc-b0ec-6ae8addf3a57,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'inv-215abe51-ea02-42ff-b3df-df83218123f6,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Ergot-Containing Drugs </h2>
<p class=,'First,'>Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan tablets within 24 hours of each other is contraindicated.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'inv-58dab56e-05d5-4913-b52a-c72277861486,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Monoamine Oxidase-A Inhibitors </h2>
<p class=,'First,'>MAO-A inhibitors increase systemic exposure by 7-fold. Therefore, the use of sumatriptan tablets in patients receiving MAO-A inhibitors is contraindicated <span class=,'Italics,'>[see Clinical Pharmacology (12.3)]</span>. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'inv-4f4e617f-cd53-4fd4-af87-90043fce08e3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Other 5-HT<span class=,'Sub,'>1</span> Agonists </h2>
<p class=,'First,'>Because their vasospastic effects may be additive, co-administration of sumatriptan tablets and other 5-HT <span class=,'Sub,'>1</span> agonists (e.g., triptans) within 24 hours of each other is contraindicated. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'inv-e7fa8af4-0c12-4291-ac8c-af13b4678c6b,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome </h2>
<p class=,'First,'>Cases of serotonin syndrome have been reported during co-administration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors <span class=,'Italics,'>[see Warnings and Precautions (5.7)]</span>. </p>
</div>
</div>"
"succinylcholine","bbf13b54-9230-bf1b-e053-2995a90a221b","none found"
"tacrolimus","0addf3f5-9bd5-4ef3-8c7f-52be20c16cf9","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'DRUG_INTERACTIONS,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_b992fb27-d2dc-9813-f898-40cb4c49a412,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2> 7.1 Mycophenolic Acid</h2>
<p class=,'First,'>When tacrolimus is prescribed with a given dose of a mycophenolic acid (MPA) product, exposure to MPA is higher with tacrolimus co-administration than with cyclosporine co-administration with MPA, because cyclosporine interrupts the enterohepatic recirculation of MPA while tacrolimus does not. Monitor for MPA-associated adverse reactions and reduce the dose of concomitantly administered mycophenolic acid products as needed.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_ae530d6d-766e-6741-d24b-eb43b2d6d14e,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2> 7.2 Effects of Other Drugs on tacrolimus </h2>
<p class=,'First,'>Table 15 displays the effects of other drugs on tacrolimus</p>
<p>
<span class=,'Bold,'>Table 15: Effects of Other Drugs/Substances on Tacrolimus<span class=,'Sup,'>*</span></span>
</p>
<div class=,'scrollingtable,'><table width=,'100%,'>
<col width=,'33%,'/>
<col width=,'33%,'/>
<col width=,'33%,'/>
<tbody class=,'Headless,'>
<tr class=,'First,'>
<td class=,'Toprule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Drug/Substance Class or Name </span>
</p>
</td><td class=,'Toprule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Drug Interaction Effect</span>
</p>
</td><td class=,'Toprule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Recommendations</span>
</p>
</td>
</tr>
<tr>
<td valign=,'top,'>
<p class=,'First,'> Grapefruit or grapefruit juice<span class=,'Sup,'>†</span>
</p>
</td><td valign=,'top,'>
<p class=,'First,'> May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see <span class=,'Bold,'>Warnings and Precautions</span> (<a href=,'#_6c58d880-0731-32f6-fc2f-48b62ea0f34c,'>5.6</a>, <a href=,'#_dc63967f-8dce-04c0-f4a6-b5609d0483f7,'>5.11</a>, <a href=,'#_27aa2a64-7011-ee51-8b2a-d5252cbe81a2,'>5.12</a>)].<br/>
<br/>
</p>
</td><td valign=,'top,'>
<p class=,'First,'> Avoid grapefruit or grapefruit juice. </p>
</td>
</tr>
<tr>
<td valign=,'top,'>
<p class=,'First,'> Strong CYP3A Inducers<span class=,'Sup,'>‡</span>: Antimycobacterials (e.g., rifampin, rifabutin), anticonvulsants (e.g., phenytoin, carbamazepine and phenobarbital), St John’s Wort   </p>
</td><td valign=,'top,'>
<p class=,'First,'> May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection [see <span class=,'Bold,'>Warnings and Precautions</span> (<a href=,'#_dc63967f-8dce-04c0-f4a6-b5609d0483f7,'>5.11</a>)]. <br/>   </p>
</td><td valign=,'top,'>
<p class=,'First,'> Increase tacrolimus dose and monitor tacrolimus whole blood trough concentrations [see <span class=,'Bold,'>Dosage and Administration</span> (<a href=,'#_a17eaea8-2b11-5d5e-1a25-2c8fd5dd78b4,'>2.2</a><a href=,'#_a17eaea8-2b11-5d5e-1a25-2c8fd5dd78b4,'>,</a><a href=,'#_4c11e474-0cf1-738d-70b3-aad07f9c206c,'>2.6</a>) and <span class=,'Bold,'>Clinical Pharmacology</span> (<a href=,'#PHARMACOKINETICS,'>12.3</a>)]. </p>
</td>
</tr>
<tr>
<td valign=,'top,'>
<p class=,'First,'> Strong CYP3A Inhibitors<span class=,'Sup,'>‡</span>: Protease inhibitors (e.g., nelfinavir, telaprevir, boceprevir, ritonavir), azole antifungals (e.g., voriconazole, posaconazole, itraconazole, ketoconazole), antibiotics (e.g., clarithromycin, troleandomycin, chloramphenicol), nefazodone, letermovir, <span class=,'Italics,'>Schisandra sphenanthera</span> extracts   </p>
</td><td valign=,'top,'>
<p class=,'First,'> May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see <span class=,'Bold,'>Warnings and Precautions</span> (<a href=,'#_6c58d880-0731-32f6-fc2f-48b62ea0f34c,'>5.6</a>, <a href=,'#_dc63967f-8dce-04c0-f4a6-b5609d0483f7,'>5.11,</a><a href=,'#_27aa2a64-7011-ee51-8b2a-d5252cbe81a2,'>5.12</a>)]. <br/>   </p>
</td><td valign=,'top,'>
<p class=,'First,'> Reduce tacrolimus dose (for voriconazole and posaconazole, give one-third of the original dose) and adjust dose based on tacrolimus whole blood trough concentrations [see <span class=,'Bold,'>Dosage and Administration</span> (<a href=,'#_a17eaea8-2b11-5d5e-1a25-2c8fd5dd78b4,'>2.2</a><a href=,'#_a17eaea8-2b11-5d5e-1a25-2c8fd5dd78b4,'>,</a><a href=,'#_4c11e474-0cf1-738d-70b3-aad07f9c206c,'> 2.6</a>) and <span class=,'Bold,'>Clinical Pharmacology</span> (<a href=,'#PHARMACOKINETICS,'>12.3</a>)]. </p>
</td>
</tr>
<tr>
<td valign=,'top,'>
<p class=,'First,'> Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., erythromycin, fluconazole), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole   </p>
</td><td valign=,'top,'>
<p class=,'First,'> May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see <span class=,'Bold,'>Warnings and Precautions</span> (<a href=,'#_6c58d880-0731-32f6-fc2f-48b62ea0f34c,'>5.6</a>, <a href=,'#_dc63967f-8dce-04c0-f4a6-b5609d0483f7,'>5.11</a>, <a href=,'#_27aa2a64-7011-ee51-8b2a-d5252cbe81a2,'>5.12</a>)]. <br/>
</p>
</td><td valign=,'top,'>
<p class=,'First,'> Monitor tacrolimus whole blood trough concentrations and reduce tacrolimus dose if needed [see <span class=,'Bold,'>Dosage and Administration</span> (<a href=,'#_a17eaea8-2b11-5d5e-1a25-2c8fd5dd78b4,'>2.2</a><a href=,'#_a17eaea8-2b11-5d5e-1a25-2c8fd5dd78b4,'>,</a><a href=,'#_4c11e474-0cf1-738d-70b3-aad07f9c206c,'> 2.6</a>) and <span class=,'Bold,'>Clinical Pharmacology</span> (<a href=,'#PHARMACOKINETICS,'>12.3</a>)]. </p>
</td>
</tr>
<tr>
<td valign=,'top,'>
<p class=,'First,'> Other drugs, such as: Magnesium and aluminum hydroxide antacids Metoclopramide </p>
</td><td valign=,'top,'>
<p class=,'First,'>
<br/> May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see <span class=,'Bold,'>Warnings and Precautions</span> (<a href=,'#_6c58d880-0731-32f6-fc2f-48b62ea0f34c,'>5.6</a>, <a href=,'#_dc63967f-8dce-04c0-f4a6-b5609d0483f7,'>5.11</a>, <a href=,'#_27aa2a64-7011-ee51-8b2a-d5252cbe81a2,'>5.12</a>)]. </p>
</td><td valign=,'top,'>
<p class=,'First,'> Monitor tacrolimus whole blood trough concentrations and reduce tacrolimus dose if needed [see <span class=,'Bold,'>Dosage and Administration</span> (<a href=,'#_a17eaea8-2b11-5d5e-1a25-2c8fd5dd78b4,'>2.2</a><a href=,'#_a17eaea8-2b11-5d5e-1a25-2c8fd5dd78b4,'>,</a><a href=,'#_4c11e474-0cf1-738d-70b3-aad07f9c206c,'> 2.6</a>) and <span class=,'Bold,'>Clinical Pharmacology</span> (<a href=,'#PHARMACOKINETICS,'>12.3</a>)]. </p>
</td>
</tr>
<tr class=,'Last,'>
<td class=,'Botrule,' valign=,'top,'>
<p class=,'First,'> Mild or Moderate CYP3A Inducers Methylprednisolone, prednisone </p>
</td><td class=,'Botrule,' valign=,'top,'>
<p class=,'First,'> May decrease tacrolimus concentrations. </p>
</td><td class=,'Botrule,' valign=,'top,'>
<p class=,'First,'> Monitor tacrolimus whole blood trough concentrations and adjust tacrolimus dose if needed [see <span class=,'Bold,'>Dosage and Administration</span> (<a href=,'#_a17eaea8-2b11-5d5e-1a25-2c8fd5dd78b4,'>2.2</a><a href=,'#_a17eaea8-2b11-5d5e-1a25-2c8fd5dd78b4,'>,</a><a href=,'#_4c11e474-0cf1-738d-70b3-aad07f9c206c,'> 2.6</a>)].</p>
</td>
</tr>
</tbody>
</table></div>
<p>* Tacrolimus dosage adjustment recommendation based on observed effect of coadministered drug on tacrolimus exposures [see <span class=,'Bold,'>Clinical Pharmacology</span> (<a href=,'#PHARMACOKINETICS,'>12.3</a>)], literature reports of altered tacrolimus exposures, or the other drug’s known CYP3A inhibitor/inducer status. </p>
<p>
<span class=,'Sup,'>†</span> High dose or double strength grapefruit juice is a strong CYP3A inhibitor; low dose or single strength grapefruit juice is a moderate CYP3A inhibitor.</p>
<p>
<span class=,'Sup,'>‡</span> Strong CYP3A inhibitor/inducer, based on reported effect on exposures to tacrolimus along with supporting<span class=,'Italics,'> in vitro</span> CYP3A inhibitor/inducer data, or based on drug-drug interaction studies with midazolam (sensitive CYP3A probe substrate).</p>
</div>
</div>"
"tadalafil","36350106-98bc-41fc-bede-8be5e6f54a8a","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Potential for Pharmacodynamic Interactions with Tadalafil</h2>
<p class=,'First,'>
<span class=,'Underline,'>Nitrates</span> — Administration of tadalafil to patients who are using any form of organic nitrate, is contraindicated. In clinical pharmacology studies tadalafil was shown to potentiate the hypotensive effect of nitrates. In a patient who has taken tadalafil, where nitrate administration is deemed medically necessary in a life-threatening situation, at least 48 hours should elapse after the last dose of tadalafil before nitrate administration is considered. In such circumstances, nitrates should still only be administered under close medical supervision with appropriate hemodynamic monitoring <span class=,'Italics,'>[see Dosage and Administration (<a href=,'#Section_2.7,'>2.7</a>), Contraindications (<a href=,'#Section_4.1,'>4.1</a>), and Clinical Pharmacology (<a href=,'#Section_12.2,'>12.2</a>)]</span>. <br/>
<span class=,'Underline,'>Alpha-Blockers</span> — Caution is advised when PDE5 inhibitors are coadministered with alpha-blockers. PDE5 inhibitors, including tadalafil, and alpha-adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. Clinical pharmacology studies have been conducted with coadministration of tadalafil with doxazosin, tamsulosin or alfuzosin. <span class=,'Italics,'>[see Dosage and Administration (<a href=,'#Section_2.7,'>2.7</a>), Warnings and Precautions (<a href=,'#Section_5.6,'>5.6</a>), and Clinical Pharmacology (<a href=,'#Section_12.2,'>12.2</a>)]</span>. <br/>
<span class=,'Underline,'>Antihypertensives</span> — PDE5 inhibitors, including tadalafil, are mild systemic vasodilators. Clinical pharmacology studies were conducted to assess the effect of tadalafil on the potentiation of the blood-pressure-lowering effects of selected antihypertensive medications (amlodipine, angiotensin II receptor blockers, bendrofluazide, enalapril, and metoprolol). Small reductions in blood pressure occurred following coadministration of tadalafil with these agents compared with placebo. <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#Section_5.6,'>5.6</a>) and Clinical Pharmacology (<a href=,'#Section_12.2,'>12.2</a>)]</span>. <br/>
<span class=,'Underline,'>Alcohol</span> — Both alcohol and tadalafil, a PDE5 inhibitor, act as mild vasodilators. When mild vasodilators are taken in combination, blood-pressure-lowering effects of each individual compound may be increased. Substantial consumption of alcohol (e.g., 5 units or greater) in combination with tadalafil can increase the potential for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache. Tadalafil did not affect alcohol plasma concentrations and alcohol did not affect tadalafil plasma concentrations. <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#Section_5.9,'>5.9</a>) and Clinical Pharmacology (<a href=,'#Section_12.2,'>12.2</a>)]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2	Potential for Other Drugs to Affect Tadalafil</h2>
<p class=,'First,'>
<span class=,'Italics,'>[See Dosage and Administration (<a href=,'#Section_2.7,'>2.7</a>) and Warnings and Precautions (<a href=,'#Section_5.10,'>5.10</a>)]</span>.<br/>
<span class=,'Underline,'>Antacids</span> — Simultaneous administration of an antacid (magnesium hydroxide/aluminum hydroxide) and tadalafil reduced the apparent rate of absorption of tadalafil without altering exposure (AUC) to tadalafil. <br/>
<span class=,'Underline,'>H2 Antagonists (e.g. Nizatidine</span>) — An increase in gastric pH resulting from administration of nizatidine had no significant effect on pharmacokinetics. <br/>
<span class=,'Underline,'>Cytochrome P450 Inhibitors</span> — Tadalafil is a substrate of and predominantly metabolized by CYP3A4. Studies have shown that drugs that inhibit CYP3A4 can increase tadalafil exposure. <br/> CYP3A4 (e.g., Ketoconazole) — Ketoconazole (400 mg daily), a selective and potent inhibitor of CYP3A4, increased tadalafil 20 mg single-dose exposure (AUC) by 312% and Cmax by 22%, relative to the values for tadalafil 20 mg alone. Ketoconazole (200 mg daily) increased tadalafil 10-mg single-dose exposure (AUC) by 107% and Cmax by 15%, relative to the values for tadalafil 10 mg alone<span class=,'Italics,'> [see Dosage and Administration (<a href=,'#Section_2.7,'>2.7</a>)]</span>. <br/> Although specific interactions have not been studied, other CYP3A4 inhibitors, such as erythromycin, itraconazole, and grapefruit juice, would likely increase tadalafil exposure. <br/> HIV Protease inhibitor — Ritonavir (500 mg or 600 mg twice daily at steady state), an inhibitor of CYP3A4, CYP2C9, CYP2C19, and CYP2D6, increased tadalafil 20-mg single-dose exposure (AUC) by 32% with a 30% reduction in C max , relative to the values for tadalafil 20 mg alone. Ritonavir (200 mg twice daily), increased tadalafil 20-mg single-dose exposure (AUC) by 124% with no change in Cmax , relative to the values for tadalafil 20 mg alone. Although specific interactions have not been studied, other HIV protease inhibitors would likely increase tadalafil exposure <span class=,'Italics,'>[see Dosage and Administration (<a href=,'#Section_2.7,'>2.7</a>)]</span>. <br/>
<span class=,'Underline,'>Cytochrome P450 Inducers</span> — Studies have shown that drugs that induce CYP3A4 can decrease tadalafil exposure. <br/> CYP3A4 (e.g., Rifampin) — Rifampin (600 mg daily), a CYP3A4 inducer, reduced tadalafil 10-mg single-dose exposure (AUC) by 88% and Cmax by 46%, relative to the values for tadalafil 10 mg alone. Although specific interactions have not been studied, other CYP3A4 inducers, such as carbamazepine, phenytoin, and phenobarbital, would likely decrease tadalafil exposure. No dose adjustment is warranted. The reduced exposure of tadalafil with the coadministration of rifampin or other CYP3A4 inducers can be anticipated to decrease the efficacy of tadalafil for once daily use; the magnitude of decreased efficacy is unknown.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Potential for Tadalafil to Affect Other Drugs</h2>
<p class=,'First,'>
<span class=,'Underline,'>Aspirin</span> — Tadalafil did not potentiate the increase in bleeding time caused by aspirin. <br/>
<span class=,'Underline,'>Cytochrome P450 Substrates</span> — Tadalafil is not expected to cause clinically significant inhibition or induction of the clearance of drugs metabolized by cytochrome P450 (CYP) isoforms. Studies have shown that tadalafil does not inhibit or induce P450 isoforms CYP1A2, CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP2E1. <br/> CYP1A2 (e.g. Theophylline) — Tadalafil had no significant effect on the pharmacokinetics of theophylline. When tadalafil was administered to subjects taking theophylline, a small augmentation (3 beats per minute) of the increase in heart rate associated with theophylline was observed. <br/> CYP2C9 (e.g. Warfarin) — Tadalafil had no significant effect on exposure (AUC) to S-warfarin or R-warfarin, nor did tadalafil affect changes in prothrombin time induced by warfarin. <br/> CYP3A4 (e.g. Midazolam or Lovastatin) — Tadalafil had no significant effect on exposure (AUC) to midazolam or lovastatin. <br/>
<span class=,'Underline,'>P-glycoprotein (e.g. Digoxin</span>) — Coadministration of tadalafil (40 mg once per day) for 10 days did not have a significant effect on the steady-state pharmacokinetics of digoxin (0.25 mg/day) in healthy subjects.</p>
</div>
</div>"
"tafluprost","a3173c26-0e19-47af-a01c-3fc06b2700d1","none found"
"tamoxifen","4fff5311-1129-46ba-a123-c90cfcda56f3","none found"
"tapentadol","4a6953cd-9d64-4443-b7db-5aef2c81324d","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>NUCYNTA<span class=,'Sup,'>®</span> is mainly metabolized by 
glucuronidation. The following substances have been included in a set of 
interaction studies without any clinically significant finding: acetaminophen, 
acetylsalicylic acid, naproxen and probenecid <span class=,'Italics,'>[see<a href=,'#S12.3,'> Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>The pharmacokinetics of tapentadol were not affected when gastric pH or 
gastrointestinal motility were increased by omeprazole and metoclopramide, 
respectively <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology 
(12.3)</a>]</span>.</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Drugs Metabolized by Cytochrome P450 Enzymes
</h2>
<p class=,'First,'>
<span class=,'Italics,'>In vitro</span> investigations indicate that 
NUCYNTA<span class=,'Sup,'>®</span> does not inhibit or induce P450 enzymes. Thus, 
clinically relevant interactions mediated by the cytochrome P450 system are 
unlikely to occur <span class=,'Italics,'>[see<a href=,'#S12.3,'> Clinical 
Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Drugs That Inhibit or Induce Cytochrome P450 Enzymes</h2>
<p class=,'First,'>The major pathway of tapentadol metabolism is conjugation with 
glucuronic acid to produce glucuronides. To a lesser extent, tapentadol is 
additionally metabolized to N-desmethyl tapentadol (13%) by CYP2C9 and CYP2C19 
to hydroxy tapentadol (2%) by CYP2D6, which are further metabolized by 
conjugation. Since only a minor amount of NUCYNTA<span class=,'Sup,'>®</span> is 
metabolized via the oxidative pathway clinically relevant interactions mediated 
by the cytochrome P450 system are unlikely to occur <span class=,'Italics,'>[see<a href=,'#S12.3,'> Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Centrally-Acting Drugs and Alcohol</h2>
<p class=,'First,'>Patients receiving other opioid agonist analgesics, general 
anesthetics, phenothiazines, antiemetics, other tranquilizers, sedatives, 
hypnotics, or other CNS depressants (including alcohol) concomitantly with 
NUCYNTA<span class=,'Sup,'>®</span> may exhibit an additive CNS depression. 
Interactive effects resulting in respiratory depression, hypotension, profound 
sedation, or coma may result if these drugs are taken in combination with 
NUCYNTA<span class=,'Sup,'>®</span>. When such combined therapy is contemplated, a 
dose reduction of one or both agents should be considered <span class=,'Italics,'>[see<a href=,'#S5.2,'> Warnings and Precautions (5.2) </a>and<a href=,'#S5.6,'> (5.6)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Monoamine Oxidase Inhibitors
</h2>
<p class=,'First,'>NUCYNTA<span class=,'Sup,'>®</span> is contraindicated in patients 
who are receiving monoamine oxidase (MAO) inhibitors or who have taken them 
within the last 14 days due to potential additive effects on norepinephrine 
levels which may result in adverse cardiovascular events <span class=,'Italics,'>[see<a href=,'#S4.3,'> Contraindications (4.3)</a>].</span>
</p>
</div>
</div>"
"telmisartan","20a60231-64f0-4751-aa81-6c0e64334179","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_baefe48b-3409-4efe-ae73-43db1ec389b4,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Aliskiren:</span> Do not co-administer aliskiren with telmisartan in patients with diabetes. Avoid use of aliskiren with telmisartan in patients with renal impairment (GFR &lt;60 mL/min).</p>
<p>
<span class=,'Italics,'>Digoxin:</span> When telmisartan was co-administered with digoxin, median increases in digoxin peak plasma concentration (49%) and in trough concentration (20%) were observed. Therefore, monitor digoxin levels when initiating, adjusting, and discontinuing telmisartan for the purpose of keeping the digoxin level within the therapeutic range.</p>
<p>
<span class=,'Italics,'>Lithium:</span> Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists including telmisartan. Therefore, monitor serum lithium levels during concomitant use.</p>
<p>
<span class=,'Italics,'>Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors):</span> In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including telmisartan, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving telmisartan and NSAID therapy.</p>
<p>The antihypertensive effect of angiotensin II receptor antagonists, including telmisartan may be attenuated by NSAIDs including selective COX-2 inhibitors.</p>
</div>"
"tenofovir alafenamide","85a17d00-6b7c-41ea-a6b3-5ad924820dab","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1	Not Recommended With Other Antiretroviral Medications</h2>
<p class=,'First,'>SYMTUZA is a complete regimen for HIV-1 infection and co-administration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. For this reason, information regarding potential drug-drug interactions with other antiretroviral medications is not provided.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2	Potential for SYMTUZA to Affect Other Drugs</h2>
<p class=,'First,'>Darunavir co-administered with cobicistat is an inhibitor of CYP3A and CYP2D6. Cobicistat inhibits the following transporters: P-glycoprotein (P-gp), BCRP, MATE1, OATP1B1 and OATP1B3. Therefore, co-administration of SYMTUZA with drugs that are primarily metabolized by CYP3A and/or CYP2D6, or are substrates of P-gp, BCRP, MATE1, OATP1B1 or OATP1B3 may result in increased plasma concentrations of such drugs, which could increase or prolong their therapeutic effect and can be associated with adverse events. Co-administration of SYMTUZA with drugs that have active metabolite(s) formed by CYP3A may result in reduced plasma concentrations of these active metabolite(s), potentially leading to loss of their therapeutic effect (see <a href=,'#Table4,'>Table 4</a>).</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3	Potential for Other Drugs to Affect SYMTUZA</h2>
<p class=,'First,'>Darunavir is metabolized by CYP3A. Cobicistat is metabolized by CYP3A and, to a minor extent, by CYP2D6. Co-administration of drugs that induce CYP3A activity are expected to increase the clearance of darunavir and cobicistat, resulting in lowered plasma concentrations which may lead to loss of therapeutic effect and development of resistance. Co-administration of SYMTUZA with other drugs that inhibit CYP3A may result in increased plasma concentrations of darunavir and cobicistat (see <a href=,'#Table4,'>Table 4</a>).</p>
<p>Tenofovir alafenamide (TAF) is a substrate of P-gp, BCRP, OATP1B1, and OATP1B3. Drugs that strongly affect P-gp activity may lead to changes in TAF absorption. Drugs that induce P-gp activity are expected to decrease the absorption of TAF, resulting in decreased plasma concentrations of TAF, which may lead to loss of therapeutic effect of SYMTUZA and development of resistance. Co-administration of SYMTUZA with other drugs that inhibit P-gp may increase the absorption and plasma concentrations of TAF (see <a href=,'#Table4,'>Table 4</a>).</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4	Drugs Affecting Renal Function</h2>
<p class=,'First,'>Because emtricitabine and tenofovir are primarily excreted by the kidneys through glomerular filtration and active tubular secretion, co-administration of SYMTUZA with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of emtricitabine, tenofovir, and other renally eliminated drugs and this may increase the risk of adverse reactions. Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs <span class=,'Italics,'>[see <a href=,'#S5.6,'>Warnings and Precautions (5.6)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.5,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5	Significant Drug Interactions</h2>
<p class=,'First,'>Table 4 provides a listing of established or potentially clinically significant drug interactions with SYMTUZA and recommended steps to prevent or manage these interactions. These recommendations are based on drug interaction trials conducted with the components of SYMTUZA, as individual agents or in combination, or are predicted interactions. No drug interaction trials have been performed with SYMTUZA or with all the components administered together. Drug interaction trials have been conducted with darunavir co-administered with ritonavir or cobicistat or with emtricitabine and tenofovir prodrugs. The table includes potentially significant interactions but is not all inclusive.</p>
<a name=,'Table4,'></a>
<div class=,'scrollingtable,'><table width=,'100%,'>
<caption>
<span>Table 4:	Significant Drug Interactions</span>
</caption>
<col align=,'left,' valign=,'top,' width=,'25%,'/>
<col align=,'left,' valign=,'top,' width=,'25%,'/>
<col align=,'left,' valign=,'top,' width=,'50%,'/>
<thead>
<tr class=,'First Last,'>
<th align=,'left,' class=,'Lrule Rrule,' valign=,'bottom,'>Concomitant Drug Class: Drug Name</th><th align=,'center,' class=,'Rrule,' valign=,'bottom,'>Effect on Concentration</th><th align=,'center,' class=,'Rrule,' valign=,'bottom,'>Clinical Comment</th>
</tr>
</thead>
<tfoot>
<tr class=,'First Last,'>
<td align=,'left,' colspan=,'3,'>This table is not all inclusive<br/>↑ = increase, ↓ = decrease, ↔ = no effect</td>
</tr>
</tfoot>
<tbody>
<tr class=,'Botrule First,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Alpha 1-adrenoreceptor antagonist:</span>
<br/>alfuzosin</td><td align=,'left,' class=,'Rrule,'>↑ alfuzosin</td><td align=,'left,' class=,'Rrule,'>Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as hypotension.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Antibacterials:</span>
<br/>clarithromycin, erythromycin, telithromycin</td><td align=,'left,' class=,'Rrule,'>↑ darunavir<br/>↑ cobicistat<br/>↑ antibacterial	</td><td align=,'left,' class=,'Rrule,'>Consider alternative antibiotics with concomitant use of SYMTUZA.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Anticancer agents:</span>
<br/>dasatinib, nilotinib</td><td align=,'left,' class=,'Rrule,'>↑ anticancer agent</td><td align=,'left,' class=,'Rrule,'>A decrease in the dosage or an adjustment of the dosing interval of dasatinib or nilotinib may be necessary when co-administered with SYMTUZA. Consult the dasatinib and nilotinib prescribing information for dosing instructions.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>vinblastine, vincristine</td><td align=,'left,' class=,'Rrule,'></td><td align=,'left,' class=,'Rrule,'>For vincristine and vinblastine, consider temporarily withholding the cobicistat-containing antiretroviral regimen in patients who develop significant hematologic or gastrointestinal side effects when SYMTUZA is administered concurrently with vincristine or vinblastine. If the antiretroviral regimen must be withheld for a prolonged period, consider initiating a revised regimen that does not include a CYP3A or P-gp inhibitor.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Anticoagulants:</span>
<br/>
<span class=,'Underline,'>Direct Oral Anticoagulants (DOACs)</span>
<br/>apixaban</td><td align=,'left,' class=,'Rrule,'>↑ apixaban</td><td align=,'left,' class=,'Rrule,'>Due to potentially increased bleeding risk, dosing recommendations for co-administration of apixaban with SYMTUZA depends on the apixaban dose. Refer to apixaban dosing instructions for co-administration with strong CYP3A and P-gp inhibitors in apixaban prescribing information.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'>rivaroxaban</td><td align=,'left,' class=,'Rrule,'>↑ rivaroxaban</td><td align=,'left,' class=,'Rrule,'>Co-administration of rivaroxaban with SYMTUZA is not recommended because it may lead to an increased bleeding risk.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,' valign=,'bottom,'>betrixaban<br/>dabigatran<br/>edoxaban</td><td align=,'left,' class=,'Rrule,'>↔ betrixaban<br/> ↔ dabigatran<br/> ↔ edoxaban<br/>
</td><td align=,'left,' class=,'Rrule,'>No dose adjustment is needed when betrixaban, dabigatran, or edoxaban is co-administered with SYMTUZA. </td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Underline,'>Other Anticoagulants</span></td><td align=,'left,' class=,'Rrule,'></td><td align=,'left,' class=,'Rrule,'></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>												warfarin</td><td align=,'left,' class=,'Rrule,'>warfarin: effect unknown</td><td align=,'left,' class=,'Rrule,'>Monitor international normalized ratio (INR) upon co-administration of SYMTUZA with warfarin.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Anticonvulsants:</span>
<br/>carbamazepine, phenobarbital, phenytoin</td><td align=,'left,' class=,'Rrule,'>↓ cobicistat<br/>↓ darunavir<br/>↓ tenofovir alafenamide</td><td align=,'left,' class=,'Rrule,'>Co-administration is contraindicated due to potential for loss of therapeutic effect and development of resistance. </td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Underline,'>Anticonvulsants with CYP3A induction effects that are NOT contraindicated:</span>
<br/>e.g., eslicarbazepine, oxcarbazepine</td><td align=,'left,' class=,'Rrule,'>↓ cobicistat<br/>↓ tenofovir alafenamide darunavir: effect unknown</td><td align=,'left,' class=,'Rrule,'>Consider alternative anticonvulsant or antiretroviral therapy to avoid potential changes in exposures. If co-administration is necessary, monitor for lack or loss of virologic response.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' valign=,'bottom,'><span class=,'Underline,'>Anticonvulsants that are metabolized by CYP3A:</span>
<br/>e.g., clonazepam</td><td align=,'left,' class=,'Rrule,' valign=,'bottom,'>↑ clonazepam</td><td align=,'left,' class=,'Rrule,' valign=,'bottom,'>Clinical monitoring of anticonvulsants is recommended.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Antidepressants:</span>
<br/>
<span class=,'Underline,'>Selective Serotonin Reuptake Inhibitors (SSRIs):</span>
<br/>e.g., paroxetine, sertraline</td><td align=,'left,' class=,'Rrule,'>SSRIs: effects unknown</td><td align=,'left,' class=,'Rrule,'>When co-administering with SSRIs, TCAs, or trazodone, careful dose titration of the antidepressant to the desired effect, including using the lowest feasible initial or maintenance dose, and monitoring for antidepressant response are recommended.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Underline,'>Tricyclic Antidepressants (TCAs):</span>
<br/>e.g., amitriptyline, desipramine, imipramine, nortriptyline</td><td align=,'left,' class=,'Rrule,'>↑ TCAs</td><td align=,'left,' class=,'Rrule,'></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Underline,'>Other antidepressants:</span>
<br/>trazodone</td><td align=,'left,' class=,'Rrule,'>↑ trazodone</td><td align=,'left,' class=,'Rrule,'></td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Antifungals:</span>
<br/>itraconazole, isavuconazole, ketoconazole, posaconazole</td><td align=,'left,' class=,'Rrule,'>↑ darunavir<br/>↑ cobicistat</td><td align=,'left,' class=,'Rrule,'>Monitor for increased darunavir or cobicistat and/or antifungal adverse reactions.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'></td><td align=,'left,' class=,'Rrule,'>↑ itraconazole <br/>↑ isavuconazole <br/>↑ ketoconazole<br/>↔ posaconazole (not studied)</td><td align=,'left,' class=,'Rrule,'>Specific dosing recommendations are not available for co-administration with these antifungals. Monitor for increased itraconazole or ketoconazole adverse reactions.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>voriconazole</td><td align=,'left,' class=,'Rrule,'>voriconazole: effects unknown</td><td align=,'left,' class=,'Rrule,'>Co-administration with voriconazole is not recommended unless benefit/risk assessment justifies the use of voriconazole.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Anti-gout:</span>
<br/>colchicine</td><td align=,'left,' class=,'Rrule,'>↑ colchicine</td><td align=,'left,' class=,'Rrule,'>Co-administration is contraindicated in patients with renal and/or hepatic impairment due to potential for serious and/or life-threatening reactions. <br/>
<span class=,'Underline,'>For patients without renal or hepatic impairment:</span>
<ul class=,'Disc,'>
<li>
<span class=,'Underline,'>Treatment of gout flares – co-administration of colchicine: </span>0.6 mg (1 tablet) ×1 dose, followed by 0.3 mg (half tablet) 1 hour later. Treatment course to be repeated no earlier than 3 days.</li>
<li>
<span class=,'Underline,'>Prophylaxis of gout flares – co-administration of colchicine: </span>If the original regimen was 0.6 mg twice a day, the regimen should be adjusted to 0.3 mg once a day. If the original regimen was 0.6 mg once a day, the regimen should be adjusted to 0.3 mg once every other day.</li>
<li>
<span class=,'Underline,'>Treatment of familial Mediterranean fever – co-administration of colchicine: </span>Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day).</li>
</ul>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Antimalarial:</span>
<br/>artemether/lumefantrine</td><td align=,'left,' class=,'Rrule,'>artemether: effect unknown<br/>lumefantrine: effect unknown</td><td align=,'left,' class=,'Rrule,'>Monitor for a potential decrease of antimalarial efficacy or potential QT prolongation.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Antimycobacterials:</span>
<br/>rifampin</td><td align=,'left,' class=,'Rrule,'>↓ cobicistat<br/>↓ darunavir<br/>↓ tenofovir alafenamide</td><td align=,'left,' class=,'Rrule,'>Co-administration is contraindicated due to potential for loss of therapeutic effect and development of resistance.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'>rifabutin</td><td align=,'left,' class=,'Rrule,'>↑ rifabutin<br/>↓ TAF<br/>cobicistat: effects unknown<br/>darunavir: effects unknown</td><td align=,'left,' class=,'Rrule,'>Co-administration of SYMTUZA with rifabutin is not recommended. If the combination is needed, the recommended dose of rifabutin is 150 mg every other day. Monitor for rifabutin-associated adverse reactions including neutropenia and uveitis.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>rifapentine</td><td align=,'left,' class=,'Rrule,'>↓ darunavir<br/>↓ TAF</td><td align=,'left,' class=,'Rrule,'>Co-administration with rifapentine is not recommended.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Antipsychotics:</span>
<br/>lurasidone</td><td align=,'left,' class=,'Rrule,'>↑ lurasidone</td><td align=,'left,' class=,'Rrule,'>Co-administration is contraindicated due to potential for serious and/or life-threatening reactions.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,' valign=,'middle,'>pimozide</td><td align=,'left,' class=,'Rrule,' valign=,'middle,'>↑ pimozide</td><td align=,'left,' class=,'Rrule,'>Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'>e.g., perphenazine, risperidone, thioridazine</td><td align=,'left,' class=,'Rrule,'>↑ antipsychotic</td><td align=,'left,' class=,'Rrule,'>A decrease in the dose of antipsychotics that are metabolized by CYP3A or CYP2D6 may be needed when co-administered with SYMTUZA.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>quetiapine</td><td align=,'left,' class=,'Rrule,'>↑ quetiapine</td><td align=,'left,' class=,'Rrule,'><span class=,'Underline,'>Initiation of SYMTUZA in patients taking quetiapine:</span> Consider alternative antiretroviral therapy to avoid increases in quetiapine exposure. If co-administration is necessary, reduce the quetiapine dose to 1/6 of the current dose and monitor for quetiapine-associated adverse reactions. Refer to the quetiapine prescribing information for recommendations on adverse reaction monitoring.<br/>
<span class=,'Underline,'>Initiation of quetiapine in patients taking SYMTUZA:</span> Refer to the quetiapine prescribing information for initial dosing and titration of quetiapine.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>β-Blockers:</span>
<br/>e.g., carvedilol, metoprolol, timolol</td><td align=,'left,' class=,'Rrule,'>↑ beta-blockers</td><td align=,'left,' class=,'Rrule,'>Clinical monitoring is recommended for co-administration with beta-blockers that are metabolized by CYP2D6.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Calcium channel blockers:</span>
<br/>e.g., amlodipine, diltiazem, felodipine, nifedipine, verapamil</td><td align=,'left,' class=,'Rrule,'>↑ calcium channel blockers</td><td align=,'left,' class=,'Rrule,'>Clinical monitoring is recommended for co-administration with calcium channel blockers metabolized by CYP3A.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Cardiac Disorders:</span></td><td align=,'left,' class=,'Rrule,'></td><td align=,'left,' class=,'Rrule,'></td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'>ranolazine, ivabradine</td><td align=,'left,' class=,'Rrule,'>↑ ranolazine</td><td align=,'left,' class=,'Rrule,'>Co-administration is contraindicated due to potential for serious and/or life-threatening reactions.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'>dronedarone</td><td align=,'left,' class=,'Rrule,'>↑ dronedarone</td><td align=,'left,' class=,'Rrule,'>Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Underline,'>Other antiarrhythmics</span>
<br/>e.g., amiodarone, disopyramide, flecainide, lidocaine (systemic), mexiletine, propafenone, quinidine</td><td align=,'left,' class=,'Rrule,'>↑ antiarrhythmics</td><td align=,'left,' class=,'Rrule,'>Clinical monitoring is recommended upon co-administration with antiarrhythmics.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>digoxin</td><td align=,'left,' class=,'Rrule,'>↑ digoxin</td><td align=,'left,' class=,'Rrule,'>When co-administering with digoxin, titrate the digoxin dose and monitor digoxin concentrations.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Corticosteroids:</span>
<br/>dexamethasone (systemic)</td><td align=,'left,' class=,'Rrule,'>↓ darunavir<br/>↓ cobicistat<br/>
</td><td align=,'left,' class=,'Rrule,'>Co-administration with systemic dexamethasone or other systemic corticosteroids that induce CYP3A may result in loss of therapeutic effect and development of resistance to SYMTUZA. Consider alternative corticosteroids.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>Corticosteroids primarily metabolized by CYP3A:<br/>e.g.,<br/>betamethasone<br/>budesonide<br/>ciclesonide<br/>fluticasone<br/> methylprednisolone<br/>mometasone<br/>triamcinolone</td><td align=,'left,' class=,'Rrule,'>↑ corticosteroids</td><td align=,'left,' class=,'Rrule,'>Co-administration with corticosteroids (all routes of administration) of which exposures are significantly increased by strong CYP3A inhibitors can increase the risk for Cushing's syndrome and adrenal suppression.<br/>Alternative corticosteroids including beclomethasone, prednisone, and prednisolone (for which PK and/or PD are less affected by strong CYP3A inhibitors relative to other steroids) should be considered, particularly for long term use.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Endothelin receptor antagonists:</span>
<br/>bosentan</td><td align=,'left,' class=,'Rrule,'>↓ darunavir<br/>↓ cobicistat<br/>↑ bosentan</td><td align=,'left,' class=,'Rrule,'><span class=,'Underline,'>Initiation of bosentan in patients taking SYMTUZA</span>: In patients who have been receiving SYMTUZA for at least 10 days, start bosentan at 62.5 mg once daily or every other day based upon individual tolerability.<br/>
<span class=,'Underline,'>Initiation of SYMTUZA in patients on bosentan:</span> Discontinue use of bosentan at least 36 hours prior to initiation of SYMTUZA. After at least 10 days following the initiation of SYMTUZA, resume bosentan at 62.5 mg once daily or every other day based upon individual tolerability.<br/>
<span class=,'Underline,'>Switching from darunavir co-administered with ritonavir to SYMTUZA in patients on bosentan:</span> Maintain bosentan dose.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Ergot derivatives:</span></td><td align=,'left,' class=,'Rrule,'></td><td align=,'left,' class=,'Rrule,'></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>e.g., dihydroergotamine, ergotamine, methylergonovine</td><td align=,'left,' class=,'Rrule,'>↑ ergot derivatives</td><td align=,'left,' class=,'Rrule,'>Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Hepatitis C virus (HCV):</span>
<br/>
<span class=,'Underline,'>Direct-Acting Antivirals:</span></td><td align=,'left,' class=,'Rrule,'></td><td align=,'left,' class=,'Rrule,'></td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'>elbasvir/grazoprevir</td><td align=,'left,' class=,'Rrule,'>↑ elbasvir/grazoprevir</td><td align=,'left,' class=,'Rrule,'>Co-administration is contraindicated due to potential for the increased risk of alanine transaminase (ALT) elevations.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>glecaprevir/pibrentasvir </td><td align=,'left,' class=,'Rrule,'>↑ glecaprevir<br/>↑ pibrentasvir</td><td align=,'left,' class=,'Rrule,'>Co-administration of SYTMUZA with glecaprevir/pibrentasvir is not recommended.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Herbal product:</span></td><td align=,'left,' class=,'Rrule,'></td><td align=,'left,' class=,'Rrule,'></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>St. John's wort (<span class=,'Italics,'>Hypericum perforatum</span>)</td><td align=,'left,' class=,'Rrule,'>↓ cobicistat<br/>↓ darunavir<br/>↓ tenofovir alafenamide</td><td align=,'left,' class=,'Rrule,'>Co-administration is contraindicated due to potential for loss of therapeutic effect and development of resistance.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Hormonal contraceptives:</span></td><td align=,'left,' class=,'Rrule,'></td><td align=,'left,' class=,'Rrule,'>Additional or alternative (non-hormonal) forms of contraception should be considered when estrogen based contraceptives are co-administered with SYMTUZA. </td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'>drosperinone/ethinylestradiol</td><td align=,'left,' class=,'Rrule,'>↑ drosperinone<br/>↓ ethinylestradiol</td><td align=,'left,' class=,'Rrule,' valign=,'bottom,'>For co-administration with drospirenone, clinical monitoring is recommended due to the potential for hyperkalemia. </td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>other progestin/estrogen contraceptives</td><td align=,'left,' class=,'Rrule,'>progestin: effects unknown<br/>estrogen: effects unknown</td><td align=,'left,' class=,'Rrule,' valign=,'bottom,'>No data are available to make recommendations on co-administration with oral or other hormonal contraceptives. </td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Immunosuppressants:</span>
<br/>cyclosporine, sirolimus, tacrolimus</td><td align=,'left,' class=,'Rrule,'>↑ immunosuppressants</td><td align=,'left,' class=,'Rrule,'>These immunosuppressant agents are metabolized by CYP3A. Therapeutic drug monitoring is recommended with concomitant use.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Immunosuppressant /neoplastic:</span>
<br/>everolimus</td><td align=,'left,' class=,'Rrule,'></td><td align=,'left,' class=,'Rrule,'>Co-administration of everolimus and SYMTUZA is not recommended.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>irinotecan</td><td align=,'left,' class=,'Rrule,'></td><td align=,'left,' class=,'Rrule,'>Discontinue SYMTUZA at least 1 week prior to starting irinotecan therapy. Do not administer SYMTUZA with irinotecan unless there are no therapeutic alternatives.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Inhaled beta agonist:</span></td><td align=,'left,' class=,'Rrule,'></td><td align=,'left,' class=,'Rrule,'></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>salmeterol</td><td align=,'left,' class=,'Rrule,'>↑ salmeterol</td><td align=,'left,' class=,'Rrule,'>Co-administration with salmeterol is not recommended and may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations, and sinus tachycardia.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Lipid modifying agents:</span>
<br/>
<span class=,'Underline,'>HMG-CoA reductase inhibitors:</span></td><td align=,'left,' class=,'Rrule,'></td><td align=,'left,' class=,'Rrule,'></td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'>lovastatin, simvastatin</td><td align=,'left,' class=,'Rrule,'>↑ lovastatin<br/>↑ simvastatin</td><td align=,'left,' class=,'Rrule,' valign=,'top,'>Co-administration is contraindicated due to potential for serious reactions such as myopathy including rhabdomyolysis.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,' valign=,'top,'>e.g., atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin </td><td align=,'left,' class=,'Rrule,' valign=,'top,'>↑ atorvastatin<br/>↑ fluvastatin<br/>↑ pravastatin<br/>↑ rosuvastatin<br/>pitavastatin: effect unknown</td><td align=,'left,' class=,'Rrule,' valign=,'top,'>For atorvastatin, fluvastatin, pitavastatin, pravastatin, and rosuvastatin, start with the lowest recommended dose and titrate while monitoring for safety.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'></td><td align=,'left,' class=,'Rrule,'></td><td align=,'left,' class=,'Rrule,'>Dosage recommendations with atorvastatin or rosuvastatin are as follows: 							<ul class=,'Disc,'>
<li>atorvastatin dosage should not exceed 20 mg/day </li>
<li>rosuvastatin dosage should not exceed 20 mg/day</li>
</ul>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Underline,'>Other lipid modifying agents</span>:<br/>lomitapide </td><td align=,'left,' class=,'Rrule,'>↑ lomitapide</td><td align=,'left,' class=,'Rrule,'>Co-administration is contraindicated due to potential for markedly increased transaminases associated with increased plasma concentrations of lomitapide.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Narcotic analgesics metabolized by CYP3A:</span>
<br/>e.g., fentanyl, oxycodone</td><td align=,'left,' class=,'Rrule,'>↑ fentanyl<br/>↑ oxycodone</td><td align=,'left,' class=,'Rrule,'>Careful monitoring of therapeutic effects and adverse reactions associated with CYP3A-metabolized narcotic analgesics (including potentially fatal respiratory depression) is recommended with co-administration.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>tramadol</td><td align=,'left,' class=,'Rrule,'>↑ tramadol</td><td align=,'left,' class=,'Rrule,'>A dose decrease may be needed for tramadol with concomitant use.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Narcotic analgesic for treatment of opioid dependence:</span>
<br/>buprenorphine, buprenorphine/naloxone, methadone</td><td align=,'left,' class=,'Rrule,'>buprenorphine or buprenorphine/ naloxone: effects unknown<br/>methadone: effects unknown</td><td align=,'left,' class=,'Rrule,'><span class=,'Underline,'>Initiation of buprenorphine, buprenorphine/naloxone or methadone in patients taking SYMTUZA:</span> Carefully titrate the dose of buprenorphine, buprenorphine/naloxone or methadone to the desired effect; use the lowest feasible initial or maintenance dose.<br/>
<span class=,'Underline,'>Initiation of SYMTUZA in patients taking buprenorphine, buprenorphine/naloxone, or methadone:</span> A dose adjustment for buprenorphine, buprenorphine/naloxone, or methadone may be needed. Monitor clinical signs and symptoms.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Opioid Antagonist</span></td><td align=,'left,' class=,'Rrule,'></td><td align=,'left,' class=,'Rrule,'></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>naloxegol</td><td align=,'left,' class=,'Rrule,'>↑ naloxegol</td><td align=,'left,' class=,'Rrule,'>Co-administration of SYMTUZA and naloxegol is contraindicated due to potential for precipitating opioid withdrawal symptoms.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Phosphodiesterase PDE-5 inhibitors:</span></td><td align=,'left,' class=,'Rrule,' valign=,'bottom,'>↑ PDE-5 inhibitors</td><td align=,'left,' class=,'Rrule,'></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>e.g., avanafil, sildenafil, tadalafil, vardenafil</td><td align=,'left,' class=,'Rrule,'></td><td align=,'left,' class=,'Rrule,'>Co-administration with avanafil is not recommended because a safe and effective avanafil dosage regimen has not been established.<br/>Co-administration with PDE-5 inhibitors may result in an increase in PDE-5 inhibitor-associated adverse reactions including hypotension, syncope, visual disturbances, and priapism.<br/>
<span class=,'Underline,'>Use of PDE-5 inhibitors for pulmonary arterial hypertension (PAH):</span>
<br/>Co-administration with sildenafil used for PAH is contraindicated due to potential for sildenafil associated adverse reactions (which include visual disturbances, hypotension, prolonged erection, and syncope). The following dose adjustments are recommended for use of tadalafil with SYMTUZA:<ul class=,'Disc,'>
<li>
<span class=,'Italics Underline,'>Initiation of tadalafil in patients taking SYMTUZA:</span> In patients receiving SYMTUZA for at least one week, start tadalafil at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability.</li>
<li>
<span class=,'Italics Underline,'>Initiation of SYMTUZA in patients taking tadalafil:</span> Avoid use of tadalafil during the initiation of SYMTUZA. Stop tadalafil at least 24 hours prior to starting SYMTUZA. After at least one week following the initiation of SYMTUZA, resume tadalafil at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability.</li>
<li>
<span class=,'Italics Underline,'>Patients switching from darunavir co-administered with ritonavir to SYMTUZA:</span> Maintain tadalafil dose.</li>
</ul>
<span class=,'Underline,'>Use of PDE-5 inhibitors for erectile dysfunction:</span>
<br/>Sildenafil at a single dose not exceeding 25 mg in 48 hours, vardenafil at a single dose not exceeding 2.5 mg dose in 72 hours, or tadalafil at a single dose not exceeding 10 mg dose in 72 hours can be used with increased monitoring for PDE-5 inhibitor-associated adverse reactions.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Platelet aggregation inhibitor:</span>
<br/>ticagrelor</td><td align=,'left,' class=,'Rrule,' valign=,'middle,'>↑ticagrelor</td><td align=,'left,' class=,'Rrule,' valign=,'bottom,'>Co-administration of SYMTUZA and ticagrelor is not recommended. </td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'>clopidogrel</td><td align=,'left,' class=,'Rrule,'>↓ clopidogrel active metabolite</td><td align=,'left,' class=,'Rrule,'>Co-administration of SYMTUZA and clopidogrel is not recommended due to potential reduction of the antiplatelet activity of clopidogrel.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>prasugrel</td><td align=,'left,' class=,'Rrule,'>↔ prasugrel active metabolite</td><td align=,'left,' class=,'Rrule,'>No dose adjustment is needed when prasugrel is co-administered with SYMTUZA.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Sedatives/hypnotics:</span>
<br/>orally administered midazolam, triazolam</td><td align=,'left,' class=,'Rrule,'>↑ midazolam<br/>↑ triazolam</td><td align=,'left,' class=,'Rrule,'>Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression. </td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>metabolized by CYP3A:</span>
<br/>e.g., buspirone, diazepam, estazolam, zolpidem</td><td align=,'left,' class=,'Rrule,'>↑ sedatives/hypnotics</td><td align=,'left,' class=,'Rrule,'>With concomitant use, titration is recommended with sedatives/hypnotics metabolized by CYP3A and a lower dose of the sedatives/hypnotics should be considered with monitoring for increased and prolonged effects or adverse reactions.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'>parenterally administered midazolam</td><td align=,'left,' class=,'Rrule,'></td><td align=,'left,' class=,'Rrule,'>Co-administration of parenteral midazolam should be done in a setting that ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dose reduction for parenteral midazolam should be considered, especially if more than a single dose of midazolam is administered.</td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Bold,'>Urinary antispasmodics</span></td><td align=,'left,' class=,'Rrule,'></td><td align=,'left,' class=,'Rrule,'></td>
</tr>
<tr>
<td align=,'left,' class=,'Lrule Rrule,'>fesoterodine</td><td align=,'left,' class=,'Rrule,'>↑ fesoterodine</td><td align=,'left,' class=,'Rrule,'>When fesoterodine is co-administered with SYMTUZA, do not exceed a fesoterodine dose of 4 mg once daily.</td>
</tr>
<tr class=,'Last,'>
<td align=,'left,' class=,'Lrule Rrule,'>solifenacin</td><td align=,'left,' class=,'Rrule,'>↑ solifenacin</td><td align=,'left,' class=,'Rrule,'>When solifenacin is co-administered with SYMTUZA, do not exceed a solifenacin dose of 5 mg once daily.</td>
</tr>
</tbody>
</table></div>
</div>
</div>"
"tenofovir disoproxil fumarate","14a8db19-3c49-4faa-b572-850176f1b8f1","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID195,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>
<a name=,'ID196,'></a>This section describes clinically relevant drug interactions with tenofovir disoproxil fumarate. Drug interactions trials are described elsewhere in the labeling <span class=,'Italics,'>[See Clinical Pharmacology (12.3)].</span>
</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID199,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Didanosine</h2>
<p class=,'First,'>
<a name=,'ID200,'></a>Coadministration of tenofovir disoproxil fumarate and didanosine should be undertaken with caution and patients receiving this combination should be monitored closely for didanosine associated adverse reactions. Didanosine should be discontinued in patients who develop didanosine- associated adverse reactions.</p>
<p>When administered with tenofovir disoproxil fumarate, Cmax and AUC of didanosine increased significantly <span class=,'Italics,'>[See Clinical Pharmacology (12.3)]</span>. The mechanism of this interaction is unknown. Higher didanosine concentrations could potentiate didanosine-associated adverse reactions, including pancreatitis and neuropathy. Suppression of CD4+ cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine 400 mg daily.</p>
<p>In patients weighing greater than 60 kg, the didanosine dose should be reduced to 250 mg once daily when it is coadministered with tenofovir disoproxil fumarate. In patients weighing less than60 kg, the didanosine dose should be reduced to 200 mg once daily when it is coadministered with tenofovir disoproxil fumarate. When coadministered, tenofovir disoproxil fumarate and didanosine EC may be taken under fasted conditions or with a light meal (less than 400 kcal, 20% fat). For additional information on coadministration of tenofovir disoproxil fumarate and didanosine, please refer to the full prescribing information for didanosine.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID201,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 HIV-1 Protease Inhibitors</h2>
<p class=,'First,'>
<a name=,'ID202,'></a>Tenofovir disoproxil fumarate decreases the AUC and Cmin of atazanavir <span class=,'Italics,'>[See Clinical Pharmacology (12.3)]. </span>When coadministered with tenofovir disoproxil fumarate, it is recommended that atazanavir 300 mg is given with ritonavir 100 mg. Tenofovir disoproxil fumarate should not be coadministered with atazanavir without ritonavir.</p>
<p>Lopinavir/ritonavir, atazanavir coadministered with ritonavir, and darunavir coadministered with ritonavir have been shown to increase tenofovir concentrations <span class=,'Italics,'>[See Clinical Pharmacology (12.3)]. </span>Tenofovir disoproxil fumarate is a substrate of P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) transporters. When tenofovir disoproxil fumarate is co-administered with an inhibitor of these transporters, an increase in absorption may be observed. Patients receiving tenofovir disoproxil fumarate concomitantly with lopinavir/ritonavir, ritonavir-boosted atazanavir, or ritonavir-boosted darunavir should be monitored for tenofovir disoproxil fumarate -associated adverse reactions. Tenofovir disoproxil fumarate should be discontinued in patients who develop tenofovir disoproxil fumarate-associated adverse reactions.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID203,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Hepatitis C Antiviral Agents</h2>
<p class=,'First,'>
<a name=,'ID204,'></a>Coadministration of tenofovir disoproxil fumarate and EPCLUSA<span class=,'Sup,'>®</span> (sofosbuvir/velpatasvir) or HARVONI<span class=,'Sup,'>®</span> (ledipasvir/sofosbuvir) has been shown to increase tenofovir exposure <span class=,'Italics,'>[See Clinical Pharmacology (12.3)]</span>.</p>
<p>In patients receiving Tenofovir disoproxil fumarate concomitantly with EPCLUSA, monitor for adverse reactions associated with tenofovir DF. </p>
<p>In patients receiving tenofovir disoproxil fumarate concomitantly with HARVONI without an HIV-1 protease inhibitor/ritonavir or an HIV-1 protease inhibitor/cobicistat combination, monitor for adverse reactions associated with tenofovir disoproxil fumarate.</p>
<p>In patients receiving tenofovir disoproxil fumarate concomitantly with HARVONI and an HIV-1 protease inhibitor/ritonavir or an HIV-1 protease inhibitor/cobicistat combination, consider an alternative HCV or antiretroviral therapy, as the safety of increased tenofovir concentrations in this setting has not been established. If coadministration is necessary, monitor for adverse reactions associated with tenofovir disoproxil fumarate.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID205,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Drugs Affecting Renal Function</h2>
<p class=,'First,'>
<a name=,'ID206,'></a>Since tenofovir is primarily eliminated by the kidneys <span class=,'Italics,'>[See Clinical Pharmacology (12.3)]</span>, coadministration of tenofovir disoproxil fumarate with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of tenofovir and/or increase the concentrations of other renally eliminated drugs. Some examples include, but are not limited to cidofovir, acyclovir, valacyclovir, ganciclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs <span class=,'Italics,'>[See Warnings and Precautions (5.2)].</span>
</p>
<p>In the treatment of chronic hepatitis B, tenofovir disoproxil fumarate should not be administered in combination with HEPSERA (adefovir dipivoxil).</p>
</div>
</div>"
"terbinafine","14b441a7-67ea-4a90-bfeb-381bc10362a4","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Drug-Drug Interactions</h2>
<p class=,'First,'>
<span class=,'Italics,'>In vivo </span>studies have shown that terbinafine is an inhibitor of the CYP450 2D6 isozyme. Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. Coadministration of terbinafine tablets should be done with careful monitoring and may require a reduction in dose of the 2D6-metabolized drug. In a study to assess the effects of terbinafine on desipramine in healthy volunteers characterized as normal metabolizers, the administration of terbinafine resulted in a 2-fold increase in C<span class=,'Sub,'>max</span> and a 5-fold increase in area under the curve (AUC). In this study, these effects were shown to persist at the last observation at 4 weeks after discontinuation of terbinafine tablets. In studies in healthy subjects characterized as extensive metabolizers of dextromethorphan (antitussive drug and CYP2D6 probe substrate), terbinafine increases the dextromethorphan /dextrorphan metabolite ratio in urine by 16- to 97-fold on average. Thus, terbinafine may convert extensive CYP2D6 metabolizers to poor metabolizer status.</p>
<p>
<span class=,'Italics,'>In vitro </span>studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, cyclosporine, cisapride and fluvastatin. <span class=,'Italics,'>In vivo </span>drug-drug interaction studies conducted in healthy volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin. Terbinafine decreases the clearance of caffeine by 19%. Terbinafine increases the clearance of cyclosporine by 15%. </p>
<p>The influence of terbinafine on the pharmacokinetics of fluconazole, cotrimoxazole (trimethoprim and sulfamethoxazole), zidovudine or theophylline was not considered to be clinically significant.</p>
<p>Coadministration of a single dose of fluconazole (100 mg) with a single dose of terbinafine resulted in a 52% and 69% increase in terbinafine C<span class=,'Sub,'>max</span> and AUC, respectively. Fluconazole is an inhibitor of CYP2C9 and CYP3A enzymes. Based on this finding, it is likely that other inhibitors of both CYP2C9 and CYP3A4 (e.g., ketoconazole, amiodarone) may also lead to a substantial increase in the systemic exposure (C<span class=,'Sub,'>max</span> and AUC) of terbinafine when concomitantly administered.</p>
<p>There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between terbinafine tablets and these changes has not been established. </p>
<p>Terbinafine clearance is increased 100% by rifampin, a CYP450 enzyme inducer, and decreased 33% by cimetidine, a CYP450 enzyme inhibitor. Terbinafine clearance is unaffected by cyclosporine. There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, phenytoins, thiazide diuretics, and calcium channel blockers. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Food Interactions</h2>
<p class=,'First,'>An evaluation of the effect of food on terbinafine tablets was conducted. An increase of less than 20% of the AUC of terbinafine was observed when terbinafine tablets were administered with food. Terbinafine tablets can be taken with or without food.</p>
</div>
</div>"
"terbutaline","0a95bc4f-34d3-4b5e-841b-6839e1c1e0c7","none found"
"testosterone","10dab294-6a43-4bb3-9d91-2d200c624ffb","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'s27,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s28,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Insulin</h2>
<p class=,'First,'>
<a name=,'p6701124,'></a>Changes in insulin sensitivity or glycemic control may occur in patients treated with androgens. In diabetic patients, the metabolic effects of androgens may decrease blood glucose and, therefore, may decrease insulin requirements.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s29,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Oral Anticoagulants </h2>
<p class=,'First,'>
<a name=,'p6915124,'></a>Changes in anticoagulant activity may be seen with androgens, therefore more frequent monitoring of international normalized ratio (INR) and prothrombin time are recommended in patients taking anticoagulants, especially at the initiation and termination of androgen therapy. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s30,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Corticosteroids </h2>
<p class=,'First,'>
<a name=,'p6923124,'></a>The concurrent use of testosterone with adrenocorticotropic hormone (ACTH) or corticosteroids may result in increased fluid retention and requires careful monitoring particularly in patients with cardiac, renal or hepatic disease. </p>
</div>
</div>"
"tetrabenazine","18909efa-de8a-42f1-a641-aa0319d71c35","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID_ebdad1dc-b7d7-43a0-b199-23e9efd76d91,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_43dd4287-3039-43b9-b81c-6df9038262bf,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Strong CYP2D6 Inhibitors</h2>
<p class=,'First,'>
<span class=,'Italics,'>In vitro </span>studies indicate that α-HTBZ and β-HTBZ are substrates for CYP2D6. Strong CYPD6 inhibitors (e.g., paroxetine, fluoxetine, quinidine) markedly increase exposure to these metabolites. A reduction in Tetrabenazine tablet dose may be necessary when adding a strong CYP2D6 inhibitor (e.g., fluoxetine, paroxetine, quinidine) in patients maintained on a stable dose of Tetrabenazine tablet. The daily dose of Tetrabenazine tablet should not exceed 50 mg per day and the maximum single dose of Tetrabenazine tablet should not exceed 25 mg in patients taking strong CYP2D6 inhibitors
         
 
  <span class=,'Italics,'> [see
          
  
   <a href=,'#ID_3aaafb79-35dc-474d-b0c6-5276c672c80c,'> Dosage and Administration (2.3)</a>,
          
  
   <a href=,'#ID_194a1d30-f5ad-43fd-b05f-c69f894f16d5,'> Warnings and Precautions (5.3)</a>,
          
  
   <a href=,'#ID_9f80c05a-5453-4a5f-b53f-1d9f70bb8458,'> Use in Specific Population (8.7)</a>,
          
  
   <a href=,'#ID_da32453f-283f-4c41-89b3-74020ae3082d,'>Clinical Pharmacology (12.2)</a>]
         
 
  </span>.
        

 </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_05df492c-5585-4342-bb60-5d7d04cc1ad7,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Reserpine</h2>
<p class=,'First,'>Reserpine binds irreversibly to VMAT2 and the duration of its effect is several days. Prescribers should wait for chorea to reemerge before administering Tetrabenazine tablet to avoid overdosage and major depletion of serotonin and norepinephrine in the CNS. At least 20 days should elapse after stopping reserpine before starting Tetrabenazine tablet. Tetrabenazine tablet and reserpine should not be used concomitantly
         
 
  <span class=,'Italics,'> [see
          
  
   <a href=,'#ID_7b3108fd-427c-4d24-9486-46dc8dfcbfae,'> Contraindications (4)</a>,
          
  
   <a href=,'#ID_92b1b6d1-902e-4191-895d-aa326efe5de2,'> Warnings and Precautions (5.12)</a>].
         
 
  </span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_3012da02-e4fe-4a55-812d-ae251ec1d6bc,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Monoamine Oxidase Inhibitors (MAOIs )</h2>
<p class=,'First,'>Tetrabenazine tablet is contraindicated in patients taking MAOIs. Tetrabenazine tablet should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI
         
 
  <span class=,'Italics,'> [see
          
  
   <a href=,'#ID_7b3108fd-427c-4d24-9486-46dc8dfcbfae,'> Contraindications (4)</a>,
          
  
   <a href=,'#ID_92b1b6d1-902e-4191-895d-aa326efe5de2,'> Warnings and Precautions (5.12)</a>].
         
 
  </span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_eeaea79a-ae04-48b8-b9dc-44f275ede338,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Alcohol</h2>
<p class=,'First,'>Concomitant use of alcohol or other sedating drugs may have additive effects and worsen sedation and somnolence.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_f5b58bc9-0fc8-40ff-b72e-4d969e640649,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Drugs that Cause QTc Prolongation</h2>
<p class=,'First,'>Tetrabenazine tablet causes a small prolongation of QTc (about 8 msec), concomitant use with other drugs that are known to cause QTc prolongation should be avoided, these including antipsychotic medications (e.g., chlorpromazine, haloperidol, thioridazine, ziprasidone), antibiotics (e.g., moxifloxacin), Class 1A (e.g ., quinidine, procainamide), and Class III (e.g., amiodarone, sotalol) antiarrhythmic medications or any other medications known to prolong the QTc interval. Tetrabenazine tablet should be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias. Certain conditions may increase the risk for torsade de pointes or sudden death such as, (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval [
         
 
  <span class=,'Italics,'>see
          
  
   <a href=,'#ID_1e450718-9224-43ed-810a-509812e59ea1,'> Warnings and Precautions (5.9)</a>,
          
  
   <a href=,'#ID_da32453f-283f-4c41-89b3-74020ae3082d,'> Clinical Pharmacology (12.2)</a></span>].
        

 </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_1a95a287-7a42-4b81-9514-fc7704977286,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6 Neuroleptic Drugs</h2>
<p class=,'First,'>The risk for Parkinsonism, NMS, and akathisia may be increased by concomitant use of Tetrabenazine tablet and dopamine antagonists or antipsychotics (e.g.chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone).</p>
</div>
</div>"
"thalidomide","2eda833b-1357-4ed4-a093-194524fcb061","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1   Opioids, Antihistamines, Antipsychotics, Anti-anxiety Agents, or Other CNS Depressants (Including Alcohol)</h2>
<p class=,'First,'>The use of opioids, antihistamines, antipsychotics, anti-anxiety agents, or other CNS depressants concomitantly with THALOMID may cause an additive sedative effect and should be avoided.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2   Drugs which Cause Bradycardia</h2>
<p class=,'First,'>The use of drugs which slow cardiac conduction concomitantly with THALOMID may cause an additive bradycardic effect and should be used with caution. Cardiovascular medications which may cause bradycardia include calcium channel blockers, beta blockers, alpha/beta-adrenergic blockers, and digoxin. Non-cardiac drugs that may cause bradycardia include H2 blockers (e.g., famotidine, cimetidine), lithium, tricyclic antidepressants and neuromuscular blockers (succinylcholine).</p>
<p>In 16 healthy men, the pharmacokinetic profile of a single 0.5 mg digoxin dose was similar with and without the coadministration of THALOMID 200 mg/day at steady state levels. The single dose of digoxin had no effect on the pharmacokinetic profile of THALOMID. The safety of long-term concomitant use of THALOMID and digoxin has not been evaluated.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3   Drugs which Cause Peripheral Neuropathy</h2>
<p class=,'First,'>The use of drugs which cause peripheral neuropathy (e.g., bortezomib, amiodarone, cisplatin, docetaxel, paclitaxel, vincristine, disulfiram, phenytoin, metronidazole, alcohol) can cause an additive effect and should be used with caution.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4   Hormonal Contraceptives</h2>
<p class=,'First,'>Hormonal contraceptives increase the risk of thromboembolism. It is not known whether concomitant use of hormonal contraceptives further increases the risk of thromboembolism with THALOMID.</p>
<p>In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 mcg of ethinyl estradiol were studied. The results were similar with and without coadministration of THALOMID 200 mg/day to steady-state levels.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.5,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5   Warfarin</h2>
<p class=,'First,'>In 13 healthy men, the pharmacokinetic profile and international normalized ratio (INR) of prothrombin time for warfarin, following a single oral dose of 25 mg, were similar with and without the coadministration of THALOMID 200 mg/day at steady-state levels. The single dose of warfarin had no effect on the pharmacokinetic profile of thalidomide.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.6,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6   Drugs that Interfere with Hormonal Contraceptives</h2>
<p class=,'First,'>Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. John's Wort with hormonal contraceptive agents may reduce the effectiveness of the contraception up to one month after discontinuation of these concomitant therapies. Therefore, females requiring treatment with one or more of these drugs must use two OTHER effective or highly effective methods of contraception while taking THALOMID.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.7,'></a><a name=,'section-7.7,'></a>
<p></p>
<h2>7.7   Concomitant Therapies that may Increase the Risk of Thromboembolism</h2>
<p class=,'First,'>Erythropoietic agents, or other agents that may increase the risk of thromboembolism, such as estrogen containing therapies, should be used with caution in multiple myeloma patients receiving THALOMID with dexamethasone <span class=,'Italics,'>[see <a href=,'#S5.3,'>Warnings and Precautions (5.3)</a>].</span>
</p>
</div>
</div>"
"tigecycline","230484a8-408c-dcc1-d0c4-d9dd9a46831b","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'s29,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s30,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Warfarin </h2>
<p class=,'First,'>Prothrombin time or other suitable anticoagulation test should be monitored if tigecycline is administered with warfarin <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#s43,'>12.3</a>)]</span>. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_8811644d-afed-2267-30d5-a997e40c6879,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>
<span class=,'Bold,'>7.2 Calcineurin Inhibitors</span>
</h2>
<p class=,'First,'>Concomitant use of tigecycline for injection and calcineurin inhibitors such as tacrolimus or cyclosporine may lead to an increase in serum trough concentrations of the calcineurin inhibitors. Therefore, serum concentrations of the calcineurin inhibitor should be monitored during treatment with tigecycline for injection to avoid drug toxicity. </p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s31,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Oral Contraceptives </h2>
<p class=,'First,'>Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective. </p>
</div>
</div>"
"timolol","00f62dd1-dad2-4892-8a5d-21e5e54509ce","none found"
"tinzaparin","d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee","none found"
"thioguanine","4490128b-e73f-4849-9d6e-e8591639d771","none found"
"tiotropium","25a4cb05-64a8-44b6-88c8-4292a5292e92","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1	Sympathomimetics, Methylxanthines, Steroids</h2>
<p class=,'First,'>SPIRIVA HANDIHALER has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, and oral and inhaled steroids without increases in adverse reactions.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2	Anticholinergics</h2>
<p class=,'First,'>There is potential for an additive interaction with concomitantly used anticholinergic medications.  Therefore, avoid coadministration of SPIRIVA HANDIHALER with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects <span class=,'Italics,'>[see <a href=,'#S5.4,'>Warnings and Precautions (5.4</a>, <a href=,'#S5.5,'>5.5)</a> and <a href=,'#S6,'>Adverse Reactions (6)</a>]</span>.</p>
</div>
</div>"
"tizanidine","01c0d3d3-2373-a1b7-822a-80a66291a248","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'_972a85e2-b809-9834-5d4f-58fc6a9b1df3,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_a790ed84-529c-27a5-9dd7-9548aa767235,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Fluvoxamine</h2>
<p class=,'First,'>Concomitant use of fluvoxamine and tizanidine is contraindicated. Changes in pharmacokinetics of tizanidine when administered with fluvoxamine resulted in significantly decreased blood pressure, increased drowsiness, and increased psychomotor impairment <span class=,'Italics,'>[see  <a href=,'#_d6f9fa1b-13f9-7250-5e43-54e0c93093ba,'>Contraindications  </a><a href=,'#_d6f9fa1b-13f9-7250-5e43-54e0c93093ba,'>(4) </a>and  <a href=,'#_cd922667-9722-256a-1613-30349ca1fe47,'>Clinical Pharmacology </a>
         (<a href=,'#_cd922667-9722-256a-1613-30349ca1fe47,'>12.3)</a>]. </span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_d8e0b59d-0fa7-c1da-6e6a-c2a98fc47b82,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Ciprofloxacin</h2>
<p class=,'First,'>Concomitant use of ciprofoxacin and tizanidine is contraindicated. Changes in pharmacokinetics of tizanidine when administered with ciprofloxacin resulted in significantly decreased blood pressure, increased drowsiness, and increased psychomotor impairment <span class=,'Italics,'>[See  <a href=,'#_d6f9fa1b-13f9-7250-5e43-54e0c93093ba,'>Contraindications </a><a href=,'#_d6f9fa1b-13f9-7250-5e43-54e0c93093ba,'>(4)</a> and  <a href=,'#_cd922667-9722-256a-1613-30349ca1fe47,'>Clinical  Pharmacology </a><a href=,'#_cd922667-9722-256a-1613-30349ca1fe47,'>(12.3)</a>] </span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_29d3fd3a-5509-ba51-e83e-5f57fcf31a29,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 CYP1A2 Inhibitors other than Fluvoxamine and Ciprofloxacin</h2>
<p class=,'First,'>Because of potential drug interactions, concomitant use of tizanidine with other CYP1A2 inhibitors, such as zileuton, fluoroquinolones other than strong CYP1A2 inhibitors (which are contraindicated), antiarrythmics (amiodarone, mexiletine, propafenone, and verapamil), cimetidine, famotidine, oral contraceptives, acyclovir, and ticlopidine) should be avoided. If their use is clinically necessary, therapy should be initiated with 2 mg dose and increased in 2 to 4 mg steps daily based on patient response to therapy. If adverse reactions such as hypotension, bradycardia, or excessive drowsiness occur, reduce or discontinue tizanidine therapy <span class=,'Italics,'>[see  <a href=,'#_3b44fb4d-98ef-1988-a778-5660c7a14206,'>Warnings and Precautions </a><a href=,'#_3b44fb4d-98ef-1988-a778-5660c7a14206,'>(5.5)</a> and  <a href=,'#_cd922667-9722-256a-1613-30349ca1fe47,'>Clinical Pharmacology </a><a href=,'#_cd922667-9722-256a-1613-30349ca1fe47,'>(12.3)</a>] </span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_0d060a46-f504-294d-fd84-bcc096780d4e,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Oral Contraceptives</h2>
<p class=,'First,'>Concomitant use of tizanidine with oral contraceptives is not recommended. However, if concomitant use is clinically necessary, initiate tizanidine with a single 2 mg dose and increase in 2 to 4 mg steps daily based on patient response to therapy. If adverse reactions such as hypotension, bradycardia, or excessive drowsiness occur, reduce or discontinue tizanidine therapy<span class=,'Italics,'> [see 
         <a href=,'#_cd922667-9722-256a-1613-30349ca1fe47,'>Clinical  Pharmacology </a><a href=,'#_cd922667-9722-256a-1613-30349ca1fe47,'>(12.3)</a>] </span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_8781bc31-0db7-b862-5cc6-5d3e8836e8ed,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Alcohol</h2>
<p class=,'First,'>Alcohol increases the overall amount of drug in the bloodstream after a dose of tizanidine. This was associated with an increase in adverse reactions of tizanidine. The CNS depressant effects of tizanidine and alcohol are additive<span class=,'Italics,'> [see  <a href=,'#_cd922667-9722-256a-1613-30349ca1fe47,'>Clinical Pharmacology </a><a href=,'#_cd922667-9722-256a-1613-30349ca1fe47,'>(12.3)</a>] </span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_18862f93-b432-5c33-3625-e6c9c21282d1,'></a><a name=,'section-7.6,'></a>
<p></p>
<h2>7.6 Other CNS Depressants</h2>
<p class=,'First,'>The sedative effects of tizanidine with CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants) may be additive. Monitor patients who take tizanidine with another CNS depressant for symptoms of excess sedation <span class=,'Italics,'>[see  <a href=,'#_cd922667-9722-256a-1613-30349ca1fe47,'>Clinical  Pharmacology </a><a href=,'#_cd922667-9722-256a-1613-30349ca1fe47,'>(12.3)</a>] </span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'_bb2c6c07-30ea-e8ca-ccd7-9b489b01b687,'></a><a name=,'section-7.7,'></a>
<p></p>
<h2>
<span class=,'None,'>7.7 α2-adrenergic Agonists</span>
</h2>
<p class=,'First,'>Because hypotensive effects may be cumulative, it is not recommended that tizanidine be used with other α<span class=,'Sub,'>2</span>-adrenergic agonists<span class=,'Italics,'> [see  <a href=,'#_44ccce6d-10b5-9c98-dc49-29d36a3fa54a,'>Warnings and Precautions </a><a href=,'#_44ccce6d-10b5-9c98-dc49-29d36a3fa54a,'>(5.1)</a>]<a href=,'#_7ac72350-606b-4758-21fe-4ed99663f391,'></a>  </span>
</p>
</div>
</div>"
"tobramycin","02b48684-168c-4cd9-8375-794206eff23e","none found"
"tolbutamide","3995eed8-39ec-ce5e-8cc2-062f93445c8d","none found"
"tolterodine","56e62829-5371-416a-90b3-4b6429532d25","none found"
"trandolapril","0107d19a-b43a-4a36-8b8c-4dfc247630e9","none found"
"tranexamic acid","031bf7c2-3b07-469d-bc5a-31fc6238e25f","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>No drug-drug interaction studies were conducted with tranexamic acid USP tablets.</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Combined Hormonal Contraceptives</h2>
<p class=,'First,'>Because tranexamic acid USP tablets are antifibrinolytic, concomitant use of combined hormonal contraception and tranexamic acid USP tablets may increase the thrombotic risk associated with combined hormonal contraceptives. For this reason, concomitant use of tranexamic acid USP tablets with combined hormonal contraceptives is contraindicated <span class=,'Italics,'>[see <a href=,'#Section_4,'>Contraindications (4)</a> and <a href=,'#Section_5.1,'>Warnings and Precautions (5.1)</a></span>].</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Tissue Plasminogen Activators</h2>
<p class=,'First,'>Concomitant therapy with tissue plasminogen activators may decrease the efficacy of both tranexamic acid USP tablets and tissue plasminogen activators. Discontinue tranexamic acid USP tablets if a patient requires tissue plasminogen activators.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Factor IX Complex Concentrates or Anti-Inhibitor Coagulant Concentrates</h2>
<p class=,'First,'>Tranexamic acid USP tablets are not recommended in patients taking either Factor IX complex concentrates or anti-inhibitor coagulant concentrates because the risk of thrombosis may be increased [see <span class=,'Italics,'><a href=,'#Section_5.1,'>Warnings and Precautions (5.1)</a></span>].</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 All-Trans Retinoic Acid (Oral Tretinoin)</h2>
<p class=,'First,'>Tranexamic acid USP tablets are not recommended in patients with acute promyelocytic leukemia taking all-trans retinoic acid for remission induction because of possible exacerbation of the procoagulant effect of all-trans retinoic acid [see <span class=,'Italics,'><a href=,'#Section_5.1,'>Warnings and Precautions (5.1)</a></span>].</p>
</div>
</div>"
"tranylcypromine","8ab1c887-76fb-44ca-9999-4eefd3778cfc","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1	Clinically-Significant Drug Interactions</h2>
<p class=,'First,'>Tables 3 and 4 lists drug classes and individual products, respectively, with a potential for interaction with tranylcypromine tablets, describes the predominant observed or anticipated risks, and provides advice on concomitant use. Given serious adverse reactions with multiple agents, patients should avoid taking over-the-counter medications or dietary supplements without prior consultation with a healthcare provider able to provide advice on the potential for interactions.</p>
<br/>
<p>
<span class=,'Underline,'>T</span><span class=,'Underline,'>ime to Start Tranylcypromine Tablets after Discontinuation of a Contraindicated Drug</span>
</p>
<p>For products that are contraindicated with tranylcypromine tablets, a time period of 4 to 5 half-lives of the other product or any active metabolite should elapse before starting treatment with tranylcypromine tablets. After stopping treatment with an MAO inhibitor antidepressant, a time period of at least 1 week or 4 to 5 half-lives of the other MAO inhibitor (whichever is longer) should elapse before starting treatment with tranylcypromine tablets because of the risk for clinically significant adverse reactions after discontinuation due to persistent MAO inhibition <span class=,'Italics,'>[see Dosage and Administration (2.2), Warnings and Precautions (5.9)]</span>. This period can be several weeks long (e.g., a minimum of 5 weeks for fluoxetine given fluoxetine’s long half-life). Refer to the prescribing information of the contraindicated product for relevant information.</p>
<br/>
<p>
<span class=,'Underline,'>T</span><span class=,'Underline,'>ime to Start Contraindicated Drug after Discontinuation of Tranylcypromine Tablets</span>
</p>
<p>The potential for interactions persists after discontinuation of tranylcypromine tablets until MAO activity has sufficiently recovered. Inhibition of MAO may persist up to 10 days following discontinuation <span class=,'Italics,'>[see Warnings and Precautions (5.9)]</span>. After stopping tranylcypromine tablets, at least 1 week should elapse before starting another MAOI (intended to treat MDD) or other contraindicated antidepressants. Refer to the prescribing information of any agent considered for subsequent use for recommendations on the duration of a waiting period after discontinuation of a MAO inhibitor.</p>
<br/>
<p>If in the absence of therapeutic alternatives and emergency treatment with a contraindicated drug (e.g., linezolid, intravenous methylene blue, direct-acting sympathomimetic drugs such as epinephrine) becomes necessary and cannot be delayed, discontinue tranylcypromine tablets as soon as possible before initiating treatment with the other agent, and monitor closely for adverse reactions.</p>
<p> Table 3: Clinically Significant Drug Interactions with Drug Classes* </p>
<div class=,'scrollingtable,'><table border=,'0,' cellpadding=,'0,' cellspacing=,'0,' width=,'656.2885,'>
<colgroup>
<col width=,'33.4279055628736%,'/>
<col width=,'28.452730773128%,'/>
<col width=,'38.1193636639984%,'/>
</colgroup>
<tbody class=,'Headless,'>
<tr class=,'Botrule First,'>
<td align=,'center,' class=,'Lrule Rrule,' valign=,'middle,'> <span class=,'Bold,'>P</span><span class=,'Bold,'>r</span><span class=,'Bold,'>oduct</span>
<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'>  <br/> <span class=,'Bold,'>C</span><span class=,'Bold,'>linical Comment on Concomitant Usea</span>
<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> <span class=,'Bold,'>P</span><span class=,'Bold,'>r</span><span class=,'Bold,'>e</span><span class=,'Bold,'>dominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c]</span>
<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'> Agents with blood pressure-reducing effects<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Use with cautiond<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Hypotensione<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'> Non-selective H1 receptor antagonists<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Contraindicateda<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Increased anticholinergic effects<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'> Beta-adrenergic blockers (see also agents or procedures with blood pressure-reducing effects)<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Use with cautiond<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> More pronounced bradycardia, postural<br/> hypotensione<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'>  <br/> Blood glucose-lowering agents<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Dosage reduction of such agents may be necessary. Monitor blood glucose.<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Excessive reduction of blood glucose (additive effect)f<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'> CNS depressant agents (including opioids, alcohol, sedatives, hypnotics)<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Use with cautiond<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Increased CNS depression<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'> Dietary supplements containing<br/> sympathomimetics<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Contraindicateda<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'>  <br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'> Antidepressants including but not limited to:<br/> <ul class=,'Disc,'>
<li>Other MAOIs (e.g., linezolid, intravenous methylene blue, selective MAOIs) <br/>
</li>
<li>Selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) <br/>
</li>
<li>Tricyclic antidepressants <br/>
</li>
<li>Amoxapine, bupropion, maprotiline, nefazodone, trazodone, vilazodone, vortioxetine</li>
</ul> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Contraindicateda<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> SS for all antidepressants<br/> For MAOIs, increased MAO inhibition and risk of adverse reactions, SS, and HRg<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'> Amphetamines and methylphenidates andderivatives<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Contraindicateda<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> HR<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'> Sympathomimetic drugs**<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Contraindicateda<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> HR; Including risk of intracerebral<br/> hemorrhage<br/> </td>
</tr>
<tr class=,'Last,'>
<td class=,'Lrule Rrule,' valign=,'middle,'> Triptans<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Contraindicateda<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> SS<br/> </td>
</tr>
</tbody>
</table></div>
<p>* Some drugs in these groups may also be listed in Table 4 below.</p>
<p>** Sympathomimetic drugs include amphetamines as well as cold, hay fever or weight-reducing products that contain vasoconstrictors such as pseudoephedrine, phenylephrine, and ephedrine)</p>
<p>a   <span class=,'Italics,'>[S</span><span class=,'Italics,'>ee Contraindications (4.1)]; </span>b<span class=,'Italics,'> </span><span class=,'Italics,'>[S</span><span class=,'Italics,'>ee Warnings and Precautions (5.2)]; </span>c <span class=,'Italics,'>[</span><span class=,'Italics,'>S</span><span class=,'Italics,'>ee Warnings and Precautions (5.3)]</span>
</p>
<p>
<span class=,'Sup,'>d</span> If not otherwise specified in this table, consider avoiding concomitant use (see also information on medication-free intervals, use agent at the lowest appropriate dosage, monitor for effects of the interaction, advise the patient to report potential effects).</p>
<p>
<span class=,'Sup,'>e</span><span class=,'Italics,'> [S</span><span class=,'Italics,'>ee Warnings and Precautions (5.5)]; </span>f   <span class=,'Italics,'>[S</span><span class=,'Italics,'>ee Warnings and Precautions (5.14)]; </span>g <span class=,'Italics,'>[S</span><span class=,'Italics,'>ee Overdosage (10.1)]</span>
</p>
<br/>
<p>Table 4: Clinically Significant Drug Interactions with Individual Products*</p>
<br/>
<p>                                                                                                                                              </p>
<div class=,'scrollingtable,'><table border=,'0,' cellpadding=,'0,' cellspacing=,'0,' width=,'645.582,'>
<colgroup>
<col width=,'31.7161104243923%,'/>
<col width=,'30.5830243098475%,'/>
<col width=,'37.7008652657602%,'/>
</colgroup>
<tbody class=,'Headless,'>
<tr class=,'Botrule First,'>
<td align=,'center,' class=,'Lrule Rrule,' valign=,'top,'>  <br/> <span class=,'Bold,'>P</span><span class=,'Bold,'>r</span><span class=,'Bold,'>oduct</span>
<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'>  <br/> <span class=,'Bold,'>C</span><span class=,'Bold,'>linical Comment on Concomitant Usea</span>
<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <span class=,'Bold,'>P</span><span class=,'Bold,'>r</span><span class=,'Bold,'>e</span><span class=,'Bold,'>dominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c]</span>
<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Altretamine<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Use with cautiond<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Orthostatic hypotensione<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Buspirone<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Contraindicateda<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> HR<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Carbamazepine<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Contraindicateda<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> SS<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Chlorpromazine<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Use with cautiond<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Hypotensive effectse<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Cyclobenzaprine<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Contraindicateda<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> SS<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Dextromethorphan<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Contraindicateda<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> SS; Psychosis, bizarre behavior<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Dopamine<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Contraindicateda<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> HR<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Droperidol<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Use with cautiond<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> QT interval prolongation<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Entacapone<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Use with cautiond<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> HR<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Fentanyl<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Use with cautiond<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> SS<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Hydroxytryptophan<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Contraindicateda<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> SS<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Levodopa<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Contraindicateda<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> HR<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Lithium<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Use with cautiond<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> SS<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Meperidine<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Contraindicateda<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> SS<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Methadone<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Use with cautiond<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> SS<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Methyldopa<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Contraindicateda<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> HR<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Metoclopramide<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Use with cautiond<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> HR/SS<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Mirtazapine<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Contraindicateda<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> SS<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'>  <br/> Oxcarbazepine<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Use with cautiond because of<br/> close structural relationship with tricyclic antidepressants<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> SS<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Rasagiline<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Contraindicateda<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> HR<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Reserpine<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Contraindicateda<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> HR<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> S-adenosyl-L-methionine (SAM-e)<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Contraindicateda<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> SS<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Tapentadol<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Contraindicateda<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> HR/SS<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Tetrabenazine<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Contraindicateda<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> HR<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Tolcapone<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Use with cautiond<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> HR<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Tramadol<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Use with cautiond<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> SS; Increased seizure risk<br/> </td>
</tr>
<tr class=,'Last,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Tryptophan<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> Contraindicateda<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> SS<br/> </td>
</tr>
</tbody>
</table></div>
<p>* Some drugs in this table may also belong to groups listed in Table 3 above, and may be associated with additional</p>
<p>interactions.</p>
<p>a   <span class=,'Italics,'>[S</span><span class=,'Italics,'>ee Contraindications (4.1)]; </span>b <span class=,'Italics,'>[S</span><span class=,'Italics,'>ee Warnings and Precautions (5.3)]; </span>c <span class=,'Italics,'>[</span><span class=,'Italics,'>S</span><span class=,'Italics,'>ee Warnings and Precautions (5.7)]</span>
</p>
<p>
<span class=,'Sup,'>d</span> If not otherwise specified in this table, consider avoiding concomitant use (see also information on medication-free intervals, use agent at the lowest appropriate dose, monitor for effects of the interaction, advise the patient to report potential effects, and be prepared to discontinue the agent and treat effects of the interaction</p>
<p>
<span class=,'Sup,'>e</span><span class=,'Italics,'> [S</span><span class=,'Italics,'>ee Warnings and Precautions (5.5)<br/>
</span>
</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2	Tyramine-Containing Foods and Beverages</h2>
<p class=,'First,'>Tranylcypromine tablets inhibits intestinal MAO, which is responsible for the catabolism of tyramine in food and beverages. As a result of this inhibition, large amounts of tyramine may enter the systemic circulation and precipitate a sudden elevation in blood pressure or hypertensive crisis <span class=,'Italics,'>[see Warnings and Precautions (5.2)]</span>. Instruct tranylcypromine tablet-treated patients to avoid foods and beverages with significant tyramine content during treatment with tranylcypromine tablets or within 2 weeks of stopping treatment (see Table 5 for a list of food and beverages containing significant amounts of tyramine).</p>
<p> Table 5: Foods and Beverages with and without Significant Amounts of Tyramine </p>
<br/>
<br/>
<p>                                </p>
<div class=,'scrollingtable,'><table border=,'0,' cellpadding=,'0,' cellspacing=,'0,' width=,'638,'>
<colgroup>
<col width=,'14.9107236086457%,'/>
<col width=,'52.6260833246319%,'/>
<col width=,'32.4631930667224%,'/>
</colgroup>
<tbody class=,'Headless,'>
<tr class=,'Botrule First,'>
<td align=,'center,' class=,'Lrule Rrule,' valign=,'middle,'> <span class=,'Bold,'>C</span><span class=,'Bold,'>lass of</span>
<br/> <span class=,'Bold,'>F</span><span class=,'Bold,'>ood or Beverage</span>
<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> <span class=,'Bold,'>Tyramine-Rich Foods and Beverages to Avoid</span>
<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> <span class=,'Bold,'>Acce</span><span class=,'Bold,'>ptable Foods and</span>
<br/> <span class=,'Bold,'>Dr</span><span class=,'Bold,'>inks, Containing No or Little Tyramine</span>
<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'> Meat, Poultry, and Fish<br/> </td><td class=,'Rrule,' valign=,'middle,'> Air dried, aged and fermented meats, sausages and salamis (including cacciatore, hard salami and mortadella); pickled herring; and any spoiled or improperly stored meat, poultry, and fish (e.g., foods that have undergone changes in coloration, odor, or become moldy); spoiled or improperly stored animal livers<br/> </td><td class=,'Rrule,' valign=,'middle,'> Fresh meat, poultry, and fish, including fresh processed meats (e.g., lunch meats, hot dogs, breakfast sausage, and cooked sliced ham)<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'> Vegetables<br/> </td><td class=,'Rrule,' valign=,'middle,'> Broad bean pods (fava bean pods)<br/> </td><td class=,'Rrule,' valign=,'middle,'> All other vegetables<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'> Dairy<br/> </td><td class=,'Rrule,' valign=,'middle,'> Aged cheeses<br/> </td><td class=,'Rrule,' valign=,'middle,'> Processed cheeses, mozzarella,<br/> ricotta cheese, cottage cheese, and yogurt<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'> Beverages<br/> </td><td class=,'Rrule,' valign=,'middle,'> All varieties of tap beer and beers that have not been pasteurized so as to allow for ongoing fermentation and excessive amounts of caffeine.<br/> </td><td class=,'Rrule,' valign=,'middle,'> Concomitant use of alcohol with tranylcypromine tablets is not recommended. (Bottled and canned beers and wines contain little or no tyramine.)<br/> </td>
</tr>
<tr class=,'Last,'>
<td class=,'Lrule Rrule,' valign=,'middle,'> Other<br/> </td><td class=,'Rrule,' valign=,'middle,'> Concentrated yeast extract (e.g., Marmite), sauerkraut, most soybean products (including soy sauce and tofu), OTC supplements containing tyramine, and chocolate<br/> </td><td class=,'Rrule,' valign=,'middle,'> Brewer’s yeast, baker’s yeast, soy milk, commercial chain restaurant pizzas prepared with cheeses low in tyramine<br/> </td>
</tr>
</tbody>
</table></div>
</div>
</div>"
"trastuzumab","9a94f5b2-b84e-4987-8ea1-c4346db5a5fa","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'_7_DRUG_INTERACTIONS,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Patients who receive anthracycline after stopping trastuzumab products may be at increased risk of cardiac dysfunction because of trastuzumab's long washout period based on population PK analysis <span class=,'Italics,'>[see Clinical Pharmacology (</span><span class=,'Italics,'><a href=,'#_12_3_Pharmacokinetics,'>12.3</a></span><span class=,'Italics,'>)]</span>. If possible, physicians should avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab products. If anthracyclines are used, the patient's cardiac function should be monitored carefully.</p>
</div>"
"ado-trastuzumab emtansine","23f3c1f4-0fc8-4804-a9e3-04cf25dd302e","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>No formal drug-drug interaction studies with KADCYLA have been conducted.  <span class=,'Italics,'>In vitro</span> studies indicate that DM1, the cytotoxic component of KADCYLA, is metabolized mainly by CYP3A4 and to a lesser extent by CYP3A5.  Concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole) with KADCYLA should be avoided due to the potential for an increase in DM1 exposure and toxicity.  Consider an alternate medication with no or minimal potential to inhibit CYP3A4.  If concomitant use of strong CYP3A4 inhibitors is unavoidable, consider delaying KADCYLA treatment until the strong CYP3A4 inhibitors have cleared from the circulation (approximately 3 elimination half-lives of the inhibitors) when possible.  If a strong CYP3A4 inhibitor is coadministered and KADCYLA treatment cannot be delayed, patients should be closely monitored for adverse reactions. </p>
</div>"
"travoprost","98fb77b8-ee41-e2fc-7bcd-bc350e19cc10","none found"
"trazodone","17b3356e-458d-47f6-89a5-80828ab48d4c","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_55ae044f-c54f-4ef9-8140-ec3e39c79d70,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_bb96d749-c24b-43ff-bd3a-473629962fee,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Drugs Having
Clinically Important Interactions with Trazodone Hydrochloride Tablets</h2>
<div class=,'scrollingtable,'><table border=,'1,' cellpadding=,'0,' cellspacing=,'0,'>
<col width=,'275.4pt,'/>
<col width=,'275.4pt,'/>
<tbody class=,'Headless,'>
<tr class=,'First,'>
<td colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>Table 3: Clinically Important Drug Interactions with Trazodone Hydrochloride Tablets</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,' colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>Monoamine Oxidase Inhibitors (MAOIs)</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>Clinical Impact:</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>The concomitant use of MAOIs and serotonergic drugs including trazodone hydrochloride tablets increases the risk of serotonin syndrome.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>Intervention:</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Trazodone hydrochloride tablets are contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue 
             
     
      <span class=,'Italics,'>[see Contraindications (4), Dosage and Administration (
              
      
       <a href=,'#LINK_40c5a17c-95d0-4f42-bffd-6bf157ea780f,'>2.3</a>, 
              
      
       <a href=,'#LINK_77b77a37-87e4-46df-b647-60a3269eae55,'>2.4</a>), and Warnings and Precautions (
              
      
       <a href=,'#LINK_cf379c06-28c2-4b63-88e2-3a7399713a96,'>5.2</a>)].
             
     
      </span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>Examples:</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>isocarboxazid, moclobemide, phenelzine, selegiline, tranylcypromine</p>
</td>
</tr>
<tr>
<td class=,'Toprule,' colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>Other Serotonergic Drugs</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>Clinical Impact:</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>The concomitant use of serotonergic drugs including trazodone hydrochloride tablets and other serotonergic drugs increases the risk of serotonin syndrome.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>Intervention:</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Monitor patients for signs and symptoms of serotonin syndrome, particularly during trazodone hydrochloride tablets initiation. If serotonin syndrome occurs, consider discontinuation of trazodone hydrochloride tablets and/or concomitant serotonergic drugs 
             
     
      <span class=,'Italics,'>[see Warnings and Precautions (
              
      
       <a href=,'#LINK_cf379c06-28c2-4b63-88e2-3a7399713a96,'>5.2</a>)].
             
     
      </span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>Examples:</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort</p>
</td>
</tr>
<tr>
<td class=,'Toprule,' colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>Antiplatelet Agents and Anticoagulants</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>Clinical Impact:</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Serotonin release by platelets plays an important role in hemostasis. The concurrent use of an antiplatelet agent or anticoagulant with trazodone hydrochloride tablets may potentiate the risk of bleeding.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>Intervention:</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Inform patients of the increased risk of bleeding with the concomitant use of trazodone hydrochloride tablets and antiplatelet agents and anticoagulants. For patients taking warfarin, carefully monitor the international normalized ratio (INR) when initiating or discontinuing trazodone hydrochloride tablets 
             
     
      <span class=,'Italics,'>[see Warnings and Precautions (
              
      
       <a href=,'#LINK_5d72156d-3bc6-43d3-b33a-67cd23ee7df0,'>5.5</a>)].
             
     
      </span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>Examples:</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>warfarin, rivaroxaban, dabigatran, clopidogrel</p>
</td>
</tr>
<tr>
<td class=,'Toprule,' colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>Strong CYP3A4 Inhibitors</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>Clinical Impact:</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>The concomitant use of trazodone hydrochloride tablets and strong CYP3A4 inhibitors increased the exposure of trazodone compared to the use of trazodone hydrochloride tablets alone.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>Intervention:</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>If trazodone hydrochloride tablets is used with a potent CYP3A4 inhibitor, the risk of adverse reactions, including cardiac arrhythmias, may be increased and a lower dose of trazodone hydrochloride tablets should be considered 
             
     
      <span class=,'Italics,'>[see Dosage and Administration (
              
      
       <a href=,'#LINK_a66e887a-1337-4a57-835f-df5e90328c7c,'>2.5</a>), Warnings and Precautions (
              
      
       <a href=,'#LINK_6c1e72cb-ecde-4b71-bb86-b63255e5a83e,'>5.3</a>)].
             
     
      </span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>Examples:</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>itraconazole, ketoconazole, clarithromycin, indinavir</p>
</td>
</tr>
<tr>
<td class=,'Toprule,' colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>Strong CYP3A4 Inducers</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>Clinical Impact:</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>The concomitant use of trazodone hydrochloride tablets and strong CYP3A4 inducers decreased the exposure of trazodone compared to the use of trazodone hydrochloride tablets alone.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>Intervention:</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Patients should be closely monitored to see if there is a need for an increased dose of trazodone hydrochloride tablets when taking CYP3A4 inducers 
             
     
      <span class=,'Italics,'>[see Dosage and Administration (
              
      
       <a href=,'#LINK_a66e887a-1337-4a57-835f-df5e90328c7c,'>2.5</a>)].
             
     
      </span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>Examples:</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>rifampin, carbamazepine, phenytoin, St. John’s wort</p>
</td>
</tr>
<tr>
<td class=,'Toprule,' colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>Digoxin and Phenytoin</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>Clinical Impact:</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Digoxin and phenytoin are narrow therapeutic index drugs. Concomitant use of trazodone hydrochloride tablets can increase digoxin or phenytoin concentrations.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>Intervention:</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Measure serum digoxin or phenytoin concentrations before initiating concomitant use of trazodone hydrochloride tablets. Continue monitoring and reduce digoxin or phenytoin dose as necessary.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>Examples:</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>digoxin, phenytoin</p>
</td>
</tr>
<tr>
<td class=,'Toprule,' colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>Central Nervous System (CNS) Depressants</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>Clinical Impact:</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Trazodone hydrochloride tablets may enhance the response CNS depressants.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>Intervention:</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Patients should be counseled that trazodone hydrochloride tablets may enhance the response to alcohol, barbiturates, and other CNS depressants.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>Examples:</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>alcohol, barbiturates</p>
</td>
</tr>
<tr>
<td class=,'Toprule,' colspan=,'2,'>
<p class=,'First,'>
<span class=,'Bold,'>QT Interval Prolongation</span>
</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>Clinical Impact:</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Concomitant use of drugs that prolong the QT interval may add to the QT effects of trazodone hydrochloride tablets and increase the risk of cardiac arrhythmia.</p>
</td>
</tr>
<tr>
<td class=,'Toprule,'>
<p class=,'First,'>Intervention:</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Avoid the use of trazodone hydrochloride tablets in combination with other drugs known to prolong QTc 
             
     
      <span class=,'Italics,'>[see Warnings and Precautions (
              
      
       <a href=,'#LINK_6c1e72cb-ecde-4b71-bb86-b63255e5a83e,'>5.3</a>)].
             
     
      </span>
</p>
</td>
</tr>
<tr class=,'Last,'>
<td class=,'Toprule,'>
<p class=,'First,'>Examples:</p>
</td><td class=,'Lrule Toprule,'>
<p class=,'First,'>Class 1A antiarrhythmics: quinidine, procainamide, disopyramide; Class 3 antiarrhythmics: amiodarone, sotalol; Antipsychotics: ziprasidone, chlorpromazine, thioridazine; Antibiotics: gatifloxacin</p>
</td>
</tr>
</tbody>
</table></div>
<br/>
</div>
</div>"
"tretinoin","045258e2-5efb-4147-bf74-4c43af04dccc","none found"
"triamcinolone","063728a5-87b5-4b53-957a-d8e497fcf8b0","none found"
"triazolam","12c0c495-a032-382e-9b04-37018090cad0","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID_37ccd330-7b6a-44d1-8b42-df4b9f954476,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_cf0d47d1-5fe0-4111-9fb4-1785c8852a82,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Drugs Having Clinically Important Interactions with Triazolam </h2>
<p class=,'First,'>Table 2 includes clinically significant drug interactions with triazolam <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#ID_2552e810-f8d5-4f93-8300-d6dcf092c4a5,'>12.3</a>)].</span>
</p>
<div class=,'scrollingtable,'><table width=,'100%,'>
<caption>
<span>Table 2: Clinically Important Drug Interactions with Triazolam</span>
</caption>
<col width=,'25%,'/>
<col width=,'75%,'/>
<tbody class=,'Headless,'>
<tr class=,'First,'>
<td class=,'Botrule Lrule Rrule Toprule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Opioids</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical implication</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABA<span class=,'Sub,'>A</span> sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Prevention or management</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Limit dosage and duration of concomitant use of triazolam and opioids, and monitor patients closely for respiratory depression and sedation <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#ID_e29b6b58-6fe4-4c0c-a0b0-d6133402e278,'>5.1</a>)].</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Examples</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorphanol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>CNS Depressants</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical implication</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Triazolam produces additive CNS depressant effects when co-administered with other CNS depressants.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Prevention or management</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Limit dosage and duration of triazolam during concomitant use with CNS depressants.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Examples</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Psychotropic medications, anticonvulsants, antihistamines, ethanol, and other drugs which themselves produce CNS depression.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Strong Inhibitors of CYP 3A</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical implication</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Concomitant use of triazolam with strong CYP3A inhibitors has a profound effect on the clearance of triazolam, resulting in increased concentrations of triazolam and increased risk of adverse reactions <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#ID_2552e810-f8d5-4f93-8300-d6dcf092c4a5,'>12.3</a>)].</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Prevention or management</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Do not administer triazolam with a strong CYP3A4 inhibitor <span class=,'Italics,'>[see Contraindications (<a href=,'#ID_8352c5dd-6953-4d75-880b-7d0e19a1f2ee,'>4</a>), Warnings and Precautions (<a href=,'#ID_d0535e2c-d372-4d2c-89f8-22d21333892c,'>5.7</a>)].</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Examples</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Ketoconazole, clarithromycin, grapefruit juice, itraconazole, nefazodone, and several HIV protease inhibitors (e.g. ritonavir, indinavir, nelfinavir, saquinavir and lopinavir).</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Moderate and Weak Inhibitors of CYP 3A</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical implication</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Concomitant use of triazolam with moderate or weak inhibitors of CYP3A inhibitors may increase the concentrations of triazolam, resulting in increased risk of adverse reactions <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#ID_2552e810-f8d5-4f93-8300-d6dcf092c4a5,'>12.3</a>)].</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Prevention or management</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Use with caution and consider appropriate dose reduction of triazolam when coadministered with moderate and weak CYP3A inhibitors <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#ID_d0535e2c-d372-4d2c-89f8-22d21333892c,'>5.7</a>)].</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Examples</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Macrolide antibiotics (such as erythromycin), cimetidine, isoniazid, oral contraceptives, ranitidine.</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' colspan=,'2,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Bold,'>Interactions Based on Experience with Other Benzodiazepines or <span class=,'Italics,'>in vitro</span> Studies with Triazolam</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Clinical implication</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Available data from clinical studies of benzodiazepines other than triazolam, from <span class=,'Italics,'>in vitro</span> studies with triazolam, or from <span class=,'Italics,'>in vitro</span> studies with benzodiazepines other than triazolam suggest a possible drug interaction with triazolam <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#ID_2552e810-f8d5-4f93-8300-d6dcf092c4a5,'>12.3</a>)].</span>
</p>
</td>
</tr>
<tr>
<td class=,'Botrule Lrule Rrule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Prevention or management</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Caution is recommended during coadministration of triazolam with any of these drugs. <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#ID_d0535e2c-d372-4d2c-89f8-22d21333892c,'>5.7</a>)].</span>
</p>
</td>
</tr>
<tr class=,'Last,'>
<td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>
<span class=,'Italics,'>Examples</span>
</p>
</td><td class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>
<p class=,'First,'>Fluvoxamine, diltiazem, verapamil, sertraline, paroxetine, ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.  </p>
</td>
</tr>
</tbody>
</table></div>
</div>
</div>"
"trifluoperazine","c7961b19-3f23-4372-b071-34423124d801","none found"
"trihexyphenidyl","1d6f628c-8553-4117-970f-e40a2f048be9","none found"
"trimethoprim","249e938d-f181-47c4-a082-372d65462f33","none found"
"trimipramine","4f31df66-7dc2-1f04-e054-00144ff88e88","none found"
"triptorelin","f41380e7-b830-432d-a5f5-a872932f107e","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Drug-Drug Interactions</h2>
<p class=,'First,'>Results of <span class=,'Italics,'>in vitro</span> studies show that drug-drug interactions with triptorelin are unlikely <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>. However, in the absence of relevant data and as a precaution, hyperprolactinemic drugs should not be used concomitantly with triptorelin since hyperprolactinemia reduces the number of pituitary GnRH receptors.</p>
</div>
<div class=,'Section,' data-sectioncode=,'34074-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Drug-Laboratory Test Interactions</h2>
<p class=,'First,'>Administration of TRIPTODUR results in suppression of the pituitary-gonadal system.</p>
<p>The effect of TRIPTODUR on pituitary and gonadal function is expected to disappear within six to twelve months after treatment discontinuation. Therefore, diagnostic tests of pituitary gonadotropic and gonadal functions conducted during treatment or after discontinuation of treatment may be affected.</p>
</div>
</div>"
"tropicamide","002e4f96-7a74-4501-8b81-dc6f092c807a","none found"
"trospium","11367381-62c6-4a8c-84c7-031dd75372e2","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Lccc6fa3b-c783-40e8-830c-596c1db4e2c4,'></a><a name=,'section-7,'></a>
<p></p>
<h1></h1>
<p class=,'First,'></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'L318fe49d-a3f6-4a29-a24c-04d31b8f3ab3,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Digoxin</h2>
<p class=,'First,'>Concomitant use of trospium chloride and digoxin did not affect the pharmacokinetics of either drug [<span class=,'Italics,'>see <a href=,'#Lf451cd9c-7f75-4a6b-8572-99e43280e5da,'>Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'L341cfe3d-04eb-44c1-9b8d-55bebe0484f6,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Drugs Eliminated by Active Tubular Secretion</h2>
<p class=,'First,'>Although demonstrated in a drug-drug interaction study not to affect the pharmacokinetics of digoxin, trospium chloride has the  potential for pharmacokinetic  interactions with other drugs that are eliminated by active tubular secretion (e.g., procainamide, pancuronium, morphine, vancomycin, and tenofovir). Coadministration of trospium chloride with these drugs may increase the serum concentration of trospium chloride and/or the coadministered drug due to competition for this elimination pathway. Careful patient monitoring is recommended in patients receiving such drugs [<span class=,'Italics,'>see </span><span class=,'Italics,'>Clinical Pharmacology (12.3)</span>].</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'L9b5dfdc0-6635-445e-acf6-4c7e592c3362,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Antimuscarinic Agents</h2>
<p class=,'First,'>The concomitant use of trospium chloride with other antimuscarinic agents that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects. Trospium chloride may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Ld6061673-7760-4ecc-b807-ee63093bc02a,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Metformin</h2>
<p class=,'First,'>Co-administration of 500 mg metformin immediate release tablets twice daily with trospium chloride 60 mg extended release reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC0-24 and by 34% for mean Cmax [<span class=,'Italics,'>see</span><span class=,'Italics,'></span><span class=,'Italics,'>Clinical Pharmacology (12.3)</span>].</p>
</div>
</div>"
"trospium chloride","11367381-62c6-4a8c-84c7-031dd75372e2","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Lccc6fa3b-c783-40e8-830c-596c1db4e2c4,'></a><a name=,'section-7,'></a>
<p></p>
<h1></h1>
<p class=,'First,'></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'L318fe49d-a3f6-4a29-a24c-04d31b8f3ab3,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Digoxin</h2>
<p class=,'First,'>Concomitant use of trospium chloride and digoxin did not affect the pharmacokinetics of either drug [<span class=,'Italics,'>see <a href=,'#Lf451cd9c-7f75-4a6b-8572-99e43280e5da,'>Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'L341cfe3d-04eb-44c1-9b8d-55bebe0484f6,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Drugs Eliminated by Active Tubular Secretion</h2>
<p class=,'First,'>Although demonstrated in a drug-drug interaction study not to affect the pharmacokinetics of digoxin, trospium chloride has the  potential for pharmacokinetic  interactions with other drugs that are eliminated by active tubular secretion (e.g., procainamide, pancuronium, morphine, vancomycin, and tenofovir). Coadministration of trospium chloride with these drugs may increase the serum concentration of trospium chloride and/or the coadministered drug due to competition for this elimination pathway. Careful patient monitoring is recommended in patients receiving such drugs [<span class=,'Italics,'>see </span><span class=,'Italics,'>Clinical Pharmacology (12.3)</span>].</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'L9b5dfdc0-6635-445e-acf6-4c7e592c3362,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Antimuscarinic Agents</h2>
<p class=,'First,'>The concomitant use of trospium chloride with other antimuscarinic agents that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects. Trospium chloride may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Ld6061673-7760-4ecc-b807-ee63093bc02a,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Metformin</h2>
<p class=,'First,'>Co-administration of 500 mg metformin immediate release tablets twice daily with trospium chloride 60 mg extended release reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC0-24 and by 34% for mean Cmax [<span class=,'Italics,'>see</span><span class=,'Italics,'></span><span class=,'Italics,'>Clinical Pharmacology (12.3)</span>].</p>
</div>
</div>"
"ulipristal","04bb31a9-1682-4941-a7cb-a6526d226776","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_85969015-6b96-4b8e-929c-826857efddca,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Several <span class=,'Italics,'>in vivo</span> drug interaction studies have shown that <span class=,'Bold,'>ella</span> is predominantly metabolized by CYP3A4.</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_f4840aa5-c57c-43f0-bc0c-fa5ff110f1ba,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Changes in Emergency Contraceptive Effectiveness Associated with Co-Administration of Other Products</h2>
<p class=,'First,'>Drugs or herbal products that induce CYP3A4 decrease the plasma concentrations of <span class=,'Bold,'>ella</span>, and may decrease its effectiveness <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#Leec548f8-0513-44ef-b934-cd0decd16c9a,'>5.4</a>) and</span><span class=,'Italics,'> Pharmacokinetics (<a href=,'#LINK_aad5d722-ff2f-4387-aff1-9c1a2f271e34,'>12.3</a>)]</span>. Avoid co-administration of <span class=,'Bold,'>ella</span> and drugs or herbal products such as:</p>
<ul class=,'Disk,'>
<li>barbiturates</li>
<li>bosentan</li>
<li>carbamazepine</li>
<li>felbamate</li>
<li>griseofulvin</li>
<li>oxcarbazepine</li>
<li>phenytoin</li>
<li>rifampin</li>
<li>St. John's Wort</li>
<li>topiramate</li>
</ul>
<p>Hormonal contraceptives: Progestin-containing contraceptives may impair the ability of <span class=,'Bold,'>ella</span> to delay ovulation <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#LINK_94c46528-93c6-49a5-aef1-3597044978d2,'>5.5</a>) and Pharmacodynamics (<a href=,'#LINK_fbdee23c-a48e-4acf-96b3-7d2f1fb5134c,'>12.2</a>)]</span>. Avoid co-administration of <span class=,'Bold,'>ella </span>and hormonal contraceptives. If a woman wishes to start or resume hormonal contraception after the intake of <span class=,'Bold,'>ella</span>, she should do so no sooner than 5 days afterwards, and she should use a reliable barrier method until the next menstrual period.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_ae6239bb-dddd-4680-b332-a28ca53e9ef3,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Increase in Plasma Concentrations of <span class=,'Bold,'>ella</span> Associated with Co-Administered Drugs</h2>
<p class=,'First,'>CYP3A4 inhibitors such as itraconazole or ketoconazole increase plasma concentrations of <span class=,'Bold,'>ella</span><span class=,'Italics,'> [see Pharmacokinetics (<a href=,'#LINK_aad5d722-ff2f-4387-aff1-9c1a2f271e34,'>12.3</a>)]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_0c8c9f93-e7cf-4a30-8f0d-8f0e469e05ed,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Effects of <span class=,'Bold,'>ella </span>on Co-Administered Drugs</h2>
<p class=,'First,'>Hormonal contraceptives: <span class=,'Bold,'>ella</span> may impact the effect of the progestin component of hormonal contraceptives. Therefore, if a woman wishes to use hormonal contraception after using <span class=,'Bold,'>ella</span>, she should use a reliable barrier method for subsequent acts of intercourse until her next menstrual period <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#LINK_94c46528-93c6-49a5-aef1-3597044978d2,'>5.5</a>) and Clincial Pharmacology(<a href=,'#LINK_fbdee23c-a48e-4acf-96b3-7d2f1fb5134c,'>12.2</a>)]</span>.</p>
</div>
</div>"
"umeclidinium","dbb64747-1505-49d7-9a33-99dd402e96d3","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID_cef0250d-2df5-4124-9f1a-703c628fdd2b,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_3d17baf8-0ef5-48e0-940d-2e173dfee9c6,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Anticholinergics</h2>
<p class=,'First,'>There is potential for an additive interaction with concomitantly used anticholinergic medicines. Therefore, avoid coadministration of INCRUSE ELLIPTA with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects <span class=,'Italics,'>[see Warnings and Precautions (<a href=,'#ID_030bfb9c-9fe6-4025-a2f8-0e8175baac28,'>5.4</a>, <a href=,'#ID_446cb67e-1672-4a50-bdd3-f71829952f26,'>5.5</a>), Adverse Reactions (<a href=,'#ID_922a83f7-1842-4ae4-9516-2ff0e0c6e88f,'>6</a>)]</span>.</p>
</div>
</div>"
"urea","2e1cdb54-949f-4a18-bbec-6265c9b3bbd3","none found"
"valacyclovir","b0e6fa63-7b34-4453-a259-34ffd917f4d7","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_b2465321-22e4-40d8-9600-6bfc321aa046,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>
		     
	No clinically significant drug-drug or drug-food interactions with valacyclovir are known <span class=,'Italics,'>[see </span><span class=,'Italics,'><a href=,'#LINK_af13b12e-7252-4fae-98b7-3c3334d786f4,'>Clinical Pharmacology (12.3)</a></span><span class=,'Italics,'>].</span>
</p>
</div>"
"valganciclovir","39452b74-161d-4525-a0f7-fe486f001513","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>In vivo</span> drug-drug interaction studies were not conducted with valganciclovir. However, because valganciclovir is rapidly and extensively converted to ganciclovir, drug-drug interactions associated with ganciclovir will be expected for Valganciclovir. Drug-drug interaction studies with ganciclovir were conducted in patients with normal renal function. Following concomitant administration of valganciclovir and other renally excreted drugs, patients with impaired renal function may have increased concentrations of ganciclovir and the coadministered drug. Therefore, these patients should be closely monitored for toxicity of ganciclovir and the coadministered drug.
 </p>
<p>Established and other potentially significant drug interactions conducted with ganciclovir are listed in Table 9.
  <br/>
<br/>
<span class=,'Bold,'>Table 9 Established and Other Potentially Significant Drug Interactions with Ganciclovir</span>
</p>
<div class=,'scrollingtable,'><table border=,'0,' cellpadding=,'0,' cellspacing=,'0,'>
<tbody class=,'Headless,'>
<tr class=,'Botrule First,'>
<td align=,'center,' class=,'Lrule Rrule,' valign=,'middle,'>
<br/>
<br/>
<span class=,'Bold,'>Name of the Concomitant
      <br/>
<br/>
			Drug 
     </span></td><td align=,'center,' class=,'Rrule,' valign=,'middle,'>
<br/>
<br/>
<span class=,'Bold,'>Change in the Concentration of
      <br/>
<br/>
			Ganciclovir or Concomitant Drug 
     </span></td><td align=,'center,' class=,'Rrule,' valign=,'middle,'>
<br/>
<br/>
<span class=,'Bold,'>Clinical </span><span class=,'Bold,'>Comment</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' valign=,'middle,'>
<br/>
<br/>
			Imipenem-cilastatin
    </td><td class=,'Rrule,' valign=,'middle,'>Unknown</td><td class=,'Rrule,' valign=,'middle,'>Coadministration with imipenem­cilastatin is not recommended because generalized seizures have been reported in patients who received ganciclovir and imipenemcilastatin</td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'>Cyclosporine or amphotericin B</td><td class=,'Rrule,' valign=,'middle,'>Unknown</td><td class=,'Rrule,' valign=,'middle,'>Monitor renal function when Valganciclovir hydrochloride is coadministered with cyclosporine or amphotericin B because of potential increase in serum creatinine
     <br/>
<br/>
<span class=,'Italics,'>[see 
      <a href=,'#Section_5.2,'>Warningsand Precautions (5.2)</a>]. 
     </span></td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'>Mycophenolate mofetil (MMF)</td><td class=,'Rrule,' valign=,'middle,'>↔ Ganciclovir (in patients with
     <br/>
			normal renal function)
     <br/>
<br/>
			↔ MMF (in patients with normal renal function)
    </td><td align=,'justify,' class=,'Rrule,' valign=,'middle,'>
<br/>
<br/>
			Based on increased risk, patients should be monitored for hematological and renal toxicity.
    </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'>Other drugs associated with myelosuppresion
     <br/>
			or nephrotoxicity (e.g., adriamycin, dapsone,
     <br/>
			doxorubicin, flucytosine, hydroxyurea,
     <br/>
			pentamidine, tacrolimus, trimethoprim/
     <br/>
			sulfamethoxazole, vinblastine, vincristine,
     <br/>
			and zidovudine)
    </td><td class=,'Rrule,' valign=,'middle,'>Unknown</td><td align=,'justify,' class=,'Rrule,' valign=,'middle,'>
<br/>
<br/>
			Because of potential for higher toxicity, coadministration with Valganciclovir hydrochloride should be considered only if the potential benefits are judged to outweigh the risks.
    </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'middle,'>Didanosine</td><td class=,'Rrule,' valign=,'middle,'>↔Ganciclovir
     <br/>
<br/>
			↑ Didanosine
    </td><td align=,'justify,' class=,'Rrule,' valign=,'middle,'>
<br/>
<br/>
			Patients should be closely monitored for didanosine toxicity (e.g., pancreatitis)
    </td>
</tr>
<tr class=,'Last,'>
<td class=,'Lrule Rrule,' valign=,'middle,'>Probenecid</td><td class=,'Rrule,' valign=,'middle,'>↑ Ganciclovir</td><td align=,'justify,' class=,'Rrule,' valign=,'middle,'>
<br/>
<br/>
			Valganciclovir hydrochloride dose may need to be reduced. Monitor for evidence of ganciclovir toxicity.
    </td>
</tr>
</tbody>
</table></div>
<p></p>
<p></p>
</div>"
"valproic acid","002d4c7e-b94e-49b6-8554-0aa0c60d5bde","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Effects of Co-Administered Drugs on Valproate Clearance</h2>
<p class=,'First,'>Drugs that affect the level of expression of hepatic enzymes, particularly those that elevate levels of glucuronosyltransferases, may increase the clearance of valproate. For example, phenytoin, carbamazepine, and phenobarbital (or primidone) can double the clearance of valproate. Thus, patients on monotherapy will generally have longer half-lives and higher concentrations than patients receiving polytherapy with antiepilepsy drugs.</p>
<p>In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation.</p>
<p>Because of these changes in valproate clearance, monitoring of valproate and concomitant drug concentrations should be increased whenever enzyme inducing drugs are introduced or withdrawn.</p>
<p>The following list provides information about the potential for an influence of several commonly prescribed medications on valproate pharmacokinetics. The list is not exhaustive nor could it be, since new interactions are continuously being reported.</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1.1,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Underline,'>Drugs for which a potentially important interaction has been observed</span>
</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1.1.1,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Aspirin</span>
</p>
<p>A study involving the co-administration of aspirin at antipyretic doses (11 to 16 mg/kg) with valproate to pediatric patients (n = 6) revealed a decrease in protein binding and an inhibition of metabolism of valproate. Valproate free fraction was increased 4-fold in the presence of aspirin compared to valproate alone. The β-oxidation pathway consisting of 2-E-valproic acid, 3-OH-valproic acid, and 3-keto valproic acid was decreased from 25% of total metabolites excreted on valproate alone to 8.3% in the presence of aspirin. Caution should be observed if valproate and aspirin are to be co-administered.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1.1.2,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Carbapenem Antibiotics</span>
</p>
<p>A clinically significant reduction in serum valproic acid concentration has been reported in patients receiving carbapenem antibiotics (for example, ertapenem, imipenem, meropenem; this is not a complete list) and may result in loss of seizure control. The mechanism of this interaction is not well understood. Serum valproic acid concentrations should be monitored frequently after initiating carbapenem therapy. Alternative antibacterial or anticonvulsant therapy should be considered if serum valproic acid concentrations drop significantly or seizure control deteriorates <span class=,'Italics,'>[see<a href=,'#S5.14,'> Warnings and Precautions (5.14)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1.1.3,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Felbamate</span>
</p>
<p>A study involving the co-administration of 1200 mg/day of felbamate with valproate to patients with epilepsy (n = 10) revealed an increase in mean valproate peak concentration by 35% (from 86 to 115 mcg/mL) compared to valproate alone. Increasing the felbamate dose to 2400 mg/day increased the mean valproate peak concentration to 133 mcg/mL (another 16% increase). A decrease in valproate dosage may be necessary when felbamate therapy is initiated.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1.1.4,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Rifampin</span>
</p>
<p>A study involving the administration of a single dose of valproate (7 mg/kg) 36 hours after 5 nights of daily dosing with rifampin (600 mg) revealed a 40% increase in the oral clearance of valproate. Valproate dosage adjustment may be necessary when it is co-administered with rifampin.</p>
</div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1.2,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Underline,'>Drugs for which either no interaction or a likely clinically unimportant interaction has been observed </span>
</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1.2.1,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Antacids</span>
</p>
<p>A study involving the co-administration of valproate 500 mg with commonly administered antacids (Maalox, Trisogel, and Titralac - 160 mEq doses) did not reveal any effect on the extent of absorption of valproate.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1.2.2,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Chlorpromazine</span>
</p>
<p>A study involving the administration of 100 to 300 mg/day of chlorpromazine to schizophrenic patients already receiving valproate (200 mg BID) revealed a 15% increase in trough plasma levels of valproate.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1.2.3,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Haloperidol</span>
</p>
<p>A study involving the administration of 6 to 10 mg/day of haloperidol to schizophrenic patients already receiving valproate (200 mg BID) revealed no significant changes in valproate trough plasma levels.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.1.2.4,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Cimetidine and Ranitidine</span>
</p>
<p>Cimetidine and ranitidine do not affect the clearance of valproate.</p>
</div>
</div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Effects of Valproate on Other Drugs</h2>
<p class=,'First,'>Valproate has been found to be a weak inhibitor of some P450 isozymes, epoxide hydrase, and glucuronyltransferases.</p>
<p>The following list provides information about the potential for an influence of valproate co-administration on the pharmacokinetics or pharmacodynamics of several commonly prescribed medications. The list is not exhaustive, since new interactions are continuously being reported.</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.1,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Underline,'>Drugs for which a potentially important valproate interaction has been observed</span>
</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.1.1,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Amitriptyline/Nortriptyline</span>
</p>
<p>Administration of a single oral 50 mg dose of amitriptyline to 15 normal volunteers (10 males and 5 females) who received valproate (500 mg BID) resulted in a 21% decrease in plasma clearance of amitriptyline and a 34% decrease in the net clearance of nortriptyline. Rare postmarketing reports of concurrent use of valproate and amitriptyline resulting in an increased amitriptyline level have been received. Concurrent use of valproate and amitriptyline has rarely been associated with toxicity. Monitoring of amitriptyline levels should be considered for patients taking valproate concomitantly with amitriptyline. Consideration should be given to lowering the dose of amitriptyline/nortriptyline in the presence of valproate.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.1.2,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Carbamazepine/carbamazepine-10,11-Epoxide</span>
</p>
<p>Serum levels of carbamazepine (CBZ) decreased 17% while that of carbamazepine-10,11-epoxide (CBZ-E) increased by 45% upon co-administration of valproate and CBZ to epileptic patients.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.1.3,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Clonazepam</span>
</p>
<p>The concomitant use of valproate and clonazepam may induce absence status in patients with a history of absence type seizures.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.1.4,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Diazepam</span>
</p>
<p>Valproate displaces diazepam from its plasma albumin binding sites and inhibits its metabolism. Co-administration of valproate (1500 mg daily) increased the free fraction of diazepam (10 mg) by 90% in healthy volunteers (n = 6). Plasma clearance and volume of distribution for free diazepam were reduced by 25% and 20%, respectively, in the presence of valproate. The elimination half-life of diazepam remained unchanged upon addition of valproate.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.1.5,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Ethosuximide</span>
</p>
<p>Valproate inhibits the metabolism of ethosuximide. Administration of a single ethosuximide dose of 500 mg with valproate (800 to 1600 mg/day) to healthy volunteers (n=6) was accompanied by a 25% increase in elimination half-life of ethosuximide and a 15% decrease in its total clearance as compared to ethosuximide alone. Patients receiving valproate and ethosuximide, especially along with other anticonvulsants, should be monitored for alterations in serum concentrations of both drugs.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.1.6,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Lamotrigine</span>
</p>
<p>In a steady-state study involving 10 healthy volunteers, the elimination half-life of lamotrigine increased from 26 to 70 hours with valproate co-administration (a 165% increase). The dose of lamotrigine should be reduced when co-administered with valproate. Serious skin reactions (such as Stevens-Johnson Syndrome and toxic epidermal necrolysis) have been reported with concomitant lamotrigine and valproate administration. See lamotrigine package insert for details on lamotrigine dosing with concomitant valproate administration.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.1.7,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Phenobarbital</span>
</p>
<p>Valproate was found to inhibit the metabolism of phenobarbital. Co-administration of valproate (250 mg BID for 14 days) with phenobarbital to normal subjects (n = 6) resulted in a 50% increase in half-life and a 30% decrease in plasma clearance of phenobarbital (60 mg single-dose). The fraction of phenobarbital dose excreted unchanged increased by 50% in presence of valproate.</p>
<p>There is evidence for severe CNS depression, with or without significant elevations of barbiturate or valproate serum concentrations. All patients receiving concomitant barbiturate therapy should be closely monitored for neurological toxicity. Serum barbiturate concentrations should be obtained, if possible, and the barbiturate dosage decreased, if appropriate.</p>
<p>Primidone, which is metabolized to a barbiturate, may be involved in a similar interaction with valproate.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.1.8,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Phenytoin</span>
</p>
<p>Valproate displaces phenytoin from its plasma albumin binding sites and inhibits its hepatic metabolism. Co-administration of valproate (400 mg TID) with phenytoin (250 mg) in normal volunteers (n = 7) was associated with a 60% increase in the free fraction of phenytoin. Total plasma clearance and apparent volume of distribution of phenytoin increased 30% in the presence of valproate. Both the clearance and apparent volume of distribution of free phenytoin were reduced by 25%.</p>
<p>In patients with epilepsy, there have been reports of breakthrough seizures occurring with the combination of valproate and phenytoin. The dosage of phenytoin should be adjusted as required by the clinical situation.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.1.9,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Tolbutamide</span>
</p>
<p>From <span class=,'Italics,'>in vitro </span>experiments, the unbound fraction of tolbutamide was increased from 20% to 50% when added to plasma samples taken from patients treated with valproate. The clinical relevance of this displacement is unknown.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.1.10,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Warfarin</span>
</p>
<p>In an <span class=,'Italics,'>in vitro </span>study, valproate increased the unbound fraction of warfarin by up to 32.6%. The therapeutic relevance of this is unknown; however, coagulation tests should be monitored if valproate therapy is instituted in patients taking anticoagulants.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.1.11,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Zidovudine</span>
</p>
<p>In six patients who were seropositive for HIV, the clearance of zidovudine (100 mg q8h) was decreased by 38% after administration of valproate (250 or 500 mg q8h); the half-life of zidovudine was unaffected.</p>
</div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.2,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Underline,'>Drugs for which either no interaction or a likely clinically unimportant interaction has been observed</span>
</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.2.1,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Acetaminophen</span>
</p>
<p>Valproate had no effect on any of the pharmacokinetic parameters of acetaminophen when it was concurrently administered to three epileptic patients.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.2.2,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Clozapine</span>
</p>
<p>In psychotic patients (n = 11), no interaction was observed when valproate was co-administered with clozapine.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.2.3,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Lithium</span>
</p>
<p>Co-administration of valproate (500 mg BID) and lithium carbonate (300 mg TID) to normal male volunteers (n = 16) had no effect on the steady-state kinetics of lithium.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.2.4,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Lorazepam</span>
</p>
<p>Concomitant administration of valproate (500 mg BID) and lorazepam (1 mg BID) in normal male volunteers (n = 9) was accompanied by a 17% decrease in the plasma clearance of lorazepam.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.2.5,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>Oral Contraceptive Steroids</span>
</p>
<p>Administration of a single-dose of ethinyloestradiol (50 mcg)/levonorgestrel (250 mcg) to 6 women on valproate (200 mg BID) therapy for 2 months did not reveal any pharmacokinetic interaction.</p>
</div>
</div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Topiramate</h2>
<p class=,'First,'>Concomitant administration of valproate and topiramate has been associated with hyperammonemia with and without encephalopathy <span class=,'Italics,'>[see<a href=,'#S4,'> Contraindications (4) </a>and<a href=,'#S5.10,'> Warnings and Precautions (5.10</a>,<a href=,'#S5.11,'> 5.11)</a>]</span>. Concomitant administration of topiramate with valproate has also been associated with hypothermia in patients who have tolerated either drug alone. It may be prudent to examine blood ammonia levels in patients in whom the onset of hypothermia has been reported <span class=,'Italics,'>[see<a href=,'#S5.10,'> Warnings and Precautions (5.10</a>,<a href=,'#S5.12,'> 5.12)</a>]</span>.</p>
</div>
</div>"
"valsartan","0135bbe4-0b38-4e92-8d7c-a4da3b6a544e","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'LINK_1dd59bba-9730-4d50-9859-10a035213819,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>No clinically significant pharmacokinetic interactions were observed when valsartan was coadministered with amlodipine, atenolol, cimetidine, digoxin, furosemide, glyburide, hydrochlorothiazide, or indomethacin. The valsartan-atenolol combination was more antihypertensive than either component, but it did not lower the heart rate more than atenolol alone.</p>
<p>Coadministration of valsartan and warfarin did not change the pharmacokinetics of valsartan or the time-course of the anticoagulant properties of warfarin.</p>
<p>
<span class=,'Italics,'>CYP 450 Interactions:</span>  <span class=,'Italics,'>In vitro</span> metabolism studies indicate that CYP 450 mediated drug interactions between valsartan and coadministered drugs are unlikely because of the low extent of metabolism <span class=,'Italics,'>[see Clinical Pharmacology (12.3)]</span>.</p>
<p>
<span class=,'Italics,'>Transporters: </span>The results from an <span class=,'Italics,'>in vitro</span> study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1 and the hepatic efflux transporter MRP2. Coadministration of inhibitors of the uptake transporter (rifampin, cyclosporine) or efflux transporter (ritonavir) may increase the systemic exposure to valsartan. </p>
<p>
<span class=,'Italics,'>Potassium:</span> Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium sparing diuretics (e.g. spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.  If co-medication is considered necessary, monitoring of serum potassium is advisable. </p>
<p>
<span class=,'Italics,'>Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors):  </span>In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including valsartan, may result in deterioration of renal function, including possible acute renal failure.  These effects are usually reversible.  Monitor renal function periodically in patients receiving valsartan and NSAID therapy.  </p>
<p>The antihypertensive effect of angiotensin II receptor antagonists, including valsartan may be attenuated by NSAIDs including selective COX-2 inhibitors.</p>
<p>
<span class=,'Italics,'>Dual Blockade of the Renin-Angiotensin System (RAS): </span>Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Closely monitor blood pressure, renal function and electrolytes in patients on valsartan and other agents that affect the RAS.  </p>
<p>Do not coadminister aliskiren with valsartan in patients with diabetes.  Avoid use of aliskiren with valsartan in patients with renal impairment (GFR &lt;60 mL/min).</p>
<p>
<span class=,'Italics,'>Lithium:  </span>Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists, including valsartan. Monitor serum lithium levels during concomitant use. </p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'LINK_ecb7ddee-1d15-47ae-bd20-e48302fe7f46,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1     Clinical Laboratory Test Findings</h2>
<p class=,'First,'>In controlled clinical trials, clinically important changes in standard laboratory parameters were rarely associated with administration of valsartan.</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Creatinine: </span></span> Minor elevations in creatinine occurred in 0.8% of patients taking valsartan and 0.6% given placebo in controlled clinical trials of hypertensive patients. In heart failure trials, greater than 50% increases in creatinine were observed in 3.9% of valsartan-treated patients compared to 0.9% of placebo-treated patients. In post-myocardial infarction patients, doubling of serum creatinine was observed in 4.2% of valsartan-treated patients and 3.4% of captopril-treated patients. </p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Hemoglobin and Hematocrit:</span></span>  Greater than 20% decreases in hemoglobin and hematocrit were observed in 0.4% and 0.8%, respectively, of valsartan patients, compared with 0.1% and 0.1% in placebo-treated patients. One valsartan patient discontinued treatment for microcytic anemia.</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Liver Function Tests:</span></span>  Occasional elevations (greater than 150%) of liver chemistries occurred in valsartan-treated patients. Three patients (&lt; 0.1%) treated with valsartan discontinued treatment for elevated liver chemistries.</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Neutropenia:</span></span>  Neutropenia was observed in 1.9% of patients treated with valsartan and 0.8% of patients treated with placebo.</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Serum Potassium:</span></span>  In hypertensive patients, greater than 20% increases in serum potassium were observed in 4.4% of valsartan-treated patients compared to 2.9% of placebo-treated patients. In heart failure patients, greater than 20% increases in serum potassium were observed in 10.0% of valsartan-treated patients compared to 5.1% of placebo-treated patients.</p>
<p>
<span class=,'Bold,'><span class=,'Italics,'>Blood Urea Nitrogen (BUN):</span></span>  In heart failure trials, greater than 50% increases in BUN were observed in 16.6% of valsartan-treated patients compared to 6.3% of placebo-treated patients.</p>
</div>
</div>"
"vancomycin","60bee69b-be70-412c-9e83-a24a0a8a5e7b","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Anesthetic Agents</h2>
<p class=,'First,'>Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing <span class=,'Italics,'>[see <a href=,'#S5.2,'>Warnings and Precautions (5.2)</a></span> and <span class=,'Italics,'><a href=,'#S8.4,'>Use in Specific Populations (8.4)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Piperacillin-Tazobactam</h2>
<p class=,'First,'>Studies have detected an increased incidence of acute kidney injury in patients administered concomitant piperacillin/tazobactam and vancomycin as compared to vancomycin alone. Monitor kidney function in patients receiving concomitant piperacillin/tazobactam and vancomycin. No pharmacokinetic interactions have been noted between piperacillin/tazobactam and vancomycin.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Ototoxic and/or Nephrotoxic Drugs</h2>
<p class=,'First,'>Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs requires more frequent monitoring of renal function.</p>
</div>
</div>"
"vardenafil","0ad213e0-d18a-4e67-a405-df95322eaa52","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>The drug interaction studies described below were conducted using vardenafil film-coated tablets.</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Potential for Pharmacodynamic Interactions with vardenafil hydrochloride orally disintegrating tablet</h2>
<p class=,'First,'>
<span class=,'Bold,'>Nitrates: </span>Concomitant use of vardenafil hydrochloride orally disintegrating tablet and nitrates is contraindicated. The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours after vardenafil were potentiated by a 20 mg dose of vardenafil in healthy middle-aged subjects. These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG). Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of vardenafil hydrochloride orally disintegrating tablet and nitrates is contraindicated <span class=,'Italics,'>[see Contraindications (<a href=,'#Section_4.1,'>4.1</a>) and Clinical Pharmacology (<a href=,'#Section_12.2,'>12.2</a>)]</span>.</p>
<br/>
<p>
<span class=,'Bold,'>Alpha-Blockers: </span>Patients taking alpha-blockers should not initiate vardenafil therapy with vardenafil hydrochloride orally disintegrating tablet. Patients treated with alpha-blockers who have previously used vardenafil film-coated tablets may be switched to vardenafil hydrochloride orally disintegrating tablet at the advice of their healthcare provider. Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers. PDE5 inhibitors, including vardenafil hydrochloride orally disintegrating tablet and alpha-adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. Clinical pharmacology studies have been conducted with co-administration of vardenafil with alfuzosin, terazosin or tamsulosin. <span class=,'Italics,'>[See Dosage and Administration (<a href=,'#Section_2.4,'>2.4</a>), Warnings and Precautions (<a href=,'#Section_5.6,'>5.6</a>), and Clinical Pharmacology (<a href=,'#Section_12.2,'>12.2</a>).]</span>
</p>
<br/>
<p>
<span class=,'Bold,'>Antihypertensives: </span>Vardenafil hydrochloride orally disintegrating tablet may add to the blood pressure lowering effect of antihypertensive agents. In a clinical pharmacology study of patients with erectile dysfunction, single doses of 20 mg vardenafil caused a mean maximum decrease in supine blood pressure of 7 mmHg systolic and 8 mmHg diastolic (compared to placebo), accompanied by a mean maximum increase of heart rate of 4 beats per minute. The maximum decrease in blood pressure occurred between 1 and 4 hours after dosing. Following multiple dosing for 31 days, similar blood pressure responses were observed on Day 31 as on Day 1.</p>
<br/>
<p>
<span class=,'Bold,'>Alcohol: </span>Vardenafil 20 mg did not potentiate the hypotensive effects of alcohol during the 4-hour observation period in healthy volunteers when administered with alcohol (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person). Alcohol and vardenafil plasma levels were not altered when dosed simultaneously.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Effect of Other Drugs on Vardenafil</h2>
<p class=,'First,'>
<span class=,'Italics,'>In vitro studies</span>
</p>
<p>Studies in human liver microsomes showed that vardenafil is metabolized primarily by cytochrome P450 (CYP) isoforms 3A4/5, and to a lesser degree by CYP2C9. Therefore, inhibitors of these enzymes are expected to reduce vardenafil clearance <span class=,'Italics,'>[see Dosage and Administration (<a href=,'#Section_2.4,'>2.4</a>) and Warnings and Precautions (<a href=,'#Section_5.2,'>5.2</a>)]</span>.</p>
<br/>
<p>
<span class=,'Italics,'>In vivo studies </span>
</p>
<p>Do not use vardenafil hydrochloride orally disintegrating tablet with moderate and potent CYP3A4 inhibitors such as erythromycin, grapefruit juice, clarithromycin, ketoconazole, itraconazole, indinavir, saquinavir, atazanavir, ritonavir as the systemic concentration of vardenafil is increased in their presence <span class=,'Italics,'>[see Warnings and Precautions <a href=,'#Section_5,'>(5)</a> and Dosage and Administration (<a href=,'#Section_2.4,'>2.4</a>)]</span>.</p>
<br/>
<br/>
<p>
<span class=,'Underline,'>Potent CYP3A4 inhibitors</span>
</p>
<p>Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil area under the curve (AUC) and a 4-fold increase in maximum concentration (C<span class=,'Sub,'>max</span>) when co-administered with vardenafil 5 mg in healthy volunteers. <span class=,'Italics,'>[See Dosage and Administration (<a href=,'#Section_2.4,'>2.4</a>) and Warnings and Precautions (<a href=,'#Section_5,'>5</a>).]</span>
</p>
<br/>
<p>Indinavir (800 mg t.i.d.) co-administered with vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil C<span class=,'Sub,'>max</span> and a 2-fold increase in vardenafil half-life. <span class=,'Italics,'>[See Dosage and Administration <a href=,'#Section_2.4,'>(2.4)</a> and Warnings and Precautions (<a href=,'#Section_5,'>5</a>).]</span>
</p>
<br/>
<p>Ritonavir (600 mg b.i.d.) co-administered with vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil C<span class=,'Sub,'>max</span>. The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a HIV protease inhibitor and a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9. <span class=,'Italics,'>[See Dosage and Administration (<a href=,'#Section_2.4,'>2.4)</a> and Warnings and Precautions (<a href=,'#Section_5.2,'>5.2).]</a></span>
</p>
<br/>
<p>
<span class=,'Underline,'>Moderate CYP3A4 inhibitors </span>
</p>
<p>Erythromycin (500 mg t.i.d.) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in vardenafil C<span class=,'Sub,'>max</span> when co-administered with vardenafil 5 mg in healthy volunteers <span class=,'Italics,'>[see Dosage and Administration (<a href=,'#Section_2,'>2</a>) and Warnings and Precautions (<a href=,'#Section_5,'>5</a>)].</span>
</p>
<br/>
<p>
<span class=,'Italics,'>Other Drug Interactions </span>
</p>
<p>No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, warfarin, digoxin, an antacid based on magnesium-aluminum hydroxide, and ranitidine. In the warfarin study, vardenafil had no effect on the prothrombin time or other pharmacodynamic parameters.</p>
<p>Cimetidine (400 mg b.i.d.) had no effect on AUC and C<span class=,'Sub,'>max</span> of vardenafil when co-administered with 20 mg vardenafil in healthy volunteers.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Effects of Vardenafil on Other Drugs</h2>
<p class=,'First,'>
<span class=,'Italics,'>In vitro studies</span>
<br/> Vardenafil and its metabolites had no effect on CYP1A2, 2A6, and 2E1 (Ki &gt;100 micromolar). Weak inhibitory effects toward other isoforms (CYP2C8, 2C9, 2C19, 2D6, 3A4) were found, but Ki values were in excess of plasma concentrations achieved following dosing. The most potent inhibitory activity was observed for vardenafil metabolite M1, which had a Ki of 1.4 micromolar toward CYP3A4, which is about 20 times higher than the M1 Cmax values after an 80 mg vardenafil dose.</p>
<p>
<span class=,'Italics,'>In vivo studies</span>
<br/>
<span class=,'Bold,'>Nifedipine:</span> Vardenafil 20 mg (film-coated tablets), when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative AUC or Cmax of nifedipine, a drug that is metabolized via CYP3A4. Nifedipine did not alter the plasma levels of vardenafil when taken in combination.  Vardenafil hydrochloride orally disintegrating tablet, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily in patients whose hypertension was controlled with nifedipine, produced mean  additional supine systolic/diastolic blood pressure reductions of 3/4 mmHg (age group 65 to 69 years) and 5/5 mmHg (age group 70 to 80 years) compared to placebo.</p>
<p>
<span class=,'Bold,'>Ritonavir and Indinavir:</span> Upon concomitant administration of 5 mg vardenafil with 600 mg b.i.d. ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%. Upon administration of 10 mg of vardenafil (film-coated tablets) with 800 mg t.i.d. indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.<br/>
<span class=,'Bold,'>Aspirin:</span> Vardenafil 10 mg and 20 mg did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets). <br/>
<span class=,'Bold,'>Other Interactions:</span> Vardenafil had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).</p>
<br/>
</div>
</div>"
"varenicline","0fefd790-b526-4f2f-8c83-5f39f7306556","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Based on varenicline characteristics and clinical experience to date, CHANTIX has no clinically meaningful pharmacokinetic drug interactions <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>].</span>
</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1  Use With Other Drugs for Smoking Cessation</h2>
<p class=,'First,'>Safety and efficacy of CHANTIX in combination with other smoking cessation therapies have not been studied.</p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_8f0e79d9-5705-4f92-b3d5-0438519a6eaa,'></a><a name=,'section-7.1.1,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Underline,'><span class=,'Italics,'>Bupropion</span>: </span>Varenicline (1 mg twice daily) did not alter the steady-state pharmacokinetics of bupropion (150 mg twice daily) in 46 smokers. The safety of the combination of bupropion and varenicline has not been established.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID_7dfe2549-02a8-4daf-9155-687857f5f2bb,'></a><a name=,'section-7.1.2,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'><span class=,'Underline,'>Nicotine replacement therapy (NRT</span>)</span>: Although co-administration of varenicline (1 mg twice daily) and transdermal nicotine (21 mg/day) for up to 12 days did not affect nicotine pharmacokinetics, the incidence of nausea, headache, vomiting, dizziness, dyspepsia, and fatigue was greater for the combination than for NRT alone. In this study, eight of twenty-two (36%) patients treated with the combination of varenicline and NRT prematurely discontinued treatment due to adverse events, compared to 1 of 17 (6%) of patients treated with NRT and placebo.</p>
</div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2  Effect of Smoking Cessation on Other Drugs</h2>
<p class=,'First,'>  Physiological changes resulting from smoking cessation, with or without treatment with CHANTIX, may alter the pharmacokinetics or pharmacodynamics of certain drugs (e.g., theophylline, warfarin, insulin) for which dosage adjustment may be necessary.</p>
</div>
</div>"
"varicella-zoster virus vaccine live (Oka-Merck) strain","524cf052-e90e-4595-af0a-608edbe9bd31","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1	Salicylates</h2>
<p class=,'First,'>No cases of Reye syndrome have been observed following vaccination with VARIVAX. Vaccine recipients should avoid use of salicylates for 6 weeks after vaccination with VARIVAX, as Reye syndrome has been reported following the use of salicylates during wild-type varicella infection <span class=,'Italics,'>[see<a href=,'#S5.5,'> Warnings and Precautions (5.5)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2	Immune Globulins and Transfusions</h2>
<p class=,'First,'>Administration of immune globulins and other blood products concurrently with VARIVAX may interfere with the expected immune response <span class=,'Italics,'>[see <a href=,'#S5.4,'>Warnings and Precautions (5.4)</a>]</span> {<a href=,'#S15,'>9</a>}. The ACIP has specific recommendations for intervals between administration of antibody-containing products and live virus vaccines.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3	Tuberculin Skin Testing</h2>
<p class=,'First,'>Tuberculin skin testing, with tuberculin purified protein derivative (PPD), may be performed before VARIVAX is administered or on the same day, or at least 4 weeks following vaccination with VARIVAX, as other live virus vaccines may cause a temporary depression of tuberculin skin test sensitivity leading to false negative results.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4	Use with Other Vaccines</h2>
<p class=,'First,'>VARIVAX can be administered concurrently with other live viral vaccines. If not given concurrently, at least 1 month should elapse between a dose of a live attenuated measles virus-containing vaccine and a dose of VARIVAX. In children through the age of 12 years at least 3 months should elapse between administration of 2 doses of a live attenuated varicella virus-containing vaccine. For adolescents and adults, 2 doses of VARIVAX may be separated by 1 month <span class=,'Italics,'>[see <a href=,'#S2.1,'>Dosage and Administration (2.1)</a>].</span>
</p>
<p>VARIVAX may be administered concomitantly with M-M-R II® (Measles, Mumps, and Rubella Virus Vaccine Live), <span class=,'Italics,'>Haemophilus influenzae</span> type b conjugate (meningococcal protein conjugate) and hepatitis B (recombinant). Additionally, VARIVAX may be administered concomitantly with inactivated diphtheria-tetanus and acellular pertussis vaccines <span class=,'Italics,'>[see <a href=,'#S14.4,'>Clinical Studies (14.4)</a>].</span>
</p>
</div>
</div>"
"vecuronium","dceeec01-2910-4489-8d70-9c0c711d17ab","none found"
"venlafaxine","0a320cd2-38ca-44f3-a338-9b4c528845b3","none found"
"verapamil","8a7002e7-e01f-43f9-e053-2a95a90a7191","none found"
"vinblastine","f073b58e-56d6-4c8d-a2ce-b37719402d77","none found"
"vincristine","49596de6-ab18-49d1-9e5b-30968fc21c36","none found"
"vinorelbine","6a16e044-7d0e-44bd-8e7e-588a5063935f","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID83,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,'>
<a name=,'ID86,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 CYP3A Inhibitors</h2>
<p class=,'First,'>
<a name=,'ID87,'></a>Exercise caution in patients concurrently taking drugs known to inhibit CYP3A.Concurrent administration of vinorelbine injection with a CYP3A inhibitor may cause an earlier onset and/or an increased severity of adverse reactions.</p>
</div>
</div>"
"voriconazole","16a80777-f1f3-45bb-a312-998b07767fe3","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>Voriconazole is metabolized by, and inhibits the activity of, cytochrome P450 isoenzymes, CYP2C19, CYP2C9, and CYP3A4. Inhibitors or inducers of these isoenzymes may increase or decrease voriconazole plasma concentrations, respectively, and there is potential for voriconazole to increase the plasma concentrations of substances metabolized by these CYP450 isoenzymes.</p>
<br/>
<p>Tables 10 and 11 provide the clinically significant interactions between voriconazole and other medical products.</p>
<div class=,'scrollingtable,'><table border=,'0,' cellpadding=,'0,' cellspacing=,'0,' width=,'100%,'>
<caption>
<span>Table 10:Effect of Other Drugs on Voriconazole Pharmacokinetics [see Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)]</span>
</caption>
<colgroup>
<col width=,'37.48%,'/>
<col width=,'31.36%,'/>
<col width=,'31.14%,'/>
</colgroup>
<thead>
<tr class=,'First Last,'>
<th align=,'center,' class=,'Lrule Rrule Toprule,'> <span class=,'Bold,'>Drug/Drug Class </span>
<br/> <span class=,'Bold,'>(Mechanism of Interaction by the Drug)</span>
<br/> </th><th align=,'center,' class=,'Lrule Rrule Toprule,'> <span class=,'Bold,'>Voriconazole Plasma Exposure (C<span class=,'Sub,'>max</span> and AUC</span><span class=,'Bold,'><span class=,'Sub,'>τ </span></span><span class=,'Bold,'>after 200 mg every 12 hours)</span>
<br/> </th><th align=,'center,' class=,'Lrule Rrule Toprule,'> <span class=,'Bold,'>Recommendations for Voriconazole Dosage Adjustment/Comments</span>
<br/> </th>
</tr>
</thead>
<tfoot>
<tr class=,'First Last,'>
<td colspan=,'3,'><span class=,'Sup,'>*    </span>Results based on <span class=,'Italics,'>in vivo </span>clinical studies generally following repeat oral dosing with 200 mg every 12 hours voriconazole to healthy subjects<br/>
<span class=,'Sup,'>**   </span>Results based on <span class=,'Italics,'>in vivo </span>clinical study following repeat oral dosing with 400 mg every 12 hours for 1 day, then 200 mg every 12 hours for at least 2 days voriconazole to healthy subjects<br/> <span class=,'Sup,'>***   </span>Non-Nucleoside Reverse Transcriptase Inhibitors<br/>
</td>
</tr>
</tfoot>
<tbody>
<tr class=,'Botrule First,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Rifampin* and Rifabutin* (CYP450 Induction)<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Significantly Reduced<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <span class=,'Bold,'>Contraindicated</span>
<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'> Efavirenz (400 mg every 24 hours)** <br/> (CYP450 Induction) <br/>  <br/> Efavirenz (300 mg every 24 hours)** <br/> (CYP450 Induction) <br/>  <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Significantly Reduced<br/>  <br/>  <br/> Slight Decrease in AUC<span class=,'Sub,'>τ</span>
<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <span class=,'Bold,'>Contraindicated </span>
<br/>  <br/>  <br/> When voriconazole is coadministered with efavirenz, voriconazole oral maintenance dose should be increased to 400 mg every 12 hours and efavirenz should be decreased to 300 mg every 24 hours.<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> High-dose Ritonavir (400 mg every 12 hours)** <br/> (CYP450 Induction) <br/>  <br/> Low-dose Ritonavir (100 mg every 12 hours)** (CYP450 Induction)<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Significantly Reduced <br/>  <br/>  <br/>  <br/> Reduced<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <span class=,'Bold,'>Contraindicated</span>
<br/>  <br/>  <br/>  <br/> Coadministration of voriconazole and low-dose ritonavir (100 mg every 12 hours) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole.<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Carbamazepine<br/> (CYP450 Induction)<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Not Studied <span class=,'Italics,'>In Vivo </span>or <span class=,'Italics,'>In Vitro</span>, but Likely to Result in Significant Reduction<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <span class=,'Bold,'>Contraindicated</span>
<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Long Acting Barbiturates (e.g., phenobarbital, mephobarbital) (CYP450 Induction)<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Not Studied <span class=,'Italics,'>In Vivo </span>or <span class=,'Italics,'>In Vitro</span>, but Likely to Result in Significant Reduction<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <span class=,'Bold,'>Contraindicated</span>
<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Phenytoin* <br/> (CYP450 Induction)<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Significantly Reduced<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Increase voriconazole maintenance dose from 4 mg/kg to 5 mg/kg IV every 12 hours or from 200 mg to 400 mg orally every 12 hours (100 mg to 200 mg orally every 12 hours in patients weighing less than 40 kg).<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Letermovir <br/> (CYP2C9/2C19 Induction)<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Reduced<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'middle,'> If concomitant administration of voriconazole with letermovir cannot be avoided, monitor for reduced effectiveness of voriconazole.<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> St. John’s Wort <br/> (CYP450 inducer; P-gp inducer)<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Significantly Reduced<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <span class=,'Bold,'>Contraindicated</span>
<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Oral Contraceptives** <br/> containing ethinyl estradiol and norethindrone (CYP2C19 Inhibition)<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Increased<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Monitoring for adverse events and toxicity related to voriconazole is recommended when coadministered with oral contraceptives.<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Fluconazole** (CYP2C9, CYP2C19 and CYP3A4 Inhibition) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Significantly Increased<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Avoid concomitant administration of voriconazole and fluconazole. Monitoring for adverse events and toxicity related to voriconazole is started within 24 hours after the last dose of fluconazole.<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Other HIV Protease Inhibitors (CYP3A4 Inhibition) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <span class=,'Italics,'>In Vivo </span>Studies Showed No Significant Effects of Indinavir on Voriconazole Exposure<br/>  <br/> <span class=,'Italics,'>In Vitro </span>Studies Demonstrated Potential for Inhibition of Voriconazole Metabolism <br/> (Increased Plasma Exposure)<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> No dosage adjustment in the voriconazole dosage needed when coadministered with indinavir.<br/>  <br/> Frequent monitoring for adverse events and toxicity related to voriconazole when coadministered with other HIV protease inhibitors.<br/> </td>
</tr>
<tr class=,'Last,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'> Other NNRTIs*** <br/> (CYP3A4 Inhibition or CYP450 Induction) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <span class=,'Italics,'>In Vitro </span>Studies Demonstrated Potential for Inhibition of Voriconazole Metabolism by Delavirdine and Other NNRTIs (Increased Plasma Exposure)<br/>  <br/> A Voriconazole-Efavirenz Drug Interaction Study Demonstrated the Potential for the Metabolism of Voriconazole to be Induced by Efavirenz and Other NNRTIs <br/> (Decreased Plasma Exposure)<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Frequent monitoring for adverse events and toxicity related to voriconazole.<br/>  <br/>  <br/>  <br/>  <br/> Careful assessment of voriconazole effectiveness.<br/> </td>
</tr>
</tbody>
</table></div>
<br/>
<p>
<span class=,'Bold,'> </span>
</p>
<p>                                                                                                                                                          </p>
<div class=,'scrollingtable,'><table border=,'0,' cellpadding=,'0,' cellspacing=,'0,' width=,'100%,'>
<caption>
<span>Table 11:Effect of Voriconazole on Pharmacokinetics of Other Drugs [see Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)]</span>
</caption>
<colgroup>
<col width=,'37.48%,'/>
<col width=,'28.4%,'/>
<col width=,'34.12%,'/>
</colgroup>
<thead>
<tr class=,'First Last,'>
<th align=,'center,' class=,'Lrule Rrule Toprule,'> <span class=,'Bold,'>Drug/Drug Class </span>
<br/> <span class=,'Bold,'>(Mechanism of Interaction by Voriconazole)</span>
<br/> </th><th align=,'center,' class=,'Lrule Rrule Toprule,'> <span class=,'Bold,'>Drug Plasma Exposure </span>
<br/> <span class=,'Bold,'>(C<span class=,'Sub,'>max</span> and AUC</span><span class=,'Bold,'><span class=,'Sub,'>τ</span></span><span class=,'Bold,'>)</span>
<br/> </th><th align=,'center,' class=,'Lrule Rrule Toprule,'> <span class=,'Bold,'>Recommendations for Drug Dosage Adjustment/Comments</span>
<br/> </th>
</tr>
</thead>
<tfoot>
<tr class=,'First Last,'>
<td colspan=,'3,'><span class=,'Sup,'>*      </span>Results based on <span class=,'Italics,'>in vivo </span>clinical studies generally following repeat oral dosing with 200 mg BID voriconazole to healthy subjects<br/>
<span class=,'Sup,'>**     </span>Results based on <span class=,'Italics,'>in vivo </span>clinical study following repeat oral dosing with 400 mg every 12 hours for1 day, then 200 mg every 12 hours  for at least 2 days voriconazole to healthy subjects<br/>
<span class=,'Sup,'>***    </span>Results based on <span class=,'Italics,'>in vivo </span>clinical study following repeat oral dosing with 400 mg every 12 hours for 1 day, then 200 mg every 12 hours  for 4 days voriconazole to subjects receiving a methadone maintenance dose (30-100 mg every 24 hours)<br/>
<span class=,'Sup,'>****    </span>Non-Steroidal Anti-Inflammatory Drug<br/> <span class=,'Sup,'>*****  </span>Non-Nucleoside Reverse Transcriptase Inhibitors <br/>
</td>
</tr>
</tfoot>
<tbody>
<tr class=,'Botrule First,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'> Sirolimus* <br/> (CYP3A4 Inhibition) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Significantly Increased<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <span class=,'Bold,'>Contraindicated</span>
<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'> Rifabutin* <br/> (CYP3A4 Inhibition) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Significantly Increased<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <span class=,'Bold,'>Contraindicated</span>
<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'> Efavirenz (400 mg every 24 hours)** (CYP3A4 Inhibition) <br/>  <br/> Efavirenz (300 mg every 24 hours)** (CYP3A4 Inhibition) <br/>  <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Significantly Increased<br/>  <br/>  <br/> Slight Increase in AUC<span class=,'Bold,'><span class=,'Sub,'>τ</span></span>
<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <span class=,'Bold,'>Contraindicated</span>
<br/>  <br/>  <br/> When voriconazole is coadministered with efavirenz, voriconazole oral maintenance dose should be increased to 400 mg every 12 hours and efavirenz should be decreased to 300 mg every 24 hours.<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'> High-dose Ritonavir (400 mg every 12 hours )**(CYP3A4 Inhibition) <br/>  <br/>  <br/> Low-dose Ritonavir (100 mg every 12 hours)**<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> No Significant Effect of Voriconazole on Ritonavir C<span class=,'Sub,'>max</span> or AUC<span class=,'Sub,'>τ</span>
<br/>  <br/>  <br/> Slight Decrease in Ritonavir C<span class=,'Sub,'>max</span> and AUC<span class=,'Sub,'>τ</span>
<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <span class=,'Bold,'>Contraindicated </span>
<br/> because of significant reduction of voriconazole C<span class=,'Sub,'>max</span> and AUC<span class=,'Sub,'>τ.</span>
<br/>  <br/> Coadministration of voriconazole and low-dose ritonavir (100 mg every 12 hours) should be avoided (due to the reduction in voriconazole C<span class=,'Sub,'>max</span> and AUC<span class=,'Sub,'>τ</span>) unless an assessment of the benefit/risk to the patient justifies the use of voriconazole.<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'> Cisapride, Pimozide, Quinidine, Ivabradine (CYP3A4 Inhibition) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Not Studied <span class=,'Italics,'>In Vivo </span>or <span class=,'Italics,'>In Vitro</span>, but Drug Plasma Exposure Likely to be Increased<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <span class=,'Bold,'>Contraindicated </span>because of potential for QT prolongation and rare occurrence of <span class=,'Italics,'>torsade de pointes.</span>
<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'> Ergot Alkaloids<br/> (CYP450 Inhibition) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Not Studied <span class=,'Italics,'>In Vivo </span>or <span class=,'Italics,'>In Vitro</span>, but Drug Plasma Exposure Likely to be Increased<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <span class=,'Bold,'>Contraindicated</span>
<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'> Naloxegol <br/> (CYP3A4 Inhibition) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Not Studied <span class=,'Italics,'>In Vivo</span> or <span class=,'Italics,'>In Vitro</span>, but Drug Plasma Exposure Likely to be Increased which may Increase the Risk of Adverse Reactions<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <span class=,'Bold,'>Contraindicated </span>
<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'> Tolvaptan <br/> (CYP3A4 Inhibition) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Although Not Studied Clinically, Voriconazole is Likely to Significantly Increase the Plasma Concentrations of Tolvaptan<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <span class=,'Bold,'>Contraindicated </span>
<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Venetoclax <br/>             (CYP3A4 Inhibition)</td><td align=,'center,' class=,'Rrule,' valign=,'top,'>
<br/> Not studied <span class=,'Italics,'>In Vivo </span>or <span class=,'Italics,'>In Vitro</span>, but Venetoclax Plasma Exposure Likely to be Significantly Increased</td><td align=,'center,' class=,'Rrule,' valign=,'top,'>
<br/>Coadministration of voriconazole is <span class=,'Bold,'>contraindicated </span>at initiation and during the ramp-up phase in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Refer to the venetoclax labeling for safety monitoring and dose reduction in the steady daily dosing phase in CLL/SLL patients. <br/>For patients with acute myeloid leukemia (AML), dose reduction and safety monitoring are recommended across all dosing phases when coadministering voriconazole tablets with venetoclax. Refer to the venetoclax prescribing information for dosing instructions.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'> Cyclosporine* <br/> (CYP3A4 Inhibition) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> AUC<span class=,'Sub,'>τ</span> Significantly Increased; No Significant Effect on C<span class=,'Sub,'>max</span>
<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> When initiating therapy with voriconazole tablets in patients already receiving cyclosporine, reduce the cyclosporine dose to one-half of the starting dose and follow with frequent monitoring of cyclosporine blood levels. Increased cyclosporine levels have been associated with nephrotoxicity. When voriconazole tablets are discontinued, cyclosporine concentrations must be frequently monitored and the dose increased as necessary.<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'> Methadone*** (CYP3A4 Inhibition) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Increased<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Increased plasma concentrations of methadone have been associated with toxicity including QT prolongation. Frequent monitoring for adverse events and toxicity related to methadone is recommended during coadministration. Dose reduction of methadone may be needed.<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'> Fentanyl (CYP3A4 Inhibition) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Increased<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Reduction in the dose of fentanyl and other long-acting opiates metabolized by CYP3A4 should be considered when coadministered with voriconazole<span class=,'Bold,'></span>tablets. Extended and frequent monitoring for opiate-associated adverse events may be necessary.<br/>
</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'> Alfentanil <br/> (CYP3A4 Inhibition) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Significantly Increased<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> An increase in the incidence of delayed and persistent alfentanil-associated nausea and vomiting were observed when coadministered with voriconazole tablets.<br/>             Reduction in the dose of alfentanil and other opiates metabolized by CYP3A4 (e.g., sufentanil) should be considered when coadministered with voriconazole tablets.<br/>             A longer period for monitoring respiratory and other opiate-associated adverse events may be necessary.<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'> Oxycodone (CYP3A4 Inhibition) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Significantly Increased<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Increased visual effects (heterophoria and miosis) of oxycodone were observed when coadministered with voriconazole tablets.<br/>             Reduction in the dose of oxycodone and other longacting opiates metabolized by CYP3A4 should be considered when coadministered with voriconazole tablets.<br/>             Extended and frequent monitoring for opiateassociated adverse events may be necessary.<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'> NSAIDs**** including ibuprofen and diclofenac <br/> (CYP2C9 Inhibition) <br/>  <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Increased<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Frequent monitoring for adverse events and toxicity related to NSAIDs. Dose reduction of NSAIDs may be needed<span class=,'Italics,'>.</span>
<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'> Tacrolimus* <br/> (CYP3A4 Inhibition) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Significantly Increased<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> When initiating therapy with voriconazole tablets in patients already receiving tacrolimus, reduce the tacrolimus dose to one-third of the starting dose and follow with frequent monitoring of tacrolimus blood levels. Increased tacrolimus levels have been associated with nephrotoxicity. When voriconazole tablets are discontinued, tacrolimus concentrations must be frequently monitored and the dose increased as necessary.<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'> Phenytoin* <br/> (CYP2C9 Inhibition) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Significantly Increased<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Frequent monitoring of phenytoin plasma concentrations and frequent monitoring of adverse effects related to phenytoin.<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'> Oral Contraceptives containing ethinyl estradiol and norethindrone <br/> (CYP3A4 Inhibition)** <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Increased<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Monitoring for adverse events related to oral contraceptives is recommended during coadministration.<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td align=,'justify,' class=,'Lrule Rrule,' valign=,'top,'> Prednisolone and other corticosteroids <br/> (CYP3A4 Inhibition) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <span class=,'Italics,'>In Vivo</span> Studies Showed No Significant Effects of voriconazole tablets on Prednisolone Exposure<br/>  <br/>  <br/> Not Studied <span class=,'Italics,'>In vitro</span> or <span class=,'Italics,'>In vivo</span> for Other Corticosteroids, but Drug Exposure Likely to be Increased <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> No dosage adjustment for prednisolone when coadministered with voriconazole tablets <span class=,'Italics,'>[see Clinical Pharmacology (<a href=,'#Section_12.3,'>12.3</a>)].</span>
<br/>  <br/> Monitor for potential adrenal dysfunction when voriconazole tablets is administered with other corticosteroids <span class=,'Italics,'>[See Warnings and Precautions (<a href=,'#Section_5.8,'>5.8</a>)].</span>
<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Warfarin* <br/> (CYP2C9 Inhibition)<br/>Other Oral Coumarin Anticoagulants (CYP2C9/3A4 Inhibition) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Prothrombin Time Significantly Increased<br/>Not Studied <span class=,'Italics,'>In Vivo </span>or <span class=,'Italics,'>In Vitro </span>for other Oral Coumarin Anticoagulants, but Drug Plasma Exposure Likely to be Increased  <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> If patients receiving coumarin preparations are treated simultaneously with voriconazole, the prothrombin time or other suitable anticoagulation tests should be monitored at close intervals and the dosage of anticoagulants adjusted accordingly.<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Ivacaftor <br/> (CYP3A4 Inhibition) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Not Studied <span class=,'Italics,'>In Vivo</span> or <span class=,'Italics,'>In Vitro</span>, but Drug Plasma Exposure Likely to be Increased which may Increase the Risk of Adverse Reactions <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Dose reduction of ivacaftor is recommended. Refer to the prescribing information for ivacaftor <br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Omeprazole* <br/> (CYP2C19/3A4 Inhibition) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Significantly Increased<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> When initiating therapy with voriconazole tablets in patients already receiving omeprazole doses of 40 mg or greater, reduce the omeprazole dose by one-half. The metabolism of other proton pump inhibitors that are CYP2C19 substrates may also be inhibited by voriconazole and may result in increased plasma concentrations of other proton pump inhibitors.<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Other HIV Protease Inhibitors <br/> (CYP3A4 Inhibition) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <span class=,'Italics,'>In Vivo </span>Studies Showed No Significant Effects on Indinavir Exposure<br/>  <br/>  <br/> <span class=,'Italics,'>In Vitro </span>Studies Demonstrated Potential for Voriconazole to Inhibit Metabolism<br/> (Increased Plasma Exposure)<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> No dosage adjustment for indinavir when coadministered with voriconazole tablets.<br/>  <br/>  <br/> Frequent monitoring for adverse events and toxicity related to other HIV protease inhibitors.<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Other NNRTIs***** <br/> (CYP3A4 Inhibition) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> A Voriconazole-Efavirenz Drug Interaction Study Demonstrated the Potential for Voriconazole to Inhibit Metabolism of Other NNRTIs (Increased Plasma Exposure)<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Frequent monitoring for adverse events and toxicity related to NNRTI.<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Benzodiazepines (CYP3A4 Inhibition) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <span class=,'Italics,'>In Vitro </span>Studies Demonstrated Potential for Voriconazole to Inhibit Metabolism<br/> (Increased Plasma Exposure)<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Frequent monitoring for adverse events and toxicity (i.e., prolonged sedation) related to benzodiazepines metabolized by CYP3A4 (e.g., midazolam, triazolam, alprazolam). Adjustment of benzodiazepine dosage may be needed.<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> HMG-CoA Reductase Inhibitors (Statins) (CYP3A4 Inhibition) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <span class=,'Italics,'>In Vitro </span>Studies Demonstrated Potential for Voriconazole to Inhibit Metabolism<br/> (Increased Plasma Exposure)<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Frequent monitoring for adverse events and toxicity related to statins. Increased statin concentrations in plasma have been associated with rhabdomyolysis. Adjustment of the statin dosage may be needed.<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Dihydropyridine Calcium Channel Blockers <br/> (CYP3A4 Inhibition) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> <span class=,'Italics,'>In Vitro </span>Studies Demonstrated Potential for Voriconazole to Inhibit Metabolism<br/> (Increased Plasma Exposure)<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Frequent monitoring for adverse events and toxicity related to calcium channel blockers. Adjustment of calcium channel blocker dosage may be needed.<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Sulfonylurea Oral Hypoglycemics (CYP2C9 Inhibition) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Not Studied <span class=,'Italics,'>In Vivo </span>or <span class=,'Italics,'>In Vitro</span>, but Drug Plasma Exposure Likely to be Increased<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Frequent monitoring of blood glucose and for signs and symptoms of hypoglycemia. Adjustment of oral hypoglycemic drug dosage may be needed.<br/> </td>
</tr>
<tr class=,'Botrule,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Vinca Alkaloids (CYP3A4 Inhibition) <br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Not Studied <span class=,'Italics,'>In Vivo </span>or <span class=,'Italics,'>In Vitro</span>, but Drug Plasma Exposure Likely to be Increased<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Frequent monitoring for adverse events and toxicity (i.e., neurotoxicity) related to vinca alkaloids. Reserve azole antifungals, including voriconazole, for patients receiving a vinca alkaloid who have no alternative antifungal treatment options.<br/> </td>
</tr>
<tr class=,'Last,'>
<td class=,'Lrule Rrule,' valign=,'top,'> Everolimus <br/> (CYP3A4 Inhibition)<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Not Studied <span class=,'Italics,'>In Vivo or In Vitro</span>, but Drug Plasma Exposure Likely to be Increased<br/> </td><td align=,'center,' class=,'Rrule,' valign=,'top,'> Concomitant administration of voriconazole and everolimus is not recommended.<br/> </td>
</tr>
</tbody>
</table></div>
</div>"
"vortioxetine","1a5b68e2-14d0-419d-9ec6-1ca97145e838","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'S7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1	Drugs Having Clinically Important Interactions with TRINTELLIX</h2>
<div class=,'scrollingtable,'><table width=,'80%,'>
<caption>
<span>Table 4: Clinically Important Drug Interactions with TRINTELLIX </span>
</caption>
<col align=,'left,' valign=,'top,' width=,'34%,'/>
<col align=,'left,' valign=,'top,' width=,'66%,'/>
<tbody class=,'Headless,'>
<tr class=,'Botrule First,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Monoamine Oxidase Inhibitors (MAOIs)</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Clinical Impact</span></td><td align=,'left,' class=,'Rrule,'>The concomitant use of SSRIs and SNRIs including TRINTELLIX with MAOIs increases the risk of serotonin syndrome.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention</span></td><td align=,'left,' class=,'Rrule,'>Concomitant use of TRINTELLIX is contraindicated:<ul>
<li>With an MAOI intended to treat psychiatric disorders or within 21 days of stopping treatment with TRINTELLIX.</li>
<li>Within 14 days of stopping an MAOI intended to treat psychiatric disorders.</li>
<li>In a patient who is being treated with linezolid or intravenous methylene blue.</li>
</ul>
<span class=,'Italics,'>[see <a href=,'#S2.4,'>Dosage and Administration (2.4)</a>, <a href=,'#S4,'>Contraindications (4)</a>, <a href=,'#S5.2,'>Warnings and Precautions (5.2)</a>].</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Examples</span></td><td align=,'left,' class=,'Rrule,'>selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Other Serotonergic Drugs</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Clinical Impact</span></td><td align=,'left,' class=,'Rrule,'>Concomitant use of TRINTELLIX with other serotonergic drugs increases the risk of serotonin syndrome.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention</span></td><td align=,'left,' class=,'Rrule,'>Monitor for symptoms of serotonin syndrome when TRINTELLIX is used concomitantly with other drugs that may affect the serotonergic neurotransmitter systems. If serotonin syndrome occurs, consider discontinuation of TRINTELLIX and/or concomitant serotonergic drugs <span class=,'Italics,'>[see <a href=,'#S5.2,'>Warnings and Precautions (5.2)</a>].</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Examples</span></td><td align=,'left,' class=,'Rrule,'>Other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St. John's Wort</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Strong Inhibitors of CYP2D6</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Clinical Impact</span></td><td align=,'left,' class=,'Rrule,'>Concomitant use of TRINTELLIX with strong CYP2D6 inhibitors increases plasma concentrations of vortioxetine.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention</span></td><td align=,'left,' class=,'Rrule,'>Reduce TRINTELLIX dose by half when a strong CYP2D6 inhibitor is coadministered <span class=,'Italics,'>[see <a href=,'#S2.5,'>Dosage and Administration (2.5)</a>].</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Examples</span></td><td align=,'left,' class=,'Rrule,'>bupropion, fluoxetine, paroxetine, quinidine</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Strong CYP Inducers</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Clinical Impact</span></td><td align=,'left,' class=,'Rrule,'>Concomitant use of TRINTELLIX with a strong CYP inducer decreases plasma concentrations of vortioxetine.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention</span></td><td align=,'left,' class=,'Rrule,'>Consider increasing the TRINTELLIX dose when a strong CYP inducer is coadministered. The maximum dose is not recommended to exceed three times the original dose <span class=,'Italics,'>[see <a href=,'#S2.6,'>Dosage and Administration (2.6)</a>].</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Examples</span></td><td align=,'left,' class=,'Rrule,'>rifampin, carbamazepine, phenytoin</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Drugs that Interfere with Hemostasis</span> (antiplatelets agents and anticoagulants)</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Clinical Impact</span></td><td align=,'left,' class=,'Rrule,'>Concomitant use of TRINTELLIX with an antiplatelet or anticoagulant drug may potentiate the risk of bleeding.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention</span></td><td align=,'left,' class=,'Rrule,'>Inform patients of the increased risk of bleeding associated with the concomitant use of TRINTELLIX and antiplatelet agents and anticoagulants. For patients taking warfarin, carefully monitor the international normalized ratio <span class=,'Italics,'>[see <a href=,'#S5.3,'>Warnings and Precautions (5.3)</a>, <a href=,'#S7.2,'>Drug Interactions (7.2)</a>]</span>.</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Examples</span></td><td align=,'left,' class=,'Rrule,'>aspirin, clopidogrel, heparin, warfarin</td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,' colspan=,'2,'><span class=,'Bold,'>Drugs Highly Bound to Plasma Protein</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Clinical Impact</span></td><td align=,'left,' class=,'Rrule,'>TRINTELLIX is highly bound to plasma protein. The concomitant use of TRINTELLIX with another drug that is highly bound to plasma protein may increase free concentrations of TRINTELLIX or other tightly-bound drugs in plasma<span class=,'Italics,'>.</span></td>
</tr>
<tr class=,'Botrule,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Intervention</span></td><td align=,'left,' class=,'Rrule,'>Monitor for adverse reactions and reduce dosage of TRINTELLIX or other protein bound drugs as warranted <span class=,'Italics,'>[see <a href=,'#S7.2,'>Drug Interactions (7.2)</a>]</span>.</td>
</tr>
<tr class=,'Botrule Last,'>
<td align=,'left,' class=,'Lrule Rrule,'><span class=,'Italics,'>Examples</span></td><td align=,'left,' class=,'Rrule,'>Warfarin</td>
</tr>
</tbody>
</table></div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2	Effect of TRINTELLIX on Other Drugs</h2>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.1,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Bold,'>Other CNS Active Agents</span>
</p>
<p>No clinically relevant effect was observed on steady-state lithium exposure following coadministration with multiple daily doses of TRINTELLIX. Multiple doses of TRINTELLIX did not affect the pharmacokinetics or pharmacodynamics (composite cognitive score) of diazepam <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>A clinical study has shown that TRINTELLIX (single dose of 20 or 40 mg) did not increase the impairment of mental and motor skills caused by alcohol (single dose of 0.6 g/kg) <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.2,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Bold,'>Drugs That Interfere with Hemostasis</span>
</p>
<p>Following coadministration of stable doses of warfarin (1 to 10 mg/day) with multiple daily doses of TRINTELLIX, no significant effects were observed in INR, prothrombin values or total warfarin (protein bound plus free drug) pharmacokinetics for both R- and S-warfarin. Coadministration of aspirin 150 mg/day with multiple daily doses of TRINTELLIX had no significant inhibitory effect on platelet aggregation or pharmacokinetics of aspirin and salicylic acid <span class=,'Italics,'>[see <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>. Patients receiving other drugs that interfere with hemostasis should be carefully monitored when TRINTELLIX is initiated or discontinued <span class=,'Italics,'>[see <a href=,'#S5.3,'>Warnings and Precautions (5.3)</a>, <a href=,'#S7.1,'>Drug Interactions (7.1)</a>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'section-7.2.3,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Bold,'>Highly Protein Bound Drugs</span>
</p>
<p>In a clinical study with coadministration of TRINTELLIX (10 mg/day) and warfarin (1 mg/day to 10 mg/day), a highly protein bound drug, no significant change in INR was observed <span class=,'Italics,'>[see <a href=,'#S7.1,'>Drug Interactions (7.1)</a>, <a href=,'#S12.3,'>Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'S7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3	Interference with Urine Enzyme Immunoassays for Methadone</h2>
<p class=,'First,'>False positive results in urine enzyme immunoassays for methadone have been reported in patients who have taken vortioxetine. An alternative analytical technique (e.g., chromatographic methods) should be considered to confirm positive methadone urine drug screen results.</p>
</div>
</div>"
"warfarin","03845452-4ec4-4593-abdf-5a6cc8d241a9","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID64,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'ID197,'></a><a name=,'section-7.1,'></a>
<p></p>
<p class=,'First,'>
<a name=,'ID65,'></a>Drugs may interact with warfarin sodium through pharmacodynamic or pharmacokinetic mechanisms. Pharmacodynamic mechanisms for drug interactions with warfarin sodium are synergism (impaired hemostasis, reduced clotting factor synthesis), competitive antagonism (vitamin K), and alteration of the physiologic control loop for vitamin K metabolism (hereditary resistance). Pharmacokinetic mechanisms for drug interactions with warfarin sodium are mainly enzyme induction, enzyme inhibition, and reduced plasma protein binding. It is important to note that some drugs may interact by more than one mechanism.</p>
<p>More frequent INR monitoring should be performed when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs, including drugs intended for short-term use (e.g., antibiotics, antifungals, corticosteroids) [see
                                    <span class=,'Italics,'>].
                                        <a href=,'#ID1,'>Boxed Warning</a></span>
</p>
<p>Consult the labeling of all concurrently used drugs to obtain further information about interactions with warfarin sodium or adverse reactions pertaining to bleeding.</p>
</div>
<div class=,'Section,'>
<a name=,'ID66,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.1 CYP450 Interactions</h2>
<p class=,'First,'>
<a name=,'ID67,'></a>CYP450 isozymes involved in the metabolism of warfarin include CYP2C9, 2C19, 2C8, 2C18, 1A2, and 3A4. The more potent warfarin -enantiomer is metabolized by CYP2C9 while the -enantiomer is metabolized by CYP1A2 and 3A4.
                                    <span class=,'Italics,'>S</span><span class=,'Italics,'>R</span>
</p>
<ul>
<li>Inhibitors of CYP2C9, 1A2, and/or 3A4 have the potential to increase the effect (increase INR) of warfarin by increasing the exposure of warfarin.</li>
<li>Inducers of CYP2C9, 1A2, and/or 3A4 have the potential to decrease the effect (decrease INR) of warfarin by decreasing the exposure of warfarin.</li>
</ul>
<p>
<a name=,'ID69,'></a>Examples of inhibitors and inducers of CYP2C9, 1A2, and 3A4 are below in Table 2; however, this list should not be considered all-inclusive. Consult the labeling of all concurrently used drugs to obtain further information about CYP450 interaction potential. The CYP450 inhibition and induction potential should be considered when starting, stopping, or changing dose of concomitant mediations. Closely monitor INR if a concomitant drug is a CYP2C9, 1A2, and/or 3A4 inhibitor or inducer.</p>
<a name=,'ID70,'></a>
<div class=,'scrollingtable,'><table width=,'99%,'>
<caption>
<span>Table 2 Examples of CYP450 Interactions with Warfarin</span>
</caption>
<col width=,'18%,'/>
<col width=,'45%,'/>
<col width=,'36%,'/>
<tbody class=,'Headless,'>
<tr class=,'First,'>
<td align=,'center,' class=,'Botrule Lrule Rrule Toprule,' valign=,'middle,'><span class=,'Bold,'>Enzyme</span>
<br/>
</td><td align=,'center,' class=,'Botrule Lrule Rrule Toprule,' valign=,'middle,'><span class=,'Bold,'>Inhibitors</span>
<br/>
</td><td align=,'center,' class=,'Botrule Lrule Rrule Toprule,' valign=,'middle,'><span class=,'Bold,'>Inducers</span>
<br/>
</td>
</tr>
<tr>
<td align=,'justify,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>CYP2C9 
                                                <br/>
</td><td align=,'justify,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>amiodarone, capecitabine, cotrimoxazole, etravirine, fluconazole, fluvastatin, fluvoxamine, metronidazole miconazole, oxandrolone, sulfinpyrazone, tigecycline, voriconazole, zafirlukast
                                                <br/>
</td><td align=,'justify,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>aprepitant, bosentan, carbamazepine, phenobarbital, rifampin 
                                                <br/>
</td>
</tr>
<tr>
<td align=,'justify,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>CYP1A2 
                                                <br/>
</td><td align=,'justify,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>acyclovir, allopurinol, caffeine, cimetidine, ciprofloxacin, disulfiram, enoxacin, famotidine, fluvoxamine, methoxsalen, mexiletine, norfloxacin, oral contraceptives, phenylpropanolamine, propafenone, propranolol, terbinafine, thiabendazole, ticlopidine, verapamil, zileuton
                                                <br/>
</td><td align=,'justify,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>montelukast, moricizine, omeprazole, phenobarbital, phenytoin, cigarette smoking 
                                                <br/>
</td>
</tr>
<tr class=,'Last,'>
<td align=,'justify,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>CYP3A4 
                                                <br/>
</td><td align=,'justify,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>alprazolam, amiodarone, amlodipine, amprenavir, aprepitant, atorvastatin, atazanavir, bicalutamide, cilostazol, cimetidine, ciprofloxacin, clarithromycin, conivaptan, cyclosporine, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fluoxetine, fluvoxamine, fosamprenavir, imatinib, indinavir, isoniazid, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, nilotinib, oral contraceptives, posaconazole, ranitidine, ranolazine, ritonavir, saquinavir, telithromycin, tipranavir, voriconazole, zileuton
                                                <br/>
</td><td align=,'justify,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>armodafinil, amprenavir, aprepitant, bosentan, carbamazepine, efavirenz, etravirine, modafinil, nafcillin, phenytoin, pioglitazone, prednisone, rifampin, rufinamide 
                                                <br/>
</td>
</tr>
</tbody>
</table></div>
</div>
<div class=,'Section,'>
<a name=,'ID71,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.2 Drugs that Increase Bleeding Risk</h2>
<p class=,'First,'>
<a name=,'ID72,'></a>Examples of drugs known to increase the risk of bleeding are presented in Table 3. Because bleeding risk is increased when these drugs are used concomitantly with warfarin, closely monitor patients receiving any such drug with warfarin.</p>
<a name=,'ID73,'></a>
<div class=,'scrollingtable,'><table width=,'100%,'>
<caption>
<span>Table 3Drugs that Can Increase the Risk of Bleeding</span>
</caption>
<col width=,'46%,'/>
<col width=,'54%,'/>
<tbody class=,'Headless,'>
<tr class=,'First,'>
<td align=,'center,' class=,'Botrule Lrule Rrule Toprule,' valign=,'middle,'><span class=,'Bold,'>Drug </span><span class=,'Bold,'>Class</span>
<br/>
</td><td align=,'center,' class=,'Botrule Lrule Rrule Toprule,' valign=,'middle,'><span class=,'Bold,'>Specific </span><span class=,'Bold,'>Drugs</span>
<br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' valign=,'middle,'>Anticoagulants 
                                                <br/>
</td><td align=,'justify,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin 
                                                <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' valign=,'middle,'>Antiplatelet Agents 
                                                <br/>
</td><td align=,'justify,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine 
                                                <br/>
</td>
</tr>
<tr>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Nonsteroidal Anti-Inflammatory Agents 
                                                <br/>
</td><td align=,'justify,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac 
                                                <br/>
</td>
</tr>
<tr class=,'Last,'>
<td align=,'left,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>Serotonin Reuptake Inhibitors 
                                                <br/>
</td><td align=,'justify,' class=,'Botrule Lrule Rrule Toprule,' valign=,'top,'>citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 
                                                <br/>
</td>
</tr>
</tbody>
</table></div>
</div>
<div class=,'Section,'>
<a name=,'ID74,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.3 Antibiotics and Antifungals</h2>
<p class=,'First,'>
<a name=,'ID75,'></a>There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown consistent effects of these agents on plasma concentrations of warfarin.</p>
<p>Closely monitor INR when starting or stopping any antibiotic or antifungal in patients taking warfarin.</p>
</div>
<div class=,'Section,'>
<a name=,'ID76,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.4 Botanical (Herbal) Products and Foods</h2>
<p class=,'First,'>
<a name=,'ID77,'></a>Exercise caution when botanical (herbal) products are taken concomitantly with warfarin sodium. Few adequate, well-controlled studies evaluating the potential for metabolic and/or pharmacologic interactions between botanicals and warfarin sodium exist. Due to a lack of manufacturing standardization with botanical medicinal preparations, the amount of active ingredients may vary. This could further confound the ability to assess potential interactions and effects on anticoagulation.</p>
<p></p>
<p>Some botanicals may cause bleeding events when taken alone (e.g., garlic and Ginkgo biloba) and may have anticoagulant, antiplatelet, and/or fibrinolytic properties. These effects would be expected to be additive to the anticoagulant effects of warfarin sodium. Conversely, some botanicals may decrease the effects of warfarin sodium (e.g., co-enzyme Q , St. John’s wort ginseng). Some botanicals and foods can interact with warfarin sodium through CYP450 interactions (e.g., echinacea, grapefruit juice, ginkgo, goldenseal, St. John’s wort).
                                    <span class=,'Sub,'>10</span>
</p>
<p></p>
<p>Monitor the patient’s response with additional INR determinations when initiating or discontinuing any botanicals.</p>
</div>
</div>"
"xylometazoline","0b1f1890-044a-4bc2-bf87-648bdc479a13","none found"
"zidovudine","536735fc-566c-4ad4-b83e-602199ff82b4","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'ID91,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,'>
<a name=,'ID94,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Antiretroviral Agents</h2>
<p class=,'First,'>
<a name=,'ID95,'></a><span class=,'Underline,'>Stavudine</span>
</p>
<p>Concomitant use of zidovudine with stavudine should be avoided since an antagonistic relationship has been demonstrated <span class=,'Italics,'>in vitro</span>.</p>
<p>
<span class=,'Underline,'>Nucleoside Analogues Affecting DNA Replication</span>
</p>
<p>Some nucleoside analogues affecting DNA replication, such as ribavirin, antagonize the <span class=,'Italics,'>in vitro</span> antiviral activity of zidovudine against HIV-1; concomitant use of such drugs should be avoided.</p>
</div>
<div class=,'Section,'>
<a name=,'ID96,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Doxorubicin</h2>
<p class=,'First,'>
<a name=,'ID97,'></a>Concomitant use of zidovudine with doxorubicin should be avoided since an antagonistic relationship has been demonstrated <span class=,'Italics,'>in vitro</span>.</p>
</div>
<div class=,'Section,'>
<a name=,'ID98,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Hematologic/Bone Marrow Suppressive/Cytotoxic Agents</h2>
<p class=,'First,'>
<a name=,'ID99,'></a>Coadministration of ganciclovir, interferon alfa, ribavirin, and other bone marrow suppressive or cytotoxic agents may increase the hematologic toxicity of zidovudine.</p>
</div>
</div>"
"zoledronic acid","1349fb63-3d9d-4dc0-bdbb-5af0429f9a72","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'s7,'></a><a name=,'section-7,'></a>
<p></p>
<p class=,'First,'>
<span class=,'Italics,'>In-vitro</span> studies indicate that the plasma protein binding of zoledronic acid is low, with the unbound fraction ranging from 60%-77%. 
       
 
  
       
 
  <span class=,'Italics,'>In-vitro</span> studies also indicate that zoledronic acid does not inhibit microsomal CYP450 enzymes. 
       
 
  
       
 
  <span class=,'Italics,'>In-vivo</span> studies showed that zoledronic acid is not metabolized, and is excreted into the urine as the intact drug. 
      

 
      

 </p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7p1,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Aminoglycosides and Calcitonin</h2>
<p class=,'First,'>Caution is advised when bisphosphonates are administered with aminoglycosides or calcitonin, since these agents may have an additive effect to lower serum calcium level for prolonged periods. This effect has not been reported in zoledronic acid injection clinical trials.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7p2,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 Loop Diuretics</h2>
<p class=,'First,'>Caution should also be exercised when zoledronic acid injection is used in combination with loop diuretics due to an increased risk of hypocalcemia.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7p3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 Nephrotoxic Drugs</h2>
<p class=,'First,'>Caution is indicated when zoledronic acid injection is used with other potentially nephrotoxic drugs.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'s7p4,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Thalidomide</h2>
<p class=,'First,'>No dose adjustment for zoledronic acid injection 4 mg is needed when coadministered with thalidomide. In a pharmacokinetic study of 24 patients with multiple myeloma, zoledronic acid injection 4 mg given as a 15 minute infusion was administered either alone or with thalidomide (100 mg once daily on days 1-14 and 200 mg once daily on Days 15-28). Coadministration of thalidomide with zoledronic acid injection did not significantly change the pharmacokinetics of zoledronic acid or creatinine clearance. </p>
</div>
</div>"
"zolmitriptan","b5c5cb44-7581-4856-8324-13c02a6101dd","<div class=,'Section toggle-content closed long-content,' data-sectioncode=,'34073-7,'>
<a name=,'Section_7,'></a><a name=,'section-7,'></a>
<p></p>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.5,'></a><a name=,'section-7.1,'></a>
<p></p>
<h2>7.1 Ergot-containing Drugs</h2>
<p class=,'First,'>Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine containing or ergot-type medications (like dihydroergotamine or methysergide) and zolmitriptan tablets within 24 hours of each other is contraindicated <span class=,'Italics,'>[see </span><span class=,'Italics,'><a href=,'#Section_4,'>Contraindications (4)</a></span><span class=,'Italics,'>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.4,'></a><a name=,'section-7.2,'></a>
<p></p>
<h2>7.2 MAO-A Inhibitors</h2>
<p class=,'First,'>MAO-A inhibitors increase the systemic exposure of zolmitriptan and its active N-desmethyl metabolite. Therefore, the use of zolmitriptan tablets in patients receiving MAO-A inhibitors is contraindicated<span class=,'Italics,'> [see </span><span class=,'Italics,'><a href=,'#Section_4,'>Contraindications (4)</a></span>, <span class=,'Italics,'><a href=,'#Section_12.3,'>Clinical Pharmacology (12.3)</a></span><span class=,'Italics,'>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.3,'></a><a name=,'section-7.3,'></a>
<p></p>
<h2>7.3 5-HT<span class=,'Sub,'>1B/1D</span> agonists</h2>
<p class=,'First,'>Concomitant use of other 5-HT<span class=,'Sub,'>1B/1D</span> agonists (including triptans) within 24 hours of zolmitriptan tablets treatment is contraindicated because the risk of vasospastic reactions may be additive <span class=,'Italics,'>[see </span><span class=,'Italics,'><a href=,'#Section_4,'>Contraindications (4)</a></span><span class=,'Italics,'>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.2,'></a><a name=,'section-7.4,'></a>
<p></p>
<h2>7.4 Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors</h2>
<p class=,'First,'>Cases of life-threatening serotonin syndrome have been reported during co-administration of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) <span class=,'Italics,'>[see </span><span class=,'Italics,'><a href=,'#Section_5.3,'>Warnings and Precautions (5.7)</a></span><span class=,'Italics,'>]</span>.</p>
</div>
<div class=,'Section,' data-sectioncode=,'42229-5,'>
<a name=,'Section_7.1,'></a><a name=,'section-7.5,'></a>
<p></p>
<h2>7.5 Cimetidine</h2>
<p class=,'First,'>Following administration of cimetidine, the half-life and blood levels of zolmitriptan and its active N-desmethyl metabolite were approximately doubled <span class=,'Italics,'>[see </span><span class=,'Italics,'><a href=,'#Section_12.3,'>Clinical Pharmacology (12.3)</a></span><span class=,'Italics,'>]</span>. If cimetidine and zolmitriptan tablets are used concomitantly, limit the maximum single dose of zolmitriptan tablets to 2.5 mg, not to exceed 5 mg in any 24-hour period<span class=,'Italics,'> [see </span><span class=,'Italics,'><a href=,'#Section_2.3,'>Dosage and Administration (2.4)</a></span>, <span class=,'Italics,'><a href=,'#Section_12.3,'>Clinical Pharmacology (12.3)</a></span><span class=,'Italics,'>]</span>.</p>
</div>
</div>"
